PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DAJ	Gaudio, E; Hoffman, LC; Schabort, GA; Shepstone, CA; Bauer, G; De Benedictis, GM				Gaudio, Eugenio; Hoffman, Louwrens C.; Schabort, George A.; Shepstone, Craig A.; Bauer, Gary; De Benedictis, Giulia Maria			EVALUATION OF THE QUALITY OF IMMOBILIZATION AND CARDIORESPIRATORY EFFECTS OF ETORPHINE-MEDETOMIDINE-AZAPERONE COMBINATION IN PLAINS ZEBRAS (EQUUS QUAGGA): A PILOT STUDY	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						Azaperone; Equus quagga; etorphine; field capture; medetomidine; zebra		Five free-ranging male (subadults, n= 3; adults, n = 2) plains zebras (Equus quagga) were immobilized using a combination of etorphine (0.017 mg/kg), medetomidine (0.017 mg/kg), and azaperone (0.24 mg/kg) by means of a blank cartridge-fired projector. Time to recumbency was recorded and a descriptive score used to assess the quality of immobilization, manipulation, maintenance, and recovery. Physiological parameters were recorded at 5-min intervals for 20 min. At the end of the procedure, naltrexone (0.23 mg/kg) was administered intramuscularly and time to standing documented. The combination evaluated in this study allowed for successful immobilization and safe recovery of all animals, including during the subsequent 15 days. Despite the good outcome in this pilot study, as a result of the periodic apneic events and hypercapnia documented in the zebras, the authors suggest that physiological parameters be thoroughly monitored when using this protocol. Further studies are needed to improve upon chemical immobilization protocols in free-ranging plains zebras.	[Gaudio, Eugenio; De Benedictis, Giulia Maria] Univ Padua, Sch Agr Sci & Vet Med, Dept Anim Med Prod & Hlth, I-35020 Legnaro, PD, Italy; [Hoffman, Louwrens C.; Shepstone, Craig A.] Stellenbosch Univ, Fac AgriSci, Dept Anim Sci, ZA-7602 Stellenbosch, South Africa; [Hoffman, Louwrens C.] Univ Queensland, Ctr Nutr & Food Sci, Queensland Alliance Agr & Food Innovat, Coopers Plains 4108, Australia; [Schabort, George A.] Wellington Anim Hosp, ZA-7655 Wellington, South Africa; [Bauer, Gary] Gondwana Wildlife Serv, ZA-0387 Thabazimbi, South Africa	Gaudio, E (reprint author), Univ Padua, Sch Agr Sci & Vet Med, Dept Anim Med Prod & Hlth, I-35020 Legnaro, PD, Italy.	eugenio.gaudio@phd.unipd.it	Hoffman, Louwrens C/U-8467-2018	Hoffman, Louwrens C/0000-0003-2736-1933; De Benedictis, Giulia Maria/0000-0002-8422-6829	Erasmus+ KA107 mobility funds; South African Research Chairs Initiative; South African Department of Science and Technology; NRF	This research was possible thanks to the Erasmus+ KA107 mobility funds. This research is supported by the South African Research Chairs Initiative and co-funded by the South African Department of Science and Technology (UID: 84633), as administered by the National Research Foundation (NRF) of South Africa. The financial assistance of the NRF toward this research is hereby acknowledged. The opinions expressed and conclusions are those of the authors and are not necessarily to be attributed to the NRF. The authors also wish to thank the Quagga project (https://quaggaproject.org) for allowing them to be part of their relocation activities and Prof. Antonella Dalle Zotte for a careful and critical proofreading of the manuscript.	ALLEN JL, 1994, J ZOO WILDLIFE MED, V25, P205; EBEDES H, 1971, Madoqua, V1, P67; Gaudio E, 2018, VET ANAESTH ANALG, V45, P351, DOI 10.1016/j.vaa.2018.01.004; Grimm KA, 2015, VET ANESTHESIA ANALG; Klein L, 1995, JOIT C AAZV WDA AAWV, P257; Kock MD, 2012, CHEM PHYS RESTRAINT, P235; Koenig J, 2003, CAN J VET RES, V67, P169; Lance William R., 2008, P1914; LEES P, 1976, BRIT J PHARMACOL, V56, P263, DOI 10.1111/j.1476-5381.1976.tb07637.x; Muir WW, 2009, EQUINE ANESTHESIA MO; West G, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P1, DOI 10.1002/9781118792919; Wiedner Ellen B, 2012, Compend Contin Educ Vet, V34, pE4; Yamashita K, 2000, J VET MED SCI, V62, P1025, DOI 10.1292/jvms.62.1025	13	0	0	1	1	AMER ASSOC ZOO VETERINARIANS	YULEE	581705 WHITE OAK ROAD, YULEE, FL 32097 USA	1042-7260	1937-2825		J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	JAN	2020	50	4					988	992		10.1638/2018-0157			5	Veterinary Sciences	Veterinary Sciences	KC0LX	WOS:000506880100030	31926533				2020-06-26	J	Olofsen, E; Boom, M; Sarton, E; van Velzen, M; Baily, P; Smith, KJ; Oksche, A; Dahan, A; Niesters, M				Olofsen, Erik; Boom, Merel; Sarton, Elise; van Velzen, Monique; Baily, Paul; Smith, Kevin J.; Oksche, Alexander; Dahan, Albert; Niesters, Marieke			Analgesic and Respiratory Depressant Effects of R-dihydroetorphine A Pharmacokinetic-Pharmacodynamic Analysis in Healthy Male Volunteers	ANESTHESIOLOGY			English	Article							NOCICEPTIN/ORPHANIN FQ PEPTIDE; MU-OPIOID RECEPTORS; VENTILATORY RESPONSE; SEX-DIFFERENCES; BUPRENORPHINE; MORPHINE; AGONIST; FENTANYL; CEBRANOPADOL; UTILITY	Background: There is an ongoing need for potent opioids with less adverse effects than commonly used opioids. R-dihydroetorphine is a full opioid receptor agonist with relatively high affinity at the mu-, delta- and kappa-opioid receptors and low affinity at the nociception/orphanin FQ receptor. The authors quantified its antinociceptive and respiratory effects in healthy volunteers. The authors hypothesized that given its receptor profile, R-dihydroetorphine will exhibit an apparent plateau in respiratory depression, but not in antinociception. Methods: The authors performed a population pharmacokinetic-pharmacodynamic study (Eudract registration No. 2009-010880-17). Four intravenous R-dihydroetorphine doses were studied: 12.5, 75, 125, and 150 ng/kg (infused more than 10 min) in 4 of 4, 6 of 6, 6 of 6, and 4 of 4 male subjects in pain and respiratory studies, respectively. The authors measured isohypercapnic ventilation, pain threshold, and tolerance responses to electrical noxious stimulation and arterial blood samples for pharmacokinetic analysis. Results: R-dihydroetorphine displayed a dose-dependent increase in peak plasma concentrations at the end of the infusion. Concentration-effect relationships differed significantly between endpoints. R-dihydroetorphine produced respiratory depression best described by a sigmoid E-MAX-model. A 50% reduction in ventilation in between baseline and minimum ventilation was observed at an R-dihydroetorphine concentration of 17 +/- 4 pg/ml (median +/- standard error of the estimate). The maximum reduction in ventilation observed was at 33% of baseline. In contrast, over the dose range studied, R-dihydroetorphine produced dose-dependent analgesia best described by a linear model. A 50% increase in stimulus intensity was observed at 34 +/- 11 pg/ml. Conclusions: Over the dose range studied, R-dihydroetorphine exhibited a plateau in respiratory depression, but not in analgesia. Whether these experimental advantages extrapolate to the clinical setting and whether analgesia has no plateau at higher concentrations than investigated requires further studies.	[Olofsen, Erik; Boom, Merel; Sarton, Elise; van Velzen, Monique; Dahan, Albert; Niesters, Marieke] Leiden Univ, Med Ctr, Dept Anesthesiol, H5-22,Albinusdreef 2, NL-2333 ZA Leiden, Netherlands; [Baily, Paul; Smith, Kevin J.; Oksche, Alexander] Mundipharma Res Ltd, Cambridge, England; [Oksche, Alexander] Univ Giessen, Rudolph Buchheim Inst Pharmacol, Giessen, Germany; [Baily, Paul] Sosei Heptares, Cambridge, England	Dahan, A (reprint author), Leiden Univ, Med Ctr, Dept Anesthesiol, H5-22,Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.	a.dahan@lumc.nl	Oksche, Alexander/M-6678-2019; van Velzen, Monique/H-7697-2019	Oksche, Alexander/0000-0003-4592-1770; van Velzen, Monique/0000-0002-0289-6432	Mundipharma Research Ltd. (Cambridge, United Kingdom)	This trial was sponsored by Mundipharma Research Ltd. (Cambridge, United Kingdom) and supported by departmental and institutional funds.	Aguado D, 2018, EUR J ANAESTH, V35, P505, DOI 10.1097/EJA.0000000000000803; Beckett EAH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23717-4; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3281, DOI 10.1021/ja00989a032; Boom MCA, 2013, THESIS; Boom M, 2013, ANESTHESIOLOGY, V119, P663, DOI 10.1097/ALN.0b013e31829ce4cb; Carr GV, 2008, J NEUROSCI, V28, P2299, DOI 10.1523/JNEUROSCI.5679-07.2008; CHIEN CC, 1994, J PHARMACOL EXP THER, V271, P1583; Comets E, 2010, J SFDS, V151, P106; Cremeans CM, 2012, J PHARMACOL EXP THER, V343, P72, DOI 10.1124/jpet.112.194308; DAHAN A, 1990, J PHYSIOL-LONDON, V428, P485, DOI 10.1113/jphysiol.1990.sp018223; Dahan A, 1998, ANESTHESIOLOGY, V88, P903, DOI 10.1097/00000542-199804000-00009; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; Dahan A, 2017, CLIN ANESTH, P505; Dahan A, 1990, THESIS, P68; Dahan A, 2007, PLOS MED, V4, P1195, DOI 10.1371/journal.pmed.0040239; Dahan A, 2017, ANESTHESIOLOGY, V126, P697, DOI 10.1097/ALN.0000000000001529; DOSAKAAKITA K, 1993, J PHARMACOL EXP THER, V264, P631; Gray PA, 1999, SCIENCE, V286, P1566, DOI 10.1126/science.286.5444.1566; Gunther T, 2018, BRIT J PHARMACOL, V175, P2857, DOI 10.1111/bph.13809; Henthorn TK, 2018, ANESTHESIOLOGY, V128, P867, DOI 10.1097/ALN.0000000000002177; Hutchinson MR, 2010, BRAIN BEHAV IMMUN, V24, P83, DOI 10.1016/j.bbi.2009.08.004; Jonkman K, 2018, BRIT J ANAESTH, V120, P1117, DOI 10.1016/j.bja.2018.02.021; Kest B, 2000, ANESTHESIOLOGY, V93, P539, DOI 10.1097/00000542-200008000-00034; Khanna A, 2019, CRIT CARE MED, V47, P18; Kharasch ED, 2013, ANESTHESIOLOGY, V119, P504, DOI 10.1097/ALN.0b013e31829ce70b; Lewis JW, 2004, CURR PHARM DESIGN, V10, P717, DOI 10.2174/1381612043453027; Li E, 1995, ZHONGGUO YAO LI XUE, V16, P137; Linz K, 2017, ANESTHESIOLOGY, V126, P708, DOI 10.1097/ALN.0000000000001530; Lutfy K, 2003, J NEUROSCI, V23, P10331; Manglik A, 2016, NATURE, V537, P185, DOI 10.1038/nature19112; Mao H, 1982, ACTA PHARM SIN, V3, P9; Niesters M, 2010, PAIN, V151, P61, DOI 10.1016/j.pain.2010.06.012; Ohmori S, 2002, CNS DRUG REV, V8, P391; Olesen AE, 2019, J PHARMACOL EXP THER, V371, P416, DOI 10.1124/jpet.118.253716; Olofsen E, 2005, ANESTHESIOLOGY, V103, P130, DOI 10.1097/00000542-200507000-00020; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Raehal KM, 2011, NEUROPHARMACOLOGY, V60, P58, DOI 10.1016/j.neuropharm.2010.08.003; Raehal KM, 2005, J PHARMACOL EXP THER, V314, P1195, DOI 10.1124/jpet.105.087254; Roozekrans M, 2018, ANESTHESIOLOGY, V128, P932, DOI 10.1097/ALN.0000000000002138; Sarton E, 2000, ANESTHESIOLOGY, V93, P1245, DOI 10.1097/00000542-200011000-00018; Schmid CL, 2017, CELL, V171, P1165, DOI 10.1016/j.cell.2017.10.035; Tansley JG, 1998, J APPL PHYSIOL, V84, P431; Yassen A, 2007, CLIN PHARMACOL THER, V81, P50, DOI 10.1038/sj.clpt.6100025; Yi SP, 2017, ACTA PHARMACOL SIN, V38, P977, DOI 10.1038/aps.2017.14	44	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	DEC	2019	131	6					1327	1339		10.1097/ALN.0000000000002991			13	Anesthesiology	Anesthesiology	JM8KS	WOS:000496457600018	31651529				2020-06-26	J	Pfitzer, S; Laubscher, L; Meyer, L; Warren, K; Vaughan-Higgins, R; Raath, JP; Laurence, M				Pfitzer, Silke; Laubscher, Liesel; Meyer, Leith; Warren, Kristin; Vaughan-Higgins, Rebecca; Raath, Jacobus P.; Laurence, Michael			Dose-effect study of the serotonin agonist R-8-OH-DPAT on opioid-induced respiratory depression in blesbok (Damaliscus pygargus philipsi) and impala (Aepyceros melampus)	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						8-OH-DPAT; etorphine; respiratory depression; wildlife immobilization	5-HT1A RECEPTORS; ACTIVATION; ETORPHINE; 8-OH-DPAT; 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; IMMOBILIZATION; HYPOXEMIA; XYLAZINE; REVERSAL; HYPOXIA	Objective To determine whether the R-enantiomer of 8hydroxy-2-(di-n-propylamino) tetralin (R-8-OH-DPAT) alleviates respiratory depression in antelope species immobilized with etorphine. The experiment also aimed to establish the most clinically effective dose of this serotonin 5-HT1A receptor agonist. Animals A group of six female blesbok and six female impala. Study design Each animal was subjected to four immobilization treatments in a prospective four-way crossover design-dcontrol treatment consisting of only etorphine at 0.09 mg kg(-1) and three treatments consisting of etorphine at 0.09 mg kg(-1) combined with 0.005, 0.02 and 0.07 mg kg(-1) of R-8-OH-DPAT, respectively. Induction, quality of immobilization and recovery were monitored in each treatment. Physiological variables including heart rate, respiratory rate, arterial blood pressure and blood gases were measured for 35 minutes during immobilization. A linear mixed model was used to assess the effects of treatments over the recumbency period. Results R-8-OH-DPAT did not influence induction, immobilization or recovery scores. Respiratory rate in blesbok was increased in the medium- and high-dosage R-8-OH-DPAT treatment group. However, this increased respiratory rate did not translate into improvements of arterial partial pressure of oxygen (PaO2) values in the blesbok. The medium and higher dosages of R-8-OH-DPAT in impala led to an improved PaO2 as well as to decreased opioid-induced tachycardia during the first 10 minutes of immobilization. Conclusions and clinical relevance Previous reports indicated that the racemic mixture of 8-OH-DPAT injected intravenously had a positive effect on blood-gas values in etorphine-treated hypoxemic goats. In this experiment, similar effects could be seen in impala at the higher dosage rates of R-8-OH-DPAT. However, failure to achieve an improvement of blood-gas values in blesbok was an unexpected result. It could be speculated that the dosage, species-specific differences of serotonin receptors or the use of the R-enantiomer of 8-OH-DPAT might play a role.	[Pfitzer, Silke; Warren, Kristin; Vaughan-Higgins, Rebecca; Laurence, Michael] Murdoch Univ, Sch Vet & Life Sci, Murdoch, WA, Australia; [Meyer, Leith] Univ Pretoria, Ctr Vet Wildlife Studies, Pretoria, South Africa; [Meyer, Leith] Univ Pretoria, Dept Paraclin Sci, Fac Vet Sci, Pretoria, South Africa; [Laubscher, Liesel; Raath, Jacobus P.] Wildlife Pharmaceut South Africa Pty Ltd, Mpumalanga, South Africa; [Laubscher, Liesel] Univ Stellenbosch, Dept Anim Sci, Stellenbosch, South Africa	Pfitzer, S (reprint author), Postnet Suite 228,Private Bag X 9910, ZA-1240 White River, South Africa.	silke.pfitzer@icloud.com		Warren, Kristin/0000-0002-9328-2013; Laurence, Michael/0000-0003-1215-2848; Pfitzer, Silke/0000-0001-8119-3999; Vaughan-Higgins, Rebeccca/0000-0001-7609-9818	Wildlife Pharmaceuticals PTY LTD; Murdoch University; Wildlife Group of the South African Veterinary Association	The authors would like to thank the staff of Wildlifevets.com for their assistance during the field trials. The research was funded by Wildlife Pharmaceuticals PTY LTD, Murdoch University as well as by the research fund of the Wildlife Group of the South African Veterinary Association.	Buss PE, 2001, J S AFR VET ASSOC, V72, P137; CARLI M, 1988, PSYCHOPHARMACOLOGY, V94, P84, DOI 10.1007/BF00735886; Christoffersen CL, 1998, NEUROPSYCHOPHARMACOL, V18, P399; Hadrava V, 1996, J PSYCHIATR NEUROSCI, V21, P101; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P391; Herman JK, 2001, RESP PHYSIOL, V124, P95, DOI 10.1016/S0034-5687(00)00191-2; Horiuchi J, 2011, AM J PHYSIOL-REG I, V301, pR1088, DOI 10.1152/ajpregu.00144.2011; Howard LL, 2004, J ZOO WILDLIFE MED, V35, P312, DOI 10.1638/03-090; Huber C, 2001, J ZOO WILDLIFE MED, V32, P329, DOI 10.1638/1042-7260(2001)032[0329:EOLTSI]2.0.CO;2; Kock MD, 2012, CHEM PHYS RESTRAINT, P235; Koehler H, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0381-1; LALLEY PM, 1994, NEUROSCI LETT, V172, P59, DOI 10.1016/0304-3940(94)90662-9; Lejeune F, 1997, J PHARMACOL EXP THER, V280, P1241; Li Q, 2012, NEUROPHARMACOLOGY, V62, P474, DOI 10.1016/j.neuropharm.2011.09.002; McCrimmon DR, 2003, AM J PHYSIOL-REG I, V285, pR1274, DOI 10.1152/ajpregu.00428.2003; Meyer LCR, 2006, AM J PHYSIOL-REG I, V290, pR405; Meyer LCR, 2010, J WILDLIFE DIS, V46, P514, DOI 10.7589/0090-3558-46.2.514; Ngampramuan S, 2008, AM J PHYSIOL-REG I, V294, pR132, DOI 10.1152/ajpregu.00464.2007; Pfitzer S, 2019, J VET PHARMACOL THER, V42, P251, DOI 10.1111/jvp.12741; Picazo O, 2000, PSYCHONEUROENDOCRINO, V25, P693, DOI 10.1016/S0306-4530(00)00019-6; Risling TE, 2011, ANIM PROD SCI, V51, P355, DOI 10.1071/AN10190; Sahibzada N, 2000, J PHARMACOL EXP THER, V292, P704; Sawicka J, 2015, AFR J WILDL RES, V45, P100, DOI 10.3957/056.045.0111; Vianna DML, 2009, AM J PHYSIOL-REG I, V297, pR495, DOI 10.1152/ajpregu.00232.2009; Yu H, 1996, EUR J PHARMACOL, V303, P151, DOI 10.1016/0014-2999(96)00051-9; Zmudzka E, 2018, LIFE SCI, V210, P106, DOI 10.1016/j.lfs.2018.08.050	26	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	NOV	2019	46	6					796	806		10.1016/j.vaa.2019.06.006			11	Veterinary Sciences	Veterinary Sciences	JK7FP	WOS:000495006800011	31521514				2020-06-26	J	Stemmet, GP; Meyer, LCR; Bruns, A; Buss, P; Zimmerman, D; Koeppel, K; Zeiler, GE				Stemmet, Gideon P.; Meyer, Leith C. R.; Bruns, Angela; Buss, Peter; Zimmerman, David; Koeppel, Katja; Zeiler, Gareth E.			Compared to etorphine-azaperone, the ketamine-butorphanol-medetomidine combination is also effective at immobilizing zebra (Equus zebra)	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						butorphanol; Equus zebra; immobilisation; ketamine; medetomidine; zebra	ANESTHESIA; ANTAGONISM; HYPERTENSION; PRZEWALSKII	Objective To compare immobilization efficacy of a nonpotent opioid drug combination, ketamine-butorphanol-medetomidine (KBM) to the preferred etorphine-azaperone (EA) combination in zebras. Study design Randomized crossover trial. Animals A group of ten adult zebra (six females and four male). Methods KBM and EA were administered once to the zebras in random order by dart, 3 weeks apart. Once a zebra was recumbent and instrumentedw, physiological parameters were measured and recorded at 5-minute intervals until 20 minutes. Antagonist drugs were administered at 25 minutes. KBM was antagonised using atipamezole (7.5 mg mg(-1) medetomidine dose) and naltrexone (2 mg mg(-1) butorphanol dose). EA was antagonized using naltrexone (20 mg mg(-1) etorphine dose). Induction and recovery (following antagonist administration) times were recorded. Physiological parameters, including invasive blood pressure and blood gas analysis, were compared between combinations using a general linear mixed model. Data are reported as mean +/- standard deviation or median (interquartile range). Results The doses of KBM and EA administered were 3.30 +/- 0.18, 0.40 +/- 0.02 and 0.16 +/- 0.01 mg kg(-1); and 0.02 +/- 0.001 and 0.20 +/- 0.01 mg kg(-1), respectively. KBM and EA induction times were 420 (282-564) and 240 (204-294) seconds, respectively (p = 0.03). Zebras remained recumbent throughout the study procedures. Systolic blood pressure (226 +/- 42 and 167 +/- 42 mmHg) and oxygen partial pressure (64 +/- 12 and 47 +/- 13 mmHg) were higher for KBM compared to EA (p < 0.01). Recovery time, after administering antagonists, was 92 (34-1337) and 26 (22-32) seconds for KBM and EA, respectively (p = 0.03). Conclusions and clinical relevance Compared to EA, KBM also immobilized zebras effectively. Systemic hypertension and moderate hypoxaemia are clinical concerns of KBM and severe hypoxaemia is a concern of EA. This occurrence of hypoxaemia highlights the importance of oxygen administration during immobilization.	[Stemmet, Gideon P.; Zeiler, Gareth E.] Univ Pretoria, Dept Compan Anim Studies, Fac Vet Sci, Pretoria, South Africa; [Meyer, Leith C. R.] Univ Pretoria, Dept Paraclin Sci, Fac Vet Sci, Pretoria, South Africa; [Bruns, Angela; Buss, Peter; Zimmerman, David] South African Natl Parks, Vet Wildlife Serv, Pretoria, South Africa; [Koeppel, Katja] Univ Pretoria, Dept Prod Anim Sci, Fac Vet Sci, Pretoria, South Africa; [Zeiler, Gareth E.] Valley Farm Anim Hosp, Anaesthesia & Crit Care Serv, Pretoria, South Africa; [Meyer, Leith C. R.] Univ Pretoria, Ctr Vet Wildlife Studies, Fac Vet Sci, Onderstepoort, South Africa	Zeiler, GE (reprint author), Univ Pretoria, Dept Compan Anim Clin Studies, Fac Vet Sci, Private Bag X04, ZA-0110 Onderstepoort, South Africa.	leith.meyer@up.ac.za; gareth.zeiler@up.ac.za	Meyer, Leith/AAN-4930-2020	Koeppel, Katja/0000-0001-5816-9245	South African Veterinary Foundation	The authors wish to thank Wildlife Pharmaceuticals for providing the immobilization drugs and the South African Veterinary Foundation for funding the blood gas analysis. The capture team and boma staff of South African National Parks are thanked for their support.	Adin DB, 2007, AM J VET RES, V68, P148, DOI 10.2460/ajvr.68.2.148; ALFORD BT, 1974, J AM VET MED ASSOC, V164, P702; ALLEN JL, 1990, J ZOO WILDLIFE MED, V21, P292; ALLEN JL, 1994, J ZOO WILDLIFE MED, V25, P205; Brown S, 2007, J VET INTERN MED, V21, P542, DOI 10.1892/0891-6640(2007)21[542:GFTIEA]2.0.CO;2; Buss P, 2018, VET ANAESTH ANALG, V45, P57, DOI 10.1016/j.vaa.2017.03.008; Gerlach CA, 2017, J ZOO WILDLIFE MED, V48, P62, DOI 10.1638/2016-0010.1; Haskins S.C., 2015, VET ANAESTH ANALG, P86; Kastner SBR, 2006, VET ANAESTH ANALG, V33, P79, DOI 10.1111/j.1467-2995.2005.00243.x; Kock MD, 2012, CHEM PHYS RESTRAINT, P198; LEBLANC PH, 1987, J ZOO WILDLIFE MED, V18, P141, DOI 10.2307/20094825; Matthews NS, 1995, J ZOO WILDLIFE MED, V26, P231; Meyer LCR, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0337-5; PLOTKA ED, 1987, J WILDLIFE DIS, V23, P471, DOI 10.7589/0090-3558-23.3.471; SCHEININ H, 1989, PROG NEURO-PSYCHOPH, V13, P635, DOI 10.1016/0278-5846(89)90051-1; Senthilkumar K., 2005, Zoos Print Journal, V20, P1914; VIRTANEN R, 1989, ACTA VET SCAND, P29; Walzer Chris, 2006, Mongolian Journal of Biological Sciences, V4, P19; Woolnough AP, 2012, J WILDLIFE DIS, V48, P435, DOI 10.7589/0090-3558-48.2.435; Young E., 1972, Koedoe, V15, P95; Zeiler GE, 2017, J S AFR VET ASSOC, V80, P1	21	0	0	2	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JUL	2019	46	4					466	475		10.1016/j.vaa.2019.01.008			10	Veterinary Sciences	Veterinary Sciences	IF1ZF	WOS:000472875800008	31176572				2020-06-26	J	Picone, N; Op den Camp, HJM				Picone, Nunzia; Op den Camp, Huub J. M.			Role of rare earth elements in methanol oxidation	CURRENT OPINION IN CHEMICAL BIOLOGY			English	Review							METHYLOBACTERIUM-EXTORQUENS AM1; DEHYDROGENASE; XOXF; EXPRESSION; CYTOCHROME; SITE	For decades rare earth elements (or lanthanides) were considered not to be involved in biological processes, until their discovery in the active site of the XoxF-type methanol dehydrogenase of the methanotrophic bacterium Methylacidiphilum fumariolicum SolV. Follow-up studies revealed the presence of lanthanides in other pyrroloquinoline quinone-containing enzymes involved in alcohol metabolism. This review discusses the biochemistry of the lanthanide-dependent enzymes and the ability of these metals of influencing the gene expression and the type of methanol dehydrogenase used by microorganisms. Furthermore, it highlights novel insights on the uptake mechanism of rare earth elements into bacterial cells.	[Picone, Nunzia; Op den Camp, Huub J. M.] Radboud Univ Nijmegen, IWWR, Dept Microbiol, Heyendaalseweg 135, NL-6525 AJ Nijmegen, Netherlands	Op den Camp, HJM (reprint author), Radboud Univ Nijmegen, IWWR, Dept Microbiol, Heyendaalseweg 135, NL-6525 AJ Nijmegen, Netherlands.	h.opdencamp@science.ru.nl	Op den Camp, Huub/F-5114-2011	Op den Camp, Huub/0000-0003-1990-9030	European Research Council (ERC)European Research Council (ERC) [VOLCANO 669371]	This work was supported by the European Research Council (ERC Advanced Grant project VOLCANO 669371).	Afolabi PR, 2001, BIOCHEMISTRY-US, V40, P9799, DOI 10.1021/bi002932l; Anthony C, 2000, Subcell Biochem, V35, P73; Bogart JA, 2015, CHEM-EUR J, V21, P1743, DOI 10.1002/chem.201405159; Bonificio WD, 2016, ENVIRON SCI TECH LET, V3, P180, DOI 10.1021/acs.estlett.6b00064; Castor S.B., 2006, IND MIN ROCK, P769; Chu F, 2016, PEERJ, V4, DOI 10.7717/peerj.2435; Chu F, 2016, J BACTERIOL, V198, P1317, DOI 10.1128/JB.00959-15; Dalton H, 1982, THE BIOCHEMISTRY OF; Bustillos-Cristales MD, 2017, MICROBES ENVIRON, V32, P244, DOI 10.1264/jsme2.ME17070; Farhan Ul Haque M, 2016, APPL ENVIRON MICROB, V82, P1549, DOI 10.1128/AEM.03615-15; Farhan Ul Haque M, 2015, APPL ENVIRON MICROB, V81, P7546, DOI 10.1128/AEM.02542-15; Fitriyanto NA, 2011, J BIOSCI BIOENG, V111, P613, DOI 10.1016/j.jbiosc.2011.01.015; Good NM, 2016, J BACTERIOL, V198, P3109, DOI 10.1128/JB.00478-16; Good NM, 2018, BIORXIV, DOI [10.1101/329011., DOI 10.1101/329011]; Gu WY, 2017, APPL MICROBIOL BIOT, V101, P8499, DOI 10.1007/s00253-017-8572-2; Gu WY, 2016, FEMS MICROBIOL LETT, V363, DOI 10.1093/femsle/fnw129; Hogendoorn C, 2018, APPL ENVIRON MICROB, V84, DOI 10.1128/AEM.02887-17; Howat AM, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00766; Huang J, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01366; Jahn B, 2018, CHEMBIOCHEM, V19, P1147, DOI 10.1002/cbic.201800130; Lumpe H, 2018, DALTON T, V47, P10463, DOI 10.1039/c8dt01238e; Lv HX, 2018, ENVIRON MICROBIOL, V20, P1204, DOI 10.1111/1462-2920.14062; Masuda S, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00462-17; Migaszewski ZM, 2015, CRIT REV ENV SCI TEC, V45, P429, DOI 10.1080/10643389.2013.866622; Nakagawa T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050480; Pol A, 2014, ENVIRON MICROBIOL, V16, P255, DOI 10.1111/1462-2920.12249; Prejano M, 2017, CHEM-EUR J, V23, P8652, DOI 10.1002/chem.201700381; Semrau JD, 2018, APPL ENVIRON MICROB, V84, DOI 10.1128/AEM.02289-17; Shiller AM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11060-z; Skovran E, 2015, SCIENCE, V348, P862, DOI 10.1126/science.aaa9091; Skovran E, 2011, J BACTERIOL, V193, P6032, DOI 10.1128/JB.05367-11; Takahashi Y, 2005, CHEM GEOL, V219, P53, DOI 10.1016/j.chemgeo.2005.02.009; Taubert M, 2015, ENVIRON MICROBIOL, V17, P3937, DOI 10.1111/1462-2920.12896; Vekeman B, 2016, MICROB ECOL, V72, P503, DOI 10.1007/s00248-016-0808-7; Vu HN, 2016, J BACTERIOL, V198, P1250, DOI 10.1128/JB.00937-15; Wehrmann M, 2017, MBIO, V8, DOI 10.1128/mBio.00570-17; Williams P, 2006, J MOL BIOL, V357, P151, DOI 10.1016/j.jmb.2005.12.055; YU Z, 2017, [No title captured], V8; Zheng Y, 2018, MBIO, V9, DOI 10.1128/mBio.02430-17; 2011, J BIOSCI BIOENG, V111, P547; 2014, APPL MICROBIOL BIOTE, V98, P6163; 2017, P NATL ACAD SCI US, V114, P358; 2015, APPL ENV MICROBIOL, V81, P1442	43	13	13	5	19	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1367-5931	1879-0402		CURR OPIN CHEM BIOL	Curr. Opin. Chem. Biol.	APR	2019	49						39	44		10.1016/j.cbpa.2018.09.019			6	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	HW1OX	WOS:000466453300008	30308436	Other Gold, Green Published	Y	N	2020-06-26	J	Bryant, B; Pittard, S; Jordan, NR; McMahon, CR				Bryant, B.; Pittard, S.; Jordan, N. R.; McMahon, C. R.			Chemical capture of wild swamp buffalo (Bubalus bubalis) in tropical northern Australia using thiafentanil, etorphine and azaperone combinations	AUSTRALIAN VETERINARY JOURNAL			English	Article						acidosis; anaesthesia; capnography; capture myopathy; oximetry; swamp buffalo	MANAGEMENT	Background Studying wild animals in situ is fundamental to collecting baseline information, but generally they need to be immobilised for examination, sampling, marking and/or equipping with tracking apparatus. Capturing wild animals is inherently risky and there is a need for immobilisation methods that are safe for both the animals and researchers. Methods A total of 16 free-ranging swamp buffalo (Bubalus bubalis) were chemically captured by dart for the application of satellite tracking collars in tropical northern Australia; 7 animals were anesthetised with a thiafentanil-etorphine-azaperone (TEA) combination and 9 animals with a thiafentanil-azaperone (TA) combination. Anaesthesia was reversed with intravenous naltrexone. Mean dosages of etorphine and thiafentanil for animals in the TEA group were 0.01 mg/kg of each drug and mean dosage of thiafentanil for animals in the TA group was 0.02 mg/kg. Total dose per animal of azaperone and naltrexone was 80 mg and 150 mg, respectively. Anaesthetic monitoring was by physical observation of physiological variables, pulse oximetry and capnography. Blood laboratory parameters including creatine kinase (CK), aspartate transaminase (AST), serum bicarbonate and anion gap were measured. Results All subject animals recovered well from anaesthesia despite the occurrence of subclinical acidosis in some patients. There was no significant difference between the treatment groups. Conversely, chase time had an adverse effect on body temperature, irrespective of the anaesthetic combination used. Conclusions Thiafentanil and azaperone, with or without etorphine, delivered rapid safe, effective, reversible field anaesthesia in healthy swamp buffalo.	[Bryant, B.; Jordan, N. R.] Taronga Western Plains Zoo, Dubbo, NSW, Australia; [Pittard, S.] Charles Darwin Univ, Res Inst Environm & Livelihoods, Darwin, NT, Australia; [Jordan, N. R.] Univ New South Wales, Australia Ctr Ecosyst Sci, Sch Biol Earth & Environm Sci, Sydney, NSW, Australia; [McMahon, C. R.] Sydney Inst Marine Sci, Mosman, NSW, Australia	Bryant, B (reprint author), Taronga Western Plains Zoo, Dubbo, NSW, Australia.	bbryant@zoo.nsw.gov.au	McMahon, Clive R/D-5713-2013	McMahon, Clive R/0000-0001-5241-8917; Jordan, Neil/0000-0002-0712-8301	Australian Research Council Linkage Project SchemeAustralian Research Council; Director of National Parks (Australia); Research Institute for the Environment and Livelihoods; Charles Darwin University	The Australian Research Council Linkage Project Scheme, Director of National Parks (Australia), the Research Institute for the Environment and Livelihoods and Charles Darwin University funded and supported this research. The findings and views expressed are those of the authors and do not necessarily represent the views of Parks Australia, the Director of National Parks or the Australian Government.	Arnemo Jon M., 2007, P103, DOI 10.1002/9780470376478.ch8; Australian Government . Department of Sustainability Environment Water Population and Communities., 2011, FER WAT BUFF BUB BUB; BAYLISS P, 1989, AUST WILDLIFE RES, V16, P651; Burroughs Richard, 2012, P53; CANFIELD PJ, 1984, AUST VET J, V61, P89, DOI 10.1111/j.1751-0813.1984.tb15525.x; CLERBAUX T, 1993, COMP BIOCHEM PHYS A, V106, P687, DOI 10.1016/0300-9629(93)90382-E; Curro Thomas G., 2007, P635, DOI 10.1002/9780470376478.ch57; FINLAYSON CM, 1996, [No title captured], P1; George JW, 1994, VET LAB MED CLIN PAT, P94; Haigh JC, 1978, CHEM IMMOBILISATION, P46; Hampton JO, 2016, WILDLIFE RES, V43, P429, DOI 10.1071/WR15230; Harthoorn A.M., 1973, P14; Harthoorn A.M., 1973, P51; HARTHOORN AM, 1965, RES VET SCI, V6, P290; Harthoorn AM, 1965, WILDLIFE MONOGR, V14, P1; Haskins S.C., 1996, LUMB JONES VET ANEST, P409; KNIGHTON AD, 1991, GEOLOGY, V19, P831, DOI 10.1130/0091-7613(1991)019<0831:TCEASI>2.3.CO;2; Lance William R., 2012, P589; Mcmahon CR, 2008, AUST VET J, V86, P235, DOI 10.1111/j.1751-0813.2008.00303.x; Nowak RM, 1991, WALKERS MAMMALS WORL, VII, P1334; Pienaar U de V, 1969, Acta Zool Pathol Antverp, V48, P163; Pienaar UV, 1973, CAPTURE CARE WILD AN, P35; Radostits OM, 2006, VET MED TXB DIS CATT, P626; Radostits OM, 2006, VET MED TXB DIS CATT, P3; Radunz B, 2006, VET MICROBIOL, V112, P283, DOI 10.1016/j.vetmic.2005.11.017; Robinson CJ, 2005, CONSERV BIOL, V19, P1385, DOI 10.1111/j.1523-1739.2005.00196.x; Schumacher Juergen, 2008, P455, DOI 10.1016/B978-141604047-7.50059-2; Soares FS, 2011, ASIAN AUSTRAL J ANIM, V24, P1587, DOI 10.5713/ajas.2011.11070	28	3	3	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0005-0423	1751-0813		AUST VET J	Aust. Vet. J.	JAN	2019	97	1-2					33	38		10.1111/avj.12782			6	Veterinary Sciences	Veterinary Sciences	HJ3IT	WOS:000457064400007	30693492	Bronze			2020-06-26	J	Boesch, JM; Gleed, RD; Buss, P; Hofmeyr, M; Tordiffe, A; Zeiler, G; Meyer, L				Boesch, Jordyn M.; Gleed, R. D.; Buss, Peter; Hofmeyr, Markus; Tordiffe, Adrian; Zeiler, Gareth; Meyer, Leith			EFFECTS OF A SUPPLEMENTAL ETORPHINE DOSE ON PULMONARY ARTERY PRESSURE AND CARDIAC OUTPUT IN IMMOBILIZED, BOMA-HABITUATED WHITE RHINOCEROS (CERATOTHERIUM SIMUM): A PRELIMINARY STUDY	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						Cardiac output; Ceratotherium simum; etorphine; pulmonary artery catheter; pulmonary artery pressure; white rhinoceros	CARDIOVASCULAR PARAMETERS	The effects of etorphine on the pulmonary vascular system of white rhinoceros (Ceratotherium simum) have not been described and could play a role in the severe hypoxemia that develops after immobilization with etorphine-based drug combinations. Characterization of these effects requires measurement of pulmonary vascular pressures and cardiac output (CO). To refine a technique for pulmonary arterial catheterization, live boma-habituated white rhinoceros (three females and two males weighing 1,012-1,572 kg) were immobilized by remote injection with etorphine plus azaperone followed by butorphanol. This afforded the opportunity to perform a pilot study and acquire preliminary measurements of pulmonary arterial pressure (PAP) and CO before and after supplemental etorphine given intravenously. Ultrasonographic guidance was used to insert a sheath introducer into a linguofacial branch of a jugular vein. A 160-cm-long pulmonary artery catheter with a balloon and thermistor was then passed through the introducer and positioned with its tip in the pulmonary artery. It was not long enough to permit wedging for measurement of pulmonary artery occlusion pressure. Mean PAP was 35 mm Hg (minimum, maximum 32, 47 mm Hg) and increased (P = 0.031) by 83% (28, 106%) after supplemental etorphine. Thermodilution CO was 120 L/min (92, 145 L/min) and increased 27% (3, 43%) (P= 0.031). Heart rate was 100 (88, 112) beats/min and increased 20% (4, 45%) (P = 0.031), whereas arterial partial pressure of oxygen was 35 mm Hg (30, 94 mm Hg) and decreased 47% (20, 72%) (P= 0.031). The cardiovascular observations could result from etorphine-induced generalized sympathetic outflow, as has been reported in horses. Further studies of etorphine in isolation are needed to test this suggestion and to discern how the changes in pulmonary vascular pressures and blood flow might relate to hypoxemia in etorphine-immobilized white rhinoceros.	[Boesch, Jordyn M.; Gleed, R. D.] Cornell Univ, Dept Clin Sci, Coll Vet Med, 930 Campus Rd, Ithaca, NY 14853 USA; [Buss, Peter; Hofmeyr, Markus] Kruger Natl Pk, Vet Wildlife Serv, South African Natl Pk, Private Bag X402, ZA-1350 Skukuza, South Africa; [Boesch, Jordyn M.; Hofmeyr, Markus; Tordiffe, Adrian; Meyer, Leith] Univ Pretoria, Fac Vet Sci, Dept Paraclin Sci, Private Bag X04, ZA-0110 Onderstepoort, South Africa; [Zeiler, Gareth] Univ Pretoria, Fac Vet Sci, Dept Compan Anim Clin Studies, Private Bag X04, ZA-0110 Onderstepoort, South Africa; [Hofmeyr, Markus] Great Plains Conservat, POB 22127, Boseja, Maun, Namibia	Boesch, JM (reprint author), Cornell Univ, Dept Clin Sci, Coll Vet Med, 930 Campus Rd, Ithaca, NY 14853 USA.; Boesch, JM (reprint author), Univ Pretoria, Fac Vet Sci, Dept Paraclin Sci, Private Bag X04, ZA-0110 Onderstepoort, South Africa.	jmb264@cornell.edu	Meyer, Leith/AAN-4930-2020; Zeiler, Gareth/AAJ-7812-2020	Zeiler, Gareth/0000-0001-7653-7726	South African Veterinary Association Wildife Group; South African National Research FoundationNational Research Foundation - South Africa; Department of Paraclinical Sciences, University of Pretoria; John T. and Jane A. Wiederhold Foundation, Cornell University	The authors acknowledge the South African Veterinary Association Wildife Group, the South African National Research Foundation, the Department of Paraclinical Sciences, University of Pretoria, and the John T. and Jane A. Wiederhold Foundation, Cornell University, for funding the study. They also thank South African National Parks and the Veterinary Wildlife Services Capture Team for their expertise and operational assistance during the immobilizations.	BOGAN JA, 1978, VET REC, V103, P471, DOI 10.1136/vr.103.21.471; Buss P, 2018, VET ANAESTH ANALG, V45, P57, DOI 10.1016/j.vaa.2017.03.008; Buss P, 2016, J ZOO WILDLIFE MED, V47, P834; Buss P, 2015, J ZOO WILDLIFE MED, V46, P224, DOI 10.1638/2014-0089R.1; Citino SB, 2007, J ZOO WILDLIFE MED, V38, P375, DOI 10.1638/2006-0007R1.1; DANIEL M, 1972, VET REC, V90, P336, DOI 10.1136/vr.90.12.336; de Lange SS, 2017, J S AFR VET ASSOC, V88, DOI 10.4102/jsava.v88i0.1466; EBERLY VE, 1964, AM J VET RES, V25, P1712; EBERLY VE, 1966, J APPL PHYSIOL, V21, P883; Haw A, 2015, J S AFR VET ASSOC, V86, DOI [10.4102/jsava.v86i1.1276, 10.4102/JSAVA.V86I1.1276]; Haw A, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0253-0; Lees P., 1975, Equine Veterinary Journal, V7, P184, DOI 10.1111/j.2042-3306.1975.tb03265.x; Meyer LCR, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0337-5; Miller M, 2016, J WILDLIFE DIS, V52, pS78, DOI 10.7589/52.2S.S85; SCHLARMA.B, 1973, AM J VET RES, V34, P411; Schmidt-Nielsen K., 1991, SCALING WHY IS ANIMA; Sinha AK, 1996, J APPL PHYSIOL, V80, P1792; Wilkins PA, 2005, AM J VET RES, V66, P878, DOI 10.2460/ajvr.2005.66.878; Wilkins PA, 2001, J APPL PHYSIOL, V91, P2442	19	0	0	0	4	AMER ASSOC ZOO VETERINARIANS	YULEE	581705 WHITE OAK ROAD, YULEE, FL 32097 USA	1042-7260	1937-2825		J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	DEC	2018	49	4					849	855		10.1638/2017-0120.1			7	Veterinary Sciences	Veterinary Sciences	HG2CX	WOS:000454771200003	30592907				2020-06-26	J	Grondahl, C; Andersen-Ranberg, EU; Mosbacher, JB; Stelvig, M; Hansen, LH; Schmidt, NM				Grondahl, Carsten; Andersen-Ranberg, Emilie U.; Mosbacher, Jesper B.; Stelvig, Mikkel; Hansen, Lars H.; Schmidt, Niels M.			IMMOBILIZING MUSKOX (OVIBOS MOSCHATUS) UNDER HIGH ARCTIC CONDITIONS	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						Anesthesia; etorphine; ketamine; medetomidine; muskox (Ovibos moschatus); xylazine	WHITE-TAILED DEER; MEDETOMIDINE-KETAMINE ANESTHESIA; CARFENTANIL-XYLAZINE; ETORPHINE; HYPOXEMIA; ATIPAMEZOLE; COMBINATION; PATTERNS; EFFICACY; NITROGEN	Immobilizing and handling large, free-ranging animals without proper facilities in harsh environmental conditions poses significant challenges. During two field expeditions, a total of 29 female muskoxen (Ovibos moschatus) were immobilized in Northeast Greenland (74 degrees N, 20 degrees E). Fixed doses of immobilizing drugs were used regardless of animal size: 2 mg etorphine, 30 mg xylazine, 0.3 mg medetomidine, and 40 mg ketamine. Physiologic and behavioral monitoring was performed during the second expedition on 15 female muskoxen. The observed heart rates were 35-58 beats/min and respiratory rates were 25-30 breaths/min. Mean arterial pressures measured using oscillometry ranged between 117-142 mmHg. Pulse oximeter readings ranged from 91-98% with oxygen supplementation, nasal end-tidal carbon dioxide values were 24-42 mmHg, and rectal temperature ranged from 38.9-39.6 degrees C. Induction time was 6-8 min, recovery time 2-6 min after reversal, and duration of anesthesia was 50-100 min. This anesthetic regime thus provided reliable immobilization with minimal pathophysiologic alterations.	[Grondahl, Carsten; Stelvig, Mikkel] Ctr Zoo & Wild Anim Hlth, Copenhagen Zoo, Roskildevej 38, DK-2000 Frederiksberg, Denmark; [Andersen-Ranberg, Emilie U.; Mosbacher, Jesper B.; Hansen, Lars H.; Schmidt, Niels M.] Aarhus Univ, Dept Biosci, Arctic Res Ctr, Frederiksborgvej 399, DK-4000 Roskilde, Denmark; [Andersen-Ranberg, Emilie U.] Tierarztfiche Hsch Hannover, Inst Terrestr & Aquat Wildtierforsch, Werftstr 6, D-25761 Busum, Germany	Grondahl, C (reprint author), Ctr Zoo & Wild Anim Hlth, Copenhagen Zoo, Roskildevej 38, DK-2000 Frederiksberg, Denmark.	cg@zoo.dk	Schmidt, Niels Martin/G-3843-2011	Schmidt, Niels Martin/0000-0002-4166-6218; Hansen, Lars Holst/0000-0003-2956-7388; Stelvig, Mikkel/0000-0002-2272-7492	15 Juni Fonden; Danish Environmental Protection Agency	Aarhus University is thanked for logistics at Zackenberg and Claus Stjernegaard, University of Copenhagen, is thanked for conducting the cortisol analyses. This project is indebted to 15 Juni Fonden and the Danish Environmental Protection Agency for their financial support.	Arnemo JM, 2011, J WILDLIFE DIS, V47, P755, DOI 10.7589/0090-3558-47.3.755; Blix AS, 2011, ACTA VET SCAND, V53, DOI 10.1186/1751-0147-53-42; BLIX AS, 1984, ACTA PHYSIOL SCAND, V122, P443, DOI 10.1111/j.1748-1716.1984.tb07532.x; Chittick E, 2001, J ZOO WILDLIFE MED, V32, P168, DOI 10.1638/1042-7260(2001)032[0168:CAOMKA]2.0.CO;2; CLAUSEN B, 1984, Journal of Wildlife Diseases, V20, P141; Evans AL, 2013, J WILDLIFE DIS, V49, P1037, DOI 10.7589/2013-03-049; Fahlman A, 2012, J ZOO WILDLIFE MED, V43, P67, DOI 10.1638/2011-0064.1; Falk JM, 2015, ENVIRON RES LETT, V10, DOI 10.1088/1748-9326/10/4/045001; FONG DW, 1982, J WILDLIFE MANAGE, V46, P560, DOI 10.2307/3808683; Forchhammer MC, 2005, ECOLOGY, V86, P2644, DOI 10.1890/04-1281; Grobler D, 2001, J S AFR VET ASSOC, V72, P81; Grondahl C, 2010, P INT C DIS ZOO WILD, P196; Hansen BU, 2008, ADV ECOL RES, V40, P111, DOI 10.1016/S0065-2504(07)00006-2; Harms NJ, 2012, ARCTIC, V65, P401; Howard LL, 2004, J ZOO WILDLIFE MED, V35, P312, DOI 10.1638/03-090; JINGFORS K, 1989, CAN J ZOOL, V67, P1120, DOI 10.1139/z89-160; Kilgallon CP, 2010, J ZOO WILDLIFE MED, V41, P567, DOI 10.1638/2010-0021.1; KRAUSMAN PR, 1986, SOUTHWEST NAT, V31, P411, DOI 10.2307/3671855; KREEGER TJ, 1987, J WILDLIFE DIS, V23, P619, DOI 10.7589/0090-3558-23.4.619; Kristensen DK, 2011, CAN J ZOOL, V89, P892, DOI [10.1139/Z11-073, 10.1139/z11-073]; Lapid R, 2015, J ZOO WILDLIFE MED, V46, P291, DOI 10.1638/2014-0202R1.1; Lian M, 2017, J WILDLIFE DIS, V53, P356, DOI 10.7589/2016-04-085; Lian M, 2016, J WILDLIFE DIS, V52, P327, DOI 10.7589/2015-04-101; Lian M, 2014, ACTA VET SCAND, V56, DOI 10.1186/s13028-014-0051-5; Lumb AB, 2010, NUNNS APPL RESP PHYS, P159; Mosbacher JB, 2016, ARCT ANTARCT ALP RES, V48, P229, DOI 10.1657/AAAR0015-034; Mosbacher JB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152874; NANJI AA, 1984, CAN ANAESTH SOC J, V31, P568, DOI 10.1007/BF03009545; Paterson JM, 2009, J ZOO WILDLIFE MED, V40, P39, DOI 10.1638/2007-0107.1; Perrin KL, 2015, J ZOO WILDLIFE MED, V46, P870, DOI 10.1638/2015-0114.1; Pon K, 2016, J ZOO WILDLIFE MED, V47, P29, DOI 10.1638/2015-0121.1; Risling TE, 2011, ANIM PROD SCI, V51, P355, DOI 10.1071/AN10190; Schmidt NM, 2016, WILDLIFE BIOL, V22, P253, DOI 10.2981/wlb.00219; Schmidt NM, 2015, POLAR BIOL, V38, P1667, DOI 10.1007/s00300-015-1733-9; Sente C, 2014, J WILDLIFE DIS, V50, P359, DOI 10.7589/2012-10-267; Shury T, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P109; Shury TK, 2010, CAN VET J, V51, P501; Solomonov N G, 2011, Dokl Biol Sci, V438, P158, DOI 10.1134/S0012496611030045; Srisan Panida, 2011, J Med Assoc Thai, V94 Suppl 3, pS9; Zeiler GE, 2015, J ZOO WILDLIFE MED, V46, P755, DOI 10.1638/2015-0052.1	40	2	2	1	7	AMER ASSOC ZOO VETERINARIANS	YULEE	581705 WHITE OAK ROAD, YULEE, FL 32097 USA	1042-7260	1937-2825		J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	DEC	2018	49	4					856	862		10.1638/2016-0290.1			7	Veterinary Sciences	Veterinary Sciences	HG2CX	WOS:000454771200004	30592918				2020-06-26	J	Mora, IM; Langan, JN; Bailey, RS; Aitken-Palmer, C; Adkesson, MJ; Tang, KN; Chinnadurai, CK				Mora, Ignacio Monge; Langan, Jennifer N.; Bailey, Ryan S.; Aitken-Palmer, Copper; Adkesson, Michael J.; Tang, Karisa N.; Chinnadurai, Christoph K.			REPEATED ANESTHESIA IN A BLACK RHINOCEROS (DICEROS BICORNIS) TO MANAGE UPPER RESPIRATORY OBSTRUCTION	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						Chemical restraint; Diceros bicornis; etorphine; ketamine; medetomidine; midazolam; rhinoceros	CHEMICAL IMMOBILIZATION; CERATOTHERIUM-SIMUM; ETORPHINE; INSUFFLATION; COMBINATIONS; PARAMETERS; RECUMBENCY	This report describes weekly repeated anesthesia in a 7-yr-old, 1,030 kg, female Eastern black rhinoceros (Diceros bicornis michaeli), that was immobilized six times using a combination of 2 mg etorphine (0.002 mg/kg), 5 mg medetomidine (0.005 mg/kg), 25 mg midazolam (0.024 mg/kg), and 300 mg ketamine (0.29 mg/kg) delivered intramuscularly (IM) via remote dart to facilitate long-term medical care of a bilateral, obstructive Actinomyces sp. rhinitis. The drug combination described in this study resulted in reliable, rapid recumbency of the animal within 2-8 min after initial administration via dart and produced deep anesthesia for 34-78 min without supplemental anesthetic administration. Antagonist drugs (100 mg naltrexone [0.1 mg/kg] and 25 mg atipamezole [0.024 mg/kg] IM) produced reliable and uneventful recoveries in all the procedures. During each anesthetic procedure, the animal was intubated and provided intermittent positive pressure ventilation with a megavertebrate demand ventilator. Tachycardia and hypoxia noted after induction resolved after positive pressure ventilation with oxygen. This report provides useful information on a novel anesthetic protocol used repeatedly for intensive medical management in a black rhinoceros.	[Mora, Ignacio Monge] Univ Veritas, Escuela Med & Cirugia Vet San Francisco de Asis, San Rafael De Coronado, Costa Rica; [Langan, Jennifer N.; Bailey, Ryan S.; Aitken-Palmer, Copper; Adkesson, Michael J.; Tang, Karisa N.; Chinnadurai, Christoph K.] Brookfield Zoo, Chicago Zool Soc, 3300 Golf Rd, Brookfield, IL 60513 USA; [Langan, Jennifer N.] Univ Illinois, Coll Vet Med, 1008 W Hazelwood Dr, Urbana, IL 61802 USA; [Tang, Karisa N.] Illinois Zool & Aquat Anim Residency Program, 1008 W Hazelwood Dr, Urbana, IL 61802 USA	Langan, JN (reprint author), Brookfield Zoo, Chicago Zool Soc, 3300 Golf Rd, Brookfield, IL 60513 USA.; Langan, JN (reprint author), Univ Illinois, Coll Vet Med, 1008 W Hazelwood Dr, Urbana, IL 61802 USA.	jennifer.langan@czs.org					Atkinson MW, 2002, J ZOO WILDLIFE MED, V33, P157, DOI 10.1638/1042-7260(2002)033[0157:RCIOAC]2.0.CO;2; Bush M, 2004, J S AFR VET ASSOC, V75, P79; Bush M, 2005, JOINT P AM ASS ZOO V, P259; Christman J., 2011, INT STUDBOOK WHITE R, V12; Citino SB, 2008, JOINT P AM ASS ZOO V, P108; Citino SB, 2007, J ZOO WILDLIFE MED, V38, P375, DOI 10.1638/2006-0007R1.1; Fahlman A, 2004, JOINT P AM ASS ZOO V, P519; Fahlman A, 2016, J S AFR VET ASSOC, V87, DOI 10.4102/jsava.v87i1.1328; HEARD DJ, 1992, J ZOO WILDLIFE MED, V23, P197; Kock MD, 1995, J ZOO WILDLIFE MED, V26, P207; Langhout MV, 2016, J ZOO WILDLIFE MED, V47, P827; Morkel PV, 2010, J WILDLIFE DIS, V46, P236, DOI 10.7589/0090-3558-46.1.236; Portas T, 2004, AUST VET J, V82, P542, DOI 10.1111/j.1751-0813.2004.tb11196.x; Raath J.P., 1999, P556; Radcliffe RW, 2007, ZOO ANIMAL WILDLIFE, P741; Reuter H, 1998, P AM ASS ZOO VET, P410; Walzer C, 2010, J ZOO WILDLIFE MED, V41, P115, DOI 10.1638/2009-0150.1	17	0	0	0	2	AMER ASSOC ZOO VETERINARIANS	YULEE	581705 WHITE OAK ROAD, YULEE, FL 32097 USA	1042-7260	1937-2825		J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	DEC	2018	49	4					1041	1046		10.1638/2018-0095.1			6	Veterinary Sciences	Veterinary Sciences	HG2CX	WOS:000454771200031	30592926				2020-06-26	J	Izwan, A; Snelling, EP; Seymour, RS; Meyer, LCR; Fuller, A; Haw, A; Mitchell, D; Farrell, AP; Costello, MA; Maloney, SK				Izwan, Adian; Snelling, Edward P.; Seymour, Roger S.; Meyer, Leith C. R.; Fuller, Andrea; Haw, Anna; Mitchell, Duncan; Farrell, Anthony P.; Costello, Mary-Ann; Maloney, Shane K.			Ameliorating the adverse cardiorespiratory effects of chemical immobilization by inducing general anaesthesia in sheep and goats: implications for physiological studies of large wild mammals	JOURNAL OF COMPARATIVE PHYSIOLOGY B-BIOCHEMICAL SYSTEMS AND ENVIRONMENTAL PHYSIOLOGY			English	Article						Cardiac output; Etorphine; Mammal; Opioid; Propofol; Ventilation	INDUCED RESPIRATORY DEPRESSION; DEER ODOCOILEUS-VIRGINIANUS; MUSCLE VASCULAR-RESISTANCE; IMPALA AEPYCEROS-MELAMPUS; LOW-DOSE PROPOFOL; BLOOD-PRESSURE; CERATOTHERIUM-SIMUM; BODY-TEMPERATURE; ETORPHINE; AZAPERONE	Chemical immobilization is necessary for the physiological study of large wild animals. However, the immobilizing drugs can adversely affect the cardiovascular and respiratory systems, yielding data that do not accurately represent the normal, resting state. We hypothesize that these adverse effects can be ameliorated by reversing the immobilizing agent while holding the animal under general anaesthesia. We used habituated sheep Ovis aries (N=5, 46.9 +/- 5.3kg body mass, mean +/- SEM) and goats Capra hircus (N=4, 27.7 +/- 2.8kg) as ungulate models for large wild animals, and measured their cardiorespiratory function under three conditions: (1) mild sedation (midazolam), as a proxy for the normal resting state, (2) immobilization (etorphine and azaperone), and (3) general anaesthesia (propofol) followed by etorphine antagonism (naltrexone). Cardiac output for both sheep and goats remained unchanged across the three conditions (overall means of 6.2 +/- 0.9 and 3.3 +/- 0.3L min(-1), respectively). For both sheep and goats, systemic and pulmonary mean arterial pressures were significantly altered from initial midazolam levels when administered etorphine+azaperone, but those arterial pressures were restored upon transition to propofol anaesthesia and antagonism of the etorphine. Under etorphine+azaperone, minute ventilation decreased in the sheep, though this decrease was corrected under propofol, while the minute ventilation in the goats remained unchanged throughout. Under etorphine+azaperone, both sheep and goats displayed arterial blood hypoxia and hypercapnia (relative to midazolam levels), which failed to completely recover under propofol, indicating that more time might be needed for the blood gases to be adequately restored. Nonetheless, many of the confounding cardiorespiratory effects of etorphine were ameliorated when it was antagonized with naltrexone while the animal was held under propofol, indicating that this procedure can largely restore the cardiovascular and respiratory systems closer to a normal, resting state.	[Izwan, Adian; Mitchell, Duncan; Maloney, Shane K.] Univ Western Australia, Sch Human Sci, 35 Stirling Hwy, Crawley, WA, Australia; [Snelling, Edward P.; Meyer, Leith C. R.; Fuller, Andrea; Haw, Anna; Mitchell, Duncan; Maloney, Shane K.] Univ Witwatersrand, Brain Funct Res Grp, Sch Physiol, Johannesburg, South Africa; [Seymour, Roger S.] Univ Adelaide, Sch Biol Sci, Adelaide, SA, Australia; [Meyer, Leith C. R.; Fuller, Andrea] Univ Pretoria, Dept Paraclin Sci, Pretoria, South Africa; [Farrell, Anthony P.] Univ British Columbia, Dept Zool, Vancouver, BC, Canada; [Farrell, Anthony P.] Univ British Columbia, Fac Land & Food Syst, Vancouver, BC, Canada; [Costello, Mary-Ann] Univ Witwatersrand, Cent Anim Serv, Johannesburg, South Africa	Izwan, A (reprint author), Univ Western Australia, Sch Human Sci, 35 Stirling Hwy, Crawley, WA, Australia.	Adian.izwan@research.uwa.edu.au	Meyer, Leith/AAN-4930-2020	maloney, shane k/0000-0002-5878-2266; Seymour, Roger/0000-0002-3395-0059; Izwan, Adian/0000-0002-6283-564X; Mitchell, Duncan/0000-0001-8989-4773; Meyer, Leith/0000-0002-5122-2469	Australian Research CouncilAustralian Research Council [DP-120102081]; Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada	The authors acknowledge the expertise and contribution made by the academics, technicians, and volunteers at the School of Physiology, and the Central Animal Service, at the University of the Witwatersrand. We thank especially David Gray, Zipho Zwane, Robyn Hetem, Benjamin Rey, Nico Douths, Peter Kamerman, Richard McFarland, Hilary Lease, Peter Buss, Michelle Miller, Tapiwa Chinaka, and W. Maartin Strauss. We also thank Tobias Wang of Aarhus University, and one anonymous reviewer, for providing valuable feedback on the manuscript. This research was supported by an Australian Research Council Discovery Project Award to R. S. Seymour, S. K. Maloney, and A. P. Farrell (DP-120102081). E. P. Snelling holds a South African Claude Leon Foundation Postdoctoral Fellowship. A. P. Farrell holds a Canada Research Chair and is supported by a Discovery Grant from the Natural Sciences and Engineering Research Council of Canada.	ALFORD BT, 1974, J AM VET MED ASSOC, V164, P702; American Society of Anesthesiologists, 2004, CONT DEPTH SED DEF G; Atkinson MW, 2002, J ZOO WILDLIFE MED, V33, P157, DOI 10.1638/1042-7260(2002)033[0157:RCIOAC]2.0.CO;2; Barenbrug A. W. T., 1974, PSYCHROMETRY PSYCHRO; BARKE KE, 1993, LIFE SCI, V53, P1391, DOI 10.1016/0024-3205(93)90581-M; Beker A, 2010, J APPL ANIM RES, V37, P1; Boesch JM, 2011, J ZOO WILDLIFE MED, V42, P18, DOI 10.1638/2009-0146.1; Boom M, 2012, CURR PHARM DESIGN, V18, P5994, DOI 10.2174/138161212803582469; Brondum E, 2009, AM J PHYSIOL-REG I, V297, pR1058, DOI 10.1152/ajpregu.90804.2008; Buss PE, 2001, J S AFR VET ASSOC, V72, P137; Buss P, 2016, J ZOO WILDLIFE MED, V47, P834; CABRAL AMS, 1980, [No title captured], V67, P527, DOI DOI 10.1016/S0300-9629(80)80037-5; Chahl LA., 1996, AUST PRESCR, V19, P63; CLARKE KW, 1969, VET REC, V85, P649; Curran-Everett D, 2006, ADV PHYSIOL EDUC, V30, P58, DOI 10.1152/advan.00076.2005; DASKALOPOULOS NT, 1975, EUR J PHARMACOL, V33, P91, DOI 10.1016/0014-2999(75)90142-9; Egermann M, 2008, LAB ANIM-UK, V42, P453, DOI 10.1258/la.2007.007001; FEGLER G, 1954, Q J EXP PHYSIOL CMS, V39, P153, DOI 10.1113/expphysiol.1954.sp001067; Fernandez C, 2012, ANIM FEED SCI TECH, V178, P115, DOI 10.1016/j.anifeedsci.2012.09.007; GAUTRET B, 1984, EUR J PHARMACOL, V102, P159, DOI 10.1016/0014-2999(84)90351-0; GAUTRET B, 1985, J CARDIOVASC PHARM, V7, P649, DOI 10.1097/00005344-198507000-00006; GOODMAN NW, 1987, BRIT J ANAESTH, V59, P1497, DOI 10.1093/bja/59.12.1497; Greene S A., 2002, VET ANESTHESIA PAIN; GRETH A, 1993, AFR J ECOL, V31, P66, DOI 10.1111/j.1365-2028.1993.tb00519.x; Grossman M, 1996, CLIN PHARMACOL THER, V60, P554, DOI 10.1016/S0009-9236(96)90151-4; HAKIM TS, 1992, PULM PHARMACOL, V5, P159, DOI 10.1016/0952-0600(92)90036-G; HATTINGH J, 1994, S AFR J WILDL RES, V24, P15; HEARD DJ, 1990, J ZOO WILDLIFE MED, V21, P166; Hoka S, 1998, ANESTHESIOLOGY, V89, P1495, DOI 10.1097/00000542-199812000-00028; HOLT JP, 1968, AM J PHYSIOL, V215, P704; Jackson P., 2008, CLIN EXAMINATION FAR; Koehler H, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0381-1; LAUBIE M, 1974, EUR J PHARMACOL, V28, P66, DOI 10.1016/0014-2999(74)90113-7; LEES P, 1976, BRIT J PHARMACOL, V56, P263, DOI 10.1111/j.1476-5381.1976.tb07637.x; Lenaerts I, 2013, EUROPACE, V15, P754, DOI 10.1093/europace/eut012; LOWENSTEIN E, 1972, J PHARMACOL EXP THER, V180, P359; LYNCH GM, 1981, J WILDLIFE MANAGE, V45, P981, DOI 10.2307/3808108; MACKENZIE G, 1977, VET REC, V101, P30, DOI 10.1136/vr.101.2.30; Madan AK, 2010, VET ARHIV, V80, P27; MANSOUR E, 1970, AM J CARDIOL, V26, P648, DOI 10.1016/0002-9149(70)90503-5; Marano G, 1996, J CARDIOVASC PHARM, V28, P513, DOI 10.1097/00005344-199610000-00006; MCQUEEN DS, 1983, BRIT MED BULL, V39, P77, DOI 10.1093/oxfordjournals.bmb.a071795; Meyer LCR, 2010, J WILDLIFE DIS, V46, P514, DOI 10.7589/0090-3558-46.2.514; Mir SA, 2000, SMALL RUMINANT RES, V37, P13, DOI 10.1016/S0921-4488(99)00123-6; MIRENDA J, 1995, CHEST, V108, P539, DOI 10.1378/chest.108.2.539; MUZI M, 1992, ANESTH ANALG, V74, P877; Nieuwenhuijs D, 2001, ANESTHESIOLOGY, V95, P889, DOI 10.1097/00000542-200110000-00017; OKEEFE RJ, 1987, J PHARMACOL EXP THER, V242, P699; Ozeki LM, 2014, J ZOO WILDLIFE MED, V45, P819, DOI 10.1638/2014-0039.1; PAINTAL AS, 1969, J PHYSIOL-LONDON, V203, P511, DOI 10.1113/jphysiol.1969.sp008877; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Perrin KL, 2015, J ZOO WILDLIFE MED, V46, P870, DOI 10.1638/2015-0114.1; PRESNELL K R, 1973, Journal of Wildlife Diseases, V9, P336; Price EO, 1999, APPL ANIM BEHAV SCI, V65, P245, DOI 10.1016/S0168-1591(99)00087-8; Radcliffe RW, 2014, J ZOO WILDLIFE MED, V45, P263, DOI [10.1638/1042-7260-45.2.263, 1]; Rey B, 2016, J THERM BIOL, V55, P47, DOI 10.1016/j.jtherbio.2015.11.010; ROSA G, 1992, ACTA ANAESTH SCAND, V36, P128, DOI 10.1111/j.1399-6576.1992.tb03438.x; ROUSSEL YE, 1975, J WILDLIFE MANAGE, V39, P634, DOI 10.2307/3800411; RUNCIMAN WB, 1990, BRIT J ANAESTH, V65, P353, DOI 10.1093/bja/65.3.353; Seymour RS, 2000, PHYSIOL BIOCHEM ZOOL, V73, P389, DOI 10.1086/317741; SHAW ML, 1995, J AM VET MED ASSOC, V206, P833; SHOOK JE, 1990, AM REV RESPIR DIS, V142, P895, DOI 10.1164/ajrccm/142.4.895; Sinclair MD, 2003, CAN VET J, V44, P885; Snelling EP, 2016, J APPL PHYSIOL, V121, P900, DOI 10.1152/japplphysiol.00435.2016; SPLINTER WM, 1995, CAN J ANAESTH, V42, P201, DOI 10.1007/BF03010676; Springer A, 2015, J ZOO WILDLIFE MED, V46, P482, DOI 10.1638/2014-0154.1; STAHL WR, 1967, J APPL PHYSIOL, V22, P453; Stegmann G F, 2001, Vet Anaesth Analg, V28, P49, DOI 10.1046/j.1467-2987.2000.00034.x; Trapani G, 2000, CURR MED CHEM, V7, P249, DOI 10.2174/0929867003375335; Upton RN, 2009, BRIT J ANAESTH, V103, P848, DOI 10.1093/bja/aep269; Vahle-Hinz C, 2002, BRIT J ANAESTH, V89, P123, DOI 10.1093/bja/aef166; Wenger S, 2007, J ZOO WILDLIFE MED, V38, P380, DOI 10.1638/2006-0038R.1; WILLETTE RN, 1982, EUR J PHARMACOL, V78, P61, DOI 10.1016/0014-2999(82)90372-7; WILLETTE RN, 1982, J CARDIOVASC PHARM, V4, P1006, DOI 10.1097/00005344-198211000-00020; Woolf A., 1973, Journal Zool Anim Med, V4, P16, DOI 10.2307/20094207; WOOLF A, 1970, J AM VET MED ASSOC, V157, P636	76	0	0	0	7	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0174-1578	1432-136X		J COMP PHYSIOL B	J. Comp. Physiol. B-Biochem. Syst. Environ. Physiol.	NOV	2018	188	6					991	1003		10.1007/s00360-018-1184-z			13	Physiology; Zoology	Physiology; Zoology	GW9KN	WOS:000447305500009	30232543				2020-06-26	J	Buss, P; Miller, M; Fuller, A; Haw, A; Stout, E; Olea-Popelka, F; Meyer, L				Buss, Peter; Miller, Michele; Fuller, Andrea; Haw, Anna; Stout, Eliza; Olea-Popelka, Francisco; Meyer, Leith			Postinduction butorphanol administration alters oxygen consumption to improve blood gases in etorphine-immobilized white rhinoceros	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						butorphanol; etorphine; oxygen consumption; white rhinoceros	CERATOTHERIUM-SIMUM; AZAPERONE; COMBINATIONS; VENTILATION; DETOMIDINE; PARAMETERS; ANESTHESIA; HYPOXEMIA; AGONISTS	Objective To investigate the effects of post-induction butorphanol administration in etorphine-immobilized white rhinoceros on respiration and blood gases. Study design Randomized crossover study. Animals A group of six sub-adult male white rhinoceros. Methods Etorphine, or etorphine followed by butorphanol 12 minutes after recumbency, was administered intramuscularly [2.5 mg etorphine, 25 mg butorphanol (1000-1250 kg), or 3.0 mg etorphine, 30 mg butorphanol (1250-1500 kg)]. Sampling started at 10 minutes after initial recumbency, and was repeated at 5 minute intervals for 25 minutes. Arterial blood gases, limb muscle tremors, expired minute ventilation and respiratory frequency were measured at each sampling point. Calculated values included alveolar-arterial oxygen gradient [P(A-a)(O2)], expected respiratory minute volume (<(V)over dot>(Epsilon)), tidal volume (V-T), oxygen consumption (<(V)over dot>(Omicron 2)) and carbon dioxide production (<(V)over dot>(CO2)). Results Etorphine administration resulted in an initial median (range) hypoxaemia [arterial partial pressure of oxygen 25.0 (23.0-28.0) mmHg], hypercapnia [arterial partial pressure of carbon dioxide 76.2 (67.2-81.2) mmHg], increased P(A-a)(O2) [41.7 (36.6-45.1) mmHg, <(V)over dot>(O2) [11.1 (10.0-12.0) L minute(-1)] and muscle tremors. Butorphanol administration was followed by rapid, although moderate, improvements in arterial partial pressure of oxygen [48.5 (42.0-51.0) mmHg] and arterial partial pressure of carbon dioxide [62.8 (57.9-75.2) mmHg]. In rhinoceros administered butorphanol, <(V)over dot>(O2) [4.4 (3.6-5.1) L minute(-1)] and <(V)over dot>(CO2) [4.2 (3.8-4.4) L minute(-1)] were lower than in those not administered butorphanol. Increased arterial oxygen tension was associated with lower oxygen consumption (p = 0.002) which was positively associated with lower muscle tremor scores (p < 0.0001). Conclusions and clinical relevance Hypoxaemia and hypercapnia in etorphine-immobilized rhinoceros resulted from an increased [P(A-a)(O2)] and increased <(V)over dot>(O2) and <(V)over dot>(CO2) associated with muscle tremors. Rather than being associated with changes in <(V)over dot>(E), it appears that improved blood gases following butorphanol administration were a consequence of decreased <(V)over dot>(O2) associated with reduced muscle tremoring.	[Buss, Peter] Kruger Natl Pk, South African Natl Pk, Vet Wildlife Serv, Private Bag X402, ZA-1350 Skukuza, South Africa; [Buss, Peter; Fuller, Andrea; Haw, Anna; Meyer, Leith] Univ Pretoria, Dept Paraclin Sci, Fac Vet Sci, Onderstepoort, South Africa; [Buss, Peter; Fuller, Andrea; Meyer, Leith] Univ Witwatersrand, Sch Physiol, Brain Funct Res Grp, Fac Hlth Sci, Johannesburg, South Africa; [Miller, Michele] Stellenbosch Univ, Natl Res Fdn Ctr Excellence Biomed TB Res, Div Mol Biol & Human Genet, Med Res Council,Ctr TB Res,Fac Med & Hlth Sci,Dep, Cape Town, South Africa; [Stout, Eliza; Olea-Popelka, Francisco] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Clin Sci, Ft Collins, CO 80523 USA	Buss, P (reprint author), Kruger Natl Pk, South African Natl Pk, Vet Wildlife Serv, Private Bag X402, ZA-1350 Skukuza, South Africa.	peter.buss@sanparks.org	Meyer, Leith/AAN-4930-2020		South African National Parks; South African Veterinary Foundation; University of Witwatersrand [00125485211015 12110500000000000000004992]	The authors thank Markus Hofmeyr, Marius Kruger, Milandie Kruger, Leana Rossouw, Guy Hausler and holding-facility staff of Veterinary Wildlife Services, Kruger National Park. The assistance of members of the Brain Function Research Group, University of Witwatersrand Medical School, and staff and students of the Faculty of Veterinary Science, University of Pretoria, is also acknowledged. Financial and in-kind support was provided by South African National Parks. The project was supported by funding grants from the South African Veterinary Foundation and University of Witwatersrand (00125485211015 12110500000000000000004992).	Bide RW, 1997, 673 DEF RES EST SUFF; Boardman WSJ, 2014, J WILDLIFE DIS, V50, P849, DOI 10.7589/2013-12-327; Buss P, 2016, J ZOO WILDLIFE MED, V47, P834; Buss P, 2015, J ZOO WILDLIFE MED, V46, P224, DOI 10.1638/2014-0089R.1; Citino SB, 2007, J ZOO WILDLIFE MED, V38, P375, DOI 10.1638/2006-0007R1.1; De Lange SS, 2015, THESIS; Doherty T, 2008, MANUAL EQUINE ANESTH; EVANS DL, 1988, J EXP BIOL, V134, P397; Haw A, 2015, J S AFR VET ASSOC, V86, DOI [10.4102/jsava.v86i1.1276, 10.4102/JSAVA.V86I1.1276]; Haw A, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0253-0; HEISTAD DD, 1972, J CLIN INVEST, V51, P1469, DOI 10.1172/JCI106943; Kock MD, 1995, J ZOO WILDLIFE MED, V26, P207; MCARDLE WD, 1986, EXERCISE PHYSL ENERG, P637; Meyer LCR, 2010, J WILDLIFE DIS, V46, P514, DOI 10.7589/0090-3558-46.2.514; Meyer LCR, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0337-5; Miller M, 2013, J ZOO WILDLIFE MED, V44, P55, DOI 10.1638/1042-7260-44.1.55; Moens Y, 2013, VET CLIN N AM-EQUINE, V29, P51, DOI 10.1016/j.cveq.2012.12.002; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Portas T, 2004, AUST VET J, V82, P542, DOI 10.1111/j.1751-0813.2004.tb11196.x; PORTER RK, 1995, AM J PHYSIOL-REG I, V269, pR226; RALLEY FE, 1988, CAN J ANAESTH, V35, P332, DOI 10.1007/BF03010851; Read MR, 2003, J ZOO WILDLIFE MED, V34, P134, DOI 10.1638/1042-7260(2003)034[0134:AROAAA]2.0.CO;2; Swan GE, 1993, WILDLIFE DECISION SU, P1; Tusman G, 2012, ANESTH ANALG, V114, P866, DOI 10.1213/ANE.0b013e318247f6cc; Wagner PD, 2008, CRIT CARE, V12, DOI 10.1186/cc6888; Wenger S, 2007, J ZOO WILDLIFE MED, V38, P380, DOI 10.1638/2006-0038R.1; West JB, 2008, RESP PHYSL ESSENTIAL, P172; Yaksh T.L, 2011, GOODMAN GILMANS PHAR, P481	28	7	7	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JAN	2018	45	1					57	67		10.1016/j.vaa.2017.03.008			11	Veterinary Sciences	Veterinary Sciences	GL4KG	WOS:000437119200008	29242121				2020-06-26	J	O'Dell, JH; Kock, MD; Thompson, PN; Meyer, LCR				O'Dell, Jacques Henry; Kock, Michael David; Thompson, Peter Neil; Meyer, Leith Carl Rodney			Minimum effective naltrexone dose to antagonise etorphine immobilisation and prevent the complications of renarcotisation in domestic goats	VETERINARY RECORD			English	Article							CARFENTANIL IMMOBILIZATION; HYPERTHERMIA	Naltrexone is used to antagonise etorphine immobilisation, but a safe and effective dose for this purpose has not been objectively determined. Eight domestic goats were immobilised with etorphine (0.07 mg/kg) eight times at >= 13 day intervals. Naltrexone at doses of 0.5, 1, 2, 5, 10, 20 and 40 mg/mg etorphine were administered intravenously 17 minutes after etorphine injection. Effectiveness of antagonism was recorded based on recovery and renarcotisation scores and clinical observations. All doses produced rapid recovery to the point of standing (median 59 seconds, range 33-157 seconds), with no significant differences in recovery times (P=0.44). The lower naltrexone doses resulted in renarcotisation in some goats: 4/8 in the 10-mg dose trial, 7/8 in the 5-mg dose trial, and 8/8 in the 2-mg, 1-mg and 0.5-mg dose trials. Lower doses resulted in more severe signs of renarcotisation. Complications of renarcotisation included increased body temperature; this occurred just before signs of renarcotisation and was greater in animals with high renarcotisation scores (P<0.01). The lowest, safest effective naltrexone dose that we used to antagonise etorphine immobilisation was 20 mg/mg etorphine, which produced rapid recovery to standing with no renarcotisation.	[O'Dell, Jacques Henry; Kock, Michael David; Thompson, Peter Neil] Univ Pretoria, Dept Prod Anim Studies, Fac Vet Sci, Onderstepoort, South Africa; [Meyer, Leith Carl Rodney] Univ Pretoria, Fac Vet Sci, Dept Paraclin Sci, Onderstepoort, South Africa	O'Dell, JH (reprint author), Univ Pretoria, Dept Prod Anim Studies, Fac Vet Sci, Onderstepoort, South Africa.	jacques.odell@up.ac.za	Thompson, Peter N/J-2534-2013; Meyer, Leith/AAN-4930-2020	Thompson, Peter/0000-0002-2268-9748; O'Dell, Jacques/0000-0002-4966-4073; Meyer, Leith/0000-0002-5122-2469	The South African Veterinary Foundation	The South African Veterinary Foundation funded the project.	Allen JL, 1996, J ZOO WILDLIFE MED, V27, P496; ALLEN JL, 1989, J ZOO WILDLIFE MED, V20, P423; Buss PE, 2001, J S AFR VET ASSOC, V72, P137; Capacchione JF, 2009, ANESTH ANALG, V109, P1065, DOI 10.1213/ane.0b013e3181a9d8d9; Grimm Kurt A., 2007, P3; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P391; HEARD DJ, 1990, J ZOO WILDLIFE MED, V21, P166; Heard DJ, 1996, AM J VET RES, V57, P87; Hetem RS, 2013, BIOL LETTERS, V9, DOI 10.1098/rsbl.2013.0472; Hetem RS, 2012, J EXP BIOL, V215, P3917, DOI 10.1242/jeb.074666; MCKEAN TA, 1978, J WILDLIFE MANAGE, V42, P176, DOI 10.2307/3800709; Meyer LCR, 2006, AM J PHYSIOL-REG I, V290, pR405; Meyer LCR, 2008, J WILDLIFE DIS, V44, P404, DOI 10.7589/0090-3558-44.2.404; Miller MW, 1996, J WILDLIFE DIS, V32, P234, DOI 10.7589/0090-3558-32.2.234; Plumb DC, 2011, PLUMBS VET DRUG HDB; Shaw M. L., 1993, Proceedings of the American Association of Zoo Veterinarians, Saint Louis, 10-15 October 1993, P261; Stafford K, 2001, PHARMACOL BIOCHEM BE, V69, P233, DOI 10.1016/S0091-3057(01)00525-1; Swan G.E., 1993, P2; THURMON JC, 1974, J AM VET MED ASSOC, V165, P168; WILDLIFE_ PHARMACEUTICAL_ USA, 2012, WILDL PHARM INC	20	1	1	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0042-4900	2042-7670		VET REC	Vet. Rec.	NOV	2017	181	18					481	+		10.1136/vr.104435			6	Veterinary Sciences	Veterinary Sciences	FM1BP	WOS:000414706200013	28978715				2020-06-26	J	Lapid, R; King, R; Bdolah-Abram, T; Shilo-Benjamini, Y				Lapid, Roi; King, Roni; Bdolah-Abram, Tali; Shilo-Benjamini, Yael			A RETROSPECTIVE COMPARISON OF CHEMICAL IMMOBILIZATION WITH THIAFENTANIL, THIAFENTANIL-AZAPERONE, OR ETORPHINE-ACEPROMAZINE IN CAPTIVE PERSIAN FALLOW DEER (DAMA DAMA MESOPOTAMICA)	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						Azaperone; Dama dama mesopotamica; etorphine; immobilization; Persian fallow deer; thiafentanil	RHINOCEROS DICEROS-BICORNIS; CARFENTANIL-XYLAZINE; ODOCOILEUS-VIRGINIANUS; INDUCTION TIME; MULE DEER; OXYGEN; COMBINATIONS	Records of 56 Persian fallow deer (Dama dama mesopotamica) immobilized for translocation were reviewed. Twenty-three were administered 0.05 +/- 0.01 (mean +/- SD) mg/kg thiafentanil (THIA), 20 were administered 0.045 +/- 0.008 mg/kg thiafentanil combined with 0.19 +/- 0.03 mg/kg azaperone (THIA-AZP), and 13 were administered 0.032 +/- 0.04 mg/kg etorphine-acepromazine (ETOR-ACP) by intramuscular remote injection. Parameters recorded and compared between groups included induction and recovery times, heart rate, respiratory rate, rectal temperature, oxygen saturation, blood pressure, reflexes, quality of immobilization, and blood concentrations of lactate and glucose. Naltrexone (THIA groups) or diprenorphine (ETOR-ACP) were administered for reversal. Mean induction time was significantly shorter in the THIA group versus the ETOR-ACP group (2.0 +/- 1.3 and 4.8 +/- 2.8 min, respectively), but not significantly shorter than the THIA-AZP group (2.8 +/- 3.1 min). Respiratory rate was significantly higher in the THIA group in comparison to the two other groups. None of the protocols provided excellent immobilization quality, which was significantly poorer in the THIA group. Following antagonist administration, all deer from the THIA and ETOR-ACP groups recovered quickly, while there were five perianesthetic morbidity and mortality cases in the THIA-AZP group. Mean recovery time was significantly shorter in the THIA group versus the THIA-AZP and ETOR-ACP groups (0.5 +/- 0.3, 1.1 +/- 0.8, and 2.3 +/- 1.1 min, respectively). In conclusion, the use of THIA provided faster induction and recovery, with less respiratory depression, but poorer immobilization. The THIA-AZP combination should be used with caution in Persian fallow deer until further investigation.	[Lapid, Roi] Hai Pk Zoo, 79 HaHashmonaim St, IL-2633761 Kiryat Motzkin, Israel; [King, Roni] Israel Nat & Pk Author, Sci & Conservat Div, 3 Ve Olamo St, IL-9546304 Jerusalem, Israel; [Bdolah-Abram, Tali; Shilo-Benjamini, Yael] Hebrew Univ Jerusalem, Koret Sch Vet Med, Robert H Smith Fac Agr Food & Environm, IL-7610001 Rehovot, Israel	Shilo-Benjamini, Y (reprint author), Hebrew Univ Jerusalem, Koret Sch Vet Med, Robert H Smith Fac Agr Food & Environm, IL-7610001 Rehovot, Israel.	shilo.yael@gmail.com					Bergvall UA, 2015, J WILDLIFE DIS, V51, P484, DOI 10.7589/2013-11-290; Burdick S, 2012, JAVMA-J AM VET MED A, V240, P596, DOI 10.2460/javma.240.5.596; Caulkett N.A., 2015, VET ANAESTH ANALG, P764, DOI 10.1002/9781119421375.ch40; Caulkett NA, 2000, CAN J VET RES, V64, P64; Caulkett N, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P823; Fahlman A, 2014, J ZOO WILDLIFE MED, V45, P272, DOI 10.1638/2013-0097R.1; Fernandez-Moran J, 2000, J ZOO WILDLIFE MED, V31, P62, DOI 10.1638/1042-7260(2000)031[0062:MTZAXT]2.0.CO;2; Gerritsmann H, 2016, J WILDLIFE DIS, V52, P642, DOI 10.7589/2015-07-198; Haga HA, 2009, VET ANAESTH ANALG, V36, P555, DOI 10.1111/j.1467-2995.2009.00498.x; Hall J., 2016, GUYTON HALL TXB MED, P972; Howard LL, 2004, J ZOO WILDLIFE MED, V35, P312, DOI 10.1638/03-090; Kilgallon C, 2008, J ZOO WILDLIFE MED, V39, P6, DOI 10.1638/2006-0025.1; KOCK MD, 1992, J ZOO WILDLIFE MED, V23, P181; Kreeger TJ, 2012, HDB WILDLIFE CHEM IM, P158; Lance William R., 2012, P589; LEMKE KA, 2007, [No title captured], P203; Masters N. J., 2015, FOWLERS ZOO WILD ANI, V8, P611; Meyer LCR, 2008, J S AFR VET ASSOC, V79, P121; Morkel PV, 2010, J WILDLIFE DIS, V46, P236, DOI 10.7589/0090-3558-46.1.236; Paterson JM, 2009, J ZOO WILDLIFE MED, V40, P39, DOI 10.1638/2007-0107.1; Werner Y. L., 2015, IUCN RED LIST THREAT; Wolfe BA, 2015, FOWLERS ZOO WILD ANI, V8, P626; Wolfe LL, 2004, J WILDLIFE DIS, V40, P282, DOI 10.7589/0090-3558-40.2.282	23	2	2	0	5	AMER ASSOC ZOO VETERINARIANS	YULEE	581705 WHITE OAK ROAD, YULEE, FL 32097 USA	1042-7260	1937-2825		J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	SEP	2017	48	3					627	635		10.1638/2016-0280.1			9	Veterinary Sciences	Veterinary Sciences	FH4WN	WOS:000411163100003	28920822				2020-06-26	J	Zeiler, GE; Meyer, LCR				Zeiler, Gareth E.; Meyer, Leith C. R.			Blood acid-base status in impala (Aepyceros melampus) immobilised and maintained under total intravenous anaesthesia using two different drug protocols	BMC VETERINARY RESEARCH			English	Article						Blood pH; Impala; Aepyceros melampus; Immobilisation; General anaesthesia; Henderson-Hasselbalch; Stewart approach	STRONG ION DIFFERENCE; GOATS CAPRA-HIRCUS; RESPIRATORY DEPRESSION; METABOLIC-ACIDOSIS; ELECTROLYTE STATUS; PREGNANCY TOXEMIA; DIARRHEIC CALVES; BALANCE; ETORPHINE; ARTERIAL	Background: In mammals, homeostasis and survival are dependent on effective trans-membrane movement of ions and enzyme function, which are labile to extreme acid-base changes, but operate efficiently within a narrow regulated pH range. Research in patients demonstrating a pH shifts outside the narrow regulated range decreased the cardiac output and systemic vascular resistance and altered the oxygen binding to haemoglobin. These cardiopulmonary observations may be applicable to the risks associated with anaesthesia and performance of wildlife ungulates on game farms. The aim of this study was to compare blood pH changes over time in impala immobilised and anaesthetised with two different drug protocols (P-TMP - immobilisation: thiafentanil-medetomidine; maintenance: propofol-ketamine-medetomidine; P-EME - immobilisation: etorphine-medetomidine; maintenance: etorphineketamine-medetomidine). Additionally, we discuss the resultant blood pH using both the Henderson-Hasselbalch and the Stewart approaches. Two data collection time points were defined, Time1 before maintenance of general anaesthesia and Time 2 at end of maintenance of general anaesthesia. We hypothesise that blood pH would not be different between drug protocols and would not change over time. Results: Significant differences were detected over time but not between the two drug protocols. Overall, the blood pH decreased over time from 7.37 +/- 0.04 to 7.31 +/- 0.05 (p = 0.001). Overall, over time arterial partial pressure of carbon dioxide changed from 51.3 +/- 7.5 mmHg to 72.6 +/- 12.4 mmHg (p < 0.001); strong ion difference from 44.6 +/- 2.4 mEq/L to 46.9 +/- 3.1 mEq/L (p < 0.001); anion gap from 15.0 +/- 3.1 mEq/L to 10.9 +/- 2.2 mEq/L (p < 0.001); and total weak acids from 16.1 +/- 1.2 mmol/L to 14.0 +/- 1.1 mmol/L (p < 0.001). The bicarbonate changed from 29.6 +/- 2.7 mEq/L to 36.0 +/- 4. 1 mEq/L (p < 0.001); and lactate changed from 2.9 +/- 1.5 mEq/L to 0.3 +/- 0.03 mEq/L (p < 0.001) over time. Conclusions: The profound increase in the partial pressure of carbon dioxide that worsened during the total intravenous anaesthesia in both protocols initiated a substantial metabolic compensatory response to prevent severe acidaemia. This compensation resulted in a clinically acceptable mild acidaemic state, which worsened over time but not between the protocols, in healthy impala. However, these important compensatory mechanisms require normal physiological function and therefore when immobilising ill or anorexic wild ungulates their acid-base status should be carefully assessed.	[Zeiler, Gareth E.; Meyer, Leith C. R.] Univ Pretoria, Dept Paraclin Sci, Fac Vet Sci, Private Bag X04, ZA-0110 Pretoria, Gauteng, South Africa	Zeiler, GE (reprint author), Univ Pretoria, Dept Paraclin Sci, Fac Vet Sci, Private Bag X04, ZA-0110 Pretoria, Gauteng, South Africa.	gareth.zeiler@up.ac.za	Zeiler, Gareth/AAJ-7812-2020; Meyer, Leith/AAN-4930-2020	Zeiler, Gareth/0000-0001-7653-7726; Meyer, Leith/0000-0002-5122-2469	University of Pretoria	The study was funded by the University of Pretoria.	Ascenzi P, 2014, J MOL STRUCT, V1077, P4, DOI 10.1016/j.molstruc.2013.09.053; Berchtold JE, 2005, J VET INTERN MED, V19, P240, DOI 10.1892/0891-6640(2005)19&lt;240:EOIHSB&gt;2.0.CO;2; Boscan P, 2005, VET ANAESTH ANALG, V32, P16; Buck RK, 2017, VET ANAESTH ANALG, V44, P138, DOI 10.1111/vaa.12402; Bush M, 2004, J S AFR VET ASSOC, V75, P14; Buss PE, 2001, J S AFR VET ASSOC, V72, P137; Castillo C, 2000, VET MED-CZECH, V45, P241; Clarke KW, 2014, VET ANAESTHESIA, P53; Constable PD, 1999, VET CLIN N AM-FOOD A, V15, P447, DOI 10.1016/S0749-0720(15)30158-4; Constable PD, 2005, J VET INTERN MED, V19, P581, DOI 10.1892/0891-6640(2005)19[581:UOAQSI]2.0.CO;2; Constable PD, 2014, VET CLIN N AM-FOOD A, V30, P295, DOI 10.1016/j.cvfa.2014.03.001; Cook CJ, 2000, BIOLOGY OF ANIMAL STRESS, P123, DOI 10.1079/9780851993591.0123; Corey HE, 2003, KIDNEY INT, V64, P777, DOI 10.1046/j.1523-1755.2003.00177.x; Crimi E, 2012, J CRIT CARE, V27, P108, DOI 10.1016/j.jcrc.2011.06.001; Gonzalez FHD, 2012, VET J, V193, P598, DOI 10.1016/j.tvjl.2011.11.022; Dugdale A, 2010, VET ANAESTHESIA PRIN, P182; Haskins S.C., 2015, VET ANAESTH ANALG, P86; Hasselbalch K. A, 1916, BIOCHEM Z, V78, P112; HATTINGH J, 1988, COMP BIOCHEM PHYS A, V89, P231, DOI 10.1016/0300-9629(88)91084-5; Haw AJ, 2016, VET ANAESTH ANALG, V43, P539, DOI 10.1111/vaa.12343; Henderson LJ, 1908, AM J PHYSIOL, V21, P173; Hickish T, 2012, ANAEST INTENS CARE M, V13, P567, DOI 10.1016/j.mpaic.2012.09.003; Karesh WB, 1997, J ZOO WILDLIFE MED, V28, P361; Kastner SBR, 2006, VET ANAESTH ANALG, V33, P79, DOI 10.1111/j.1467-2995.2005.00243.x; Kellum J.A., 2009, STEWARTS TXB ACID BA; Ko S, 2003, CAN J ANAESTH, V50, P679, DOI 10.1007/BF03018710; Koehler H, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0381-1; McDonell WN, 2015, VET ANAESTH ANALG, P513; MITCHELL JH, 1972, KIDNEY INT, V1, P375, DOI 10.1038/ki.1972.48; Muller KR, 2012, J VET INTERN MED, V26, P674, DOI 10.1111/j.1939-1676.2012.00917.x; Muir W.W., 2015, VET ANAESTH ANALG, P357; Stevens JB, 2009, VET CLIN PATH, V23, P19; STEWART PA, 1978, RESP PHYSIOL, V33, P9, DOI 10.1016/0034-5687(78)90079-8; Tharwat M, 2014, SMALL RUMINANT RES, V117, P73, DOI 10.1016/j.smallrumres.2013.12.026; Trefz FM, 2015, J VET INTERN MED, V29, P678, DOI 10.1111/jvim.12556; Trefz FM, 2013, J DAIRY SCI, V96, P7234, DOI 10.3168/jds.2013-6945; West E, 2013, VET ANAESTH ANALG, V40, P482, DOI 10.1111/vaa.12021; Whiteley JP, 2002, BRIT J ANAESTH, V88, P771, DOI 10.1093/bja/88.6.771; Yamauchi H, 2011, BRIT J ANAESTH, V107, P631, DOI 10.1093/bja/aer171; Zeiler GE, 2015, J ZOO WILDLIFE MED, V46, P755, DOI 10.1638/2015-0052.1; Zeiler GE, J ZOO WILDL IN PRESS	41	0	0	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-6148			BMC VET RES	BMC Vet. Res.	AUG 16	2017	13								246	10.1186/s12917-017-1163-8			10	Veterinary Sciences	Veterinary Sciences	FD7WJ	WOS:000407736400005	28814306	DOAJ Gold, Green Published			2020-06-26	J	Zeiler, GE; Meyer, LCR				Zeiler, Gareth E.; Meyer, Leith C. R.			Comparison of thiafentanil-medetomidine to etorphine-medetomidine immobilisation of impalas (Aepyceros melampus)	JOURNAL OF THE SOUTH AFRICAN VETERINARY ASSOCIATION			English	Article							TOTAL INTRAVENOUS ANESTHESIA; KETAMINE; DERIVATIVES; RESPONSES; CORTISOL; FENTANYL; AGONISTS; ANIMALS; WILD	Impalas (Aepyceros melampus) are increasingly valuable in the South African wildlife industry, and there is a greater need to chemically immobilise them, ideally with minimal risk. This study aimed to compare the times to recumbency and physiological effects of thiafentanil-medetomidine versus etorphine-medetomidine immobilisation. A combination of thiafentanil (2 mg) + medetomidine (2.2 mg) and etorphine (2 mg) + medetomidine (2.2 mg) was administered (to nine impalas; crossover design) via a dart. After darting, a stopwatch was started to record times to recumbency (time from darting until recumbent without attempts to stand). If apnoea was present, the impalas received one or more boluses of butorphanol (1:1 potent opioid dose). Data collection included arterial blood gas analysis and the number of butorphanol boluses. Two-sample t-tests were used to compare differences between combinations. The time to recumbency for thiafentanil-medetomidine was 12.2 (+/- 6.8) min and no different from 14.5 (+/- 5.2) min for etorphine- medetomidine (p = 0.426). The thiafentanil-medetomidine combination required more butorphanol boluses (median: 2; interquartile range: 2-3) compared to etorphine- medetomidine (median: 0; interquartile range: 0-1) (p = 0.001). Despite butorphanol treatment and resolution of apnoea, all impalas suffered hypoxaemia (PaO2 +/- 44.0 mmHg). Thiafentanil-medetomidine did not immobilise impalas more rapidly than etorphine- medetomidine, and resulted in more apnoea that required rescue butorphanol boluses. Marked hypoxaemia resulted from both combinations, mainly because of right-to-left intrapulmonary shunting and not because of hypoventilation. Butorphanol and oxygen supplementation should be considered as essential rescue interventions for all impalas immobilised with these potent opioid combinations.	[Zeiler, Gareth E.; Meyer, Leith C. R.] Univ Pretoria, Dept Paraclin Sci, Pretoria, South Africa	Zeiler, GE (reprint author), Univ Pretoria, Dept Paraclin Sci, Pretoria, South Africa.	gareth.zeiler@up.ac.za	Zeiler, Gareth/AAJ-7812-2020; Meyer, Leith/AAN-4930-2020	Zeiler, Gareth/0000-0001-7653-7726; Meyer, Leith/0000-0002-5122-2469	Hannover Zoo; Wuppertal Zoo; University of Hannover; University of Pretoria; South African Veterinary Association (SAVA) Wildlife Group; South African Veterinary Foundation	The authors would like to thank the Hannover and Wuppertal Zoos, University of Hannover and the University of Pretoria, the South African Veterinary Association (SAVA) Wildlife Group and the South African Veterinary Foundation for financial support. We thank the many staff and students from the University of Pretoria that helped with the capture, transport and husbandry of the impala and gave logistical support during the impala studies.	BAKIMA M, 1988, RES VET SCI, V45, P332, DOI 10.1016/S0034-5288(18)30960-3; BENTHUYSEN JL, 1986, ANESTHESIOLOGY, V64, P440, DOI 10.1097/00000542-198604000-00005; BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; Bowdle TA, 1998, DRUG SAFETY, V19, P173, DOI 10.2165/00002018-199819030-00002; Buck RK, 2017, VET ANAESTH ANALG, V44, P138, DOI 10.1111/vaa.12402; Burroughs R, 2012, CHEM PHYS RESTRAINT, P168; CHENEY CS, 1988, J S AFR VET ASSOC, V59, P13; De van Pienaar UJ, 1966, J S AFR VET ASSOC, V37, P277; Gerlach CA, 2017, J ZOO WILDLIFE MED, V48, P62, DOI 10.1638/2016-0010.1; HAIGH JC, 1977, VET REC, V100, P386, DOI 10.1136/vr.100.18.386; HALES JRS, 1967, J PHYSIOL-LONDON, V190, P241, DOI 10.1113/jphysiol.1967.sp008205; Hart KA, 2012, VET J, V192, P137, DOI 10.1016/j.tvjl.2012.03.016; HARTHOORN AM, 1967, FED PROC, V26, P1251; Haw AJ, 2016, VET ANAESTH ANALG, V43, P539, DOI 10.1111/vaa.12343; JANSSEN DL, 1993, J ZOO WILDLIFE MED, V24, P11; Kastner SBR, 2006, VET ANAESTH ANALG, V33, P79, DOI 10.1111/j.1467-2995.2005.00243.x; KING JM, 1965, RES VET SCI, V6, P447; KNOX CM, 1990, COMP BIOCHEM PHYS C, V95, P247, DOI 10.1016/0742-8413(90)90113-N; Koehler H, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0381-1; Lance William R., 2012, P589; Meyer LCR, 2008, J S AFR VET ASSOC, V79, P121; Meyer LCR, 2010, J WILDLIFE DIS, V46, P514, DOI 10.7589/0090-3558-46.2.514; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; PEARCE PC, 1989, RES VET SCI, V46, P380, DOI 10.1016/S0034-5288(18)31184-6; Pienaar U de V, 1969, Acta Zool Pathol Antverp, V48, P163; SEAL US, 1985, J WILDLIFE DIS, V21, P411, DOI 10.7589/0090-3558-21.4.411; Smith I.L., 1993, P AM ASS ZOO VET, P367; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Vodoz JF, 2009, BMC CARDIOVASC DISOR, V9, DOI 10.1186/1471-2261-9-15; Weisner H., 1984, J ZOO ANIM MED, V15, P18; Woolf A., 1973, Journal Zool Anim Med, V4, P16, DOI 10.2307/20094207; Yaksh TL, 2011, GOODMAN GILMANS PHAR; Zeiler G.E., J ZOO WILDLIFE MED; Zeiler GE, 2015, J ZOO WILDLIFE MED, V46, P755, DOI 10.1638/2015-0052.1	34	2	2	1	2	AOSIS	CAPE TOWN	POSTNET SUITE 55, PRIVATE BAG X22, TYGERVALLEY, CAPE TOWN, 00000, SOUTH AFRICA	1019-9128	2224-9435		J S AFR VET ASSOC	J. S. Afr. Vet. Assoc.	AUG 4	2017	88								a1520	10.4102/jsava.v88i0.1520			8	Veterinary Sciences	Veterinary Sciences	FC6BW	WOS:000406926400001	28828865	DOAJ Gold, Green Published			2020-06-26	J	Lian, M; Bjorck, S; Arnemo, JM; Esteruelas, NF; Angel, M; Minsaas, SC; Jones, KL; Evans, AL				Lian, Marianne; Bjorck, Sven; Arnemo, Jon M.; Esteruelas, Nuria Fandos; Angel, Martine; Minsaas, Solveig C.; Jones, Krista L.; Evans, Alina L.			Severe Hypoxemia in Muskoxen (Ovibos moschatus) Immobilized with Etorphine and Xylazine Corrected with Supplemental Nasal Oxygen	JOURNAL OF WILDLIFE DISEASES			English	Article						Alpha-2-adrenoceptor agonist; blood gas; etorphine; hypoxemia; i-STAT; muskox; pulse oximeter; xylazine	ACEPROMAZINE; MEDETOMIDINE; SHEEP	Twenty-three muskoxen (Ovibos moschatus) housed in a captive facility for rewilding in Sweden were chemically immobilized for annual health evaluations and hoof trimming. The muskoxen were darted in May to September (2012-15) in their holding pen with etorphine (0.015 mg/kg) and xylazine (0.1 mg/kg) intramuscularly. Twenty-two of the 23 animals were immobilized with a single dart injection. The mean (SD) induction time was 4 (2) min. Arterial blood gases were collected from 18 animals. All animals were severely hypoxemic with varying degrees of respiratory acidosis. The hypoxemia resolved in 17 of 18 animals with intranasal oxygen supplementation at 1 L/min per 100 kg. Relative arterial oxygen saturation (SpO(2)) measured by pulse oximetry was significantly higher than the arterial oxygen saturation calculated from the partial pressure of arterial oxygen (SaO(2)) obtained by a blood gas analyzer. Based on these findings, muskox can be immobilized successfully with etorphine (0.015 mg/kg) and xylazine (0.1 mg/kg) but should receive supplemental oxygen.	[Lian, Marianne] Univ Alaska Fairbanks, Dept Vet Med, 901 Koyukuk Dr,182 Arctic Hlth Res Bldg, Fairbanks, AK 99709 USA; [Lian, Marianne] Univ Alaska Fairbanks, Dept Chem & Biochem, 900 Yukon Dr,Room 194, Fairbanks, AK 99775 USA; [Lian, Marianne; Arnemo, Jon M.; Esteruelas, Nuria Fandos; Angel, Martine; Minsaas, Solveig C.; Jones, Krista L.; Evans, Alina L.] Hedmark Univ Appl Sci, Dept Forestry & Wildlife Management, Campus Evenstad, NO-2480 Koppang, Norway; [Bjorck, Sven] Myskoxcentrum, Bygatan 29, SE-84094 Tannas, Sweden; [Arnemo, Jon M.] Swedish Univ Agr Sci, Dept Wildlife Fish & Environm Studies, SE-90183 Umea, Sweden	Lian, M (reprint author), Univ Alaska Fairbanks, Dept Vet Med, 901 Koyukuk Dr,182 Arctic Hlth Res Bldg, Fairbanks, AK 99709 USA.; Lian, M (reprint author), Univ Alaska Fairbanks, Dept Chem & Biochem, 900 Yukon Dr,Room 194, Fairbanks, AK 99775 USA.; Lian, M (reprint author), Hedmark Univ Appl Sci, Dept Forestry & Wildlife Management, Campus Evenstad, NO-2480 Koppang, Norway.	mlian@alaska.edu	Evans, Alina/AAH-8881-2019	Jones, Krista/0000-0001-9373-0982	Conservation Medicine Group at Campus Evenstad, Hedmark University of Applied Sciences	We thank the managers at Tannas Muskox Center, especially Hielke Chaudron. This project had the help of a number of technicians and students: L. Eriksen, B. Fuchs, S. Gronmo, E. E. Magnuson, R. C. Martinez, M. R. Saursaunet, C. M. Stolhaug, and Z. Walton. The i-STAT 1 machine and cartridges and travel funds for the authors and volunteers were provided by the Conservation Medicine Group at Campus Evenstad, Hedmark University of Applied Sciences.	Blix AS, 2011, ACTA VET SCAND, V53, DOI 10.1186/1751-0147-53-42; Caulkett NA, 1996, J ZOO WILDLIFE MED, V27, P217; Celly CS, 1999, J PHARMACOL EXP THER, V289, P712; CLAUSEN B, 1984, Journal of Wildlife Diseases, V20, P141; del Portillo I.P., 2014, ZOO ANIMAL WILDLIFE, P69; Evans AL, 2012, ACTA VET SCAND, V54, DOI 10.1186/1751-0147-54-77; Hall JE., 2016, GUYTON HALL TXB MED, P561; Harms NJ, 2012, ARCTIC, V65, P401; Hassanin Alexandre, 1998, Journal of Mammalian Evolution, V5, P217, DOI 10.1023/A:1020560412929; JINGFORS K, 1989, CAN J ZOOL, V67, P1120, DOI 10.1139/z89-160; Kreeger T. J., 2012, HDB WILDLIFE CHEM IM; Lian M, 2014, ACTA VET SCAND, V56, DOI 10.1186/s13028-014-0051-5; McDonell WN, 2015, VET ANAESTH ANALG, P513; R Development Core Team, 2014, R LANG ENV STAT COMP	14	2	2	0	2	WILDLIFE DISEASE ASSOC, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA	0090-3558	1943-3700		J WILDLIFE DIS	J. Wildl. Dis.	APR	2017	53	2					356	360		10.7589/2016-04-085			5	Veterinary Sciences	Veterinary Sciences	ER9OT	WOS:000399156700016	28051570				2020-06-26	J	Gerlach, CA; Kummrow, MS; Meyer, LC; Zeiler, GE; Stegmann, GF; Buck, RK; Fosgate, GT; Kastner, SB				Gerlach, Christina A.; Kummrow, Maya S.; Meyer, Leith C.; Zeiler, Gareth E.; Stegmann, George F.; Buck, Roxanne K.; Fosgate, Geoffrey T.; Kaestner, Sabine B.			CONTINUOUS INTRAVENOUS INFUSION ANESTHESIA WITH MEDETOMIDINE, KETAMINE, AND MIDAZOLAM AFTER INDUCTION WITH A COMBINATION OF ETORPHINE, MEDETOMIDINE, ANDMIDAZOLAMORWITHMEDETOMIDINE, KETAMINE, AND BUTORPHANOL IN IMPALA (AEPYCEROS MELAMPUS)	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						Aepyceros melampus; CII; impala; ketamine; medetomidine; midazolam	WILD IMPALA; ACEPROMAZINE; XYLAZINE; A3080; IMMOBILIZATION; DETOMIDINE; CAPTURE; HORSES	In order to develop a long-term anesthesia for flighty antelope species in field situations, two different protocols for induction and maintenance with an intravenous infusion were evaluated in wild-caught impala (Aepyceros melampus). Ten adult female impala were induced with two induction protocols: one consisted of 0.2 mg/kg medetomidine, 4 mg/kg ketamine, and 0.15 mg/kg butorphanol (MKB) and one consisted of 0.375 mg/kg etorphine, 0.2 mg/kg medetomidine, and 0.2 mg/kg midazolam (EMM). In both treatments, anesthesia was maintained with a continuous intravenous infusion (CII) at an initial dose rate of 1.2 mu g/kg per hr medetomidine, 2.4 mg/kg per hr ketaminen and 36 mu g/kg per hr midazolam. Partial reversal was achieved with naltrexone (2 : 1 mg butorphanol; 20 : 1 mg etorphine) and atipamezole (5 : 1 mg medetomidine). Evaluation of anesthesia included respiratory rate, heart rate, rectal temperature, arterial blood pressure, oxygen saturation, end tidal carbon dioxide tension, and tidal volume at 5-min intervals, palpebral reflex and response to painful stimuli at 15-min intervals, and arterial blood gases at 30-min intervals. Plasma cortisol concentration was determined after induction and before reversal. Duration and quality of induction and recovery were evaluated. EMM caused a faster induction of 9.5 +/- 2.9 min compared to 11.0 +/- 6.4 min in MKB. Recovery was also quicker in EMM(EMM: 6.3 +/- 5.4 min; MKB: 9.8 +/- 6.0 min). However, EMM also produced more cardiopulmonary side effects, including hypoxemia and hypercapnia, and calculated oxygenation indices (PaCO2-PETCO2) were worse than in MKB. One animal died after induction with EMM. The CII provided surgical anesthesia in 7 of 10 animals in MKB and in 9 of 9 animals in EMM for 120 min. In conclusion, the MKB induction protocol had advantages for prolonged anesthesia in impala with significantly less cardiopulmonary depression compared to EMM. The comparably decreased anesthetic depth could easily be adjusted by an increase of the CII.	[Gerlach, Christina A.; Kaestner, Sabine B.] Univ Vet Med Hanover, Small Anim Clin, Bunteweg 9, D-30559 Hannover, Germany; [Kummrow, Maya S.] Zoo Wuppertal, Hubertusallee 30, D-42117 Wuppertal, Germany; [Meyer, Leith C.] Univ Pretoria, Fac Vet Sci, Dept Paraclin Studies, Private Bag X04, ZA-0110 Onderstepoort, South Africa; [Zeiler, Gareth E.; Stegmann, George F.; Buck, Roxanne K.] Univ Pretoria, Fac Vet Sci, Dept Compan Anim Clin Studies, Private Bag X04, ZA-0110 Onderstepoort, South Africa; [Fosgate, Geoffrey T.] Univ Pretoria, Fac Vet Sci, Dept Prod Anim Studies, Private Bag X04, ZA-0110 Onderstepoort, South Africa; [Gerlach, Christina A.] Silleruper Str 1, D-24969 Grossenwiehe, Germany	Gerlach, CA (reprint author), Univ Vet Med Hanover, Small Anim Clin, Bunteweg 9, D-30559 Hannover, Germany.; Gerlach, CA (reprint author), Silleruper Str 1, D-24969 Grossenwiehe, Germany.	christina.hogrebe@gmx.net	Fosgate, Geoffrey T/N-8700-2014; Zeiler, Gareth/AAJ-7812-2020; Meyer, Leith/AAN-4930-2020; Kummrow, Maya/A-4743-2018	Fosgate, Geoffrey T/0000-0002-9432-0042; Zeiler, Gareth/0000-0001-7653-7726; Kummrow, Maya/0000-0002-5343-1336; Stegmann, George/0000-0002-6732-5980; Meyer, Leith/0000-0002-5122-2469; Stegmann, Frik/0000-0002-6122-4847	Wuppertal Zoo; Hannover Zoo; University of Pretoria	The authors would like to thank Wuppertal Zoo, Hannover Zoo, and the University of Pretoria for financial and logistic support during the impala study. Many thanks to Dr. Johan Steyl and his capture crew for transporting the impala to and from Onderstepoort.	Aarnes TK, 2013, AM J VET RES, V74, P294, DOI 10.2460/ajvr.74.2.294; Auer U, 2010, J WILDLIFE DIS, V46, P1196, DOI 10.7589/0090-3558-46.4.1196; Bergman S A, 1999, Anesth Prog, V46, P10; Berthier JL, 1996, P EAZWV, P1; BettschartWolfensberger R, 1996, AM J VET RES, V57, P1472; BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; Bush M, 2004, J S AFR VET ASSOC, V75, P14; Buss PE, 2001, J S AFR VET ASSOC, V72, P137; Caulkett N., 2003, Large Animal Veterinary Rounds, V3, P1; Citino SB, 2001, J S AFR VET ASSOC, V72, P29; Clarke K. W, 2014, VET ANAESTHESIA; Cooper DV, 2005, J S AFR VET ASSOC, V76, P18; Coruh B, 2013, CHEST, V143, P1145, DOI 10.1378/chest.12-2131; Grobler D, 2001, J S AFR VET ASSOC, V72, P81; HATTINGH J, 1988, J EXP ZOOL, V248, P109, DOI 10.1002/jez.1402480114; Haw A, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0253-0; Jacobs PL, 1999, J EXERC PHYSL, V2, P20; JANTZEN JP, 1985, ANAESTHESIST, V34, P346; Kastner SBR, 2006, VET ANAESTH ANALG, V33, P79, DOI 10.1111/j.1467-2995.2005.00243.x; KNOX CM, 1993, S AFR J WILDL RES, V23, P1; Kock MD, 2012, CHEM PHYS RESTRAINT, P235; Koehler H, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0381-1; Marntell S, 2005, VET ANAESTH ANALG, V32, P83, DOI 10.1111/j.1467-2995.2004.00178.x; Meyer LCR, 2008, J S AFR VET ASSOC, V79, P121; Meyer LCR, 2008, J WILDLIFE DIS, V44, P404, DOI 10.7589/0090-3558-44.2.404; Meyer LCR, 2010, J WILDLIFE DIS, V46, P514, DOI 10.7589/0090-3558-46.2.514; Miller M, 2013, J ZOO WILDLIFE MED, V44, P55, DOI 10.1638/1042-7260-44.1.55; MORTON DJ, 1995, VET REC, V136, P60, DOI 10.1136/vr.136.3.60; PEARCE PC, 1989, RES VET SCI, V46, P380, DOI 10.1016/S0034-5288(18)31184-6; Perrin KL, 2015, J ZOO WILDLIFE MED, V46, P870, DOI 10.1638/2015-0114.1; Portas TJ, 2003, J ZOO WILDLIFE MED, V34, P269, DOI 10.1638/02-062; Xie AL, 2001, J APPL PHYSIOL, V91, P1555; Yamashita K, 2007, J VET MED SCI, V69, P7, DOI 10.1292/jvms.69.7; Yamauchi H, 2011, BRIT J ANAESTH, V107, P631, DOI 10.1093/bja/aer171; Zeiler GE, 2015, J ZOO WILDLIFE MED, V46, P755, DOI 10.1638/2015-0052.1	35	4	4	1	9	AMER ASSOC ZOO VETERINARIANS	YULEE	581705 WHITE OAK ROAD, YULEE, FL 32097 USA	1042-7260	1937-2825		J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	MAR	2017	48	1					62	71		10.1638/2016-0010.1			10	Veterinary Sciences	Veterinary Sciences	ET5UO	WOS:000400353900009	28363076				2020-06-26	J	de Lange, SS; Fuller, A; Haw, A; Hofmeyr, M; Buss, P; Miller, M; Meyer, LCR				de Lange, Stephanie S.; Fuller, Andrea; Haw, Anna; Hofmeyr, Markus; Buss, Peter; Miller, Michele; Meyer, Leith C. R.			Tremors in white rhinoceroses (Ceratotherium simum) during etorphine-azaperone immobilisation	JOURNAL OF THE SOUTH AFRICAN VETERINARY ASSOCIATION			English	Article							CHEMICAL IMMOBILIZATION; BUTORPHANOL; CATECHOLAMINES; COMBINATIONS; ANESTHESIA; HYPOXEMIA; PH; DETOMIDINE; ADRENALINE; POTASSIUM	Little is known about the mechanisms causing tremors during immobilisation of rhinoceros and whether cardiorespiratory supportive interventions alter their intensity. Therefore, we set out to determine the possible mechanisms that lead to muscle tremors and ascertain whether cardiorespiratory supportive interventions affect tremor intensity. We studied tremors and physiological responses during etorphine-azaperone immobilisation in eight boma-held and 14 free-living white rhinoceroses. Repeated measures analysis of variance and a Friedman test were used to determine differences in variables over time and between interventions. Spearman and Pearson correlations were used to test for associations between variables. Tremor intensity measured objectively by activity loggers correlated well (p < 0.0001; r(2) = 0.9) with visual observations. Tremor intensity was greatest when animals were severely hypoxaemic and acidaemic. Tremor intensity correlated strongly and negatively with partial pressure of oxygen (PaO2) (p = 0.0003; r(2) = 0.9995) and potential of hydrogen (pH) (p = 0.02, r(2) = 0.97). It correlated strongly and positively with adrenaline concentrations (p = 0.003; r(2) = 0.96), and adrenaline correlated strongly and negatively with PaO2 (p = 0.03; r(2) = 0.95) and pH (p = 0.03; r(2) = 0.94). Therefore, hypoxaemia and acidaemia were likely associated with the intensity of tremors through their activation of the release of tremorgenic levels of adrenaline. Tremors can be reduced if circulating adrenaline is reduced, and this can be achieved by the administration of butorphanol plus oxygen insufflation. Furthermore, to assist with reducing the risks associated with rhinoceros immobilisation, tremor intensity could be used as a clinical indicator of respiratory and metabolic compromise.	[de Lange, Stephanie S.; Fuller, Andrea; Hofmeyr, Markus; Meyer, Leith C. R.] Univ Pretoria, Dept Paraclin Sci, Pretoria, South Africa; [Fuller, Andrea; Haw, Anna; Meyer, Leith C. R.] Univ Witwatersrand, Sch Physiol, Johannesburg, South Africa; [Hofmeyr, Markus; Buss, Peter] Kruger Natl Pk, South African Natl Pk, Vet Wildlife Serv, Pretoria, South Africa; [Buss, Peter] Univ Pretoria, Dept Prod Anim Sci, Pretoria, South Africa; [Miller, Michele] Univ Stellenbosch, Div Mol Biol & Human Genet, ZA-7600 Stellenbosch, South Africa	Meyer, LCR (reprint author), Univ Pretoria, Dept Paraclin Sci, Pretoria, South Africa.; Meyer, LCR (reprint author), Univ Witwatersrand, Sch Physiol, Johannesburg, South Africa.	leith.meyer@up.ac.za	Meyer, Leith/AAN-4930-2020	Meyer, Leith/0000-0002-5122-2469	National Research Foundation (NRF); Brain Function Research Group, at the University of the Witwatersrand; Faculty of Veterinary Science at the University of Pretoria	We would like to thank the staff of the SANParks Veterinary Wildlife Services for their exceptional care and handling of the animals and assisting with data collection. Additionally, we would like to thank Mr Francois Viljoen from the University of the North-West, Potchefstroom, for doing the catecholamine analysis, Dr Robyn Hetem for assisting with the activity loggers and Dr Peter Kamerman and Prof Duncan Mitchell for assisting with the data analysis. In particular, we would like to thank the National Research Foundation (NRF) for funding and the Brain Function Research Group, at the University of the Witwatersrand, and the Faculty of Veterinary Science at the University of Pretoria for financial and research support.	Atkinson MW, 2002, J ZOO WILDLIFE MED, V33, P157, DOI 10.1638/1042-7260(2002)033[0157:RCIOAC]2.0.CO;2; Berne R.M., 2000, PRINCIPLES PHYSL, P256; BURNELL JM, 1956, J CLIN INVEST, V35, P935, DOI 10.1172/JCI103352; Burroughs Richard, 2012, P143; Bush M, 2004, J S AFR VET ASSOC, V75, P79; Buss P, 2016, J ZOO WILDLIFE MED, V47, P834; Buss P, 2015, J ZOO WILDLIFE MED, V46, P224, DOI 10.1638/2014-0089R.1; Carithers R.W., 1995, TXB VET INTERNAL MED, V4, P143; Cazzola M, 2012, PULM PHARMACOL THER, V25, P4, DOI 10.1016/j.pupt.2011.12.004; Coetzee D., 2006, THESIS; DANIEL M, 1972, VET REC, V90, P336, DOI 10.1136/vr.90.12.336; DEVILLIERS AS, 1987, PSYCHIAT RES, V22, P127, DOI 10.1016/0165-1781(87)90100-4; Elble RJ, 2006, BRAIN, V129, P2660, DOI 10.1093/brain/awl190; Fahlman A., 2008, THESIS; Findley LJ, 1996, J CLIN NEUROPHYSIOL, V13, P122, DOI 10.1097/00004691-199603000-00003; Foley T.H., 1967, J PHYSL, V189, P65; Frishman WH, 2003, CIRCULATION, V107, pE117, DOI 10.1161/01.CIR.0000070983.15903.A2; GRAYSON J, 1983, J PHYSIOL-LONDON, V343, P311, DOI 10.1113/jphysiol.1983.sp014894; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P391; Haw A, 2015, J S AFR VET ASSOC, V86, DOI [10.4102/jsava.v86i1.1276, 10.4102/JSAVA.V86I1.1276]; Haw A, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0253-0; HEARD DJ, 1992, J ZOO WILDLIFE MED, V23, P197; Jeffers L A, 1986, AANA J, V54, P148; KANIA BF, 1985, J S AFR VET ASSOC, V56, P89; Kock MD, 1995, J ZOO WILDLIFE MED, V26, P207; Lakie M, 2010, EXP PHYSIOL, V95, P441, DOI 10.1113/expphysiol.2009.047555; Langhout MV, 2016, J ZOO WILDLIFE MED, V47, P827; MARSDEN CD, 1970, J PHYSIOL-LONDON, V207, P429, DOI 10.1113/jphysiol.1970.sp009071; MARSHALL J, 1966, J NEUROL NEUROSUR PS, V29, P214, DOI 10.1136/jnnp.29.3.214; Meltzer David, 2012, P81; Mentaberre G, 2010, J WILDLIFE DIS, V46, P923, DOI 10.7589/0090-3558-46.3.923; Mercadante S, 1998, PAIN, V74, P5, DOI 10.1016/S0304-3959(97)00090-0; Miller M.A., 2012, ZOO WILD ANIMAL MED, P538; Miller M, 2013, J ZOO WILDLIFE MED, V44, P55, DOI 10.1638/1042-7260-44.1.55; MORATINOS J, 1993, FUNDAM CLIN PHARM, V7, P143, DOI 10.1111/j.1472-8206.1993.tb00228.x; Moreira L.P.R., 2010, THESIS; NAGATA S, 1999, [No title captured], V30, P570, DOI DOI 10.1111/J.2042-3306.1999.TB05286.X; Nahas G G, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P73; PERRY SF, 1989, RESP PHYSIOL, V77, P351, DOI 10.1016/0034-5687(89)90122-9; Portas T, 2004, AUST VET J, V82, P542, DOI 10.1111/j.1751-0813.2004.tb11196.x; Prabhakar NR, 2000, J APPL PHYSIOL, V88, P2287; Prado TM, 2008, AM J VET RES, V69, P182, DOI 10.2460/ajvr.69.2.182; PRIMMETT DRN, 1986, J EXP BIOL, V122, P139; Radcliffe RW, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P741; Radcliffe RW, 2000, J ZOO WILDLIFE MED, V31, P196, DOI 10.1638/1042-7260(2000)031[0196:BAAAAS]2.0.CO;2; ROSE RJ, 1977, EQUINE VET J, V9, P68, DOI [10.1111/j.2042-3306.1977.tb03982.x, 10.1111/j.2042-3306.1977.tb04002.x]; Stackhouse SK, 2001, PHYS THER, V81, P1897, DOI 10.1093/ptj/81.12.1897; Vella-Brincat Jane, 2007, J Pain Palliat Care Pharmacother, V21, P15, DOI 10.1300/J354v21n01_05; WASSER JS, 1991, RESP PHYSIOL, V84, P363, DOI 10.1016/0034-5687(91)90130-B; Wenger S, 2007, J ZOO WILDLIFE MED, V38, P380, DOI 10.1638/2006-0038R.1; Yates DT, 2012, J PHYSIOL-LONDON, V590, P5439, DOI 10.1113/jphysiol.2012.237347	51	5	5	0	8	AOSIS	CAPE TOWN	POSTNET SUITE 55, PRIVATE BAG X22, TYGERVALLEY, CAPE TOWN, 00000, SOUTH AFRICA	1019-9128	2224-9435		J S AFR VET ASSOC	J. S. Afr. Vet. Assoc.	FEB 24	2017	88								a1466	10.4102/jsava.v88i0.1466			10	Veterinary Sciences	Veterinary Sciences	EQ0SD	WOS:000397780000002	28281770	DOAJ Gold, Green Published			2020-06-26	J	Fahlman, A; Edner, A; Wenger, S; Foggin, C; Nyman, G				Fahlman, Asa; Edner, Anna; Wenger, Sandra; Foggin, Chris; Nyman, Gorel			Pulmonary gas exchange and acid-base status during immobilisation of black rhinoceroses (Diceros bicornis) in Zimbabwe	JOURNAL OF THE SOUTH AFRICAN VETERINARY ASSOCIATION			English	Article							BEARS URSUS-ARCTOS; CERATOTHERIUM-SIMUM; OXYGEN INSUFFLATION; ANESTHETIZED HORSES; WHITE RHINOCEROSES; BLOOD-GAS; CHEMICAL IMMOBILIZATION; DEAD SPACE; ANESTHESIA; MEDETOMIDINE	When immobilising wildlife, adverse side effects can include hypoxaemia, acidosis and hypertension. Pulmonary gas exchange and acid-base status were evaluated during immobilisation of 25 free-ranging and one boma-held black rhinoceros (Diceros bicornis) in Zimbabwe. The effect of different body positions on arterial oxygenation was evaluated. A combination of the following drugs was used: an opioid (etorphine or thiafentanil), azaperone and an alpha(2)-adrenoceptor agonist (detomidine or xylazine). Respiratory and heart rates, rectal temperature and pulse oximetry-derived haemoglobin oxygen saturation were recorded. Serial arterial blood samples were analysed immediately in the field. Marked hypoxaemia and hypercapnia were recorded in immobilised free-ranging black rhinoceroses. Arterial oxygenation was higher during sternal compared to lateral recumbency. Most rhinoceroses developed acidaemia of respiratory and metabolic origin. Initially high lactate concentrations in free-ranging rhinoceroses decreased during immobilisation. Pulse oximetry was unreliable in the detection of hypoxaemia. Positioning in sternal recumbency and routine use of oxygen supplementation are recommended in the management of immobilised rhinoceroses as measures to improve arterial oxygenation.	[Fahlman, Asa; Edner, Anna; Nyman, Gorel] Swedish Univ Agr Sci, Dept Clin Sci, S-90183 Umea, Sweden; [Wenger, Sandra] Univ Zurich, Clin Zoo Anim Exot Pets & Wildlife, Vetsuisse Fac, CH-8006 Zurich, Switzerland; [Foggin, Chris] Victoria Falls Wildlife Trust, Victoria Falls, Zimbabwe	Fahlman, A (reprint author), Swedish Univ Agr Sci, Dept Clin Sci, S-90183 Umea, Sweden.	asa_fahlman@hotmail.com		Nyman, Gorel/0000-0002-2212-2151	U.S. Fish and Wildlife Service Rhinoceros and Tiger Conservation FundUS Fish & Wildlife Service; Animal Welfare Association in Vaxjo (Djurskyddet Kronoberg), Sweden	We thank the staff at the Wildlife Veterinary Unit, Parks and Wildlife Management Authority, Bubiana Conservancy, Malilangwe Trust, World Wide Fund for Nature (Southern African Regional Program Office), and Raoul du Toit, Director of the Lowveld Rhino Trust, for their valuable assistance during preparations and field operations in Zimbabwe. Also, many thanks to helicopter pilot John McTaggart. This study was supported by the U.S. Fish and Wildlife Service Rhinoceros and Tiger Conservation Fund, and the Animal Welfare Association in Vaxjo (Djurskyddet Kronoberg), Sweden. Statistical analyses were performed by Elisabeth Berg at the Medical Statistics Unit, Karolinska Institutet, Stockholm, Sweden. B. Zimmerman, Wildlife Pharmaceuticals (USA), Goran Hallgren, Abbott Scandinavia (Solna, Sweden) and GE Healthcare Information Technologies AB (Stockholm, Sweden) are also thanked for assisting with material support to the study.	Adams WA, 2005, VET ANAESTH ANALG, V32, P53, DOI 10.1111/j.1467-2995.2004.00181.x; Ball Ray L., 2001, P176; Basson P. A., 1975, CAPTURE CARE WILD AN, P151; Boardman WSJ, 2014, J WILDLIFE DIS, V50, P849, DOI 10.7589/2013-12-327; Bush M, 2004, J S AFR VET ASSOC, V75, P79; Buss P, 2015, J ZOO WILDLIFE MED, V46, P224, DOI 10.1638/2014-0089R.1; Citino SB, 2001, J S AFR VET ASSOC, V72, P29; CORNICKSEAHORN JL, 1995, J AM VET MED ASSOC, V206, P508; Di Bartola SP, 2006, FLUID ELECTROLYTE AC; Fahlman A., 2008, THESIS; Fahlman A, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P69; Fahlman A, 2011, J ZOO WILDLIFE MED, V42, P1, DOI 10.1638/2008-0117.1; Fahlman A, 2010, J ZOO WILDLIFE MED, V41, P161, DOI 10.1638/2009-0036.1; FRIEND SCE, 1981, CAN VET J, V22, P367; GLEED RD, 1988, RES VET SCI, V44, P255, DOI 10.1016/S0034-5288(18)30851-8; Grobler D, 2001, J S AFR VET ASSOC, V72, P81; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P391; HATTINGH J, 1994, S AFR J WILDL RES, V24, P12; Haw A, 2015, J S AFR VET ASSOC, V86, DOI [10.4102/jsava.v86i1.1276, 10.4102/JSAVA.V86I1.1276]; Haw A, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0253-0; Haymerle A, 2016, VET ANAESTH ANALG, V43, P566, DOI 10.1111/vaa.12334; HEARD DJ, 1992, J ZOO WILDLIFE MED, V23, P197; HEARD DJ, 1986, J AM VET MED ASSOC, V189, P1071; JANSSEN DL, 1993, J ZOO WILDLIFE MED, V24, P11; Johnston GM, 2004, EQUINE VET J, V36, P64, DOI 10.2746/0425164044864723; Kock MD, 1995, J ZOO WILDLIFE MED, V26, P207; Kock R. A., 1985, Journal of the Association of Veterinary Anaesthetists of Great Britain and Ireland, V13, P59; LINDSAY WA, 1985, AM J VET RES, V46, P688; Matthews NS, 2003, VET ANAESTH ANALG, V30, P3, DOI 10.1046/j.1467-2995.2003.00121.x; Mich PM, 2008, J ZOO WILDLIFE MED, V39, P480, DOI 10.1638/2007-0150.1; Miller M, 2013, J ZOO WILDLIFE MED, V44, P55, DOI 10.1638/1042-7260-44.1.55; MOENS Y, 1989, EQUINE VET J, V21, P282, DOI 10.1111/j.2042-3306.1989.tb02168.x; Morkel PV, 2010, J WILDLIFE DIS, V46, P236, DOI 10.7589/0090-3558-46.1.236; NYMAN G, 1989, EQUINE VET J, V21, P274, DOI 10.1111/j.2042-3306.1989.tb02167.x; NYMAN G, 1990, EQUINE VET J, V22, P317, DOI 10.1111/j.2042-3306.1990.tb04280.x; Radcliffe RW, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P741; Radcliffe RW, 2014, J ZOO WILDLIFE MED, V45, P263, DOI [10.1638/1042-7260-45.2.263, 1]; Smith KM, 2006, J ZOO WILDLIFE MED, V37, P513, DOI 10.1638/06-027.1; Spraker Terry R., 1993, P481; STANLEY TH, 1988, J WILDLIFE MANAGE, V52, P577, DOI 10.2307/3800910; Stegmann GF, 2001, J S AFR VET ASSOC, V72, P239; WALZER C, 2000, [No title captured], P98; Wenger S, 2007, J ZOO WILDLIFE MED, V38, P380, DOI 10.1638/2006-0038R.1	43	1	1	0	7	AOSIS	CAPE TOWN	POSTNET SUITE 55, PRIVATE BAG X22, TYGERVALLEY, CAPE TOWN, 00000, SOUTH AFRICA	1019-9128	2224-9435		J S AFR VET ASSOC	J. S. Afr. Vet. Assoc.	DEC 2	2016	87	1							a1328	10.4102/jsava.v87i1.1328			9	Veterinary Sciences	Veterinary Sciences	EI3IM	WOS:000392383700001	28155294	DOAJ Gold, Green Published			2020-06-26	J	Wang, XF; Barbier, E; Chiu, YT; He, Y; Zhan, J; Bi, GH; Zhang, HY; Feng, B; Liu-Chen, LY; Wang, JB; Xi, ZX				Wang, Xiao-Fei; Barbier, Elisabeth; Chiu, Yi-Ting; He, Yi; Zhan, Jia; Bi, Guo-Hua; Zhang, Hai-Ying; Feng, Bo; Liu-Chen, Lee-Yuan; Wang, Jia Bei; Xi, Zheng-Xiong			T394A Mutation at the mu Opioid Receptor Blocks Opioid Tolerance and Increases Vulnerability to Heroin Self-Administration in Mice	JOURNAL OF NEUROSCIENCE			English	Article						addiction; heroin; mu opioid receptor; mutation; self-administration; T394A	MORPHINE-INDUCED ANALGESIA; OPRM1 A118G POLYMORPHISM; MOLECULAR-MECHANISMS; OPIATE ADDICTION; THREONINE 394; MOUSE MODEL; PHOSPHORYLATION; DESENSITIZATION; DEPENDENCE; INTERNALIZATION	The etiology and pathophysiology underlying opioid tolerance and dependence are still unknown. Because mu opioid receptor (MOR) plays an essential role in opioid action, many vulnerability-related studies have focused on single nucleotide polymorphisms of MOR, particularly on A118G. In this study, we found that a single-point mutation at the MOR T394 phosphorylation site could be another important susceptive factor in the development of opioid tolerance and dependence in mice. T394A mutation, in which a threonine at 394 was replaced by an alanine, did not alter agonist binding to MOR and opioid analgesia, but resulted in loss of etorphine-induced MOR internalization in spinal dorsal horn neurons and opioid analgesic tolerance induced by either morphine or etorphine. In addition, this mutation also caused an increase in intravenous heroin self-administration and in nucleus accumbens dopamine response to heroin. These findings suggest that T394 phosphorylation following MOR activation causes MOR internalization and desensitization, which subsequently contributes to the development of tolerance in both opioid analgesia and opioid reward. Accordingly, T394A mutation blocks opioid tolerance and leads to an increase in brain dopamine response to opioids and in opioid-taking behavior. Thus, the T394may serve as a new drug target for modulating opioid tolerance and the development of opioid abuse and addiction.	[Wang, Xiao-Fei; He, Yi; Zhan, Jia; Bi, Guo-Hua; Zhang, Hai-Ying; Xi, Zheng-Xiong] NIDA, Mol Targets & Medicat Discovery Branch, Intramural Res Program, Baltimore, MD 21224 USA; [Barbier, Elisabeth; Feng, Bo; Wang, Jia Bei] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; [Chiu, Yi-Ting; Liu-Chen, Lee-Yuan] Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; [Wang, Xiao-Fei] Beijing Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China	Wang, JB (reprint author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.; Xi, ZX (reprint author), NIDA, Intramural Res Program, Baltimore, MD 21224 USA.	jwang@rx.umaryland.edu; zxi@mail.nih.gov	He, Yi/L-1772-2016; Wang, Xiaofei/B-1243-2019		National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA11925, DA018722]	This work was supported by the Intramural Research Program of the National Institute on Drug Abuse and National Institute on Drug Abuse Grants DA11925 and DA018722 to J.B.W.	Ahmed SH, 2000, NEUROPSYCHOPHARMACOL, V22, P413, DOI 10.1016/S0893-133X(99)00133-5; Bergen AW, 1997, MOL PSYCHIATR, V2, P490, DOI 10.1038/sj.mp.4000331; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Bohn LM, 2002, J NEUROSCI, V22, P10494; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; BUSTO U, 1986, CLIN PHARMACOKINET, V11, P144, DOI 10.2165/00003088-198611020-00004; Cheng PY, 1996, J COMP NEUROL, V371, P522, DOI 10.1002/(SICI)1096-9861(19960805)371:4<522::AID-CNE3>3.0.CO;2-6; Christie MJ, 2008, BRIT J PHARMACOL, V154, P384, DOI 10.1038/bjp.2008.100; Connor M, 2004, BRIT J PHARMACOL, V143, P685, DOI 10.1038/sj.bjp.0705938; Deng HB, 2000, BIOCHEMISTRY-US, V39, P5492, DOI 10.1021/bi991938b; El Kouhen R, 2001, J BIOL CHEM, V276, P12774, DOI 10.1074/jbc.M009571200; Franke P, 2001, AM J MED GENET, V105, P114, DOI 10.1002/1096-8628(20010108)105:1<114::AID-AJMG1074>3.0.CO;2-L; Grecksch G, 2011, J NEUROSCI, V31, P13890, DOI 10.1523/JNEUROSCI.2304-11.2011; Guang W, 2004, MOL PHARMACOL, V66, P1285, DOI 10.1124/mol.66.5.; Haerian BS, 2013, PHARMACOGENOMICS, V14, P813, DOI [10.2217/PGS.13.57, 10.2217/pgs.13.57]; Heilig M, 2011, NAT REV NEUROSCI, V12, P670, DOI 10.1038/nrn3110; Huang P, 2008, BIOCHEM BIOPH RES CO, V365, P82, DOI 10.1016/j.bbrc.2007.10.128; Ikeda K, 2002, NEUROSCI RES, V44, P121, DOI 10.1016/S0168-0102(02)00094-9; Koch T, 2008, PHARMACOL THERAPEUT, V117, P199, DOI 10.1016/j.pharmthera.2007.10.003; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Liu JG, 2001, BRAIN RES REV, V38, P1, DOI 10.1016/S0165-0173(01)00057-1; Luo F, 2004, NEUROIMAGE, V22, P1328, DOI 10.1016/j.neuroimage.2004.03.017; Mague SD, 2009, P NATL ACAD SCI USA, V106, P10847, DOI 10.1073/pnas.0901800106; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Nikolov MA, 2011, DRUG ALCOHOL DEPEN, V117, P62, DOI 10.1016/j.drugalcdep.2010.12.026; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; Reed B, 2014, CURR PSYCHIAT REP, V16, DOI 10.1007/s11920-014-0504-6; Sim-Selley LJ, 2000, J NEUROSCI, V20, P4555, DOI 10.1523/JNEUROSCI.20-12-04555.2000; Song R, 2012, P NATL ACAD SCI USA, V109, P17675, DOI 10.1073/pnas.1205297109; VOLKOW ND, 1995, ARCH GEN PSYCHIAT, V52, P456; Wang H, 2007, NEUROREPORT, V18, P1969, DOI 10.1097/WNR.0b013e3282f228b2; Williams JT, 2013, PHARMACOL REV, V65, P223, DOI 10.1124/pr.112.005942; Wise RA, 1996, CURR OPIN NEUROBIOL, V6, P243, DOI 10.1016/S0959-4388(96)80079-1; Wolf R, 1999, MOL PHARMACOL, V55, P263; Xi ZX, 2011, NAT NEUROSCI, V14, P1160, DOI 10.1038/nn.2874; Xi ZX, 1998, J PHARMACOL EXP THER, V284, P151; Xi ZX, 2004, MAGN RESON MED, V52, P108, DOI 10.1002/mrm.20119; Xi ZX, 2002, ALCOHOL ALCOHOLISM, V37, P485, DOI 10.1093/alcalc/37.5.485; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang Y, 2015, NEUROPSYCHOPHARMACOL, V40, P1091, DOI 10.1038/npp.2014.286; Zhao J, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-38	42	9	9	1	12	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	OCT 5	2016	36	40					10392	10403		10.1523/JNEUROSCI.0603-16.2016			12	Neurosciences	Neurosciences & Neurology	EC8BM	WOS:000388365000015	27707973	Bronze, Green Published			2020-06-26	J	Haw, AJ; Meyer, LCR; Greer, JJ; Fuller, A				Haw, Anna J.; Meyer, Leith C. R.; Greer, John J.; Fuller, Andrea			Ampakine CX1942 attenuates opioid-induced respiratory depression and corrects the hypoxaemic effects of etorphine in immobilized goats (Capra hircus)	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						CX1942; doxapram; hyperventilation; wildlife	EXCITATORY AMINO-ACIDS; RATS; DOXAPRAM; CX717; TRANSMISSION; CARFENTANIL; GENERATION; HYPOXIA; COMPLEX; RHYTHM	ObjectivesTo determine whether CX1942 reverses respiratory depression in etorphine-immobilized goats, and to compare its effects with those of doxapram hydrochloride. Study designA prospective, crossover experimental trial conducted at 1753m.a.s.l. AnimalsEight adult female Boer goats (Capra hircus) with a meanstandard deviation mass of 27.11.6kg. MethodsFollowing immobilization with 0.1mgkg(-1) etorphine, goats received one of doxapram, CX1942 or sterile water intravenously, in random order in three trials. Respiratory rate, ventilation and tidal volume were measured continuously. Arterial blood samples for the determination of PaO2, PaCO2, pH and SaO(2) were taken 2minutes before and then at 5minute intervals after drug administration for 25minutes. ResultsDoxapram corrected etorphine-induced respiratory depression but also led to arousal and hyperventilation at 2minutes after its administration, as indicated by the low PaCO2 (27.8 +/- 4.5mmHg) and ventilation of 5.32 +/- 5.24Lminute(-1) above pre-immobilization values. CX1942 improved respiratory parameters and corrected etorphine's hypoxaemic effects more gradually than did doxapram, with a more sustained improvement in PaO2 and SaO(2) in comparison with the control trial. ConclusionsCX1942 attenuated opioid-induced respiratory depression and corrected the hypoxaemic effects of etorphine in immobilized goats. Clinical relevanceAmpakines potentially offer advantages over doxapram, a conventional treatment, in reversing etorphine-induced respiratory depression without causing unwanted side effects, particularly arousal, in immobilized animals.	[Haw, Anna J.; Meyer, Leith C. R.; Fuller, Andrea] Univ Witwatersrand, Brain Funct Res Grp, Fac Hlth Sci, Sch Physiol, 7 York Rd, ZA-2193 Parktown, South Africa; [Meyer, Leith C. R.; Fuller, Andrea] Univ Pretoria, Dept Paraclin Sci, Fac Vet Sci, Onderstepoort, South Africa; [Greer, John J.] Univ Alberta, Fac Med & Dent, Dept Physiol, Edmonton, AB, Canada	Haw, AJ (reprint author), Univ Witwatersrand, Brain Funct Res Grp, Fac Hlth Sci, Sch Physiol, 7 York Rd, ZA-2193 Parktown, South Africa.	anna.haw@wits.ac.za	Fuller, Andrea/P-3133-2016; Meyer, Leith/AAN-4930-2020	Fuller, Andrea/0000-0001-6370-8151; Meyer, Leith/0000-0002-5122-2469	Faculty Research Committee Grant, University of the Witwatersrand; National Research Foundation, South AfricaNational Research Foundation - South Africa	The authors thank the staff of the Central Animal Services of the University of the Witwatersrand for their animal management and technical support, and staff and students of the Brain Function Research Group for their help with animal handling and data collection. We also thank Dr Jun Ren, Research Associate at the University of Alberta, for his guidance and help in acquiring CX1942, and Dr Arnold Lippa, Cortex Pharmaceuticals, Inc. (NJ, USA), for the provision of CX1942. This work was funded by a Faculty Research Committee Grant, University of the Witwatersrand, awarded to AJH, and a Thuthuka grant from the National Research Foundation, South Africa, awarded to LCRM.	Arai AC, 2004, NEUROSCIENCE, V123, P1011, DOI 10.1016/j.neuroscience.2003.10.033; Bleul U, 2012, VET J, V194, P240, DOI 10.1016/j.tvjl.2012.04.007; Bleul U, 2010, THERIOGENOLOGY, V73, P612, DOI 10.1016/j.theriogenology.2009.10.017; BRUCE RB, 1965, J MED CHEM, V8, P157, DOI 10.1021/jm00326a004; Burroughs Richard, 2012, P53; Buss PE, 2001, J S AFR VET ASSOC, V72, P137; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; ElMallah MK, 2015, AM J RESP CELL MOL, V53, P326, DOI 10.1165/rcmb.2014-0374OC; Feldman JL, 2013, ANNU REV PHYSIOL, V75, P423, DOI 10.1146/annurev-physiol-040510-130049; FUNK GD, 1993, J NEUROPHYSIOL, V70, P1497; GREER JJ, 1991, J PHYSIOL-LONDON, V437, P727, DOI 10.1113/jphysiol.1991.sp018622; Haw A, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0253-0; HEARD DJ, 1990, J ZOO WILDLIFE MED, V21, P166; Heard DJ, 1996, AM J VET RES, V57, P87; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Laffey JG, 2002, NEW ENGL J MED, V347, P43, DOI 10.1056/NEJMra012457; Lynch G, 2006, CURR OPIN PHARMACOL, V6, P82, DOI 10.1016/j.coph.2005.09.005; Meyer LCR, 2006, AM J PHYSIOL-REG I, V290, pR405; Meyer LCR, 2010, J WILDLIFE DIS, V46, P514, DOI 10.7589/0090-3558-46.2.514; Meyer LCR, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0337-5; Oertel BG, 2010, CLIN PHARMACOL THER, V87, P204, DOI 10.1038/clpt.2009.194; Pace RW, 2007, J PHYSIOL-LONDON, V582, P113, DOI 10.1113/jphysiol.2007.133660; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Ren J, 2006, AM J RESP CRIT CARE, V174, P1384, DOI 10.1164/rccm.200606-778OC; Ren J, 2015, AM J RESP CRIT CARE, V191, P704, DOI 10.1164/rccm.201410-1898OC; Ren J, 2013, ANESTHESIOLOGY, V118, P1437, DOI 10.1097/ALN.0b013e318291079c; Ren J, 2012, J APPL PHYSIOL, V113, P1004, DOI 10.1152/japplphysiol.00752.2012; Ren J, 2009, ANESTHESIOLOGY, V110, P1364, DOI 10.1097/ALN.0b013e31819faa2a; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; van der Schier Rutger, 2014, F1000Prime Rep, V6, P79, DOI 10.12703/P6-79; Yost CS, 2006, CNS DRUG REV, V12, P236, DOI 10.1111/j.1527-3458.2006.00236.x	31	5	5	1	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	SEP	2016	43	5					528	538		10.1111/vaa.12358			11	Veterinary Sciences	Veterinary Sciences	DW3UR	WOS:000383569100009	27531058				2020-06-26	J	Haw, AJ; Meyer, LCR; Fuller, A				Haw, Anna J.; Meyer, Leith C. R.; Fuller, Andrea			Nalbuphine and butorphanol reverse opioid-induced respiratory depression but increase arousal in etorphine-immobilized goats (Capra hircus)	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						immobilization; mixed opioid agonist-antagonists; opioids; wildlife	RHINOCEROS CERATOTHERIUM-SIMUM; RHESUS-MONKEYS; AGONIST; ANESTHESIA; ANALGESIA; RECEPTORS	ObjectivesTo evaluate and compare the efficacy of two opioid agonist-antagonists, nalbuphine and butorphanol, in reversing etorphine-induced respiratory depression in immobilized goats. Study designProspective, crossover, experimental trial conducted at 1753m.a.s.l. AnimalsEight adult female Boer goats (Capra hircus). MethodsEight minutes following immobilization with an intramuscular injection of 0.1mgkg(-1) etorphine, goats were given one of nalbuphine (0.8mgkg(-1)), butorphanol (0.1mgkg(-1)) or sterile water intravenously, in random order in three trials. Respiratory rate (f(R)), ventilation, tidal volume, oxygen consumption (VO2) and carbon dioxide production (VCO2) were measured continuously. Arterial blood samples to determine PaO2 and PaCO2 were taken 2minutes before and at 5minute intervals after etorphine administration for 25minutes. ResultsBoth nalbuphine and butorphanol increased mean PaO2 from 44mmHg (5.9kPa) to 63mmHg (8.4kPa) after etorphine administration. Butorphanol, but not nalbuphine, also corrected hypopnea and hypoventilation such that f(R) increasedfrom 134 to 217breathsminute(-1) (compared with 16 +/- 6breathsminute(-1) following nalbuphine) and ventilation increased from 4.69 +/- 3.04 to 6.91 +/- 4.42Lminute(-1) following butorphanol administration. Despite decreases in PaCO2 following nalbuphine and butorphanol, PaCO2 remained elevated compared with pre-immobilization values [nalbuphine: 34 +/- 3mmHg (4.5 +/- 0.3kPa); butorphanol: 34 +/- 2mmHg (4.5 +/- 0.3kPa)] throughout the immobilization. Both agents also decreased the level of immobilization, and increased O-2 and CO2. ConclusionsNalbuphine and butorphanol significantly improved respiratory function in immobilized goats, with butorphanol eliciting a greater positive response than nalbuphine. However, both opioid agonist-antagonists partly reversed etorphine-induced immobilization. Clinical relevanceButorphanol and nalbuphine can be used to improve respiratory parameters in etorphine-immobilized wildlife, with butorphanol being more effective, but unwanted arousal can occur.	[Haw, Anna J.; Meyer, Leith C. R.; Fuller, Andrea] Univ Witwatersrand, Brain Funct Res Grp, Fac Hlth Sci, Sch Physiol, 7 York Rd, ZA-2193 Parktown, Joahnnesburg, South Africa; [Meyer, Leith C. R.; Fuller, Andrea] Univ Pretoria, Dept Paraclin Sci, Fac Vet Sci, Onderstepoort, South Africa	Haw, AJ (reprint author), Univ Witwatersrand, Brain Funct Res Grp, Fac Hlth Sci, Sch Physiol, 7 York Rd, ZA-2193 Parktown, Joahnnesburg, South Africa.	anna.haw@wits.ac.za	Meyer, Leith/AAN-4930-2020; Fuller, Andrea/P-3133-2016	Fuller, Andrea/0000-0001-6370-8151; Meyer, Leith/0000-0002-5122-2469	Faculty Research Committee Grant, University of the Witwatersrand; National Research Foundation, South AfricaNational Research Foundation - South Africa	The authors thank the staff of the Central Animal Services of the University of the Witwatersrand for their animal management and technical support, and the staff and students of the Brain Function Research Group for their help with animal handling and data collection. This work was funded by a Faculty Research Committee Grant, University of the Witwatersrand, awarded to AJH and a Thuthuka grant from the National Research Foundation, South Africa, awarded to LCRM.	BOWDLE TA, 1987, ANESTH ANALG, V66, P517; Bowdle TA, 1998, DRUG SAFETY, V19, P173, DOI 10.2165/00002018-199819030-00002; Burroughs R, 2012, CHEM PHYS RESTRAINT, P53; BUTELMAN ER, 1995, J PHARMACOL EXP THER, V272, P845; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; Goodwin SD, 1998, CONTEMP TOP LAB ANIM, V37, P51; Haw A, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0253-0; HOSKIN PJ, 1991, DRUGS, V41, P326, DOI 10.2165/00003495-199141030-00002; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; LING GSF, 1985, J PHARMACOL EXP THER, V232, P149; Meyer LCR, 2006, AM J PHYSIOL-REG I, V290, pR405; Miller M, 2013, J ZOO WILDLIFE MED, V44, P55, DOI 10.1638/1042-7260-44.1.55; Oertel BG, 2010, CLIN PHARMACOL THER, V87, P204, DOI 10.1038/clpt.2009.194; PALLASCH TJ, 1985, ORAL SURG ORAL MED O, V59, P15, DOI 10.1016/0030-4220(85)90108-2; Pasternak Gavril, 2011, Acta Anaesthesiol Taiwan, V49, P21, DOI 10.1016/j.aat.2010.12.008; Pasternak GW, 2014, NEUROPHARMACOLOGY, V76, P198, DOI 10.1016/j.neuropharm.2013.03.039; Roozekrans M, 2014, ANESTHESIOLOGY, V121, P459, DOI 10.1097/ALN.0000000000000367; SCHMIDT WK, 1985, DRUG ALCOHOL DEPEN, V14, P339, DOI 10.1016/0376-8716(85)90066-3; Shang Y, 2015, EUR J PHARMACOL, V763, P206, DOI 10.1016/j.ejphar.2015.05.012; Vivian JA, 1999, J PHARMACOL EXP THER, V290, P259; ZUCKER JR, 1987, ANESTH ANALG, V66, P879	22	5	6	0	10	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	SEP	2016	43	5					539	548		10.1111/vaa.12343			10	Veterinary Sciences	Veterinary Sciences	DW3UR	WOS:000383569100010	26878827				2020-06-26	J	Gerritsmann, H; Stalder, GL; Kaczensky, P; Buuveibaatar, B; Payne, J; Boldbaatar, S; Walzer, C				Gerritsmann, Hanno; Stalder, Gabrielle L.; Kaczensky, Petra; Buuveibaatar, Bayarbaatar; Payne, John; Boldbaatar, Sukhbaatar; Walzer, Chris			Arterial pH and Blood Lactate Levels of Anesthetized Mongolian Khulan (Equus hemionus hemionus) in the Mongolian Gobi Correlate with Induction Time	JOURNAL OF WILDLIFE DISEASES			English	Article						Anesthesia; arterial; equid; Equus hemionus; lactate; pH; wild		Research and conservation of wide-ranging wild equids in most cases necessitate capture and handling of individuals. For freeroaming Mongolian khulan (Equus hemionus hemionus), also known as the khulan, capture involves a strenuous, high-speed chase, and physiologic responses have yet to be elucidated. We analyzed sequential arterial blood gas (ABG) samples as a proxy for respiratory and metabolic status of khulan during capture-related anesthesia. We recorded precise chase and induction times and monitored vital parameters and ABG from free-ranging khulan during anesthesia performed for GPS collaring. At the initiation of anesthesia, animals had ABG values similar to those recorded for thoroughbred horses (Equus caballus) after maximal exercise. Longer induction times resulted in higher arterial pH (P< 0.001) and lower blood lactate (P< 0.002). This trend of improvement continued over the course of anesthesia. The most important factor explaining pH and lactate was the time that elapsed between cessation of the chase and obtaining the first ABG sample, which, under field conditions, is tightly linked to induction time. All animals recovered uneventfully. Our data show that khulan recover and shift their metabolic status back toward expected normal values during opioid-based field anesthesia.	[Gerritsmann, Hanno; Stalder, Gabrielle L.; Kaczensky, Petra; Walzer, Chris] Univ Vet Med, Dept Integrat Biol & Evolut, Res Inst Wildlife Ecol, Savoyenstr 1, A-1160 Vienna, Austria; [Buuveibaatar, Bayarbaatar; Payne, John] Wildlife Conservat Soc, Mongolia Program, POB 485,PO 38, Ulaanbaatar 15141, Mongolia; [Boldbaatar, Sukhbaatar] State Cent Vet Lab, Khan Uul Dist 17024, Ulaanbaatar, Mongolia	Walzer, C (reprint author), Univ Vet Med, Dept Integrat Biol & Evolut, Res Inst Wildlife Ecol, Savoyenstr 1, A-1160 Vienna, Austria.	Chris.Walzer@vetmeduni.ac.at		Kaczensky, Petra/0000-0001-5428-1176	Wildlife Conservation Society (WCS)	Funding for the capture and collaring of khulan was received from the Wildlife Conservation Society (WCS), administered through a cooperative agreement with Sustainability East Asia LLC (SEA), and originating from Oyu Tolgoi (OT) gold and copper mining company. Many people provided input and logistic, practical, and emotional support for this project. We thank R. Hengsberger for her assistance with the manuscript; WCS staff: A. Edwards, S. Enkhtuvshin, J. Losolmaa, K. Murphy, U. Narantsatsral, P. Zahler; OT staff: G. Anudari, D. Hosack, B. Dashnyam, S. Dorjderem, T. Onon, T. Purevsuren; SEA staff: B. Nyamdorj, S. Gills; drivers: K. Bagitjan, Z. Bat-Uul, and D. Galbadrakh; and all others who helped. All data for this study were obtained during regular anesthesia monitoring of khulan. No changes were made to the established protocol for the routine anesthesia done. Permission for capture was given by the Ministry of Environment and Green Development of Mongolia, issued 1 August 2013, reference: 6/4136.	Batsaikhan N, 2014, CONSERV BIOL, V28, P1736, DOI 10.1111/cobi.12297; Birks EK, 1991, EQUINE EXERCISE PHYS, V3, P179; Hubbell JAE, 2000, AM J VET RES, V61, P1545, DOI 10.2460/ajvr.2000.61.1545; Kaczensky P, 2006, MONGOLIA ROOM ROAM T; Manohar M, 2001, J APPL PHYSIOL, V90, P2371; R Development Core Team, 2013, R LANG ENV STAT COMP; Wagner AE, 2008, VET CLIN N AM-EQUINE, V24, P735, DOI 10.1016/j.cveq.2008.10.002; Walzer C, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P719; Walzer Chris, 2006, Mongolian Journal of Biological Sciences, V4, P19	9	2	2	0	4	WILDLIFE DISEASE ASSOC, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA	0090-3558	1943-3700		J WILDLIFE DIS	J. Wildl. Dis.	JUL	2016	52	3					642	646		10.7589/2015-07-198			5	Veterinary Sciences	Veterinary Sciences	DT5NA	WOS:000381528700025	27243152				2020-06-26	J	Chen, CG; Chiu, YT; Wu, WM; Huang, P; Mann, A; Schulz, S; Liu-Chen, LY				Chen, Chongguang; Chiu, Yi-Ting; Wu, Wenman; Huang, Peng; Mann, Anika; Schulz, Stefan; Liu-Chen, Lee-Yuan			Determination of sites of U50,488H-promoted phosphorylation of the mouse kappa opioid receptor (KOPR): disconnect between KOPR phosphorylation and internalization	BIOCHEMICAL JOURNAL			English	Article						endocytosis threshold; kappa opioid receptor; phospho-kappa opioid receptor-specific antibody; phosphorylation sites; SILAC	PROTEIN-KINASE ACTIVATION; BETA-ARRESTIN; 6'-GUANIDINONALTRINDOLE 6'-GNTI; FUNCTIONAL SELECTIVITY; COUPLED RECEPTOR; AGONIST; DESENSITIZATION; TRAFFICKING; ANTIBODIES; MECHANISM	Phosphorylation sites of KOPR (kappa opioid receptor) following treatment with the selective agonist U50,488H {(-)(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidiny)cyclo-hexyl] benzeneacetamide} were identified after affinity purification, SDS/PAGE, in-gel digestion with Glu-C and HPLC-MS/MS. Single-and double-phosphorylated peptides were identified containing phosphorylated Ser(356), Thr(357), Thr(363) and Ser(369) in the C-terminal domain. Antibodies were generated against three phosphopeptides containing pSer(356)/pThr(357), pThr(363) and pSer(369) respectively, and affinity-purified antibodies were found to be highly specific for phospho-KOPR. U50,488H markedly enhanced staining of theKOPR by pThr(363)-, pSer(369)- and pSer(356)/pThr(357)-specific antibodies in immunoblotting, which was blocked by the selective KOPR antagonist norbinaltorphimine. Ser(369) phosphorylation affected Thr(363) phosphorylation and vice versa, and Thr(363) or Ser(369) phosphorylation was important for Ser(356)/Thr(357) phosphorylation, revealing a phosphorylation hierarchy. U50,488H, but not etorphine, promoted robust KOPR internalization, although both were full agonists. U50,488H induced higher degrees of phosphorylation than etorphine at Ser(356)/Thr(357), Thr(363) and Ser(369) as determined by immunoblotting. Using SILAC (stable isotope labelling by amino acids in cell culture) and HPLC-MS/MS, we found that, compared with control (C), U50,488H (U) and etorphine (E) KOPR promoted single phosphorylation primarily at Thr(363) and Ser(369) with U/E ratios of 2.5 and 2 respectively. Both induced double phosphorylation at Thr(363) + Ser(369) and Thr(357) + Ser(369) with U/E ratios of 3.3 and 3.4 respectively. Only U50,488H induced triple phosphorylation at Ser(356) + Thr(357) + Ser(369). An unphosphorylated KOPR-(354-372) fragment containing all of the phosphorylation sites was detected with a C/E/U ratio of 1/0.7/0.4, indicating that similar to 60% and similar to 30% of the mouse KOPR are phosphorylated following U50,488H and etorphine respectively. Thus KOPR internalization requires receptor phosphorylation above a certain threshold, and higher-order KOPR phosphorylation may be disproportionally important.	[Chen, Chongguang; Chiu, Yi-Ting; Wu, Wenman; Huang, Peng; Liu-Chen, Lee-Yuan] Temple Univ, Lewis Katz Sch Med, Ctr Substance Abuse Res, Philadelphia, PA 19140 USA; [Chen, Chongguang; Chiu, Yi-Ting; Wu, Wenman; Huang, Peng; Liu-Chen, Lee-Yuan] Temple Univ, Lewis Katz Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; [Mann, Anika; Schulz, Stefan] Univ Jena, Jena Univ Hosp, Inst Pharmacol & Toxicol, D-07747 Jena, Germany	Liu-Chen, LY (reprint author), Temple Univ, Lewis Katz Sch Med, Ctr Substance Abuse Res, Philadelphia, PA 19140 USA.; Liu-Chen, LY (reprint author), Temple Univ, Lewis Katz Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA.	lliuche@temple.edu	Schulz, Stefan/A-6928-2017	Schulz, Stefan/0000-0002-5997-8885	National Institutes of Health National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA017302, R03 DA036802, P30 DA013429]	This work was supported by the National Institutes of Health National Institute on Drug Abuse [grant numbers R01 DA017302, R03 DA036802 and P30 DA013429].	Barber A, 1997, Expert Opin Investig Drugs, V6, P1351, DOI 10.1517/13543784.6.10.1351; BREDDAM K, 1992, EUR J BIOCHEM, V206, P103, DOI 10.1111/j.1432-1033.1992.tb16906.x; Bruchas MR, 2007, J NEUROSCI, V27, P11614, DOI 10.1523/JNEUROSCI.3769-07.2007; Busillo JM, 2010, J BIOL CHEM, V285, P7805, DOI 10.1074/jbc.M109.091173; Butcher AJ, 2011, J BIOL CHEM, V286, P11506, DOI 10.1074/jbc.M110.154526; Chen CG, 2006, J BIOL CHEM, V281, P7983, DOI 10.1074/jbc.M509805200; DiMattio KM, 2015, EUR J PHARMACOL, V761, P235, DOI 10.1016/j.ejphar.2015.05.054; Doll C, 2011, BRIT J PHARMACOL, V164, P298, DOI 10.1111/j.1476-5381.2011.01382.x; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Lau EK, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001748; Law P.-Y., 2011, THE OPIATE RECEPTORS; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; Li JG, 2007, BIOCHEMISTRY-US, V46, P10960, DOI 10.1021/bi700443j; Liu-Chen LY, 2004, LIFE SCI, V75, P511, DOI 10.1016/j.lfs.2003.10.041; Mann M, 2006, NAT REV MOL CELL BIO, V7, P952, DOI 10.1038/nrm2067; McLaughlin JP, 2004, J BIOL CHEM, V279, P1810, DOI 10.1074/jbc.M305796200; McLaughlin JP, 2003, J BIOL CHEM, V278, P34631, DOI 10.1074/jbc.M304022200; McLennan GP, 2008, J NEUROCHEM, V107, P1753, DOI 10.1111/j.1471-4159.2008.05745.x; Michel MC, 2009, N-S ARCH PHARMACOL, V379, P385, DOI 10.1007/s00210-009-0395-y; Nobles KN, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001707; Ong SE, 2006, NAT PROTOC, V1, P2650, DOI 10.1038/nprot.2006.427; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; Rives ML, 2012, J BIOL CHEM, V287, P27050, DOI 10.1074/jbc.C112.387332; Schmid CL, 2013, J BIOL CHEM, V288, P22387, DOI 10.1074/jbc.M113.476234; Schulz S, 2004, EMBO J, V23, P3282, DOI 10.1038/sj.emboj.7600334; SLIZGI GR, 1982, J PHARMACOL EXP THER, V220, P585; Togashi Y, 2002, EUR J PHARMACOL, V435, P259, DOI 10.1016/S0014-2999(01)01588-6; Torrecilla I, 2007, J CELL BIOL, V177, P127, DOI 10.1083/jcb.200610018; Trester-Zedlitz M, 2005, BIOCHEMISTRY-US, V44, P6133, DOI 10.1021/bi0475469; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7; White KL, 2015, J PHARMACOL EXP THER, V352, P98, DOI 10.1124/jpet.114.216820; Zhou L, 2013, J BIOL CHEM, V288, P36703, DOI 10.1074/jbc.M113.504381	34	9	9	0	8	PORTLAND PRESS LTD	LONDON	CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND	0264-6021	1470-8728		BIOCHEM J	Biochem. J.	FEB 15	2016	473		4				497	508		10.1042/BJ20141471			12	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	DK2ZR	WOS:000374785000013	26635353	Green Accepted			2020-06-26	J	Perrin, KL; Denwood, MJ; Grondahl, C; Nissen, P; Bertelsen, MF				Perrin, Kathryn L.; Denwood, Matthew J.; Grondahl, Carsten; Nissen, Peter; Bertelsen, Mads F.			COMPARISON OF ETORPHINE-ACEPROMAZINE AND MEDETOMIDINE-KETAMINE ANESTHESIA IN CAPTIVE IMPALA (AEPYCEROS MELAMPUS)	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						Acepromazine; Aepyceros melampus; etorphine; impala; ketamine; medetomidine	NEAR-INFRARED SPECTROSCOPY; CLINICALLY HEALTHY; IMMOBILIZATION; COMBINATION; HYPOXEMIA; HORSE; ATIPAMEZOLE; OXYGENATION; REVERSAL; AGONISTS	Impala (Aepyceros melampus) are a notoriously difficult species to manage in captivity, and anesthesia is associated with a high risk of complications including mortality. The aim of this study was to compare an opioid-based protocol with an alpha-2 agonist-based protocol. Nine female impala were studied in a random cross-over design. Subjects received either an etorphine-acepromazine (EA) protocol: 15 mu g/kg etorphine and 0.15 mg/kg acepromazine, or a medetomidine-ketamine (MK) protocol: 109 mu g/kg medetomidine and 4.4 mg/kg ketamine on day 1. Anaesthesia was repeated 3 days later with the alternative protocol. Subjective assessments of the quality of induction, muscle relaxation, and recovery were made by a blinded observer. Objective monitoring included blood pressure, end-tidal CO2, regional tissue oxygenation, and blood gas analysis. EAprovided a significantly quicker (mean EA, 7.17 mins; MK, 17.6 mins) and more-reliable (score range EA, 3-5; MK, 1-5) induction. Respiratory rates were lower for EA with higher end-tidal CO2, but no apnoea was observed. As expected, blood pressures with EAwere lower, with higher heart rates; however, arterial oxygenation and tissue oxygenation were equal or higher than with the MK protocol. In conclusion, at these doses, EAprovided superior induction and equivalent muscle relaxation and recovery with apparent improved oxygen tissue delivery when compared to MK.	[Perrin, Kathryn L.; Grondahl, Carsten; Bertelsen, Mads F.] Copenhagen Zoo, Ctr Zoo & Wild Anim Hlth, DK-2000 Frederiksberg, Denmark; [Denwood, Matthew J.] Univ Copenhagen, Sect Anim Welf & Dis Control, DK-1870 Frederiksberg, Denmark; [Nissen, Peter] Rigshosp, Dept Anesthesia, DK-2100 Copenhagen, Denmark	Perrin, KL (reprint author), Copenhagen Zoo, Ctr Zoo & Wild Anim Hlth, Roskildevej 38, DK-2000 Frederiksberg, Denmark.	kap@zoo.dk		Bertelsen, Mads/0000-0001-9201-7499; Perrin, Kathryn/0000-0002-3887-6302			Allan JL, 1991, P AM ASS ZOO VET, P333; Ball RL, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P831; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Burroughs R, 2012, CHEM PHYS RESTRAINT, P168; Bush M, 2004, J S AFR VET ASSOC, V75, P14; Cooper DV, 2005, J S AFR VET ASSOC, V76, P18; Dahan A, 2001, ANESTHESIOLOGY, V94, P824, DOI 10.1097/00000542-200105000-00021; Fahlman A, 2012, J ZOO WILDLIFE MED, V43, P67, DOI 10.1638/2011-0064.1; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P391; Hall KE, 2008, J VET EMERG CRIT CAR, V18, P594, DOI 10.1111/j.1476-4431.2008.00369.x; JALANKA HH, 1990, J ZOO WILDLIFE MED, V21, P259; JALANKA HH, 1989, J ZOO WILDLIFE MED, V20, P413; JANSSEN DL, 1993, J ZOO WILDLIFE MED, V24, P11; Kuznetsova A, 2014, IMERTEST TESTS RANDO; Lamont LA, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P5; LEES P, 1983, VET RES COMMUN, V7, P201, DOI 10.1007/BF02228617; Leise BS, 2007, VET SURG, V36, P717, DOI 10.1111/j.1532-950X.2007.00325.x; Meyer LCR, 2008, J S AFR VET ASSOC, V79, P121; Meyer LCR, 2010, J WILDLIFE DIS, V46, P514, DOI 10.7589/0090-3558-46.2.514; Murrell JC, 2005, VET ANAESTH ANALG, V32, P117, DOI 10.1111/j.1467-2995.2005.00233.x; Nissen P, 2010, NEUROCRIT CARE, V12, P17, DOI 10.1007/s12028-009-9313-x; Ozeki L, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P43; PARRY BW, 1982, AUST VET J, V59, P148, DOI 10.1111/j.1751-0813.1982.tb02761.x; Phillips LG, 1998, P AM ASS ZOO VET, P19; Pringle J, 2000, EQUINE VET J, V32, P59, DOI 10.2746/042516400777611973; R-Core-Team, 2014, R LANG ENV STAT COMP; Read MR, 2003, J ZOO WILDLIFE MED, V34, P134, DOI 10.1638/1042-7260(2003)034[0134:AROAAA]2.0.CO;2; Read MR, 2001, CAN VET J, V42, P861; Redlin M, 2008, J THORAC CARDIOV SUR, V136, P962, DOI 10.1016/j.jtcvs.2007.12.058; RUSKO H, 1986, EUR J APPL PHYSIOL O, V55, P181, DOI 10.1007/BF00715002; Schumacher J, 1997, AM J VET RES, V58, P157; Shimizu S, 2012, CIRC J, V76, P152, DOI 10.1253/circj.CJ-11-0574; Taylor JH, 2005, J TRAUMA, V58, P1119, DOI 10.1097/01.TA.0000169951.20802.20; Wiesner H, 1982, Z KOELNER ZOO, P47	34	6	6	0	11	AMER ASSOC ZOO VETERINARIANS	YULEE	581705 WHITE OAK ROAD, YULEE, FL 32097 USA	1042-7260	1937-2825		J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	DEC	2015	46	4					870	879		10.1638/2015-0114.1			10	Veterinary Sciences	Veterinary Sciences	CZ7UQ	WOS:000367306000024	26667544				2020-06-26	J	Zeiler, GE; Stegmann, GF; Fosgate, G; Buck, RK; Kastner, SBR; Kummrow, M; Gerlach, C; Meyer, LCR				Zeiler, Gareth E.; Stegmann, George F.; Fosgate, Geoffrey; Buck, Roxanne K.; Kaestner, Sabine B. R.; Kummrow, Maya; Gerlach, Christina; Meyer, Leith C. R.			ETORPHINE-KETAMINE-MEDETOMIDINE TOTAL INTRAVENOUS ANESTHESIA IN WILD IMPALA (AEPYCEROS MELAMPUS) OF 120-MINUTE DURATION	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						Aepyceros melampus; etorphine; impala; ketamine; medetomidine; TIVA	CARBON-DIOXIDE GRADIENT; RESPIRATORY DEPRESSION; NEGATIVE ARTERIAL; HYPOXEMIA; ATELECTASIS; SHUNT	There is a growing necessity to perform long-term anesthesia in wildlife, especially antelope. The costs and logistics of transporting wildlife to veterinary practices make surgical intervention a high-stakes operation. Thus there is a need for a field-ready total intravenous anesthesia (TIVA) infusion to maintain anesthesia in antelope. This study explored the feasibility of an etorphine-ketamine-medetomidine TIVA for field anesthesia. Ten wild-caught, adult impala (Aepyceros melampus) were enrolled in the study. Impala were immobilized with a standardized combination of etorphine (2 mg) and medetomidine (2.2 mg), which equated to a median (interquartile range [IQR]) etorphine and medetomidine dose of 50.1 (46.2-50.3) and 55.1 (50.8-55.4) mu g/kg, respectively. Recumbency was attained in a median (IQR) time of 13.9 (12.0-16.5) min. Respiratory gas tensions, spirometry, and arterial blood gas were analyzed over a 120-min infusion. Once instrumented, the TIVA was infused as follows: etorphine at a variable rate initiated at 40 mu g/kg per hour (adjusted according to intermittent deep-pain testing); ketamine and medetomidine at a fixed rate of 1.5 mg/kg per hour and 5 mu g/kg per hour, respectively. The etorphine had an erratic titration to clinical effect in four impala. Arterial blood pressure and respiratory and heart rates were all within normal physiological ranges. However, arterial blood gas analysis revealed severe hypoxemia, hypercapnia, and acidosis. Oxygenation and ventilation indices were calculated and highlighted possible co-etiologies to the suspected etorphine-induced respiratory depression as the cause of the blood gas derangements. Impala recovered in the boma post atipamezole (13 mg) and naltrexone (42 mg) antagonism of medetomidine and etorphine, respectively. The etorphine-ketamine-medetomidine TIVA protocol for impala may be sufficient for field procedures of up to 120-min duration. However, hypoxemia and hypercapnia are of paramount concern and thus oxygen supplementation should be considered mandatory. Other TIVA combinations may be superior and warrant further investigation.	[Zeiler, Gareth E.; Stegmann, George F.; Buck, Roxanne K.] Univ Pretoria, Fac Vet Sci, Dept Compan Anim Clin Studies, ZA-0110 Onderstepoort, South Africa; [Fosgate, Geoffrey] Univ Pretoria, Fac Vet Sci, Dept Prod Anim Studies, ZA-0110 Onderstepoort, South Africa; [Meyer, Leith C. R.] Univ Pretoria, Fac Vet Sci, Dept Paraclin Studies, ZA-0110 Onderstepoort, South Africa; [Kaestner, Sabine B. R.; Gerlach, Christina] Univ Vet Med Hannover, Small Anim Clin, D-30559 Hannover, Germany; [Kummrow, Maya] Zoo Wuppertal, D-42117 Wuppertal, Germany	Zeiler, GE (reprint author), Univ Pretoria, Fac Vet Sci, Dept Compan Anim Clin Studies, Private Bag X04, ZA-0110 Onderstepoort, South Africa.	gareth.zeiler@up.ac.za	Zeiler, Gareth/AAJ-7812-2020; Kummrow, Maya/A-4743-2018; Fosgate, Geoffrey T/N-8700-2014; Meyer, Leith/AAN-4930-2020	Zeiler, Gareth/0000-0001-7653-7726; Kummrow, Maya/0000-0002-5343-1336; Fosgate, Geoffrey T/0000-0002-9432-0042; Stegmann, Frik/0000-0002-6122-4847; Meyer, Leith/0000-0002-5122-2469; Stegmann, George/0000-0002-6732-5980	Hannover Zoo; Wuppertal Zoo; University of Hannover; University of Pretoria; SAVA Wildlife Group; South African Veterinary Foundation	The authors would like to thank the Hannover and Wuppertal Zoos, University of Hannover and the University of Pretoria, the SAVA Wildlife Group, and the South African Veterinary Foundation for financial support. We thank the many staff and students from the University of Pretoria that helped with the capture, transport, and husbandry of the impala and gave logistical support during the impala studies.	ABLES E D, 1969, East African Wildlife Journal, V7, P61; Alkire MT, 2008, SCIENCE, V322, P876, DOI 10.1126/science.1149213; Ancrenaz M, 1996, J ZOO WILDLIFE MED, V27, P209; Armstrong JAM, 2007, BJA EDUC, V7, P131, DOI 10.1093/bjaceaccp/mkm024; Bezuidenhout R, 2013, FARMERS WEEKLY  0124; Brighton Dzikiti T., 2013, J. S. Afr. Vet. Assoc., V84, P1; Buss PE, 2001, J S AFR VET ASSOC, V72, P137; De van Pienaar UJ, 1966, J S AFR VET ASSOC, V37, P277; Devendra GP, 2012, JACC-CARDIOVASC INTE, V5, P416, DOI 10.1016/j.jcin.2012.01.011; Duggan M, 2005, ANESTHESIOLOGY, V102, P838, DOI 10.1097/00000542-200504000-00021; Evans AL, 2012, ACTA VET SCAND, V54, DOI 10.1186/1751-0147-54-77; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P391; HEARD DJ, 1990, J ZOO WILDLIFE MED, V21, P166; Jacobs PL, 1999, J EXERC PHYSL, V2, P20; Kastner SBR, 2006, VET ANAESTH ANALG, V33, P79, DOI 10.1111/j.1467-2995.2005.00243.x; Kastner SBR, 2007, BSAVA MANUAL CANINE, P133; Kathirgamanathan A, 2009, BRIT J ANAESTH, V103, P291, DOI 10.1093/bja/aep140; Ko S, 2003, CAN J ANAESTH, V50, P679, DOI 10.1007/BF03018710; Koehler H, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0381-1; Kwetny I, 2006, ANESTH ANALG, V102, P815, DOI 10.1213/01.ane.0000196515.06945.fb; Lin HT, 2014, J CHIN MED ASSOC, V77, P209, DOI 10.1016/j.jcma.2014.01.002; Magnusson L, 2003, BRIT J ANAESTH, V91, P61, DOI 10.1093/bja/aeg085; McGroarty P, 2014, WALL STREET J; Meyer LCR, 2008, J S AFR VET ASSOC, V79, P121; Meyer LCR, 2010, J WILDLIFE DIS, V46, P514, DOI 10.7589/0090-3558-46.2.514; Mills GH, 2001, BRIT J ANAESTH, V1, P35; Ng A, 2010, BJA EDUC, V10, P117, DOI 10.1093/bjaceaccp/mkq019; Portas TJ, 2003, J ZOO WILDLIFE MED, V34, P269, DOI 10.1638/02-062; Ray K, 2014, BJA EDUC, V14, P236, DOI 10.1093/bjaceaccp/mkt064; Risling TE, 2011, ANIM PROD SCI, V51, P355, DOI 10.1071/AN10190; Sirian R, 2009, BJA EDUC, V9, P105, DOI 10.1093/bjaceaccp/mkp018; Tang Y, 2005, BRIT J ANAESTH, V95, P538, DOI 10.1093/bja/aei212; Theodore AC, 2013, UPTODATE, V9, P1; Vodoz JF, 2009, BMC CARDIOVASC DISOR, V9, DOI 10.1186/1471-2261-9-15; Whiteley JP, 2002, BRIT J ANAESTH, V88, P771, DOI 10.1093/bja/88.6.771; Woolf A., 1973, Journal Zool Anim Med, V4, P16, DOI 10.2307/20094207; Yamauchi H, 2011, BRIT J ANAESTH, V107, P631, DOI 10.1093/bja/aer171	37	9	9	0	16	AMER ASSOC ZOO VETERINARIANS	YULEE	581705 WHITE OAK ROAD, YULEE, FL 32097 USA	1042-7260	1937-2825		J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	DEC	2015	46	4					755	766		10.1638/2015-0052.1			12	Veterinary Sciences	Veterinary Sciences	CZ7UQ	WOS:000367306000011	26667531				2020-06-26	J	Haw, A; Hofmeyr, M; Fuller, A; Buss, P; Miller, M; Fleming, G; Meyer, L				Haw, Anna; Hofmeyr, Markus; Fuller, Andrea; Buss, Peter; Miller, Michele; Fleming, Gregory; Meyer, Leith			Butorphanol with oxygen insufflation improves cardiorespiratory function in field-immobilised white rhinoceros (Ceratotherium simum)	JOURNAL OF THE SOUTH AFRICAN VETERINARY ASSOCIATION			English	Article							CHEMICAL IMMOBILIZATION; PULMONARY-CIRCULATION; ETORPHINE ANESTHESIA; BLOOD-PRESSURE; HYPERTENSION; DETOMIDINE; PARAMETERS; AZAPERONE; GAS	Opioid-induced immobilisation results in severe respiratory compromise in the white rhinoceros (Ceratotherium simum). The effectiveness of oxygen insufflation combined with butorphanol in alleviating respiratory depression in free-ranging chemically immobilised white rhinoceroses was investigated. In this prospective intervention study 14 free-ranging white rhinoceroses were immobilised with a combination of etorphine, azaperone and hyaluronidase. Six minutes (min) after the animals became recumbent, intravenous butorphanol was administered and oxygen insufflation was initiated. Previous boma trial results were used for comparison, using repeated measures two-way analysis of variance. The initial immobilisation-induced hypoxaemia in free-ranging rhinoceroses (arterial partial pressure of oxygen [PaO2] 35.4 mmHg +/- 6.6 mmHg) was similar to that observed in boma-confined rhinoceroses (PaO2 31 mmHg +/- 6 mmHg, n = 8). Although the initial hypercapnia (PaCO2 63.0 mmHg +/- 7.5 mmHg) was not as severe as that in animals in the boma trial (79 mmHg +/- 7 mmHg), the field-immobilised rhinoceroses were more acidaemic (pH 7.10 +/- 0.14) at the beginning of the immobilisation compared with boma-immobilised rhinoceroses (pH 7.28 +/- 0.04). Compared with pre-intervention values, butorphanol with oxygen insufflation improved the PaO2 (81.2 mmHg +/- 23.7 mmHg, p < 0.001, 5 min vs 20 min), arterial partial pressure of carbon dioxide (55.3 mmHg +/- 5.2 mmHg, p < 0.01, 5 min vs 20 min), pH (7.17 +/- 0.11, p < 0.001, 5 min vs 20 min), heart rate (78 breaths/min +/- 20 breaths/min, p < 0.001, 5 min vs 20 min) and mean arterial blood pressure (105 mmHg +/- 14 mmHg, p < 0.01, 5 min vs 20 min). Oxygen insufflation combined with a single intravenous dose of butorphanol improved oxygenation and reduced hypercapnia and acidaemia in immobilised free-ranging white rhinoceroses.	[Haw, Anna; Fuller, Andrea] Univ Witwatersrand, Fac Hlth Sci, Sch Physiol, ZA-2050 Johannesburg, South Africa; [Hofmeyr, Markus; Buss, Peter] South African Natl Parks, Skukuza, South Africa; [Miller, Michele] Univ Stellenbosch, DST NRF Ctr Excellence Biomed TB, Div Human Genet & Mol Biol, ZA-7600 Stellenbosch, South Africa; [Fleming, Gregory] Disneys Anim Programs & Environm Initiat, Lake Buena Vista, FL USA; [Meyer, Leith] Univ Pretoria, Dept Paraclin Sci, Onderstepoort, South Africa	Haw, A (reprint author), 7 York Rd, ZA-2193 Johannesburg, South Africa.	anna.haw@wits.ac.za	Meyer, Leith/AAN-4930-2020; Fuller, Andrea/P-3133-2016	Fuller, Andrea/0000-0001-6370-8151; Meyer, Leith/0000-0002-5122-2469	South African National Research FoundationNational Research Foundation - South Africa; International Rhino Foundation; Disney's Animal Programs and Environmental Initiatives; SANParks; University of the Witwatersrand	We thank the staff of the SANParks Veterinary Wildlife Services for dedicated support and assistance with experimental procedures. In particular we thank Marius Kruger for managing the capture team and Jennifer Hofmeyr, Nomkhosi Mathebula and Guy Hausler for field and laboratory assistance. We also thank the South African National Research Foundation, the International Rhino Foundation, Disney's Animal Programs and Environmental Initiatives, SANParks, and the University of the Witwatersrand for financial support.	Aaronson PI, 2006, J PHYSIOL-LONDON, V570, P53, DOI 10.1113/jphysiol.2005.098855; Ball RL, 2011, P 2011 INT EL RHIN C, P1497; BAUMANN R, 1984, RESP PHYSIOL, V56, P1, DOI 10.1016/0034-5687(84)90124-5; Boardman WSJ, 2014, J WILDLIFE DIS, V50, P849, DOI 10.7589/2013-12-327; Burroughs Richard, 2012, P53; Bush M, 2004, J S AFR VET ASSOC, V75, P79; Buss P, 2015, J ZOO WILDLIFE MED, V46, P224, DOI 10.1638/2014-0089R.1; Citino SB, 2007, J ZOO WILDLIFE MED, V38, P375, DOI 10.1638/2006-0007R1.1; Commiskey S, 2005, J PHARMACOL SCI, V98, P109, DOI 10.1254/jphs.CRJ05001X; CORNICKSEAHORN JL, 1995, J AM VET MED ASSOC, V206, P508; DANIEL M, 1972, VET REC, V90, P336, DOI 10.1136/vr.90.12.336; DiBartola SP, 2006, FLUID ELECTROLYTE AC, P251; Fahlman A., 2008, THESIS; Fahlman Asa, 2004, P523; Gao YS, 2005, AM J PHYSIOL-LUNG C, V288, pL213, DOI 10.1152/ajplung.00103.2004; HARTHOORN A M, 1976, Journal of the South African Veterinary Association, V47, P187; HATTINGH J, 1994, S AFR J WILDL RES, V24, P12; Haw A, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0253-0; HEARD DJ, 1992, J ZOO WILDLIFE MED, V23, P197; Heard DJ, 1996, AM J VET RES, V57, P87; HYMAN AL, 1986, AM J PHYSIOL, V250, P1109; KADOWITZ PJ, 1973, CIRC RES, V32, P221, DOI 10.1161/01.RES.32.2.221; Kellum JA, 2007, CRIT CARE MED, V35, P2630, DOI 10.1097/01.CCM.0000286399.21008.64; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kock MD, 1995, J ZOO WILDLIFE MED, V26, P207; LEBLANC PH, 1987, J ZOO WILDLIFE MED, V18, P141, DOI 10.2307/20094825; Meyer LCR, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0337-5; Miller M, 2013, J ZOO WILDLIFE MED, V44, P55, DOI 10.1638/1042-7260-44.1.55; Portas T, 2004, AUST VET J, V82, P542, DOI 10.1111/j.1751-0813.2004.tb11196.x; RAATH JP, 1999, ZOO WILDLIFE MED CUR, V4, P556; Salvi SS, 1999, CHEST, V115, P1708, DOI 10.1378/chest.115.6.1708; Schultz HD, 2007, HYPERTENSION, V50, P6, DOI 10.1161/HYPERTENSIONAHA.106.076083; Wenger S, 2007, J ZOO WILDLIFE MED, V38, P380, DOI 10.1638/2006-0038R.1; West JB, 2012, RESP PHYSL ESSENTIAL; ZooPharm, 2013, AZ WEBS 11 2013	35	6	6	0	12	AOSIS OPEN JOURNALS	CAPE TOWN	POSTNET SUITE 55, PRIVATE BAG X22, TYGERVALLEY, CAPE TOWN, 00000, SOUTH AFRICA	1019-9128	2224-9435		J S AFR VET ASSOC	J. S. Afr. Vet. Assoc.	AUG 12	2015	86	1							1276	10.4102/jsava.v86i1.1276			10	Veterinary Sciences	Veterinary Sciences	CZ6DU	WOS:000367192200001	26304140	DOAJ Gold, Green Published			2020-06-26	J	Bergvall, UA; Kjellander, P; Ahlqvist, P; Johansson, O; Skold, K; Arnemo, JM				Bergvall, Ulrika A.; Kjellander, Petter; Ahlqvist, Per; Johansson, Orjan; Skold, Kent; Arnemo, Jon M.			Chemical Immobilization of Free-ranging Fallow Deer (Dama dama): Effect of Needle Length on Induction Time	JOURNAL OF WILDLIFE DISEASES			English	Article						Darting; etorphine; fallow deer; induction time; needle length; xylazine		We evaluated impact of the needle length, sex, and body condition on chemical immobilization induction time in 50 (29 males and 21 females) free-ranging fallow deer (Dama dama) in Sweden, 2006-11. Induction time is probably the single most important factor when immobilizing free-ranging wildlife with the use of a remote drug-delivery system. Induction times should be short to minimize stress and risk of injury, and to ensure that immobilized animals can be found and clinically monitored as soon as possible. We measured the distance between the darting location and where we recovered the immobilized animal and also the time occurring between the two events. We used two types of needles: 2.0 x 30 or 2.0 x 40 mm barbed needles with side ports. The most important result is that a 10-mm-longer dart needle can reduce the retrieval time substantially (>20 min) until an animal is under monitoring. On average after the darting, the retrieval time decreased from 51 to 29 min and the distance decreased from 519 m from the darting location to 294 m. We suggest that a needle length of 40 mm is preferable for immobilization of wild fallow deer, especially for animals in over-average to fat body condition.	[Bergvall, Ulrika A.; Kjellander, Petter; Ahlqvist, Per; Johansson, Orjan; Skold, Kent] Swedish Univ Agr Sci, Dept Ecol, Grimso Wildlife Res Stn, SE-73091 Riddarhyttan, Sweden; [Bergvall, Ulrika A.] Stockholm Univ, Dept Zool, SE-10691 Stockholm, Sweden; [Arnemo, Jon M.] Hedmark Coll, Fac Appl Ecol & Agr Sci, Dept Forestry & Wildlife Management, NO-2418 Elverum, Norway; [Arnemo, Jon M.] Swedish Univ Agr Sci, Fac Forest Sci, Dept Wildlife Fish & Environm Studies, SE-90183 Umea, Sweden	Bergvall, UA (reprint author), Swedish Univ Agr Sci, Dept Ecol, Grimso Wildlife Res Stn, SE-73091 Riddarhyttan, Sweden.	Ulrika.Alm.Bergvall@slu.se		Kjellander, Petter/0000-0002-4272-6737	Swedish Environmental Protection Agency; Swedish Association for Hunting and Wildlife Management; Swedish research councilSwedish Research Council; Helge Ax:son Johnson foundation; King Carl XVI Gustaf foundation for science, technology, and environment	We thank P. Grangstedt for help during fieldwork, the Silfverschiold family for allowing us to work at their estate, and A. Friberg for his patience with all the interruptions in his daily work. This study was part of a larger project studying roe deer and fallow deer interactions and the ecology of wild fallow deer in Sweden managed by P.K. and was supported by grants from The Swedish Environmental Protection Agency to P.K. and U.A.B., the Swedish Association for Hunting and Wildlife Management to P.K., and the Swedish research council, the Helge Ax:son Johnson foundation, and the King Carl XVI Gustaf foundation for science, technology, and environment to U.A.B.	Arnemo JM, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P139; Arnemo JM, 2011, J WILDLIFE DIS, V47, P755, DOI 10.7589/0090-3558-47.3.755; Cattet MRL, 2006, WILDLIFE SOC B, V34, P741, DOI 10.2193/0091-7648(2006)34[741:EOTPFI]2.0.CO;2; Caulkett NA, 2007, VET ANAESTH ANALG, P807; Chalmers G. A., 1982, Noninfectious diseases of wildlife, P84; HAIGH JC, 1991, J ZOO WILDLIFE MED, V22, P318; Kreeger T. J., 2012, HDB WILDLIFE CHEM IM; Ninov Nino P., 2003, Acta Zoologica Bulgarica, V55, P43	8	6	6	0	7	WILDLIFE DISEASE ASSOC, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA	0090-3558	1943-3700		J WILDLIFE DIS	J. Wildl. Dis.	APR	2015	51	2					484	487		10.7589/2013-11-290			4	Veterinary Sciences	Veterinary Sciences	CF9XT	WOS:000352921800021	25588014				2020-06-26	J	Dittberner, MJ; Venter, L; Naidoo, V				Dittberner, Mark J.; Venter, Leon; Naidoo, Vinny			Accelerated induction of etorphine immobilization in blue wildebeest (Connochaetes taurinus) through the addition of hyaluronidase	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						azaperone; blue wildebeest; etorphine; hyaluronidase; immobilization time		ObjectiveTo study the effects of the addition of hyaluronidase (HA) to an etorphine/azaperone drug combination on induction times of immobilization. Study designExperimental part-randomized blinded' cross-over study. AnimalsEight wild managed blue wildebeest (Connochaetes taurinus). MethodsAnimals were immobilized, on separate occasions separated by two weeks, with one of four treatments. Treatments were; Control drugs (CD), etorphine 0.01mgkg(-1)+azaperone at 0.1mgkg(-1); treatment 1 CD+5000IU HA; treatment 2 CD+7500 IU HA; and treatment 3 etorphine 0.007mgkg(-1)+azaperone at 0.07mgkg(-1)+7500 IU HA. Times to first effect and to immobilization (from darting to possible to approach and blindfold) were measured. anova was used to compare treatments. Results are given in meansSD (range). ResultsFor control, and treatments 1-3 respectively, times (in minutes) to first effect were 1.58 +/- 0.42 (1.02-2.10), 1.64 +/- 0.42 (0.95-2.17), 1.12 +/- 0.24 (0.80-1.48) and 1.60 +/- 0.21 (1.13-1.88) and to immobilization were 5.38 +/- 1.53 (3.82-8.07), 3.80 +/- 1.14 (2.02-5.50), 3.51 +/- 1.08 (2.28-5.52) and 4.46 +/- 0.67 (3.30-5.40). Compared to control, time to first effect for treatment 2 was significantly shorter. Time to immobilization was significantly quicker in all three treatments containing HA than that for control. Conclusion and clinical relevanceHyaluronidase can reduce the time to immobilization when used in the immobilizing dart, and might be usefully incorporated into etorphine combinations for darting wildlife.	[Dittberner, Mark J.; Venter, Leon; Naidoo, Vinny] Univ Pretoria, Fac Vet Sci, Dept Paraclin Sci, ZA-0002 Pretoria, South Africa; [Dittberner, Mark J.] Univ Pretoria, Fac Vet Sci, Dept Prod Anim Studies, ZA-0002 Pretoria, South Africa; [Naidoo, Vinny] Univ Pretoria, Fac Vet Sci, Biomed Res Ctr, ZA-0002 Pretoria, South Africa	Naidoo, V (reprint author), Univ Pretoria, Fac Vet Sci, Biomed Res Ctr, Private Bag X04, ZA-0110 Onderstepoort, South Africa.	vinny.naidoo@up.ac.za	Naidoo, Vinny/A-1508-2008	Naidoo, Vinny/0000-0003-2740-5983	University of Pretoria; South African Veterinary Foundation	The authors would like to thank Dr Cobus Raath for allowing the study to take place on his farm and supplying the animals, drugs and accommodation. Financial assistance was provided by the University of Pretoria and the South African Veterinary Foundation.	Cattet MRL, 2010, J WILDLIFE DIS, V46, P246, DOI 10.7589/0090-3558-46.1.246; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P391; HAIGH JC, 1977, J ZOO ANIM MED, V8, P22, DOI 10.2307/20460158; Kallio H, 2000, ANESTH ANALG, V91, P934, DOI 10.1097/00000539-200010000-00031; Lloyd M. L., 1994, Proceedings American Association of Zoo Veterinarians and Association of Reptilian and Amphibian Veterinarians Annual Conference Pittsburgh, USA, 22-27, October, 1994., P117; MELTZER D., 2006, CHEM PHYS RESTRAINT, P43; MOORE DC, 1950, ANESTHESIOLOGY, V11, P470, DOI 10.1097/00000542-195007000-00010; WATSON D, 1993, BRIT J ANAESTH, V71, P422, DOI 10.1093/bja/71.3.422	8	4	4	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAR	2015	42	2					173	177		10.1111/vaa.12188			5	Veterinary Sciences	Veterinary Sciences	CC1XQ	WOS:000350139100007	24962404				2020-06-26	J	Meyer, LCR; Hetem, RS; Mitchell, D; Fuller, A				Meyer, Leith Carl Rodney; Hetem, Robyn Sheila; Mitchell, Duncan; Fuller, Andrea			Hypoxia following etorphine administration in goats (Capra hircus) results more from pulmonary hypertension than from hypoventilation	BMC VETERINARY RESEARCH			English	Article						Hypoxia; Opioid; Respiratory depression; Oxygen diffusion	RESPIRATORY DEPRESSION; OPIOIDS; CARFENTANIL	Background: Etorphine, a potent opioid agonist, causes pulmonary hypertension and respiratory depression. Whether etorphine-induced pulmonary hypertension negatively influences pulmonary gas exchange and exacerbates the effects of ventilator depression and the resultant hypoxemia is unknown. To determine if these effects occurred we instrumented twelve goats with peripheral and pulmonary arterial catheters to measure systemic and pulmonary pressures before and after etorphine administration. Concurrent cardiopulmonary and arterial blood gas variables were also measured. Results: Etorphine induced hypoventilation (55% reduction to 7.6 +/- 2.7 L.min(-1), F-(11,F-44) = 15.2 P < 0.0001), hypoxia (< 45 mmHg, F(11,44) = 8.6 P < 0.0001), hypercapnia (> 40 mmHg, F-(11,F-44) = 5.6 P < 0.0001) and pulmonary hypertension (mean 23 +/- 6 mmHg, F-(11,F-44) = 8.2 P < 0.0001). Within 6 min of etorphine administration hypoxia was twice (F-(11,F-22) = 3.0 P < 0.05) as poor than that expected from etorphine-induced hypoventilation alone. This disparity appeared to result from a decrease in the movement of oxygen (gas exchange) across the alveoli membrane, as revealed by an increase in the P(A-a) O-2 gradient (F-(11,F-44) = 7.9 P < 0.0001). The P(A-a)O-2 gradient was not correlated with global changes in the ventilation perfusion ratio (P = 0.28) but was correlated positively with the mean pulmonary artery pressure (P = 0.017, r(2) = 0.97), indicating that pulmonary pressure played a significant role in altering pulmonary gas exchange. Conclusion: Attempts to alleviate etorphine-induced hypoxia therefore should focus not only on reversing the opioid-induced respiratory depression, but also on improving gas exchange by preventing etorphine-induced pulmonary hypertension.	[Meyer, Leith Carl Rodney; Fuller, Andrea] Univ Pretoria, Fac Vet Sci, Dept Paraclin Sci, ZA-0110 Onderstepoort, South Africa; [Meyer, Leith Carl Rodney; Hetem, Robyn Sheila; Mitchell, Duncan; Fuller, Andrea] Univ Witwatersrand, Sch Physiol, Brain Funct Res Grp, ZA-2193 Parktown, South Africa	Meyer, LCR (reprint author), Univ Pretoria, Fac Vet Sci, Dept Paraclin Sci, ZA-0110 Onderstepoort, South Africa.	leith.meyer@up.ac.za	Meyer, Leith/AAN-4930-2020; Hetem, Robyn Sheila/A-1438-2015; Fuller, Andrea/P-3133-2016	Hetem, Robyn Sheila/0000-0003-1953-3520; Fuller, Andrea/0000-0001-6370-8151; Meyer, Leith/0000-0002-5122-2469	Faculty Research Committee Grant, University of the Witwatersrand; Thuthuka Grant from the National Research Foundation, South Africa; Research Grant from the Wildlife Group of the South African Veterinary Association	We thank Hugo Minnaar for his help with placing the Swan-Ganz Catheters, staff of the Central Animal Services of the University of the Witwatersrand for their animal management and support, and staff and students from the Brain Function Research Group for their help with animal handling and data collection. We also thank Wildlife Pharmaceuticals, South Africa, for their generous donation of etorphine (Captivon). This work was funded by a Faculty Research Committee Grant, University of the Witwatersrand, a Thuthuka Grant from the National Research Foundation, South Africa, and a Research Grant from the Wildlife Group of the South African Veterinary Association.	AGUSTI AGN, 1993, EUR RESPIR J, V6, P1371; Barenbrug A. W. T., 1974, PSYCHROMETRY PSYCHRO; Beker A, 2010, J APPL ANIM RES, V37, P1; Boom M, 2012, CURR PHARM DESIGN, V18, P5994, DOI 10.2174/138161212803582469; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; HAKIM TS, 1992, PULM PHARMACOL, V5, P159, DOI 10.1016/0952-0600(92)90036-G; HATTINGH J, 1994, S AFR J WILDL RES, V24, P15; HEARD DJ, 1990, J ZOO WILDLIFE MED, V21, P166; Heard DJ, 1996, AM J VET RES, V57, P87; Kaye AD, 2008, ACTA ANAESTH SCAND, V52, P931, DOI 10.1111/j.1399-6576.2008.01595.x; Kimura S, 2014, EUR J PHARMACOL, V725, P87, DOI 10.1016/j.ejphar.2013.08.007; Lumb A.B., 2005, APPL RESP PHYSL; McCrimmon DR, 2003, AM J PHYSIOL-REG I, V285, pR1274, DOI 10.1152/ajpregu.00428.2003; McKenzie AA, 1993, CAPTURE CARE MANUAL; Meyer LCR, 2006, AM J PHYSIOL-REG I, V290, pR405; Meyer LCR, 2010, J WILDLIFE DIS, V46, P514, DOI 10.7589/0090-3558-46.2.514; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Robertson HT, 2011, COMPR PHYSIOL, V1, P621, DOI 10.1002/cphy.c100010; ROQUEBERT J, 1988, J AUTON PHARMACOL, V8, P39, DOI 10.1111/j.1474-8673.1988.tb00167.x; SHAW ML, 1995, J AM VET MED ASSOC, V206, P833; SHOOK JE, 1990, AM REV RESPIR DIS, V142, P895, DOI 10.1164/ajrccm/142.4.895; Swan GE, 1993, CAPTURE CARE MANUAL, P17; Torchio R, 2006, CHEST, V129, P1330, DOI 10.1378/chest.129.5.1330; West JB, 2012, RESP PHYSL ESSENTIAL	24	10	10	0	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1746-6148		BMC VET RES	BMC Vet. Res.	FEB 3	2015	11								18	10.1186/s12917-015-0337-5			9	Veterinary Sciences	Veterinary Sciences	CB8HO	WOS:000349869800003	25644810	DOAJ Gold, Green Published			2020-06-26	J	Taylor, AMW; Roberts, KW; Pradhan, AA; Akbari, HA; Walwyn, W; Lutfy, K; Carroll, FI; Cahill, CM; Evans, CJ				Taylor, A. M. W.; Roberts, K. W.; Pradhan, A. A.; Akbari, H. A.; Walwyn, W.; Lutfy, K.; Carroll, F. I.; Cahill, C. M.; Evans, C. J.			Anti-nociception mediated by a kappa opioid receptor agonist is blocked by a delta receptor agonist	BRITISH JOURNAL OF PHARMACOLOGY			English	Article							CORTICOTROPIN-RELEASING-FACTOR; IN-SITU HYBRIDIZATION; INDUCED ANALGESIA; MESSENGER-RNA; ORPHANIN-FQ; INDUCED ANTINOCICEPTION; RHESUS-MONKEYS; MICE LACKING; STRESS; POTENT	Background and Purpose The opioid receptor family comprises four structurally homologous but functionally distinct sub-groups, the (MOP), (DOP), (KOP) and nociceptin (NOP) receptors. As most opioid agonists are selective but not specific, a broad spectrum of behaviours due to activation of different opioid receptors is expected. In this study, we examine whether other opioid receptor systems influenced KOP-mediated antinociception. Experimental Approach We used a tail withdrawal assay in C57Bl/6 mice to assay the antinociceptive effect of systemically administered opioid agonists with varying selectivity at KOP receptors. Pharmacological and genetic approaches were used to analyse the interactions of the other opioid receptors in modulating KOP-mediated antinociception. Key Results Etorphine, a potent agonist at all four opioid receptors, was not anti-nociceptive in MOP knockout (KO) mice, although etorphine is an efficacious KOP receptor agonist and specific KOP receptor agonists remain analgesic in MOP KO mice. As KOP receptor agonists are aversive, we considered KOP-mediated antinociception might be a form of stress-induced analgesia that is blocked by the anxiolytic effects of DOP receptor agonists. In support of this hypothesis, pretreatment with the DOP antagonist, naltrindole (10mgkg(-1)), unmasked etorphine (3mgkg(-1)) antinociception in MOP KO mice. Further, in wild-type mice, KOP-mediated antinociception by systemic U50,488H (10mgkg(-1)) was blocked by pretreatment with the DOP agonist SNC80 (5mgkg(-1)) and diazepam (1mgkg(-1)). Conclusions and Implications Systemic DOP receptor agonists blocked systemic KOP antinociception, and these results identify DOP receptor agonists as potential agents for reversing stress-driven addictive and depressive behaviours mediated through KOP receptor activation. Linked Articles This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit	[Taylor, A. M. W.; Roberts, K. W.; Pradhan, A. A.; Walwyn, W.; Evans, C. J.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA; [Taylor, A. M. W.; Cahill, C. M.] Univ Calif Irvine, Irvine, CA USA; [Pradhan, A. A.; Akbari, H. A.] Univ Illinois, Chicago, IL USA; [Lutfy, K.] Western Univ Hlth Sci, Pomona, CA USA; [Carroll, F. I.] Res Triangle Inst, Ctr Organ & Med Chem, Res Triangle Pk, NC 27709 USA	Evans, CJ (reprint author), Univ Calif Los Angeles, 675 Charles E Young Dr South,Room 2760, Los Angeles, CA 90095 USA.	cevans@ucla.edu	Taylor, Anna/E-6504-2015; Cahill, Catherine M/J-6524-2019; Lutfy, Kabirullah/H-9995-2019	Taylor, Anna/0000-0001-7881-8783; Lutfy, Kabirullah/0000-0003-0350-3693	Shirley and Stefan Hatos Foundation; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR);  [DA005010];  [DA031243]	This work was supported by DA005010 (C. J. E.) and DA031243 (A. A. P.), the Shirley and Stefan Hatos Foundation (C. J. E., A. M. T., A. A. P.), and the Canadian Institutes of Health Research (C. M. C., A. M. T). JDTic was kindly donated by the Research Triangle Institute.	Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1459, DOI 10.1111/bph.12445; BARBER A, 1994, BRIT J PHARMACOL, V113, P1317, DOI 10.1111/j.1476-5381.1994.tb17142.x; Barrett AC, 2002, EUR J PHARMACOL, V452, P163, DOI 10.1016/S0014-2999(02)02274-4; Befort K, 2001, J BIOL CHEM, V276, P3130, DOI 10.1074/jbc.M006352200; Brandt MR, 2001, J PHARMACOL EXP THER, V299, P629; Broom DC, 2002, NEUROPSYCHOPHARMACOL, V26, P744, DOI 10.1016/S0893-133X(01)00413-4; BUCKINGHAM JC, 1986, NEUROENDOCRINOLOGY, V44, P36, DOI 10.1159/000124618; Butler RK, 2009, PROG NEUROBIOL, V88, P184, DOI 10.1016/j.pneurobio.2009.04.003; Butour JL, 1997, EUR J PHARMACOL, V321, P97, DOI 10.1016/S0014-2999(96)00919-3; Cahill CM, 2001, J COMP NEUROL, V440, P65, DOI 10.1002/cne.1370; Carroll FI, 2004, J MED CHEM, V47, P281, DOI 10.1021/jm030419a; Clark MJ, 2006, J PHARMACOL EXP THER, V317, P858, DOI 10.1124/jpet.105.096818; Contet C, 2006, NEUROPSYCHOPHARMACOL, V31, P1733, DOI 10.1038/sj.npp.1300934; Cox BM, 2015, BRIT J PHARMACOL, V172, P317, DOI 10.1111/bph.12612; Dondio G, 1997, J MED CHEM, V40, P3192, DOI 10.1021/jm9608218; Dortch-Carnes J, 2005, CNS DRUG REV, V11, P195; Faget L, 2012, J NEUROSCI, V32, P7301, DOI 10.1523/JNEUROSCI.0185-12.2012; Filaretov A A, 1996, Neurosci Behav Physiol, V26, P572, DOI 10.1007/BF02359502; Filliol D, 2000, NAT GENET, V25, P195, DOI 10.1038/76061; Gaveriaux-Ruff C, 2002, NEUROPEPTIDES, V36, P62, DOI 10.1054/npep.2002.0900; HARGREAVES KM, 1987, BRAIN RES, V422, P154, DOI 10.1016/0006-8993(87)90550-6; Holdridge SV, 2007, EUR J PAIN, V11, P685, DOI 10.1016/j.ejpain.2006.10.008; IYENGAR S, 1986, J PHARMACOL EXP THER, V238, P429; JAINUDEEN MR, 1970, J AM VET MED ASSOC, V157, P624; Kastenberger I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034251; KAVALIERS M, 1987, BRAIN RES, V425, P49, DOI 10.1016/0006-8993(87)90482-3; Kieffer BL, 2002, PROG NEUROBIOL, V66, P285, DOI 10.1016/S0301-0082(02)00008-4; Kieffer BL, 2009, NEUROPHARMACOLOGY, V56, P205, DOI 10.1016/j.neuropharm.2008.07.033; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI 10.1111/j.1476-5381.2010.00872.x; KITCHEN I, 1990, BRIT J PHARMACOL, V100, P685, DOI 10.1111/j.1476-5381.1990.tb14076.x; Knapp RJ, 1996, J PHARMACOL EXP THER, V277, P1284; Knoll AT, 2010, BRAIN RES, V1314, P56, DOI 10.1016/j.brainres.2009.09.074; Le Merrer J, 2009, PHYSIOL REV, V89, P1379, DOI 10.1152/physrev.00005.2009; Lee KO, 1999, EUR J PHARMACOL, V378, P323, DOI 10.1016/S0014-2999(99)00460-4; Leri F, 2000, NEUROREPORT, V11, P2553, DOI 10.1097/00001756-200008030-00041; Lewis JW, 2004, CURR PHARM DESIGN, V10, P717, DOI 10.2174/1381612043453027; Li JG, 2003, J PHARMACOL EXP THER, V305, P531, DOI 10.1124/jpet.102.045559; Li JG, 2000, MOL PHARMACOL, V58, P795; LUGER TJ, 1995, EUR J PHARMACOL, V275, P153, DOI 10.1016/0014-2999(94)00759-Z; Lutfy K, 2003, J NEUROSCI, V23, P10331; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x; McLaughlin JP, 2003, J NEUROSCI, V23, P5674, DOI 10.1523/jneurosci.23-13-05674.2003; MENENDEZ L, 1994, GEN PHARMACOL, V25, P903, DOI 10.1016/0306-3623(94)90094-9; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MIASKOWSKI C, 1990, BRAIN RES, V509, P165, DOI 10.1016/0006-8993(90)90327-8; MINAMI M, 1995, MOL BRAIN RES, V30, P203, DOI 10.1016/0169-328X(94)00290-U; MINAMI M, 1993, NEUROSCI LETT, V162, P161, DOI 10.1016/0304-3940(93)90585-9; MINAMI M, 1995, NEUROSCI RES, V23, P121, DOI 10.1016/0168-0102(95)00933-K; Mogil JS, 1996, NEUROSCIENCE, V75, P333, DOI 10.1016/0306-4522(96)00338-7; Mogil JS, 2003, P NATL ACAD SCI USA, V100, P4867, DOI 10.1073/pnas.0730053100; Mousa SA, 2003, PAIN, V106, P297, DOI 10.1016/S0304-3959(03)00302-6; Murphy NP, 1999, BRAIN RES, V832, P168, DOI 10.1016/S0006-8993(99)01425-0; Negus SS, 1998, J PHARMACOL EXP THER, V286, P362; Nemmani KVS, 2002, LIFE SCI, V70, P1727, DOI 10.1016/S0024-3205(02)01496-0; Nishi M, 1997, EMBO J, V16, P1858, DOI 10.1093/emboj/16.8.1858; Pawson AJ, 2014, NUCLEIC ACIDS RES, V42, pD1098, DOI 10.1093/nar/gkt1143; Payza K., 2003, DELTA RECEPTOR, P261; Perrine SA, 2006, BRIT J PHARMACOL, V147, P864, DOI 10.1038/sj.bjp.0706686; Pradhan AAA, 2005, J COMP NEUROL, V481, P416, DOI 10.1002/cne.20378; Pradhan AA, 2011, TRENDS PHARMACOL SCI, V32, P581, DOI 10.1016/j.tips.2011.06.008; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; ROSLAND JH, 1987, PHARMACOL TOXICOL, V61, P111, DOI 10.1111/j.1600-0773.1987.tb01786.x; Russell SE, 2014, BIOL PSYCHIAT, V76, P213, DOI 10.1016/j.biopsych.2013.07.042; Saitoh A, 2004, J PHARMACOL SCI, V95, P374, DOI 10.1254/jphs.FPJ04014X; Schafer M, 1996, P NATL ACAD SCI USA, V93, P6096, DOI 10.1073/pnas.93.12.6096; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; Smith MA, 2002, PSYCHOPHARMACOLOGY, V162, P255, DOI 10.1007/s00213-002-1102-6; STEIN C, 1989, J PHARMACOL EXP THER, V248, P1269; Sternberg WF, 2004, HORM BEHAV, V46, P467, DOI 10.1016/j.yhbeh.2004.05.007; Stevenson GW, 2005, J PHARMACOL EXP THER, V314, P221, DOI 10.1124/jpet.104.082685; Swanson LW, 2000, BRAIN RES, V886, P113, DOI 10.1016/S0006-8993(00)02905-X; Toll L, 1998, NIDA Res Monogr, V178, P440; van Rijn RM, 2012, BIOL PSYCHIAT, V71, P232, DOI 10.1016/j.biopsych.2011.07.015; Vazquez-DeRose J, 2013, EUR J PHARMACOL, V699, P200, DOI 10.1016/j.ejphar.2012.11.050; VONVOIGTLANDER PF, 1982, PROG NEURO-PSYCHOPH, V6, P467, DOI 10.1016/S0278-5846(82)80130-9; Wadenberg MLG, 2003, CNS DRUG REV, V9, P187; Xu H, 2008, BRAIN RES BULL, V77, P49, DOI 10.1016/j.brainresbull.2008.05.003; Zaki PA, 1998, NEUROSCIENTIST, V4, P172, DOI 10.1177/107385849800400313	80	13	14	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	JAN	2015	172	2			SI		691	703		10.1111/bph.12810			13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AX3FU	WOS:000346826500039	24923251	Green Published, Other Gold			2020-06-26	J	Haw, A; Hofmeyr, M; Fuller, A; Buss, P; Miller, M; Fleming, G; Meyer, L				Haw, Anna; Hofmeyr, Markus; Fuller, Andrea; Buss, Peter; Miller, Michele; Fleming, Gregory; Meyer, Leith			Butorphanol with oxygen insufflation corrects etorphine-induced hypoxaemia in chemically immobilized white rhinoceros (Ceratotherium simum)	BMC VETERINARY RESEARCH			English	Article						Anaesthesia; Hypoxia; Hypercapnia; Acidaemia; Blood gases; Opioids; Partial-opioid antagonist	PULMONARY GAS-EXCHANGE; INSPIRED OXYGEN; ANESTHETIZED HORSES; ANESTHESIA; ATELECTASIS; VENTILATION; DETOMIDINE; RECUMBENCY; FRACTION; VOLUME	Background: Opioid-induced immobilization is associated with severe respiratory depression in the white rhinoceros. We evaluated the efficacy of butorphanol and oxygen insufflation in alleviating opioid-induced respiratory depression in eight boma-managed rhinoceros. Results: Chemical immobilization with etorphine, azaperone and hyaluronidase, as per standard procedure for the white rhinoceros, caused severe respiratory depression with hypoxaemia (PaO2 = 27 +/- 7 mmHg [mean +/- SD]), hypercapnia (PaCO2 = 82 +/- 6 mmHg) and acidosis (pH = 7.26 +/- 0.02) in the control trial at 5 min. Compared to pre-intervention values, butorphanol administration (without oxygen) improved the PaO2 (60 +/- 3 mmHg, F-(3,F-21) = 151.9, p < 0.001), PaCO2 (67 +/- 4 mmHg, F-(3,F-21) = 22.57, p < 0.001) and pH (7.31 +/- 0.06, F-(3,F-21) = 27.60, p < 0.001), while oxygen insufflation alone exacerbated the hypercapnia (123 +/- 20 mmHg, F-(3,F-21) = 50.13, p < 0.001) and acidosis (7.12 +/- 0.07, F-(3,F-21) = 110.6, p < 0.001). Surprisingly, butorphanol combined with oxygen fully corrected the opioid-induced hypoxaemia (PaO2 = 155 +/- 53 mmHg) and reduced the hypercapnia over the whole immobilization period (p < 0.05, areas under the curves) compared to the control trial. However, this intervention (butorphanol + oxygen) did not have any effect on the arterial pH. Conclusions: Oxygen insufflation combined with a single intravenous dose of butorphanol improved the immobilization quality of boma-managed white rhinoceros by correcting the opioid-induced hypoxaemia, but did not completely reverse all components of respiratory depression. The efficacy of this intervention in reducing respiratory depression in field-captured animals remains to be determined.	[Haw, Anna; Fuller, Andrea; Meyer, Leith] Univ Witwatersrand, Fac Hlth Sci, Sch Physiol, Brain Funct Res Grp, Johannesburg, South Africa; [Hofmeyr, Markus; Meyer, Leith] Univ Pretoria, Dept Paraclin Sci, Fac Vet Sci, ZA-0002 Pretoria, South Africa; [Hofmeyr, Markus; Buss, Peter] Kruger Natl Pk, South African Natl Parks, Vet Wildlife Serv, Skukuza, South Africa; [Miller, Michele] Univ Stellenbosch, Fac Hlth Sci, Div Human Genet & Mol Biol, ZA-7600 Stellenbosch, South Africa; [Fleming, Gregory] Disneys Anim Programs & Environm Initiat, Lake Buena Vista, FL USA; [Buss, Peter] Univ Pretoria, Fac Vet Sci, Dept Prod Anim Studies, Ctr Vet Wildlife Studies, ZA-0002 Pretoria, South Africa	Meyer, L (reprint author), Univ Witwatersrand, Fac Hlth Sci, Sch Physiol, Brain Funct Res Grp, Johannesburg, South Africa.	Leith.Meyer@up.ac.za	Meyer, Leith/AAN-4930-2020; Fuller, Andrea/P-3133-2016	Fuller, Andrea/0000-0001-6370-8151; Meyer, Leith/0000-0002-5122-2469	South African National Research FoundationNational Research Foundation - South Africa; International Rhino Foundation; Disney's Animal Programs and Environmental Initiatives, SANParks; South African Veterinary Association's Wildlife Group; University of the Witwatersrand	We thank the staff of the SANParks Veterinary Wildlife Services for care and management of the boma-kept rhinoceros and for dedicated support and assistance with experimental procedures. In particular we thank Johan Malan for coordinating the husbandry of the rhinoceros, Marius Kruger for managing the capture team and Jennifer Hofmeyr, Nomkhosi Mathebula and Guy Hausler for field and laboratory assistance. We also thank the South African National Research Foundation, the International Rhino Foundation, Disney's Animal Programs and Environmental Initiatives, SANParks, the South African Veterinary Association's Wildlife Group and the University of the Witwatersrand for financial support.	Aboab J, 2006, INTENS CARE MED, V32, P1979, DOI 10.1007/s00134-006-0382-4; Burroughs R., 2012, CHEM PHYS RESTRAINT, P223; Burroughs Richard, 2012, P53; Bush M, 2004, J S AFR VET ASSOC, V75, P79; Citino SB, 2007, J ZOO WILDLIFE MED, V38, P375, DOI 10.1638/2006-0007R1.1; Crumley MN, 2012, AM J VET RES, V73, P134, DOI 10.2460/ajvr.73.1.134; FAHLMAN A, 2008, THESIS SWEDISH U AGR; HATTINGH J, 1994, S AFR J WILDL RES, V24, P12; HEARD DJ, 1992, J ZOO WILDLIFE MED, V23, P197; Kock MD, 1995, J ZOO WILDLIFE MED, V26, P207; Kukanich B, 2009, VET PHARM THERAPEUTI; Magnusson L, 2003, BRIT J ANAESTH, V91, P61, DOI 10.1093/bja/aeg085; Marntell S, 2005, VET ANAESTH ANALG, V32, P338, DOI 10.1111/j.1467-2995.2005.00199.x; Mathebula N, 2012, J ZOO WILDLIFE MED, V43, P530, DOI 10.1638/2011-0259R.1; McDonell W, 1996, LUMB JONES VET ANEST, V1, P115; Merriman JE, 1955, CAN ANAESTH SOC J, V2, P273; Miller M, 2013, J ZOO WILDLIFE MED, V44, P55, DOI 10.1638/1042-7260-44.1.55; Morkel PV, 2010, J WILDLIFE DIS, V46, P236, DOI 10.7589/0090-3558-46.1.236; NYMAN G, 1990, EQUINE VET J, V22, P317, DOI 10.1111/j.2042-3306.1990.tb04280.x; Portas T, 2004, AUST VET J, V82, P542, DOI 10.1111/j.1751-0813.2004.tb11196.x; Santos C, 2000, AM J RESP CRIT CARE, V161, P26, DOI 10.1164/ajrccm.161.1.9902084; Staffieri F, 2009, EQUINE VET J, V41, P747, DOI 10.2746/042516409X416198; SUTER PM, 1975, ANESTHESIOLOGY, V43, P617, DOI 10.1097/00000542-197512000-00003; THURMON JC, 1990, VET CLIN N AM-EQUINE, V6, P485, DOI 10.1016/S0749-0739(17)30526-6; Wenger S, 2007, J ZOO WILDLIFE MED, V38, P380, DOI 10.1638/2006-0038R.1	25	14	14	0	15	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-6148			BMC VET RES	BMC Vet. Res.	OCT 15	2014	10								253	10.1186/s12917-014-0253-0			9	Veterinary Sciences	Veterinary Sciences	AX3AZ	WOS:000346814400002	25315767	DOAJ Gold, Green Published			2020-06-26	J	Boardman, WSJ; Caraguel, CGB; Raath, JP; Langhout, MV				Boardman, Wayne S. J.; Caraguel, Charles G. B.; Raath, Jacobus P.; Langhout, Martine Van Zijll			INTRAVENOUS BUTORPHANOL IMPROVES CARDIOPULMONARY PARAMETERS IN GAME-RANCHED WHITE RHINOCEROSES (CERATOTHERIUM SIMUM) IMMOBILIZED WITH ETORPHINE AND AZAPERONE	JOURNAL OF WILDLIFE DISEASES			English	Article						Blood gas values; butorphanol; Ceratotherium simum; etorphine; hypoxemia; immobilization; white rhinoceros	CHEMICAL IMMOBILIZATION; DETOMIDINE; INSUFFLATION; RECUMBENCY; ANESTHESIA; SEDATION; OXYGEN	We immobilized 47 white rhinoceroses (Ceratotherium simum) for dehorning with 1 4 mg of etorphine HCl, 10-40 mg of azaperone, and 7,500 IU of hyaluronidase, at a game ranch in South Africa in November 2012. Forty-four received butorphanol intravenously 5 min after recumbency, at the rate of 10 mg of butorphanol per 1 mg of etorphine, and three animals did not. When possible, blood gas and physiologic parameters were measured immediately before butorphanol administration and 10 min later. Statistically significant improvements were observed, with a reduction in pH, partial pressure of carbon dioxide in arterial blood, heart rate, systolic blood pressure, and diastolic blood pressure, and with an increase in arterial partial pressure of oxygen, arterial hemoglobin oxygen saturation, and respiratory rate in animals administered butorphanol. In the three animals that did not receive butorphanol, no improvement was apparent. Butorphanol given to recumbent white rhinoceroses immediately after immobilization was associated with improved blood gas values and cardiopulmonary function for at least 10 mm. Studies on the sustainability of these effects are necessary.	[Boardman, Wayne S. J.; Caraguel, Charles G. B.] Univ Adelaide, Sch Anim & Vet Sci, Roseworthy, SA 5371, Australia; [Boardman, Wayne S. J.] UniSA, Barbara Hardy Inst, Adelaide, SA 5095, Australia; [Raath, Jacobus P.; Langhout, Martine Van Zijll] WildlifeVets, Karino, South Africa	Boardman, WSJ (reprint author), Univ Adelaide, Sch Anim & Vet Sci, Roseworthy, SA 5371, Australia.	wayne.boardman@adelaide.edu.au	Boardman, Wayne S.J/J-6479-2013; Caraguel, Charles/P-6631-2019	Caraguel, Charles/0000-0003-0019-4813; Boardman, Wayne/0000-0002-1746-0682	School of Animal and Veterinary Sciences, University of Adelaide; Wildlife Pharmaceuticals, South Africa	We thank the staff of Wildlife Vets, in particular Louis Van Wyk and Johan Myburgh for support and assistance with this study. Special thanks go to John Hume and Johnny Hennop and staff for their field assistance and hospitality. Thanks also go to Cate Creighton, Margie McEwen, Anthony Nicholson, and Todd McWhorter for helpful advice. The study was partially supported by the School of Animal and Veterinary Sciences, University of Adelaide, and Wildlife Pharmaceuticals, South Africa.	Biggs D, 2013, SCIENCE, V339, P1038, DOI 10.1126/science.1229998; Branson K. R., 2001, Veterinary pharmacology and therapeutics, P268; Burroughs R., 2012, CHEM PHYS RESTRAINT, P223; Bush M, 2004, J S AFR VET ASSOC, V75, P79; Citino SB, 2007, J ZOO WILDLIFE MED, V38, P375, DOI 10.1638/2006-0007R1.1; Hall L W, 1971, Equine Vet J, V3, P95; HATTINGH J, 1994, S AFR J WILDL RES, V24, P12; HEARD DJ, 1992, J ZOO WILDLIFE MED, V23, P197; Kock MD, 1995, J ZOO WILDLIFE MED, V26, P207; Miller M, 2013, J ZOO WILDLIFE MED, V44, P55, DOI 10.1638/1042-7260-44.1.55; MIRENDA JV, 1991, ANESTH ANALG, V72, P667; Morkel PV, 2010, J WILDLIFE DIS, V46, P236, DOI 10.7589/0090-3558-46.1.236; Nyman G, 2009, ACTA VET SCAND, V51, DOI 10.1186/1751-0147-51-22; Plumb DC, 2002, VET DRUG HDB, P142; Portas T, 2004, AUST VET J, V82, P542, DOI 10.1111/j.1751-0813.2004.tb11196.x; RAATH JP, 1999, ZOO WILDLIFE MED CUR, V4, P556; Radcliffe RW, 2000, J ZOO WILDLIFE MED, V31, P196, DOI 10.1638/1042-7260(2000)031[0196:BAAAAS]2.0.CO;2; Wenger S, 2007, J ZOO WILDLIFE MED, V38, P380, DOI 10.1638/2006-0038R.1	18	7	7	0	15	WILDLIFE DISEASE ASSOC, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA	0090-3558	1943-3700		J WILDLIFE DIS	J. Wildl. Dis.	OCT	2014	50	4					849	857		10.7589/2013-12-327			9	Veterinary Sciences	Veterinary Sciences	AQ8LB	WOS:000343075900013	25105814				2020-06-26	J	Lian, M; Evans, AL; Bertelsen, MF; Fahlman, A; Haga, HA; Ericsson, G; Arnemo, JM				Lian, Marianne; Evans, Alina L.; Bertelsen, Mads F.; Fahlman, Asa; Haga, Henning A.; Ericsson, Goran; Arnemo, Jon M.			Improvement of arterial oxygenation in free-ranging moose (Alces alces) immobilized with etorphine-acepromazine-xylazine	ACTA VETERINARIA SCANDINAVICA			English	Article						Acid-base status; Alces alces; Arterial blood gases; Atipamezole; Etorphine; Hypoxemia; Immobilization; Moose; Xylazine	CARFENTANIL-XYLAZINE; CHEMICAL IMMOBILIZATION; NASAL OXYGEN; MEDETOMIDINE; INSUFFLATION; RECUMBENCY; ANESTHESIA; HYPOXEMIA; AGONISTS	Background: The effect of intranasal oxygen and/or early reversal of xylazine with atipamezole on arterial oxygenation in free-ranging moose (Alces alces) immobilized with etorphine-acepromazine-xylazine with a cross-sectional clinical study on 33 adult moose was evaluated. Moose were darted from a helicopter with 3.37 mg etorphine, 15 mg acepromazine and 75 mg xylazine. Intranasal oxygen at a flow rate of 4 L/min and/or early reversal of xylazine with 7.5 mg atipamezole to improve oxygenation was evaluated, using four treatment regimens; intranasal oxygen (n = 10), atipamezole intramuscularly (n = 6), atipamezole intravenously (n = 10), or a combination of atipamezole intravenously and intranasal oxygen (n = 7). Arterial blood was collected 7-30 minutes (min) after darting, and again 15 min after institution of treatment and immediately analyzed using an i-STAT (R) 1 Portable Clinical Analyzer. Results: Before treatment the mean +/- SD (range) partial pressure of arterial oxygen (P-aO2) was 62 +/- 17 (26-99) mmHg. Twenty-six animals had a P-aO2 < 80 mmHg. Ten had a P-aO2 of 40-60 mmHg and three animals had a P-aO2 < 40 mmHg. Intranasal oxygen and intravenous administration of atipamezole significantly increased the mean P-aO2, as did the combination of the two. In contrast, atipamezole administered intramuscularly at the evaluated dose had no significant effect on arterial oxygenation. Conclusions: This study shows that intranasal oxygen effectively improved arterial oxygenation in immobilized moose, and that early intravenous reversal of the sedative component, in this case xylazine, in an opioid-based immobilization drug-protocol significantly improves arterial oxygenation.	[Lian, Marianne; Bertelsen, Mads F.] Ctr Zoo & Wild Anim Hlth, Copenhagen Zoo, DK-2000 Frederiksberg, Denmark; [Lian, Marianne; Evans, Alina L.; Arnemo, Jon M.] Hedmark Univ Coll, Fac Appl Ecol & Agr Sci, Dept Forestry & Wildlife Management, NO-2480 Koppang, Norway; [Evans, Alina L.] Norwegian Sch Vet Sci, Dept Food Safety & Infect Biol, Sect Arct Vet Med, NO-9292 Tromso, Norway; [Fahlman, Asa] Swedish Univ Agr Sci, Fac Vet Med & Anim Sci, Dept Clin Sci, SE-75007 Uppsala, Sweden; [Haga, Henning A.] Norwegian Sch Vet Sci, Dept Compan Anim Clin Sci, Sect Anesthesia & Radiol, NO-0033 Oslo, Norway; [Ericsson, Goran; Arnemo, Jon M.] Swedish Univ Agr Sci, Fac Forest Sci, Dept Wildlife Fish & Environm Studies, SE-90183 Umea, Sweden	Lian, M (reprint author), Ctr Zoo & Wild Anim Hlth, Copenhagen Zoo, DK-2000 Frederiksberg, Denmark.	mariannelian@gmail.com	Evans, Alina/AAH-8881-2019	Bertelsen, Mads/0000-0001-9201-7499	Det Kongelige Danske Landhusholdningsselskab, Dyrlaege W. Laenkeholms Rejselegat and PlanDanmark.	Eric Andersson, Ake Nordstrom and Fredrik Stenbacka from the Swedish University of Agricultural Science performed the moose captures and facilitated the logistics for this study. The project was conducted in cooperation with the Swedish University of Agricultural Sciences Department of Wildlife, Fish, and Environmental Studies' thematic program Wildlife and Forestry and SYDALG. The iSTAT machine was provided by The Conservation Medicine Group, Department of Forestry and Wildlife Management, Campus Evenstad, Hedmark University College. Stipend support was from Det Kongelige Danske Landhusholdningsselskab, Dyrlaege W. Laenkeholms Rejselegat and PlanDanmark.	Arnemo JM, 2004, P AAZV AAWV WDA JOIN, P515; Arnemo Jon M., 2003, Alces, V39, P243; Arnemo Jon M., 2007, P103, DOI 10.1002/9780470376478.ch8; CAULKETT NA, 1994, J ZOO WILDLIFE MED, V25, P376; Caulkett NA, 2000, CAN VET J, V41, P49; Caulkett NA, 2007, LUMB JONES VET ANEST; Celly CS, 1997, J VET PHARMACOL THER, V20, P464, DOI 10.1046/j.1365-2885.1997.00097.x; Ericsson G, 2001, ECOSCIENCE, V8, P157, DOI 10.1080/11956860.2001.11682641; Evans AL, 2012, ACTA VET SCAND, V54, DOI 10.1186/1751-0147-54-77; Fahlman A, 2008, ADVANCES WILDLIFE IM; Haga HA, 2009, VET ANAESTH ANALG, V36, P555, DOI 10.1111/j.1467-2995.2009.00498.x; HALL LW, 1984, EQUINE VET J, V16, P89, DOI 10.1111/j.2042-3306.1984.tb01866.x; Hartsfield S. M., 2007, LUMB JONES VET ANEST; Howard LL, 2004, J ZOO WILDLIFE MED, V35, P312, DOI 10.1638/03-090; Johnson RA, 2006, FLUID ELECTROLYTE AC; Kreeger T. J., 2012, HDB WILDLIFE CHEM IM; Kreeger Terry J., 2005, Alces, V41, P121; LARSEN DG, 1989, J WILDLIFE MANAGE, V53, P564, DOI 10.2307/3809177; Lemke KA, 2007, LUMB JONES VET ANEST; McDonell WN, 2007, LUMB JONES VET ANEST; McJames Scott W., 1994, Alces, V30, P21; Meyer LCR, 2010, J WILDLIFE DIS, V46, P514, DOI 10.7589/0090-3558-46.2.514; Mich PM, 2008, J ZOO WILDLIFE MED, V39, P480, DOI 10.1638/2007-0150.1; Morkel PV, 2010, J WILDLIFE DIS, V46, P236, DOI 10.7589/0090-3558-46.1.236; Neumann W, 2011, CAN J ZOOL, V89, P1013, DOI 10.1139/Z11-076; Paterson JM, 2009, J ZOO WILDLIFE MED, V40, P39, DOI 10.1638/2007-0107.1; Read MR, 2001, CAN VET J, V42, P861; Sandegren F., 1987, Swedish Wildlife Research Supplement, V1, P785; SCHMIDTNIELSEN K, 1997, [No title captured]; Schumacher J, 1997, AM J VET RES, V58, P157; WAGNER AE, 1990, AM J VET RES, V51, P7; West JB, 2008, RESP PHYSL ESSENTIAL; Williams ES, 1996, NONINFECTIOUS DIS WI	33	8	8	1	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0044-605X	1751-0147		ACTA VET SCAND	Acta Vet. Scand.	AUG 15	2014	56								51	10.1186/s13028-014-0051-5			8	Veterinary Sciences	Veterinary Sciences	AN9TS	WOS:000340952300001	25124367	DOAJ Gold, Green Published, Green Accepted			2020-06-26	S	Zheng, H; Loh, HH; Law, PY		Conn, PM		Zheng, Hui; Loh, Horace H.; Law, Ping-Yee			Posttranslation Modification of G Protein-Coupled Receptor in Relationship to Biased Agonism	G PROTEIN COUPLED RECEPTORS: MODELING, ACTIVATION, INTERACTIONS AND VIRTUAL SCREENING	Methods in Enzymology		English	Review; Book Chapter							MEDIATED ERK ACTIVATION; GPI-ANCHORED PROTEINS; OPIOID RECEPTOR; BETA-ARRESTIN; ADENYLYL-CYCLASE; LIPID RAFTS; MEMBRANE MICRODOMAINS; PROTEOMIC ANALYSIS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS	Biased signaling has been reported with a series of G protein-coupled receptors (GPCRs), including beta(2)-adrenergic receptor and mu-opioid receptor (OPRM1). The concept of biased signaling suggests that the agonists of one particular receptor may activate the downstream signaling pathways with different efficacies. Thus in an extreme case, agonists might activate different sets of signaling pathways, which provide a new route to develop drugs with increased efficacies and decreased side effects. Among the many factors, posttranslation modifications of receptor proteins have major roles in influencing the biased signaling. Take OPRM1, for example, the phosphorylation and palmitoylation of receptor can regulate the biased signaling induced by agonists. Thus, by modulating these posttranslation modifications, the biased signaling of GPCRs can be regulated. In addition, although it is not considered as posttranslation modification normally, the distribution of GPCRs on cell membrane, especially the distribution between lipid-raft and non-raft microdomains, also contributes to the biased signaling. Thus in this chapter, we described the methods used in our laboratory to study receptor phosphorylation, receptor palmitoylation, and membrane distribution of receptor by using OPRM1 as a model. A functional model was also provided on these posttranslational modifications at the last section of this chapter.	[Zheng, Hui] Chinese Acad Sci, South China Inst Stem Cell Biol & Regenerat Med, Guangzhou Inst Biomed, Stem Cell & Canc Biol Grp,Key Lab Regenerat Biol, Guangzhou, Guangdong, Peoples R China; [Zheng, Hui] Chinese Acad Sci, South China Inst Stem Cell Biol & Regenerat Med, Guangzhou Inst Hlth, Stem Cell & Canc Biol Grp,Key Lab Regenerat Biol, Guangzhou, Guangdong, Peoples R China; [Loh, Horace H.; Law, Ping-Yee] Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	Zheng, H (reprint author), Chinese Acad Sci, South China Inst Stem Cell Biol & Regenerat Med, Guangzhou Inst Biomed, Stem Cell & Canc Biol Grp,Key Lab Regenerat Biol, Guangzhou, Guangdong, Peoples R China.	zhenhui2055@hotmail.com		Zheng, Hui/0000-0001-6801-0529; Law, Ping-Yee/0000-0002-5364-1093	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA011806, P50 DA011806, R01 DA023905, DA023905]		Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; AvidorReiss T, 1997, J BIOL CHEM, V272, P5040, DOI 10.1074/jbc.272.8.5040; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Caunt CJ, 2006, J BIOL CHEM, V281, P2701, DOI 10.1074/jbc.M507242200; Chen CG, 1998, FEBS LETT, V441, P148, DOI 10.1016/S0014-5793(98)01547-6; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Chu J, 2008, CELL SIGNAL, V20, P1616, DOI 10.1016/j.cellsig.2008.05.004; Chu J, 2010, CELL SIGNAL, V22, P684, DOI 10.1016/j.cellsig.2009.12.003; Damaj BB, 1996, FASEB J, V10, P1426; Doll C, 2011, BRIT J PHARMACOL, V164, P298, DOI 10.1111/j.1476-5381.2011.01382.x; Drisdel RC, 2006, METHODS, V40, P127, DOI 10.1016/j.ymeth.2006.04.015; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; El Kouhen R, 2001, J BIOL CHEM, V276, P12774, DOI 10.1074/jbc.M009571200; Elortza F, 2003, MOL CELL PROTEOMICS, V2, P1261, DOI 10.1074/mcp.M300079-MCP200; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gesty-Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200; Grecksch G, 2011, J NEUROSCI, V31, P13890, DOI 10.1523/JNEUROSCI.2304-11.2011; Gurevich VV, 2006, PHARMACOL THERAPEUT, V110, P465, DOI 10.1016/j.pharmthera.2005.09.008; Hauge C, 2006, J CELL SCI, V119, P3021, DOI 10.1242/jcs.02950; Hawtin SR, 2001, J BIOL CHEM, V276, P38139; Helms JB, 2004, TRAFFIC, V5, P247, DOI 10.1111/j.1600-0854.2004.0181.x; Jafri F, 2006, J BIOL CHEM, V281, P19346, DOI 10.1074/jbc.M512643200; JANKNECHT R, 1994, ONCOGENE, V9, P1273; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Johnson EA, 2006, MOL PHARMACOL, V70, P676, DOI 10.1124/mol.106.022376; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P188, DOI 10.1016/S0165-6147(00)89020-3; Kohout TA, 2004, J BIOL CHEM, V279, P23214, DOI 10.1074/jbc.M402125200; Lefkowitz RJ, 2004, CURR OPIN CELL BIOL, V16, P162, DOI 10.1016/j.ceb.2004.01.001; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Liao D, 2005, P NATL ACAD SCI USA, V102, P1725, DOI 10.1073/pnas.0406797102; Liao D, 2007, MOL CELL NEUROSCI, V35, P456, DOI 10.1016/j.mcn.2007.04.007; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; Lu L, 2000, NEUROSCI LETT, V291, P191, DOI 10.1016/S0304-3940(00)01352-5; Ma L, 2007, J CELL SCI, V120, P213, DOI 10.1242/jcs.03338; Macdonald JL, 2005, J LIPID RES, V46, P1061, DOI 10.1194/jlr.D400041-JLR200; Matsuoka I, 1997, J NEUROCHEM, V68, P498; Mayor S, 2004, TRAFFIC, V5, P231, DOI 10.1111/j.1600-0854.2004.00172.x; MAYOR S, 1995, MOL BIOL CELL, V6, P929; Milligan G, 2007, ERNST SCHERING FOUND, V2, P145, DOI 10.1007/2789_2006_007; Monastyrskaya K, 2005, J BIOL CHEM, V280, P7135, DOI 10.1074/jbc.M405806200; MONS N, 1994, MOL BRAIN RES, V22, P236, DOI 10.1016/0169-328X(94)90052-3; Navratil AM, 2003, J BIOL CHEM, V278, P31593, DOI 10.1074/jbc.M304273200; Nebl T, 2002, J BIOL CHEM, V277, P43399, DOI 10.1074/jbc.M205386200; Oldham WM, 2006, Q REV BIOPHYS, V39, P117, DOI 10.1017/S0033583506004306; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; Rasmussen SGF, 2007, NATURE, V450, P383, DOI 10.1038/nature06325; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Tobin AB, 2008, TRENDS PHARMACOL SCI, V29, P413, DOI 10.1016/j.tips.2008.05.006; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Violin JD, 2007, TRENDS PHARMACOL SCI, V28, P416, DOI 10.1016/j.tips.2007.06.006; Wang Q, 2006, J BIOL CHEM, V281, P25948, DOI 10.1074/jbc.M605415200; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang L, 2006, MOL PHARMACOL, V69, P1810, DOI 10.1124/mol.105.021352; Zheng H, 2008, P NATL ACAD SCI USA, V105, P9421, DOI 10.1073/pnas.0802253105; Zheng H, 2008, MOL PHARMACOL, V73, P178, DOI 10.1124/mol.107.039842; Zheng H, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.177089; Zheng H, 2010, J BIOL CHEM, V285, P21994, DOI 10.1074/jbc.M110.112607; Zheng H, 2010, J NEUROSCI, V30, P8102, DOI 10.1523/JNEUROSCI.6069-09.2010; Zheng H, 2010, IUBMB LIFE, V62, P112, DOI 10.1002/iub.293; Zheng H, 2010, MOL PHARMACOL, V77, P102, DOI 10.1124/mol.109.060848	66	12	12	1	14	ELSEVIER ACADEMIC PRESS INC	SAN DIEGO	525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA	0076-6879		978-0-12-407865-9	METHOD ENZYMOL	Methods Enzymol.		2013	522						391	408		10.1016/B978-0-12-407865-9.00018-2			18	Biochemical Research Methods; Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	BEL04	WOS:000317147300018	23374194	Green Accepted			2020-06-26	J	Evans, AL; Fahlman, A; Ericsson, G; Haga, HA; Arnemo, JM				Evans, Alina L.; Fahlman, Asa; Ericsson, Goran; Haga, Henning Andreas; Arnemo, Jon M.			Physiological evaluation of free-ranging moose (Alces alces) immobilized with etorphine-xylazine-acepromazine in Northern Sweden	ACTA VETERINARIA SCANDINAVICA			English	Article						Alces; Moose; Anesthesia; Etorphine; Xylazine; Immobilization	CARFENTANIL-XYLAZINE; HYPOXEMIA; MEDETOMIDINE; ANESTHESIA; DEER; MORTALITY; LACTATE; MAMMALS	Background: Evaluation of physiology during capture and anesthesia of free-ranging wildlife is useful for determining the effect that capture methods have on both ecological research results and animal welfare. This study evaluates capture and anesthesia of moose (Alces alces) with etorphine-xylazine-acepromazine in Northern Sweden. Methods: Fifteen adult moose aged 3-15 years were darted from a helicopter with a combination of 3.37 mg etorphine, 75 mg xylazine, and 15 mg acepromazine. Paired arterial blood samples were collected 15 minutes apart with the first sample at 15-23 minutes after darting and were analyzed immediately with an i-STAT (R) 1 Portable Clinical Analyzer. Results: All animals developed hypoxemia (PaO2 < 10 kPa) with nine animals having marked hypoxemia (PaO2 5.5-8 kPa). All moose were acidemic (ph < 7.35) with nine moose having marked acidemia (pH < 7.20). For PaCO2, 14 moose had mild hypercapnia (PaCO2 6-8 kPa) and two had marked hypercapnia (PaCO2 > 8 kPa). Pulse, respiratory rate, pH and HCO3 increased significantly over time from darting whereas lactate decreased. Conclusions: The hypoxemia found in this study is a strong indication for investigating alternative drug doses or combinations or treatment with supplemental oxygen.	[Evans, Alina L.; Arnemo, Jon M.] Hedmark Univ Coll, Dept Forestry & Wildlife Management, NO-2480 Koppang, Norway; [Evans, Alina L.] Norwegian Sch Vet Sci, Sect Arctic Vet Med, NO-9292 Tromso, Norway; [Fahlman, Asa] Swedish Univ Agr Sci, Fac Vet Med & Anim Sci, SE-75007 Uppsala, Sweden; [Fahlman, Asa] Univ Calgary, Fac Vet Med, Calgary, AB T2N 4N1, Canada; [Ericsson, Goran; Arnemo, Jon M.] Swedish Univ Agr Sci, Dept Wildlife Fish & Environm Studies, SE-90183 Umea, Sweden; [Haga, Henning Andreas] Norwegian Sch Vet Sci, Dept Clin Sci, NO-0033 Oslo, Norway	Evans, AL (reprint author), Hedmark Univ Coll, Dept Forestry & Wildlife Management, Campus Evenstad, NO-2480 Koppang, Norway.	alinaevans@gmail.com	Evans, Alina/AAH-8881-2019		Swedish University of Agricultural Science; Swedish Association of Hunting and Wildlife Management; Sveaskog; ICEHOTEL; US-Norway Fulbright Foundation; American Scandinavian Foundation; Morris Animal Foundation	Eric Andersson and Ake Nordstrom from the Swedish University of Agricultural Science performed the moose captures and facilitated the logistics for this study. Tjarda Roberts at the Norwegian Polar institute consulted on the statistical analysis. The Wildlife & Forestry program at the Swedish University of Agricultural Science and the program ICEMOOSE of the Swedish University of Agricultural Science, the Swedish Association of Hunting and Wildlife Management, Sveaskog and the ICEHOTEL supported this project. The iSTAT machine was provided by the Norwegian School of Veterinary Science and stipend support for the first author was from the US-Norway Fulbright Foundation, the American Scandinavian Foundation and the Morris Animal Foundation.	Arnemo JM, 2006, WILDLIFE BIOL, V12, P109, DOI 10.2981/0909-6396(2006)12[109:ROCMIL]2.0.CO;2; Arnemo JM, 2004, P AAZV AAWV WDA JOIN, P515; Arnemo Jon M., 2003, Alces, V39, P243; Braaksma MA, 1999, AM J PHYSIOL-REG I, V277, pR395; Cattet M, 2008, J MAMMAL, V89, P973, DOI 10.1644/08-MAMM-A-095.1; Caulkett NA, 2000, CAN J VET RES, V64, P64; Caulkett NA, 2000, CAN VET J, V41, P49; Celly CS, 1999, AM J VET RES, V60, P154; Delvaux H, 1999, J WILDLIFE DIS, V35, P38, DOI 10.7589/0090-3558-35.1.38; Dyson A, 2007, AM J PHYSIOL-HEART C, V293, pH526, DOI 10.1152/ajpheart.00052.2007; Ericsson G, 2001, ECOSCIENCE, V8, P157, DOI 10.1080/11956860.2001.11682641; Evans RG, 2011, AM J PHYSIOL-REG I, V300, pR931, DOI 10.1152/ajpregu.00552.2010; FORSTER HV, 1972, J APPL PHYSIOL, V32, P134; Geoffrey JL, 2006, ENCY RESP MED, P302; Grimm Kurt A., 2007, P3; Gutstein HB, 2006, GOODMAN GILMANS PHAR, P560; Haga HA, 2009, VET ANAESTH ANALG, V36, P555, DOI 10.1111/j.1467-2995.2009.00498.x; JALANKA HH, 1990, J ZOO WILDLIFE MED, V21, P259; Kreeger T. J., 2012, HDB WILDLIFE CHEM IM; Kreeger Terry J., 2005, Alces, V41, P121; Kreeger TJ, 2000, WILDLIFE SOC B, V28, P751; LARSEN DG, 1989, J WILDLIFE MANAGE, V53, P564, DOI 10.2307/3809177; LYNCH GM, 1981, J WILDLIFE MANAGE, V45, P981, DOI 10.2307/3808108; Morais HA, 2011, FLUID ELECT ACID BAS, P287; Neumann W, 2011, CAN J ZOOL, V89, P1013, DOI 10.1139/Z11-076; Paterson JM, 2009, J ZOO WILDLIFE MED, V40, P39, DOI 10.1638/2007-0107.1; Read MR, 2003, J ZOO WILDLIFE MED, V34, P134, DOI 10.1638/1042-7260(2003)034[0134:AROAAA]2.0.CO;2; Read MR, 2001, CAN VET J, V42, P861; Rees S, 1999, J NEUROPATH EXP NEUR, V58, P932, DOI 10.1097/00005072-199909000-00004; Schmidt-Nielsen K., 1997, ANIMAL PHYSL ADAPTAT; SEAL US, 1985, J WILDLIFE DIS, V21, P48, DOI 10.7589/0090-3558-21.1.48; Siegal-Willott J, 2009, J WILDLIFE DIS, V45, P468, DOI 10.7589/0090-3558-45.2.468; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; Storms TN, 2005, J WILDLIFE DIS, V41, P559, DOI 10.7589/0090-3558-41.3.559; Wang P, 1997, BBA-MOL BASIS DIS, V1361, P42, DOI 10.1016/S0925-4439(97)00015-X; West JB, 2008, RESP PHYSL, P186	36	14	14	1	18	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0044-605X	1751-0147		ACTA VET SCAND	Acta Vet. Scand.	DEC 31	2012	54								77	10.1186/1751-0147-54-77			7	Veterinary Sciences	Veterinary Sciences	068AA	WOS:000313335700001	23276208	DOAJ Gold, Green Published, Green Accepted			2020-06-26	J	Maguma, HT; Dewey, WL; Akbarali, HI				Maguma, Hercules T.; Dewey, William L.; Akbarali, Hamid I.			Differences in the characteristics of tolerance to mu-opioid receptor agonists in the colon from wild type and beta-arrestin2 knockout mice	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						mu-Opioid receptor; beta-Arrestin2; Opioid; Circular smooth muscle; Tolerance	PROTEIN-KINASE-C; BETA-ARRESTIN; MORPHINE-TOLERANCE; 7-TRANSMEMBRANE RECEPTORS; CIRCULAR MUSCLE; MOUSE; DESENSITIZATION; EFFICACY; RAT; MECHANISMS	Drawbacks to opioid use include development of analgesic tolerance and persistent constipation. We previously reported that tolerance to morphine develops upon repeated exposure in the isolated ileum but not the isolated colon. The cellular mechanisms of antinociceptive tolerance vary among mu-opioid receptor agonists. In this study, we assess beta-arrestin2 deletion on the development of tolerance to different opioids in ileum and colon circular muscle. Tolerance was determined by assessing the ability of repeated in-vitro opioid exposure to induce contraction of the circular muscle from C57BL/6 wild type (WT) and beta-arrestin2 knockout (KO) mice. Repeated exposure every 30 min with in-between washes resulted in tolerance to all agonists in the ileum of both WT and KO mice. However, in the colon of WT mice, comparison of the contractions between the 4th exposure and 1st response was similar to DAMGO (100 +/- 10%; N = 5) but reduced to fentanyl (62 +/- 13%; N = 8) and etorphine (38 +/- 4%; N = 7) indicative of tolerance to fentanyl and etorphine but not DAMGO. In contrast, all agonists produced tolerance in the colon of KO: DAMGO response at the 4th exposure decreased to 52 +/- 10% (N = 5), fentanyl to 20 +/- 5% (N = 6) and etorphine 33 +/- 7% (N = 6). Differences in tolerance among opioid agonists in the colon suggest ligand bias. The deletion of beta-arrestin2 in colon appears to be necessary for tolerance to DAMGO but not fentanyl or etorphine. beta-arrestin2 potentially represents an important target for treating opioid-induced bowel dysfunction and warrants further exploration of its ligand bias. (C) 2012 Elsevier B.V. All rights reserved.	[Maguma, Hercules T.; Dewey, William L.; Akbarali, Hamid I.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, VCU Program Enter Neuromuscular Sci, Richmond, VA 23298 USA	Akbarali, HI (reprint author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, VCU Program Enter Neuromuscular Sci, 1112 E Clay St,McGuire Hall 317, Richmond, VA 23298 USA.	hiakbarali@vcu.edu	Akbarali, Hamid/Q-9344-2019	Akbarali, Hamid/0000-0003-1423-0774	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA024009]	This work was supported by NIH DA024009.	AKBARALI H, 1987, CAN J PHYSIOL PHARM, V65, P23, DOI 10.1139/y87-005; Bailey CP, 2005, CURR OPIN PHARMACOL, V5, P60, DOI 10.1016/j.coph.2004.08.012; Bernstein MA, 1998, MOL BRAIN RES, V55, P237, DOI 10.1016/S0169-328X(98)00005-9; BLOOM AS, 1978, PSYCHOPHARMACOLOGY, V57, P243, DOI 10.1007/BF00426745; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bohn LM, 2002, J NEUROSCI, V22, P10494; Gray AC, 2005, BRIT J PHARMACOL, V144, P687, DOI 10.1038/sj.bjp.0706107; GRIDER JR, 1987, J PHARMACOL EXP THER, V243, P205; HINE B, 1985, PSYCHOPHARMACOLOGY, V87, P34, DOI 10.1007/BF00431774; Holzer Peter, 2009, J Opioid Manag, V5, P145; Holzer P, 2009, REGUL PEPTIDES, V155, P11, DOI 10.1016/j.regpep.2009.03.012; Hull LC, 2010, J PHARMACOL EXP THER, V332, P1127, DOI 10.1124/jpet.109.161455; Iwata H, 2007, EUR J PHARMACOL, V574, P66, DOI 10.1016/j.ejphar.2007.06.029; Johnson EA, 2006, MOL PHARMACOL, V70, P676, DOI 10.1124/mol.106.022376; Kang MH, 2012, J PHARMACOL EXP THER, V340, P567, DOI 10.1124/jpet.111.186320; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; McPherson J, 2010, MOL PHARMACOL, V78, P756, DOI 10.1124/mol.110.066613; Narita M, 1996, BRIT J PHARMACOL, V118, P1829, DOI 10.1111/j.1476-5381.1996.tb15610.x; Nobles KN, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001707; Pawar M, 2007, EUR J PHARMACOL, V563, P92, DOI 10.1016/j.ejphar.2007.01.059; Perroy J, 2004, NAT METHODS, V1, P203, DOI 10.1038/NMETH722; Raehal KM, 2011, PHARMACOL REV, V63, P1001, DOI 10.1124/pr.111.004598; Ross GR, 2008, J PHARMACOL EXP THER, V327, P561, DOI 10.1124/jpet.108.143438; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Shukla AK, 2008, P NATL ACAD SCI USA, V105, P9988, DOI 10.1073/pnas.0804246105; Sirohi S, 2008, PHARMACOL BIOCHEM BE, V91, P115, DOI 10.1016/j.pbb.2008.06.019; Smith FL, 2006, PHARMACOL RES, V54, P474, DOI 10.1016/j.phrs.2006.09.007; Thomas J, 2008, J PAIN SYMPTOM MANAG, V35, P103, DOI 10.1016/j.jpainsymman.2007.01.017; Violin JD, 2007, TRENDS PHARMACOL SCI, V28, P416, DOI 10.1016/j.tips.2007.06.006; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	31	25	25	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	JUN 15	2012	685	1-3					133	140		10.1016/j.ejphar.2012.04.001			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	944MC	WOS:000304205600018	22521552	Green Accepted			2020-06-26	J	Aguila, B; Coulbault, L; Davis, A; Marie, N; Hasbi, A; Le Bras, F; Toth, G; Borsodi, A; Gurevich, VV; Jauzac, P; Allouche, S				Aguila, Benjamin; Coulbault, Laurent; Davis, Audrey; Marie, Nicolas; Hasbi, Ahmed; Le Bras, Florian; Toth, Geza; Borsodi, Anna; Gurevich, Vsevolod V.; Jauzac, Philippe; Allouche, Stephane			Barrestin1-biased agonism at human delta-opioid receptor by peptidic and alkaloid ligands	CELLULAR SIGNALLING			English	Article						delta-opioid receptor; Barrestin; G protein-coupled receptor; Peptidic and alkaloid ligands	PROTEIN-COUPLED RECEPTOR; NEUROBLASTOMA-CELL-LINE; SK-N-BE; ADENYLYL-CYCLASE; ARRESTIN; INTERNALIZATION; DESENSITIZATION; PHOSPHORYLATION; ACTIVATION; KINASE	We have previously reported on the differential regulation of the human delta-opioid receptor (hDOR) by alkaloid (etorphine) and peptidic (DPDPE and deltorphin 1) ligands, in terms of both receptor desensitization and post-endocytic sorting. Since Barrestins are well known to regulate G protein-coupled receptors (GPCRs) signaling and trafficking, we therefore investigated the role of Barrestin1 (the only isoform expressed in our cellular model) in the context of the hDOR. We established clonal cell lines of SK-N-BE cells over-expressing Barrestin1, its dominant negative mutant (Barrestin1(319-418)), and shRNA directed against endogenous Barrestin1. Interestingly, both binding and confocal microscopy approaches demonstrated that Barrestin1 is required for hDOR endocytosis only when activated by etorphine. Conversely, functional experiments revealed that Barrestin1 is exclusively involved in hDOR desensitization promoted by the peptides. Taken together, these results provide substantial evidence for a Barrestin1-biased agonism at hDOR, where Barrestin1 is differentially involved during receptor desensitization and endocytosis depending on the ligand. (C) 2011 Elsevier Inc. All rights reserved.	[Aguila, Benjamin; Coulbault, Laurent; Davis, Audrey; Le Bras, Florian; Jauzac, Philippe; Allouche, Stephane] Univ Caen, Lab Biol Mol & Cellulaire Signalisat, UPRES EA 3919, IFR ICORE 146, F-14032 Caen, France; [Marie, Nicolas] Univ Paris 05, INSERM, U705, CNRS,Lab Neuropsychopharmacol Addict,UMR 8206, F-75006 Paris, France; [Hasbi, Ahmed] Univ Toronto, Ctr Addict & Mental Hlth, Dept Pharmacol, Toronto, ON M5S 1A1, Canada; [Toth, Geza; Borsodi, Anna] Hungarian Acad Sci, Biol Res Ctr, Inst Biochem, H-6701 Szeged, Hungary; [Gurevich, Vsevolod V.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Aguila, B (reprint author), McGill Univ, Polypeptide Hormone Lab, Dept Expt Med, Montreal, PQ, Canada.	benjamin.aguila@mcgill.ca; allouche-s@chu-caen.fr	Marie, Nicolas/I-9129-2014; Gurevich, Vsevolod/A-3236-2008	Marie, Nicolas/0000-0002-6491-9898; Gurevich, Vsevolod/0000-0002-3950-5351; Allouche, stephane/0000-0003-3134-7501	Regional Council of Lower-Normandy, FranceRegion Normandie; National Bureau of Research and Technology (Hungary) RET/DNT; Ministry of Health (Hungary) ETT	We are thankful to Dr. A-M. Fay for her helpful comments and for critical reading of the manuscript and to Dr. C. Kerros for the molecular characterization of Barrestins expression. This work was supported by operating grant from the Regional Council of Lower-Normandy (France) to B.A, from the National Bureau of Research and Technology (Hungary) RET/DNT 2004 to G.T. and A.B. and from the Ministry of Health (Hungary) ETT to A.B.	Aguila B, 2007, BRIT J PHARMACOL, V152, P1312, DOI 10.1038/sj.bjp.0707497; Aguila B, 2011, METHODS MOL BIOL, V756, P371, DOI 10.1007/978-1-61779-160-4_23; Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Allouche S, 1999, EUR J PHARMACOL, V371, P235, DOI 10.1016/S0014-2999(99)00180-6; Allouche S, 1999, BIOCHEM J, V342, P71, DOI 10.1042/0264-6021:3420071; Aquila B, 2006, BRAIN RES, V1114, P11, DOI 10.1016/j.brainres.2006.07.069; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Celver JP, 2001, J BIOL CHEM, V276, P4894, DOI 10.1074/jbc.M007437200; Cen B, 2001, MOL PHARMACOL, V59, P758; Cheng ZJ, 1998, J BIOL CHEM, V273, P24328, DOI 10.1074/jbc.273.38.24328; Chu J, 2008, CELL SIGNAL, V20, P1616, DOI 10.1016/j.cellsig.2008.05.004; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; Drake MT, 2008, J BIOL CHEM, V283, P5669, DOI 10.1074/jbc.M708118200; Galandrin S, 2006, MOL PHARMACOL, V70, P1575, DOI 10.1124/mol.106.026716; Gurevich EV, 2002, NEUROSCIENCE, V109, P421, DOI 10.1016/S0306-4522(01)00511-5; Gurevich VV, 2006, PHARMACOL THERAPEUT, V110, P465, DOI 10.1016/j.pharmthera.2005.09.008; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; Hanson SM, 2007, EMBO J, V26, P1726, DOI 10.1038/sj.emboj.7601614; Jones BW, 2008, MOL PHARMACOL, V74, P195, DOI 10.1124/mol.108.045948; Kenakin T, 2011, J PHARMACOL EXP THER, V336, P296, DOI 10.1124/jpet.110.173948; Key TA, 2003, J BIOL CHEM, V278, P4041, DOI 10.1074/jbc.M204687200; Kim J, 2005, P NATL ACAD SCI USA, V102, P1442, DOI 10.1073/pnas.0409532102; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; Marie N, 2003, J BIOL CHEM, V278, P22795, DOI 10.1074/jbc.M300084200; Marie N, 2008, CELL SIGNAL, V20, P1209, DOI 10.1016/j.cellsig.2008.02.010; McPherson J, 2010, MOL PHARMACOL, V78, P756, DOI 10.1124/mol.110.066613; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; POLASTRON J, 1994, J NEUROCHEM, V62, P898; Qiu Y, 2007, J BIOL CHEM, V282, P22315, DOI 10.1074/jbc.M611258200; Ren XR, 2005, P NATL ACAD SCI USA, V102, P1448, DOI 10.1073/pnas.0409534102; Szatmari I, 1999, PEPTIDES, V20, P1079, DOI 10.1016/S0196-9781(99)00101-1; Vines CM, 2003, J BIOL CHEM, V278, P41581, DOI 10.1074/jbc.C300291200; Violin JD, 2007, TRENDS PHARMACOL SCI, V28, P416, DOI 10.1016/j.tips.2007.06.006; Vishnivetskiy SA, 2007, J BIOL CHEM, V282, P32075, DOI 10.1074/jbc.M706057200; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Wisler JW, 2007, P NATL ACAD SCI USA, V104, P16657, DOI 10.1073/pnas.0707936104; Xiang B, 2001, J BIOL CHEM, V276, P4709, DOI 10.1074/jbc.M006187200; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	40	8	8	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0898-6568	1873-3913		CELL SIGNAL	Cell. Signal.	MAR	2012	24	3					699	707		10.1016/j.cellsig.2011.10.018			9	Cell Biology	Cell Biology	895EG	WOS:000300478400013	22101011	Green Accepted			2020-06-26	J	Yu, G; Yan, LD; Li, YL; Wen, Q; Dong, HJ; Gong, ZH				Yu, Gang; Yan, Ling-Di; Li, Yu-Lei; Wen, Quan; Dong, Hua-Jin; Gong, Ze-Hui			TH-030418: a potent long-acting opioid analgesic with low dependence liability	NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY			English	Article						TH-030418; Dependence; Long-acting opioid analgesic; ORL1; Thienorphine	CONDITIONED PLACE PREFERENCE; RECEPTOR; DIHYDROETORPHINE; MORPHINE; AGONIST; MICE; THIENORPHINE; RATS; BUPRENORPHINE; ACQUISITION	Numerous efforts have been made on the chemical modification of opioid compounds, with the ultimate goal of developing new opioid analgesics that is highly potent and low/non-addictive. In a search for such compounds, TH-030418 [7 alpha-[(R)-1-hydroxy-1-methyl-3-(thien-3-yl)-propyl]-6,14-endo-ethanotetrahydrooripavine] was synthesized. Here, we evaluated the pharmacological activities of TH-030418, in comparison with morphine, the prototype opioid analgesic. In radioligand binding assays, TH-030418 bound potently and nonselectively to mu-, delta-, kappa-, and ORL1 (opioid receptor-like 1) receptors stably expressed in CHO (Chinese hamster ovary) cells with K (i) values of 0.56, 0.73, 0.60, and 1.55 nM, respectively. When administered subcutaneously, TH-030418 was much more potent than morphine in analgesia, with the ED(50) values of 1.37 mu g/kg and 1.70 mu g/kg in hot plate and acetic acid writhing tests, respectively. The opioid antagonist naloxone blocked the antinociceptive effect of TH-030418, indicating that the action of TH-030418 was mediated by opioid receptors. The antinociceptive effect of s.c. TH-030418 in hot plate test lasted for more than 12 h, which is much longer than those of morphine (2.5 h) and dihydroetorphine (1.5 h). In addition, naloxone did not precipitate withdrawal syndrome in the mice treated with TH-030418 previously. Most importantly, TH-030418 did not induce conditioned place preference in mice after chronic treatment. These results indicate that TH-030418 is a potent long-acting opioid analgesic with low dependence liability and may be of some value in the development of new analgesics.	[Yu, Gang; Yan, Ling-Di; Li, Yu-Lei; Wen, Quan; Dong, Hua-Jin; Gong, Ze-Hui] Beijing Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China	Gong, ZH (reprint author), Beijing Inst Pharmacol & Toxicol, 27 Taiping Rd, Beijing 100850, Peoples R China.	yg1st@163.com; Gongzeh@yahoo.com.cn			863-High Technology Research and Development Program Plan of ChinaNational High Technology Research and Development Program of China [2006AA020601]; National S&T major project of Original New Drug Research of China [2009ZXJ09004-079]	This work was supported by the 863-High Technology Research and Development Program Plan of China (2006AA020601) and National S&T major project of Original New Drug Research of China (2009ZXJ09004-079). We thank Dr. He Liu for the synthesis of TH-030418.	BARDO MT, 1995, NEUROSCI BIOBEHAV R, V19, P39, DOI 10.1016/0149-7634(94)00021-R; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3281, DOI 10.1021/ja00989a032; Contet C, 2004, CURR OPIN NEUROBIOL, V14, P370, DOI 10.1016/j.conb.2004.05.005; Davis MP, 2005, LANCET ONCOL, V6, P696, DOI 10.1016/S1470-2045(05)70317-X; Ellison Neil M., 1993, P185; HUANG M, 1982, Acta Pharmacologica Sinica, V3, P81; Khroyan TV, 2007, J PHARMACOL EXP THER, V320, P934, DOI 10.1124/jpet.106.111997; Lattanzi R, 2001, BRIT J PHARMACOL, V134, P441, DOI 10.1038/sj.bjp.0704280; LEWIS JW, 1971, ANNU REV PHARMACOLOG, V11, P241, DOI 10.1146/annurev.pa.11.040171.001325; Li JX, 2007, J PHARMACOL EXP THER, V321, P227, DOI 10.1124/jpet.106.113290; Liu CH, 2005, SYNTHETIC COMMUN, V35, P701, DOI 10.1081/SCC-200050367; Martin TJ, 1997, EUR J PHARMACOL, V324, P141, DOI 10.1016/S0014-2999(97)00074-5; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Maul C., 2002, ANALGESICS CHEM PHAR, P159; Murphy NP, 1999, BRAIN RES, V832, P168, DOI 10.1016/S0006-8993(99)01425-0; Ohmori S, 2001, EUR J PHARMACOL, V423, P157, DOI 10.1016/S0014-2999(01)01098-6; Ohmori S, 2001, J PHARMACOL EXP THER, V296, P528; Shoblock JR, 2005, NEUROPHARMACOLOGY, V49, P439, DOI 10.1016/j.neuropharm.2005.04.008; Tokuyama S, 1996, BIOL PHARM BULL, V19, P477; TOKUYAMA S, 1993, BIOL PHARM BULL, V16, P774; WANG DX, 1995, J PHARM PHARMACOL, V47, P669, DOI 10.1111/j.2042-7158.1995.tb05857.x; Yu G, 2006, J PHARMACOL EXP THER, V318, P282, DOI 10.1124/jpet.105.099937; Zaveri NT, 2004, J MED CHEM, V47, P2973, DOI 10.1021/jm034249d; Zhao WL, 2004, ACTA PHARMACOL SIN, V25, P1413; Zhu JM, 1997, J PHARMACOL EXP THER, V282, P676	25	13	14	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-1298			N-S ARCH PHARMACOL	Naunyn-Schmiedebergs Arch. Pharmacol.	AUG	2011	384	2					125	131		10.1007/s00210-011-0652-8			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	799OI	WOS:000293295600003	21594658				2020-06-26	J	Blix, AS; Lian, H; Ness, J				Blix, Arnoldus Schytte; Lian, Hans; Ness, John			Immobilization of muskoxen (Ovibos moschatus) with etorphine and xylazine	ACTA VETERINARIA SCANDINAVICA			English	Article							NORWEGIAN REINDEER; BRAIN	One hundred and thirty three "wild" muskoxen, 81 of which of known body mass, were successfully immobilized using etorphine (M99), and xylazine (Rompun (R)), delivered by use of a dart gun. A dose of 0.05 mg/kg M99, supplemented by 0.15 mg/kg Rompun was found to be very effective. This dose is much higher than currently recommended e. g. by Handbook of Wildlife Chemical Immobilization.	[Blix, Arnoldus Schytte; Lian, Hans; Ness, John] Univ Tromso, Dept Arctic & Marine Biol, N-9037 Tromso, Norway	Blix, AS (reprint author), Univ Tromso, Dept Arctic & Marine Biol, N-9037 Tromso, Norway.	asb000@uit.no					Adamczewski J., 1992, Rangifer, V12, P179; Blix Arnoldus Schytte, 2011, Rangifer, V31, P1; CLAUSEN B, 1984, Journal of Wildlife Diseases, V20, P141; Crater AR, 2007, J MAMMAL, V88, P625, DOI 10.1644/06-MAMM-A-170R1.1; DIETERICH RA, 1984, BIOL PAPERS U ALASKA, V4, P167; JINGFORS K, 1989, CAN J ZOOL, V67, P1120, DOI 10.1139/z89-160; JOHNSEN HK, 1987, AM J PHYSIOL, V253, pR848; Kreeger T. J., 2002, HDB WILDLIFE CHEM IM; KUHNEN G, 1993, ACTA PHYSIOL SCAND, V147, P281, DOI 10.1111/j.1748-1716.1993.tb09500.x; LARSEN T S, 1985, Rangifer, V5, P2; MERCER JB, 1985, AM J PHYSIOL, V248, pR679; Nilssen K. J., 1994, Rangifer, V14, P79; NILSSEN KJ, 1984, AM J PHYSIOL, V247, pR837	13	7	7	0	12	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1751-0147			ACTA VET SCAND	Acta Vet. Scand.	JUN 27	2011	53								42	10.1186/1751-0147-53-42			4	Veterinary Sciences	Veterinary Sciences	795TA	WOS:000292997500001	21707976	DOAJ Gold, Green Published			2020-06-26	J	Kaplan, E; Binyaminy, B; Gafni, M; Keren, O; Sarne, Y				Kaplan, Elena; Binyaminy, Binyamin; Gafni, Mikhal; Keren, Ora; Sarne, Yosef			Membrane-delimited proteolytic regulation of opioid receptors	BRAIN RESEARCH			English	Article						Opioid receptor; Down regulation; Serine-peptidase; Amino-peptidase; Agonist functional selectivity	INDUCED DOWN-REGULATION; PROTEIN-KINASE; CANNABINOID RECEPTORS; ADENYLYL-CYCLASE; AGONIST; INTERNALIZATION; MU; INVOLVEMENT; PATHWAYS; PHOSPHORYLATION	Prolonged exposure of opioid receptors to agonists leads to their regulation by the classical process of clathrin-dependent internalization, followed by their intracellular degradation (down regulation). We have previously shown that the opioid agonist etorphine induced an additional process of down regulation of mu-opioid receptors (MOR) that occurred in intact MOR-transfected HEK-293 cells, as well as in isolated membranes. In the present study we show that etorphine similarly down regulated rat kappa-opioid receptors (KORs), which do not undergo the classical process of internalization and down regulation. This process was resistant to inhibitors of clathrin-coated pit formation (hypertonic sucrose, mono-dansylcadaverine) and was mainly mediated by membranous serine- and amino-peptidases. We further show that various opioid ligands, besides etorphine, induced down regulation of either KOR or MOR in isolated membranes. The ability of the various opioid ligands to induce membrane-delimited KOR or MOR down regulation did not correlate to their classical pharmacological profile, suggesting functional selectivity of the effect. Levorphanol, but not its stereoisomer dextrophan, induced membrane-delimited down regulation of both KOR and MOR, indicating that stereoselective binding to the receptor was necessary to initiate the process. Our findings that this proteolytic regulation of opioid receptors occurs not only in isolated membranes but also in intact cells and that it occurs even when the receptors are resistant to the conventional process of down regulation indicate its possible physiological role in the regulation of opioid activity. (C) 2011 Elsevier B.V. All rights reserved.	[Sarne, Yosef] Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, Adelson Ctr Biol Addict Dis, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Mauerberger Chair Neuropharmacol, IL-69978 Tel Aviv, Israel	Sarne, Y (reprint author), Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, Adelson Ctr Biol Addict Dis, IL-69978 Tel Aviv, Israel.	sarney@post.tau.ac.il			Israel Anti Drug Authority	This study was supported by a grant from the Israel Anti Drug Authority.	ABOOD ME, 1994, J NEUROSCI RES, V37, P714, DOI 10.1002/jnr.490370605; Allen JA, 2007, NAT REV NEUROSCI, V8, P128, DOI 10.1038/nrn2059; BELCHEVA MM, 1992, MOL PHARMACOL, V42, P445; Berg KA, 1998, MOL PHARMACOL, V54, P94; Binyaminy B, 2008, LIFE SCI, V82, P831, DOI 10.1016/j.lfs.2008.01.015; Chaturvedi K, 2001, J BIOL CHEM, V276, P12345, DOI 10.1074/jbc.M008054200; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen Y, 2006, J PHARMACOL EXP THER, V319, P765, DOI 10.1124/jpet.106.107987; CONCHON S, 1994, FEBS LETT, V349, P365, DOI 10.1016/0014-5793(94)00703-9; Couet J, 1996, J BIOL CHEM, V271, P4545; Dhami GK, 2002, J BIOL CHEM, V277, P25266, DOI 10.1074/jbc.M203593200; Fairfax BP, 2004, J BIOL CHEM, V279, P12565, DOI 10.1074/jbc.M311389200; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Gesty-Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200; Grantcharova E, 2002, J BIOL CHEM, V277, P43933, DOI 10.1074/jbc.M208407200; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Johnson EA, 2006, MOL PHARMACOL, V70, P676, DOI 10.1124/mol.106.022376; Kenakin T, 2003, TRENDS PHARMACOL SCI, V24, P346, DOI 10.1016/S0165-6147(03)00167-6; Keren O, 2003, BRAIN RES, V980, P197, DOI 10.1016/S0006-8993(03)02970-6; Koch T, 1997, J NEUROCHEM, V69, P1767; Kojro E, 1999, EUR J BIOCHEM, V266, P538, DOI 10.1046/j.1432-1327.1999.00892.x; Korzh A, 2008, BRAIN RES, V1189, P23, DOI 10.1016/j.brainres.2007.10.070; Kramer HK, 1999, J NEUROCHEM, V72, P594, DOI 10.1046/j.1471-4159.1999.0720594.x; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Liu-Chen LY, 2004, LIFE SCI, V75, P511, DOI 10.1016/j.lfs.2003.10.041; Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216; MENG F, 1993, P NATL ACAD SCI USA, V90, P9954, DOI 10.1073/pnas.90.21.9954; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; Paila YD, 2009, GLYCOCONJUGATE J, V26, P711, DOI 10.1007/s10719-008-9218-5; Pfeiffer R, 1998, EXP CELL RES, V244, P327, DOI 10.1006/excr.1998.4159; Qiu Y, 2003, J BIOL CHEM, V278, P36733, DOI 10.1074/jbc.M305857200; Reiter E, 2006, TRENDS ENDOCRIN MET, V17, P159, DOI 10.1016/j.tem.2006.03.008; Roettger BF, 1997, MOL PHARMACOL, V51, P357; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Schmidt H, 2000, J NEUROCHEM, V74, P414, DOI 10.1046/j.1471-4159.2000.0740414.x; Schutze S, 1999, J BIOL CHEM, V274, P10203, DOI 10.1074/jbc.274.15.10203; Shapira M, 2001, MOL BRAIN RES, V96, P142, DOI 10.1016/S0169-328X(01)00283-2; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; von Zastrow M, 2004, NEUROMOL MED, V5, P51, DOI 10.1385/NMM:5:1:051; Wannemacher KM, 2007, J PHARMACOL EXP THER, V323, P614, DOI 10.1124/jpet.107.125500; Xu W, 2006, J PHARMACOL EXP THER, V317, P1295, DOI 10.1124/jpet.105.099507; Zaki PA, 1996, ANNU REV PHARMACOL, V36, P379; Zhang L, 2006, MOL PHARMACOL, V69, P1810, DOI 10.1124/mol.105.021352; Zheng H, 2008, P NATL ACAD SCI USA, V105, P9421, DOI 10.1073/pnas.0802253105	47	2	2	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 22	2011	1386						25	34		10.1016/j.brainres.2011.02.040			10	Neurosciences	Neurosciences & Neurology	755TD	WOS:000289958700003	21338590				2020-06-26	J	Zheng, H; Chu, J; Zhang, YH; Loh, HH; Law, PY				Zheng, Hui; Chu, Ji; Zhang, Yuhan; Loh, Horace H.; Law, Ping-Yee			Modulating mu-Opioid Receptor Phosphorylation Switches Agonist-dependent Signaling as Reflected in PKC epsilon Activation and Dendritic Spine Stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTINS; LIPID RAFTS; KINASE-C; MORPHINE; INTERNALIZATION; DESENSITIZATION; TOLERANCE; MEMBRANE; BINDING	A new role of G protein-coupled receptor (GPCR) phosphorylation was demonstrated in the current studies by using the mu-opioid receptor (OPRM1) as a model. Morphine induces a low level of receptor phosphorylation and uses the PKC epsilon pathway to induce ERK phosphorylation and receptor desensitization, whereas etorphine, fentanyl, and [D-Ala(2), N-Me-Phe(4), Gly(5)-ol]-enkephalin (DAMGO) induce extensive receptor phosphorylation and use the beta-arrestin2 pathway. Blocking OPRM1 phosphorylation (by mutating Ser(363), Thr(370) and Ser(375) to Ala) enabled etorphine, fentanyl, and DAMGO to use the PKC epsilon pathway. This was not due to the decreased recruitment of beta-arrestin2 to the receptor signaling complex, because these agonists were unable to use the PKC epsilon pathway when beta-arrestin2 was absent. In addition, overexpressing G protein-coupled receptor kinase 2 (GRK2) decreased the ability of morphine to activate PKC epsilon, whereas overexpressing dominant-negative GRK2 enabled etorphine, fentanyl, and DAMGO to activate PKC epsilon. Furthermore, by overexpressing wild-type OPRM1 and a phosphorylation-deficient mutant in primary cultures of hippocampal neurons, we demonstrated that receptor phosphorylation contributes to the differential effects of agonists on dendritic spine stability. Phosphorylation blockage made etorphine, fentanyl, and DAMGO function as morphine in the primary cultures. Therefore, agonist-dependent phosphorylation of GPCR regulates the activation of the PKC pathway and the subsequent responses.	[Zheng, Hui; Chu, Ji; Zhang, Yuhan; Loh, Horace H.; Law, Ping-Yee] Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; [Zheng, Hui] Chinese Acad Sci, Stem Cell & Canc Biol Grp, S China Inst Stem Cell Biol & Regenerat Med, Key Lab Regenerat Biol,Guangzhou Inst Biomed & Hl, Guangzhou 510530, Guangdong, Peoples R China	Zheng, H (reprint author), 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	zhenhui2055@hotmail.com		Zheng, Hui/0000-0001-6801-0529; Law, Ping-Yee/0000-0002-5364-1093	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA007339, DA016674, DA000564, DA011806]	This work was supported, in whole or in part, by National Institutes of Health Grants DA007339, DA016674, DA000564, and DA011806.	Cen B, 2001, MOL PHARMACOL, V59, P758; Chae JH, 2004, MOL CELLS, V18, P271; CHAKRABARTI S, 1995, MOL BRAIN RES, V30, P269, DOI 10.1016/0169-328X(95)00014-J; Chu J, 2008, CELL SIGNAL, V20, P1616, DOI 10.1016/j.cellsig.2008.05.004; Chu J, 2010, CELL SIGNAL, V22, P684, DOI 10.1016/j.cellsig.2009.12.003; Debic HH, 2005, J NEUROSCI, V25, P7847, DOI 10.1523/JNEUROSCI.5045-04.2005; DeGraff JL, 2002, J BIOL CHEM, V277, P43247, DOI 10.1074/jbc.M207495200; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; El Kouhen R, 2001, J BIOL CHEM, V276, P12774, DOI 10.1074/jbc.M009571200; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Gaudilliere B, 2004, NEURON, V41, P229, DOI 10.1016/S0896-6273(03)00841-9; Gurevich VV, 2006, PHARMACOL THERAPEUT, V110, P465, DOI 10.1016/j.pharmthera.2005.09.008; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kobayashi H, 2005, CELL SIGNAL, V17, P1248, DOI 10.1016/j.cellsig.2004.12.014; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; Lan HX, 2009, MOL PHARMACOL, V75, P113, DOI 10.1124/mol.108.050534; Law PY, 2004, NEUROPHARMACOLOGY, V47, P300, DOI 10.1016/j.neuropharm.2004.07.013; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Li JL, 2003, J BIOL CHEM, V278, P30219, DOI 10.1074/jbc.M302385200; Liao D, 2005, P NATL ACAD SCI USA, V102, P1725, DOI 10.1073/pnas.0406797102; Liao D, 2007, MOL CELL NEUROSCI, V35, P456, DOI 10.1016/j.mcn.2007.04.007; Lin H, 2009, NEUROPSYCHOPHARMACOL, V34, P2097, DOI 10.1038/npp.2009.34; Macdonald JL, 2005, J LIPID RES, V46, P1061, DOI 10.1194/jlr.D400041-JLR200; Macey TA, 2005, J NEUROCHEM, V93, P128, DOI 10.1111/j.1471-4159.2004.02998.x; Metaye T, 2005, CELL SIGNAL, V17, P917, DOI 10.1016/j.cellsig.2005.01.002; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; ROERIG SC, 1992, MOL PHARMACOL, V41, P822; Smith FL, 2007, PAIN, V127, P129, DOI 10.1016/j.pain.2006.08.009; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Violin JD, 2007, TRENDS PHARMACOL SCI, V28, P416, DOI 10.1016/j.tips.2007.06.006; von Bohlen und Halbach O, 2007, CELL TISSUE RES, V329, P409, DOI 10.1007/s00441-007-0432-4; Wess J, 1997, FASEB J, V11, P346; Xu C, 2010, J CELL SCI, V123, P4259, DOI 10.1242/jcs.073742; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zheng H, 2008, P NATL ACAD SCI USA, V105, P9421, DOI 10.1073/pnas.0802253105; Zheng H, 2008, MOL PHARMACOL, V73, P178, DOI 10.1124/mol.107.039842; Zheng H, 2010, J BIOL CHEM, V285, P21994, DOI 10.1074/jbc.M110.112607; Zheng H, 2010, J NEUROSCI, V30, P8102, DOI 10.1523/JNEUROSCI.6069-09.2010; Zheng H, 2010, IUBMB LIFE, V62, P112, DOI 10.1002/iub.293; Zheng H, 2010, MOL PHARMACOL, V77, P102, DOI 10.1124/mol.109.060848	42	34	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2011	286	14								10.1074/jbc.M110.177089			10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	744EN	WOS:000289077500083	21292762	Bronze, Green Published			2020-06-26	J	Wang, YH; Sun, JF; Tao, YM; Xu, XJ; Chi, ZQ; Liu, JG				Wang, Yu-hua; Sun, Jian-feng; Tao, Yi-min; Xu, Xue-jun; Chi, Zhi-qiang; Liu, Jing-gen			Paradoxical relationship between RAVE (relative activity versus endocytosis) values of several opioid receptor agonists and their liability to cause dependence	ACTA PHARMACOLOGICA SINICA			English	Article						RAVE; mu-opioid receptor; cyclic AMP; endocytosis; physical dependence; psychological dependence	MORPHINE-TOLERANCE; OHMEFENTANYL STEREOISOMERS; PLACE PREFERENCE; OPIATE DRUGS; CYCLIC-AMP; G-PROTEIN; IN-VIVO; MICE; INTERNALIZATION; DIHYDROETORPHINE	Aim: To examine the relationship between the RAVE (relative activity versus endocytosis) values of opiate agonists and their dependence liability by studying several potent analgesics with special profiles in the development of physical and psychological dependence. Methods: The effects of (-)-cis-(3R, 4S, 2'R) ohmefentanyl (F9202), (+)-cis-(3R, 4S, 2'S) ohmefentanyl (F9204), dihydroetorphine (DHE) and morphine on [S-35] GTP gamma S binding, forskolin-stimulated cAMP accumulation, and receptor internalization were studied in CHO cells stably expressing HA-tagged mu-opioid receptors (CHO-HA-MOR). cAMP overshoot in response to the withdrawal of these compound treatments was also tested. Results: All four agonists exhibited the same rank order of activity in stimulation of [S-35]GTP gamma S binding, inhibition of adenylyl cyclase (AC) and induction of receptor internalization: DHE>F9204>F9202> morphine. Based on these findings and the previous in vivo analgesic data obtained from our and other laboratories, the RAVE values of the four agonists were calculated. The rank order of RAVE values was morphine>F9202>F9204>DHE. For the induction of cAMP overshoot, the rank order was F9202 >= morphine>F9204 >= DHE. Conclusion: Taken in combination with previous findings of these compounds' liability to develop dependence, the present study suggests that the agonist with the highest RAVE value seems to have a relatively greater liability to develop psychological dependence relative to the agonist with the lowest RAVE value. However, the RAVE values of these agonists are not correlated with their probability of developing physical dependence or inducing cAMP overshoot, a cellular hallmark of dependence.	[Wang, Yu-hua; Sun, Jian-feng; Tao, Yi-min; Xu, Xue-jun; Chi, Zhi-qiang; Liu, Jing-gen] Chinese Acad Sci, State Key Lab Drug Res, Shanghai Inst Mat Med, Shanghai Inst Biol Sci, Shanghai 201203, Peoples R China; [Wang, Yu-hua] China Pharmaceut Univ, Sch Pharm, Nanjing 210009, Peoples R China; [Wang, Yu-hua] Nanjing Univ Chinese Med, Sch Pharm, Nanjing 210046, Peoples R China	Liu, JG (reprint author), Chinese Acad Sci, State Key Lab Drug Res, Shanghai Inst Mat Med, Shanghai Inst Biol Sci, Shanghai 201203, Peoples R China.	jgliu@mail.shcnc.ac.cn					Alt A, 2001, J PHARMACOL EXP THER, V298, P116; Alvarez V, 2001, NEURON, V32, P761, DOI 10.1016/S0896-6273(01)00530-X; Berrendero F, 2002, J NEUROSCI, V22, P10935; CAO GH, 1990, ZHONGGUO LIN CHUANG, V6, P54; COLLIER HOJ, 1975, NATURE, V255, P159, DOI 10.1038/255159b0; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Grecksch G, 2006, PSYCHOPHARMACOLOGY, V186, P177, DOI 10.1007/s00213-006-0365-8; Guo GW, 2000, LIFE SCI, V67, P113, DOI 10.1016/S0024-3205(00)00617-2; Guo GW, 2001, LIFE SCI, V68, P2383, DOI 10.1016/S0024-3205(01)01030-X; He L, 2005, CURR BIOL, V15, P1028, DOI 10.1016/j.cub.2005.04.052; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; Hiebel AC, 2007, J MED CHEM, V50, P3765, DOI 10.1021/jm061325e; Hong MH, 2009, J NEUROCHEM, V108, P102, DOI 10.1111/j.1471-4159.2008.05740.x; Huang M, 1982, Zhongguo Yao Li Xue Bao, V3, P9; HUANG M, 1994, REGUL PEPTIDES, V53, pS81; Jin WQ, 1996, ACTA PHARM SINIC, V17, P421; Keith DE, 1998, MOL PHARMACOL, V53, P377; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Kim IH, 2008, J MICROBIOL BIOTECHN, V18, P35; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; Koch T, 2008, PHARMACOL THERAPEUT, V117, P199, DOI 10.1016/j.pharmthera.2007.10.003; Liu JG, 2001, BRAIN RES REV, V38, P1, DOI 10.1016/S0165-0173(01)00057-1; Liu JG, 2002, J PHARMACOL EXP THER, V302, P1070, DOI 10.1124/jpet.102.035964; Liu JG, 1999, ACTA PHARMACOL SIN, V20, P452; Liu ZH, 2004, LIFE SCI, V74, P3001, DOI 10.1016/j.lfs.2003.10.027; Martini L, 2007, CURR OPIN NEUROBIOL, V17, P556, DOI 10.1016/j.conb.2007.10.004; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; Ohmori S, 2002, CNS DRUG REV, V8, P391; Patel MB, 2002, MOL PHARMACOL, V62, P1464, DOI 10.1124/mol.62.6.1464; Roth BL, 1999, NEURON, V23, P629, DOI 10.1016/S0896-6273(02)23443-1; SHARMA SK, 1977, P NATL ACAD SCI USA, V74, P3365, DOI 10.1073/pnas.74.8.3365; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Tokuyama S, 1996, JPN J PHARMACOL, V71, P357, DOI 10.1254/jjp.71.357; TOKUYAMA S, 1993, BIOL PHARM BULL, V16, P774; von Zastrow M, 2003, CURR OPIN NEUROBIOL, V13, P348, DOI 10.1016/S0959-4388(03)00069-2; WANG DX, 1995, J PHARM PHARMACOL, V47, P669, DOI 10.1111/j.2042-7158.1995.tb05857.x; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Yang Z, 2008, ACTA PHARMACOL SIN, V29, P781, DOI 10.1111/j.1745-7254.2008.00817.x; Zhang JL, 2009, ACTA PHARMACOL SIN, V30, P559, DOI 10.1038/aps.2009.43	44	3	5	0	3	ACTA PHARMACOLOGICA SINICA	SHANGHAI	294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA	1671-4083	1745-7254		ACTA PHARMACOL SIN	Acta Pharmacol. Sin.	APR	2010	31	4					393	398		10.1038/aps.2010.19			6	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	585OC	WOS:000276834300002	20228826	Bronze, Green Published			2020-06-26	J	Meyer, LCR; Hetem, RS; Fick, LG; Mitchell, D; Fuller, A				Meyer, Leith C. R.; Hetem, Robyn S.; Fick, Linda G.; Mitchell, Duncan; Fuller, Andrea			EFFECTS OF SEROTONIN AGONISTS AND DOXAPRAM ON RESPIRATORY DEPRESSION AND HYPOXEMIA IN ETORPHINE-IMMOBILIZED IMPALA (AEPYCEROS MELAMPUS)	JOURNAL OF WILDLIFE DISEASES			English	Article						Buspirone; doxapram; hypoxia; metoclopramide; opioid; pimozide; respiratory depression	RECEPTOR LIGANDS; 5-HYDROXYTRYPTAMINE; BUSPIRONE; GOATS; STIMULATION; CARFENTANIL; 8-OH-DPAT; RATS	Respiratory depression is a common side effect when opioids are used to immobilize wildlife. Serotonergic ligands have the potential to reverse opioid-induced respiratory depression. We examined whether any of three serotonergic ligands could reverse this depression in etorphine-immobilized (0.07 mg/kg) impala (Aepyceros melampus.). The study took place in September December 2007. Impala received intravenous injections of metoclopramide (10 mg/kg, n=6), buspirone (0.05 mg/kg, n=8), pimozide (1 mg/kg, n=8), doxapram (1 mg/kg, n=6), and control solutions on separate occasions. During the immobilization, partial pressures of oxygen (PaO(2), mmHg) and carbon dioxide (PaCO(2), mmHg), respiratory rate (breaths/min), ventilation (1/min), peripheral O(2) saturation (%), tidal volume (1), and respiratory exchange ratio were measured before and after injection of the experimental drugs. Etorphine immobilization caused respiratory depression and hypoxia (mean +/- SD, PaCO(2)=51 +/- 2 mmHg, PaO(2)=40 +/- 3 mmHg). Metoclopramide and buspirone, but not pimozide, attenuated the hypoxic effects of etorphine; 3 min after injection, metoclopramide increased the PaO(2) by 7.5 +/- 6.3 mmHg and buspirone by 6 +/- 6.6 mmHg (F=3.9, P=0.02). These effects were similar to those of doxapram (8 7 mmHg, F=3.9; P > 0.05). Neither metoclopramide nor buspirone significantly increased ventilation, but they increased PaO(2) by significantly improving the alveolar-arterial oxygen partial pressure gradient (A-a gradient, F=1.4, P < 0.05), indicating improved oxygen diffusion. Metoclopramide and buspirone transiently improved blood oxygenation of opioid-immobilized impala, probably by improving ventilation-perfusion ratios, without reversing catatonic immobilization.	[Meyer, Leith C. R.; Hetem, Robyn S.; Fick, Linda G.; Mitchell, Duncan; Fuller, Andrea] Univ Witwatersrand, Sch Physiol, Brain Funct Res Grp, ZA-2193 Parktown, South Africa	Meyer, LCR (reprint author), Univ Witwatersrand, Sch Physiol, Brain Funct Res Grp, 7 York Rd, ZA-2193 Parktown, South Africa.	Leith.Meyer@wits.ac.za	Fuller, Andrea/P-3133-2016; Hetem, Robyn Sheila/A-1438-2015; Meyer, Leith/AAN-4930-2020	Fuller, Andrea/0000-0001-6370-8151; Hetem, Robyn Sheila/0000-0003-1953-3520; Meyer, Leith/0000-0002-5122-2469; Fick, Linda/0000-0003-0673-0963	Faculty Research Committee; University of the Witwatersrand; National Research Foundation, South AfricaNational Research Foundation - South Africa	We thank the National Zoological Gardens of South Africa for allowing us to access their property and resources, and the staff at the Lichtenburg Game Breeding Centre for their help. We also thank our colleagues from the School of Physiology, University of the Witwatersrand, who helped collect data, in particular Philippa Hidden and Marna Broekman. This work was funded by a Faculty Research Committee Grant, University of the Witwatersrand, and by the National Research Foundation, South Africa.	Barenbrug A. W. T., 1974, PSYCHROMETRY PSYCHRO; BOWDLE T A, 1988, Acute Care, V12, P70; BURROUGHS R, 2006, [No title captured], P116; COCKS TM, 1992, BRIT J PHARMACOL, V107, P591, DOI 10.1111/j.1476-5381.1992.tb12788.x; DABIRE H, 1990, CLIN PHYSIOL BIOCH, V8, P56; DALONZO GE, 1983, MED CLIN N AM, V67, P557, DOI 10.1016/S0025-7125(16)31189-0; DILL DB, 1948, J APPL PHYSIOL, V1, P409; Guenther U, 2009, ANESTH ANALG, V108, P1169, DOI 10.1213/ane.0b013e318198f828; HEARD DJ, 1990, J ZOO WILDLIFE MED, V21, P166; Heard DJ, 1996, AM J VET RES, V57, P87; KADOWITZ PJ, 1973, CIRC RES, V32, P221, DOI 10.1161/01.RES.32.2.221; Langlois M, 2003, J MED CHEM, V46, P319, DOI 10.1021/jm020099f; LUMB AB, 2005, [No title captured]; Manzke T, 2003, SCIENCE, V301, P226, DOI 10.1126/science.1084674; MELTZER D, 2006, CHEM PHYS RESTRAINT, P68; Meyer LCR, 2006, AM J PHYSIOL-REG I, V290, pR405; Morcillo EJ, 1999, THERAPIE, V54, P93; NISHINO T, 1982, J APPL PHYSIOL, V52, P1261; Oertel BG, 2007, CLIN PHARMACOL THER, V81, P59, DOI 10.1038/sj.clpt.6100018; Ootsuka Y, 2003, J PHYSIOL-LONDON, V552, P303, DOI 10.1113/jphysiol.2003.048041; Pittala V, 2007, MINI-REV MED CHEM, V7, P945, DOI 10.2174/138955707781662663; Rang H. P., 2003, PHARMACOLOGY; RIBLET LA, 1982, J CLIN PSYCHIAT, V43, P11; Richter DW, 2003, TRENDS MOL MED, V9, P542, DOI 10.1016/j.molmed.2003.10.010; RILEY RL, 1946, J PHYSL, V146, P191; ROQUEBERT J, 1988, J AUTON PHARMACOL, V8, P39, DOI 10.1111/j.1474-8673.1988.tb00167.x; ROTH BL, 1994, J PHARMACOL EXP THER, V268, P1403; Sahibzada N, 2000, J PHARMACOL EXP THER, V292, P704; SAXENA PR, 1990, J CARDIOVASC PHARM, V15, P17; Swan GE, 1993, CAPTURE CARE MANUAL, P17; Sweetman SC, 1999, MARTINDALE COMPLETE; TAYLOR DP, 1988, FASEB J, V2, P2445; Wang X, 2007, HYPERTENSION, V50, P368, DOI 10.1161/HYPERTENSIONAHA.107.091033; ZWIETEN PA, 1996, CARDIOVASCULAR DRUGS, V10, P283	34	17	17	0	9	WILDLIFE DISEASE ASSOC, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA	0090-3558			J WILDLIFE DIS	J. Wildl. Dis.	APR	2010	46	2					514	524		10.7589/0090-3558-46.2.514			11	Veterinary Sciences	Veterinary Sciences	593DA	WOS:000277431200018	20688644				2020-06-26	J	Freye, E; Levy, JV				Freye, Enno; Levy, Joseph V.			No hyperalgesia following opioid withdrawal after the oripavine derivative etorphine compared to remifentanil and sufentanil	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						etorphine; nociception; opioid hyperalgesia; remifentanil; sensory-evoked potentials; skin-twitch reflex; sufentanil	SOMATOSENSORY EVOKED-POTENTIALS; RECEPTOR-MEDIATED HYPERALGESIA; LONG-LASTING HYPERALGESIA; LOW-DOSE NALTREXONE; G-BETA-GAMMA; MORPHINE-TOLERANCE; OPIATE RECEPTOR; THERMAL HYPERALGESIA; POSTOPERATIVE PAIN; GM1 GANGLIOSIDE	Background and objective The concept of opioid-induced hyperalgesia has recently gained prominence as a contributing factor for long-term treatment failure. Methods To evaluate possible differences of opioids used in anaesthesia, cumulative doses of sufentanil and remifentanil were compared with escalating doses of the oripavine derivative etorphine, in awake and trained canines. This was followed by naloxone unmasking a possible hyperalgesic state, which had developed during opioid administration. Heart rate, blood pressure and propagation of nociceptive volleys in somatosensory-evoked potentials as well as the skin-twitch reflex were evaluated. Results Opioid-related hypotension and bradycardia were reversed by naloxone with a late (30 min) overshoot of +43 and +17% after remifentanil and sufentanil, respectively. Following etorphine, overshoot in mean blood pressure was +9%, whereas heart rate still remained below -9% when compared with control. Peak hyperalgesia, as detected in the somatosensory-evoked potential and skin-twitch, increased by +70% after remifentanil and by +43% after sufentanil. This reflected a significant (P<0.005) increase in propagation of nociceptive afferents as late as 30 min after naloxone reversal. Such potentiation was not observed in the etorphine group, as peak somatosensory-evoked potential deflection and skin-twitch remained below -80% when compared with control. Conclusion The pure mu-agonists sufentanil or remifentanil seem to induce a 'bimodal' inhibitory followed by an excitatory effect. The latter is unmasked by naloxone in the postadministration period. In contrast, this is not seen with etorphine, a close congener of buprenorphine. The proposed mode of action of such hyperexcitatory effects may involve second-messenger-mediated G-protein activation, originally proposed by others. Ligands of the oripavine series may present an alternative for prevention of opioid-induced hyperalgesia in patients. Eur J Anaesthesiol 27:174-180 (c) 2010 European Society of Anaesthesiology.	[Freye, Enno] Univ Clin Duesseldorf, Clin Vasc Surg, Dusseldorf, Germany; [Freye, Enno] Ctr Ambulatory Pain Med, Neuss, Germany; [Levy, Joseph V.] Univ Pacific, Arthur Dugoni Sch Dent, Dept Physiol & Pharmacol, San Francisco, CA USA	Freye, E (reprint author), Deichstr 3A, D-41468 Neuss, Germany.						Aceto MD, 1997, EUR J PHARMACOL, V338, P215, DOI 10.1016/S0014-2999(97)81924-3; Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; Aubrun F, 2008, ANESTH ANALG, V106, P1535, DOI 10.1213/ane.0b013e318168b2ce; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3281, DOI 10.1021/ja00989a032; BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; BLANE GF, 1970, P BR PHARM SOC, V20, P252; BUCHSBAUM MS, 1983, PSYCHOPHARMACOLOGY, V79, P99, DOI 10.1007/BF00427792; BUCHSBAUM MS, 1977, NATURE, V270, P620, DOI 10.1038/270620a0; Burns Lindsay H., 2009, P3, DOI 10.1007/978-1-59745-197-0_1; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; Chakrabarti S, 1997, MOL PHARMACOL, V52, P105; CHAPMANN CR, 1979, ADV PAIN RES THER, P791; Chindalore VL, 2005, J PAIN, V6, P392, DOI 10.1016/j.jpain.2005.01.356; Crain SM, 1998, ANN NY ACAD SCI, V845, P106, DOI 10.1111/j.1749-6632.1998.tb09665.x; CRAIN SM, 1990, TRENDS PHARMACOL SCI, V11, P77, DOI 10.1016/0165-6147(90)90322-Y; Crain SM, 2001, BRAIN RES, V888, P75, DOI 10.1016/S0006-8993(00)03010-9; CRAIN SM, 1995, DISCOVERY NOVEL OPIO, P232; Crain SM, 2007, BRAIN RES, V1167, P31, DOI 10.1016/j.brainres.2007.06.058; Crawford MW, 2006, ANESTH ANALG, V102, P1662, DOI 10.1213/01.ane.0000216036.95705.c2; Cruciani R. A., 1999, Society for Neuroscience Abstracts, V25, P1478; Cruciani RA, 2003, J PAIN SYMPTOM MANAG, V25, P491, DOI 10.1016/S0885-3924(03)00139-8; Cvejic S, 1996, J BIOL CHEM, V271, P4073; Davis MP, 2007, J CLIN ONCOL, V25, P4497, DOI 10.1200/JCO.2006.09.1462; De Pascalis V, 2008, PAIN, V134, P197, DOI 10.1016/j.pain.2007.09.005; DECONNO F, 1991, PAIN, V47, P337, DOI 10.1016/0304-3959(91)90225-M; Dumont H, 2007, EUR J ANAESTH, V24, P205, DOI 10.1017/S0265021506001700; Freye E, 2006, ANESTH ANALG, V102, P1439, DOI 10.1213/01.ane.0000202382.82847.64; Freye E, 2005, ADDICT BIOL, V10, P131, DOI 10.1080/13556210500123019; Freye E, 2000, ANESTH ANALG, V90, P1359, DOI 10.1097/00000539-200006000-00018; Freye E, 1987, Funct Neurol, V2, P281; Gan TJ, 1997, ANESTHESIOLOGY, V87, P1075, DOI 10.1097/00000542-199711000-00011; Gardell LR, 2006, NEUROSCI LETT, V396, P44, DOI 10.1016/j.neulet.2005.11.009; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Hawkinson JE, 2000, EUR J PHARMACOL, V389, P107, DOI 10.1016/S0014-2999(99)00904-8; HOUDE RW, 1951, J PHARMACOL EXP THER, V103, P236; JORDAN B, 1997, LOUIS ANN M SOC NEUR, P691; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kiss I, 2005, EUR J PHARMACOL, V523, P29, DOI 10.1016/j.ejphar.2005.09.003; LANGE DG, 1980, TOXICOL APPL PHARM, V54, P177, DOI 10.1016/0041-008X(80)90185-4; Leri F, 2005, PHARMACOL BIOCHEM BE, V82, P252, DOI 10.1016/j.pbb.2005.08.008; LEVINE JD, 1988, J CLIN INVEST, V82, P1574, DOI 10.1172/JCI113768; MAO J, 1994, J NEUROSCI, V14, P2301; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; Mao JR, 1996, PAIN, V67, P361, DOI 10.1016/0304-3959(96)03120-X; Mercadante Sebastiano, 2005, Am J Hosp Palliat Care, V22, P291, DOI 10.1177/104990910502200411; Ohmori S, 2001, J PHARMACOL EXP THER, V296, P528; Okon TR, 2008, J PAIN SYMPTOM MANAG, V35, P327, DOI 10.1016/j.jpainsymman.2007.04.023; PERRY DC, 1982, MOL PHARMACOL, V21, P272; Powell KJ, 2002, J PHARMACOL EXP THER, V300, P588, DOI 10.1124/jpet.300.2.588; RICHARDS ML, 1985, EUR J PHARMACOL, V114, P343, DOI 10.1016/0014-2999(85)90379-6; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; ROSENBAUM JS, 1984, BRAIN RES, V291, P317, DOI 10.1016/0006-8993(84)91264-2; Schmidt BL, 2003, NEUROSCI LETT, V343, P144, DOI 10.1016/S0304-3940(03)00356-2; Schmidt S, 2007, CLIN J PAIN, V23, P605, DOI 10.1097/AJP.0b013e318122d1e4; Shen KF, 1997, BRAIN RES, V757, P176, DOI 10.1016/S0006-8993(97)00197-2; Siniscalchi A, 2008, ANESTH ANALG, V106, P645, DOI 10.1213/ane.0b013e3181602c3e; SJORGEN P, 1998, ACTA ANAESTH SCAND, V42, P1070; Tokuyama S, 1996, JPN J PHARMACOL, V71, P357, DOI 10.1254/jjp.71.357; TOLKOVSKY AM, 1982, MOL PHARMACOL, V22, P648; Vinik HR, 1998, ANESTH ANALG, V86, P1307, DOI 10.1097/00000539-199806000-00033; WANG DX, 1992, CHIN J PHARM TOXICOL, V6, P36; Wang HY, 2006, J NEUROBIOL, V66, P1302, DOI 10.1002/neu.20286; Wang HY, 2005, NEUROSCIENCE, V135, P247, DOI 10.1016/j.neuroscience.2005.06.003; WAUQUIER A, 1982, ALFENTANIL, P78; XIAOYUN M, 2005, ACTA PHYSL SIN, V57, P696	68	5	7	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	FEB	2010	27	2					174	180		10.1097/EJA.0b013e32832ff528			7	Anesthesiology	Anesthesiology	551AK	WOS:000274176900008	20077594				2020-06-26	J	Morkel, PV; Radcliffe, RW; Jago, M; du Preez, P; Flaminio, MJBF; Nydam, DV; Taft, A; Lain, D; Miller, MM; Gleed, RD				Morkel, P. VdB.; Radcliffe, R. W.; Jago, M.; du Preez, P.; Flaminio, M. J. B. F.; Nydam, D. V.; Taft, A.; Lain, D.; Miller, M. M.; Gleed, R. D.			ACID-BASE BALANCE AND VENTILATION DURING STERNAL AND LATERAL RECUMBENCY IN FIELD IMMOBILIZED BLACK RHINOCEROS (DICEROS BICORNIS) RECEIVING OXYGEN INSUFFLATION: A PRELIMINARY REPORT	JOURNAL OF WILDLIFE DISEASES			English	Article						Anesthesia; capnography; dead space; lactate; posture; rhinoceros	CERATOTHERIUM-SIMUM; CHEMICAL IMMOBILIZATION; WHITE RHINOCEROSES; ETORPHINE M99; ANESTHESIA; ARTERIAL; COMBINATIONS; DETOMIDINE; PARAMETERS; POSITION	Posture, ventilation, and acid-base balance using auricular venous blood values (pH, lactate, base excess [BE], HCO3-, PO2, SO2, and PCO2), oxygen saturation of hemoglobin (SpO(2)), and end-tidal carbon dioxide (PETCO2) were compared between sternal (STE) and lateral (LAT) recumbency in Free-ranging black rhinoceros (Diceros bicornis bicornis) receiving oxygen insufflation. Data are reported as median, minimum, and maximum (median [minimum, maximum]). Thirty-six desert-adapted black rhinoceros (20 male, 16 female; age 8 [1.5, 33] yr) were immobilized in Namibia in March and April of 2008, from a helicopter, by remote intramuscular injection with etorphine HCl, azaperone, and hyaluronidase. Time from darting to recumbency was 6.0 (3, 15.5) min. Data were organized into two sampling periods: sample period 1 (P1, collected within 0-20 min postdarting; 13 [6.5, 19] min) and sample period 2 (112, collected between 2040 min postdarting; 32 [223, 39] min). All animals were acidemic (pH 7.24 [7.07, 7.32]) and hypoxemic (PO2 51 [38, 95.2]; SO2 78 [64, 96] mmHg) after capture. Lactate at P1 was 7.2 (3.2, 16.8) mmol/l and decreased (P=0.01) to 4.6 (1.2, 10.9) mmol/l at P2. At P2, lactate was less (P=0.06) in LAT 3.5 (1-2, 8.6) mmol/l than in STE posture 7.4 (3.1, 10.9) mmol/l. In P2, PO2, SO2, and SpO(2) were higher (P=0.02, 0.10, and 0.01, respectively) in STE than in L,AT. End-tidal carbon dioxide in LAT was 38 (26, 47) mmHg and increased (P<0.001) rapidly to 48 (37, 55) mmHg when animals were moved into STE; no corresponding change in PCO2 was observed. These preliminary findings suggest that STE posture in recumbent black rhinoceros reduces dead-space ventilation and improves oxygenation. Lateral posture was associated with lower blood lactate, quicker lactate recovery, or both. It is possible that the posture of recumbent rhinoceros after capture affects lactate accumulation and clearance, or both, and procedures should consider positioning in order to enhance perfusion.	[Radcliffe, R. W.] Int Rhino Fdn, Rhino Conservat Med Program, Lansing, NY 14882 USA; [Morkel, P. VdB.] Frankfurl Zool Soc, ZA-6045 Newton Pk, South Africa; [Jago, M.; du Preez, P.] Namibia Minist Environm & Tourism, Windhoek, Namibia; [Radcliffe, R. W.; Flaminio, M. J. B. F.; Nydam, D. V.; Gleed, R. D.] Cornell Univ, Coll Vet Med, Ithaca, NY 14853 USA; [Taft, A.] Med Coll Georgia, Dept Resp Therapy, Augusta, GA 30912 USA; [Lain, D.] Ordion Capnog Inc, Needham, MA 02494 USA; [Miller, M. M.] Disneys Anim Kingdom, Lake Buena Vista, FL 32830 USA	Radcliffe, RW (reprint author), Int Rhino Fdn, Rhino Conservat Med Program, 1 Armstrong Rd, Lansing, NY 14882 USA.	rwr32@cornell.edu	Miller, Michele/K-7317-2019	Miller, Michele/0000-0002-5883-6076	US Fish and Wildlife Service Rhino and Tiger Conservation FundUS Fish & Wildlife Service [98210-7-G311]; International Rhino Foundation; Wilderness Wildlife Trust [98210-7-G123]; Frankfurt Zoological Society	The authors thank the Namibian Ministry of Environment and Tourism and the International Rhino Foundation for their enthusiasm during this collaboration. Financial support was provided by the US Fish and Wildlife Service Rhino and Tiger Conservation Fund, Grant 98210-7-G311, in partnership with the International Rhino Foundation, and Grant 98210-7-G123 in partnership with the Wilderness Wildlife Trust. We thank the Frankfurt Zoological Society for financial support of Pete Morkel. Sincere thanks to Disney's Animal Kingdom for donation Of an i-STAT (R) analyzer and for scientific collaboration in the field. Oridion Capnography Inc. and Nellcor (R) Puritan Bennett LLC provided kind donations of capnography-pulse oximetry equipment. Finally, a special thanks to John Laikas of the International Rhino Foundation and Gilman International Conservation, Annie and Boh Graham of the Tapeats Fund, Peter Half of Hunter Hall Investment Management Limited, Kerry Crosbie of the Asian Rhino Project, and the Fossil Him Wildlife Center for generous support of the Rhino Conservation Medicine Program.	Bush M, 2004, J S AFR VET ASSOC, V75, P79; BUSH MR, 2005, P AM ASS ZOO VET AM, P259; CAVE AJE, 1958, NATURE, V182, P196, DOI 10.1038/182196a0; Chang H, 2002, J APPL PHYSIOL, V92, P745, DOI 10.1152/japplphysiol.00377.2001; Citino SB, 2007, J ZOO WILDLIFE MED, V38, P375, DOI 10.1638/2006-0007R1.1; Fahlman Asa, 2004, P523; GLEED RD, 1988, RES VET SCI, V44, P255, DOI 10.1016/S0034-5288(18)30851-8; Grenier B, 1999, ANESTH ANALG, V88, P43, DOI 10.1097/00000539-199901000-00009; Harthoorn A.M., 1973, P51; HATTINGH J, 1994, S AFR J WILDL RES, V24, P12; HEARD DJ, 1992, J ZOO WILDLIFE MED, V23, P197; Kock MD, 1995, J ZOO WILDLIFE MED, V26, P207; KOCK MD, 1992, J ZOO WILDLIFE MED, V23, P181; KOCK MD, 1990, J ZOO WILDLIFE MED, V21, P155; LUMB AB, 2005, [No title captured]; MORKEL P, 1989, Koedoe, V32, P65; PANSARD JL, 1992, ANESTH ANALG, V75, P506; Portas T, 2004, AUST VET J, V82, P542, DOI 10.1111/j.1751-0813.2004.tb11196.x; Radcliffe Robin W., 2007, P543, DOI 10.1002/9780470376478.ch48; Radcliffe RW, 2001, THERIOGENOLOGY, V55, P1033, DOI 10.1016/S0093-691X(01)00464-2; Robergs R. A., 2001, SPORTSCIENCE, V5; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P278; THURMON JC, 1996, LUMB JONES VET ANEST, P134; WAGNER AE, 1990, AM J VET RES, V51, P7; Wenger S, 2007, J ZOO WILDLIFE MED, V38, P380, DOI 10.1638/2006-0038R.1	25	21	22	0	9	WILDLIFE DISEASE ASSOC, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA	0090-3558	1943-3700		J WILDLIFE DIS	J. Wildl. Dis.	JAN	2010	46	1					236	245		10.7589/0090-3558-46.1.236			10	Veterinary Sciences	Veterinary Sciences	548JE	WOS:000273957100025	20090037				2020-06-26	J	Ge, X; Qiu, Y; Loh, HH; Law, PY				Ge, Xin; Qiu, Yu; Loh, Horace H.; Law, Ping-Yee			GRIN1 Regulates mu-Opioid Receptor Activities by Tethering the Receptor and G Protein in the Lipid Raft	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; CELL-ADHESION MOLECULE; RICH MEMBRANE DOMAINS; NEURITE OUTGROWTH; SIGNAL-TRANSDUCTION; SPINAL-CORD; ADENYLATE-CYCLASE; COUPLED RECEPTOR; BINDING-SITE; PC12 CELLS	The lipid raft location of mu-opioid receptor (MOR) determines the receptor activities. However, the manner in which MOR is anchored within the lipid rafts is undetermined. Using the targeted proteomic approach and mass spectrometry analyses, we have identified GRIN1 (G protein-regulated inducer of neurite outgrowth 1) can tether MOR with the G protein alpha-subunit and subsequently regulate the receptor distribution within the lipid rafts. Glutathione S-transferase fusion pulldown and receptor mutational analyses indicate that GRIN1-MOR interaction involves a receptor sequence (267)GSKEK(271) within the MOR third intracellular loop that is not involved in G alpha interaction. The GRIN1 domains involved in MOR interaction are also distinct from those involved in G alpha interaction. Pertussis toxin pretreatment reduced the amount of GRIN1 co-immunoprecipitated with MOR but not the amount with G alpha. Furthermore, overexpression of GRIN1 significantly enhanced the amount of MOR in lipid raft and the receptor signaling magnitude as measured by Src kinase activation. Such increase in MOR signaling was demonstrated further by determining the GRIN1-dependent pertussis toxin-sensitive neurite outgrowth. In contrast to minimal neurite outgrowth induced by etorphine in control neuroblastoma N2A cells, overexpression of GRIN1 resulted in the increase in etorphine- and non-morphine-induced neurite outgrowth in these cells. Knocking down endogenous GRIN1 by small interfering RNA attenuated the agonist-induced neurite outgrowth. Disrupting lipid raft by methyl-beta-cyclodextrin also blocked neurite outgrowth. Hence, by tethering G alpha with MOR, GRIN1 stabilizes the receptor within the lipid rafts and potentiates the receptor signaling in the neurite outgrowth processes.	[Ge, Xin; Qiu, Yu; Loh, Horace H.; Law, Ping-Yee] Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	Ge, X (reprint author), Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA.	gexx0019@umn.edu		Law, Ping-Yee/0000-0002-5364-1093	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA007339, DA016674, DA000564, DA011806]	This work was supported, in whole or in part, by National Institutes of Health Grants DA007339, DA016674, DA000564, and DA011806.	Anafi M, 1996, J BIOL CHEM, V271, P21365, DOI 10.1074/jbc.271.35.21365; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; Balbis A, 2007, ENDOCRINOLOGY, V148, P2944, DOI 10.1210/en.2006-1674; Barnett-Norris J, 2005, LIFE SCI, V77, P1625, DOI 10.1016/j.lfs.2005.05.040; Besson JM, 1999, LANCET, V353, P1610, DOI 10.1016/S0140-6736(99)01313-6; Brailoiu E, 2004, NEUROSCI LETT, V365, P10, DOI 10.1016/j.neulet.2004.03.092; CARTER BD, 1992, J NEUROCHEM, V58, P1611, DOI 10.1111/j.1471-4159.1992.tb10032.x; Chaipatikul V, 2003, J PHARMACOL EXP THER, V305, P909, DOI 10.1124/jpet.102.046219; Chen CG, 2006, J BIOL CHEM, V281, P7983, DOI 10.1074/jbc.M509805200; Chen LT, 1999, J BIOL CHEM, V274, P26931, DOI 10.1074/jbc.274.38.26931; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Cohen AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physrev.00046.2003; CONNAUGHTON JF, 1975, ADDICT DIS, V2, P21; Di Vizio D, 2008, CELL CYCLE, V7, P2257, DOI 10.4161/cc.7.14.6475; Encinas M, 2001, J NEUROSCI, V21, P1464; Evan BJ, 2008, BIOCHEM BIOPH RES CO, V377, P1067, DOI 10.1016/j.bbrc.2008.10.108; Ge X, 2009, MOL PHARMACOL, V75, P1307, DOI 10.1124/mol.108.054064; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; He JCJ, 2005, J BIOL CHEM, V280, P33426, DOI 10.1074/jbc.M502812200; Head BP, 2007, TRENDS CELL BIOL, V17, P51, DOI 10.1016/j.tcb.2006.11.008; Head BP, 2006, J BIOL CHEM, V281, P26391, DOI 10.1074/jbc.M602577200; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; Jia CYH, 2005, MOL CELL PROTEOMICS, V4, P1155, DOI 10.1074/mcp.M500108-MCP200; Kabbani N, 2007, P NATL ACAD SCI USA, V104, P20570, DOI 10.1073/pnas.0710314104; Kahn L, 2005, EUR J NEUROSCI, V21, P493, DOI 10.1111/j.1460-9568.2005.03883.x; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Macdonald JL, 2005, J LIPID RES, V46, P1061, DOI 10.1194/jlr.D400041-JLR200; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; Miller JH, 1999, DEV BRAIN RES, V114, P69, DOI 10.1016/S0165-3806(99)00021-8; Monastyrskaya K, 2005, J BIOL CHEM, V280, P7135, DOI 10.1074/jbc.M405806200; Moron JA, 2007, MOL CELL PROTEOMICS, V6, P29, DOI 10.1074/mcp.M600184-MCP200; Mukherjee A, 2003, J BIOL CHEM, V278, P40806, DOI 10.1074/jbc.M306440200; Nakata H, 2005, MOL PHARMACOL, V67, P695, DOI 10.1124/mol.104.003913; Nassogne MC, 1998, DEV BRAIN RES, V110, P61, DOI 10.1016/S0165-3806(98)00094-7; Navratil AM, 2003, J BIOL CHEM, V278, P31593, DOI 10.1074/jbc.M304273200; Oh DY, 2007, J CELL BIOCHEM, V101, P221, DOI 10.1002/jcb.21166; Ohkubo S, 2007, YAKUGAKU ZASSHI, V127, P27, DOI 10.1248/yakushi.127.27; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Philip F, 2004, BIOCHEMISTRY-US, V43, P11691, DOI 10.1021/bi049381+; Pike LJ, 2005, J BIOL CHEM, V280, P26796, DOI 10.1074/jbc.M503805200; RAMOSMORALES F, 1995, ONCOGENE, V11, P1665; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RESH MD, 2006, [No title captured], DOI DOI 10.1126/STKE.3592006RE14; Reversi A, 2006, AM J PHYSIOL-REG I, V291, pR861, DOI 10.1152/ajpregu.00333.2006; ROERIG SC, 1992, MOL PHARMACOL, V41, P822; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; Rozengurt E, 2007, J CELL PHYSIOL, V213, P589, DOI 10.1002/jcp.21246; Schmid RS, 2000, J NEUROSCI, V20, P4177; Smith KE, 2006, J NEUROSCI, V26, P2391, DOI 10.1523/JNEUROSCI.3092-05.2006; Sugawara Y, 2007, CELL SIGNAL, V19, P1301, DOI 10.1016/j.cellsig.2007.01.012; Trujillo Keith A, 2002, Neurotox Res, V4, P373, DOI 10.1080/10298420290023954; VANOOYEN A, 1995, J THEOR BIOL, V172, P63, DOI 10.1006/jtbi.1995.0005; Williams JT, 2001, PHYSIOL REV, V81, P299; Xu W, 2006, J PHARMACOL EXP THER, V317, P1295, DOI 10.1124/jpet.105.099507; Yeh GC, 1998, NEUROSCI LETT, V252, P25, DOI 10.1016/S0304-3940(98)00528-X; Yin DL, 1997, NEUROSCI RES, V29, P121, DOI 10.1016/S0168-0102(97)00080-1; Zhang L, 2006, MOL PHARMACOL, V69, P1810, DOI 10.1124/mol.105.021352; Zhang L, 2009, J BIOL CHEM, V284, P1990, DOI 10.1074/jbc.M807971200; Zhang WD, 2002, J NEUROSCI RES, V69, P427, DOI 10.1002/jnr.10313; Zhang WS, 2007, J NEUROCHEM, V103, P1157, DOI 10.1111/j.1471-4159.2007.04813.x; Zhao H, 2006, MOL PHARMACOL, V69, P1421, DOI 10.1124/mol.105.020024; Zheng H, 2008, P NATL ACAD SCI USA, V105, P9421, DOI 10.1073/pnas.0802253105	64	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	2009	284	52					36521	36534		10.1074/jbc.M109.024109			14	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	535LT	WOS:000272970500054	19861419	Green Published, Bronze			2020-06-26	J	Eisinger, DA; Ammer, H				Eisinger, Daniela A.; Ammer, Hermann			Down-regulation of c-Cbl by Morphine Accounts for Persistent ERK1/2 Signaling in delta-Opioid Receptor-expressing HEK293 Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-COUPLED RECEPTORS; EGF RECEPTOR; KINASE; PHOSPHORYLATION; BETA; SRC; UBIQUITINATION; MEMBRANE; INTERNALIZATION	Opioids display ligand-specific differences in the time course of ERK1/2 signaling. Whereas full agonists, like etorphine, induce only transient activation of ERK1/2, the partial agonist morphine mediates persistent stimulation of mitogenic signaling. Here we report that in stably delta-opioid receptor (DOR)-expressing HEK293 (HEK/DOR) cells, the transient nature of etorphine-induced ERK1/2 signaling is due to desensitization of epidermal growth factor (EGF) receptor-mediated activation of the Ras/Raf-1/ERK1/2 cascade. Desensitization of ERK1/2 activity by etorphine is associated with down-regulation of EGF receptors, an effect mediated by the ubiquitin ligase c-Cbl. In contrast, chronic morphine treatment failed to desensitize EGF receptors, resulting in unimpeded ERK1/2 signaling. The failure of morphine to desensitize ERK1/2 signaling is mediated by persistent activation of c-Src, which induces degradation of c-Cbl. The role of c-Src in opioid-specific ERK1/2 signaling is further demonstrated by pretreatment of the cells with PP2 and SKI-I as well as overexpression of a dominant negative c-Src mutant (c-Src(dn)) or a c-Src-resistant c-Cbl mutant (CblY3F), both of which facilitate desensitization of ERK1/2 signaling by morphine. Conversely, overexpression of c-Src as well as down-regulation of c-Cbl by small interfering RNA results in persistent etorphine-induced stimulation of ERK1/2 activity. Subcellular fractionation experiments finally attributed the ability of morphine to persistently activate c-Src to its redistribution from Triton X-100-insensitive membrane rafts to DOR and EGF receptor containing high density membrane compartments implicated in ERK1/2 signaling. These results demonstrate that agonist-specific differences in the temporal and spatial pattern of c-Src activation determine the kinetics of DOR-mediated regulation of ERK1/2 signaling.	[Eisinger, Daniela A.; Ammer, Hermann] Univ Munich, Inst Pharmacol Toxicol & Pharm, D-80539 Munich, Germany	Eisinger, DA (reprint author), Univ Munich, Inst Pharmacol Toxicol & Pharm, Koeniginstr 16, D-80539 Munich, Germany.	eisinger@lrz.uni-muenchen.de		Ammer, Hermann/0000-0003-4935-0207			Adachi T, 2002, J CELL PHYSIOL, V192, P151, DOI 10.1002/jcp.10124; AMMER H, 1993, BIOCHEM J, V295, P263, DOI 10.1042/bj2950263; Andre A, 2008, BBA-BIOMEMBRANES, V1778, P1483, DOI 10.1016/j.bbamem.2008.03.017; Audet N, 2005, J BIOL CHEM, V280, P7808, DOI 10.1074/jbc.M411695200; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Belcheva MM, 2002, J PHARMACOL EXP THER, V303, P909, DOI 10.1124/jpet.102.038554; Belcheva MM, 2003, MOL PHARMACOL, V64, P1391, DOI 10.1124/mol.64.6.1391; Berhow MT, 1996, J NEUROSCI, V16, P4707; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; CARR DJJ, 1995, IMMUNOPHARMACOLOGY, V31, P59, DOI 10.1016/0162-3109(95)00033-6; Chakrabarti S, 2003, MOL BRAIN RES, V119, P144, DOI 10.1016/j.molbrainres.2003.09.002; Chakrabarti S, 2003, P NATL ACAD SCI USA, V100, P13686, DOI 10.1073/pnas.2335885100; Chakrabarti S, 2001, P NATL ACAD SCI USA, V98, P4209, DOI 10.1073/pnas.071031798; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; de Diesbach P, 2008, EXP CELL RES, V314, P1465, DOI 10.1016/j.yexcr.2008.01.015; de Melker AA, 2001, J CELL SCI, V114, P2167; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Eisinger DA, 2004, J PHARMACOL EXP THER, V309, P776, DOI 10.1124/jpet.103.061788; Eisinger DA, 2002, J NEUROSCI, V22, P10192; Eisinger DA, 2008, CELL SIGNAL, V20, P2324, DOI 10.1016/j.cellsig.2008.09.002; Ferrer-Alcon M, 2004, MOL BRAIN RES, V121, P114, DOI 10.1016/j.molbrainres.2003.11.009; Freedman NJ, 2002, J BIOL CHEM, V277, P48261, DOI 10.1074/jbc.M204431200; Grewal JS, 2001, J BIOL CHEM, V276, P27335, DOI 10.1074/jbc.M103578200; Gupta K, 2002, CANCER RES, V62, P4491; Gurevich VV, 2008, MOL PHARMACOL, V74, P312, DOI 10.1124/mol.108.049015; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Huang P, 2007, BIOCHEM PHARMACOL, V73, P534, DOI 10.1016/j.bcp.2006.10.032; Jacob C, 2005, J BIOL CHEM, V280, P16076, DOI 10.1074/jbc.M500109200; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kim J, 2003, BIOCHEMISTRY-US, V42, P2887, DOI 10.1021/bi026942t; Kodama H, 2002, J MOL CELL CARDIOL, V34, P139, DOI 10.1006/jmcc.2001.1496; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Levitt ES, 2009, J BIOL CHEM, V284, P22108, DOI 10.1074/jbc.M109.030411; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li KW, 2006, PROTEOMICS, V6, P2003, DOI 10.1002/pmic.200500045; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Liu YT, 2007, J CELL PHYSIOL, V211, P205, DOI 10.1002/jcp.20924; Mao JR, 2002, J NEUROSCI, V22, P7650; Marie N, 2008, CELL SIGNAL, V20, P1209, DOI 10.1016/j.cellsig.2008.02.010; Martini L, 2007, CURR OPIN NEUROBIOL, V17, P556, DOI 10.1016/j.conb.2007.10.004; Narita M, 2002, NEUROSCI LETT, V324, P97, DOI 10.1016/S0304-3940(02)00141-6; Oksvold MP, 2003, ONCOGENE, V22, P8509, DOI 10.1038/sj.onc.1207117; Patel HH, 2008, ANNU REV PHARMACOL, V48, P359, DOI 10.1146/annurev.pharmtox.48.121506.124841; Pennock S, 2008, MOL CELL BIOL, V28, P3020, DOI 10.1128/MCB.01809-07; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Roepstorff K, 2008, HISTOCHEM CELL BIOL, V129, P563, DOI 10.1007/s00418-008-0401-3; Rozengurt E, 2007, J CELL PHYSIOL, V213, P589, DOI 10.1002/jcp.21246; Rubio I, 2006, BIOCHEM J, V398, P243, DOI 10.1042/BJ20060160; Sood A, 2001, ENDOCR RES, V27, P215, DOI 10.1081/ERC-100107182; Swaminathan G, 2006, J CELL PHYSIOL, V209, P21, DOI 10.1002/jcp.20694; Tanowitz M, 2002, J BIOL CHEM, V277, P50219, DOI 10.1074/jbc.C200536200; Tegeder I, 2004, PHARMACOL REV, V56, P351, DOI 10.1124/pr.56.3.2; Tian GC, 2001, BIOCHEMISTRY-US, V40, P7084, DOI 10.1021/bi0100586; Timpson P, 2005, CANCER RES, V65, P3273, DOI 10.1158/0008-5472.CAN-04-2118; Xue LZ, 1998, CELL SIGNAL, V10, P339, DOI 10.1016/S0898-6568(98)00011-4; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Zhang J, 1999, J RECEPT SIGNAL TR R, V19, P301, DOI 10.3109/10799899909036653; Zhang L, 2009, J BIOL CHEM, V284, P1990, DOI 10.1074/jbc.M807971200; Zheng H, 2008, P NATL ACAD SCI USA, V105, P9421, DOI 10.1073/pnas.0802253105; Zheng H, 2008, MOL PHARMACOL, V73, P178, DOI 10.1124/mol.107.039842; Zimmerman B, 2009, CELL SIGNAL, V21, P103, DOI 10.1016/j.cellsig.2008.09.013	65	11	11	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	2009	284	50					34819	34828		10.1074/jbc.M109.042937			10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	528JG	WOS:000272439600037	19828455	Bronze, Green Published			2020-06-26	J	Madia, PA; Dighe, SV; Sirohi, S; Walker, EA; Yoburn, BC				Madia, Priyanka A.; Dighe, Shveta V.; Sirohi, Sunil; Walker, Ellen A.; Yoburn, Byron C.			Dosing protocol and analgesic efficacy determine opioid tolerance in the mouse	PSYCHOPHARMACOLOGY			English	Article						Opioid analgesia; Continuous infusion; Intermittent treatment; Acute treatment; Tolerance; Efficacy; Etorphine; Methadone; Oxycodone; Hydrocodone; Clocinnamox	CONTINUOUS INFUSION; RECEPTOR REGULATION; AGONIST EFFICACY; MORPHINE; PAIN; MAGNITUDE; AFFINITY; FENTANYL; POTENCY; RATS	Analgesic efficacy of opioids and dosing protocol have been shown to influence analgesic tolerance. This study tested the hypothesis that there is an inverse relationship between analgesic efficacy and tolerance following continuous infusion of opioid analgesics. Furthermore, it was hypothesized that analgesic efficacy plays a minor role in determining the magnitude of tolerance following intermittent or acute administration, and that acute and intermittent administration of opioid agonists produces less tolerance than continuous infusion. Analgesic (tailflick) efficacy (tau) of etorphine, methadone, oxycodone, and hydrocodone was determined using the operational model of agonism. To induce tolerance, mice were injected with opioid agonists once (acute), once per day for 7 days (intermittent) or continuously infused for 7 days. Dose-response studies were conducted using morphine following treatment. The order of analgesic efficacy was etorphine > methadone > oxycodone a parts per thousand... hydrocodone. Infusion of the higher analgesic efficacy drug etorphine produced significantly less tolerance than the lower analgesic efficacy drugs oxycodone, methadone, and hydrocodone at equi-effective doses. In general, intermittent and acute treatment produced less tolerance compared to continuous infusion even at similar daily doses. Taken together, intermittent and acute opioid agonist administration produces minimal tolerance compared to continuous infusion. Furthermore, there is an inverse relationship between analgesic efficacy and tolerance following continuous infusion. These results suggest that opioid analgesic tolerance may be increased when sustained release dosing formulations or continuous infusions are employed clinically.	[Madia, Priyanka A.; Dighe, Shveta V.; Sirohi, Sunil; Yoburn, Byron C.] St Johns Univ, Coll Pharm & Allied Hlth Profess, Dept Pharmaceut Sci, Jamaica, NY 11439 USA; [Walker, Ellen A.] Temple Univ, Dept Pharmaceut Sci, Sch Pharm, Philadelphia, PA 19140 USA	Yoburn, BC (reprint author), St Johns Univ, Coll Pharm & Allied Hlth Profess, Dept Pharmaceut Sci, 8000 Utopia Pkwy, Jamaica, NY 11439 USA.	yoburnb@stjohns.edu	SIROHI, SUNIL/E-1891-2012	SIROHI, SUNIL/0000-0001-7246-9295	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 19959]		BLACK JW, 1983, PROC R SOC SER B-BIO, V220, P141, DOI 10.1098/rspb.1983.0093; CHAPMAN CR, 1989, CANCER, V63, P1636; Chou R, 2009, J PAIN, V10, P147, DOI 10.1016/j.jpain.2008.10.007; Crawford MW, 2006, ANESTH ANALG, V102, P1662, DOI 10.1213/01.ane.0000216036.95705.c2; Dighe SV, 2009, PHARMACOL BIOCHEM BE, V92, P537, DOI 10.1016/j.pbb.2009.02.004; Duttaroy A, 1997, PHARMACOL BIOCHEM BE, V58, P67, DOI 10.1016/S0091-3057(96)00463-7; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; FINNEY DJ, 1973, PROBIT ANAL STAT TRE; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Kumar P, 2008, EUR J PHARMACOL, V597, P39, DOI 10.1016/j.ejphar.2008.08.025; McCarberg BH, 2007, PAIN MED, V8, pS8; Nicholson B, 2009, PAIN PRACT, V9, P71, DOI 10.1111/j.1533-2500.2008.00232.x; PARONIS CA, 1992, J PHARMACOL EXP THER, V262, P1; Pawar M, 2007, EUR J PHARMACOL, V563, P92, DOI 10.1016/j.ejphar.2007.01.059; Rosenblum A, 2008, EXP CLIN PSYCHOPHARM, V16, P405, DOI 10.1037/a0013628; Sirohi S, 2008, PHARMACOL BIOCHEM BE, V91, P115, DOI 10.1016/j.pbb.2008.06.019; Stafford K, 2001, PHARMACOL BIOCHEM BE, V69, P233, DOI 10.1016/S0091-3057(01)00525-1; STEVENS CW, 1989, J PHARMACOL EXP THER, V250, P1; Walker EA, 2001, PSYCHOPHARMACOLOGY, V154, P131, DOI 10.1007/s002130000620; WOLFRAM S, 1991, [No title captured]; YOBURN BC, 1985, J PHARMACOL EXP THER, V235, P282; YOBURN BC, 1985, BRAIN RES, V331, P327, DOI 10.1016/0006-8993(85)91558-6; Zernig G, 1996, J PHARMACOL TOXICOL, V35, P223, DOI 10.1016/1056-8719(96)00053-6; ZERNIG G, 1995, LIFE SCI, V57, P2113, DOI 10.1016/0024-3205(95)02204-V	24	25	25	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0033-3158	1432-2072		PSYCHOPHARMACOLOGY	Psychopharmacology	DEC	2009	207	3					413	422		10.1007/s00213-009-1673-6			10	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	519FX	WOS:000271751500007	19816677				2020-06-26	J	Haga, HA; Wenger, S; Hvarnes, S; Os, O; Rolandsen, CM; Solberg, EJ				Haga, Henning A.; Wenger, Sandra; Hvarnes, Silje; Os, Oystein; Rolandsen, Christer M.; Solberg, Erling J.			Plasma lactate concentrations in free-ranging moose (Alces alces) immobilized with etorphine	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						etorphine; lactate; moose	ACCURACY	Objective To investigate plasma lactate concentrations of etorphine-immobilized moose in relation to environmental, temporal and physiological parameters. Study design Prospective clinical study. Animals Fourteen female and five male moose (Alces alces), estimated age range 1-7 years. Methods The moose were darted from a helicopter with 7.5 mg etorphine per animal using projectile syringes and a dart gun. Once immobilized, the moose were approached, a venous blood sample was obtained and vital signs including pulse oximetry were recorded. Diprenorphine was administered to reverse the effects of etorphine. Timing of events, ambient temperature and snow depth were recorded. Blood samples were cooled and centrifuged before plasma was harvested and frozen. The plasma was thawed later and lactate analysed. Data were analysed using descriptive statistics and regression analysis. Results All animals recovered uneventfully and were alive 12 weeks after immobilization. Mean +/- SD plasma lactate was found to be 9.2 +/- 2.1 mmol L-1. Plasma lactate concentrations were related positively to snow depth and negatively to time from induction of immobilization to blood sampling. The model that best described the variability in plasma lactate concentrations used induction time (time from firing the dart to the moose being immobilized). The second best model included induction time and snow depth. Conclusions and clinical relevance Plasma lactate concentrations in these etorphine-immobilized moose were in the range reported for other immobilized wild ruminants. Decreasing induction time, which may be related to a more profound etorphine effect, and increasing snow depth possibly may increase plasma lactate concentrations in etorphine-immobilized moose.	[Haga, Henning A.; Wenger, Sandra] Norwegian Sch Vet Sci, Dept Compan Anim Clin Sci, N-0033 Oslo, Norway; [Wenger, Sandra] Univ Zurich, Dept Vet Clin Sci, Vetsuisse Fac, Zurich, Switzerland; [Hvarnes, Silje; Os, Oystein] Vetconsult AS, Folldal, Norway; [Rolandsen, Christer M.; Solberg, Erling J.] Norwegian Inst Nat Res NINA, Trondheim, Norway; [Rolandsen, Christer M.] Norwegian Univ Sci & Technol, Dept Biol, Ctr Conservat Biol, N-7034 Trondheim, Norway	Haga, HA (reprint author), Norwegian Sch Vet Sci, Dept Compan Anim Clin Sci, Pb 8146 Dep, N-0033 Oslo, Norway.	andreas.haga@veths.no					APPLE JK, 1994, J ANIM SCI, V72, P1306, DOI 10.2527/1994.7251306x; Arnemo J. M., 2004, Norsk Veterinartidsskrift, V116, P531; Arnemo Jon M., 2003, Alces, V39, P243; Austrheim G., 2008, RAP ZOOL SER NTNU VI, P1; Branson K. R., 2001, Veterinary pharmacology and therapeutics, P268; Burnham K.P., 1998, MODEL SELECTION INFE; Edner AH, 2009, ACTA VET SCAND, V51, DOI 10.1186/1751-0147-51-10; GANHAO MF, 1989, S AFR J SCI, V85, P281; GUYTON A, 1996, [No title captured]; Hamlin KL, 2000, J WILDLIFE MANAGE, V64, P441, DOI 10.2307/3803242; Hillidge C J, 1975, Equine Vet J, V7, P148, DOI 10.1111/j.2042-3306.1975.tb03254.x; HILLIDGE CJ, 1971, VET REC, V89, P280, DOI 10.1136/vr.89.10.280-a; KOCH RA, 1986, J ASS VET ANAESTH, V14, P120; Lavsund Sten, 2003, Alces, V39, P109; NOSTELL K, 2006, [No title captured], V36, P123; POULSEN JSD, 1977, NORD VET MED, V29, P271; ROBERTSON SA, 1987, EQUINE VET J, V19, P214, DOI 10.1111/j.2042-3306.1987.tb01383.x; Rolandsen CM, 2008, EUR J WILDLIFE RES, V54, P6, DOI 10.1007/s10344-007-0100-8; Snow D. H., 1994, The athletic horse: principles and practice of equine sports medicine., P145; Taylor PM, 1999, VET SURG, V28, P77, DOI 10.1053/jvet.1999.0077; Wenger S, 2007, J ZOO WILDLIFE MED, V38, P380, DOI 10.1638/2006-0038R.1; Williams Elizabeth S., 1996, P181	22	8	8	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	NOV	2009	36	6					555	561		10.1111/j.1467-2995.2009.00498.x			7	Veterinary Sciences	Veterinary Sciences	508BV	WOS:000270902700006	19845927	Green Accepted			2020-06-26	J	Heiss, A; Ammer, H; Eisinger, DA				Heiss, Anika; Ammer, Hermann; Eisinger, Daniela A.			delta-Opioid receptor-stimulated Akt signaling in neuroblastoma x glioma (NG108-15) hybrid cells involves receptor tyrosine kinase-mediated PI3K activation	EXPERIMENTAL CELL RESEARCH			English	Article						Akt; Apoptosis; Caspase-3; delta-Opioid receptor; PI3K; Receptor tyrosine kinases	GROWTH-FACTOR-I; PLECKSTRIN HOMOLOGY DOMAIN; GLYCOGEN-SYNTHASE KINASE-3; BETA-GAMMA-SUBUNITS; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; N-TERMINUS; INSULIN; PHOSPHORYLATION; BINDING	delta-Opioid receptor (DOR) agonists possess cytoprotective properties, an effect associated with activation of the "pro-survival" kinase Akt. Here we delineate the signal transduction pathway by which opioids induce Akt activation in neuroblastoma x glioma (NG108-15) hybrid cells. Exposure of the cells to both [D-Pen(2,5)]enkephalin and etorphine resulted in a time- and dose-dependent increase in Akt activity, as measured by means of an activation-specific antibody recognizing phosphoserine-473. DOR-mediated Akt signaling is blocked by the opioid antagonist naloxone and involves inhibitory G(i/o) proteins, because pre-treatment with pertussis toxin, but not overexpression of the G(q/11) scavengers EBP50 and GRK2-K220R, prevented this effect. Further studies with Wortmannin and LY294002 revealed that phophoinositol-3-kinase (PI3K) plays a central role in opioid-induced Akt activation. Opioids stimulate Akt activity through transactivation of receptor tyrosine kinases (RTK), because pre-treatment of the cells with inhibitors for neurotrophin receptor tyrosine kinases (AG879) and the insulin-like growth factor receptor IGF-1 (AG1024), but not over-expression of the G beta gamma scavenger phosducin, abolished this effect. Activated Akt translocates to the nuclear membrane, where it promotes GSK3 phosphorylation and prevents caspase-3 cleavage, two key events mediating inhibition of cell apoptosis and enhancement of cell survival. Taken together, these results demonstrate that in NG108-15 hybrid cells DOR agonists possess cytoprotective properties mediated by activation of the RTK/PI3K/Akt signaling pathway. (C) 2009 Elsevier Inc. All rights reserved.	[Heiss, Anika; Ammer, Hermann; Eisinger, Daniela A.] Univ Munich, Inst Pharmacol Toxicol & Pharm, D-80539 Muenchen Federal, Germany	Eisinger, DA (reprint author), Univ Munich, Inst Pharmacol Toxicol & Pharm, Koeniginstr 16, D-80539 Muenchen Federal, Germany.	eisinger@pharmtox.vetmed.uni-muenchen.de		Ammer, Hermann/0000-0003-4935-0207			Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELCHEVA MM, 1995, J PHARMACOL EXP THER, V274, P1513; Burgaud JL, 1996, EXP CELL RES, V223, P412, DOI 10.1006/excr.1996.0096; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen YL, 2008, CURR MED CHEM, V15, P772, DOI 10.2174/092986708783955518; Ciccarelli M, 2007, CELL SIGNAL, V19, P1949, DOI 10.1016/j.cellsig.2007.05.007; Clark MJ, 1997, J PHARMACOL EXP THER, V283, P501; Dickenson JM, 2002, BRIT J PHARMACOL, V135, P1967, DOI 10.1038/sj.bjp.0704664; Eisinger DA, 2008, FEBS LETT, V582, P3325, DOI 10.1016/j.febslet.2008.08.021; El Zein N, 2007, CELL SIGNAL, V19, P152, DOI 10.1016/j.cellsig.2006.05.031; Foerster K, 2007, AM J PHYSIOL-HEART C, V293, pH1604, DOI 10.1152/ajpheart.00418.2007; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; Gliki G, 2002, CELL BIOL INT, V26, P751, DOI 10.1016/S1065-6995(02)90926-1; Huigsloot M, 2001, BIOCHEM PHARMACOL, V62, P1087, DOI 10.1016/S0006-2952(01)00755-9; IKEDA K, 1995, BIOCHEM BIOPH RES CO, V208, P302, DOI 10.1006/bbrc.1995.1338; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KROLL SD, 1991, P NATL ACAD SCI USA, V88, P5182, DOI 10.1073/pnas.88.12.5182; Kugawa F, 2004, BIOL PHARM BULL, V27, P1340, DOI 10.1248/bpb.27.1340; Lee JWM, 1998, J NEUROCHEM, V70, P2203; Lim MA, 2003, P NATL ACAD SCI USA, V100, P14006, DOI 10.1073/pnas.2335486100; Martelli AM, 2000, J BONE MINER RES, V15, P1716, DOI 10.1359/jbmr.2000.15.9.1716; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; OHMICHI M, 1993, BIOCHEMISTRY-US, V32, P4650, DOI 10.1021/bi00068a024; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Pello OM, 2006, J IMMUNOL, V176, P1675, DOI 10.4049/jimmunol.176.3.1675; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; Rochdi MD, 2003, J BIOL CHEM, V278, P17827, DOI 10.1074/jbc.M210319200; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Russo SJ, 2007, NAT NEUROSCI, V10, P93, DOI 10.1038/nn1812; Sale EM, 2008, CELL MOL LIFE SCI, V65, P113, DOI 10.1007/s00018-007-7274-9; Sallese M, 2000, MOL PHARMACOL, V57, P826; Scheid MP, 2002, J BIOL CHEM, V277, P9027, DOI 10.1074/jbc.M106755200; Schulz K, 1996, J BIOL CHEM, V271, P22546, DOI 10.1074/jbc.271.37.22546; SEELY BL, 1995, J BIOL CHEM, V270, P19151, DOI 10.1074/jbc.270.32.19151; Selley DE, 1998, J RECEPT SIGNAL TR R, V18, P25, DOI 10.3109/10799899809039163; Sharp BM, 2006, BRAIN BEHAV IMMUN, V20, P9, DOI 10.1016/j.bbi.2005.02.002; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Strassheim D, 1998, MOL PHARMACOL, V53, P1047; Su DS, 2007, NEUROSCI LETT, V423, P113, DOI 10.1016/j.neulet.2007.06.044; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wollemann M, 2004, LIFE SCI, V75, P257, DOI 10.1016/j.lfs.2003.12.005; Wu EHT, 2005, BIOCHEM BIOPH RES CO, V334, P838, DOI 10.1016/j.bbrc.2005.06.184; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; Yamada M, 1997, J BIOL CHEM, V272, P30334, DOI 10.1074/jbc.272.48.30334; Yao LL, 2007, J CELL SCI, V120, P895, DOI 10.1242/jcs.03393; Zhang JH, 2000, BRAIN RES, V885, P143, DOI 10.1016/S0006-8993(00)02906-1; Zhang WB, 2003, J NEUROCHEM, V86, P1213, DOI 10.1046/j.1471-4159.2003.01930.x	56	24	28	0	9	ELSEVIER INC	SAN DIEGO	525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4827	1090-2422		EXP CELL RES	Exp. Cell Res.	JUL 15	2009	315	12					2115	2125		10.1016/j.yexcr.2009.04.002			11	Oncology; Cell Biology	Oncology; Cell Biology	457TL	WOS:000266956200012	19362548				2020-06-26	J	Eisinger, DA; Ammer, H				Eisinger, Daniela A.; Ammer, Hermann			delta-Opioid receptors activate ERK/MAP kinase via integrin-stimulated receptor tyrosine kinases	CELLULAR SIGNALLING			English	Article						ERK/MAP kinase; delta-Opioid receptor; EGF receptor; Integrin; Protein kinase C-delta; Phospholipase C; Focal adhesion kinase	GROWTH-FACTOR RECEPTOR; PROTEIN-COUPLED RECEPTORS; FOCAL ADHESION KINASE; PHOSPHOLIPASE-C; ERK ACTIVATION; MAP KINASE; PHOSPHORYLATION; BINDING; CALMODULIN; FAK	Integrin-mediated cell adherence to extracellular matrix proteins results in stimulation of ERK1/2 activity, a mechanism involving focal adhesion tyrosine kinases (pp125FAK, Pyk-2) and epidermal growth factor receptors (EGFRs). G protein-coupled receptors (GPCRs) may also mediate ERK1/2 activation in an integrin-dependent manner, the underlying signaling mechanism of which still remains unclear. Here we demonstrate that the delta-opioid receptor (DOR), a typical GPCR, stimulates ERK1/2 activity in HEK293 cells via integrin-mediated transactivation of EGFR function. Inhibition of integrin signaling by RGDT peptides, cytochalasin, and by keeping the cells in suspension culture both blocked [D-Ala(2), D-Leu(5)]enkephalin (DADLE)- and etorphine-stimulated ERK1/2 activity. Integrin-dependent ERK1/2 activation does not involve FAK/Pyk-2, because over-expression of the FAK/Pyk-2 inhibitor SOCS-3 failed to attenuate DOR signaling. Exposure of the cells to the EGFR inhibitors AG1478 and BPIQ-I blocked DOR-mediated ERK1/2 activation. Because RGDT peptides also prevented DOR-mediated EGFR activation, the present findings indicate that in HEK293 cells DOR-stimulated ERK1/2 activity is mediated by integrin-stimulated EGFRs. Further studies with the phospholipase C (PLC) inhibitors U73122 and ET-18-OCH3 revealed that opioid-stimulated integrin activation is sensitive to PLC. In contrast, integrin-mediated transactivation of EGFR function appears to be dependent on PKC-delta, as indicated by studies with rottlerin and siRNA knock-down. A similar ERK1/2 signaling pathway was observed for NG108-15 cells, a neuronal cell line endogenously expressing the DOR. In these cells, the nerve growth factor TrkA receptor replaces the EGFR in connecting DOR-activated integrins to the Ras/Raf/ERK1/2 pathway. Together, these data describe an alternative ERK1/2 signaling pathway in which the DOR transactivates the growth factor receptor associated mitogen-activated protein kinase cascade in an integrin-dependent manner. (c) 2008 Elsevier Inc. All rights reserved.	[Eisinger, Daniela A.; Ammer, Hermann] Univ Munich, Inst Pharmacol Toxicol & Pharm, D-80539 Munich, Germany	Eisinger, DA (reprint author), Univ Munich, Inst Pharmacol Toxicol & Pharm, Koniginstr 16, D-80539 Munich, Germany.	eisinger@lrz.uni-muenchen.de		Ammer, Hermann/0000-0003-4935-0207			Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; Belcheva MM, 2001, J BIOL CHEM, V276, P33847, DOI 10.1074/jbc.M101535200; Belcheva MM, 1998, J NEUROCHEM, V70, P635; Belcheva MM, 2005, J BIOL CHEM, V280, P27662, DOI 10.1074/jbc.M502593200; Berg KA, 2007, NEUROSCIENCE, V144, P889, DOI 10.1016/j.neuroscience.2006.10.033; Bill HM, 2004, MOL CELL BIOL, V24, P8586, DOI 10.1128/MCB.24.19.8586-8599.2004; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BOULTON TG, 1991, CELL REGUL, V2, P357; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Cohen MV, 2007, J MOL CELL CARDIOL, V42, P842, DOI 10.1016/j.yjmcc.2007.01.004; Davidson L, 2004, J BIOL CHEM, V279, P1980, DOI 10.1074/jbc.M309827200; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; Eisinger DA, 2004, J PHARMACOL EXP THER, V309, P776, DOI 10.1124/jpet.103.061788; Eisinger DA, 2002, J NEUROSCI, V22, P10192; Fagerstrom S, 1998, J BIOL CHEM, V273, P2336, DOI 10.1074/jbc.273.4.2336; Foerster K, 2007, AM J PHYSIOL-HEART C, V293, pH1604, DOI 10.1152/ajpheart.00418.2007; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Haller H, 1998, CIRC RES, V82, P157; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Hyduk SJ, 2007, BLOOD, V109, P176, DOI 10.1182/blood-2006-01-029199; Ivankovic-Dikic I, 2000, NAT CELL BIOL, V2, P574; JIN WZ, 1994, J NEUROSCI, V14, P1920; Kapur S, 2005, J BIOL CHEM, V280, P20163, DOI 10.1074/jbc.M501460200; Kim BS, 1998, J NEUROCHEM, V71, P1333; Kinashi T, 2005, NAT REV IMMUNOL, V5, P546, DOI 10.1038/nri1646; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Liu E, 2003, EMBO J, V22, P5036, DOI 10.1093/emboj/cdg503; Machelska H, 2002, J NEUROSCI, V22, P5588; Matsuo M, 2006, CANCER SCI, V97, P155, DOI 10.1111/j.1349-7006.2006.00152.x; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Murthy KS, 1996, MOL PHARMACOL, V50, P870; Narita M, 2006, J NEUROCHEM, V97, P1494, DOI 10.1111/j.1471-4159.2006.03849.x; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; Pello OM, 2006, J IMMUNOL, V176, P1675, DOI 10.4049/jimmunol.176.3.1675; Prenzel N, 1999, NATURE, V402, P884; RABET LM, 1998, BLOOD, V92, P2133; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; Sakaguchi K, 1998, MOL ENDOCRINOL, V12, P536, DOI 10.1210/me.12.4.536; Sanders MA, 2000, J BIOL CHEM, V275, P38040, DOI 10.1074/jbc.M003871200; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schulz R, 2004, EUR J PHARMACOL, V500, P487, DOI 10.1016/j.ejphar.2004.07.010; Short SM, 2000, J BIOL CHEM, V275, P12970, DOI 10.1074/jbc.275.17.12970; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Ulfman LH, 2005, J IMMUNOL, V175, P6092, DOI 10.4049/jimmunol.175.9.6092; Wang DX, 1999, J BIOL CHEM, V274, P22081, DOI 10.1074/jbc.274.31.22081; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Wu GS, 2007, J NEUROSCI, V27, P7447, DOI 10.1523/JNEUROSCI.4266-06.2007	56	29	30	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0898-6568	1873-3913		CELL SIGNAL	Cell. Signal.	DEC	2008	20	12					2324	2331		10.1016/j.cellsig.2008.09.002			8	Cell Biology	Cell Biology	381UG	WOS:000261560800018	18804531				2020-06-26	J	Eisinger, DA; Ammer, H				Eisinger, Daniela A.; Ammer, Hermann			delta-Opioid receptors stimulate ERK1/2 activity in NG108-15 hybrid cells by integrin-mediated transactivation of TrkA receptors	FEBS LETTERS			English	Article						Cell adhesion; delta-Opioid receptor; Integrin; Extracellular signal-regulated protein kinase; Tropomyosin-related kinase A	ACTIVATED PROTEIN-KINASES; GROWTH-FACTOR RECEPTOR; SYNAPTIC PLASTICITY; MORPHINE; MEMORY; NEUROTROPHIN-4; TRANSMISSION; PATHWAYS; ADHESION; CYCLASE	This study demonstrates that activation of delta-opioid receptors (DORs) in neuroblastoma x glioma (NG108-15) hybrid cells by [D-Ala(2), D-Leu(5)] enkephalin (DADLE) and etorphine significantly enhances cell adhesion to fibronectin-coated wells. This effect is blocked by both naloxone and integrin binding RGDT peptides. In addition, cell adhesion turned out to be a prerequisite for DOR-stimulated transactivation of Tropomyosin-related kinase A (TrkA) and extracellular signal-regulated kinases 1/2 (ERK1/2). Because inhibition of TrkA activation by AG879 completely blocked DOR- and integrin-mediated ERK1/2 signaling, the present results indicate that in NG10815 cells DOR- stimulated ERK1/2 activation is mediated by integrin-induced transactivation of TrkA. (C) 2008 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.	[Eisinger, Daniela A.; Ammer, Hermann] Univ Munich, Inst Pharmacol Toxicol & Pharm, D-80539 Munich, Germany	Eisinger, DA (reprint author), Univ Munich, Inst Pharmacol Toxicol & Pharm, Koeniginstr 16, D-80539 Munich, Germany.	Eisinger@lrz.uni-muenchen.de		Ammer, Hermann/0000-0003-4935-0207			Asensio VJ, 2006, EUR J PHARMACOL, V539, P49, DOI 10.1016/j.ejphar.2006.04.001; BERG KA, 1997, NEUROSCIENCE, V144, P889; Bill HM, 2004, MOL CELL BIOL, V24, P8586, DOI 10.1128/MCB.24.19.8586-8599.2004; Bourgin C, 2007, J CELL BIOL, V178, P1295, DOI 10.1083/jcb.200610139; Chan CS, 2006, J NEUROSCI, V26, P223, DOI 10.1523/JNEUROSCI.4110-05.2006; Chan CS, 2003, J NEUROSCI, V23, P7107, DOI 10.1523/JNEUROSCI.23-18-07107.2003; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Eisinger DA, 2004, J PHARMACOL EXP THER, V309, P776, DOI 10.1124/jpet.103.061788; Fuller SJ, 2008, J MOL CELL CARDIOL, V44, P831, DOI 10.1016/j.yjmcc.2008.02.278; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kyosseva SV, 2004, INT REV NEUROBIOL, V59, P201; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Lee FS, 2001, P NATL ACAD SCI USA, V98, P3555, DOI 10.1073/pnas.061020198; Lemons ML, 2008, EXP NEUROL, V209, P343, DOI 10.1016/j.expneurol.2007.05.027; LEVITZKI, 1995, SCIENCE, P1782; Lucas G, 2003, NAT NEUROSCI, V6, P221, DOI 10.1038/nn1021; Ma MC, 2005, J BIOL CHEM, V280, P16208, DOI 10.1074/jbc.M408055200; Mazzucchelli C, 2002, NEURON, V34, P807, DOI 10.1016/S0896-6273(02)00716-X; Narita M, 2006, J NEUROCHEM, V97, P1494, DOI 10.1111/j.1471-4159.2006.03849.x; New David C, 2007, J Mol Signal, V2, P2, DOI 10.1186/1750-2187-2-2; Pan HL, 2008, PHARMACOL THERAPEUT, V117, P141, DOI 10.1016/j.pharmthera.2007.09.003; Pello OM, 2006, J IMMUNOL, V176, P1675, DOI 10.4049/jimmunol.176.3.1675; Plouffe B, 2006, ENDOCRINOLOGY, V147, P4646, DOI 10.1210/en.2005-1315; Rewcastle GW, 1996, J MED CHEM, V39, P918, DOI 10.1021/jm950692f; Short SM, 2000, J BIOL CHEM, V275, P12970, DOI 10.1074/jbc.275.17.12970; Simmons ML, 1996, INT REV NEUROBIOL, V39, P145, DOI 10.1016/S0074-7742(08)60666-2; Smith DJ, 2003, NEUROSCI LETT, V340, P103, DOI 10.1016/S0304-3940(03)00084-3; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Ugolini G, 2007, P NATL ACAD SCI USA, V104, P2985, DOI 10.1073/pnas.0611253104; VACHON L, 1987, MOL PHARMACOL, V31, P159; Webb DJ, 2007, J BIOL CHEM, V282, P6929, DOI 10.1074/jbc.M610981200; Wu GS, 1997, NEUROCHEM RES, V22, P1281, DOI 10.1023/A:1021993232148	33	10	10	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-5793			FEBS LETT	FEBS Lett.	OCT 15	2008	582	23-24					3325	3329		10.1016/j.febslet.2008.08.021			5	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	371BL	WOS:000260806700013	18775707				2020-06-26	J	Arttamangkul, S; Quillinan, N; Low, MJ; von Zastrow, M; Pintar, J; Williams, JT				Arttamangkul, Seksiri; Quillinan, Nidia; Low, Malcolm J.; von Zastrow, Mark; Pintar, John; Williams, John T.			Differential activation and trafficking of mu-opioid receptors in brain slices	MOLECULAR PHARMACOLOGY			English	Article							AGONIST-SPECIFIC REGULATION; PROTEIN-COUPLED RECEPTORS; FUNCTIONAL SELECTIVITY; CELLULAR MECHANISMS; IN-VIVO; DESENSITIZATION; TOLERANCE; NEURONS; ENDOCYTOSIS; EFFICACY	The activation of G protein-coupled receptors results in a cascade of events that include acute signaling, desensitization, and internalization, and it is thought that not all agonists affect each process to the same extent. The early steps in opioid receptor signaling, including desensitization, have been characterized electrophysiologically using brain slice preparations, whereas most previous studies of opioid receptor trafficking have been conducted in heterologous cell models. This study used transgenic mice that express an epitope-tagged (FLAG) mu-opioid receptor (FLAGMOR) targeted to catecholamine neurons by regulatory elements from the tyrosine hydroxylase gene. Brain slices from these mice were used to study tagged MOR receptors in neurons of the locus ceruleus. Activation of the FLAGMOR with [Met(5)] enkephalin (ME) produced a hyperpolarization that desensitized acutely to the same extent as native MOR in slices from wild-type mice. A series of opioid agonists were then used to study desensitization and receptor trafficking in brain slices, which was monitored with a monoclonal antibody against the FLAG epitope (M1) conjugated to Alexa 594. Three patterns of receptor trafficking and desensitization were observed: 1) ME, etorphine, and methadone resulted in both receptor desensitization and internalization; 2) morphine and oxymorphone caused significant desensitization without evidence for internalization; and 3) oxycodone was ineffective in both processes. These results show that two distinct forms of signaling were differentially engaged depending on the agonist used to activate the receptor, and they support the hypothesis that ligand-specific regulation of opioid receptors occurs in neurons maintained in brain slices from adult animals.	[Arttamangkul, Seksiri; Quillinan, Nidia; Williams, John T.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA; [Low, Malcolm J.] Oregon Hlth & Sci Univ, Ctr Study Weight Regulat, Dept Behav Neurosci, Portland, OR 97239 USA; [von Zastrow, Mark] Univ Calif San Francisco, Dept Psychiat & Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; [Pintar, John] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA	Williams, JT (reprint author), Oregon Hlth & Sci Univ, Vollum Inst, L474,3181 Sam Jackson Pk Dr, Portland, OR 97239 USA.	williamj@ohsu.edu			National Alliance for Research on Schizophrenia and DepressionNARSAD; DA016627; National Research Service AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA023793];  [DA08163]	This study was supported by grant DA08163 and National Alliance for Research on Schizophrenia and Depression (to J.T.W.), grant DA016627 (to S. A.), and National Research Service Award DA023793 (to N.Q.).	Alvarez VA, 2002, J NEUROSCI, V22, P5769; Arttamangkul S, 2006, J NEUROSCI, V26, P4118, DOI 10.1523/JNEUROSCI.0303-06.2006; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bohn LM, 2004, MOL PHARMACOL, V66, P106, DOI 10.1124/mol.66.1.106; Borgland SL, 2003, J BIOL CHEM, V278, P18776, DOI 10.1074/jbc.M300525200; BUNZOW JR, 1995, J NEUROCHEM, V64, P14; CHRISTIE MJ, 1987, MOL PHARMACOL, V32, P633; Connor M, 2004, BRIT J PHARMACOL, V143, P685, DOI 10.1038/sj.bjp.0705938; Dang VC, 2005, MOL PHARMACOL, V68, P1127, DOI 10.1124/mol.105.013185; Debic HH, 2005, J NEUROSCI, V25, P7847, DOI 10.1523/JNEUROSCI.5045-04.2005; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Ford CP, 2006, J NEUROSCI, V26, P2788, DOI 10.1523/JNEUROSCI.4331-05.2006; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; HARRIS GC, 1991, J NEUROSCI, V11, P2574; Kim KA, 2003, J NEUROSCI, V23, P2075; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Luttrell LM, 2002, J CELL SCI, V115, P455; Marie N, 2006, CELL SIGNAL, V18, P1815, DOI 10.1016/j.cellsig.2006.03.015; MIN N, 1994, MOL BRAIN RES, V27, P281, DOI 10.1016/0169-328X(94)90011-6; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Pologruto TA, 2003, BIOMED ENG ONLINE, V2, DOI 10.1186/1475-925X-2-13; Rodriguez-Martin I, 2008, NEUROREPORT, V19, P589, DOI 10.1097/WNR.0b013e3282f97b64; Ryman-Rasmussen JP, 2007, NEUROPHARMACOLOGY, V52, P562, DOI 10.1016/j.neuropharm.2006.08.028; Scherrer G, 2006, P NATL ACAD SCI USA, V103, P9691, DOI 10.1073/pnas.0603359103; Schuller AGP, 1999, NAT NEUROSCI, V2, P151; Stafford K, 2001, PHARMACOL BIOCHEM BE, V69, P233, DOI 10.1016/S0091-3057(01)00525-1; Swaminath G, 2005, J BIOL CHEM, V280, P22165, DOI 10.1074/jbc.M502352200; Tanowitz M, 2003, J BIOL CHEM, V278, P45978, DOI 10.1074/jbc.M304504200; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Virk MS, 2008, MOL PHARMACOL, V73, P1301, DOI 10.1124/mol.107.042952; von Zastrow M, 2003, CURR OPIN NEUROBIOL, V13, P348, DOI 10.1016/S0959-4388(03)00069-2; Walwyn W, 2007, J NEUROSCI, V27, P5092, DOI 10.1523/JNEUROSCI.1157-07.2007; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Williams JT, 2001, PHYSIOL REV, V81, P299; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	37	83	84	0	5	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0026-895X	1521-0111		MOL PHARMACOL	Mol. Pharmacol.	OCT	2008	74	4					972	979		10.1124/mol.108.048512			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	349XV	WOS:000259317500006	18612077	Green Accepted			2020-06-26	J	Xu, H; Wang, XY; Partilla, JS; Bishop-Mathis, K; Benaderet, TS; Dersch, CM; Simpson, DS; Prisinzano, TE; Rothman, RB				Xu, Heng; Wang, Xiaoying; Partilla, John S.; Bishop-Mathis, Kristen; Benaderet, Tova S.; Dersch, Christina M.; Simpson, Denise S.; Prisinzano, Thomas E.; Rothman, Richard B.			Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors	BRAIN RESEARCH BULLETIN			English	Article						opioid; biased agonism; G protein; opioid receptor	PEPTIDE RECEPTOR; BETA-ARRESTIN; MORPHINE; ACTIVATION; TOLERANCE; EFFICACY	Recent evidence indicates that agonist ligands of G protein coupled receptors (GPCR) can activate different signaling systems. Such "agonist-directed" signaling also occurs with opioid receptors. Previous work from our laboratory showed that chronic morphine, but not DAMGO, up-regulates the expression of G alpha 12 and that both morphine and DAMGO decreased G alpha i3 expression in CHO cells expressing the cloned human mu opioid receptor. In this study, we tested the hypothesis that chronic opioid regulation of G protein expression is agonist-directed. Following a 20h treatment of CHO cells expressing the cloned human mu (hMOR-CHO), delta (hDOR-CHO) or kappa (hKOR-CHO) opioid receptors with various opioid agonists, we determined the expression level of G alpha 12 and G alpha i3 by Western blots. Among five mu agonists (morphine, etorphine, DADLE, DAMCO, herkinorin) tested with hMOR-CHO cells, only chronic morphine and etorphine up-regulated G alpha 12 expression. All five mu agonists decreased G alpha i3 expression. Among six delta agonists (SNC80, DPDPE, deltorphin-1, morphine, DADLE, etorphine) tested with hDOR-CHO cells, all six agonists down-regulated G alpha i3 expression or moderately up-regulated G alpha 12 expression. Among five kappa agonists, ((-)-ethylketocyclazocine, salvinorin A, U69,593, etorphine, (-)-U50,488) tested with hKOR-CHO cells, only chronic (-)-U50,488 and (-)-EKC up-regulated Got 12 expression. All kappa agonists decreased Gai3 expression. These data demonstrate that chronic opioid agonist regulation of G protein expression depends not only on the agonist tested, but also on the type of opioid receptor expressed in a common cellular host, providing additional evidence for agonist-directed signaling. Published by Elsevier Inc.	[Xu, Heng; Wang, Xiaoying; Partilla, John S.; Bishop-Mathis, Kristen; Benaderet, Tova S.; Dersch, Christina M.; Rothman, Richard B.] NIDA, Clin Psychopharmacol Sect, Intramural Res Program, NIH,DHHS, Baltimore, MD 21224 USA; [Simpson, Denise S.; Prisinzano, Thomas E.] Univ Kansas, Dept Med Chem, Lawrence, KS 66049 USA	Rothman, RB (reprint author), NIDA, Clin Psychopharmacol Sect, Intramural Res Program, NIH,DHHS, Baltimore, MD 21224 USA.	rrothman@mail.nih.gov	Prisinzano, Thomas E/B-7877-2010	Prisinzano, Thomas/0000-0002-0649-8052	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA018151]	This research was supported by the Intramural Research Program of the NIH, National Institute on Drug Abuse and funding NIDA grant DA018151 to Dr. Prisinzano.	Allouche S, 1999, BIOCHEM J, V342, P71, DOI 10.1042/0264-6021:3420071; Chakrabarti S, 1998, J NEUROCHEM, V71, P231; Clarke WP, 2005, MOL PHARMACOL, V67, P1819, DOI 10.1124/mol.105.013060; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Drake MT, 2008, J BIOL CHEM, V283, P5669, DOI 10.1074/jbc.M708118200; Groer CE, 2007, MOL PHARMACOL, V71, P549, DOI 10.1124/mol.106.028258; Harding WW, 2005, J MED CHEM, V48, P4765, DOI 10.1021/jm048963m; Kenakin T, 2005, NAT REV DRUG DISCOV, V4, P919, DOI 10.1038/nrd1875; Kenakin T, 2003, TRENDS PHARMACOL SCI, V24, P346, DOI 10.1016/S0165-6147(03)00167-6; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Lecoq I, 2004, J PHARMACOL EXP THER, V310, P666, DOI 10.1124/jpet.103.063958; Liu JG, 2001, J BIOL CHEM, V276, P37779; Liu-Chen LY, 2004, LIFE SCI, V75, P511, DOI 10.1016/j.lfs.2003.10.041; Robinson TE, 2004, NEUROPHARMACOLOGY, V47, P33, DOI 10.1016/j.neuropharm.2004.06.025; Sadee W, 2005, LIFE SCI, V76, P1427, DOI 10.1016/j.lfs.2004.10.024; Toll L, 1998, NIDA Res Monogr, V178, P440; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Xu H, 2001, SYNAPSE, V39, P64, DOI 10.1002/1098-2396(20010101)39:1<64::AID-SYN9>3.0.CO;2-J; Xu H, 2005, J PHARMACOL EXP THER, V315, P248, DOI 10.1124/jpet.105.089367; Xu H, 2004, SYNAPSE, V52, P209, DOI 10.1002/syn.20019; Xu H, 2003, SYNAPSE, V47, P1, DOI 10.1002/syn.10144; Xu H, 2007, SYNAPSE, V61, P166, DOI 10.1002/syn.20356	24	14	14	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230			BRAIN RES BULL	Brain Res. Bull.	SEP 5	2008	77	1					49	54		10.1016/j.brainresbull.2008.05.003			6	Neurosciences	Neurosciences & Neurology	338EK	WOS:000258488300008	18639745	Green Accepted			2020-06-26	J	Zheng, H; Chu, J; Qiu, Y; Loh, HH; Law, PY				Zheng, Hui; Chu, Ji; Qiu, Yu; Loh, Horace H.; Law, Ping-Yee			Agonist-selective signaling is determined by the receptor location within the membrane domains	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						lipid raft; opioid	MU-OPIOID RECEPTOR; PROTEIN-COUPLED RECEPTORS; LIPID RAFTS; BETA-ARRESTIN; ADENYLYL-CYCLASE; ERK ACTIVATION; CHO-CELLS; PHOSPHORYLATION; INTERNALIZATION; LIGANDS	The basis for agonist-selective signaling was investigated by using the mu-opioid receptor (MOR) as a model. In the absence of agonist, MOR located within the lipid raft domains, whereas etorphine, but not morphine, induced the translocation of MOR from lipid raft to nonraft domains, similar to the action of methyl-beta-cyclodextrin. The etorphine-induced MOR translocation required the dissociation of the receptor from G alpha i2 first and then the binding of beta-arrestin. In contrast, the low affinity of the morphine-MOR complex for beta-arrestin and the rebinding of G alpha i2 after GTP hydrolysis retained the complex within the lipid raft domains. Disruption of the MOR-G alpha i2 interaction, either by deleting the (RRITR280)-R-276 sequence of MOR or knocking down the level of G alpha i2, resulted in the translocation of MOR to the nonraft domains. In addition, lipid raft location of MOR was critical for G protein-dependent signaling, such as etorphine- and morphine-mediated inhibition of adenylyl cyclase activity and morphine-induced ERK phosphorylation, whereas beta-arrestin-dependent, etorphine-induced ERK phosphorylation required MOR to translocate into the nonraft domains. Thus, agonist-selective signaling is regulated by the location of MOR, which is determined by interactions of MOR with G proteins and beta-arrestin.	[Zheng, Hui; Chu, Ji; Qiu, Yu; Loh, Horace H.; Law, Ping-Yee] Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	Zheng, H (reprint author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	zhen0091@umn.edu		Law, Ping-Yee/0000-0002-5364-1093; Zheng, Hui/0000-0001-6801-0529	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA011806, R01 DA000564, DA000564, R56 DA000564, DA007339, R01 DA016674, K05-DA00513, K05 DA000513, K05-DA70544, R01 DA007339, P50 DA011806, DA016674]		Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Besenicar M, 2007, BIOCHIM BIOPHYS ACTA, V1778, P175; Chaipatikul V, 2003, J PHARMACOL EXP THER, V305, P909, DOI 10.1124/jpet.102.046219; CHAKRABARTI S, 1995, J NEUROCHEM, V64, P2534; Chini B, 2004, J MOL ENDOCRINOL, V32, P325, DOI 10.1677/jme.0.0320325; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; El Kouhen R, 2001, J BIOL CHEM, V276, P12774, DOI 10.1074/jbc.M009571200; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Helms JB, 2004, TRAFFIC, V5, P247, DOI 10.1111/j.1600-0854.2004.0181.x; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Huang P, 2007, BRAIN RES, V1184, P46, DOI 10.1016/j.brainres.2007.09.096; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kohout TA, 2004, J BIOL CHEM, V279, P23214, DOI 10.1074/jbc.M402125200; LAW PY, 1991, J PHARMACOL EXP THER, V256, P710; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Macdonald JL, 2005, J LIPID RES, V46, P1061, DOI 10.1194/jlr.D400041-JLR200; Massotte D, 2002, J NEUROCHEM, V81, P1372, DOI 10.1046/j.1471-4159.2002.00946.x; Mayor S, 2004, TRAFFIC, V5, P231, DOI 10.1111/j.1600-0854.2004.00172.x; Monastyrskaya K, 2005, J BIOL CHEM, V280, P7135, DOI 10.1074/jbc.M405806200; Navratil AM, 2003, J BIOL CHEM, V278, P31593, DOI 10.1074/jbc.M304273200; Nebl T, 2002, J BIOL CHEM, V277, P43399, DOI 10.1074/jbc.M205386200; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Ostrom RS, 2001, J BIOL CHEM, V276, P42063, DOI 10.1074/jbc.M105348200; Qiu Y, 2003, J BIOL CHEM, V278, P36733, DOI 10.1074/jbc.M305857200; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Violin JD, 2007, TRENDS PHARMACOL SCI, V28, P416, DOI 10.1016/j.tips.2007.06.006; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Zhai PY, 2005, J CLIN INVEST, V115, P3045, DOI 10.1172/JCI25330; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang L, 2006, MOL PHARMACOL, V69, P1810, DOI 10.1124/mol.105.021352; Zhao H, 2006, MOL PHARMACOL, V69, P1421, DOI 10.1124/mol.105.020024; Zheng H, 2008, MOL PHARMACOL, V73, P178, DOI 10.1124/mol.107.039842	38	71	74	0	4	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JUL 8	2008	105	27					9421	9426		10.1073/pnas.0802253105			6	Multidisciplinary Sciences	Science & Technology - Other Topics	326GA	WOS:000257645400052	18599439	Green Published, Bronze			2020-06-26	J	Mcmahon, CR; Bradshaw, CJA				Mcmahon, C. R.; Bradshaw, C. J. A.			To catch a buffalo: field immobilisation of Asian swamp buffalo using etorphine and xylazine	AUSTRALIAN VETERINARY JOURNAL			English	Article						allometry; Bubalus bubalis; epidemiology; etorphine; diprenorphine; global positioning system; collars; home range; disease spread	SOUTHERN ELEPHANT SEALS; CHEMICAL IMMOBILIZATION; SALTWATER INTRUSION; NORTHERN AUSTRALIA; M99; HYDROCHLORIDE; COMBINATIONS; PHARMACOLOGY; MANAGEMENT; TILETAMINE	Objective To demonstrate the efficacy of a mixture of etorphine and xylazine to safely immobilise wild buffalo (Bubalus bubalis) in the field. Methods Body mass was estimated (to calculate mass-specific dosages) by deriving a predictive relationship between morphometric measurements (body length, height) and mass based on a dataset collected in Vietnam, because the study animals could not be weighed in the field. Results Mass-specific dosages varied between 0.02 and 0.03 mg/kg for etorphine and between 0.14 and 0.22 mg/kg for xyalazine; induction times varied between 10 and 33 min, mean recumbency time was 68 min, and the mean time to standing was 10 min (range: 10-17 min). Conclusions The mixture of ethorphine and xylazine was effective for immobilisation of this species and appeared to have a relatively large safety margin, based on the mass-specific dosages used. The allometric relationships described here should prove useful for those working with wild swamp buffalo.	[Mcmahon, C. R.; Bradshaw, C. J. A.] Charles Darwin Univ, Sch Environm Res, Darwin, NT 0909, Australia	Mcmahon, CR (reprint author), Charles Darwin Univ, Sch Environm Res, Casuarina Campus, Darwin, NT 0909, Australia.	clive.mcmahon@cdu.edu.au	McMahon, Clive R/D-5713-2013; Bradshaw, Corey J.A./A-1311-2008	McMahon, Clive R/0000-0001-5241-8917; Bradshaw, Corey J.A./0000-0002-5328-7741			Ancrenaz M, 1996, J ZOO WILDLIFE MED, V27, P209; Balmford A, 2003, TRENDS ECOL EVOL, V18, P326, DOI 10.1016/S0169-5347(03)00067-3; BAYLISS P, 1989, AUST WILDLIFE RES, V16, P651; BLANE GF, 1970, BRIT J PHARMACOL, V39, pP252; BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; BOOTH NH, 1988, [No title captured]; Bradshaw CJA, 2005, AUST VET J, V83, P616, DOI 10.1111/j.1751-0813.2005.tb13273.x; Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644; Burnham KP, 2002, MODEL SELECTION MULT; Chalmers G. A., 1982, Noninfectious diseases of wildlife, P84; Clavero M, 2005, TRENDS ECOL EVOL, V20, P110, DOI 10.1016/j.tree.2005.01.003; DeKock M, 1997, PHARMACOL BIOCHEM BE, V58, P109, DOI 10.1016/S0091-3057(96)00462-5; *DEP ENV HER, 2005, [No title captured]; DOBBS HE, 1968, J PHARMACOL EXP THER, V160, P407; Fox LM, 2006, CURR OPIN INFECT DIS, V19, P588, DOI 10.1097/QCO.0b013e328010774c; GATESMAN T, 1982, J ZOO ANIM MED, V13, P11, DOI 10.2307/20094555; GRAY C W, 1970, Zoologica (New York), V55, P51; GREENE SA, 1988, J VET PHARMACOL THER, V11, P295, DOI 10.1111/j.1365-2885.1988.tb00189.x; GRIFFITHS D, 1993, MAR MAMMAL SCI, V9, P250, DOI 10.1111/j.1748-7692.1993.tb00453.x; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P391; Khan ZP, 1999, ANAESTHESIA, V54, P146, DOI 10.1046/j.1365-2044.1999.00659.x; KNIGHTON AD, 1991, GEOLOGY, V19, P831, DOI 10.1130/0091-7613(1991)019<0831:TCEASI>2.3.CO;2; KOCK MD, 1993, J ZOO WILDLIFE MED, V24, P1; Kock MD, 1995, J ZOO WILDLIFE MED, V26, P207; KOCK MD, 1990, J ZOO WILDLIFE MED, V21, P155; Koenig J., 2003, Northern Territory Naturalist, V17, P7; KOUBEK P, 1988, VET MED-CZECH, V33, P375; Laurance WF, 1999, BIOL CONSERV, V91, P109, DOI 10.1016/S0006-3207(99)00088-9; McMahon CR, 2000, VET REC, V146, P251, DOI 10.1136/vr.146.9.251; Mulrennan ME, 1998, J ENVIRON MANAGE, V54, P169, DOI 10.1006/jema.1998.0229; Osofsky SA, 2000, ORYX, V34, P27, DOI 10.1017/S0030605300030866; R Development Core Team, 2004, R LANG ENV STAT COMP; Radunz B, 2006, VET MICROBIOL, V112, P283, DOI 10.1016/j.vetmic.2005.11.017; Ramdohr S, 2001, S AFR J WILDL RES, V31, P135; SKEAT AJ, 1996, [No title captured], P155; SODHI NS, 2007, [No title captured]; Sterken J, 2004, EUR J EMERG MED, V11, P298, DOI 10.1097/00063110-200410000-00013; Tierney M, 2001, WILDLIFE RES, V28, P581, DOI 10.1071/WR00066; TULLOCH DG, 1979, AUST WILDLIFE RES, V6, P265; Walter WD, 2005, J WILDLIFE DIS, V41, P395, DOI 10.7589/0090-3558-41.2.395; WOODS R, 1994, MAR MAMMAL SCI, V10, P412, DOI 10.1111/j.1748-7692.1994.tb00498.x; Yibarbuk D, 2001, J BIOGEOGR, V28, P325, DOI 10.1046/j.1365-2699.2001.00555.x	42	15	15	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0005-0423	1751-0813		AUST VET J	Aust. Vet. J.	JUN	2008	86	6					235	241		10.1111/j.1751-0813.2008.00303.x			7	Veterinary Sciences	Veterinary Sciences	310MB	WOS:000256532600029	18498561				2020-06-26	J	Marie, N; Aguila, B; Hasbi, A; Davis, A; Jauzac, P; Allouche, S				Marie, Nicolas; Aguila, Benjamin; Hasbi, Ahmed; Davis, Audrey; Jauzac, Philippe; Allouche, Stephane			Different kinases desensitize the human delta-opioid receptor (hDOP-R) in the neuroblastoma cell line SK-N-BE upon peptidic and alkaloid agonists	CELLULAR SIGNALLING			English	Article						opioid receptor; desensitization; phosphorylation; GRK; second-messenger kinase	DEPENDENT PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; SELECTIVE INHIBITOR; NG108-15 CELLS; MU; ACTIVATION; MORPHINE; INTERNALIZATION; INVOLVEMENT; TOLERANCE	In a previous work, we described a differential desensitization of the human delta-opioid receptor (hDOP-R) by etorphine (a non-selective and alkaloid agonist) and delta-selective and peptidic agonists (DPDPE ([D-Pen(2,5)]enkephalin) and deltorphin I (Tyr-D-Ala-Pbe-Asp-Val-Val-Gly-NH2)) in the neuroblastoma cell line SK-N-BE (Allouche et al., Eur. J. Pharmacol., 371, 235, 1999). In the present study, we explored the putative role of different kinases in this differential regulation. First, selective chemical inhibitors of PKA, PKC and tyrosine kinases were used and we showed a significant reduction of etorphine-induced opioid receptor desensitization by the bisindolylmaleimide I (PKC inhibitor) while genistein (tyrosine kinase inhibitor) was potent to impair desensitization induced by the different agonists. When the PKA was inhibited by H89 pretreatment, no modification of opioid receptor desensitization was observed whatever the agonist used. Second, we further studied the role of G protein-coupled receptor kinases (GRKs) and by using western-blot experiments we observed that only the GRK2 isoform was expressed in the SK-N-BE cells. Next, the neuroblastoma cells were transfected with the wild type GRK2 or its dominant negative mutant GRK2-K220R and the inhibition on cAMP level was determined in naive and agonist-pretreated cells. We showed that over-expression of GRK2-K220R totally abolished etorphine-induced receptor desensitization while no effect was observed with peptidic agonists and over-expression of GRK2 selectively impaired cAMP inhibition promoted by etorphine suggesting that this kinase was involved in the regulation of hDOP-R activated only by etorphine. Third, correlation between functional experiments and phosphorylation of the hDOP-R after agonist activation was assessed by western-blot using the specific anti-phospho-DOP-R Ser(363) antibody. While all agonists were potent to increase phosphorylation of opioid receptor, we showed no impairment of receptor phosphorylation level after PKC inhibitor pretreatment. Upon agonist activation, no enhancement of receptor phosphorylation was observed when the GRK2 was over-expressed while the GRK2-K220R partially reduced the hDOP-R Ser(363) phosphorylation only after peptidic agonists pretreatment. In conclusion, hDOP-R desensitization upon etorphine exposure relies on the GRK2, PKC and tyrosine kinases while DPDPE and deltorphin I mediate desensitization at least via tyrosine kinases. Although the Ser(363) was described as the primary phosphorylation site of the mouse DOP-R, we observed no correlation between desensitization and phosphorylation of this amino acid. (C) 2008 Elsevier Inc. All rights reserved.	[Marie, Nicolas; Aguila, Benjamin; Hasbi, Ahmed; Davis, Audrey; Jauzac, Philippe; Allouche, Stephane] Univ Caen, Lab Biol Mol & Cellulaire Signalisat, UPRES EA 3919, IFR ICORE 146, F-14032 Caen, France	Allouche, S (reprint author), Ctr Hosp, Biochim Lab, Ave Cote Nacre, F-14033 Caen, France.	allouche-s@chu-caen.fr	Marie, Nicolas/I-9129-2014	Marie, Nicolas/0000-0002-6491-9898; Allouche, stephane/0000-0003-3134-7501			AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Allouche S, 1999, EUR J PHARMACOL, V371, P235, DOI 10.1016/S0014-2999(99)00180-6; Allouche S, 1996, J NEUROCHEM, V67, P2461; Appleyard SM, 2000, J BIOL CHEM, V275, P38281, DOI 10.1074/jbc.M006756200; Aquila B, 2006, BRAIN RES, V1114, P11, DOI 10.1016/j.brainres.2006.07.069; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Chakrabarti S, 1998, J NEUROCHEM, V71, P231; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cong M, 2001, J BIOL CHEM, V276, P15192, DOI 10.1074/jbc.M009130200; El Kouhen R, 1999, J BIOL CHEM, V274, P9207, DOI 10.1074/jbc.274.14.9207; Fields H, 2004, NAT REV NEUROSCI, V5, P565, DOI 10.1038/nrn1431; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Guo J, 2000, MOL PHARMACOL, V58, P1050; Hasbi A, 1998, J NEUROCHEM, V70, P2129; Johnson EA, 2006, MOL PHARMACOL, V70, P676, DOI 10.1124/mol.106.022376; Kramer HK, 2000, BIOCHEM PHARMACOL, V60, P781, DOI 10.1016/S0006-2952(00)00400-7; Li AH, 2001, J NEUROCHEM, V77, P435, DOI 10.1046/j.1471-4159.2001.00267.x; Li J, 2002, MOL PHARMACOL, V61, P73, DOI 10.1124/mol.61.1.73; LOH HH, 1988, SYNAPSE, V2, P457, DOI 10.1002/syn.890020414; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; Marie N, 2003, J BIOL CHEM, V278, P22795, DOI 10.1074/jbc.M300084200; McLaughlin JP, 2001, MOL PHARMACOL, V59, P1360; MESTEK A, 1995, J NEUROSCI, V15, P2396; Metaye T, 2005, CELL SIGNAL, V17, P917, DOI 10.1016/j.cellsig.2005.01.002; Morikawa H, 1998, BRIT J PHARMACOL, V123, P1111, DOI 10.1038/sj.bjp.0701733; Mundell SJ, 2004, MOL PHARMACOL, V65, P1507, DOI 10.1124/mol.65.6.1507; Namir N, 1997, J NEUROCHEM, V68, P1764; Narita M, 1996, BRIT J PHARMACOL, V118, P1829, DOI 10.1111/j.1476-5381.1996.tb15610.x; Narita M, 2001, J NEUROSCI, V21, P3715, DOI 10.1523/JNEUROSCI.21-11-03715.2001; Navratilova E, 2005, EUR J PHARMACOL, V519, P212, DOI 10.1016/j.ejphar.2005.07.024; Noble F, 1996, BRIT J PHARMACOL, V117, P161, DOI 10.1111/j.1476-5381.1996.tb15169.x; Pak Y, 1999, J BIOL CHEM, V274, P27610, DOI 10.1074/jbc.274.39.27610; Palczewski K, 1997, EUR J BIOCHEM, V248, P261, DOI 10.1111/j.1432-1033.1997.00261.x; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; PEI G, 1995, MOL PHARMACOL, V48, P173; RAYNOR K, 1994, J PHARMACOL EXP THER, V270, P1381; Romero-Avila MT, 2002, BIOCHEM J, V368, P581, DOI 10.1042/BJ20021052; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Wang ZJ, 2000, EUR J PHARMACOL, V389, P165, DOI 10.1016/S0014-2999(99)00881-X; Willets J, 2001, EUR J PHARMACOL, V431, P133, DOI 10.1016/S0014-2999(01)01360-7; Xiang B, 2001, J BIOL CHEM, V276, P4709, DOI 10.1074/jbc.M006187200; YU VC, 1988, J PHARMACOL EXP THER, V245, P350; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449; Zhang Z, 1999, J NEUROCHEM, V73, P1502, DOI 10.1046/j.1471-4159.1999.0731502.x	47	13	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0898-6568	1873-3913		CELL SIGNAL	Cell. Signal.	JUN	2008	20	6					1209	1220		10.1016/j.cellsig.2008.02.010			12	Cell Biology	Cell Biology	306HJ	WOS:000256238600023	18395423				2020-06-26	J	Binyaminy, B; Gafni, M; Shapira, M; Sarne, Y				Binyaminy, Binyamin; Gafni, Mikhal; Shapira, Ma'anit; Sarne, Yosef			Agonist-specific down regulation of mu-opioid receptors: Different cellular pathways are activated by different opioid agonists	LIFE SCIENCES			English	Article						opioid receptors; down regulation; proteases; agonist-specific effect	BETA-ADRENERGIC-RECEPTOR; PROTEIN-KINASE; PHOSPHORYLATION; INTERNALIZATION; INVOLVEMENT; DESENSITIZATION; CELLS; MECHANISMS; METALLOPROTEASE; RESENSITIZATION	Opioid agonists are known to induce down regulation of opioid receptors through the classical pathway that involves phosphorylation, clathrin-dependent endocytosis and lysosomal/endosomal degradation of the internalized receptors. As expected, exposure of mu-opioid receptor (MOR)-transfected HEK-293 cells to either DAMGO (a specific mu-opioid agonist) or etorphine (a wide spectrum opioid agonist) resulted in down regulation of the receptors that was blocked by the kinase inhibitor staurosporine, by hypertonic sucrose and by the lysosomal and proteasomal inhibitors chloroquine and lactacystin. High concentration of etorphine, but not of DAMGO, induced an additional process of down regulation that was resistant to staurosporine, to hypertonic sucrose and to chloroquine-lactacystin. Etorphine, but not DAMGO, also induced down regulation of mu-opioid receptors in isolated membranes of HEK cells. This membrane-delimited down regulation was blocked by selective inhibitors of protease enzymes, suggesting the involvement of membranous serine- and amino-peptidases. This membranous down regulation of opioid receptors was dependent on the concentration of etorphine and was blocked by the opioid antagonist naloxone. Etorphine induced similar down regulation in membranes of HEK-293 cells transfected with delta-opioid receptors (DOR) as well in membranes of cells that endogenously express opioid receptors. This agonist-specific membrane-delimited regulatory process appears to be physiologically relevant and should be taken into account when studying long term effects of opioid drugs. (C) 2008 Elsevier Inc. All rights reserved.	[Binyaminy, Binyamin; Gafni, Mikhal; Shapira, Ma'anit; Sarne, Yosef] Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, Mauerberger Chair Neuropharmacol, IL-69978 Tel Aviv, Israel	Sarne, Y (reprint author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, Mauerberger Chair Neuropharmacol, IL-69978 Tel Aviv, Israel.	sarney@post.tau.ac.il					ABOOD ME, 1994, J NEUROSCI RES, V37, P714, DOI 10.1002/jnr.490370605; BAUMHAKER Y, 1994, BRAIN RES, V665, P94, DOI 10.1016/0006-8993(94)91156-8; Berg KA, 1998, MOL PHARMACOL, V54, P94; BIDLACK JM, 1992, EUR J PHARM-MOLEC PH, V227, P257, DOI 10.1016/0922-4106(92)90003-E; Chaturvedi K, 2001, J BIOL CHEM, V276, P12345, DOI 10.1074/jbc.M008054200; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Couet J, 1996, J BIOL CHEM, V271, P4545; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Cvejic S, 1996, J BIOL CHEM, V271, P4073; Dhami GK, 2002, J BIOL CHEM, V277, P25266, DOI 10.1074/jbc.M203593200; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Gesty-Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200; Grantcharova E, 2002, J BIOL CHEM, V277, P43933, DOI 10.1074/jbc.M208407200; Jans R, 2004, ARCH DERMATOL RES, V296, P30, DOI 10.1007/s00403-004-0469-0; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kenakin T, 2003, TRENDS PHARMACOL SCI, V24, P346, DOI 10.1016/S0165-6147(03)00167-6; Keren O, 2003, BRAIN RES, V980, P197, DOI 10.1016/S0006-8993(03)02970-6; Koch T, 1997, J NEUROCHEM, V69, P1767; Kojro E, 1999, EUR J BIOCHEM, V266, P538, DOI 10.1046/j.1432-1327.1999.00892.x; Kramer HK, 1999, J NEUROCHEM, V72, P594, DOI 10.1046/j.1471-4159.1999.0720594.x; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Morales P, 2004, MOL REPROD DEV, V68, P115, DOI 10.1002/mrd.20052; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Olivares-Reyes JA, 2001, J BIOL CHEM, V276, P37761; Perez DM, 2005, PHARMACOL REV, V57, P147, DOI 10.1124/pr.57.2.2; Qiu Y, 2003, J BIOL CHEM, V278, P36733, DOI 10.1074/jbc.M305857200; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Reiter E, 2006, TRENDS ENDOCRIN MET, V17, P159, DOI 10.1016/j.tem.2006.03.008; Schmidt H, 2000, J NEUROCHEM, V74, P414, DOI 10.1046/j.1471-4159.2000.0740414.x; Shapira M, 2001, MOL BRAIN RES, V96, P142, DOI 10.1016/S0169-328X(01)00283-2; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; von Zastrow M, 2004, NEUROMOL MED, V5, P51, DOI 10.1385/NMM:5:1:051	36	8	10	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205			LIFE SCI	Life Sci.	APR 9	2008	82	15-16					831	839		10.1016/j.lfs.2008.01.015			9	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	292MA	WOS:000255269000003	18358497				2020-06-26	J	Virk, MS; Williams, JT				Virk, Michael S.; Williams, John T.			Agonist-specific regulation of mu-opioid receptor desensitization and recovery from desensitization	MOLECULAR PHARMACOLOGY			English	Article							LOCUS-COERULEUS NEURONS; IN-VIVO; OPIATE DRUGS; TOLERANCE; MORPHINE; INTERNALIZATION; RATS; ENDOCYTOSIS; MECHANISMS; DEPENDENCE	Agonist-selective actions of opioids on the desensitization of mu-opioid receptors ( MORs) have been well characterized, but few if any studies have examined agonist-dependent recovery from desensitization. The outward potassium current induced by several opioids was studied using whole-cell voltage-clamp recordings in locus ceruleus neurons. A brief application of the irreversible opioid antagonist beta-chlornaltrexamine (beta-CNA) was applied immediately after treatment of slices with saturating concentrations of opioid agonists. This approach permitted the measurement of desensitization and recovery from desensitization using multiple opioid agonists, including [ Met](5)enkephalin ( ME), [ D-Ala(2), N-Me-Phe(4), Gly(5)-ol]-enkephalin ( DAMGO), etorphine, fentanyl, methadone, morphine, morphine-6-glucuronide, oxycodone, and oxymorphone. The results indicate that desensitization protects receptors from irreversible antagonism with beta-CNA. The amount of desensitization was measured as the decrease in current during a 10-min application of a saturating agonist concentration and was a good predictor of the extent of receptor protection from irreversible inactivation with beta-CNA. After desensitization with ME or DAMGO and treatment with beta-CNA, there was an initial profound inhibition of MOR-induced current that recovered significantly after 45 min. There was, however, no recovery of MOR-mediated current with time after treatment with agonists that did not cause desensitization, such as oxycodone. These results demonstrate that desensitization prevents irreversible inactivation of receptors by mu-CNA.	[Virk, Michael S.; Williams, John T.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA	Williams, JT (reprint author), Oregon Hlth & Sci Univ, Vollum Inst, L474,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	williamj@ohsu.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA08163, 1F30-DA021466, F30 DA021466, R01 DA008163]		Alvarez VA, 2002, J NEUROSCI, V22, P5769; Arttamangkul S, 2006, J NEUROSCI, V26, P4118, DOI 10.1523/JNEUROSCI.0303-06.2006; AvidorReiss T, 1997, J BIOL CHEM, V272, P5040, DOI 10.1074/jbc.272.8.5040; Bailey CP, 2005, CURR OPIN PHARMACOL, V5, P60, DOI 10.1016/j.coph.2004.08.012; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Borgland SL, 2003, J BIOL CHEM, V278, P18776, DOI 10.1074/jbc.M300525200; Celver J, 2004, MOL PHARMACOL, V65, P528, DOI 10.1124/mol.65.3.528; Christie M J, 1986, NIDA Res Monogr, V75, P591; Connor M, 2004, BRIT J PHARMACOL, V143, P685, DOI 10.1038/sj.bjp.0705938; Dang VC, 2005, MOL PHARMACOL, V68, P1127, DOI 10.1124/mol.105.013185; Dang VC, 2004, J NEUROSCI, V24, P7699, DOI 10.1523/JNEUROSCI.2499-04.2004; Fiorillo CD, 1996, J NEUROSCI, V16, P1479; Grecksch G, 2006, PSYCHOPHARMACOLOGY, V186, P177, DOI 10.1007/s00213-006-0365-8; HARRIS GC, 1991, J NEUROSCI, V11, P2574; Johnson EA, 2006, MOL PHARMACOL, V70, P676, DOI 10.1124/mol.106.022376; Keith DE, 1998, MOL PHARMACOL, V53, P377; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Koch T, 2004, J NEUROCHEM, V88, P680, DOI 10.1046/j.1471-4159.2003.02189.x; Law PY, 2000, MOL PHARMACOL, V58, P388; Lemberg KK, 2006, ANESTHESIOLOGY, V105, P801, DOI 10.1097/00000542-200610000-00027; OSBORNE PB, 1995, BRIT J PHARMACOL, V115, P925, DOI 10.1111/j.1476-5381.1995.tb15899.x; Patel MB, 2002, MOL PHARMACOL, V62, P1464, DOI 10.1124/mol.62.6.1464; Pawar M, 2007, EUR J PHARMACOL, V563, P92, DOI 10.1016/j.ejphar.2007.01.059; Peckham EM, 2006, J PHARMACOL EXP THER, V316, P1195, DOI 10.1124/jpet.105.094276; Schulz S, 2004, EMBO J, V23, P3282, DOI 10.1038/sj.emboj.7600334; Stafford K, 2001, PHARMACOL BIOCHEM BE, V69, P233, DOI 10.1016/S0091-3057(01)00525-1; von Zastrow M, 2004, NEUROPHARMACOLOGY, V47, P286, DOI 10.1016/j.neuropharm.2004.05.007; Walker EA, 2001, PSYCHOPHARMACOLOGY, V154, P131, DOI 10.1007/s002130000620; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Williams JT, 2001, PHYSIOL REV, V81, P299; WILLIAMS JT, 1984, NEUROSCIENCE, V13, P137, DOI 10.1016/0306-4522(84)90265-3; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1997, RECEPTOR CHANNEL, V5, P193	34	36	38	0	3	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0026-895X			MOL PHARMACOL	Mol. Pharmacol.	APR	2008	73	4					1301	1308		10.1124/mol.107.042952			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	275IK	WOS:000254064900028	18198283	Green Accepted			2020-06-26	J	Khoronenkova, SV; Tishkov, VI				Khoronenkova, Svetlana V.; Tishkov, Vladimir I.			High-throughput screening assay for D-amino acid oxidase	ANALYTICAL BIOCHEMISTRY			English	Article						D-amino acid oxidase; high-throughput screening; peroxidase reaction; membrane; recombinant Escherichia coli cells; mutant library	TRIGONOPSIS-VARIABILIS; DIRECTED EVOLUTION; HYDROGEN-PEROXIDE; CEPHALOSPORIN-C; ENZYME; SCHIZOPHRENIA; SELECTIVITY; METHIONINE; CONVERSION; GENES	A membrane-based high-throughput screening (HTS) assay for active D-amino acid oxidase (DAAO) in liquid samples as well as in intact Escherichia coli cells has been developed and optimized. The detection limit of the assay was less than 1 ng per sample. The method proposed can be used for quantitative DAAO determination in the range of 0.13 to 3.60 ng enzyme per probe. The protocol was successfully tested to screen a library of E coli clones containing mutant DAAOs active toward target substrates. (C) 2007 Elsevier Inc. All rights reserved.	[Khoronenkova, Svetlana V.; Tishkov, Vladimir I.] Moscow MV Lomonosov State Univ, Dept Chem Enzymol, Moscow 119992, Russia; [Khoronenkova, Svetlana V.] Innovat & High Technol MSU Ltd, Moscow 109551, Russia	Tishkov, VI (reprint author), Moscow MV Lomonosov State Univ, Dept Chem Enzymol, Moscow 119992, Russia.	vit@enz.chem.nisu.ru	Khoronenkova, Svetlana V/B-1378-2014; Tishkov, Vladimir I/J-6769-2012	Khoronenkova, Svetlana V/0000-0002-7439-9320; Tishkov, Vladimir I/0000-0002-6997-7229			Beard TM, 2002, CHEM COMMUN, P246, DOI 10.1039/b107580m; Cloninger CR, 2002, P NATL ACAD SCI USA, V99, P13365, DOI 10.1073/pnas.222532599; COHEN HJ, 1973, ANAL BIOCHEM, V53, P208, DOI 10.1016/0003-2697(73)90423-5; CONLON HD, 1995, BIOTECHNOL BIOENG, V46, P510, DOI 10.1002/bit.260460603; Davydova E. E, 2002, MOSC U CHEM B, V43, P353; Dominguez R, 2001, ANAL BIOCHEM, V298, P275, DOI 10.1006/abio.2001.5371; Gabler M, 2000, ENZYME MICROB TECH, V27, P605, DOI 10.1016/S0141-0229(00)00262-3; Harrison PJ, 2003, LANCET, V361, P417, DOI 10.1016/S0140-6736(03)12379-3; Inaba Y, 2003, BIOSENS BIOELECTRON, V19, P423, DOI 10.1016/S0956-5663(03)00200-8; Ju SS, 2000, FEMS MICROBIOL LETT, V186, P215, DOI 10.1016/S0378-1097(00)00151-8; Kawazoe T, 2007, BIOCHEM BIOPH RES CO, V355, P385, DOI 10.1016/j.bbrc.2007.01.181; Kuchner O, 1997, TRENDS BIOTECHNOL, V15, P523, DOI 10.1016/S0167-7799(97)01138-4; LARUE TA, 1967, CAN J MICROBIOL, V13, P777, DOI 10.1139/m67-103; MAN EH, 1987, J NEUROCHEM, V48, P510, DOI 10.1111/j.1471-4159.1987.tb04122.x; NAKAJIMA N, 1990, J FERMENT BIOENG, V70, P322, DOI 10.1016/0922-338X(90)90142-J; OHTANI S, 1995, GROWTH DEVELOP AGING, V59, P55; Pilone MS, 2000, CELL MOL LIFE SCI, V57, P1732, DOI 10.1007/PL00000655; Pollegioni L, 2007, CELL MOL LIFE SCI, V64, P1373, DOI 10.1007/s00018-007-6558-4; Sacchi S, 2004, PROTEIN ENG DES SEL, V17, P517, DOI 10.1093/protein/gzh064; Savin S. S., 2006, MOSC U CHEM B, V47, P25; SZWAJCER E, 1985, BIOTECHNOL LETT, V7, P1, DOI 10.1007/BF01032410; [Тишков В.И. Tishkov V.I.], 2005, [Биохимия, BIOCHEMISTRY (MOSCOW), Biokhimiya], V70, P51; Yue WH, 2007, NEUROSCI LETT, V416, P96, DOI 10.1016/j.neulet.2007.01.056	23	9	10	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0003-2697	1096-0309		ANAL BIOCHEM	Anal. Biochem.	MAR 15	2008	374	2					405	410		10.1016/j.ab.2007.12.021			6	Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	265EM	WOS:000253341900022	18191464				2020-06-26	J	Korzh, A; Keren, O; Gafni, M; Bar-Josef, H; Sarne, Y				Korzh, Alexander; Keren, Ora; Gafni, Mikhal; Bar-Josef, Hilla; Sarne, Yosef			Modulation of extracellular signal-regulated kinase (ERK) by opioid and cannabinoid receptors that are expressed in the same cell	BRAIN RESEARCH			English	Article						opioid; cannabinoid; extracellular signal-regulated kinase; vascular endothelial growth; factor receptors; receptor tyrosine kinase	ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; N18TG2 NEUROBLASTOMA-CELLS; DOWN-REGULATION; CB1; PATHWAY; PHOSPHORYLATION; MORPHINE; DELTA(9)-TETRAHYDROCANNABINOL; MECHANISMS	In the present study we investigated the signal transduction pathways leading to the activation of extracellular signal-regulated kinase (ERK) by opioid or cannabinoid drugs, when their receptors are coexpressed in the same cell-type. In N18TG2 neuroblastoma cells, the opioid agonist etorphine and the cannabinoid agonist CP-55940 induced the phosphorylation of ERK by a similar mechanism that involved activation of delta-opioid receptors or CB1 cannabinoid receptors coupled to Gi/Go proteins, matrix metalloproteases, vascular endothelial growth factor (VEGF) receptors and MAPK/ERK kinase (MEK). In HEK-293 cells, these two drugs induced the phosphorylation of ERK by separate mechanisms. While CP-55940 activated ERK by transactivation of VEGFRs, similar to its effect in N18TG2 cells, the opioid agonist etorphine activated ERK by a mechanism that did not involve transactivation of a receptor tyrosine kinase. Interestingly, the activation of ERK by etorphine was resistant to the inhibition of MEK, suggesting the possible existence of a novel, undescribed yet mechanism for the activation of ERK by opioids. This mechanism was found to be specific to etorphine, as activation of ERK by the mu-opioid receptor (MOR) agonist DAMGO ([D-Ala(2), N-Me-Phe(4), Gly(5)-ol] enkephalin) was mediated by MEK in these cells, suggesting that etorphine and DAMGO activate distinct, ligand-specific, conformations of MOR. The characterization of cannabinoid- and opioid-induced ERK activation in these two cell-lines enables future studies into possible interactions between these two groups of drugs at the level of MAPK signaling. (c) 2007 Elsevier B.V. All rights reserved.	[Korzh, Alexander; Keren, Ora; Gafni, Mikhal; Bar-Josef, Hilla; Sarne, Yosef] Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, Mauerberger Chair Neuropharmacol, IL-69978 Tel Aviv, Israel	Sarne, Y (reprint author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, Mauerberger Chair Neuropharmacol, IL-69978 Tel Aviv, Israel.	sarney@post.tau.ac.il					ABOOD ME, 1994, J NEUROSCI RES, V37, P714, DOI 10.1002/jnr.490370605; Abood ME, 1997, BIOCHEM PHARMACOL, V53, P207, DOI 10.1016/S0006-2952(96)00727-7; Ai WD, 1999, FEBS LETT, V456, P196, DOI 10.1016/S0014-5793(99)00949-7; Belcheva MM, 2002, J PHARMACOL EXP THER, V303, P909, DOI 10.1124/jpet.102.038554; Belcheva MM, 2001, J BIOL CHEM, V276, P33847, DOI 10.1074/jbc.M101535200; Belcheva MM, 2003, MOL PHARMACOL, V64, P1391, DOI 10.1124/mol.64.6.1391; Belcheva MM, 2002, NEUROSIGNALS, V11, P34, DOI 10.1159/000057320; Berg KA, 1998, MOL PHARMACOL, V54, P94; CAUNT CJ, 2006, TRENDS ENDOCRIN MET, V371, P1; Cerioni L, 2003, FEBS LETT, V547, P92, DOI 10.1016/S0014-5793(03)00675-6; Chen C, 2006, CURR NEUROVASC RES, V3, P171, DOI 10.2174/156720206778018767; CHILDERS SR, 1991, LIFE SCI, V48, P1991, DOI 10.1016/0024-3205(91)90154-4; Cichewicz DL, 1999, J PHARMACOL EXP THER, V289, P859; Davis MI, 2003, J BIOL CHEM, V278, P48973, DOI 10.1074/jbc.M305697200; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Derkinderen P, 2003, J NEUROSCI, V23, P2371; Di Toro R, 1998, LIFE SCI, V63, pPL197, DOI 10.1016/S0024-3205(98)00390-7; Eisinger DA, 2004, J PHARMACOL EXP THER, V309, P776, DOI 10.1124/jpet.103.061788; Eitan S, 2003, J NEUROSCI, V23, P8360; Galve-Roperh I, 2002, MOL PHARMACOL, V62, P1385, DOI 10.1124/mol.62.6.1385; Gavi S, 2006, TRENDS ENDOCRIN MET, V17, P46, DOI 10.1016/j.tem.2006.01.006; Gesty-Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200; Guzman M, 2001, J MOL MED-JMM, V78, P613, DOI 10.1007/s001090000177; HOWLETT AC, 1995, CANNABINOID RECEPTOR, P169; Johnson EA, 2006, MOL PHARMACOL, V70, P676, DOI 10.1124/mol.106.022376; Kenakin T, 2003, TRENDS PHARMACOL SCI, V24, P346, DOI 10.1016/S0165-6147(03)00167-6; Kramer H Kenneth, 2002, BMC Pharmacol, V2, P5, DOI 10.1186/1471-2210-2-5; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Lefkowitz RJ, 2002, MOL PHARMACOL, V62, P971, DOI 10.1124/mol.62.5.971; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Liu QR, 2002, J BIOL CHEM, V277, P13312, DOI 10.1074/jbc.M107558200; LOH HH, 1990, ANNU REV PHARMACOL, V30, P123; Mao LM, 2005, J BIOL CHEM, V280, P12602, DOI 10.1074/jbc.M411709200; McLaughlin JP, 2001, MOL PHARMACOL, V59, P1360; Persson AI, 2003, MOL CELL NEUROSCI, V23, P360, DOI 10.1016/S1044-7431(03)00061-7; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Pickel VM, 2004, NEUROSCIENCE, V127, P101, DOI 10.1016/j.neuroscience.2004.05.015; Reche I, 1996, EUR J PHARMACOL, V301, P75, DOI 10.1016/0014-2999(96)00045-3; Reche I, 1996, EUR J PHARMACOL, V312, P391, DOI 10.1016/0014-2999(96)00538-9; Reisine Terry, 1994, Current Opinion in Neurobiology, V4, P406, DOI 10.1016/0959-4388(94)90103-1; Reiter E, 2006, TRENDS ENDOCRIN MET, V17, P159, DOI 10.1016/j.tem.2006.03.008; Rios C, 2006, BRIT J PHARMACOL, V148, P387, DOI 10.1038/sj.bjp.0706757; Rodriguez JJ, 2001, J NEUROSCI, V21, P823; Rubino T, 2005, J NEUROCHEM, V93, P984, DOI 10.1111/j.1471-4159.2005.03101.x; Rubino T, 2004, MOL CELL NEUROSCI, V25, P355, DOI 10.1016/j.mcn.2003.11.003; Rubovitch V, 2004, MOL BRAIN RES, V120, P138, DOI 10.1016/j.molbrainres.2003.10.012; Salio C, 2001, NEUROREPORT, V12, P3689, DOI 10.1097/00001756-200112040-00017; Sanchez MG, 2003, CELL SIGNAL, V15, P851, DOI 10.1016/S0898-6568(03)00036-6; Schmidt H, 2000, J NEUROCHEM, V74, P414, DOI 10.1046/j.1471-4159.2000.0740414.x; Shahabi NA, 1999, J NEUROIMMUNOL, V94, P48, DOI 10.1016/S0165-5728(98)00211-2; Shapira M, 2003, BRAIN RES, V960, P190, DOI 10.1016/S0006-8993(02)03842-8; Shapira M, 2001, MOL BRAIN RES, V96, P142, DOI 10.1016/S0169-328X(01)00283-2; Shapira M, 1998, BRAIN RES, V806, P26, DOI 10.1016/S0006-8993(98)00697-0; Singleton PA, 2006, MICROVASC RES, V72, P3, DOI 10.1016/j.mvr.2006.04.004; Smith FL, 1998, PHARMACOL BIOCHEM BE, V60, P559, DOI 10.1016/S0091-3057(98)00012-4; SOOD PP, 1985, CELL MOL BIOL, V31, P469; Tegeder I, 2004, PHARMACOL REV, V56, P351, DOI 10.1124/pr.56.3.2; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; Vigano D, 2005, PHARMACOL BIOCHEM BE, V81, P360, DOI 10.1016/j.pbb.2005.01.021; WELCH SP, 1994, PHARMACOL BIOCHEM BE, V49, P929, DOI 10.1016/0091-3057(94)90245-3	60	21	22	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 16	2008	1189						23	32		10.1016/j.brainres.2007.10.070			10	Neurosciences	Neurosciences & Neurology	264MN	WOS:000253291800003	18068691				2020-06-26	J	Huang, P; Xu, W; Yoon, SI; Chen, CG; Chong, PLG; Unterwald, EM; Liu-Chen, LY				Huang, Peng; Xu, Wei; Yoon, Su-In; Chen, Chongguang; Chong, Parkson Lee-Gau; Unterwald, Ellen M.; Liu-Chen, Lee-Yuan			Agonist treatment did not affect association of mu opioid receptors with lipid rafts and cholesterol reduction had opposite effects on the receptor-mediated signaling in rat brain and CHO cells	BRAIN RESEARCH			English	Article						mu opioid receptor; lipid rafts; brain; cholesterol; morphine; methyl-beta-cyclodextrin	PROTEIN-COUPLED RECEPTOR; GPI-ANCHORED PROTEINS; ADENYLYL-CYCLASE; MOLECULAR-MECHANISMS; CARDIAC MYOCYTES; CAVEOLAE; MICRODOMAINS; MEMBRANES; LOCALIZATION; BINDING	Lipid rafts are small cholesterol- and glycosphingolipid-enriched membrane subdomains. Here we compared the mu opioid receptor (MOR)-lipid rafts relationship in the rat brain, where neurons have non-caveolae rafts, and in CHO cells stably transfected with HA-rat MOR (CHO-HA-rMOR), which are enriched in caveolae. Membranes of rat caudate putamen (CPu) and thalamus or CHO-HA-rMOR cells were homogenized, sonicated in a detergent-free 0.5 M Na2CO3 buffer and fractionated through sucrose density gradients. Western blot and [H-3]diprenorphine binding showed that similar to 70% of MOR in CHO-HA-rMOR was present in low-density (5-20% sucrose) fractions enriched in cholesterol and/or ganglioside M1 (GM1) (lipid rafts) in plasma membranes, whereas about 70% and 45% of MOR in CPu and thalamus, respectively, were associated with lipid rafts. Incubation with a saturating concentration of etorphine or morphine at 37 degrees C for 30 min failed to change the MOR location in rafts in CHO-HA-rMOR, indicating that the internalized MOR does not move out of rafts, in contrast to the delta opioid receptor. in vivo, rafts association of MOR in CPu and thalamus was not affected significantly in rats implanted with two 75-mg morphine pellets for 72 h. In addition, cholesterol reduction by methyl-beta-cyclodextrin (MCD) disrupted rafts and shifted MOR to higher density fractions in both CHO-HA-rMOR and CPu membranes. However, MCD treatment had opposite impacts on MOR signaling in the two tissues: it attenuated MOR-mediated [S-35]GTP gamma S binding in CPu but enhanced it in CHO-HA-rMOR. (C) 2007 Elsevier B.V. All rights reserved.	[Huang, Peng; Xu, Wei; Chen, Chongguang; Unterwald, Ellen M.; Liu-Chen, Lee-Yuan] Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; [Yoon, Su-In; Chong, Parkson Lee-Gau] Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; [Huang, Peng; Xu, Wei; Yoon, Su-In; Chen, Chongguang; Chong, Parkson Lee-Gau; Unterwald, Ellen M.; Liu-Chen, Lee-Yuan] Temple Univ, Sch Med, Ctr Subst Abuse Res, Philadelphia, PA 19140 USA	Liu-Chen, LY (reprint author), Temple Univ, Sch Med, Dept Pharmacol, 3420 N Broad St, Philadelphia, PA 19140 USA.	lliuche@temple.edu	Chong, Parkson Lee-gau/I-3297-2019		NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA04745, P30 DA013429, R01 DA004745, R01 DA017302, DA17302]		BELL J, 1988, DRUG ALCOHOL DEPEN, V21, P189, DOI 10.1016/0376-8716(88)90069-5; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cameron PL, 1997, J NEUROSCI, V17, P9520; Chini B, 2004, J MOL ENDOCRINOL, V32, P325, DOI 10.1677/jme.0.0320325; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Cohen AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physrev.00046.2003; Head BP, 2005, J BIOL CHEM, V280, P31036, DOI 10.1074/jbc.M502540200; Huang P, 2001, J PHARMACOL EXP THER, V297, P688; Huang P, 2001, BIOCHEMISTRY-US, V40, P13501, DOI 10.1021/bi010917q; Huang P, 2007, BIOCHEM PHARMACOL, V73, P534, DOI 10.1016/j.bcp.2006.10.032; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Li J, 2001, MOL PHARMACOL, V60, P1064; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Macdonald JL, 2005, J LIPID RES, V46, P1061, DOI 10.1194/jlr.D400041-JLR200; Maher CE, 2000, BIOCHEM PHARMACOL, V59, P1395, DOI 10.1016/S0006-2952(00)00272-0; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Navratil AM, 2003, J BIOL CHEM, V278, P31593, DOI 10.1074/jbc.M304273200; Nicolau DV, 2006, MOL CELL BIOL, V26, P313, DOI 10.1128/MCB.26.1.313-323.2006; Noble F, 1996, BRIT J PHARMACOL, V117, P161, DOI 10.1111/j.1476-5381.1996.tb15169.x; Ostrom RS, 2004, BRIT J PHARMACOL, V143, P235, DOI 10.1038/sj.bjp.0705930; Parton RG, 2003, NAT REV MOL CELL BIO, V4, P162, DOI 10.1038/nrm1017; PASTERNAK GW, 1988, [No title captured]; Patel HH, 2006, AM J PHYSIOL-HEART C, V291, pH344, DOI 10.1152/ajpheart.01100.2005; Pike LJ, 2006, J LIPID RES, V47, P1597, DOI 10.1194/jlr.E600002-JLR200; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9; Shaw AS, 2006, NAT IMMUNOL, V7, P1139, DOI 10.1038/ni1405; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; Wang H, 2003, J COMP NEUROL, V467, P343, DOI 10.1002/cne.10920; WHALEY BS, 1994, MOL PHARMACOL, V45, P481; Xu W, 2006, J PHARMACOL EXP THER, V317, P1295, DOI 10.1124/jpet.105.099507; Zhao H, 2006, MOL PHARMACOL, V69, P1421, DOI 10.1124/mol.105.020024; Zhu JM, 1997, J PHARMACOL EXP THER, V282, P676	38	32	32	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 12	2007	1184						46	56		10.1016/j.brainres.2007.09.096			11	Neurosciences	Neurosciences & Neurology	247RF	WOS:000252096600006	17980352	Green Accepted			2020-06-26	J	Wenger, S; Boardman, W; Buss, P; Govender, D; Foggin, C				Wenger, Sandra; Boardman, Wayne; Buss, Peter; Govender, Danny; Foggin, Chris			The cardiopulmonary effects of etorphine, azaperone, detomidine, and butorphanol in field-anesthetized white rhinoceroses (Ceratotherium simum)	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Review						ceratotherium simum; rhinoceros; anesthesia; hypoxemia; butorphanol; etorphine	CHEMICAL IMMOBILIZATION; DICEROS-BICORNIS; ANESTHESIA; FENTANYL; M99; COMBINATIONS; RECUMBENCY; REVERSAL; CAPTURE; POSTURE	White rhinoceroses (Ceratotherium simum) anesthetized with etorphine combinations develop severe pathophysiologic changes, including hypoventilation, hypoxemia and metabolic acidosis. The aim of this study was to evaluate the addition of butorphanol to the immobilizing mixture on the cardiopulmonary effects in free-ranging white rhinoceroses darted from the helicopter. In the control group (n = 15), the rhinoceroses were anesthetized with etorphine, azaperone, detomidine, and hyaluronidase administered intramuscularly. In the treatment group (n = 16), 10-20 mg of butorphanol was added to the combination. Within 10 min of becoming immobile, vital parameters (heart rate, respiratory rate, and temperature) and blood gas analyses were taken, and measurements were repeated after 10 (treatment group) and 20 min (control group). Both groups showed respiratory and metabolic acidosis, hypoxemia, and hypercapnia. In the control group, the arterial partial pressure of oxygen was significantly higher and the alveolar-to-arterial oxygen pressure gradients were significantly lower in all body positions compared with the butorphanol group. Oxygen hemoglobin saturation in the control group was higher than in the butorphanol group only in the lateral position. Improvements in arterial oxygen levels were observed in all animals when placed in sternal recumbency. There were no significant differences in the mean induction times between groups, but the distance the butorphanol group ran was significantly less after darting than in the control group. By adding butorphanol to the immobilizing mixture, no benefits in ventilation were seen; although, size differences make comparisons difficult. Running for a shorter distance during induction could be beneficial in the prevention of severe acid-base imbalances and capture myopathy.	Univ London Royal Vet Coll, London NW1 9LT, England; Zool Soc London, Dept Vet, London NW1 4RY, England; Kruger Natl Pk, Vet Wildlife Serv, S African Natl Parks, ZA-1350 Skukuza, South Africa; Wildlife Vet Unit, Harare, Zimbabwe	Wenger, S (reprint author), Univ London Royal Vet Coll, Royal Coll St, London NW1 9LT, England.	sasywenger@gmx.net	Boardman, Wayne S.J/J-6479-2013	Boardman, Wayne/0000-0002-1746-0682			BAUMANN R, 1984, RESP PHYSIOL, V56, P1, DOI 10.1016/0034-5687(84)90124-5; Branson K. R., 2001, Veterinary pharmacology and therapeutics, P268; Bush M, 2004, J S AFR VET ASSOC, V75, P79; Carlson GP, 2002, LARGE ANIMAL INTERNA, P389; CORNICKSEAHORN JL, 1995, J AM VET MED ASSOC, V206, P508; England GCW, 1996, BRIT VET J, V152, P641, DOI 10.1016/S0007-1935(96)80118-7; GLEED RD, 1988, RES VET SCI, V44, P255, DOI 10.1016/S0034-5288(18)30851-8; Hall L W, 1971, Equine Vet J, V3, P95; HARTHOORN AM, 1965, RES VET SCI, V6, P290; HATTINGH J, 1994, S AFR J WILDL RES, V24, P12; HEARD DJ, 1992, J ZOO WILDLIFE MED, V23, P197; HU C, 1992, LAB ANIM-UK, V26, P15, DOI 10.1258/002367792780809075; JAFFE RS, 1988, ANESTHESIOLOGY, V68, P254, DOI 10.1097/00000542-198802000-00012; Kastner SBR, 2006, VET ANAESTH ANALG, V33, P79, DOI 10.1111/j.1467-2995.2005.00243.x; Kock MD, 1995, J ZOO WILDLIFE MED, V26, P207; KOCK MD, 1992, J ZOO WILDLIFE MED, V23, P181; KOCK MD, 1990, J ZOO WILDLIFE MED, V21, P155; KOCK MD, 1990, J ZOO WILDLIFE MED, V21, P414; KREEHER TJ, 1996, [No title captured]; MARTIN L, 1999, ALL YOU REALLY NEED, P65; MCCRACKIN MA, 1994, VET SURG, V23, P67, DOI 10.1111/j.1532-950X.1994.tb00447.x; Miller E.R., 2003, ZOO WILD ANIMAL MED, P558; NIELSEN L, 1999, CHEM IMMOBILIZATION, P200; NYMAN G, 1989, EQUINE VET J, V21, P274, DOI 10.1111/j.2042-3306.1989.tb02167.x; PIRCIO AW, 1976, ARCH INT PHARMACOD T, V220, P231; Portas T, 2004, AUST VET J, V82, P542, DOI 10.1111/j.1751-0813.2004.tb11196.x; Prado ME, 1999, AM J VET RES, V60, P1242; RAATH JP, 1999, ZOO WILDLIFE MED CUR, V4, P556; Radcliffe RW, 2000, J ZOO WILDLIFE MED, V31, P196, DOI 10.1638/1042-7260(2000)031[0196:BAAAAS]2.0.CO;2; Spraker Terry R., 1993, P481; STEFFEY EP, 1990, AM J VET RES, V51, P11; STEGMANN GF, 1987, J S AFR VET ASSOC, V58, P21; Swan GE, 1993, CAPTURE CARE MANUAL, P17; Thurmon JC, 1996, LUMB JONES VET ANEST, P183; WALZER C, 2001, RES UPDATE ELEPHANTS, P237; West JB, 2000, RESP PHYSL ESSENTIAL, P45; Williams Elizabeth S., 1996, P181	37	26	26	0	29	AMER ASSOC ZOO VETERINARIANS	YULEE	581705 WHITE OAK ROAD, YULEE, FL 32097 USA	1042-7260	1937-2825		J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	SEP	2007	38	3					380	387		10.1638/2006-0038R.1			8	Veterinary Sciences	Veterinary Sciences	210LC	WOS:000249456700002	17939346				2020-06-26	J	Pawar, M; Kumar, P; Sunkaraneni, S; Sirohi, S; Walker, EA; Yoburn, BC				Pawar, Mohit; Kumar, Priyank; Sunkaraneni, Soujanya; Sirohi, Sunil; Walker, Ellen A.; Yoburn, Byron C.			Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						etorphine; oxycodone; morphine; clocinnamox; efficacy; tolerance; analgesia	PROTEIN-COUPLED RECEPTORS; SWISS WEBSTER MICE; MOUSE SPINAL-CORD; IN-VIVO; ANTAGONIST TREATMENT; BETA-FUNALTREXAMINE; PHARMACOLOGICAL AGONISM; CONTINUOUS INFUSION; ANALGESIC ACTIVITY; OPERATIONAL MODEL	It has been proposed that opioid agonist efficacy may play a role in tolerance and the regulation of opioid receptor density. To address this issue, the present studies estimated the in vivo efficacy of three opioid agonists and then examined changes in spinal mu-opioid receptor density following chronic treatment in the mouse. In addition, tolerance and regulation of the trafficking protein dynamin-2 were determined. To evaluate efficacy, the method of irreversible receptor atkylation was employed and the efficacy parameter T estimated. Mice were injected with the irreversible mu-opioid. receptor antagonist clocinnamox. (0.32-25.6 mg/kg, i.p), and 24 h later, the analgesic potency of s.c. morphine, oxycodone and etorphine were determined. Clocinnamox dose-dependently antagonized the analgesic effects of morphine, etorphine and oxycodone. The shift to the right of he dose-response curves was greater for morphine and oxycodone compared to etorphine and the highest dose of clocinnamox reduced the maximal effect of morphine and oxycodone, but not etorphine. The order of efficacy calculated from these results was etorphine >morphine> oxycodone. Other mice were infused for 7 days with oxycodone (10-150 mg/kg/day, s.c.) or etorphine (50-250 mu g/kg/day, s.c.) and-the analgesic potency of s.c.. morphine determined. The low efficacy agonist (oxycodone) produced more tolerance than the high efficacy agonist (etorphine) at equi-effective infusion doses. In saturation binding experiments, the low efficacy opioid agonists (morphine, oxycodone) did not regulate the density of spinal g-opioid receptors, while etorphine produced approximate to 40% reduction in mu-opioid receptor density. Furthermore, etorphine increased spinal dynamin-2 abundance, while oxycodone did not produce any significant change in dynamin-2 abundance. Overall, these data indicate that high efficacy,agonists produce less tolerance at equi-effective doses. Furthermore, increased efficacy was associated with g-opioid receptor downregulation and, dynamin-2 upregulation. Conversely, lower efficacy agonists produced more tolerance at equi-effective doses, but did not regulate mu-opioid receptor density or dynamin-2 abundance. Taken together, these studies indicate that agonist efficacy plays an important role in tolerance and regulation of receptors and trafficking proteins. (c) 2007 Elsevier B.V. All rights reserved.	St Johns Univ, Coll Pharm & Allied Hlth Profess, Dept Pharmaceut Sci, Jamaica, NY 11439 USA; Temple Univ, Dept Pharmaceut Sci, Sch Pharm, Philadelphia, PA 19140 USA	Yoburn, BC (reprint author), St Johns Univ, Coll Pharm & Allied Hlth Profess, Dept Pharmaceut Sci, 8000 Utopia Pkwy, Jamaica, NY 11439 USA.	Yoburnb@stjohns.edu	SIROHI, SUNIL/E-1891-2012	SIROHI, SUNIL/0000-0001-7246-9295; Kumar, Priyank/0000-0002-4772-2073	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA019959-01A1, R01 DA019959]		Aceto MD, 1997, EUR J PHARMACOL, V338, P215, DOI 10.1016/S0014-2999(97)81924-3; ADAMS JU, 1990, J PHARMACOL EXP THER, V255, P1027; Ananthan S, 2006, AAPS J, V8, pE118, DOI 10.1208/aapsj080114; Barrett AC, 2003, J PHARMACOL EXP THER, V305, P1061, DOI 10.1124/jpet.102.047068; BLACK JW, 1983, PROC R SOC SER B-BIO, V220, P141, DOI 10.1098/rspb.1983.0093; BLACK JW, 1985, BRIT J PHARMACOL, V84, P561, DOI 10.1111/j.1476-5381.1985.tb12941.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKE TF, 1994, J PHARMACOL EXP THER, V271, P715; Chan K, 1995, EUR J PHARMACOL, V287, P135, DOI 10.1016/0014-2999(95)00488-2; COMER SD, 1992, J PHARMACOL EXP THER, V262, P1051; Duttaroy A, 1999, LIFE SCI, V65, P113, DOI 10.1016/S0024-3205(99)00228-3; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; Duttaroy A, 2000, SYNAPSE, V37, P118, DOI 10.1002/1098-2396(200008)37:2<118::AID-SYN6>3.0.CO;2-2; Finney DJ, 1973, PROBIT ANAL; Furchgott R.F., 1966, ADV DRUG RES, P21; HEBERSTOCKDEBIC H, 2005, J NEUROSCI, V25, P7847; Keith DE, 1998, MOL PHARMACOL, V53, P377; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kenakin T, 2002, ANNU REV PHARMACOL, V42, P349, DOI 10.1146/annurev.pharmtox.42.091401.113012; Kenakin T, 2004, TRENDS PHARMACOL SCI, V25, P186, DOI 10.1016/j.tips.2004.02.012; Kenakin T, 2002, NAT REV DRUG DISCOV, V1, P103, DOI 10.1038/nrd722; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; Lalovic B, 2006, CLIN PHARMACOL THER, V79, P461, DOI 10.1016/j.clpt.2006.01.009; LEFF P, 1990, J PHARMACOL METHOD, V23, P225, DOI 10.1016/0160-5402(90)90066-T; MOTULSKY HJ, 2004, [No title captured]; Nozaki C, 2006, EUR J PHARMACOL, V535, P145, DOI 10.1016/j.ejphar.2006.02.002; PARONIS CA, 1991, J PHARMACOL EXP THER, V259, P582; PARONIS CA, 1992, J PHARMACOL EXP THER, V262, P1; Paronis CA, 1997, EUR J PHARMACOL, V337, P27, DOI 10.1016/S0014-2999(97)01296-X; Patel M, 2002, EUR J PHARMACOL, V446, P37, DOI 10.1016/S0014-2999(02)01823-X; Patel MB, 2002, MOL PHARMACOL, V62, P1464, DOI 10.1124/mol.62.6.1464; Rajashekara V, 2003, PHARMACOL BIOCHEM BE, V75, P909, DOI 10.1016/S0091-3057(03)00166-7; Ross FB, 1997, PAIN, V73, P151, DOI 10.1016/S0304-3959(97)00093-6; Sehba F, 1997, EUR J PHARMACOL, V339, P33, DOI 10.1016/S0014-2999(97)01360-5; Stafford K, 2001, PHARMACOL BIOCHEM BE, V69, P233, DOI 10.1016/S0091-3057(01)00525-1; STEVENS CW, 1989, J PHARMACOL EXP THER, V250, P1; TEMPEL A, 1982, LIFE SCI, V31, P1401, DOI 10.1016/0024-3205(82)90391-5; UNTERWALD EM, 1995, MOL BRAIN RES, V33, P351, DOI 10.1016/0169-328X(95)00143-G; Walker EA, 1998, PSYCHOPHARMACOLOGY, V136, P15; Walker EA, 2001, PSYCHOPHARMACOLOGY, V154, P131, DOI 10.1007/s002130000620; YOBURN B C, 1988, Reviews in Clinical and Basic Pharmacology, V7, P109; YOBURN BC, 1995, PHARMACOL BIOCHEM BE, V51, P535, DOI 10.1016/0091-3057(94)00375-S; Yoburn BC, 2004, EUR J PHARMACOL, V498, P87, DOI 10.1016/j.ejphar.2004.07.052; YOBURN BC, 1993, J PHARMACOL EXP THER, V265, P314; Zernig G, 1996, J PHARMACOL TOXICOL, V35, P223, DOI 10.1016/1056-8719(96)00053-6; ZERNIG G, 1995, LIFE SCI, V57, P2113, DOI 10.1016/0024-3205(95)02204-V; Zhang QY, 2005, SYNAPSE, V56, P123, DOI 10.1002/syn.20137; Zhang X, 2006, TRENDS PHARMACOL SCI, V27, P324, DOI 10.1016/j.tips.2006.04.005; ZIMMERMAN DM, 1987, J PHARMACOL EXP THER, V241, P374	50	44	45	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	JUN 1	2007	563	1-3					92	101		10.1016/j.ejphar.2007.01.059			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	169RC	WOS:000246608300010	17349996	Green Accepted			2020-06-26	J	Huang, P; Xu, W; Yoon, SI; Chen, CG; Chong, PLG; Liu-Chen, LY				Huang, Peng; Xu, Wei; Yoon, Su-In; Chen, Chongguang; Chong, Parkson Lee-Gau; Liu-Chen, Lee-Yuan			Cholesterol reduction by methyl-beta-cyclodextrin attenuates the delta opioid receptor-mediated signaling in neuronal cells but enhances it in non-neuronal cells	BIOCHEMICAL PHARMACOLOGY			English	Article						lipid rafts; opioid receptors; cholesterol; methyl-beta-cyclodextrin; caveolin; brain; neuron	PROTEIN-COUPLED RECEPTOR; AGONIST-SPECIFIC REGULATION; LIPID RAFTS; PLASMA-MEMBRANE; ADENYLYL-CYCLASE; CARDIAC MYOCYTES; MICE DEFICIENT; KNOCKOUT MICE; RAT STRIATUM; CAVEOLAE	Opioid receptors have been shown to be located in and regulated by lipid rafts/caveolae in caveolin-rich non-neuronal cells. Here, we found that caveolin-1 level was very low in rat brain and undetectable in NG108-15 cells, which endogenously express delta opioid receptors (DOR). Rat caudate putamen (CPu) membranes, NG108-15 cells and CHO cells stably transfected with FLAG-mouse-DOR (CHO-FLAG-mDOR) were homogenized, sonicated in a detergent-free 0.5 M Na2CO3 buffer and fractionated through discontinuous or continuous sucrose density gradients. About 70% of opioid receptors in CPu and DOR in both cell lines were present in low-density (5-20% sucrose) membrane domains enriched in cholesterol and ganglioside M1 (GM1), characteristics of lipid rafts in plasma membranes. In both cells, stimulation with permeable or non-permeable full agonists, but not with partial or inverse agonists, for 30 min shifted similar to 25% of DORs out of rafts, by a naloxone-reversible and pertussis toxin-insensitive mechanism, which may undergo internalization. Methyl-P-cyclodextrin (MCD) treatment greatly reduced cholesterol and shifted DOR to higher density fractions and decreased DPDPE affinities. MCD treatment attenuated DPDPE-induced [S-35] GTR gamma S binding in CPu and NG108-15 cells, but enhanced it in CHO-FLAG-mDOR cells. In CHO-FLAG-mDOR cells, G(alpha i) co-immunoprecipitated with caveolin-1, which was shown to inhibit G(alpha i/o), and MCD treatment dramatically reduced the association leading to disinhibition. Thus, although localization in rafts and agonist-induced shift of DOR are independent of caveolin-1, lipid rafts sustain DOR-mediated signaling in caveolin-deficient neuronal cells, but appear to inhibit it in caveolin- enriched non-neuronal cells. Cholesterol-dependent association of caveolin-1 with and the resulting inhibition of G proteins may be a contributing factor. (c) 2006 Elsevier Inc. All rights reserved.	Temple Univ, Sch Med, Ctr Substance Abuse Res, Dept Pharmacol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Ctr Substance Abuse Res, Dept Biochem, Philadelphia, PA 19140 USA	Liu-Chen, LY (reprint author), Temple Univ, Sch Med, Ctr Substance Abuse Res, Dept Pharmacol, 3420 N Broad St, Philadelphia, PA 19140 USA.	lliuche@temple.edu	Chong, Parkson Lee-gau/I-3297-2019		NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA017302-03, DA17302, R01 DA004745, DA04745, R01 DA004745-16, R01 DA017302]		Alves ID, 2005, BIOCHEMISTRY-US, V44, P9168, DOI 10.1021/bi050207a; Bari M, 2005, J BIOL CHEM, V280, P12212, DOI 10.1074/jbc.M411642200; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Bell SP, 2000, J AM COLL CARDIOL, V36, P2296, DOI 10.1016/S0735-1097(00)01011-1; Bot G, 1997, MOL PHARMACOL, V52, P272; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cameron PL, 1997, J NEUROSCI, V17, P9520; CHEN CG, 1995, J BIOL CHEM, V270, P17866, DOI 10.1074/jbc.270.30.17866; Chini B, 2004, J MOL ENDOCRINOL, V32, P325, DOI 10.1677/jme.0.0320325; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Cohen AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physrev.00046.2003; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Eisinger DA, 2002, J NEUROSCI, V22, P10192; Elliott MH, 2003, BIOCHEMISTRY-US, V42, P7892, DOI 10.1021/bi027162n; Filliol D, 2000, NAT GENET, V25, P195, DOI 10.1038/76061; Gross GJ, 2003, J MOL CELL CARDIOL, V35, P709, DOI 10.1016/S0022-2828(03)00135-4; HASEGAWA JI, 1987, J NEUROCHEM, V49, P1007, DOI 10.1111/j.1471-4159.1987.tb09987.x; Head BP, 2005, J BIOL CHEM, V280, P31036, DOI 10.1074/jbc.M502540200; Huang P, 2001, J PHARMACOL EXP THER, V297, P688; Igbavboa U, 1997, J NEUROCHEM, V69, P1661; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Kwik J, 2003, P NATL ACAD SCI USA, V100, P13964, DOI 10.1073/pnas.2336102100; Lang DM, 1998, J NEUROBIOL, V37, P502, DOI 10.1002/(SICI)1097-4695(199812)37:4<502::AID-NEU2>3.0.CO;2-S; LAW PY, 1982, MOL PHARMACOL, V21, P492; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Lawrence JC, 2003, BIOPHYS J, V84, P1827, DOI 10.1016/S0006-3495(03)74990-X; Li J, 2001, MOL PHARMACOL, V60, P1064; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Macdonald JL, 2005, J LIPID RES, V46, P1061, DOI 10.1194/jlr.D400041-JLR200; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Murthy KS, 2000, J BIOL CHEM, V275, P30211, DOI 10.1074/jbc.M002194200; Nishimura SY, 2006, BIOPHYS J, V90, P927, DOI 10.1529/biophysj.105.070524; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ostrom RS, 2004, BRIT J PHARMACOL, V143, P235, DOI 10.1038/sj.bjp.0705930; Patel HH, 2006, AM J PHYSIOL-HEART C, V291, pH344, DOI 10.1152/ajpheart.01100.2005; Peart JN, 2005, VASC PHARMACOL, V42, P211, DOI 10.1016/j.vph.2005.02.003; Pike LJ, 2006, J LIPID RES, V47, P1597, DOI 10.1194/jlr.E600002-JLR200; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Rajendran L, 2003, P NATL ACAD SCI USA, V100, P8241, DOI 10.1073/pnas.1331629100; RAO BG, 1984, PROG NEURO-PSYCHOPH, V8, P719, DOI 10.1016/0278-5846(84)90045-9; RAPAKA RS, 1991, PHARM RES-DORDR, V8, P1, DOI 10.1023/A:1015809702296; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Schultz JJ, 1997, J MOL CELL CARDIOL, V29, P2187, DOI 10.1006/jmcc.1997.0454; Schwencke C, 1999, J CELL BIOCHEM, V75, P64, DOI 10.1002/(SICI)1097-4644(19991001)75:1<64::AID-JCB7>3.3.CO;2-C; Shaw AS, 2006, NAT IMMUNOL, V7, P1139, DOI 10.1038/ni1405; Sim LJ, 1996, EUR J PHARMACOL, V307, P97, DOI 10.1016/0014-2999(96)00211-7; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Szekeres PG, 1997, J PHARMACOL EXP THER, V283, P1276; Toselli M, 2001, J PHYSIOL-LONDON, V536, P361, DOI 10.1111/j.1469-7793.2001.0361c.xd; Unterwald EM, 2000, NEUROPHARMACOLOGY, V39, P372, DOI 10.1016/S0028-3908(99)00154-9; Varga EV, 2004, LIFE SCI, V76, P599, DOI 10.1016/j.lfs.2004.07.020; WHALEY BS, 1994, MOL PHARMACOL, V45, P481; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; Xu W, 2006, J PHARMACOL EXP THER, V317, P1295, DOI 10.1124/jpet.105.099507; Zhang J, 1999, J RECEPT SIGNAL TR R, V19, P301, DOI 10.3109/10799899909036653; Zhao H, 2006, MOL PHARMACOL, V69, P1421, DOI 10.1124/mol.105.020024; Zhu JM, 1998, J PHARMACOL EXP THER, V285, P28; Zhu JM, 1997, J PHARMACOL EXP THER, V282, P676; Zhu YX, 1999, NEURON, V24, P243, DOI 10.1016/S0896-6273(00)80836-3	65	65	65	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0006-2952	1873-2968		BIOCHEM PHARMACOL	Biochem. Pharmacol.	FEB 15	2007	73	4					534	549		10.1016/j.bcp.2006.10.032			16	Pharmacology & Pharmacy	Pharmacology & Pharmacy	134BQ	WOS:000244058000008	17141202	Green Accepted			2020-06-26	J	Liao, DZ; Grigoriants, OO; Loh, HH; Law, PY				Liao, Dezhi; Grigoriants, Olga O.; Loh, Horace H.; Law, Ping-Yee			Agonist-dependent postsynaptic effects of opioids on miniature excitatory postsynaptic currents in cultured hippocampal neurons	JOURNAL OF NEUROPHYSIOLOGY			English	Article							DENDRITIC SPINES; AMPA RECEPTOR; POTASSIUM CONDUCTANCE; MOLECULAR-MECHANISMS; MORPHINE-TOLERANCE; RAT HIPPOCAMPUS; SILENT SYNAPSES; DESENSITIZATION; ENDOCYTOSIS; MEMORY	Although chronic treatment with morphine is known to alter the function and morphology of excitatory synapses, the effects of other opioids on these synapses are not clear. Here we report distinct effects of several opioids ( morphine, [D-ala(2), me-phe(4), gly(5)-ol]enkephalin (DAMGO), and etorphine) on miniature excitatory postsynaptic currents (mEPSCs) in cultured hippocampal neurons: 1) chronic treatment with morphine for > 3 days decreased the amplitude, frequency, rise time and decay time of mEPSCs. In contrast, "internalizing" opioids such as etorphine and DAMGO increased the frequency of mEPSCs and had no significant effect on the amplitude and kinetics of mEPSCs. These results demonstrate that different opioids can have distinct effects on the function of excitatory synapses. 2) mu opioid receptor fused with green fluorescence protein (MOR-GFP) is clustered in dendritic spines in most hippocampal neurons but is concentrated in axon-like processes in striatal and corticostriatal nonspiny neurons. It suggests that MORs might mediate pre- or postsynaptic effects depending on cell types. 3) Neurons were cultured from MOR knock-out mice and were exogenously transfected with MOR-GFP. Chronic treatment with morphine suppressed mEPSCs only in neurons that contained postsynaptic MOR-GFP, indicating that opioids can modulate excitatory synaptic transmission postsynaptically. 4) Morphine acutely decreased mEPSC amplitude in neurons expressing exogenous MOR-GFP but had no effect on neurons expressing GFP. It indicates that the low level of endogenous MORs could only allow slow opioid-induced plasticity of excitatory synapses under normal conditions. 5) A theoretical model suggests that morphine might affect the function of spines by decreasing the electrotonic distance from synaptic inputs to the soma.	Univ Minnesota, Basic Res Ctr Mol & Cell Biol & Drug Addict, Dept Neurosci, Minneapolis, MN 55455 USA; Univ Minnesota, Basic Res Ctr Mol & Cell Biol & Drug Addict, Dept Pharmacol, Minneapolis, MN 55455 USA	Liao, DZ (reprint author), Univ Minnesota, Basic Res Ctr Mol & Cell Biol & Drug Addict, Dept Neurosci, 321 Church St SE, Minneapolis, MN 55455 USA.	liaox020@umn.edu		Law, Ping-Yee/0000-0002-5364-1093	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K05 DA 70554, R01 DA016674, R01 DA020582-01A1, DA 016674, K05 DA000513, R01 DA000564, R01 DA020582, DA 000564, DA 011806, DA 007339, R01 DA007339, K05 DA070554, R01 DA 020582, R56 DA000564, K05 DA 000513]		Alvarez VA, 2002, J NEUROSCI, V22, P5769; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; Bailey CP, 2003, J NEUROSCI, V23, P10515; Biala G, 2005, EUR J NEUROSCI, V21, P3089, DOI 10.1111/j.1460-9568.2005.04132.x; Bloodgood BL, 2005, SCIENCE, V310, P866, DOI 10.1126/science.1114816; Brustovetsky N, 2001, J NEUROCHEM, V76, P425, DOI 10.1046/j.1471-4159.2001.00052.x; CARNEVALE NT, 1982, J NEUROPHYSIOL, V47, P606; Celver J, 2004, MOL PHARMACOL, V65, P528, DOI 10.1124/mol.65.3.528; Cox BM, 2005, MOL PHARMACOL, V67, P12, DOI 10.1124/mol.104.008433; Dang VC, 2005, MOL PHARMACOL, V68, P1127, DOI 10.1124/mol.105.013185; Dang VC, 2004, J NEUROSCI, V24, P7699, DOI 10.1523/JNEUROSCI.2499-04.2004; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; Fan GH, 1999, MOL PHARMACOL, V56, P39; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; Jin WZ, 1999, BRAIN RES, V821, P286, DOI 10.1016/S0006-8993(99)01089-6; Johnston D., 1995, FDN CELLULAR NEUROPH, P400; Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kieffer BL, 2002, CELL, V108, P587, DOI 10.1016/S0092-8674(02)00666-9; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Kovoor A, 1998, MOL PHARMACOL, V54, P704; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Liao D, 2005, P NATL ACAD SCI USA, V102, P1725, DOI 10.1073/pnas.0406797102; Liao DH, 1999, NAT NEUROSCI, V2, P37; Liao DZ, 2001, J NEUROSCI, V21, P6008; Lin H, 2004, BIOCHEM BIOPH RES CO, V316, P501, DOI 10.1016/j.bbrc.2004.02.086; Lippman J, 2005, J NEUROBIOL, V64, P47, DOI 10.1002/neu.20149; Loh HH, 1998, MOL BRAIN RES, V54, P321, DOI 10.1016/S0169-328X(97)00353-7; LUO L, 2000, NAT REV NEUROSCI, V1, P73; MADISON DV, 1988, J PHYSIOL-LONDON, V398, P123, DOI 10.1113/jphysiol.1988.sp017033; Malinow R, 2000, CURR OPIN NEUROBIOL, V10, P352, DOI 10.1016/S0959-4388(00)00099-4; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; Minnis JG, 2003, NEUROSCIENCE, V119, P33, DOI 10.1016/S0306-4522(03)00135-0; Nestler EJ, 2002, NEUROBIOL LEARN MEM, V78, P637, DOI 10.1006/nlme.2002.4084; Nimchinsky EA, 2002, ANNU REV PHYSIOL, V64, P313, DOI 10.1146/annurev.physiol.64.081501.160008; Onoprishvili I, 2003, MOL PHARMACOL, V64, P1092, DOI 10.1124/mol.64.5.1092; Passafaro M, 2003, NATURE, V424, P677, DOI 10.1038/nature01781; RALL W, 1985, [No title captured], P191; Robinson TE, 2002, SYNAPSE, V46, P271, DOI 10.1002/syn.10146; Robinson TE, 2004, NEUROPHARMACOLOGY, V47, P33, DOI 10.1016/j.neuropharm.2004.06.025; Segal M, 2003, EUR J NEUROSCI, V17, P2573, DOI 10.1046/j.1460-9568.2003.02696.x; SEGEV I, 1988, J NEUROPHYSIOL, V60, P499; SPRUSTON N, 1993, J NEUROPHYSIOL, V70, P781; Stellwagen D, 2005, J NEUROSCI, V25, P3219, DOI 10.1523/JNEUROSCI.4486-04.2005; Stephens DN, 2003, TRENDS NEUROSCI, V26, P181, DOI 10.1016/S0166-2236(03)00080-8; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Thiagarajan TC, 2005, NEURON, V47, P725, DOI 10.1016/j.neuron.2005.06.037; Tsay D, 2004, TRENDS NEUROSCI, V27, P77, DOI 10.1016/j.tins.2003.11.008; Vekovischeva OY, 2001, J NEUROSCI, V21, P4451, DOI 10.1523/JNEUROSCI.21-12-04451.2001; von Zastrow M, 2003, CURR OPIN NEUROBIOL, V13, P348, DOI 10.1016/S0959-4388(03)00069-2; von Zastrow M, 2001, PARKINSONISM RELAT D, V7, P265, DOI 10.1016/S1353-8020(00)00069-9; Vorel SR, 2001, SCIENCE, V292, P1175, DOI 10.1126/science.1058043; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Wiens KM, 2005, J NEUROSCI, V25, P10627, DOI 10.1523/JNEUROSCI.1947-05.2005; Williams JT, 2001, PHYSIOL REV, V81, P299; WIMPEY TL, 1991, NEURON, V6, P281, DOI 10.1016/0896-6273(91)90363-5; Xu NJ, 2003, J NEUROSCI, V23, P4775; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869	63	19	20	0	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	FEB	2007	97	2					1485	1494		10.1152/jn.00790.2006			10	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	134NQ	WOS:000244090500049	17122315	Green Accepted			2020-06-26	J	Aquila, B; Roussel, M; Jauzac, P; Allouche, S				Aquila, Benjamin; Roussel, Mikel; Jauzac, Philippe; Allouche, Stphane			High-purity selection and maintenance of gene expression in human neuroblastoma cells stably over-expressing GFP fusion protein - Application for opioid receptors desensitization studies	BRAIN RESEARCH			English	Article						FACS; GFP; SK-N-BE; hDOR; beta-arrestin1; desensitization	SK-N-BE; 2-MEDIATED DESENSITIZATION; ADENYLATE-CYCLASE; XENOPUS OOCYTES; MU; PHOSPHORYLATION; ARRESTIN; KINASE; INTERNALIZATION; TRAFFICKING	Chronic use of opiates such as morphine is associated with drug tolerance, which is correlated with the desensitization of opioid receptors. This latter process involves phosphorylation of opioid receptors by G protein-coupled receptors kinases (GRKs) and subsequent uncoupling by beta-arrestins. To explore these molecular mechanisms, neuronal cell lines, endogenously expressing the opioid receptors, provide an ideal cellular model. Unfortunately, there are two major drawbacks: (1) these cells are refractory to cDNA introduction, resulting in low transfection efficiency; (2) continuous culturing of transfected cells invariably leads to phenotypic drift of the cultures even after an antibiotic selection. So, these cells were dropped in favor of heterologous expression systems, which are easier to transfect but whose relevance as adequate cellular model for studying opioid receptor regulation should be questioned, as recently demonstrated by [Haberstock-Debic, H., Kim, K.A.,Yu, Y.J., von Zastrow, M., 2005. Morphine promotes rapid, arrestin-dependent endocytosis of mu-opioid receptors in striatal neurons. J. Neurosci. 25, 7847-7857]. In this work, we describe a method, based on fluorescence-activated cell sorting (FACS), to select and maintain a high proportion of transfected SK-N-BE cells (a neuronal cell line endogenously expressing human Delta-Opioid Receptor (hDOR)), expressing the beta-arrestin1 fused to green fluorescent protein (GFP). While in functional experiments, we were not able to observe a major effect in non-sorted SK-N-BE cells expressing beta-arrestin1-GFP, the enrichment by 18-fold with FACS resulted in a robust increase of beta-arrestin1-GFP expression associated with strong hDOR desensitization. Moreover, this method also allows to counteract the phenotypic drift and to maintain a high-purity selection of SK-N-BE cells expressing beta-arrestin1-GFP. Thus, this approach provides a valuable tool for exploring opioid receptors desensitization in neuronal cells. (c) 2006 Elsevier B.V. All rights reserved.	Univ Caen, UPRES EA 3919, Lab Biol Cellulaire & Mol Signalisat, F-14032 Caen, France	Allouche, S (reprint author), Univ Caen, UPRES EA 3919, Lab Biol Cellulaire & Mol Signalisat, F-14032 Caen, France.	allouche-s@chu-caen.fr	Roussel, Mikael/C-3080-2017	Roussel, Mikael/0000-0002-9741-0668; Allouche, stephane/0000-0003-3134-7501			Allouche S, 1999, EUR J PHARMACOL, V371, P235, DOI 10.1016/S0014-2999(99)00180-6; Appleyard SM, 1999, J BIOL CHEM, V274, P23802, DOI 10.1074/jbc.274.34.23802; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; Celver J, 2004, MOL PHARMACOL, V65, P528, DOI 10.1124/mol.65.3.528; Celver JP, 2001, J BIOL CHEM, V276, P4894, DOI 10.1074/jbc.M007437200; Debic HH, 2005, J NEUROSCI, V25, P7847, DOI 10.1523/JNEUROSCI.5045-04.2005; El Kouhen R, 1999, J BIOL CHEM, V274, P9207, DOI 10.1074/jbc.274.14.9207; Groarke DA, 1999, J BIOL CHEM, V274, P23263, DOI 10.1074/jbc.274.33.23263; Hasbi A, 1998, J NEUROCHEM, V70, P2129; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; KAZMI SMI, 1986, BIOCHEM BIOPH RES CO, V137, P813, DOI 10.1016/0006-291X(86)91152-6; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Leclere PG, 2005, J NEUROSCI METH, V142, P137, DOI 10.1016/j.jneumeth.2004.08.012; Lefkowitz RJ, 2004, CURR OPIN CELL BIOL, V16, P162, DOI 10.1016/j.ceb.2004.01.001; Lowe JD, 2002, J BIOL CHEM, V277, P15729, DOI 10.1074/jbc.M200612200; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; PEI G, 1995, MOL PHARMACOL, V48, P173; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; POLASTRON J, 1994, J NEUROCHEM, V62, P898; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P590, DOI 10.1073/pnas.72.2.590; SHARMA SK, 1977, P NATL ACAD SCI USA, V74, P3365, DOI 10.1073/pnas.74.8.3365; Wang HL, 2000, NEUROPHARMACOLOGY, V39, P353, DOI 10.1016/S0028-3908(99)00174-4; Whistler JL, 2001, J BIOL CHEM, V276, P34331, DOI 10.1074/jbc.M104627200; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; YU VC, 1986, J BIOL CHEM, V261, P1065; Zuo ZY, 2005, ANESTH ANALG, V101, P728, DOI 10.1213/01.ANE.0000160588.32007.AD	28	6	6	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 9	2006	1114						11	18		10.1016/j.brainres.2006.07.069			8	Neurosciences	Neurosciences & Neurology	096SY	WOS:000241398300002	16938287				2020-06-26	J	Narita, M; Suzuki, M; Narita, M; Niikura, K; Nakamura, A; Miyatake, M; Yajima, Y; Suzuki, T				Narita, M; Suzuki, M; Narita, M; Niikura, K; Nakamura, A; Miyatake, M; Yajima, Y; Suzuki, T			mu-Opioid receptor internalization-dependent and -independent mechanisms of the development of tolerance to mu-opioid receptor agonists: Comparison between etorphine and morphine	NEUROSCIENCE			English	Article						opioid tolerance; mu-opioid receptor; desensitization; astrocytes; morphine; spinal cord	PROTEIN-KINASE-C; SPINAL-CORD; NERVE INJURY; ACTIVATION; ENDOCYTOSIS; DESENSITIZATION; TRAFFICKING; MOUSE; PHOSPHORYLATION; INVOLVEMENT	A growing body of evidences suggests that receptor desensitization is implicated in the development of tolerance to opioids, which is generally regulated by protein kinases and receptor trafficking proteins. In the present study, we demonstrated that repeated s.c. treatment with etorphine, but not morphine, produced a significant increase in protein levels of G protein-coupled receptor kinase 2, dynamin II, beta-arrestin 2 and phosphorylated-conventional protein kinase C in membranes of the mouse spinal cord, suggesting that the etorphine-induced mu-opioid receptor desensitization may result from G protein-coupled receptor kinase 2/dynaminII/beta-arrestin2-dependent phosphorylation of mu-opioid receptors. Unlike etorphine, morphine failed to change the levels of these trafficking proteins. Furthermore, we found that the level of glial fibrillary acidic protein in the mouse spinal cord was clearly increased by chronic in vivo and in vitro treatment with morphine, whereas no such effect was noted by etorphine. In the behavioral study, intraperitoneal pretreatment with the glial-modulating agent propentofylline suppressed the development of tolerance to morphine-induced anti nociception. In addition, intrathecal injection of astrocytes and astrocyte-conditioned medium mixture, which were obtained from cultured astrocytes of the newborn mouse spinal cord, aggravated the development of tolerance to morphine. In contrast, these agents failed to affect the development of tolerance induced by etorphine. These findings provide direct evidence for the distinct mechanisms between etorphine and morphine on the development of tolerance to spinal antinociception. These findings raise the possibility that the increased astroglia response produced by chronic morphine could be associated with the lack of mu-opioid receptor internalization. (c) 2005 IBRO. Published by Elsevier Ltd. All rights reserved.	Hoshi Univ, Dept Toxicol, Sch Pharm & Pharmaceut Sci, Shinagawa Ku, Tokyo 1428501, Japan	Narita, M (reprint author), Hoshi Univ, Dept Toxicol, Sch Pharm & Pharmaceut Sci, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan.	narita@hoshi.ac.jp; suzuki@hoshi.ac.jp					Berrada K, 2000, J BIOL CHEM, V275, P27229; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burford NT, 1998, EUR J PHARMACOL, V342, P123, DOI 10.1016/S0014-2999(97)01556-2; Capeyrou R, 1997, FEBS LETT, V415, P200, DOI 10.1016/S0014-5793(97)01124-1; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Colburn RW, 1999, EXP NEUROL, V157, P289, DOI 10.1006/exnr.1999.7065; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Froes MM, 1999, P NATL ACAD SCI USA, V96, P7541, DOI 10.1073/pnas.96.13.7541; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Honore P, 2000, NEUROSCIENCE, V98, P585, DOI 10.1016/S0306-4522(00)00110-X; Hurle MA, 2001, J NEUROCHEM, V77, P486, DOI 10.1046/j.1471-4159.2001.00268.x; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; Ji SP, 2003, FRONT BIOSCI, V8, pA34, DOI 10.2741/987; Keith DE, 1998, MOL PHARMACOL, V53, P377; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KOUHEN ER, 2001, J BIOL CHEM, V276, P12774; Kovoor A, 1998, MOL PHARMACOL, V54, P704; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Krenz NR, 2000, J NEUROCHEM, V74, P730, DOI 10.1046/j.1471-4159.2000.740730.x; Narita M, 2004, EUR J NEUROSCI, V19, P479, DOI 10.1111/j.0953-816X.2003.03119.x; Narita M, 2001, J BIOL CHEM, V276, P15409, DOI 10.1074/jbc.M009716200; Ozaki S, 2003, NEUROSCIENCE, V116, P89, DOI 10.1016/S0306-4522(02)00699-1; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; Patel CN, 2003, SYNAPSE, V50, P67, DOI 10.1002/syn.10246; Patel MB, 2002, MOL PHARMACOL, V62, P1464, DOI 10.1124/mol.62.6.1464; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PREMONT RT, 1995, FASEB J, V9, P175; Raghavendra V, 2004, NEUROPSYCHOPHARMACOL, V29, P327, DOI 10.1038/sj.npp.1300315; Raghavendra V, 2002, J NEUROSCI, V22, P9980, DOI 10.1523/jneurosci.22-22-09980.2002; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Shavit Y, 2005, PAIN, V115, P50, DOI 10.1016/j.pain.2005.02.003; Song P, 2001, NEUROSCI RES, V39, P281, DOI 10.1016/S0168-0102(00)00226-1; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; Svensson CI, 2003, NEUROREPORT, V14, P1153, DOI 10.1097/00001756-200306110-00010; Tawfik VL, 2005, J PHARMACOL EXP THER, V313, P1239, DOI 10.1124/jpet.104.082420; von Zastrow M, 2003, CURR OPIN NEUROBIOL, V13, P348, DOI 10.1016/S0959-4388(03)00069-2; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; Xu M, 2004, J NEUROSCI, V24, P4576, DOI 10.1523/JNEUROSCI.5552-03.2004; Yoburn BC, 2004, EUR J PHARMACOL, V498, P87, DOI 10.1016/j.ejphar.2004.07.052; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang QY, 2005, SYNAPSE, V56, P123, DOI 10.1002/syn.20137	44	32	36	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2006	138	2					609	619		10.1016/j.neuroscience.2005.11.046			11	Neurosciences	Neurosciences & Neurology	022HL	WOS:000236046100022	16417975				2020-06-26	J	Zhang, QY; Purohit, V; Yoburn, BC				Zhang, QY; Purohit, V; Yoburn, BC			Continuous opioid agonist treatment dose-dependently regulates mu-opioid receptors and dynamin-2 in mouse spinal cord	SYNAPSE			English	Article						mu opioid receptors (mu OR); dynamin-2; mouse spinal cord; downregulation; mRNA; etorphine	PROTEINS IN-VIVO; ANTAGONIST TREATMENT; TOLERANCE	Continuous opioid agonist treatment produces tolerance and in some cases L opioid receptor (mu OR) down-regulation. Previous studies indicate that down-regulation of mu OR is more likely with high-efficacy opioid agonists (e.g., etorphine), whereas lower efficacy agonists (e.g., morphine) do not regulate mu OR density. It has been suggested that mu OR down-regulation may depend upon increases in Dynamin-2 (DYN-2) proteins. Therefore, the present study examined the effect of various infusion doses of etorphine on mu OR density, DYN-2 protein, and DYN-2 mRNA abundance in mouse spinal cord. Mice were implanted sc with an osmotic pump that infused etorphine (50-250 mu g/kg/day). Controls were implanted with inert placebo pellets. At the end of 7 days, mice were sacrificed, spinal cord removed and processed for radioligand binding, quantitative Western blotting, or RT-PCR assay. Results indicate that etorphine induced dose-dependent regulation of mu OR density, DYN-2 proteins, and mRNA abundance in mouse spinal cord. Higher infusion doses significantly down-regulated mu OR density, increased DYN-2 protein abundance, and decreased DYN-2 mRNA. Analysis of these results indicated a significant correlation between mu OR down-regulation and DYN-2 abundance in mouse spinal cord. Taken together, mu OR regulation may depend on changes in DYN-2 abundance induced by high-efficacy opioid agonists in mouse spinal cord. Synapse 56:123-128, 2005. (c) 2005 Wiley-Liss, Inc.	St Johns Univ, Coll Pharm & Allied Hlth Profess, Dept Pharmaceut Sci, Queens, NY 11439 USA	Yoburn, BC (reprint author), St Johns Univ, Coll Pharm & Allied Hlth Profess, Dept Pharmaceut Sci, 8000 Utopia Pkwy, Queens, NY 11439 USA.	yoburnb@stjohns.edu			PHS HHSUnited States Public Health Service [12868]		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; Noble F, 2000, MOL PHARMACOL, V58, P159; Patel M, 2002, EUR J PHARMACOL, V446, P37, DOI 10.1016/S0014-2999(02)01823-X; Patel MB, 2002, MOL PHARMACOL, V62, P1464, DOI 10.1124/mol.62.6.1464; Rajashekara V, 2003, PHARMACOL BIOCHEM BE, V75, P909, DOI 10.1016/S0091-3057(03)00166-7; Stafford K, 2001, PHARMACOL BIOCHEM BE, V69, P233, DOI 10.1016/S0091-3057(01)00525-1; TAO PC, 1989, J PHARMACOL EXP THER, V240, P809; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; YOBURN BC, 1995, PHARMACOL BIOCHEM BE, V51, P535, DOI 10.1016/0091-3057(94)00375-S; Yoburn BC, 2004, EUR J PHARMACOL, V498, P87, DOI 10.1016/j.ejphar.2004.07.052; YOBURN BC, 1993, J PHARMACOL EXP THER, V265, P314; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	15	11	11	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0887-4476	1098-2396		SYNAPSE	Synapse	JUN 1	2005	56	3					123	128		10.1002/syn.20137			6	Neurosciences	Neurosciences & Neurology	914JU	WOS:000228224600001	15765525				2020-06-26	J	Adams, WA; Robinson, KJ; Jones, RS; Edwards, GB				Adams, WA; Robinson, KJ; Jones, RS; Edwards, GB			Overdose during chemical restraint in a black rhinoceros (Diceros bicornis)	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						anaesthesia; resuscitation; overdose; rhinoceros	CERATOTHERIUM-SIMUM-SIMUM; ETORPHINE M99; IMMOBILIZATION; COMBINATIONS; DETOMIDINE; ANESTHESIA; XYLAZINE; FENTANYL	A juvenile female black rhinoceros (Diceros bicornis) was successfully treated after overdose of drugs used for chemical restraint. Subsequent general anaesthesia for surgical reduction of a recurrent rectal prolapse was uneventful. Over a 25-minute period before transportation to the veterinary hospital, the animal received a total dose of 1.225 mg etorphine, 30 mg acepromazine and 30 mg detomidine. Based on an estimated mass of 200 kg, these corresponded to doses of 6.1. mug kg(-1) etorphine, 150 mug kg(-1) acepromazine, and 150 mug kg(-1) detomidine which constitutes considerable overdose for each drug given separately, notwithstanding the synergy that probably resulted when the three drugs were present concurrently. The estimated body mass may have substantially overestimated the actual body mass and exacerbated overdosage. The animal was recumbent and apnoeic on arrival at the hospital. Heart sounds were auscultated and a weak peripheral pulse was palpated; no pulse deficits were detected, although the heart rate was low. The trachea was intubated, inspired breath was enriched with oxygen and the lungs ventilated manually. Diprenorphine (1.5 mg) was given intravenously and spontaneous breathing resumed 11 minutes later. After induction of general anaesthesia using isoflurane, emergency surgery for correction of rectal prolapse was performed, from which the animal recovered uneventfully. The case highlights some of the practical problems that may be encountered in dealing with dangerous and unfamiliar species.	Univ Clin Dept, Dept Anaesthesia, Liverpool L6A 3GA, Merseyside, England; Dept Vet Sci & Anim Husbandry, Div Equine Studies, Neston, England	Adams, WA (reprint author), Univ Clin Dept, Dept Anaesthesia, Duncan Bldg,Daulby St, Liverpool L6A 3GA, Merseyside, England.	wendy.adams5@hotmail.com					ALFORD BT, 1974, J AM VET MED ASSOC, V164, P702; ALITALO I, 1986, ADV VET SCAND S, V82, P59; Atkinson MW, 2002, J ZOO WILDLIFE MED, V33, P157, DOI 10.1638/1042-7260(2002)033[0157:RCIOAC]2.0.CO;2; CORNICKSEAHORN JL, 1995, J AM VET MED ASSOC, V206, P508; HEARD DJ, 1992, J ZOO WILDLIFE MED, V23, P197; Kock MD, 1995, J ZOO WILDLIFE MED, V26, P207; KOCK MD, 1990, J ZOO WILDLIFE MED, V21, P155; LEBLANC PH, 1987, J ZOO WILDLIFE MED, V18, P141, DOI 10.2307/20094825; NARTHROORN AM, 1975, CHEM CAPTURE ANIMALS, P201; NATHOORN AM, 1962, CAN J COMP MED VET S, V26, P203; Nelson L., 1986, P934; RAATH JP, 1999, ZOO WILDLIFE MED CUR, V4, P556; Radcliffe RM, 2000, J ZOO WILDLIFE MED, V31, P201, DOI 10.1638/1042-7260(2000)031[0201:SLGUBI]2.0.CO;2; Radcliffe RW, 2000, J ZOO WILDLIFE MED, V31, P196, DOI 10.1638/1042-7260(2000)031[0196:BAAAAS]2.0.CO;2; SALONEN JS, 1989, J VET PHARMACOL THER, V12, P65, DOI 10.1111/j.1365-2885.1989.tb00643.x; SCHLARMA.B, 1973, AM J VET RES, V34, P411; SELISKAR A, 2000, P 7 WORLD C VET AN B, P147; Stegmann GF, 2001, J S AFR VET ASSOC, V72, P239	18	5	6	0	6	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1467-2987			VET ANAESTH ANALG	Vet. Anaesth. Analg.	JAN	2005	32	1					53	57		10.1111/j.1467-2995.2004.00181.x			5	Veterinary Sciences	Veterinary Sciences	898BS	WOS:000227051500008	15663740				2020-06-26	J	Sterken, J; Troubleyn, J; Gasthuys, F; Maes, V; Diltoer, M; Verborgh, C				Sterken, Joeri; Troubleyn, Joris; Gasthuys, Frank; Maes, Viviane; Diltoer, Mark; Verborgh, Christian			Intentional overdose of Large Animal Immobilon	EUROPEAN JOURNAL OF EMERGENCY MEDICINE			English	Article						Analgesics; opioid; etorphine; antagonists; opioid; diprenorphine; naloxone		We describe a case of voluntary self-injection with Large Animal Immobilon, a veterinary anaesthesia product containing etorphine, a very strong opioid, and acepromazine, a phenothiazine. This resulted in cardiorespiratory arrest and the need for sustained haemodynamic support after resuscitation. Large Animal Immobilon is used under specific conditions only, mainly in zoo and wildlife medicine. Primary toxicological analysis, although guided by the presumed toxin, could only detect a metabolite of acepromazine in the urine. Further analysis was able to show some traces of etorphine. A number of topics are treated, including the apparent potency of the etorphine and the selection of a suitable antidote, taking into account the different properties of the respective agents. (C) 2004 Lippincott Williams & Wilkins.	[Sterken, Joeri; Verborgh, Christian] Vrije Univ Brussel, Univ Hosp, Dept Emergency Med, B-1090 Brussels, Belgium; [Troubleyn, Joris; Diltoer, Mark] Vrije Univ Brussel, Univ Hosp, Dept Intens Care, B-1090 Brussels, Belgium; [Maes, Viviane] Vrije Univ Brussel, Univ Hosp, Dept Clin Chem, B-1090 Brussels, Belgium; [Gasthuys, Frank] Univ Ghent, Fac Vet Med, Dept Surg & Anaesthesiol Domest Anim, Merelbeke, Belgium	Verborgh, C (reprint author), Vrije Univ Brussel, Univ Hosp, Dept Emergency Med, Laarbeeklaan 101, B-1090 Brussels, Belgium.	christian.verborgh@az.vub.ac.be					[Anonymous], 1977, LANCET, V2, P178; BERKOWITZ BA, 1975, J PHARMACOL EXP THER, V195, P499; BERNS SD, 1993, AM J EMERG MED, V11, P247, DOI 10.1016/0735-6757(93)90137-Z; BLANE GF, 1970, BRIT J PHARMACOL, V39, pP252; BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; Bot G, 1998, J NEUROCHEM, V70, P358; Buss PE, 2001, J S AFR VET ASSOC, V72, P137; CLUTTON RE, 1985, VET HUM TOXICOL, V27, P391; DEROSSETT SE, 1984, J PHARMACOL EXP THER, V228, P669; DOBBS HE, 1968, J PHARMACOL EXP THER, V160, P407; Elliott SP, 1999, FORENSIC SCI INT, V101, P9, DOI 10.1016/S0379-0738(99)00009-2; FIRN S, 1973, LANCET, V2, P95; GOODRICH PGE, 1977, VET REC, V100, P458, DOI 10.1136/vr.100.21.458; Grabus SD, 1999, PHARMACOL BIOCHEM BE, V63, P481, DOI 10.1016/S0091-3057(99)00008-8; Lee KO, 1999, EUR J PHARMACOL, V378, P323, DOI 10.1016/S0014-2999(99)00460-4; Manzanares J, 1999, TRENDS PHARMACOL SCI, V20, P287, DOI 10.1016/S0165-6147(99)01339-5; Melichar JK, 2003, EUR J PHARMACOL, V459, P217, DOI 10.1016/S0014-2999(02)02872-8; MEULEMANS A, 1990, ACTA CLIN BELG, V45, P13, DOI 10.1080/17843286.1990.11718123; NGAI SH, 1976, ANESTHESIOLOGY, V44, P398, DOI 10.1097/00000542-197605000-00008; ORR CM, 1977, VET REC, V100, P574; PAUL D, 1991, J PHARMACOL EXP THER, V257, P1; Quillan JM, 2002, J PHARMACOL EXP THER, V302, P1002, DOI 10.1124/jpet.302.3.1002; Ramsay EC, 1998, J ZOO WILDLIFE MED, V29, P45; RODRIGUEZ FD, 1992, J NEUROCHEM, V59, P467, DOI 10.1111/j.1471-4159.1992.tb09393.x; Schmidt W, 1997, CRIT CARE MED, V25, P1925, DOI 10.1097/00003246-199711000-00036; Stegmann GF, 1999, J S AFR VET ASSOC, V70, P164; Stowell LI, 1998, J ANAL TOXICOL, V22, P166, DOI 10.1093/jat/22.2.166; TREMBLAY E, 1976, PSYCHOPHARMACOLOGY, V49, P41; VOLANS GN, 1976, BRIT MED J, V2, P472, DOI 10.1136/bmj.2.6033.472-c	29	12	12	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0969-9546	1473-5695		EUR J EMERG MED	Eur. J. Emerg. Med.	OCT	2004	11	5					298	301		10.1097/00063110-200410000-00013			4	Emergency Medicine	Emergency Medicine	V41AC	WOS:000209518100013	15359207				2020-06-26	J	Schulz, R; Eisinger, DA; Wehmeyer, A				Schulz, R; Eisinger, DA; Wehmeyer, A			Opioid control of MAP kinase cascade	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						MAP kinase; opioid; epidermal growth factor receptor; human embryonic kidney 293 cell; extracellular signal-regulated kinase; G protein-coupled receptor	EPIDERMAL-GROWTH-FACTOR; PROTEIN-COUPLED RECEPTORS; GREEN FLUORESCENT PROTEIN; EGF RECEPTOR; BETA-ARRESTIN; ACTIVATION; CELLS; TRANSACTIVATION; PHOSPHORYLATION; PATHWAYS	Activation of G protein-coupled receptors (GPCRs) may result in phosphorylation of extracellular signal-regulated kinases 1/2 (ERK 1/2). The signaling pathway involves ectodomain shedding, generating epidermal growth factor (EGF)-like ligands, which in turn stimulate the mitogen-activated protein kinase (MAPK) via EGF receptors. The present study investigates into the control of MAPKs by opioidergic GPCRs in human embryonic kidney cells (HEK 293). Experiments were conducted with cells expressing opioid receptors, G protein-coupled receptor kinases, and ERKs. The outcome of our studies let us suggest that EGF-like ligands released by opioid receptor stimulation utilize different EGF receptors to phosphorylate ERKs, while EGF utilizes type 1 receptors. Differences between multiple opioid receptors are apparent with respect to the activation of ERKs. EGF rapidly triggers internalization of the fluorescent EGF receptor type 1, but we failed to observe any sequestration of this receptor type upon exposure of cells to an opioid, since opioids most likely trigger stimulation of a different EGF receptor type. In conclusion, G protein-coupled opioid receptors control the MAPK cascade in a similar fashion as described for non-opioid GPCRs, although distinct differences exist between mu-, delta- and kappa-receptors. EGF-induced ERK activation is mediated by EGF receptor type 1 while opioid receptor activation seems to brings about stimulation via EGF receptor type. (C) 2004 Elsevier B.V. All rights reserved.	Univ Munich, Inst Pharmacol Toxicol & Pharm, D-80539 Munich, Germany	Schulz, R (reprint author), Univ Munich, Inst Pharmacol Toxicol & Pharm, Koniginstr 16, D-80539 Munich, Germany.	schulz@pharmtox.vetined.uni-muenchen.de					Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; Belcheva MM, 2002, J PHARMACOL EXP THER, V303, P909, DOI 10.1124/jpet.102.038554; Bokemeyer D, 2000, KIDNEY INT, V58, P549, DOI 10.1046/j.1523-1755.2000.t01-1-00201.x; Burt AR, 1996, BIOCHEM J, V320, P227, DOI 10.1042/bj3200227; CARPENTER G, 1979, J BIOL CHEM, V254, P4884; Carpenter G, 1991, PEPTIDE GROWTH FACTO, P69; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Grewal JS, 2001, J BIOL CHEM, V276, P27335, DOI 10.1074/jbc.M103578200; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; JOHNSON SM, 1989, PHARMACOL REV, V41, P435; Kramer H Kenneth, 2002, BMC Pharmacol, V2, P5, DOI 10.1186/1471-2210-2-5; Kramer HK, 2000, BIOCHEM PHARMACOL, V60, P781, DOI 10.1016/S0006-2952(00)00400-7; Leserer M, 2000, IUBMB LIFE, V49, P405; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Luttrell LM, 2003, J MOL ENDOCRINOL, V30, P117, DOI 10.1677/jme.0.0300117; Luttrell LM, 2002, CAN J PHYSIOL PHARM, V80, P375, DOI 10.1139/Y02-045; Moss ML, 2001, DRUG DISCOV TODAY, V6, P417, DOI 10.1016/S1359-6446(01)01738-X; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Prenzel N, 1999, NATURE, V402, P884; Raab G, 1997, BBA-REV CANCER, V1333, pF179, DOI 10.1016/S0304-419X(97)00024-3; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; Schmidt H, 2000, J NEUROCHEM, V74, P414, DOI 10.1046/j.1471-4159.2000.0740414.x; Schulz R, 1999, EUR J PHARMACOL, V375, P349, DOI 10.1016/S0014-2999(99)00223-X; Schulz R, 1998, BRAIN RES, V790, P347, DOI 10.1016/S0006-8993(98)00114-0; Schulz R, 2002, J PHARMACOL EXP THER, V300, P376, DOI 10.1124/jpet.300.2.376; Shah BH, 2004, TRENDS NEUROSCI, V27, P48, DOI 10.1016/j.tins.2003.11.003; Tanimura S, 2002, J BIOL CHEM, V277, P28256, DOI 10.1074/jbc.M202866200; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	38	27	30	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	OCT 1	2004	500	1-3					487	497		10.1016/j.ejphar.2004.07.010			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	864LQ	WOS:000224635400040	15464054				2020-06-26	J	Dangolla, A; Silva, I; Kuruwita, VY				Dangolla, A; Silva, I; Kuruwita, VY			Neuroleptanalgesia in wild Asian elephants (Elephas maximus maximus)	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						acepromazine; anaesthesia; diprenorphine; elephants; etorphine; tranquilization		Objective To evaluate the suitability of etorphine with acepromazine for producing prolonged neuroleptanalgesia in wild Asian elephants. Animals Ten adult wild elephants (four males, six females), free-roaming in the jungles of the northwestern province of Sri Lanka. Materials and methods Ten wild elephants were tranquilized for attachment of radio transmitter collars from September to November 1997, using Large-Animal Immobilon (C-Vet Veterinary Products, Leyland, UK), which is a combination of etorphine (2.45 mg mL(-1)) and acepromazine (10 mg mL(-1)). This was injected using projectile syringes fired from a Cap-Chur gun (Palmer Chemical Co. Inc., Atlanta, USA). A volume of 3.3 (2.5-4.5) mL Immobilon (6.12-11.02 mg of etorphine and 25-45 mg acepromazine) was injected intramuscularly after body mass estimation of individual elephants. Results The body condition of all darted elephants was good, and the mean (minimum-maximum) shoulder height was 225 (180-310) cm. The average approximate distance to elephants at firing was 26 (15-50) m. The average time to recumbency after injection was 18 (15-45) minutes. Nine out of 10 elephants remained in lateral recumbency (and did not require additional dosing) for a period of 42 (28-61) minutes. The respiratory and heart rates during anaesthesia were 7 (4-10) breaths and 52 (40-60) beats minute(-1), respectively. An equal volume (8.15-14.67 mg) of diprenorphine hydrochloride (Revivon, 3.26 mg mL(-1) diprenorphine; C-Veterinary Products, Leyland, UK) was given intravenously when the procedure was completed. Recovery (return to standing position) occurred in 6 (212) minutes after diprenorphine injection. Immediately afterwards, all elephants slowly retreated into the jungle without complications. Continuous radio tracking of the animals involved in this study indicated no post-operative mortality for several months after restraint. Conclusions/clinical relevance Etorphine-acepromazine combinations can be used safely in healthy wild Asian elephants for periods of restraint lasting up to 1 hour.	Univ Peradeniya, Fac Vet Med & Anim Sci, Dept Vet Clin Studies, Peradeniya, Sri Lanka	Dangolla, A (reprint author), Univ Peradeniya, Fac Vet Med & Anim Sci, Dept Vet Clin Studies, Peradeniya, Sri Lanka.	adangolla@yahoo.com					BONGSO TA, 1978, VET REC, V102, P339, DOI 10.1136/vr.102.15.339; FOWLER ME, 1973, JAVMA, V165, P539; GRAY C W, 1970, Zoologica (New York), V55, P51; HORNER IB, 1954, COLLECTION MIDDLE LE, V1, P220; JAINUDEEN MR, 1971, VET REC, V89, P686, DOI 10.1136/vr.89.26.686; Kurt F., 1968, Ceylon Veterinary Journal, V16, P24; KURUWITA VY, 1991, SRI LANKA VET J, V38, P25; Page CD., 1994, MED MANAGEMENT ELEPH, P41	8	3	4	0	8	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1467-2987			VET ANAESTH ANALG	Vet. Anaesth. Analg.	OCT	2004	31	4					276	279		10.1111/j.1467-2995.2004.00166.x			4	Veterinary Sciences	Veterinary Sciences	871PX	WOS:000225146800006	15509293				2020-06-26	J	Yoburn, BC; Purohit, V; Patel, K; Zhang, QY				Yoburn, BC; Purohit, V; Patel, K; Zhang, QY			Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						mu-opioid receptor; up-regulation; down-regulation; intermittent and continuous dosing	G-PROTEIN ACTIVATION; SWISS WEBSTER MICE; DOWN-REGULATION; UP-REGULATION; GENE-EXPRESSION; INTERNALIZATION; TOLERANCE; EFFICACY; DESENSITIZATION; MORPHINE	Opioid agonists and antagonists can regulate the density of p-opioid receptors in whole animal and in cell culture. High intrinsic efficacy agonists (e.g., etorphine), but not lower intrinsic efficacy agonists (e.g., morphine), produce mu-opioid receptor down-regulation and can alter the abundance of mu-opioid receptor mRNA. Conversely, opioid antagonists substantially increase the density of mu-opioid receptors without changing its mRNA. p-Opioid receptor up-regulation has been associated with decreases in the trafficking protein dynamin-2, whereas mu-opioid receptor down-regulation produces an increase in dynamin-2 abundance. To probe the differences between opioid agonist and antagonist-induced mu-opioid receptor regulation, the current study determined changes in mu-opioid receptor density using a combined radioligand binding ([H-3] DAMGO) and quantitative Western blotting approach in mouse spinal cord. Furthermore, the differences between intermittent and continuous dosing protocols were evaluated. Continuous (7-8 days) s.c. infusions of naloxone (5 mg/kg/day) or naltrexone (15 mg s.c. implant pellet) increased p-opioid receptor density in radioligand binding assays (approximate to+80%) in mouse spinal cord and down-regulated dynamin-2 abundance (approximate to-30%), but had no effect on the abundance of immunoreactive It-opioid receptor. Continuous (7 days) s.c. infusion of etorphine (200 mug/kg/day) decreased immunoreactive mu-opioid receptor (approximate to-35%) and [H-3] DAMGO binding (approximate to-30%), and concurrently increased dynamin-2 abundance (approximate to+40%). Continuous (7 days) morphine infusion (40 mg/kg/day plus 25 mg s.c. implant pellet) had no effect on any outcome measure. Delivery of the same daily dose of etorphine or naloxone using intermittent (every 24 h for 7 days) s.c. administration had no effect on immunoreactive mu-opioid receptor, [H-3] DAMGO binding or dynamin-2 abundance. These data indicate that mu-opioid receptor density, determined in radioligand binding assays, and immunoreactive dynamin-2 abundance are regulated by continuous, but not intermittent, opioid ligand treatment. Furthermore, the differential regulation of mu-opioid receptor abundance by agonists and antagonists in immunoblotting assays contrasts with changes in [H-3] DAMGO binding. Taken together, these results suggest that etorphine-induced down-regulation may depend upon It-opioid receptor degradation and changes in dynamin-2-mediated receptor trafficking. Conversely, antagonist-induced up-regulation does not require an increase in p-opioid receptor synthesis and may entail conversion of receptors to an appropriate conformation to bind ligand, as well as changes in receptor trafficking. (C) 2004 Elsevier B.V. All rights reserved.	St Johns Univ, Coll Pharm & Allied Hlth Profess, Dept Pharmaceut Sci, Queens, NY 11439 USA	Yoburn, BC (reprint author), St Johns Univ, Coll Pharm & Allied Hlth Profess, Dept Pharmaceut Sci, 8000 Utopia Pkwy, Queens, NY 11439 USA.	yoburnb@stjohns.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 12868]		Alvarez VA, 2002, J NEUROSCI, V22, P5769; Barrett AC, 2003, J PHARMACOL EXP THER, V305, P1061, DOI 10.1124/jpet.102.047068; Borgland SL, 2003, J BIOL CHEM, V278, P18776, DOI 10.1074/jbc.M300525200; BOURNE HR, 2004, BASIC CLIN PHARM, P11; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brady LS, 1999, MOL BRAIN RES, V68, P193, DOI 10.1016/S0169-328X(99)00090-X; Celver J, 2004, MOL PHARMACOL, V65, P528, DOI 10.1124/mol.65.3.528; Chakrabarti S, 1997, MOL PHARMACOL, V52, P105; CHANG SCJL, 1991, PHARMACOL BIOCHEM BE, V38, P853, DOI 10.1016/0091-3057(91)90253-X; Cichewicz DL, 2001, J PHARMACOL EXP THER, V297, P121; Cox BM, 2004, MOL PHARMACOL, V65, P492, DOI 10.1124/mol.65.3.492; Duttaroy A, 1999, LIFE SCI, V65, P113, DOI 10.1016/S0024-3205(99)00228-3; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; Duttaroy A, 2000, SYNAPSE, V37, P118, DOI 10.1002/1098-2396(200008)37:2<118::AID-SYN6>3.0.CO;2-2; Emmerson PJ, 1996, J PHARMACOL EXP THER, V278, P1121; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Gomes BA, 2002, PHARMACOL BIOCHEM BE, V72, P273, DOI 10.1016/S0091-3057(01)00757-2; Keith DE, 1998, MOL PHARMACOL, V53, P377; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KENAKIN T, 1997, [No title captured]; Li J, 2001, MOL PHARMACOL, V60, P1064; Li JG, 2000, MOL PHARMACOL, V58, P795; Patel CN, 2003, SYNAPSE, V50, P67, DOI 10.1002/syn.10246; Patel M, 2002, EUR J PHARMACOL, V446, P37, DOI 10.1016/S0014-2999(02)01823-X; Patel MB, 2002, MOL PHARMACOL, V62, P1464, DOI 10.1124/mol.62.6.1464; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Rajashekara V, 2003, PHARMACOL BIOCHEM BE, V75, P909, DOI 10.1016/S0091-3057(03)00166-7; Sehba F, 1997, EUR J PHARMACOL, V339, P33, DOI 10.1016/S0014-2999(97)01360-5; Shah S, 1997, BRAIN RES BULL, V42, P479, DOI 10.1016/S0361-9230(96)00375-9; Shen J, 2000, SYNAPSE, V38, P322, DOI 10.1002/1098-2396(20001201)38:3<322::AID-SYN11>3.0.CO;2-1; Stafford K, 2001, PHARMACOL BIOCHEM BE, V69, P233, DOI 10.1016/S0091-3057(01)00525-1; STEPHENSON RP, 1956, BRIT J PHARM CHEMOTH, V11, P379, DOI 10.1111/j.1476-5381.1956.tb00006.x; TEMPEL A, 1986, DEV BRAIN RES, V25, P287, DOI 10.1016/0165-3806(86)90218-X; UNTERWALD EM, 1995, MOL BRAIN RES, V33, P351, DOI 10.1016/0169-328X(95)00143-G; Unterwald EM, 1998, NEUROSCIENCE, V85, P897, DOI 10.1016/S0306-4522(97)00659-3; Walker EA, 1998, PSYCHOPHARMACOLOGY, V136, P15; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Yoburn BC, 2003, SYNAPSE, V47, P109, DOI 10.1002/syn.10149; YOBURN BC, 1993, J PHARMACOL EXP THER, V265, P314; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; ZADINA JE, 1994, J PHARMACOL EXP THER, V270, P1086; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; ZUKIN RS, 1986, BIOCHEM PHARMACOL, V35, P1623, DOI 10.1016/0006-2952(86)90314-X	44	29	30	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	SEP 13	2004	498	1-3					87	96		10.1016/j.ejphar.2004.07.052			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	856KM	WOS:000224044100012	15363980				2020-06-26	J	Portas, T				Portas, T			A review of drugs and techniques used for sedation and anaesthesia in a captive rhineceros species	AUSTRALIAN VETERINARY JOURNAL			English	Review							RHINOCEROS DICEROS-BICORNIS; CHEMICAL IMMOBILIZATION; ETORPHINE M99; COMBINATIONS; MANAGEMENT; FENTANYL; CAPTURE; SIMUM	Captive rhinoceros species are most frequently sedated and/or anaesthetised with the potent opioid, etorphine hydrochloride in combination with an alpha-2 adrenoreceptor agonist or the butyrophenone, azaperone. Carfentanil citrate based combinations have also been used to a lesser extent. In recent years butorphanol tartrate based combinations have been used with good success to induce neuroleptanalgesia. Sedation and anaesthesia are complicated by the large size of all rhinoceros species and their sensitivity to potent opioids. Potential complications include respiratory depression, hypoxaemia, hypertension, pulmonary shunting and ventilation/perfusion mismatch. The pharmacology of the principal drugs used for sedating/anaesthetising rhinoceros is reviewed. Techniques for sedating/anaesthetising the various species and potential complications associated with chemical restraint are discussed.	Western Plains Zoo, Dubbo, NSW 2830, Australia	Portas, T (reprint author), Western Plains Zoo, POB 831, Dubbo, NSW 2830, Australia.						ALLEN JL, 1991, PROCEEDINGS : AMERICAN ASSOCIATION OF ZOO VETERINARIANS - ANNUAL MEETING 1991, P343; Allen JL, 1996, J ZOO WILDLIFE MED, V27, P496; Atkinson MW, 2002, J ZOO WILDLIFE MED, V33, P157, DOI 10.1638/1042-7260(2002)033[0157:RCIOAC]2.0.CO;2; BAIER J, 1997, P AM ASS ZOO VET, P172; Ball Ray L., 2001, P176; BLUMER E, 1996, AZA RHINOCEROS HUSBA, P47; CORNICKSEAHORN JL, 1995, J AM VET MED ASSOC, V206, P508; DINERSTEIN E, 1990, WILDLIFE SOC B, V18, P36; DUTOIT JG, 1998, RHINO RANCHING, P31; Gandolf AR, 2000, J ZOO WILDLIFE MED, V31, P112, DOI 10.1638/1042-7260(2000)031[0112:MCUMIA]2.0.CO;2; HEARD DJ, 1992, J ZOO WILDLIFE MED, V23, P197; Jones D.M., 1979, International Zoo Yearbook, V19, P239, DOI 10.1111/j.1748-1090.1979.tb00572.x; Klein LV, 1997, P AM ASS ZOO VET, P127; Kock MD, 1995, J ZOO WILDLIFE MED, V26, P207; KOCK MD, 1992, J ZOO WILDLIFE MED, V23, P181; KOCK MD, 1990, J ZOO WILDLIFE MED, V21, P155; Langan J, 2001, J ZOO WILDLIFE MED, V32, P118, DOI 10.1638/1042-7260(2001)032[0118:DAMOAP]2.0.CO;2; LEBLANC PH, 1987, J ZOO WILDLIFE MED, V18, P141, DOI 10.2307/20094825; LEES P, 1976, BRIT J PHARMACOL, V56, P263, DOI 10.1111/j.1476-5381.1976.tb07637.x; Miller C, 1998, NAT GENET, V20, P228; Miller RE, 1998, P AM ASS ZOO VET AM, P213; Moresco A, 2001, J ZOO WILDLIFE MED, V32, P81, DOI 10.1638/1042-7260(2001)032[0081:UONTRC]2.0.CO;2; NANCE MD, 1998, P AM ASS ZOO VET, P208; RAATH JP, 1999, ZOO WILDLIFE MED CUR, V4, P556; Radcliffe RW, 2000, J ZOO WILDLIFE MED, V31, P196, DOI 10.1638/1042-7260(2000)031[0196:BAAAAS]2.0.CO;2; Radcliffe RW, 2000, J ZOO WILDLIFE MED, V31, P71, DOI 10.1638/1042-7260(2000)031[0071:ALLIAJ]2.0.CO;2; Reuter H, 1998, P AM ASS ZOO VET, P410; Rogers P.S., 1993, P512; Swan GE, 1993, CAPTURE CARE MANUAL, P17; WALZER C, 2000, [No title captured], P98	30	24	27	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0005-0423	1751-0813		AUST VET J	Aust. Vet. J.	SEP	2004	82	9					542	549		10.1111/j.1751-0813.2004.tb11196.x			8	Veterinary Sciences	Veterinary Sciences	855FM	WOS:000223958600016	15478725				2020-06-26	J	Howard, LL; Kearns, KS; Clippinger, TL; Larsen, RS; Morris, PJ				Howard, LL; Kearns, KS; Clippinger, TL; Larsen, RS; Morris, PJ			Chemical immobilization of rhebok (Pelea capreolus) with carfentanil-xylazine or etorphine-xylazine	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						rhebok; Pelea capreolus; carfentanil; etorphine; xylazine; anesthesia; yohimbine; naltrexone	PULSE OXIMETRY	Twelve adult rhebok (Pelea capreolus) were immobilized using a combination of 0.4 mg/kg xylazine and either 0.01 mg/kg of carfentanil (n = 6) or 0.01 mg/kg etorphine (n = 6), delivered i.m. using a remote injection system. Induction and recovery times, heart rate, respiratory rate, rectal temperature, oxygen saturation, end-tidal CO. (ETCO2). anesthetic depth, indirect blood pressure, and arterial blood gases were recorded. Rhebok were not intubated but nasal oxygen was administered. Forty minutes after induction, anesthesia was antagonized with naltrexone and yohimbine. Mean initial heart rate was significantly higher in the carfentanil group than in the etorphine group. Mean initial oxygen saturation was consistent with hypoxia in both the carfentanil group and the etorphine group. In both groups, arterial pH decreased and partial pressure of carbon dioxide increased during the first 15 min of anesthesia. and values were similar in both groups. These findings were consistent with respiratory acidosis and decreased ventilation. Values for respiratory rate, temperature, oxygen saturation, ETCO2, and blood pressure were similar for both groups at all time periods. During the first 5 min of anesthesia. rhebok in the carfentanil group were more responsive to stimuli than rhebok in the etorphine group. After administration of antagonists, time to first arousal was significantly shorter in the etorphine group than in the carfentanil group. Although cardiopulmonary values were similar for the two groups, rhebok in the carfentanil group were at a comparatively lighter plane of anesthesia, and some individuals in this group required additional manual and chemical restraint for medical procedures to be performed. In conclusion, for captive adult rhebok, 0.01 mg/kg of etorphine and 0.4 mg/kg of xylazine are recommended over 0.01 mg/kg carfentanil and 0.4 mg/kg xylazine because of qualitatively better anesthetic episodes and shorter recovery times.	Zool Soc San Diego, San Diego, CA 92112 USA; Univ Calif Davis, Sch Vet Med, Dept Med & Epidemiol, Davis, CA 95616 USA	Howard, LL (reprint author), Zool Soc San Diego, POB 120551, San Diego, CA 92112 USA.						ALFORD BT, 1974, J AM VET MED ASSOC, V164, P702; Allen Jack L., 1999, P2; ALLEN JL, 1989, J ZOO WILDLIFE MED, V20, P423; ALLEN JL, 1991, P AM ASS ZOO VET ANN, P336; Burroughs R.E.J., 1993, P348; GROSKY W, 1995, IEEE MULTIMEDIA, V2, P7; Hackett TB, 2002, VET CLIN N AM-SMALL, V32, P1021, DOI 10.1016/S0195-5616(02)00042-6; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P391; HASKINS SC, 1996, 1996 LUMB JONES VET, P409; Heard DJ, 1996, AM J VET RES, V57, P87; HORAK IG, 1982, ONDERSTEPOORT J VET, V49, P147; KOCK RA, 1985, J ASS VET ANAESTH, V13, P58; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; NEILSEN L, 1996, 1996 LUMB JONES VET, P736; NOWAK RM, 1997, [No title captured]; Schumacher J, 1997, J ZOO WILDLIFE MED, V28, P166; SNYDER SH, 1977, SCI AM, V236, P44, DOI 10.1038/scientificamerican0377-44; Thurmon JC, 1996, LUMB JONES VET ANEST, P183; Wright B, 1996, COMP CONT EDUC PRACT, V18, P1083	19	17	18	1	8	AMER ASSOC ZOO VETERINARIANS	MEDIA	6 NORTH PENNELL ROAD, MEDIA, PA 19063 USA	1042-7260			J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	SEP	2004	35	3					312	319		10.1638/03-090			8	Veterinary Sciences	Veterinary Sciences	857UH	WOS:000224143400005	15526885				2020-06-26	J	Eisinger, DA; Schulz, R				Eisinger, DA; Schulz, R			Extracellular signal-regulated kinase/mitogen-activated protein kinases block internalization of delta-opioid receptors	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							AGONIST-SPECIFIC REGULATION; BETA-ARRESTIN; GROWTH-FACTOR; ENDOCYTOSIS; MORPHINE; PHOSPHORYLATION; INHIBITION; DEPENDENCE; ERK; DESENSITIZATION	Translocation of G protein-coupled receptors (GPCRs) from the cell membrane to cytosol depends on the kind of ligand activating the receptor. This principle is clearly demonstrated for opioid receptors, because diverse opiate agonists rapidly induce receptor internalization, whereas morphine almost fails. We report here the impact of mitogen-activated protein (MAP) kinase isoforms extracellular signal-regulated kinase (ERK)1/2 on the internalization of delta-opioid receptors (DORs) expressed in human embryonic kidney (HEK)293 cells. Receptor activation by etorphine turned out to transiently phosphorylate ERK/MAP kinases and bring about DOR internalization within 20 min. In contrast, prolonged exposure of HEK293 cells to morphine excited persistent phosphorylation of ERK/MAP kinases, and those cells failed to internalize the opioid receptor. When ERK/MAP kinase phosphorylation was blocked by 2'-Amino-3'-methoxyflavone (PD98059), morphine gained the ability to strongly induce DOR endocytosis. The importance of activated MAP kinases for DOR internalization is further demonstrated by glutamate and paclitaxel because these substances induce phosphorylation of ERK1/2 and concomitantly prevent DOR sequestration by etorphine. In addition, receptor internalization by morphine was facilitated by inhibition of protein kinase C and opioid-mediated transactivation of epidermal growth factor receptor (EGFR), both activating ERK/MAP kinases by opioids. The mechanism affording DOR internalization by PD98059 may relate to arrestin, which uncouples GPCRs and thus triggers receptor internalization. Arrestin considerably translocates toward the cell membrane upon DOR activation by morphine in presence of the MAP kinase blocker, but it fails in the absence of PD98059. We conclude that ERK/MAP kinase activity prevents opioid receptor desensitization and sequestration by blocking arrestin 2 interaction with activated DORs.	Univ Munich, Inst Pharmacol Toxicol & Pharm, D-80539 Munich, Germany	Eisinger, DA (reprint author), Univ Munich, Inst Pharmacol Toxicol & Pharm, Koeniginstr 16, D-80539 Munich, Germany.	eisinger@pharmtox.vetmed.uni-muenchen.de					Ai WD, 1999, FEBS LETT, V456, P196, DOI 10.1016/S0014-5793(99)00949-7; Ammer H, 1997, MOL PHARMACOL, V52, P993; Ammer H, 2000, FEBS LETT, V485, P157, DOI 10.1016/S0014-5793(00)02207-9; Belcheva MM, 2001, J BIOL CHEM, V276, P33847, DOI 10.1074/jbc.M101535200; Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Earnest S, 1996, FEBS LETT, V396, P62, DOI 10.1016/0014-5793(96)01074-5; Eisinger DA, 2002, J NEUROSCI, V22, P10192; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HENIS YI, 1981, P NATL ACAD SCI-BIOL, V78, P1072, DOI 10.1073/pnas.78.2.1072; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kramer HK, 2000, BIOCHEM PHARMACOL, V60, P781, DOI 10.1016/S0006-2952(00)00400-7; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; Liu QR, 2002, J BIOL CHEM, V277, P13312, DOI 10.1074/jbc.M107558200; Mundell SJ, 1998, BRIT J PHARMACOL, V125, P1594, DOI 10.1038/sj.bjp.0702234; Nagao K, 2002, DEV CELL, V2, P2, DOI 10.1016/S1534-5807(01)00112-5; Narita M, 2001, PHARMACOL THERAPEUT, V89, P1, DOI 10.1016/S0163-7258(00)00099-1; Okano J, 2001, J BIOL CHEM, V276, P19555, DOI 10.1074/jbc.M011164200; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Rao S, 1999, J BIOL CHEM, V274, P37990, DOI 10.1074/jbc.274.53.37990; Sano M, 1998, BRAIN RES, V785, P299, DOI 10.1016/S0006-8993(97)01403-0; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Schmidt H, 2000, J NEUROCHEM, V74, P414, DOI 10.1046/j.1471-4159.2000.0740414.x; Schulz R, 2002, J PHARMACOL EXP THER, V300, P376, DOI 10.1124/jpet.300.2.376; Shah BH, 2002, MOL ENDOCRINOL, V16, P610, DOI 10.1210/me.16.3.610; SOOD PP, 1985, CELL MOL BIOL, V31, P469; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Ueda H, 2001, J NEUROSCI, V21, P2967, DOI 10.1523/JNEUROSCI.21-09-02967.2001; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Williams JT, 2001, PHYSIOL REV, V81, P299; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1999, J RECEPT SIGNAL TR R, V19, P301, DOI 10.3109/10799899909036653	46	23	24	0	7	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	MAY 1	2004	309	2					776	785		10.1124/jpet.103.061788			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	814KF	WOS:000220972900043	14742744				2020-06-26	J	Elliott, JC; Picker, MJ; Nelson, CJ; Carrigan, KA; Lysle, DT				Elliott, JC; Picker, MJ; Nelson, CJ; Carrigan, KA; Lysle, DT			Sex differences in opioid-induced enhancement of contact hypersensitivity	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Article						contact dermatitis; morphine; etorphine; buprenorphine	CD8(+) T-CELLS; MORPHINE MODULATION; PHYSICAL-DEPENDENCE; SUBSTANCE-P; MAST-CELLS; GENDER; RESPONSIVENESS; BUPRENORPHINE; GONADECTOMY; SENSITIVITY	Previous research has demonstrated that, in male rats, the magnitude of contact hypersensitivity (CHS) can be enhanced by morphine treatment. The present experiments test the hypothesis that the mu-opioids morphine, etorphine, and buprenorphine would produce significant sex differences in the magnitude of 2,4-dinitrofluorobenzene-induced CHS. During tests conducted over a 192-h period, morphine, etorphine, and buprenorphine administered before elicitation of CHS on the external surface of the ear (pinna) potentiated the CHS response, and the magnitude of this enhancement was significantly greater in females than males. By contrast, morphine had no effect on croton oil-induced irritant contact dermatitis, indicating that morphine's effects on CHS do not generalize to immunologically nonspecific forms of contact dermatitis. Activation of brain mu-opioid receptors is responsible for the effects of morphine on CHS, because intracere-broventricular treatment with the mu-opioid receptor antagonist beta-funaltrexamine blocked morphine potentiation of CHS in females and males. The sex differences in morphine potentiation of CHS appear to be a result of the gonadal hormonal milieu, because castration enhanced the CHS response following vehicle and morphine treatment, whereas ovariectomy significantly attenuated the enhancement of CHS by morphine. Because ovariectomy had no effect on the CHS response following vehicle treatment, the presence of female gonadal hormones may underlie the sex differences in morphine potentiation of CHS in gonadally intact animals. Overall, these results support an increased sensitivity to the modulatory effects of opioids on the CHS response in females that depends on the interaction between gonadal hormones and the central mu-opioid system.	Univ N Carolina, Dept Psychol, Biol Psychol Program, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Neurobiol, Chapel Hill, NC 27599 USA	Lysle, DT (reprint author), Univ N Carolina, Dept Psychol, Biol Psychol Program, CB 3270,Davie Hall, Chapel Hill, NC 27599 USA.	dlysle@email.unc.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 07481, DA 10277, DA 15709]		Aceto MD, 1997, EUR J PHARMACOL, V338, P215, DOI 10.1016/S0014-2999(97)81924-3; BAADSGAARD O, 1991, INT J DERMATOL, V30, P161, DOI 10.1111/j.1365-4362.1991.tb03844.x; Baumann MH, 2000, BRAIN RES, V858, P320, DOI 10.1016/S0006-8993(99)02479-8; BOUR H, 1995, EUR J IMMUNOL, V25, P3006, DOI 10.1002/eji.1830251103; CHER DJ, 1987, J IMMUNOL, V138, P3688; Cicero TJ, 2002, PHARMACOL BIOCHEM BE, V72, P691, DOI 10.1016/S0091-3057(02)00740-2; Cicero TJ, 1996, J PHARMACOL EXP THER, V279, P767; Cook CD, 2000, PSYCHOPHARMACOLOGY, V150, P430, DOI 10.1007/s002130000453; Di Bello MG, 1998, INFLAMM RES, V47, P122, DOI 10.1007/s000110050299; Eisenstein TK, 1998, J NEUROIMMUNOL, V83, P36, DOI 10.1016/S0165-5728(97)00219-1; EMMERSON PJ, 1994, J PHARMACOL EXP THER, V271, P1630; ENK AH, 1992, P NATL ACAD SCI USA, V89, P1398, DOI 10.1073/pnas.89.4.1398; FECHO K, 1994, J IMMUNOL, V152, P5845; Gades NM, 2000, CONTEMP TOP LAB ANIM, V39, P8; Grabbe S, 1998, IMMUNOL TODAY, V19, P37, DOI 10.1016/S0167-5699(97)01186-9; HOLZER P, 1992, REV PHYSIOL BIOCH P, V121, P49, DOI 10.1007/BFb0033194; KIRK RE, 1982, [No title captured]; KONDO S, 1995, J INVEST DERMATOL, V105, P334, DOI 10.1111/1523-1747.ep12320329; Leposavic G, 1996, PHARMACOL BIOCHEM BE, V54, P269, DOI 10.1016/0091-3057(95)02165-5; LYSLE DT, 1993, J PHARMACOL EXP THER, V265, P1071; Marks JG, 2002, CONTACT OCCUPATIONAL; MARONE G, 1993, ANN FR ANESTH, V12, P116, DOI 10.1016/S0750-7658(05)81020-2; McHale JF, 1999, J IMMUNOL, V162, P1648; McMurray RW, 2001, INT IMMUNOPHARMACOL, V1, P995, DOI 10.1016/S1567-5769(01)00045-5; Mellon RD, 1998, J NEUROIMMUNOL, V83, P19, DOI 10.1016/S0165-5728(97)00217-8; NEGUS SS, 1988, EUR J PHARMACOL, V156, P77, DOI 10.1016/0014-2999(88)90149-5; Nelson CJ, 2001, CLIN IMMUNOL, V98, P370, DOI 10.1006/clim.2000.4995; Nelson CJ, 2001, J NEUROIMMUNOL, V115, P101, DOI 10.1016/S0165-5728(01)00258-2; Nelson CJ, 1999, CLIN IMMUNOL, V93, P176, DOI 10.1006/clim.1999.4783; Niizeki H, 1999, J INVEST DERMATOL, V112, P437, DOI 10.1046/j.1523-1747.1999.00534.x; RAY MC, 1983, J IMMUNOL, V131, P1096; REES JL, 1989, BRIT J DERMATOL, V120, P371, DOI 10.1111/j.1365-2133.1989.tb04162.x; Sarton E, 2000, ANESTHESIOLOGY, V93, P1245, DOI 10.1097/00000542-200011000-00018; Sarton E, 1999, ANESTHESIOLOGY, V90, P1329, DOI 10.1097/00000542-199905000-00017; SHAAR CJ, 1975, J ENDOCRINOL, V66, P45, DOI 10.1677/joe.0.0660045; Terner JM, 2002, PSYCHOPHARMACOLOGY, V163, P183, DOI 10.1007/s00213-002-1143-x; Travi BL, 2002, INFECT IMMUN, V70, P2288, DOI 10.1128/IAI.70.5.2288-2296.2002; Tzschentke TM, 2002, PSYCHOPHARMACOLOGY, V161, P1, DOI 10.1007/s00213-002-1003-8; Whitacre CC, 1999, SCIENCE, V283, P1277, DOI 10.1126/science.283.5406.1277; Xu H, 1996, J EXP MED, V183, P1001, DOI 10.1084/jem.183.3.1001; Zun LS, 2002, AM J EMERG MED, V20, P151, DOI 10.1053/ajem.2002.32631	41	12	12	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	NOV	2003	121	5					1053	1059		10.1046/j.1523-1747.2003.12569.x			7	Dermatology	Dermatology	739VM	WOS:000186367200024	14708606				2020-06-26	J	Qiu, Y; Law, PY; Loh, HH				Qiu, Y; Law, PY; Loh, HH			mu-opioid receptor desensitization - Role of receptor phosphorylation, internalization, and resensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; AGONIST-INDUCED DESENSITIZATION; INDUCED DOWN-REGULATION; BETA-ARRESTIN; AMINO-ACIDS; HOMOLOGOUS DESENSITIZATION; MEDIATED ENDOCYTOSIS; TERMINAL TAIL; KINASES; IDENTIFICATION	It is generally accepted that the internalization and desensitization of mu-opioid receptor (MOR) involves receptor phosphorylation and beta-arrestin recruitment. However, a mutant MOR, which is truncated after the amino acid residue Ser(363) (MOR363D), was found to undergo phosphorylation-independent internalization and desensitization. As expected, MOR363D, missing the putative agonist-induced phosphorylation sites, did not exhibit detectable agonist-induced phosphorylation. MOR363D underwent slower internalization as reflected in the attenuation of membrane translocation of beta-arrestin 2 when compared with wild type MOR, but the level of receptor being internalized was similar to that of wild type MOR after 4 h of etorphine treatment. Furthermore, MOR363D was observed to desensitize faster than that of wild type MOR upon agonist activation. Surface biotinylation assay demonstrated that the wild type receptors recycled back to membrane after agonist-induced internalization, which contributed to the receptor resensitization and thus partially reversed the receptor desensitization. On the contrary, MOR363D did not recycle after internalization. Hence, MOR desensitization is controlled by the receptor internalization and the recycling of internalized receptor to cell surface in an active state. Taken together, our data indicated that receptor phosphorylation is not absolutely required in the internalization, but receptor phosphorylation and subsequent beta-arrestin recruitment play important roles in the resensitization of internalized receptors.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	Qiu, Y (reprint author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.			Law, Ping-Yee/0000-0002-5364-1093	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA11806, DA07339, DA0564, K05 DA70544, K05 DA00513]		Afify EA, 1998, MOL BRAIN RES, V54, P24, DOI 10.1016/S0169-328X(97)00315-X; Allouche S, 1999, EUR J PHARMACOL, V371, P235, DOI 10.1016/S0014-2999(99)00180-6; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Baratti-Elbaz C, 1999, MOL ENDOCRINOL, V13, P1751, DOI 10.1210/me.13.10.1751; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Brasselet S, 2002, FEBS LETT, V516, P124, DOI 10.1016/S0014-5793(02)02517-6; Burd AL, 1998, J BIOL CHEM, V273, P34488, DOI 10.1074/jbc.273.51.34488; Celver JP, 2001, J BIOL CHEM, V276, P4894, DOI 10.1074/jbc.M007437200; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Deng HB, 2000, BIOCHEMISTRY-US, V39, P5492, DOI 10.1021/bi991938b; Deng HB, 2001, BRAIN RES, V898, P204, DOI 10.1016/S0006-8993(01)02179-5; Dhami GK, 2002, J BIOL CHEM, V277, P25266, DOI 10.1074/jbc.M203593200; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; El Kouhen R, 1999, J BIOL CHEM, V274, P9207, DOI 10.1074/jbc.274.14.9207; El Kouhen R, 2001, J BIOL CHEM, V276, P12774, DOI 10.1074/jbc.M009571200; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Kishi M, 2001, MOL ENDOCRINOL, V15, P1624, DOI 10.1210/me.15.9.1624; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Kovoor A, 1998, MOL PHARMACOL, V54, P704; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Law PY, 2000, MOL PHARMACOL, V58, P388; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Olivares-Reyes JA, 2001, J BIOL CHEM, V276, P37761; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Richardson MD, 2003, J NEUROCHEM, V84, P854, DOI 10.1046/j.1471-4159.2003.01577.x; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; Wang HL, 2002, BIOCHEM PHARMACOL, V64, P257, DOI 10.1016/S0006-2952(02)01114-0; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449	39	62	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36733	36739		10.1074/jbc.M305857200			7	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	721LR	WOS:000185318300105	12860981	Bronze			2020-06-26	J	Wang, W; Loh, HH; Law, PY				Wang, W; Loh, HH; Law, PY			The intracellular trafficking of opioid receptors directed by carboxyl tail and a di-leucine motif in Neuro2A cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; C-TERMINAL TAIL; AGONIST-SPECIFIC REGULATION; INDUCED DOWN-REGULATION; NG108-15 HYBRID-CELLS; BETA-ARRESTIN; MEDIATED ENDOCYTOSIS; BETA(2)-ADRENERGIC RECEPTOR; OPIATE RECEPTOR; ALPHA(2)-ADRENERGIC RECEPTORS	The mu- and delta-opioid receptors (MOR and DOR) differ significantly in their intracellular trafficking. MORs recycle back to the cell surface upon agonist treatment, whereas most internalized DORs are targeted to lysosomes for degradation. By exchanging the carboxyl tail domains of MOR and DOR and expressing the receptor chimeras in mouse neuroblastoma Neuro2A cells, it could be demonstrated that the carboxyl tail domain is not the sole determinant in directing the intracellular trafficking in these Neuro2A cells. Deletion of the dileucine motif ( Leu(245)-Leu(246)) within the third intracellular loop of DOR or the mutation of Leu(245) to Met slowed the lysosomal targeting of these delta-opioid receptors. Meanwhile the mutation of Met(264) to Leu increased the rate of agonist-induced receptor internalization and the lysosomal targeting of the wild type and the delta-opioid receptor carboxyl tail chimera of the mu-opioid receptor. These studies suggest interplay between a di-leucine motif and the carboxyl tail in the lysosomal targeting of the receptor.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	Law, PY (reprint author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	lawxx001@umn.edu		Law, Ping-Yee/0000-0002-5364-1093	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA07339, DA11806, K05 DA70544, K05 DA00513]		Afify EA, 1998, MOL BRAIN RES, V54, P24, DOI 10.1016/S0169-328X(97)00315-X; Bohn LM, 2000, J NEUROCHEM, V74, P574, DOI 10.1046/j.1471-4159.2000.740574.x; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Burd AL, 1998, J BIOL CHEM, V273, P34488, DOI 10.1074/jbc.273.51.34488; Cen B, 2001, MOL PHARMACOL, V59, P758; Cen B, 2001, J NEUROCHEM, V76, P1887, DOI 10.1046/j.1471-4159.2001.00204.x; Chaipatikul V, 2003, J PHARMACOL EXP THER, V305, P909, DOI 10.1124/jpet.102.046219; CHANG KJ, 1982, NATURE, V296, P446, DOI 10.1038/296446a0; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; DeGraff JL, 2002, J BIOL CHEM, V277, P43247, DOI 10.1074/jbc.M207495200; El Kouhen R, 2001, J BIOL CHEM, V276, P12774, DOI 10.1074/jbc.M009571200; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Georgoussi Z, 1997, BBA-MOL CELL RES, V1359, P263, DOI 10.1016/S0167-4889(97)00097-9; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Ignatova EG, 1999, J NEUROSCI, V19, P56; Johnson AO, 2001, MOL BIOL CELL, V12, P367, DOI 10.1091/mbc.12.2.367; Jones SM, 2002, AM J PHYSIOL-CELL PH, V282, pC420, DOI 10.1152/ajpcell.00253.2001; Ko JL, 1999, MOL BRAIN RES, V69, P171, DOI 10.1016/S0169-328X(99)00094-7; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Law PY, 2000, MOL PHARMACOL, V58, P388; LAW PY, 1982, MOL PHARMACOL, V22, P1; LAW PY, 1984, J BIOL CHEM, V259, P4096; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; Merkouris M, 1996, MOL PHARMACOL, V50, P985; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Moore RH, 1999, J CELL SCI, V112, P329; Mundell SJ, 1998, BRIT J PHARMACOL, V125, P1594, DOI 10.1038/sj.bjp.0702234; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Nakamura K, 1999, MOL PHARMACOL, V56, P728; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; Neilan CL, 1999, BRIT J PHARMACOL, V128, P556, DOI 10.1038/sj.bjp.0702816; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Pak Y, 1999, J BIOL CHEM, V274, P27610, DOI 10.1074/jbc.274.39.27610; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Preisser L, 1999, FEBS LETT, V460, P303, DOI 10.1016/S0014-5793(99)01360-5; Roth BL, 1998, DRUG ALCOHOL DEPEN, V51, P73, DOI 10.1016/S0376-8716(98)00067-2; SADEE W, 1995, ADV EXP MED BIOL, V373, P85; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; Sandoval IV, 2000, J BIOL CHEM, V275, P39874, DOI 10.1074/jbc.M006261200; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Schulein R, 1998, MOL PHARMACOL, V54, P525; Setaluri V, 2000, PIGM CELL RES, V13, P128, DOI 10.1034/j.1600-0749.2000.130302.x; Simmen T, 1999, J CELL SCI, V112, P45; Smythies J, 2000, P ROY SOC B-BIOL SCI, V267, P1363, DOI 10.1098/rspb.2000.1151; Tang BL, 1999, FEBS LETT, V446, P211, DOI 10.1016/S0014-5793(99)00195-7; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Wang DX, 1999, J BIOL CHEM, V274, P22081, DOI 10.1074/jbc.274.31.22081; Wang HL, 1999, J NEUROCHEM, V72, P1307, DOI 10.1046/j.1471-4159.1999.0721307.x; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 2001, J BIOL CHEM, V276, P34331, DOI 10.1074/jbc.M104627200; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Wolf R, 1999, MOL PHARMACOL, V55, P263; ZADINA JE, 1993, J PHARMACOL EXP THER, V265, P254; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1999, J RECEPT SIGNAL TR R, V19, P301, DOI 10.3109/10799899909036653; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	72	33	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36848	36858		10.1074/jbc.M301540200			11	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	721LR	WOS:000185318300118	12851402	Bronze			2020-06-26	J	Schutz, J; Spetea, M; Koch, M; Aceto, MD; Harris, LS; Coop, A; Schmidhammer, H				Schutz, J; Spetea, M; Koch, M; Aceto, MD; Harris, LS; Coop, A; Schmidhammer, H			Synthesis and biological evaluation of 14-alkoxymorphinans. 20. 14-phenylpropoxymetopon: An extremely powerful analgesic	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							OPIOID RECEPTOR AGONIST; TIC-PHE-OH; HIGHLY POTENT; BINDING CHARACTERISTICS; SIGNAL-TRANSDUCTION; MU; 14-METHOXYMETOPON; ANTAGONISTS; CONFORMATION; EFFICACY	The synthesis and the biological and pharmacological evaluation of several 14-phenylpropoxy analogues of 14-methoxymetopon are described. Most of the new compounds were nonselective and exhibited binding affinities in the subnanomolar or low nanomolar range at opioid receptors (mu, kappa, delta), with 14-phenylpropoxymetopon (PPOM; 7) displaying the highest affinity for all three opioid receptor types. The most striking finding of this study is that the derivatives from the novel series of N-methyl-14-phenylpropoxymorphinans acted as extremely powerful antinociceptives with potencies higher than that of 14-methoxymetopon (1) and even etorphine. 14-Phenylpropoxymetopon (PPOM; 7) showed considerably increased potency in the in vivo assays in mice (25-fold in the tail-flick assay, 10-fold in the hot-plate assay, and 2.5-fold in the paraphenylquinone writhing test) when compared to etorphine, while it was equipotent to dihydroetorphine in the hot-plate assay and the paraphenylquinone writhing test and ca. twice as potent in the tail-flick assay than this reference compound. The 3-O-alkyl ethers of PPOM, compounds 6 and 8, showed less potency in in vivo assays, but partly surpassed the potency of the 3-OH analogue 14-methoxymetopon (1).	Univ Innsbruck, Inst Pharm, Dept Pharmaceut Chem, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Pharm, Dept Pharmacol & Toxicol, A-6020 Innsbruck, Austria; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA	Schmidhammer, H (reprint author), Univ Innsbruck, Inst Pharm, Dept Pharmaceut Chem, Innrain 52a, A-6020 Innsbruck, Austria.	helmut.schmidhammer@uibk.ac.at		Spetea, Mariana/0000-0002-2379-5358; Schmidhammer, Helmut/0000-0001-8752-5050			Aceto MD, 1997, EUR J PHARMACOL, V338, P215, DOI 10.1016/S0014-2999(97)81924-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandt W, 1998, J COMPUT AID MOL DES, V12, P615, DOI 10.1023/A:1008003421291; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; DEWEY WL, 1971, J PHARMACOL EXP THER, V179, P652; EDDY NB, 1953, J PHARMACOL EXP THER, V107, P385; Freye E, 2000, ANESTH ANALG, V90, P1359, DOI 10.1097/00000539-200006000-00018; FURST Z, 1993, EUR J PHARMACOL, V236, P209, DOI 10.1016/0014-2999(93)90591-5; Greiner E, 2003, J MED CHEM, V46, P1758, DOI 10.1021/jm021118o; HANDA BK, 1981, EUR J PHARMACOL, V70, P531, DOI 10.1016/0014-2999(81)90364-2; Husbands SM, 1998, J MED CHEM, V41, P3493, DOI 10.1021/jm9810248; King MA, 2003, EUR J PHARMACOL, V459, P203, DOI 10.1016/S0014-2999(02)02821-2; LAHTI RA, 1985, EUR J PHARMACOL, V109, P281, DOI 10.1016/0014-2999(85)90431-5; LAUS G, 2003, IN PRESS HELV CHIM A; MacPherson RD, 2000, PHARMACOL THERAPEUT, V88, P163, DOI 10.1016/S0163-7258(00)00090-5; MAY EL, 1994, J MED CHEM, V37, P3408, DOI 10.1021/jm00046a026; NEVIN ST, 1994, NEUROPEPTIDES, V26, P261, DOI 10.1016/0143-4179(94)90080-9; NIWA M, 1995, LIFE SCI PL, V56, P395; Pasternak GW, 2001, TRENDS PHARMACOL SCI, V22, P67, DOI 10.1016/S0165-6147(00)01616-3; PORTOGHESE PS, 1994, J MED CHEM, V37, P579, DOI 10.1021/jm00031a006; PORTOGHESE PS, 1993, J MED CHEM, V36, P2572, DOI 10.1021/jm00069a017; SCHILLER PW, 1992, P NATL ACAD SCI USA, V89, P11871, DOI 10.1073/pnas.89.24.11871; SCHMIDHAMMER H, 1983, MED RES REV, V3, P1, DOI 10.1002/med.2610030102; SCHMIDHAMMER H, 1984, J MED CHEM, V27, P1575, DOI 10.1021/jm00378a009; SCHMIDHAMMER H, 1990, HELV CHIM ACTA, V73, P1784, DOI 10.1002/hlca.19900730623; SCHMIDHAMMER H, 1988, HELV CHIM ACTA, V71, P1801, DOI 10.1002/hlca.19880710721; Schmidhammer H, 1993, CURR TOP MED CHEM, V1, P261; SCHMIDT R, 1994, J MED CHEM, V37, P1136, DOI 10.1021/jm00034a011; SCHULLNER F, 2003, IN PRESS HELV CHIM A; Schutz J, 2003, Z KRIST-NEW CRYST ST, V218, P181; Spetea M, 2003, EUR J NEUROSCI, V18, P290, DOI 10.1046/j.1460-9568.2003.02744.x; Spetea M, 2001, LIFE SCI, V69, P1775, DOI 10.1016/S0024-3205(01)01271-1; Uriguen L, 2002, BRAIN RES BULL, V57, P661, DOI 10.1016/S0361-9230(01)00760-2; WILKES BC, 1994, BIOPOLYMERS, V34, P1213, DOI 10.1002/bip.360340909; WILKES BC, 1995, BIOPOLYMERS, V37, P391, DOI 10.1002/bip.360370606; Zernig G, 2000, LIFE SCI, V66, P1871, DOI 10.1016/S0024-3205(00)00510-5	36	22	23	0	1	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623			J MED CHEM	J. Med. Chem.	SEP 11	2003	46	19					4182	4187		10.1021/jm030878b			6	Chemistry, Medicinal	Pharmacology & Pharmacy	719YM	WOS:000185232700024	12954070				2020-06-26	J	Portas, TJ; Lynch, MJ; Vogelnest, L				Portas, TJ; Lynch, MJ; Vogelnest, L			Comparison of etorphine-detomidine and medetomidine-ketamine anesthesia in captive addax (Addax nasomaculatus)	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						addax; Addax nasomaculatus; anesthesia; medetomidine; ketamine; etorphine; detomidine	ORYX ORYX-LEUCORYX; SHEEP OVIS-OVIS; INDUCED IMMOBILIZATION; ATIPAMEZOLE; REVERSAL; XYLAZINE; COMBINATION	Thirty-five anesthetic events involving 15 captive addax (Addax nasomaculatus) were performed between August 1998 and February 2002 using a combination of etorphine (33.7 +/- 7.9 mug/kg) and detomidine (21.9 +/- 4.6 mug/kg) or a combination of medetomidine (57.4 +/- 8.6 mug/kg) and ketamine (1.22 +/- 0.3 mug/kg), with or without supplemental injectable or inhalant anesthetic agents. Etorphine-detomidine anesthesia was antagonized with diprenorphine (107.1 +/- 16.4 mug/kg) and atipamezole (100.9 +/- 42.4 mug/kg). Medetomidine-ketamine anesthesia was antagonized with atipamezole (245.3 +/- 63.4 mug/kg). Animals became recumbent within 5 min when the combination of etorphine and detomidine was used and within 11 min when the combination of medetomidine and ketamine was used. Both drug combinations were suitable for use as primary immobilizing agents producing short-duration restraint and analgesia. Bradycardia was noted with both combinations. Further investigation of the cardiopulmonary effects of both combinations is warranted.	Victorias Open Range Zoo, Werribee, Vic 3030, Australia; Royal Melbourne Zool Gardens, Parkville, Vic 3052, Australia	Portas, TJ (reprint author), Western Plains Zoo, Dubbo, NSW 2830, Australia.						Allen Jack L., 1999, P2; ALLEN JL, 1991, PROCEEDINGS : AMERICAN ASSOCIATION OF ZOO VETERINARIANS - ANNUAL MEETING 1991, P343; Ancrenaz M, 1996, J ZOO WILDLIFE MED, V27, P209; Asa CS, 1996, J REPROD FERTIL, V107, P119; Bush M, 2001, J AM VET MED ASSOC, V218, P245, DOI 10.2460/javma.2001.218.245; CAULKETT NA, 1994, J ZOO WILDLIFE MED, V25, P376; Caulkett NA, 1996, J ZOO WILDLIFE MED, V27, P217; Chittick E, 2001, J ZOO WILDLIFE MED, V32, P168, DOI 10.1638/1042-7260(2001)032[0168:CAOMKA]2.0.CO;2; Citino SB, 2001, J S AFR VET ASSOC, V72, P29; deMaar TWJ, 1998, P AM ASS ZOO VET ANN, P54; DENSMORE MA, 1987, J ZOO WILDLIFE MED, V18, P123, DOI 10.2307/20460260; GRETH A, 1993, J ZOO WILDLIFE MED, V24, P445; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P391; Heard DJ, 1996, AM J VET RES, V57, P87; JALANKA H, 1989, ACTA VET SCAND, P193; JALANKA H, 1988, J ZOO WILDLIFE MED, V19, P95, DOI 10.2307/20094864; JALANKA HH, 1989, J ZOO WILDLIFE MED, V20, P154; KLEIN L, 1994, P AM ASS ZOO VET, P200; Kock R.A., 1988, P75; MACHADO CR, 1983, J ZOO ANIM MED, V14, P107, DOI 10.2307/20094653; Matthews NS, 1995, J ZOO WILDLIFE MED, V26, P231; MONFORT SL, 1999, P AM ASS ZOO VET, P77; Phillips LG, 1998, P AM ASS ZOO VET, P19; Ryeng KA, 2001, AM J VET RES, V62, P406, DOI 10.2460/ajvr.2001.62.406; Tsuruga H, 1999, J WILDLIFE DIS, V35, P774, DOI 10.7589/0090-3558-35.4.774; VAINIO O, 1989, ACTA VET SCAND, P85; VIRTANEN R, 1989, ACTA VET SCAND, P29	27	11	12	0	10	AMER ASSOC ZOO VETERINARIANS	YULEE	581705 WHITE OAK ROAD, YULEE, FL 32097 USA	1042-7260	1937-2825		J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	SEP	2003	34	3					269	273		10.1638/02-062			5	Veterinary Sciences	Veterinary Sciences	729EL	WOS:000185759600007	14582789				2020-06-26	J	Chaipatikul, V; Erickson-Herbrandson, LJ; Loh, HH; Law, PY				Chaipatikul, V; Erickson-Herbrandson, LJ; Loh, HH; Law, PY			Rescuing the traffic-deficient mutants of rat mu-opioid receptors with hydrophobic ligands	MOLECULAR PHARMACOLOGY			English	Article							CELL-SURFACE EXPRESSION; 3RD INTRACELLULAR LOOP; TRANSMEMBRANE CONDUCTANCE REGULATOR; VASOPRESSIN V-2 RECEPTOR; INDUCED UP-REGULATION; C-TERMINAL TAIL; BETA(2)-ADRENERGIC RECEPTOR; PHARMACOLOGICAL CHAPERONES; CONSTITUTIVE ACTIVATION; GONADOTROPIN RECEPTOR	Deletion of a sequence near the fifth transmembrane domain ((RLSKV262)-R-258, i3-1 mutant) and a motif residing at the proximal carboxyl tail ((KFCTR348)-K-344, C-2 mutant) resulted in mu-opioid receptor mutants that were poorly expressed on the surface of transfected human embryonic kidney 293 cells. Treatment with the opioid antagonist naloxone, the agonist etorphine, and other hydrophobic ligands enhanced cell surface expression of i3-1 and C-2 mutants. The observed enhancement was time- and concentration-dependent, required the ligands to be membrane permeable, and was not the result of the reversal of the constitutive activities of the mutant receptors. The binding of the ligands resulted in the trafficking of the mutant receptors retained in the endoplasmic reticulum to the cell surface. The cell surface-expressed mutant C-2, but not i3-1, fully retained ability to mediate inhibition of adenylyl cyclase activity. Furthermore, the Golgi-disturbing agents brefeldin A and monensin completely blocked naloxone-enhanced expression of i3-1 and C-2 mutants. Results of these studies suggest that intracellular interactions of agonist and antagonist with mutant receptors can serve as chaperones in the trafficking of the mutants to the cell surface.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	Law, PY (reprint author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.			Law, Ping-Yee/0000-0002-5364-1093	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA07339, DA11806, KO5-DA00513, KO5-DA70554]		Bradbury FA, 1997, J BIOL CHEM, V272, P5921, DOI 10.1074/jbc.272.9.5921; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; Chicchi GG, 1997, J BIOL CHEM, V272, P7765, DOI 10.1074/jbc.272.12.7765; Couvineau A, 1996, BIOCHEMISTRY-US, V35, P1745, DOI 10.1021/bi952022h; Georgoussi Z, 1997, BBA-MOL CELL RES, V1359, P263, DOI 10.1016/S0167-4889(97)00097-9; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Halaban R, 2000, P NATL ACAD SCI USA, V97, P5889, DOI 10.1073/pnas.97.11.5889; HEINFLINK M, 1995, MOL ENDOCRINOL, V9, P1455, DOI 10.1210/me.9.11.1455; Huang P, 2001, BIOCHEMISTRY-US, V40, P13501, DOI 10.1021/bi010917q; Krause G, 2000, MOL PHARMACOL, V57, P232; Law PY, 2000, MOL PHARMACOL, V58, P388; Law PY, 1999, BIOPOLYMERS, V51, P440, DOI 10.1002/(SICI)1097-0282(1999)51:6<440::AID-BIP6>3.0.CO;2-T; LE AQ, 1994, J BIOL CHEM, V269, P7514; Li J, 2001, BIOCHEMISTRY-US, V40, P12039, DOI 10.1021/bi0100945; LOO TW, 1994, J BIOL CHEM, V269, P28683; MacEwan DJ, 1996, MOL PHARMACOL, V50, P1479; McLean AJ, 1999, MOL PHARMACOL, V56, P1182; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Oksche A, 1998, FEBS LETT, V424, P57, DOI 10.1016/S0014-5793(98)00140-9; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; PIND S, 1994, J BIOL CHEM, V269, P12784; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; Rozell TG, 1998, ENDOCRINOLOGY, V139, P1588, DOI 10.1210/en.139.4.1588; Rozzell T G, 1995, Mol Endocrinol, V9, P1727, DOI 10.1210/me.9.12.1727; Samama P, 1997, P NATL ACAD SCI USA, V94, P137, DOI 10.1073/pnas.94.1.137; Schulein R, 1998, MOL PHARMACOL, V54, P525; SMIRNOV D, 2002, 5151 VIEW IT PLA SOC; Stevens PA, 2000, MOL PHARMACOL, V58, P438; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; WILLIAMS AM, 1993, J BIOL CHEM, V268, P12780; Wonerow P, 1998, J BIOL CHEM, V273, P7900, DOI 10.1074/jbc.273.14.7900; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480	37	43	45	0	2	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0026-895X			MOL PHARMACOL	Mol. Pharmacol.	JUL	2003	64	1					32	41		10.1124/mol.64.1.32			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	691NV	WOS:000183613100005	12815158				2020-06-26	J	Marie, N; Lecoq, I; Jauzac, P; Allouche, S				Marie, N; Lecoq, I; Jauzac, P; Allouche, S			Differential sorting of human delta-opioid receptors after internalization by peptide and alkaloid agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SK-N-BE; NEUROBLASTOMA CELL-LINE; PROTEIN-COUPLED RECEPTORS; HAMSTER OVARY CELLS; MOLECULAR MECHANISMS; DOWN-REGULATION; INDUCED DESENSITIZATION; ENDOCYTOSIS; MU; PHOSPHORYLATION	Desensitization and internalization of G protein-coupled receptors observed after agonist activation are considered two important regulatory processes of receptor transduction. Endogenous human delta-opioid receptors (hDOR) are differentially regulated in terms of desensitization by peptide ([D-Pen(2,5)] enkephalin (DPDPE) and Deltorphin I) and alkaloid (etorphine) agonists in the neuroblastoma cell line SK-N-BE (Allouche, S., Roussel, M., Marie, N., and Jauzac, P. (1999) Eur. J. Pharmacol. 371, 235 - 240). In the present study, we examined the role of hDOR internalization and down-regulation in this differential desensitization. Sustained activation by peptides for 30 min caused a marked decrease of both [H-3] diprenorphine binding sites and hDOR immunoreactivity, observed in a Western blot, whereas a moderate reduction by 30% was observed after a 30- and 60-min etorphine exposure in binding experiments without opioid receptor degradation. Using fluorescence microscopy, we visualized hDOR internalization promoted by different agonists in SK-N-BE cells expressing FLAG-tagged hDOR. Agonist withdrawal results in a greater recycling process correlated with a stronger hDOR resensitization after etorphine treatment compared with DPDPE or Deltorphin I, as shown in binding, immunocytochemical, and functional experiments. This suggests a distinct sorting of opioid receptors after their internalization. We demonstrated a lysosomal hDOR targeting upon peptides by using chloroquine in binding, Western blot, and immunocytochemical experiments and by colocalization of this receptor with a late endosome marker. In contrast, when the recycling endosome blocker monensin was used, acceleration of desensitization associated with a strong intracellular immunostaining was observed upon etorphine treatment. The possibility of separate endocytic pathways responsible for the differential sorting of hDOR upon peptide and alkaloid ligand exposure was ruled out by binding and immunocytochemical experiments using sucrose hypertonic solution. First, these results showed complex relationships between hDOR internalization/ down-regulation and desensitization. Second, we demonstrated for the first time that the same receptor could undergo a distinct sorting after internalization by peptide and alkaloid agonists.	Univ Caen, Ctr Hosp & Univ Caen, Lab Pharmacol Mol Tolerance Opiaces, F-14033 Caen, France	Allouche, S (reprint author), CHU Caen, Biochim Lab A, Ave Cote Nacre, F-14033 Caen, France.	allouche-se@chu-caen.fr	Marie, Nicolas/I-9129-2014	Marie, Nicolas/0000-0002-6491-9898; Allouche, stephane/0000-0003-3134-7501			Allouche S, 1999, EUR J PHARMACOL, V371, P235, DOI 10.1016/S0014-2999(99)00180-6; Allouche S, 1996, J NEUROCHEM, V67, P2461; Allouche S, 1999, BIOCHEM J, V342, P71, DOI 10.1042/0264-6021:3420071; Allouche S, 2000, BIOCHEM PHARMACOL, V59, P915, DOI 10.1016/S0006-2952(99)00404-9; Bot G, 1997, MOL PHARMACOL, V52, P272; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Chaturvedi K, 2001, J BIOL CHEM, V276, P12345, DOI 10.1074/jbc.M008054200; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Hasbi A, 2000, J PHARMACOL EXP THER, V293, P237; Hasbi A, 1998, J NEUROCHEM, V70, P2129; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; JOSEPH DB, 1995, J PHARMACOL EXP THER, V272, P970; Ko JL, 1999, MOL BRAIN RES, V69, P171, DOI 10.1016/S0169-328X(99)00094-7; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; Law PY, 2000, J BIOL CHEM, V275, P32057, DOI 10.1074/jbc.M002395200; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; Namir N, 1997, J NEUROCHEM, V68, P1764; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; Pak Y, 1996, MOL PHARMACOL, V50, P1214; PASTERNAK GW, 1993, CLIN NEUROPHARMACOL, V16, P1, DOI 10.1097/00002826-199302000-00001; POLASTRON J, 1994, J NEUROCHEM, V62, P898; PRATHER PL, 1994, J PHARMACOL EXP THER, V270, P177; RAYNOR K, 1994, J PHARMACOL EXP THER, V270, P1381; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Zhu JM, 1998, J PHARMACOL EXP THER, V285, P28	35	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22795	22804		10.1074/jbc.M300084200			10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	689QF	WOS:000183503900083	12672796	Bronze			2020-06-26	J	Li, JG; Zhang, FQ; Jin, XL; Liu-Chen, LY				Li, JG; Zhang, FQ; Jin, XL; Liu-Chen, LY			Differential regulation of the human kappa opioid receptor by agonists: Etorphine and levorphanol reduced dynorphin A- and U50,488H-induced internalization and phosphorylation	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							PROTEIN-COUPLED RECEPTORS; HAMSTER OVARY CELLS; DOWN-REGULATION; MORPHINE-TOLERANCE; BETA-ARRESTIN; DESENSITIZATION; ENDOCYTOSIS; RAT; ACTIVATION; BINDING	We previously observed that ( trans)-3,4-dichloro-N-methyl-N-[ 2-(1-pyrrolidinyl)-cyclohexyl] benzeneacetamide (U50,488H) promoted internalization and phosphorylation of the FLAG-tagged human kappa opioid receptor (FLAG-hkor) stably expressed in Chinese hamster ovary (CHO) cells. In this study, we compared regulation of the FLAG-hkor expressed in CHO cells by U50,488H, dynorphin A, etorphine, and levorphanol, which were potent full agonists as determined by stimulation of guanosine 5'-O-(3[ S-35] thio) triphosphate binding. Using fluorescence flow cytometry, we found that dynorphin A(1-17), like U50,488H, promoted internalization of the FLAG-hkor in a time- and dose-dependent manner. The antagonists naloxone and norbinaltorphimine, having no effect on FLAG-hkor internalization, effectively blocked dynorphin A(1-17)- and U50,488H-induced internalization. Interestingly, the full agonists etorphine and levorphanol did not cause internalization of the FLAG-hkor but significantly reduced dynorphin A(1-17)-and U50,488H-induced internalization in a dose-dependent manner. Immunofluorescence staining of FLAG-hkor yielded similar results. Dynorphin A(1-17) and U50,488H enhanced phosphorylation of FLAG-hkor to a greater extent than etorphine, but levorphanol did not increase FLAG-hkor phosphorylation. Etorphine or levorphanol decreased dynorphin- or U50,488H-induced phosphorylation. It is likely that conformations of the hkor required for phosphorylation and initiation of internalization are different from those for activation of G proteins. We also examined whether the four agonists had differential effects on superactivation of adenylate cyclase. Pretreatment with U50,488H, dynorphin A(1-17), or etorphine enhanced forskolin-stimulated adenylate cyclase activity to similar to200 to 250% of the control, whereas levorphanol pretreatment did not result in significant adenylate cyclase superactivation. Thus, the degree of superactivation caused by an agonist is unrelated to its ability to promote internalization of the hkor.	Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Ctr Subst Abuse Res, Philadelphia, PA 19140 USA	Liu-Chen, LY (reprint author), Temple Univ, Sch Med, Dept Pharmacol, 3420 N Broad St, Philadelphia, PA 19140 USA.	lliuche@astro.temple.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA13429, DA 04745, DA11263]		Alvarez VA, 2002, J NEUROSCI, V22, P5769; Appleyard SM, 1999, J BIOL CHEM, V274, P23802, DOI 10.1074/jbc.274.34.23802; Appleyard SM, 1997, J NEUROCHEM, V69, P2405; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; AVIDORREISS T, 1995, FEBS LETT, V361, P70, DOI 10.1016/0014-5793(95)00154-2; BHARGAVA HN, 1989, J PHARMACOL EXP THER, V251, P21; Blake AD, 1997, J NEUROCHEM, V68, P1846; Blake AD, 1997, J BIOL CHEM, V272, P782, DOI 10.1074/jbc.272.2.782; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bot G, 1997, MOL PHARMACOL, V52, P272; CHANG KJ, 1984, RECEPTORS, V1, P1; CHEN CG, 1995, J BIOL CHEM, V270, P17866, DOI 10.1074/jbc.270.30.17866; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; DYKSTRA LA, 1987, J PHARMACOL EXP THER, V242, P413; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; Huang P, 2001, J PHARMACOL EXP THER, V297, P688; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2000, DNA CELL BIOL, V19, P19, DOI 10.1089/104454900314672; JOSEPH DB, 1995, J PHARMACOL EXP THER, V272, P970; Keith DE, 1998, MOL PHARMACOL, V53, P377; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KNAPP RJ, 1995, FASEB J, V9, P516; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Li J, 2002, MOL PHARMACOL, V61, P73, DOI 10.1124/mol.61.1.73; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; Li JG, 2000, MOL PHARMACOL, V58, P795; Ling K, 1998, NEUROSCI LETT, V240, P25, DOI 10.1016/S0304-3940(97)00921-X; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; Mhaouty-Kodja S, 1999, MOL PHARMACOL, V55, P339; MORRIS BJ, 1989, NEUROSCIENCE, V29, P433, DOI 10.1016/0306-4522(89)90070-5; Murray C, 1988, NIDA Res Monogr, V81, P136; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Scaramellini C, 1998, ANN NY ACAD SCI, V861, P97; Schulz R, 2002, MOL PHARMACOL, V61, P1444, DOI 10.1124/mol.61.6.1444; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Tallent M, 1998, NEUROSCIENCE, V85, P873, DOI 10.1016/S0306-4522(97)00675-1; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7; XUE JC, 1994, J BIOL CHEM, V269, P30195; Zhang FQ, 2002, J PHARMACOL EXP THER, V302, P1184, DOI 10.1124/jpet.302.3.1184; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhu JM, 1998, J PHARMACOL EXP THER, V285, P28; Zhu JM, 1997, J PHARMACOL EXP THER, V282, P676	48	37	39	0	1	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	MAY	2003	305	2					531	540		10.1124/jpet.102.045559			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	669GL	WOS:000182343500017	12606694				2020-06-26	J	Gerak, LR; Gauthier, CA; France, CP				Gerak, LR; Gauthier, CA; France, CP			Discriminative stimulus and antinociceptive effects of dihydroetorphine in rhesus monkeys	PSYCHOPHARMACOLOGY			English	Article; Proceedings Paper	Experimental Biology 99 Meeting	APR 17-21, 1999	WASHINGTON, D.C.			dihydroetorphine; etorphine; morphine; discriminative stimulus effects; antinociception; rhesus monkeys	OPIOID RECEPTOR FUNCTIONS; PHYSICAL-DEPENDENCE; TOLERANCE DEPENDENCE; DRUG-DISCRIMINATION; SENSORY NEURONS; MORPHINE; MICE; BUPRENORPHINE; ANTAGONISTS; ANALGESIA	Rationale: Although dihydroetorphine has mu opioid agonist activity there is evidence to suggest that it is not identical to that of morphine. Objective: This study compared dihydroetorphine to other opioids under behavioral conditions that are sensitive to p opioid agonism. Methods: The acute effects of dihydroetorphine, etorphine and morphine were evaluated using two procedures. In one procedure, monkeys received 3.2 mg/kg per day of morphine and discriminated naltrexone from saline while responding under a fixed-ratio 5 schedule of stimulus shock termination. In addition, a war-m-water, tail-withdrawal procedure was used in untreated monkeys. Results: When acutely deprived of morphine, monkeys responded on the naltrexone lever, and this effect was reversed by dihydroetorphine, etorphine and morphine. Each agonist produced the maximum (20-s latency) antinociceptive effect in 50degreesC water. Naltrexone antagonized the discriminative stimulus and antinociceptive effects of dihydroetorphine and etorphine, although Schild analyses yielded large variability in slopes and pA(2) values. Naltrexone reversed established effects of dihydroetorphine and morphine in both procedures and pretreatment with dihydroetorphine (2, 6 or 24 h) did not alter the discriminative stimulus effects of morphine. Conclusions: Taken together, these data support the notion that dihydroetorphine is a p agonist with a short duration of action; however, variability in antagonism of dihydroetorphine and morphine might be a manifestation of differences that have been reported for these drugs at the cellular level.	Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78229 USA; Louisiana State Univ, Hlth Sci Ctr, Natl Ctr Excellence, New Orleans, LA 70112 USA	France, CP (reprint author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, 1901 Perdido St, New Orleans, LA 70112 USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA00211, DA05018]		Aceto MD, 1997, EUR J PHARMACOL, V338, P215, DOI 10.1016/S0014-2999(97)81924-3; Aceto MD, 2000, EUR J PHARMACOL, V387, P31, DOI 10.1016/S0014-2999(99)00758-X; Beardsley PM, 1997, DRUG ALCOHOL DEPEN, V48, P77, DOI 10.1016/S0376-8716(97)00112-9; BOAS RA, 1985, BRIT J ANAESTH, V57, P192, DOI 10.1093/bja/57.2.192; Brandt MR, 1997, J PHARMACOL EXP THER, V282, P574; Crain SM, 1998, TRENDS PHARMACOL SCI, V19, P358, DOI 10.1016/S0165-6147(98)01241-3; Crain SM, 1996, NEUROCHEM RES, V21, P1347, DOI 10.1007/BF02532375; CRAIN SM, 1995, P NATL ACAD SCI USA, V92, P10540, DOI 10.1073/pnas.92.23.10540; Eckersell CB, 1998, J NEUROSCI, V18, P3967; FRANCE CP, 1984, J PHARMACOL EXP THER, V230, P652; FRANCE CP, 1989, J PHARMACOL EXP THER, V250, P937; FRANCE CP, 1990, J PHARMACOL EXP THER, V252, P600; GERAK LR, 1994, J PHARMACOL EXP THER, V271, P993; Gerak LR, 1999, FASEB J, V13, pA802; Gerak LR, 1996, J PHARMACOL EXP THER, V276, P523; Gerak LR, 1998, PSYCHOPHARMACOLOGY, V137, P164, DOI 10.1007/s002130050606; Kamei J, 1996, NEUROSCI LETT, V215, P87, DOI 10.1016/S0304-3940(96)12942-6; Keith DE, 1998, MOL PHARMACOL, V53, P377; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Lelas S, 2000, J PHARMACOL EXP THER, V294, P902; Martin TJ, 1997, EUR J PHARMACOL, V324, P141, DOI 10.1016/S0014-2999(97)00074-5; Ohmori S, 2001, EUR J PHARMACOL, V423, P157, DOI 10.1016/S0014-2999(01)01098-6; Ohmori S, 2001, J PHARMACOL EXP THER, V296, P528; Paronis CA, 1999, J PHARMACOL EXP THER, V290, P1222; Schulz R, 1999, EUR J PHARMACOL, V375, P349, DOI 10.1016/S0014-2999(99)00223-X; SHEN KF, 1994, BRAIN RES, V636, P286, DOI 10.1016/0006-8993(94)91028-6; TALLARIDA RJ, 1987, [No title captured]; Tokuyama S, 1998, GEN PHARMACOL, V30, P697, DOI 10.1016/S0306-3623(97)00376-5; Tokuyama S, 1996, JPN J PHARMACOL, V71, P357, DOI 10.1254/jjp.71.357; TOKUYAMA S, 1994, BIOL PHARM BULL, V17, P1056; TOKUYAMA S, 1993, BIOL PHARM BULL, V16, P774; WALKER EA, 1995, J PHARMACOL EXP THER, V273, P1345; WANG DX, 1995, J PHARM PHARMACOL, V47, P669, DOI 10.1111/j.2042-7158.1995.tb05857.x	33	6	7	0	1	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0033-3158			PSYCHOPHARMACOLOGY	Psychopharmacology	APR	2003	166	4					351	359		10.1007/s00213-002-1268-y			9	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	671LA	WOS:000182465200004	12601499				2020-06-26	J	Yoburn, BC; Gomes, BA; Rajashekara, V; Patel, C; Patel, M				Yoburn, BC; Gomes, BA; Rajashekara, V; Patel, C; Patel, M			Role of G(i alpha 2)-protein in opioid tolerance and mu-opioid receptor downregulation in vivo	SYNAPSE			English	Article						G-proteins; opioids; downregulation; tolerance; antisense; mRNA	PROTEIN ALPHA-SUBUNITS; ANTISENSE OLIGODEOXYNUCLEOTIDES; PERTUSSIS TOXIN; DOWN-REGULATION; DIFFERENTIAL BLOCKADE; IN-VIVO; MORPHINE; DEPENDENCE; ANALGESIA; MICE	Although opioid receptors are G-protein coupled, the role that specific G-protein subunits play in the development of opioid tolerance and the regulation of opioid receptor number is not well understood. In the present study, we used a G(ialpha2) antisense oligodeoxynucleotide (ODN) to examine the contribution of G(ialpha2) proteins to mu-opioid tolerance and receptor downregulation in the mouse. Mice were injected intracerebroventricularly (ICV) and into the spinal intrathecal space (IT) for 4-5 consecutive days (30 mug/site/day), with an antisense ODN or a mismatch ODN directed at mRNA for the G(ialpha2) subunit of G-proteins. Controls were treated with dH(2)O. On the second day of ODN treatment continuous subcutaneous (SC) infusion of etorphine (200 mug/kg/day) or morphine (40 mg/kg/day + 25 mg pellet) was begun. Control mice were implanted with inert placebo pellets. Three days later, pumps and pellets were removed and mice were tested for morphine analgesia or mu-opioid receptor density was determined in whole brain. Etorphine produced significant tolerance (ED50 shift = similar to11-fold) and downregulation of R-opioid receptors (approximate to25%). Morphine treatment produced significant tolerance (ED50 shift approximate to9-fold), but no mu-opioid receptor downregulation. Antisense treatment reduced G(ialpha2) protein levels in striatum and spinal cord by similar to25%. G(ialpha2) antisense reduced the acute potency of morphine. G(ialpha2) antisense blocked the development of tolerance to morphine treatment and reduced the development of tolerance to etorphine treatment. Antisense did not have any effect on etorphine-induced mu-opioid receptor downregulation. In another experiment, 7-day treatment with morphine or etorphine similarly increased Gi(alpha2) mRNA and protein abundance in spinal cord. Overall, these results support an important role for G(ialpha2)-protein in the acute effects of opioids and opioid tolerance. However, G(ialpha2) is not required for agonist-induced mu-opioid receptor density regulation in vivo.	St Johns Univ, Coll Pharm & Allied Hlth Profess, Dept Pharmaceut Sci, Jamaica, NY 11439 USA	Yoburn, BC (reprint author), St Johns Univ, Coll Pharm & Allied Hlth Profess, Dept Pharmaceut Sci, 8000 Utopia Pkwy, Jamaica, NY 11439 USA.	YoburnB@stjohns.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 12868]		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG SCJL, 1991, PHARMACOL BIOCHEM BE, V38, P853, DOI 10.1016/0091-3057(91)90253-X; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; Duttaroy A, 1997, PHARMACOL BIOCHEM BE, V58, P67, DOI 10.1016/S0091-3057(96)00463-7; Finney DJ, 1973, PROBIT ANAL; FUNADA M, 1993, N-S ARCH PHARMACOL, V348, P88, DOI 10.1007/BF00168542; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Gomes BA, 2002, PHARMACOL BIOCHEM BE, V72, P273, DOI 10.1016/S0091-3057(01)00757-2; Kaewsuk S, 2001, EUR J PHARMACOL, V411, P11, DOI 10.1016/S0014-2999(00)00768-8; Kato S, 1998, EUR J PHARMACOL, V345, P221, DOI 10.1016/S0014-2999(98)00023-5; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; LAW PY, 1985, J BIOL CHEM, V260, P4818; NESTLER EJ, 1989, BRAIN RES, V476, P230, DOI 10.1016/0006-8993(89)91243-2; PAROLARO D, 1990, PHARMACOL BIOCHEM BE, V35, P137, DOI 10.1016/0091-3057(90)90218-7; RAFFA RB, 1994, EUR J PHARMACOL, V258, pR5, DOI 10.1016/0014-2999(94)90073-6; ROSSI GC, 1995, NEUROSCI LETT, V198, P99, DOI 10.1016/0304-3940(95)11977-5; SanchezBlazquez P, 1995, J PHARMACOL EXP THER, V275, P1590; SANCHEZBLAZQUEZ P, 1994, LIFE SCI, V55, pPL445, DOI 10.1016/0024-3205(94)90098-1; SanchezBlazquez P, 1997, J PHARMACOL EXP THER, V280, P1423; Shen J, 2000, SYNAPSE, V38, P322, DOI 10.1002/1098-2396(20001201)38:3<322::AID-SYN11>3.0.CO;2-1; Shen J, 1998, MOL BRAIN RES, V59, P247, DOI 10.1016/S0169-328X(98)00133-8; Stafford K, 2001, PHARMACOL BIOCHEM BE, V69, P233, DOI 10.1016/S0091-3057(01)00525-1; Standifer KM, 1996, MOL PHARMACOL, V50, P293; TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D; VOGEL Z, 1990, J NEUROSCI RES, V27, P106, DOI 10.1002/jnr.490270116; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Williams JT, 2001, PHYSIOL REV, V81, P299; Yabaluri N, 1997, MOL PHARMACOL, V52, P896, DOI 10.1124/mol.52.5.896; YOBURN BC, 1988, LIFE SCI, V43, P1319, DOI 10.1016/0024-3205(88)90587-5; YOBURN BC, 1993, J PHARMACOL EXP THER, V265, P314; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	35	17	24	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0887-4476	1098-2396		SYNAPSE	Synapse	FEB	2003	47	2					109	116		10.1002/syn.10149			8	Neurosciences	Neurosciences & Neurology	630RP	WOS:000180122900003	12454948				2020-06-26	J	Sterious, SN; Walker, EA				Sterious, SN; Walker, EA			Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid mu-agonists in an antinociception assay	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							OPIOID RECEPTOR ANTAGONISTS; APPARENT PA(2) ANALYSIS; BLOOD-BRAIN-BARRIER; SOMATOSTATIN ANALOGS; SUPRASPINAL MU; HIGHLY POTENT; MORPHINE; DELTA; SELECTIVITY; BINDING	D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP) is a peptide antagonist that demonstrates potent and selective affinity for mu-opioid receptors in radioligand binding assays and in vitro bioassays. However, previous studies indicate that CTAP may possess unusual pharmacology under certain conditions. Therefore, CTAP was evaluated as an antagonist of the antinociceptive effects of a range of structurally diverse high- and low-efficacy peptide and alkaloid opioid agonists and compared with the traditional antagonist naltrexone. Male Sprague-Dawley rats (N = 227) were loosely restrained and the latency for tail withdrawal from 55degreesC water was measured. Morphine s.c. and i.c.v., buprenorphine s.c., etorphine s.c. and i.c.v., [N-Me-Phe(3),D-Pro(4)]-morphiceptin and [D-Ala(2),N-Me-Phe(4),Gly(5)ol]-enkephalin produced antinociceptive effects. CTAP was at least 10-fold more potent than naltrexone as an antagonist of the antinociceptive effects of all five agonists. High doses of CTAP produced a noncompetitive antagonism of etorphine s.c. and morphine s.c. suggesting that CTAP may interact with additional opioid receptors in vivo or produce insurmountable antagonism at these doses. CTAP was approximately 300-fold more potent as an antagonist of DAMGO than the other agonists, indicating that CTAP may distinguish some peptide agonists such as DAMGO from other agonists based on binding interactions within the mu-opioid receptor or pharmacodynamic properties of these peptides. Naltrexone, however, administered by either s.c. or i.c.v. routes of administration was approximately equipotent as an antagonist of the antinociceptive effects of most agonists. Taken together, these data indicate that the peptide antagonist CTAP possesses a unique pharmacology unlike traditional opioid antagonists such as naltrexone.	Albert Einstein Healthcare Network, Off Res & Technol Dev, Philadelphia, PA 19141 USA; Temple Univ, Dept Biol, Philadelphia, PA 19122 USA; La Salle Univ, Dept Psychol, Philadelphia, PA 19141 USA	Walker, EA (reprint author), Albert Einstein Healthcare Network, Off Res & Technol Dev, 5501 Old York Rd,Korman 100, Philadelphia, PA 19141 USA.						Abbruscato TJ, 1997, J PHARMACOL EXP THER, V280, P402; ADAMS JU, 1994, DRUG ALCOHOL DEPEN, V35, P197, DOI 10.1016/0376-8716(94)90074-4; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; Bilsky EJ, 1996, J PHARMACOL EXP THER, V277, P484; CHANG KJ, 1983, J PHARMACOL EXP THER, V227, P403; Egleton RD, 1998, J PHARM SCI-US, V87, P1433, DOI 10.1021/js980062b; Emmerson PJ, 1996, J PHARMACOL EXP THER, V278, P1121; Garner HR, 1997, J PHARMACOL EXP THER, V282, P1253; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; GRIDER JR, 1991, AM J PHYSIOL, V260, pG103; He L, 1998, J PHARMACOL EXP THER, V285, P1181; Hurley RW, 2001, J NEUROSCI, V21, P2536; KAZMIERSKI W, 1988, J MED CHEM, V31, P2170, DOI 10.1021/jm00119a019; KOSTERLITZ HW, 1980, PROC R SOC SER B-BIO, V210, P113, DOI 10.1098/rspb.1980.0122; KRAMER TH, 1989, J PHARMACOL EXP THER, V249, P544; LANGE DG, 1980, TOXICOL APPL PHARM, V54, P177, DOI 10.1016/0041-008X(80)90185-4; Liu JG, 2001, MOL PHARMACOL, V60, P53; MALDONADO R, 1992, NEUROPHARMACOLOGY, V31, P1231, DOI 10.1016/0028-3908(92)90051-P; MEDZIHRADSKY F, 1992, J PHARMACOL TOXICOL, V27, P67, DOI 10.1016/1056-8719(92)90023-T; Mundey MK, 2000, BRIT J PHARMACOL, V131, P893, DOI 10.1038/sj.bjp.0703659; NEGUS SS, 1993, J PHARMACOL EXP THER, V267, P896; NEIL A, 1984, N-S ARCH PHARMACOL, V328, P24, DOI 10.1007/BF00496100; ONOGI T, 1995, FEBS LETT, V357, P93, DOI 10.1016/0014-5793(94)01341-W; PELTON JT, 1986, J MED CHEM, V29, P2370, DOI 10.1021/jm00161a037; Riba P, 2002, J PHARMACOL EXP THER, V300, P265, DOI 10.1124/jpet.300.1.265; SCHILLER PW, 1989, J MED CHEM, V32, P698, DOI 10.1021/jm00123a035; SHOOK JE, 1989, J PHARMACOL EXP THER, V249, P83; SHOOK JE, 1987, J PHARMACOL EXP THER, V243, P492; Szeto HH, 2001, J PHARMACOL EXP THER, V298, P57; TAKASUNA M, 1994, BEHAV PHARMACOL, V5, P189, DOI 10.1097/00008877-199404000-00010; TAKEMORI AE, 1984, EUR J PHARMACOL, V104, P101, DOI 10.1016/0014-2999(84)90374-1; TAKEMORI AE, 1974, NARCOTIC ANTAGONISTS, P335; TALLARIDA RJ, 1987, [No title captured]; Tiano MJ, 1998, ANALGESIA, V3, P251; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; WALKER EA, 1994, J PHARMACOL EXP THER, V271, P959; Walker EA, 1998, PSYCHOPHARMACOLOGY, V136, P15; Walker EA, 1996, PSYCHOPHARMACOLOGY, V125, P113, DOI 10.1007/BF02249409; WANG Z, 1994, [No title captured], V54, P339; XUE JC, 1995, J BIOL CHEM, V270, P12977; Zar J.H., 1996, BIOSTATISTICAL ANAL	41	15	15	0	0	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	JAN	2003	304	1					301	309		10.1124/jpet.102.042093			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	626UR	WOS:000179892200038	12490605				2020-06-26	J	Husbands, SM; Lewis, JW				Husbands, Stephen M.; Lewis, John W.			Opioid Ligands Having Delayed Long-Term Antagonist Activity: Potential Pharmacotherapies for Opioid Abuse	MINI-REVIEWS IN MEDICINAL CHEMISTRY			English	Review								Buprenorphine is a partial agonist at the mu-opioid receptor with long duration of action and also exhibits delayed antagonist activity. Buprenorphine is finding increasing use as a treatment agent for opioid abuse, though its low efficacy is not well tolerated by all addicts. There is interest in developing a higher efficacy version of buprenorphine and in this mini-review some of the ligands recently discovered, that share with buprenorphine a profile of agonism followed by delayed antagonism, are discussed.	[Husbands, Stephen M.; Lewis, John W.] Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England	Husbands, SM (reprint author), Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England.	S.M.Husbands@bath.ac.uk	Husbands, Stephen M/D-5926-2011	Husbands, Stephen M/0000-0002-9928-6322			Aceto M.D., 2000, NIDA RES MONOGR, V180, P346; Aceto MD, 1997, EUR J PHARMACOL, V338, P215, DOI 10.1016/S0014-2999(97)81924-3; ACETO MD, 1989, ARZNEIMITTEL-FORSCH, V39-1, P570; ARCHER S, 1994, J MED CHEM, V37, P1578, DOI 10.1021/jm00037a008; BENNETT DB, 1985, J NEUROSCI, V5, P3010; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3281, DOI 10.1021/ja00989a032; BENTLEY KW, 1972, AGONIST ANTAGONIST A, P7; BIDLACK JM, 1991, MED CHEM RES, V1, P43; BOWEN WD, 1987, J BIOL CHEM, V262, P13434; CALCAGNETTI DJ, 1989, PEPTIDES, V10, P319, DOI 10.1016/0196-9781(89)90037-5; COMER SD, 1992, J PHARMACOL EXP THER, V262, P1051; COWAN A, 1977, BRIT J PHARMACOL, V60, P547, DOI 10.1111/j.1476-5381.1977.tb07533.x; COWAN A, 1977, BRIT J PHARMACOL, V60, P537, DOI 10.1111/j.1476-5381.1977.tb07532.x; Cowan A., 1995, BUPRENORPHINE; Cowan Alan, 1995, P31; Derrick I, 2000, J MED CHEM, V43, P3348, DOI 10.1021/jm0009641; DOLE VP, 1988, JAMA-J AM MED ASSOC, V260, P3025, DOI 10.1001/jama.260.20.3025; Doverty M, 2001, PAIN, V93, P155, DOI 10.1016/S0304-3959(01)00306-2; DUM JE, 1981, BRIT J PHARMACOL, V74, P627, DOI 10.1111/j.1476-5381.1981.tb10473.x; Gatch MB, 1996, J PHARMACOL EXP THER, V278, P1282; Husbands S.M., 1997, NIDA RES MONOG, V174, P152; Husbands SM, 1998, J MED CHEM, V41, P3493, DOI 10.1021/jm9810248; Husbands SM, 1995, BIOORG MED CHEM LETT, V5, P2969, DOI 10.1016/0960-894X(95)00522-1; Jaffe JH, 1990, PHARMACOL BASIS THER, P522; JAFFE JH, 1990, [No title captured], P485; JASINSKI DR, 1978, ARCH GEN PSYCHIAT, V35, P501; JIANG Q, 1990, Journal of Pharmacology and Experimental Therapeutics, V255, P636; JIANG Q, 1995, J PHARMACOL EXP THER, V273, P680; JIANG Q, 1992, J PHARMACOL EXP THER, V262, P526; Kamei J, 1996, NEUROSCI LETT, V215, P87, DOI 10.1016/S0304-3940(96)12942-6; LAW PY, 1984, J BIOL CHEM, V259, P4096; Lewis J. W., 2000, Drug and Alcohol Dependence, V60, pS126; Lewis J.W., 1983, ADV SUBSTANC ABUSE, V3, P103; Lewis J.W., 1988, NIDA RES MONOGR, V80, P136; Lewis J.W., 1998, COLL PROBL DRUG DEP; LEWIS JW, 1971, J CHEM SOC C, P1161, DOI 10.1039/j39710001161; LEWIS JW, 1970, J MED CHEM, V13, P525, DOI 10.1021/jm00297a041; Li JG, 2000, MOL PHARMACOL, V58, P795; MARTIN WR, 1973, ARCH GEN PSYCHIAT, V28, P286; McLaughlin JP, 1999, J PHARMACOL EXP THER, V289, P304; Negus S.S., 1995, BUPRENORPHINE, P31; Neilan C.L., 1999, NIDA RES MONOG, V179, P93; Neiland N.P.R., 1998, THESIS; Neiland N.P.R., 1995, ANALGESIA, V1, P611; Pak Y, 1996, MOL PHARMACOL, V50, P1214; Portoghese PS, 2001, J MED CHEM, V44, P2259, DOI 10.1021/jm010158+; RANCE MJ, 1980, ENDOGENOUS EXOGENOUS, P387; SAYRE LM, 1984, J MED CHEM, V27, P1325, DOI 10.1021/jm00376a018; SCHECTER A, 1980, AM J DRUG ALCOHOL AB, V7, P1, DOI 10.3109/00952998009028406; SCHMIDT JF, 1985, ANAESTHESIA, V40, P583; SCHULZ R, 1976, OPIATES ENDOGENOUS O, P319; TOKUYAMA S, 1993, BIOL PHARM BULL, V16, P774; Toll L, 1998, NIDA Res Monogr, V178, P440; Traynor J.R., 2001, DRUG ALCOHOL DEPEN, V63, pS159; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; WANG SF, 1992, CHIN J CLIN PHARM, V8, P106; Woods J H, 1995, NIDA Res Monogr, V147, P195; YOBURN BC, 1990, LIFE SCI, V46, P343, DOI 10.1016/0024-3205(90)90013-H; YOUNG AM, 1991, J PHARMACOL EXP THER, V257, P795; ZERNIG G, 1994, J PHARMACOL EXP THER, V269, P57; Zernig G, 1995, ANALGESIA, V1, P874	62	14	16	0	1	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1389-5575	1875-5607		MINI-REV MED CHEM	Mini-Rev. Med. Chem.		2003	3	2					137	144		10.2174/1389557033405395			8	Chemistry, Medicinal	Pharmacology & Pharmacy	V56HB	WOS:000210550200006	12570846				2020-06-26	J	Patel, MB; Patel, CN; Rajashekara, V; Yoburn, BC				Patel, MB; Patel, CN; Rajashekara, V; Yoburn, BC			Opioid Agonists differentially regulate mu-opioid receptors and trafficking proteins in vivo	MOLECULAR PHARMACOLOGY			English	Article							INDUCED DOWN-REGULATION; MESSENGER-RNA LEVELS; SWISS WEBSTER MICE; IN-VIVO; CHRONIC MORPHINE; GENE-EXPRESSION; BETA-ARRESTIN; RAT-BRAIN; TOLERANCE; ENDOCYTOSIS	Chronic opioid agonist treatment produces tolerance and in some cases opioid receptor internalization and down-regulation. Both morphine and etorphine induce tolerance; however, only etorphine produces mu-opioid receptor (muOR) down-regulation. In vitro studies implicate dynamin-2 (DYN-2) and G-protein receptor kinase-2 (GRK-2) in these processes. Therefore, we examined etorphine and morphine effects on regulation of GRK-2 and DYN-2 in mouse spinal cord. Mice were treated for 7 days with etorphine (200 mug/kg/day infusion) or morphine (40 mg/kg/day infusion + one 25-mg implant pellet). Controls were implanted with a placebo pellet. On the 7th day after implantation mice were tested for i.t. [D-Ala(2),NMe-Phe(4)Gly(5)-ol]-enkephalin (DAMGO) analgesia. In other mice, spinal cord was removed for [H-3]DAMGO binding studies or GRK-2 and DYN-2 protein and mRNA abundance were determined. Both etorphine and morphine produced significant tolerance (ED50 shift = 7.6- and 7.3-fold for morphine and etorphine, respectively). Etorphine decreased spinal muOR density by approximate to30%, whereas morphine did not change muOR density. Etorphine increased (approximate to70%) DYN-2 protein abundance and decreased its mRNA (31%), whereas it had no effect on GRK-2 protein and mRNA abundance. Morphine had no effect on either DYN-2 or GRK-2 protein or mRNA abundance. These data raise the possibility that unequal receptor regulation by etorphine and morphine might be due to differential regulation of trafficking proteins. Overall, receptor down-regulation associated with chronic etorphine treatment may accelerate dynamin-related activity. Finally, the decrease in DYN-2 mRNA may be related to stabilization of DYN-2 protein abundance, which might inhibit transcription.	St Johns Univ, Coll Pharm & Allied Hlth Profess, Dept Pharmaceut Sci, Jamaica, NY 11439 USA	Yoburn, BC (reprint author), St Johns Univ, Coll Pharm & Allied Hlth Profess, Dept Pharmaceut Sci, 8000 Utopia Pkwy, Jamaica, NY 11439 USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA12868]		Alvarez VA, 2002, J NEUROSCI, V22, P5769; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY M, 1995, BRAIN RES BULL, V38, P135, DOI 10.1016/0361-9230(95)00079-T; Burd AL, 1998, J BIOL CHEM, V273, P34488, DOI 10.1074/jbc.273.51.34488; Burford NT, 1998, EUR J PHARMACOL, V342, P123, DOI 10.1016/S0014-2999(97)01556-2; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Castelli MP, 1997, MOL BRAIN RES, V45, P149, DOI 10.1016/S0169-328X(96)00305-1; Duttaroy A, 1999, LIFE SCI, V65, P113, DOI 10.1016/S0024-3205(99)00228-3; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; Duttaroy A, 2000, SYNAPSE, V37, P118, DOI 10.1002/1098-2396(200008)37:2<118::AID-SYN6>3.0.CO;2-2; Gaborik Z, 2001, MOL PHARMACOL, V59, P239; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Gomes BA, 2002, PHARMACOL BIOCHEM BE, V72, P273, DOI 10.1016/S0091-3057(01)00757-2; Hasbi A, 2000, J PHARMACOL EXP THER, V293, P237; Hurle MA, 2001, J NEUROCHEM, V77, P486, DOI 10.1046/j.1471-4159.2001.00268.x; JENAB S, 1995, BRAIN RES, V691, P69, DOI 10.1016/0006-8993(95)00615-W; Kato S, 1998, EUR J PHARMACOL, V345, P221, DOI 10.1016/S0014-2999(98)00023-5; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KIM DS, 1995, FEBS LETT, V376, P11, DOI 10.1016/0014-5793(95)01233-6; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; Li JG, 2000, MOL PHARMACOL, V58, P795; Patel M, 2002, EUR J PHARMACOL, V446, P37, DOI 10.1016/S0014-2999(02)01823-X; Sehba F, 1997, EUR J PHARMACOL, V339, P33, DOI 10.1016/S0014-2999(97)01360-5; Shen J, 2000, SYNAPSE, V38, P322, DOI 10.1002/1098-2396(20001201)38:3<322::AID-SYN11>3.0.CO;2-1; Stafford K, 2001, PHARMACOL BIOCHEM BE, V69, P233, DOI 10.1016/S0091-3057(01)00525-1; TERWILLIGER RZ, 1994, J NEUROCHEM, V63, P1983; Trafton JA, 2000, J NEUROSCI, V20, P8578; UNTERWALD EM, 1995, MOL BRAIN RES, V33, P351, DOI 10.1016/0169-328X(95)00143-G; Van Bockstaele EJ, 2001, NEUROSCIENCE, V108, P467, DOI 10.1016/S0306-4522(01)00426-2; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 2001, J BIOL CHEM, V276, P34331, DOI 10.1074/jbc.M104627200; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Yabaluri N, 1997, MOL PHARMACOL, V52, P896, DOI 10.1124/mol.52.5.896; YOBURN BC, 1995, PHARMACOL BIOCHEM BE, V51, P535, DOI 10.1016/0091-3057(94)00375-S; YOBURN BC, 1993, J PHARMACOL EXP THER, V265, P314; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	38	53	54	0	1	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0026-895X			MOL PHARMACOL	Mol. Pharmacol.	DEC	2002	62	6					1464	1470		10.1124/mol.62.6.1464			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	615VY	WOS:000179268900023	12435815				2020-06-26	J	Enserink, M; Stone, R				Enserink, M; Stone, R			Toxicology - Questions swirl over knockout gas used in hostage crisis	SCIENCE			English	News Item																	0	9	11	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 8	2002	298	5596					1150	1151		10.1126/science.298.5596.1150			2	Multidisciplinary Sciences	Science & Technology - Other Topics	612MQ	WOS:000179080400002	12424343				2020-06-26	J	Whistler, JL; Tsao, P; von Zastrow, M				Whistler, JL; Tsao, P; von Zastrow, M			A phosphorylation-regulated brake mechanism controls the initial endocytosis of opioid receptors but is not required for post-endocytic sorting to lysosomes.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ADRENERGIC-RECEPTOR; NG108-15 HYBRID-CELLS; DOWN-REGULATION; OPIATE RECEPTOR; MOLECULAR MECHANISMS; KINASE-C; DESENSITIZATION; ARRESTIN; RESENSITIZATION	The delta -opioid receptor (DOR) can undergo proteolytic down-regulation by endocytosis of receptors followed by sorting of internalized receptors to lysosomes. Although phosphorylation of the receptor is thought to play an important role in controlling receptor downregulation, previous studies disagree on whether phosphorylation is actually required for the agonist-induced endocytosis of opioid receptors. Furthermore, no previous studies have determined whether phosphorylation is required for subsequent sorting of internalized receptors to lysosomes. We have addressed these questions by examining the endocytic trafficking of a series of mutant versions of DOR expressed in stably transfected HEK 293 cells. Our results confirm that phosphorylation is not required for agonist-induced endocytosis of truncated mutant receptors that lack the distal carboxyl-terminal cytoplasmic domain containing sites of regulatory phosphorylation. However, phosphorylation is required for endocytosis of full-length receptors. Mutation of all serine/threonine residues located in the distal carboxyl-terminal tail domain of the full-length receptor to alanine creates functional mutant receptors that exhibit no detectable agonist-induced endocytosis. Substitution of these residues with aspartate restores the ability of mutant receptors to undergo agonist-induced endocytosis. Studies using green fluorescent protein-tagged versions of arrestin-3 suggest that the distal tail domain, when not phosphorylated, inhibits receptor-mediated recruitment of beta -arrestins to the plasma membrane. Biochemical and radioligand binding studies indicate that, after endocytosis occurs, phosphorylation-defective mutant receptors traffic to lysosomes with similar kinetics as wild type receptors. We conclude that phosphorylation controls endocytic trafficking of opioid receptors primarily by regulating a "brake" mechanism that prevents endocytosis of full-length receptors in the absence of phosphorylation. After endocytosis occurs, subsequent steps of membrane trafficking mediating sorting and transport to lysosomes do not require receptor phosphorylation.	Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, Emeryville, CA 94608 USA; Univ Calif San Francisco, Program Cell Biol, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Cell Biol, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Cell Biol, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	Whistler, JL (reprint author), Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, 5858 Horton St,Suite 200, Emeryville, CA 94608 USA.	shooz2@itsa.ucsf.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA12864]; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM08120]		ARDEN JR, 1995, J NEUROCHEM, V65, P1636; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burd AL, 1998, J BIOL CHEM, V273, P34488, DOI 10.1074/jbc.273.51.34488; Cao TT, 1999, NATURE, V401, P286; Chaturvedi K, 2000, MOL BRAIN RES, V80, P166, DOI 10.1016/S0169-328X(00)00134-0; Cvejic S, 1996, J BIOL CHEM, V271, P4073; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; GUCKER S, 1992, MOL PHARMACOL, V42, P656; Guo J, 2000, MOL PHARMACOL, V58, P1050; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; Hasbi A, 2000, J PHARMACOL EXP THER, V293, P237; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; LAW PY, 1982, MOL PHARMACOL, V22, P1; LAW PY, 1984, J BIOL CHEM, V259, P4096; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; Malbon C C, 1991, Chin J Physiol, V34, P105; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Pak Y, 1999, J BIOL CHEM, V274, P27610, DOI 10.1074/jbc.274.39.27610; PEI G, 1995, MOL PHARMACOL, V48, P173; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Roth BL, 1998, DRUG ALCOHOL DEPEN, V51, P73, DOI 10.1016/S0376-8716(98)00067-2; Trapaidze N, 2000, DNA CELL BIOL, V19, P93, DOI 10.1089/104454900314609; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Tsao P, 2000, CURR OPIN NEUROBIOL, V10, P365, DOI 10.1016/S0959-4388(00)00096-9; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhu JM, 1998, J PHARMACOL EXP THER, V285, P28	41	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34331	34338		10.1074/jbc.M104627200			8	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	471CP	WOS:000170910200137	11443128	Bronze			2020-06-26	J	Jordan, BA; Trapaidze, N; Gomes, I; Nivarthi, R; Devi, LA				Jordan, BA; Trapaidze, N; Gomes, I; Nivarthi, R; Devi, LA			Oligomerization of opioid receptors with beta(2)-adrenergic receptors: A role in trafficking and mitogen-activated protein kinase activation	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						receptor subtypes; G-protein-coupled receptor; endocytosis; dimers; heterodimerization	GABA(B) RECEPTORS; COUPLED RECEPTORS; RAT-HEART; DIMERIZATION; HETERODIMERIZATION; INTERNALIZATION; PEPTIDE	G-protein-coupled receptors (GPCRs) have recently joined the list of cell surface receptors that dimerize. Dimerization has been shown to alter the ligand-binding, signaling, and trafficking properties of these receptors. Recent studies have shown that GPCRs heterodimerize with closely related members, resulting in the modulation of their function. In this study, we have attempted to determine whether members of GPCR superfamilies that couple to different families of G-proteins can associate and form oligomers, We chose the beta (2) adrenergic receptor that couples to stimulatory G-proteins and delta & kappa opioid receptors that couple to inhibitory G-proteins. beta (2) and delta receptors undergo robust agonist-mediated endocytosis, whereas kappa receptors do not. We find that when coexpressed, beta (2) receptors can form heteromeric complexes with both delta and kappa receptors, This heterooligomerization does not significantly alter the ligand binding or coupling properties of the receptors. However, it affects the trafficking properties of the receptors, For example, we find that delta receptors, when coexpressed with beta (2) receptors, undergo isoproterenol-mediated endocytosis. Conversely, beta (2) receptors in these cells undergo etorphine-mediated endocytosis, However, beta (2) receptors, when coexpressed with kappa receptors, undergo neither opioid- nor isoproterenol-mediated endocytosis. Moreover, these cells exhibit a substantial decrease in the isoproterenol-induced phosphorylation of mitogen-activated protein kinases. Taken together, these results provide direct evidence of heteromerization of GPCRs that couple to different types of G-proteins, which results in the modulation of receptor trafficking and signal transduction.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	Devi, LA (reprint author), NYU, Sch Med, Dept Pharmacol, MSB 411,550 1st Ave, New York, NY 10016 USA.	lakshmi.devi@med.nyu.edu		Jordan, Bryen/0000-0002-4967-444X	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-08863, DA-00458, R56 DA008863, R37 DA008863, T32 DA007254, DA-07254, K02 DA000458, R01 DA008863]		Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Cvejic S, 1996, J BIOL CHEM, V271, P4073; Devi LA, 2000, NEUROPSYCHOPHARMACOL, V23, pS3, DOI 10.1016/S0893-133X(00)00154-8; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM J, V330, P287; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2000, DNA CELL BIOL, V19, P19, DOI 10.1089/104454900314672; Kaupmann K, 1998, NATURE, V396, P683; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Lefkowitz RJ, 1996, NAT BIOTECHNOL, V14, P283, DOI 10.1038/nbt0396-283; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; Pepe S, 1997, CIRCULATION, V95, P2122, DOI 10.1161/01.CIR.95.8.2122; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Salahpour A, 2000, TRENDS ENDOCRIN MET, V11, P163, DOI 10.1016/S1043-2760(00)00260-5; Sullivan R, 2000, J PHARMACOL EXP THER, V293, P460; Trapaidze N, 2000, DNA CELL BIOL, V19, P195, DOI 10.1089/104454900314465; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Trapaidze N, 2000, MOL BRAIN RES, V76, P220, DOI 10.1016/S0169-328X(00)00002-4; White JH, 1998, NATURE, V396, P679; Xiao RP, 1997, AM J PHYSIOL-HEART C, V272, pH797; Yu XC, 1999, J MOL CELL CARDIOL, V31, P1809, DOI 10.1006/jmcc.1999.1014; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487	31	278	286	0	13	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JAN 2	2001	98	1					343	348		10.1073/pnas.011384898			6	Multidisciplinary Sciences	Science & Technology - Other Topics	389DD	WOS:000166222600064	11134510	Green Published			2020-06-26	J	Ohmori, S; Sugiyama, Y; Morimoto, Y				Ohmori, S; Sugiyama, Y; Morimoto, Y			A protective effect against undesirable increase of dihydroetorphine permeation through damaged skin by using pressure-sensitive adhesive tape with an ethylene-vinyl acetate co-polymer membrane	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						dihydroetorphine; ethylene-vinyl acetate co-polymer; diffusion controlling membrane; damaged skin; pressure sensitive adhesive; hairless rat	CONTROLLED TRANSDERMAL DELIVERY; MORPHINE; ESTRADIOL; RATS	The release kinetics of dihydroetorphine (DHE) from pressure-sensitive adhesive (PSA) tape with an ethylene-vinyl acetate co-polymer (EVA) membrane as a diffusion-controlling membrane and its protective effect from an unpredictable increase in skin permeation of DHE caused by stratum corneum damage were investigated. The DHE dull through the EVA membrane was enhanced with the increase of vinyl acetate content. Although the DHE release from the PSA tape was proportional to the square root of the time, the release from the PSA tape covered with the EVA membrane was dominated by zero-order rate, The release rate increased by the addition of isopropyl myristate to the PSA layer, due to the increase of solubility and diffusivity of DHE in the PSA. layer, and not a decrease of permeation resistance in the EVA membrane. When using the PSA tape with the EVA membrane, the steady-state flux of DHE through hairless rat skin with stratum corneum damage was not 2-fold more than that through non-damaged skin. Plasma DHE concentration rose promptly above 5 ng/ml after the application of the PSA tape onto the damaged skin in hairless rat. In contrast, when the PSA tape with the EVA. membrane nas applied onto the damaged or non-damaged skin, plasma concentrations in the both cases were maintained in the therapeutic range (0.2-1.2 ng/ml). These results suggest that the PSA tape with the EVA membrane can be used to protect from the unpredictable increase in skin permeation of DHE due to stratum corneum damage.	Josai Univ, Fac Pharmaceut Sci, Sakado, Saitama 3500295, Japan	Morimoto, Y (reprint author), Josai Univ, Fac Pharmaceut Sci, 1-1 Keyakidai, Sakado, Saitama 3500295, Japan.	morimoto@josai.ac.jp					Aceto MD, 1997, EUR J PHARMACOL, V338, P215, DOI 10.1016/S0014-2999(97)81924-3; AitkenNichol C, 1996, PHARMACEUT RES, V13, P804, DOI 10.1023/A:1016076306279; Altenburger R, 1998, PHARMACEUT RES, V15, P1238, DOI 10.1023/A:1011944025262; Baker RW, 1989, TRANSDERMAL DRUG DEL, P293; BARBER RB, 1975, J MED CHEM, V18, P1074, DOI 10.1021/jm00245a006; Benfeldt E, 1999, ARCH DERMATOL RES, V291, P517, DOI 10.1007/s004030050447; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3281, DOI 10.1021/ja00989a032; BRONAUGH RL, 1985, J PHARM SCI, V74, P1062, DOI 10.1002/jps.2600741008; CHEN GS, 1995, J CONTROL RELEASE, V34, P129, DOI 10.1016/0168-3659(95)00005-S; Chiaretti A, 1997, ACTA PAEDIATR, V86, P330, DOI 10.1111/j.1651-2227.1997.tb08902.x; Crank J., 1975, MATH DIFFUSION; FEDORS RF, 1974, POLYM ENG SCI, V14, P147, DOI 10.1002/pen.760140211; Franz T. J., 1992, TREATISE CONTROLLED, P341; HIGUCHI T, 1961, J PHARM SCI, V50, P874, DOI 10.1002/jps.2600501018; KAJIMOTO H, 1995, J PHARM SCI TECHNOL, V55, P127; Ohmori S, 2000, J CHROMATOGR B, V740, P253, DOI 10.1016/S0378-4347(00)00129-8; OHMORI S, 2001, IN PRESS J PHARM PHA; OHMORI S, 2001, IN PRESS J PHARM EXP; Ouellet DMC, 1997, J PHARMACOL EXP THER, V281, P713; SEKI T, 1990, CHEM PHARM BULL, V38, P740, DOI 10.1248/cpb.38.740; Tokuyama S, 1996, BIOL PHARM BULL, V19, P477; WANG DX, 1995, J PHARM PHARMACOL, V47, P669, DOI 10.1111/j.2042-7158.1995.tb05857.x; WU GQ, 1991, CHINESE J ONCOL, V13, P64; Yoshiiki Takashi, 1993, Journal of Dermatological Science, V5, P92, DOI 10.1016/0923-1811(93)90076-2	24	3	3	0	2	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	JAN	2001	24	1					78	83		10.1248/bpb.24.78			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	391GT	WOS:000166348800014	11201250	Bronze, Green Published			2020-06-26	J	Ohmori, S; Hayashi, T; Kawase, M; Saito, S; Sugibayashi, K; Morimoto, Y				Ohmori, S; Hayashi, T; Kawase, M; Saito, S; Sugibayashi, K; Morimoto, Y			Transdermal delivery of the potent analgesic dihydroetorphine: Kinetic analysis of skin permeation and analgesic effect in the hairless rat	JOURNAL OF PHARMACY AND PHARMACOLOGY			English	Article							PENETRATION ENHANCERS; DRUG DELIVERY; MORPHINE; TOLERANCE; PERMEABILITY	Dihydroetorphine is an extraordinarily strong opioid analgesic. To assess its effectiveness after topical application in hairless rats we have examined the kinetic analysis of skin permeation through excised skin and the in-vitro reservoir effect of skin, and have investigated the predictability of plasma concentration and analgesic effect following in-vivo transdermal application. Dihydroetorphine was moderately permeable from an aqueous suspension through excised hairless rat skin. Dihydroetorphine flux from drug-dispersed pressure-sensitive adhesive tape was threefold that from the applied aqueous suspension. The fluxes through the abdominal and the dorsal skin during tape application fitted the Fickian diffusion equation well after the tape was removed peeling off the outer layer of the stratum corneum. The relationship between the plasma concentration and the analgesic effect was examined for four different rates of infusion of dihydroetorphine. A non-linear pharmacokinetic disposition was observed. Following abdominal (0 . 28 cm(2), 20 ug) and dorsal (0 . 50 cm(2), 35 mug) applications of the dihydroetorphine tape, plasma concentration (0 .2-0 .8 ng mL(-1)) and analgesic effect were maintained at a suitable level, for more than 8 h, until removal of the tape. These profiles were predictable using the combined equation for percutaneous absorption, disposition and the analgesic effect, but the analgesic effect was slightly lower than the predicted value. The results show that it was possible to control the plasma concentration and the analgesic effect of dihydroetorphine by topical application of the analgesic using pressure sensitive adhesive tape in the hairless rat. It was possible to predict the result using mathematical modelling.	Josai Univ, Fac Pharmaceut Sci, Sakado, Saitama 3500295, Japan	Morimoto, Y (reprint author), Josai Univ, Fac Pharmaceut Sci, 1-1 Keyakidai, Sakado, Saitama 3500295, Japan.						BARBER RB, 1975, J MED CHEM, V18, P1074, DOI 10.1021/jm00245a006; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3281, DOI 10.1021/ja00989a032; BRONAUGH RL, 1983, J SOC COSMET CHEM, V34, P127; CHEN XP, 1996, ACTA PHARMACOL SINIC, V31, P770; Crank J., 1975, MATH DIFFUSION; Finnin BC, 1999, J PHARM SCI-US, V88, P955, DOI 10.1021/js990154g; Franz T. J., 1992, TREATISE CONTROLLED, P341; GUO QD, 1997, CHIN PHARM J, V32, P349; JOLICOEUR LM, 1992, PHARMACEUT RES, V9, P963, DOI 10.1023/A:1015877621976; KUBOTA K, 1994, J PHARM SCI-US, V83, P1300, DOI 10.1002/jps.2600830922; LI YS, 1996, CHIN J NEW DRUG, V5, P122; MORIMOTO Y, 1992, J PHARM PHARMACOL, V44, P634, DOI 10.1111/j.2042-7158.1992.tb05484.x; MORIMOTO Y, 1992, STP PHARMA SCI, V2, P253; Ohmori S, 2000, J CHROMATOGR B, V740, P253, DOI 10.1016/S0378-4347(00)00129-8; OHMORI S, 2000, IN PRESS J PHARM EXP; OHMORI S, 2000, IN PRESS BIOL PHARM; OKAMOTO H, 1988, J PHARM SCI-US, V77, P418, DOI 10.1002/jps.2600770513; Ouellet DMC, 1997, J PHARMACOL EXP THER, V281, P713; SATO K, 1991, J PHARM SCI, V80, P104, DOI 10.1002/jps.2600800203; SOUTHAM MA, 1995, ANTI-CANCER DRUG, V6, P29, DOI 10.1097/00001813-199504003-00005; Stinchcomb AL, 1996, PHARMACEUT RES, V13, P1519, DOI 10.1023/A:1016079513007; SUGIBAYASHI K, 1995, INT J PHARM, V113, P189, DOI 10.1016/0378-5173(94)00194-A; SUGIBAYASHI K, 1989, SELECT CANCER THER, V5, P119, DOI 10.1089/sct.1989.5.119; Suh H, 1996, J PHARM PHARMACOL, V48, P812, DOI 10.1111/j.2042-7158.1996.tb03979.x; TOJO K, 1987, J CHEM ENG JPN, V20, P300, DOI 10.1252/jcej.20.300; TOJO K, 1988, INT J PHARM, V43, P201, DOI 10.1016/0378-5173(88)90274-8; TOKUYAMA S, 1993, BIOL PHARM BULL, V16, P774; Toro P., 1999, PERCUTANEOUS ABSORPT, P3; VACCARINO AL, 1993, BRAIN RES, V627, P287, DOI 10.1016/0006-8993(93)90332-H; WANG CY, 1999, J DRUG DEPEND, V8, P210; *WHO EXP COMM, 1999, WHO TECHN REP SER, V887; WU GQ, 1991, CHINESE J ONCOL, V13, P64; 臧东莲, 1999, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V8, P204	33	9	9	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3573	2042-7158		J PHARM PHARMACOL	J. Pharm. Pharmacol.	DEC	2000	52	12					1437	1449		10.1211/0022357001777649			13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	395UK	WOS:000166599500002	11197071				2020-06-26	J	Janovsky, M; Tataruch, F; Ambuehl, M; Giacometti, M				Janovsky, M; Tataruch, F; Ambuehl, M; Giacometti, M			A Zoletil (R)-Rompun (R) mixture as an alternative to the use of opioids for immobilization of feral red deer	JOURNAL OF WILDLIFE DISEASES			English	Article						Cervus elaphus hippelaphus; ethorphine; immobilization; red deer; sarmazenile; tiletamine; xylazine; yohimbine; zolazepam	YOHIMBINE HYDROCHLORIDE; KETAMINE-XYLAZINE; TELAZOL; FIELD; ELK	Sixty chemical immobilizations of red deer (Cervus elaphus hippelaphus) have been carried out during an etho-ecological study from August 1994 to December 1996 in a 35 ha pen in the district of Nitra (Slovac Republic). Our objective was to determine the efficacy and standard dosages of Zoletil(R) and Rompun(R) for the immobilization of adult red deer in feral conditions as an alternative to the use of the highly rode opioids. We therefore compared an Immobilon(R)- Rompun(R) combination (ImRo) with a 1:1 mixture of Zoletil(R) and Rompun(R) (ZoRo) as an injectable solution. Use of both combinations led to the immobilization of >92% of deer with an injection volume <3 ml. Mean (SD) dose to achieve immobilization was 35 (14) <mu>g/kg ethorphine + 0.14 (0.056) mg/kg acepromazine + 0.36 (0.14) mg/kg xylazine compared to 1.2 (0.8) mg/kg tiletamine + 1.2 (0.8) mg/kg zolazepam + 2.3 (1.6) mg/kg xylazine. This corresponds to a volume of 1.8 (0.7) ml/100 kg body mass (BM) for ImRo (range = 1.0 to 4.6) and to 2.3 (1.6) ml/100 kg BM for ZoRo (range = 0.7 to 4.0), respectively. Heart rate, respiratory rate and oxyhaemoglobin saturation values did not differ significantly between the two groups during immobilization. Three deer (5%) died during immobilization, but fatalities could not be directly associated with the drug effect. Mean (SD) time from darting to complete immobilization was 5.5 (4.2) min for ImRo and 7.5 (6.1) min for ZoRo, respectively. Differences were not statistically significant. Anesthesia with both combinations of immobilizing agents could be reversed within 2 min using sarmazenile-yohimbine for ZoRo and diprenorphine-yohimbine for ImXy immobilizations, respectively. We conclude that the 1:1 combination of Zoletil(R) and xylazine is a valuable alternative to the use of opioids for the immobilization of adult red deer including feral adult animals.	Univ Vet Med, Res Inst Wildlife Ecol, A-1160 Vienna, Austria; Univ Bern, Inst Math Stat & Actuarial Sci, CH-3012 Bern, Switzerland	Janovsky, M (reprint author), Inst Anim Pathol, Ctr Fish & Wildlife Hlth, Langgassstr 122, CH-3012 Bern, Switzerland.						Baronetzky-Mercier A., 1995, P12; BERGERUD ARTHUR T., 1964, JOUR WILDL MGMT, V28, P49, DOI 10.2307/3797935; BOCH J, 1961, [No title captured], V7, P18; BURROUGHS REJ, 1993, WILDLIFE DECISION SU, P65; CARRUTHERS SG, 1979, CLIN TOXICOL, V15, P281, DOI 10.3109/15563657908989878; COGGINS VL, 1975, J WILDLIFE MANAGE, V39, P814, DOI 10.2307/3800249; Delvaux H, 1999, J WILDLIFE DIS, V35, P38, DOI 10.7589/0090-3558-35.1.38; GOLIGHTLY RT, 1989, WILDLIFE SOC B, V17, P53; HAIGH JC, 1980, VET HUM TOXICOL, V22, P1; HAIGH JC, 1993, FARMING WAPITI RED D, P83; HOUSTON DB, 1969, J WILDLIFE MANAGE, V33, P534, DOI 10.2307/3799375; JALANKA HH, 1990, J ZOO WILDLIFE MED, V21, P259; JANOVSKY M, 1996, THESIS U VIENNA VIEN; JOLICOUER H, 1977, TECHNIQUES MARQUAGE; Kilpatrick HJ, 1999, WILDLIFE SOC B, V27, P566; LIN HC, 1993, J VET PHARMACOL THER, V16, P383, DOI 10.1111/j.1365-2885.1993.tb00206.x; LIN HC, 1996, [No title captured], P241; LOESCHER W, 1999, PHARMAKOTHERAPIE HAU, P67; MILLSPAUGH JJ, 1995, J WILDLIFE DIS, V31, P259, DOI 10.7589/0090-3558-31.2.259; Nielsen L., 1999, CHEM IMMOBILIZATION; NIELSON AE, 1967, HELICOPTER DART GUN; PEDERSEN RJ, 1975, J WILDLIFE MANAGE, V39, P617, DOI 10.2307/3800406; Perez JM, 1997, WILDLIFE SOC B, V25, P89; POND DB, 1996, RES MANAGEMENT TECHN, P139; ROFFE TJ, 1996, WILDLIFE SOC, P324; SCHLOETH R., 1960, REV SUISSE ZOOL, V67, P281; THURMON JC, 1989, VET MED-US, V84, P824; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; WEIGERSTORFER E, 1996, THESIS U VIENNA VIEN; Wiesner H, 1998, TIERARZTL PRAX G N, V26, P225; WILSON PR, 1983, NEW ZEAL VET J, V31, P1, DOI 10.1080/00480169.1983.34943; 1995, USER MANUAL STATXACT	32	28	31	0	4	WILDLIFE DISEASE ASSN, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA	0090-3558			J WILDLIFE DIS	J. Wildl. Dis.	OCT	2000	36	4					663	669		10.7589/0090-3558-36.4.663			7	Veterinary Sciences	Veterinary Sciences	371GK	WOS:000165170300005	11085427	Bronze			2020-06-26	J	Cook, CD; Barrett, AC; Roach, EL; Bowman, JR; Picker, MJ				Cook, CD; Barrett, AC; Roach, EL; Bowman, JR; Picker, MJ			Sex-related differences in the antinociceptive effects of opioids: importance of rat genotype, nociceptive stimulus intensity, and efficacy at the mu opioid receptor	PSYCHOPHARMACOLOGY			English	Article						sex difference; opioid; antinociception; genotype; efficacy	MORPHINE-INDUCED ANALGESIA; DISCRIMINATIVE STIMULUS; INTRINSIC EFFICACY; BETA-FUNALTREXAMINE; STRAINS; GONADECTOMY; SENSITIVITY; AGONISTS; FISCHER; GENDER	Rationale: Recent studies indicate that morphine is more potent as an antinociceptive agent in male than female rodents and monkeys. Objectives: To evaluate the influence of sex, nociceptive stimulus intensity and an opioid's relative efficacy on opioid-induced antinotiception in rat strains (F344 and Lewis) that display differential sensitivity to morphine antinociception. Methods: Antinociceptive testing was conducted using a rat warm-water (50-56 degrees C) tail-withdrawal procedure. Dose-response and time-course determinations were performed with various opioids. Results: Across the nociceptive stimulus intensities tested, the high-efficacy mu opioids morphine, etorphine, and levorphanol were equally effective in males and females, but on average 2.5-fold more potent in males. At moderate stimulus intensities, the low-efficacy mu opioid buprenorphine was approximately 0.4-fold more potent in males, and at higher stimulus intensities more patent and effective (greater maximal effect) in males. At low stimulus intensities, the low-efficacy mu opioid dezocine and the mu/kappa opioid butorphanol were greater than 8.9-fold more potent in males, and at moderate stimulus intensities were more potent and effective in males. At a low stimulus intensity, the mu/kappa opioid nalbuphine was more potent and effective in males. At stimulus intensities in which buprenorphine, dezocine, butorphanol, and nalbuphine produced maximal effects in males but not females, these opioids antagonized the effects of morphine in females. Genotype-related differences were noted as opioids were generally more potent in F344 than Lewis males, whereas no consistent differences were observed between F344 and Lewis females. Conclusions: That sex differences in the potency and effectiveness of opioids increased with decreases in the opioid's relative efficacy and with increases in the nociceptive stimulus intensity suggests that the relative efficacy of mu opioids as antinociceptive agents is greater in male than female rats.	Univ N Carolina, Dept Psychol, Chapel Hill, NC 27599 USA	Picker, MJ (reprint author), Univ N Carolina, Dept Psychol, Chapel Hill, NC 27599 USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA05888, DA10277]; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH07431]		ADAMS JU, 1990, J PHARMACOL EXP THER, V255, P1027; ALI BH, 1995, CLIN EXP PHARMACOL P, V22, P342, DOI 10.1111/j.1440-1681.1995.tb02012.x; Bartok RE, 1997, J PHARMACOL EXP THER, V282, P769; Boyer JS, 1998, BRAIN RES, V796, P315, DOI 10.1016/S0006-8993(98)00353-9; CALCAGNETTI DJ, 1990, BRAIN RES, V537, P157, DOI 10.1016/0006-8993(90)90352-C; Cicero TJ, 1997, J PHARMACOL EXP THER, V282, P939; Cicero TJ, 1996, J PHARMACOL EXP THER, V279, P767; Craft RM, 1996, BEHAV PHARMACOL, V7, P764; Dhabhar FS, 1997, NEUROENDOCRINOLOGY, V65, P360, DOI 10.1159/000127196; Elmer GI, 1998, PAIN, V75, P129, DOI 10.1016/S0304-3959(97)00215-7; ELMER GI, 1995, PSYCHOPHARMACOLOGY, V117, P23, DOI 10.1007/BF02245094; GERAK LR, 1994, J PHARMACOL EXP THER, V271, P993; GOSNELL BA, 1993, PHARMACOL BIOCHEM BE, V44, P919, DOI 10.1016/0091-3057(93)90025-O; GUITART X, 1993, BRAIN RES, V611, P7, DOI 10.1016/0006-8993(93)91770-S; ISLAM AK, 1993, PHYSIOL BEHAV, V54, P45, DOI 10.1016/0031-9384(93)90042-E; KASSON BG, 1984, LIFE SCI, V34, P1627, DOI 10.1016/0024-3205(84)90633-7; KENAKIN T, 1993, [No title captured]; KEPLER KL, 1989, PHARMACOL BIOCHEM BE, V34, P119, DOI 10.1016/0091-3057(89)90363-8; Kest B, 1999, J PHARMACOL EXP THER, V289, P1370; LEANDER JD, 1983, EUR J PHARMACOL, V86, P467, DOI 10.1016/0014-2999(83)90198-X; Mogil JS, 1999, PAIN, V80, P83, DOI 10.1016/S0304-3959(98)00196-1; Mogil JS, 1996, J PHARMACOL EXP THER, V276, P532; Mogil JS, 1997, PAIN, V70, P267, DOI 10.1016/S0304-3959(97)03333-2; Morgan D, 1999, ANESTH ANALG, V88, P407, DOI 10.1097/00000539-199902000-00035; Morgan D, 1999, J PHARMACOL EXP THER, V289, P965; Negus SS, 1999, J PHARMACOL EXP THER, V290, P1132; NYLANDER I, 1995, BRAIN RES, V683, P25, DOI 10.1016/0006-8993(95)00279-Y; PICKER MJ, 1993, J PHARMACOL EXP THER, V266, P756; Smith MA, 1999, PSYCHOPHARMACOLOGY, V143, P261, DOI 10.1007/s002130050945; SUDAKOV SK, 1993, PSYCHOPHARMACOLOGY, V112, P183, DOI 10.1007/BF02244908; TALLARIDA RJ, 1987, [No title captured]; Tiano MJ, 1998, ANALGESIA, V3, P251; WALKER EA, 1994, J PHARMACOL EXP THER, V271, P959; Walker EA, 1999, PSYCHOPHARMACOLOGY, V144, P45, DOI 10.1007/s002130050975; Walker EA, 1998, PSYCHOPHARMACOLOGY, V136, P15; WOOLFOLK DR, 1995, PHARMACOL BIOCHEM BE, V51, P699, DOI 10.1016/0091-3057(94)00440-T; YOUNG AM, 1992, J PHARMACOL EXP THER, V261, P246; YOUNG AM, 1991, J PHARMACOL EXP THER, V257, P795	38	127	131	0	6	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0033-3158			PSYCHOPHARMACOLOGY	Psychopharmacology	JUL	2000	150	4					430	442		10.1007/s002130000453			13	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	336WB	WOS:000088325000010	10958085				2020-06-26	J	Shapira, M; Vogel, Z; Sarne, Y				Shapira, M; Vogel, Z; Sarne, Y			Opioid and cannabinoid receptors share a common pool of GTP-binding proteins in cotransfected cells, but not in cells which endogenously coexpress the receptors	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						opioid receptors; cannabinoid receptors; GTP-binding proteins; cell transfection; [S-35]GTP gamma S binding; neuroblastoma	NEUROBLASTOMA SH-SY5Y CELLS; II ADENYLYL-CYCLASE; MULTIPLE G-PROTEINS; FUNCTIONAL EXPRESSION; CALCIUM CHANNELS; PHOSPHOLIPASE-C; HYBRID-CELLS; MU; ACTIVATION; MEMBRANES	Opioid (mu. delta, kappa) and cannabinoid (CB1, CB2) receptors are coupled mainly to G(i)/G(o) GTP-binding proteins. The goal of the present study was to determine whether different subtypes of opioid and cannabinoid receptors, when coexpressed in the same cell, share a common reservoir. or utilize different pools, of G proteins. The stimulation of [S-35]GTP gamma S binding by selective opioid and cannabinoid agonists was tested in transiently transfected COS-7 cells, as well as in neuroblastoma cell lines. In COS-7 cells, cotransfection of mu- and delta-opioid receptors led to stimulation of [S-35]GTP gamma S binding by either mu-selective (DAMGO) or delta-selective (DPDPE) agonists. The combined effect of the two agonists was similar to the effect of either DAMGO or DPDPE alone, suggesting the activation of a common G-protein reservoir by the two receptor subtypes. The same phenomenon was observed when COS-7 cells were cotransfected with CB1 cannabinoid receptors and either mu- or delta-opioid receptors. On the other hand. in N18STG2 neuroblastoma cells, which endogenously coexpress CB1 and delta-opioid receptors, as well as in SK-N-SH neuroblastoma cells, which coexpress mu- and delta-opioid receptors, the combined effects of the various agonists (the selective cannabinoid DALN and the selective opioids DPDPE and DAMGO) were additive, implying the activation of different pools of G proteins by each receptor subtype. These results suggest a fundamental difference between native and artificially transfected cells regarding the compartmentalization of receptors and GTP-binding proteins.	Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Sackler Fac Med, Mauerberger Chair Neuropharmacol, IL-69978 Tel Aviv, Israel	Sarne, Y (reprint author), Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.						BAUMHAKER Y, 1993, MOL PHARMACOL, V44, P461; Bouaboula M, 1997, J BIOL CHEM, V272, P22330, DOI 10.1074/jbc.272.35.22330; BREIVOGEL CS, 1997, J NEUROCHEM, V68, P462; CHAKRABARTI S, 1995, J NEUROCHEM, V64, P2534; CHAN JSC, 1995, J NEUROCHEM, V65, P2682; CHILDERS SR, 1991, LIFE SCI, V48, P1991, DOI 10.1016/0024-3205(91)90154-4; DEVANE WA, 1986, J NEUROCHEM, V46, P1929; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; Glass M, 1997, J NEUROSCI, V17, P5327, DOI 10.1523/jneurosci.17-14-05327.1997; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; GRAESER D, 1993, MOL PHARMACOL, V43, P434; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HILF G, 1989, EUR J BIOCHEM, V186, P725, DOI 10.1111/j.1432-1033.1989.tb15266.x; HOWLETT AC, 1986, MOL PHARMACOL, V29, P307; HOWLETT AC, 1995, CANNABINOID RECEPTOR, P169; Keren O, 1997, BRAIN RES, V764, P277, DOI 10.1016/S0006-8993(97)00599-4; LAI HWL, 1995, FEBS LETT, V360, P97, DOI 10.1016/0014-5793(95)00088-Q; LAUGWITZ KL, 1993, NEURON, V10, P233, DOI 10.1016/0896-6273(93)90314-H; LAW PY, 1982, MOL PHARMACOL, V21, P483; Lee JWM, 1998, J NEUROCHEM, V70, P2203; LEWIS DL, 1998, 1998 S CANN INT CANN, P25; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; OFFERMANNS S, 1991, J BIOL CHEM, V266, P3365; Onaivi ES, 1996, PROG NEUROBIOL, V48, P275, DOI 10.1016/0301-0082(95)00044-5; PACHECO MA, 1993, BRAIN RES, V603, P102, DOI 10.1016/0006-8993(93)91304-B; PRATHER PL, 1994, J BIOL CHEM, V269, P21293; ROERIG SC, 1992, MOL PHARMACOL, V41, P822; Sarne Y, 1998, BIOCHEM BIOPH RES CO, V246, P128, DOI 10.1006/bbrc.1998.8582; Shapira M, 1998, BRAIN RES, V806, P26, DOI 10.1016/S0006-8993(98)00697-0; SHEN KF, 1990, BRAIN RES, V525, P225, DOI 10.1016/0006-8993(90)90868-C; Sim LJ, 1996, EUR J PHARMACOL, V307, P97, DOI 10.1016/0014-2999(96)00211-7; Standifer KM, 1997, CELL SIGNAL, V9, P237, DOI 10.1016/S0898-6568(96)00174-X; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; TSU RC, 1995, J NEUROCHEM, V64, P2700; VOGEL Z, 1993, J NEUROCHEM, V61, P352, DOI 10.1111/j.1471-4159.1993.tb03576.x; YU VC, 1986, J BIOL CHEM, V261, P1065	38	48	50	0	2	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340			CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	JUN	2000	20	3					291	304		10.1023/A:1007058008477			14	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	306NB	WOS:000086601800003	10789829				2020-06-26	J	Evans, CJ; Monteillet-Agius, G; Saliminejad, N; Zaki, PA				Evans, CJ; Monteillet-Agius, G; Saliminejad, N; Zaki, PA			Opiate drugs: 'guilt by association'	MOLECULAR PSYCHIATRY			English	Editorial Material							BUPRENORPHINE		Univ Calif Los Angeles, Inst Neuropsychiat, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA	Evans, CJ (reprint author), Univ Calif Los Angeles, NPI, Room 2760,MRL,675 Charles E Young Dr S, Los Angeles, CA 90095 USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [P50 DA005010]		BODKIN JA, 1995, J CLIN PSYCHOPHARM, V15, P49, DOI 10.1097/00004714-199502000-00008; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; Keith DE, 1998, MOL PHARMACOL, V53, P377; LING W, 1994, J PSYCHOACTIVE DRUGS, V26, P119, DOI 10.1080/02791072.1994.10472259; Massotte D, 1998, ESSAYS BIOCHEM, V33, P65, DOI 10.1042/bse0330065; Rocha BA, 1998, NAT NEUROSCI, V1, P132; WALSH SL, 1994, CLIN PHARMACOL THER, V55, P569, DOI 10.1038/clpt.1994.71; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; ZAKI PA, 2000, IN PRESS JPET, V292	9	12	12	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	1359-4184			MOL PSYCHIATR	Mol. Psychiatr.	MAR	2000	5	2					122	123		10.1038/sj.mp.4000739			2	Biochemistry & Molecular Biology; Neurosciences; Psychiatry	Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry	307AF	WOS:000086630600001	10822333				2020-06-26	J	Filizola, M; Laakkonen, L; Loew, GH				Filizola, M; Laakkonen, L; Loew, GH			3D modeling, ligand binding and activation studies of the cloned mouse delta, mu and kappa opioid receptors	PROTEIN ENGINEERING			English	Article						G-protein coupled receptors; ligand binding site; opioid receptors; transmembrane helices	PROTEIN-COUPLED RECEPTORS; MEMBRANE-SPANNING SEGMENT; SELECTIVE AGONIST BINDING; DOPAMINE D2 RECEPTOR; TRANSMEMBRANE DOMAIN; PROJECTION STRUCTURE; ADENYLYL-CYCLASE; PHARMACOLOGICAL CHARACTERIZATION; FUNCTIONAL EXPRESSION; IRREVERSIBLE BINDING	Refined 3D models of the transmembrane domains of the cloned delta, mu and kappa opioid receptors belonging to the superfamily of G-protein coupled receptors (GPCRs) were constructed from a multiple sequence alignment using the alpha carbon template of rhodopsin recently reported. Other key steps in the procedure were relaxation of the 3D helix bundle by unconstrained energy optimization and assessment of the stability of the structure by performing unconstrained molecular dynamics simulations of the energy optimized structure. The results were stable ligand-free models of the TM domains of the three opioid receptors. The ligand-free delta receptor was then used to develop a systematic and reliable procedure to identify and assess putative binding sites that would be suitable for similar investigation of the other two receptors and GPCRs in general. To this end, a non-selective, 'universal' antagonist, naltrexone, and agonist, etorphine, were used as probes. These ligands were first docked in all sites of the model delta opioid receptor which were sterically accessible and to which the protonated amine of the ligands could be anchored to a complementary proton-accepting residue. Using these criteria, nine ligand-receptor complexes with different binding pockets were identified and refined by energy minimization. The properties of all these possible ligand-substrate complexes were then examined for consistency with known experimental results of mutations in both opioid and other GPCRs. Using this procedure, the lowest energy agonist-receptor and antagonist-receptor complexes consistent with these experimental results were identified. These complexes were then used to probe the mechanism of receptor activation by identifying differences in receptor conformation between the agonist and the antagonist complex during unconstrained dynamics simulation. The results lent support to a possible activation mechanism of the mouse delta opioid receptor similar to that recently proposed for several other GPCRs. They also allowed the selection of candidate sites for future mutagenesis experiments.	Mol Res Inst, Mt View, CA 94043 USA	Loew, GH (reprint author), Mol Res Inst, 2495 Old Middlefield Way, Mt View, CA 94043 USA.			Filizola, Marta/0000-0002-4382-8276	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA02622]		Alkorta I, 1996, PROTEIN ENG, V9, P573, DOI 10.1093/protein/9.7.573; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3578; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; BALLESTEROS JA, 1995, [No title captured], V25, P366, DOI DOI 10.1016/S1043-9471(05)80049-7; Barker WC, 1998, NUCLEIC ACIDS RES, V26, P27, DOI 10.1093/nar/26.1.27; Befort K, 1996, J BIOL CHEM, V271, P10161, DOI 10.1074/jbc.271.17.10161; Befort K, 1996, MOL PHARMACOL, V49, P216; Benson DA, 1998, NUCLEIC ACIDS RES, V26, P1, DOI 10.1093/nar/26.1.1; BOCKAERT J, 1991, THERAPIE, V46, P413; CHEN CG, 1995, J BIOL CHEM, V270, P17866, DOI 10.1074/jbc.270.30.17866; CHEN Y, 1993, MOL PHARMACOL, V44, P8; Claude PA, 1996, P NATL ACAD SCI USA, V93, P5715, DOI 10.1073/pnas.93.12.5715; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; CORNETTE JL, 1987, J MOL BIOL, V195, P659, DOI 10.1016/0022-2836(87)90189-6; Davies A, 1996, J STRUCT BIOL, V117, P36, DOI 10.1006/jsbi.1996.0067; DICKENSON AH, 1991, BRIT MED BULL, V47, P690, DOI 10.1093/oxfordjournals.bmb.a072501; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Filizola M, 1999, J COMPUT AID MOL DES, V13, P397, DOI 10.1023/A:1008079823736; Filizola M, 1998, J COMPUT AID MOL DES, V12, P111, DOI 10.1023/A:1007969112988; FRISCH MJ, 1995, [No title captured]; Fu DY, 1996, BIOCHEMISTRY-US, V35, P11278, DOI 10.1021/bi960928x; FUKUDA K, 1995, J BIOL CHEM, V270, P6702, DOI 10.1074/jbc.270.12.6702; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; FUKUDA K, 1995, FEBS LETT, V373, P177, DOI 10.1016/0014-5793(95)01034-C; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Hargrave PA, 1991, CURR OPIN STRUC BIOL, V1, P575, DOI 10.1016/S0959-440X(05)80080-6; HENRY DJ, 1995, MOL PHARMACOL, V47, P551; HJORTH SA, 1995, MOL PHARMACOL, V47, P1089; Huang P, 1997, J COMPUT AID MOL DES, V11, P21, DOI 10.1023/A:1008067209563; JAFFE JH, 1990, [No title captured], P485; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Javitch JA, 1998, BIOCHEMISTRY-US, V37, P998, DOI 10.1021/bi972241y; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KOMIYA H, 1988, P NATL ACAD SCI USA, V85, P9012, DOI 10.1073/pnas.85.23.9012; KONG HY, 1994, P NATL ACAD SCI USA, V91, P8042, DOI 10.1073/pnas.91.17.8042; KONG HY, 1993, J BIOL CHEM, V268, P23055; LUO XC, 1994, PROTEIN ENG, V7, P1441, DOI 10.1093/protein/7.12.1441; MA GH, 1995, MOL PHARMACOL, V47, P1035; Malatynska E, 1996, J PHARMACOL EXP THER, V278, P1083; MALDONADO R, 1992, NEUROPHARMACOLOGY, V31, P1231, DOI 10.1016/0028-3908(92)90051-P; MATHER LE, 1992, MED J AUSTRALIA, V156, P796, DOI 10.5694/j.1326-5377.1992.tb121567.x; MAUSOUR A, 1997, J NEUROCHEM, V68, P344; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MENG F, 1995, J BIOL CHEM, V270, P12730, DOI 10.1074/jbc.270.21.12730; MENG F, 1993, P NATL ACAD SCI USA, V90, P9954, DOI 10.1073/pnas.90.21.9954; MIN KC, 1993, J BIOL CHEM, V268, P9400; MINAMI M, 1995, FEBS LETT, V364, P23, DOI 10.1016/0014-5793(95)00340-F; MISICKA A, 1994, INT J PEPT PROT RES, V44, P80; Murthy KS, 1996, MOL PHARMACOL, V50, P870; OLIVEIRA L, 1994, TRENDS PHARMACOL SCI, V15, P170, DOI 10.1016/0165-6147(94)90137-6; Olson GA, 1996, PEPTIDES, V17, P1421, DOI 10.1016/S0196-9781(96)00225-2; ONOGI T, 1995, FEBS LETT, V357, P93, DOI 10.1016/0014-5793(94)01341-W; PEARLMAN DA, 1991, [No title captured]; Piros ET, 1996, MOL PHARMACOL, V50, P947; PIROS ET, 1995, MOL PHARMACOL, V47, P1041; Pogozheva ID, 1998, BIOPHYS J, V75, P612, DOI 10.1016/S0006-3495(98)77552-6; PRATHER PL, 1994, MOL PHARMACOL, V45, P997; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; SANKARARAMAKRISHNAN R, 1990, BIOPOLYMERS, V30, P287, DOI 10.1002/bip.360300307; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; Segredo V, 1997, J NEUROCHEM, V68, P2395; Strahs D, 1997, PROTEIN ENG, V10, P1019, DOI 10.1093/protein/10.9.1019; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; TANG TL, 1995, MOL PHARMACOL, V48, P189; Thirstrup K, 1996, J BIOL CHEM, V271, P7875, DOI 10.1074/jbc.271.14.7875; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; Unger VM, 1997, NATURE, V389, P203; Valiquette M, 1996, J BIOL CHEM, V271, P18789, DOI 10.1074/jbc.271.31.18789; WANG JB, 1994, J BIOL CHEM, V269, P25966; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; XUE JC, 1994, J BIOL CHEM, V269, P30195; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; ZHANG DQ, 1993, J MED CHEM, V36, P934, DOI 10.1021/jm00059a021; ZHOU W, 1994, MOL PHARMACOL, V45, P165; Zhu JM, 1996, J BIOL CHEM, V271, P1430, DOI 10.1074/jbc.271.3.1430; Zhu JM, 1996, FEBS LETT, V384, P198, DOI 10.1016/0014-5793(96)00312-2	87	39	40	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0269-2139			PROTEIN ENG	Protein Eng.	NOV	1999	12	11					927	942		10.1093/protein/12.11.927			16	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology	264MZ	WOS:000084187200005	10585498	Bronze			2020-06-26	J	Elliott, SP; Hale, KA				Elliott, SP; Hale, KA			A previously unidentified acepromazine metabolite in humans: Implications for the measurement of acepromazine in blood	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							DRUG		City Hosp NHS Teaching Trust, Reg Lab Toxicol, Birmingham B18 7QH, W Midlands, England	Elliott, SP (reprint author), City Hosp NHS Teaching Trust, Reg Lab Toxicol, Dudley Rd, Birmingham B18 7QH, W Midlands, England.						COSSUM PA, 1988, BIOPHARM DRUG DISPOS, V9, P321, DOI 10.1002/bod.2510090402; DEWEY J, 1980, [No title captured], V9, P1; Elliott SP, 1999, FORENSIC SCI INT, V101, P9, DOI 10.1016/S0379-0738(99)00009-2; ELLIOTT SP, 1998, J ANAL TOXICOL, V22, P280; Stowell LI, 1998, J ANAL TOXICOL, V22, P166, DOI 10.1093/jat/22.2.166; TRACQUI A, 1993, AM J FOREN MED PATH, V14, P309, DOI 10.1097/00000433-199312000-00007; Weir J J, 1972, Equine Vet J, V4, P88, DOI 10.1111/j.2042-3306.1972.tb03885.x	7	7	7	0	0	PRESTON PUBLICATIONS INC	NILES	7800 MERRIMAC AVE PO BOX 48312, NILES, IL 60648 USA	0146-4760			J ANAL TOXICOL	J. Anal. Toxicol.	SEP	1999	23	5					367	371		10.1093/jat/23.5.367			5	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	232CV	WOS:000082348900011	10488925	Bronze			2020-06-26	J	Whistler, JL; von Zastrow, M				Whistler, JL; von Zastrow, M			Dissociation of functional roles of dynamin in receptor-mediated endocytosis and mitogenic signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MU-OPIOID RECEPTOR; COATED VESICLE FORMATION; IN-VIVO; AGONIST; INTERNALIZATION; DESENSITIZATION; RESENSITIZATION; MECHANISMS; NEURONS	Dynamin plays a critical role in the membrane fission mechanism that mediates regulated endocytosis of many G protein-coupled receptors. in addition, dynamin is required for ligand-induced activation of mitogen-activated protein kinase by certain receptors, raising a general question about the role of dynamin in mitogenic signal transduction. Here we report that endocytosis of mu and delta opioid receptors is not required for efficient ligand-induced activation of mitogen-activated protein kinase. Nevertheless, mitogenic signaling mediated by these receptors is specifically dynamin-dependent. Thus a functional role of dynamin in mitogenic signaling can be dissociated from its role in receptor-mediated endocytosis, suggesting a previously unidentified and distinct role of dynamin in signal transduction by certain G protein-coupled receptors.	Univ Calif San Francisco, Dept Psychiat, Cell Biol Program, Nina Ireland Lab, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, Cell Biol Program, San Francisco, CA 94143 USA	von Zastrow, M (reprint author), Univ Calif San Francisco, Dept Psychiat, Cell Biol Program, Nina Ireland Lab, Box 0984 IRE,401 Parnassus Ave, San Francisco, CA 94143 USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA10711, DA05844]		Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; Burt RP, 1996, BRIT J PHARMACOL, V117, P224, DOI 10.1111/j.1476-5381.1996.tb15178.x; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Evans CJ, 1993, BIOL BASIS SUBSTANCE, P31; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Ignatova EG, 1999, J NEUROSCI, V19, P56; Keith DE, 1998, MOL PHARMACOL, V53, P377; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; Li LY, 1996, MOL PHARMACOL, V50, P599; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Raynor K, 1996, NIDA Res Monogr, V161, P83; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Schulz S, 1998, EUR J NEUROSCI, V10, P1196, DOI 10.1046/j.1460-9568.1998.00103.x; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	33	89	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	1999	274	35					24575	24578		10.1074/jbc.274.35.24575			4	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	229KH	WOS:000082193400020	10455121	Bronze			2020-06-26	J	Gaibelet, G; Meilhoc, E; Riond, J; Saves, I; Exner, T; Liaubet, L; Nurnberg, B; Masson, JM; Emorine, LJ				Gaibelet, G; Meilhoc, E; Riond, J; Saves, I; Exner, T; Liaubet, L; Nurnberg, B; Masson, JM; Emorine, LJ			Nonselective coupling of the human mu-opioid receptor to multiple inhibitory G-protein isoforms	EUROPEAN JOURNAL OF BIOCHEMISTRY			English	Article						G-protein-coupled receptor; heterologous expression; Saccharomyces cerevisiae	3RD CYTOPLASMIC LOOP; ADENYLYL-CYCLASE; ALPHA-SUBUNITS; ESCHERICHIA-COLI; PHARMACOLOGICAL CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; LIGAND-BINDING; CHO CELLS; ANTISENSE OLIGODEOXYNUCLEOTIDES; FUNCTIONAL EXPRESSION	The human mu-opioid receptor was expressed in Saccharomyces cerevisiae. Binding of [H-3]diprenorphine to yeast spheroplasts was specific and saturable (K-d = 1 nM, B-max = 0.2-1 pmol.mg(-1) of membrane proteins). Inhibition of [H-3]diprenorphine binding by antagonists and agonists with varying opioid selectivities (mu, delta and kappa) occurred with the same order of potency as in mammalian tissues. Affinities of antagonists were the same with yeast spheroplasts as in reference tissues whereas those of agonists, except etorphine and buprenorphine, were 10-fold to 100-fold lower. Addition of heterotrimeric G(i,o)-proteins purified from bovine brain shifted the mu-opioid receptor into a high-affinity state for agonists. Using individually purified G(alpha)-subunits re-associated with beta gamma-dimers, we showed that alpha o1, alpha o2, alpha i1, alpha i2 and alpha i3 reconstituted high-affinity agonist binding with equal efficiency. This suggests that the structural determinants of the mu-opioid receptor responsible for G-protein coupling are not able to confer a high degree of specificity towards any member of the G(i,o) family. The selective effects of opioid observed in specialized tissues upon opioid stimulation may be a result of regulation of G-protein activity by cell-specific factors which should conveniently be analysed using the reconstitution assay described here.	Inst Natl Sci Appl, Inst Pharmacol & Biol Struct, CNRS, Unite Propre 9062, F-31077 Toulouse, France; Free Univ Berlin, Inst Pharmakol Thielalle Berlin, D-1000 Berlin, Germany	Emorine, LJ (reprint author), Inst Natl Sci Appl, Inst Pharmacol & Biol Struct, CNRS, Unite Propre 9062, 205 Route Narbonne, F-31077 Toulouse, France.		meilhoc, eliane/AAG-4396-2020; Riond, Joelle/R-6414-2016	Riond, Joelle/0000-0002-6281-2376; Liaubet, Laurence/0000-0003-0201-0264			BERTIN B, 1992, J BIOL CHEM, V267, P8200; Blake AD, 1997, J BIOL CHEM, V272, P782, DOI 10.1074/jbc.272.2.782; Capeyrou R, 1997, FEBS LETT, V415, P200, DOI 10.1016/S0014-5793(97)01124-1; CARTER BD, 1993, P NATL ACAD SCI USA, V90, P4062, DOI 10.1073/pnas.90.9.4062; CHAKRABARTI S, 1995, J NEUROCHEM, V64, P2534; CHAN JSC, 1995, J NEUROCHEM, V65, P2682; CRUCIANI RA, 1993, P NATL ACAD SCI USA, V90, P3019, DOI 10.1073/pnas.90.7.3019; Degtiar VE, 1997, J PHYSIOL-LONDON, V502, P321, DOI 10.1111/j.1469-7793.1997.321bk.x; Dietrich G, 1998, J NEUROCHEM, V70, P2106; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; FRANCES B, 1985, EUR J PHARMACOL, V117, P223, DOI 10.1016/0014-2999(85)90607-7; FREISSMUTH M, 1991, P NATL ACAD SCI USA, V88, P8548, DOI 10.1073/pnas.88.19.8548; FREISSMUTH M, 1991, J BIOL CHEM, V266, P177; Gaibelet G, 1997, FEBS LETT, V408, P135, DOI 10.1016/S0014-5793(97)00407-9; GOLSTEIN A, 1989, MOL PHARM, V36, P265; HUANG HJ, 1992, BIOCHEM BIOPH RES CO, V182, P1180, DOI 10.1016/0006-291X(92)91856-L; KING K, 1990, SCIENCE, V250, P121, DOI 10.1126/science.2171146; KOSAWA T, 1995, J BIOL CHEM, V270, P1734; LAUGWITZ KL, 1993, NEURON, V10, P233, DOI 10.1016/0896-6273(93)90314-H; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; LEPLATOIS P, 1992, GENE, V122, P139, DOI 10.1016/0378-1119(92)90041-M; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; MANGOURA D, 1993, P NATL ACAD SCI USA, V90, P2915, DOI 10.1073/pnas.90.7.2915; MARULLO S, 1989, BIO-TECHNOL, V7, P923, DOI 10.1038/nbt0989-923; MARULLO S, 1988, P NATL ACAD SCI USA, V85, P7551, DOI 10.1073/pnas.85.20.7551; MEILHOC E, 1990, BIO-TECHNOL, V8, P223, DOI 10.1038/nbt0390-223; Murthy KS, 1996, MOL PHARMACOL, V50, P870; NURNBERG B, 1994, BIOCHEM J, V300, P387; Nurnberg B, 1997, BACTERIAL TOXINS TOO, P47; Obukhov AG, 1996, EMBO J, V15, P5833, DOI 10.1002/j.1460-2075.1996.tb00970.x; PAYETTE P, 1990, FEBS LETT, V266, P21, DOI 10.1016/0014-5793(90)81496-B; PRATHER PL, 1995, MOL BRAIN RES, V29, P336, DOI 10.1016/0169-328X(94)00264-F; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; RAFFA RB, 1994, EUR J PHARMACOL, V258, pR5, DOI 10.1016/0014-2999(94)90073-6; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Roth BL, 1997, J PHARMACOL EXP THER, V280, P576; SanchezBlazquez P, 1995, J PHARMACOL EXP THER, V275, P1590; SANDER P, 1994, FEBS LETT, V344, P41, DOI 10.1016/0014-5793(94)00335-1; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SHERMAN F, 1986, [No title captured]; Smart D, 1997, BRIT J PHARMACOL, V120, P1165, DOI 10.1038/sj.bjp.0701012; SMART D, 1994, J NEUROCHEM, V62, P1009; Standifer KM, 1996, MOL PHARMACOL, V50, P293; Standifer KM, 1997, CELL SIGNAL, V9, P237, DOI 10.1016/S0898-6568(96)00174-X; TOLKOVSKY AM, 1982, MOL PHARMACOL, V22, P648; WANG L, 1994, J NEUROCHEM, V63, P1726; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Weiss HM, 1995, FEBS LETT, V377, P451; Zadina JE, 1997, NATURE, V386, P499, DOI 10.1038/386499a0	50	17	17	0	1	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0014-2956			EUR J BIOCHEM	Eur. J. Biochem.	APR	1999	261	2					517	523		10.1046/j.1432-1327.1999.00301.x			7	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	199GB	WOS:000080471400022	10215864				2020-06-26	J	Burd, AL; El-Kouhen, R; Erickson, LJ; Loh, HH; Law, PY				Burd, AL; El-Kouhen, R; Erickson, LJ; Loh, HH; Law, PY			Identification of serine 356 and serine 363 as the amino acids involved in etorphine-induced down-regulation of the mu-opioid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; UBIQUITIN-DEPENDENT PROTEOLYSIS; COOH-TERMINAL TAIL; PROTEIN-KINASE-C; INDUCED INTERNALIZATION; CARBOXYL-TERMINUS; OPIATE RECEPTOR; BETA-ARRESTIN; PHOSPHORYLATION; RESIDUES	Agonist-induced internalization of G protein-coupled receptors is influenced by many structural determinants including the carboxyl tail. To investigate the role of serine and threonine residues within the carboxyl tail, several mutants were constructed by truncating the carboxyl tail of the hemagglutinin-tagged mu-opioid receptor, thereby removing serines and threonines systematically. Neuro(2A) cells stably expressing the truncated receptors did not exhibit a significant alteration in the affinity of [H-3]diprenorphine or etorphine for the receptor or the potency of etorphine to inhibit forskolin-stimulated adenylyl cyclase activity. Chronic etorphine treatment resulted in a Lime-dependent down-regulation of all the truncated receptors, except MOR1TAG355D, thus revealing the importance of the four amino acids between Ser(355) and Glu(359) (STIE). Surprisingly, deletion of the STIE sequence resulted in a receptor that down-regulated the same as the wild-type receptor. The involvement of multiple amino acids within the carboxyl tail was demonstrated by combining alanine substitutions of several putative G-protein-coupled receptor kinase phosphorylation sites. Systematic analysis of these receptors indicated that mutation of Ser(356) and Ser(363) to alanine attenuated agonist-mediated down-regulation. The magnitude of etorphine-induced phosphorylation of this mutant receptor, however, was similar to that of the wild-type mu-opioid receptor. Thus, phosphorylation of the carboxyl tail of the mu-opioid receptor is not an obligatory event for etorphine-induced down-regulation of the receptor.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	Burd, AL (reprint author), Univ Minnesota, Sch Med, Dept Pharmacol, 3-249 Millard Hall, Minneapolis, MN 55455 USA.	litt0044@maroon.tc.umn.edu		Law, Ping-Yee/0000-0002-5364-1093	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA05695, DA5064, DA7339]		ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; Capeyrou R, 1997, FEBS LETT, V415, P200, DOI 10.1016/S0014-5793(97)01124-1; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; Chakrabarti S, 1997, MOL PHARMACOL, V52, P105; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng Y. C., 1973, BIOCHEM PHARMACOL, V22, P413; Cvejic S, 1996, J BIOL CHEM, V271, P4073; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Fukushima Y, 1997, J BIOL CHEM, V272, P19464, DOI 10.1074/jbc.272.31.19464; Gaudriault G, 1997, J BIOL CHEM, V272, P2880, DOI 10.1074/jbc.272.5.2880; GUCKER S, 1992, MOL PHARMACOL, V42, P656; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; LAW PY, 1983, MOL PHARMACOL, V24, P413; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; MORO O, 1993, J BIOL CHEM, V268, P6862; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OBIN M, 1994, BIOCHEM BIOPH RES CO, V200, P1169, DOI 10.1006/bbrc.1994.1574; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; PEI G, 1995, MOL PHARMACOL, V48, P173; Pohl M, 1997, J BIOL CHEM, V272, P18179, DOI 10.1074/jbc.272.29.18179; Roth A, 1997, J BIOL CHEM, V272, P23769, DOI 10.1074/jbc.272.38.23769; SMITH SA, 1998, INT NARC RES C JUL 2, P33; Tsuga H, 1998, J BIOL CHEM, V273, P5323, DOI 10.1074/jbc.273.9.5323; WALSETH TF, 1989, J BIOL CHEM, V264, P21106; WHITE AA, 1978, ANAL BIOCHEM, V85, P451, DOI 10.1016/0003-2697(78)90242-7; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449; ZIMPRICH A, 1995, FEBS LETT, V359, P142, DOI 10.1016/0014-5793(95)00028-8	31	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34488	34495		10.1074/jbc.273.51.34488			8	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	148PZ	WOS:000077542200083	9852117	Bronze			2020-06-26	J	Sarne, Y; Gafni, M; Fields, A				Sarne, Y; Gafni, M; Fields, A			Reexamination of opioid stimulation of cGMP formation in cell lines of neuronal origin	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						opioids; cyclic GMP; nitric oxide; calcium; neuroblastoma; NG108-15; SK-N-SH	NG 108-15 CELLS; NITRIC-OXIDE; CYCLIC-GMP; MORPHINE-TOLERANCE; INTRACELLULAR CALCIUM; BRADYKININ; RECEPTORS; LEVEL; INVOLVEMENT; DEPENDENCE	1. The present study reexamines a previous notion on opioid stimulation of cyclic GMP (cGMP) formation and the retraction of the original findings. 2. The effect of opioid agonists on cGMP accumulation in two cell lines of neuronal origin was measured. The proportion of cGMP stimulation in NG108-15 neuroblastoma x glioma hybrid cells resembled the proportion of [Ca2+](in) elevation by opioids in this culture. The failure of opioids to stimulate cGMP formation in SK-N-SH human neuroblastoma coincided with the lack of cGMP stimulation by other Ca2+ mobilizing agents in these cells. The nitric oxide donor nitroprusside elevated cGMP in both cell lines. 3. The implication of the opioid-Ca2+-NO-cGMP cellular pathway for opioid activity in vivo is discussed.	Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, Mauerberger Chair Neuropharmacol, IL-69978 Tel Aviv, Israel	Sarne, Y (reprint author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, Mauerberger Chair Neuropharmacol, IL-69978 Tel Aviv, Israel.						BHARGAVA HN, 1995, GEN PHARMACOL, V26, P1049, DOI 10.1016/0306-3623(94)00271-N; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BURTON CK, 1990, J PHARMACOL EXP THER, V252, P104; CAPPENDIJK SLT, 1993, NEUROSCI LETT, V162, P97, DOI 10.1016/0304-3940(93)90569-7; CONOR MA, 1994, REGUL PEPTIDES, V54, P65; Dambisya YM, 1996, BRIT J PHARMACOL, V117, P914, DOI 10.1111/j.1476-5381.1996.tb15280.x; FERREIRA SH, 1991, EUR J PHARMACOL, V201, P121, DOI 10.1016/0014-2999(91)90333-L; FIELDS A, 1995, BRAIN RES, V687, P94, DOI 10.1016/0006-8993(95)00475-6; GOY MF, 1991, TRENDS NEUROSCI, V14, P293, DOI 10.1016/0166-2236(91)90140-P; GULLIS R, 1975, NATURE, V256, P57, DOI 10.1038/256057a0; GWYNN GJ, 1982, P NATL ACAD SCI-BIOL, V79, P690, DOI 10.1073/pnas.79.2.690; HAMPRECHT B, 1997, NATURE, V265, P764; JIN WZ, 1992, MOL PHARMACOL, V42, P1083; JIN WZ, 1994, J NEUROSCI, V14, P1920; KOLESNIKOV YA, 1992, EUR J PHARMACOL, V221, P399, DOI 10.1016/0014-2999(92)90732-J; MINNEMAN KP, 1976, NATURE, V262, P313, DOI 10.1038/262313a0; OKAJIMA F, 1993, BIOCHEM J, V290, P241, DOI 10.1042/bj2900241; OKAJIMA F, 1992, FEBS LETT, V301, P223, DOI 10.1016/0014-5793(92)81252-H; RACAGNI G, 1976, J PHARM PHARMACOL, V28, P258, DOI 10.1111/j.2042-7158.1976.tb04146.x; REISER G, 1990, EUR J BIOCHEM, V189, P547, DOI 10.1111/j.1432-1033.1990.tb15521.x; REISER G, 1995, J NEUROCHEM, V64, P61; REISER G, 1984, BRAIN RES, V290, P367, DOI 10.1016/0006-8993(84)90958-2; Sarne Y, 1996, BRAIN RES, V722, P203, DOI 10.1016/0006-8993(96)00191-6	23	1	1	0	0	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340			CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	AUG	1998	18	4					425	428		10.1023/A:1022501632502			4	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	ZP688	WOS:000073778500006	9619297				2020-06-26	J	Zhang, J; Ferguson, SSG; Barak, LS; Bodduluri, SR; Laporte, SA; Law, PY; Caron, MG				Zhang, J; Ferguson, SSG; Barak, LS; Bodduluri, SR; Laporte, SA; Law, PY; Caron, MG			Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article							BETA(2)-ADRENERGIC RECEPTOR; BETA-ARRESTIN; FUNCTIONAL-ANALYSIS; INTERNALIZATION; PHOSPHORYLATION; SEQUESTRATION; DESENSITIZATION; ENDOCYTOSIS; MUTANT; CELLS	The G protein-coupled mu-opioid receptor (mu OR) mediates the physiological effects of endogenous opioid peptides as well as the structurally distinct opioid alkaloids morphine and etorphine. An intriguing feature of mu OR signaling is the differential receptor trafficking and desensitization properties following activation by distinct agonists, which have been proposed as possible mechanisms related to opioid tolerance. Here we report that the ability of distinct opioid agonists to differentially regulate mu OR internalization and desensitization is related to their ability to promote G protein-coupled receptor kinase (GRK)-dependent phosphorylation of the mu OR. Although both etorphine and morphine effectively activate the mu OR, only etorphine elicits robust mu OR phosphorylation followed by plasma membrane translocation of beta-arrestin and dynamin dependent receptor internalization. In contrast, corresponding to its inability to cause mu OR internalization, morphine is unable to either elicit mu OR phosphorylation or stimulate beta-arrestin translocation. However, upon the overexpression of GRK2, morphine gains the capacity to induce mu OR phosphorylation, accompanied by the rescue of beta-arrestin translocation and receptor sequestration. Moreover, overexpression of GRK2 also leads to an attenuation of morphine-mediated inhibition of adenylyl cyclase. These findings point to the existence of marked differences in the ability of different opioid agonists to promote mu OR phosphorylation by GRK. These differences may provide the molecular basis underlying the different analgesic properties of opioid agonists and contribute to the distinct ability of various opioids to induce drug tolerance.	Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	Caron, MG (reprint author), Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Box 3287, Durham, NC 27710 USA.		Laporte, Stephane A/F-3282-2012	Law, Ping-Yee/0000-0002-5364-1093	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL 03422]; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS019576, NS 19576]		Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Blake AD, 1997, J BIOL CHEM, V272, P782, DOI 10.1074/jbc.272.2.782; Capeyrou R, 1997, FEBS LETT, V415, P200, DOI 10.1016/S0014-5793(97)01124-1; Chakrabarti S, 1997, MOL PHARMACOL, V52, P105; CHEN Y, 1994, J BIOL CHEM, V269, P7839; Cherny NI, 1996, DRUGS, V51, P713, DOI 10.2165/00003495-199651050-00002; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/cjpp-74-10-1095; FERGUSON SSG, 1996, MOL MECHANISMS NEURO, P219; Gaudriault G, 1997, J BIOL CHEM, V272, P2880, DOI 10.1074/jbc.272.5.2880; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; Iacovelli L, 1996, MOL ENDOCRINOL, V10, P1138, DOI 10.1210/me.10.9.1138; Itokawa M, 1996, MOL PHARMACOL, V49, P560; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; Mestek A, 1996, NIDA Res Monogr, V161, P104; MESTEK A, 1995, J NEUROSCI, V15, P2396; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; Peppel K, 1997, J BIOL CHEM, V272, P25425, DOI 10.1074/jbc.272.41.25425; Piros ET, 1996, NEUROCHEM RES, V21, P1277, DOI 10.1007/BF02532368; Raynor K, 1996, NIDA Res Monogr, V161, P83; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; Schlador ML, 1997, J BIOL CHEM, V272, P18882, DOI 10.1074/jbc.272.30.18882; Segredo V, 1997, J NEUROCHEM, V68, P2395; Standifer KM, 1997, CELL SIGNAL, V9, P237, DOI 10.1016/S0898-6568(96)00174-X; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; TERWILLIGER RZ, 1994, J NEUROCHEM, V63, P1983; TOTA MR, 1991, TRENDS PHARMACOL SCI, V12, P4, DOI 10.1016/0165-6147(91)90479-C; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449	47	407	420	0	10	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JUN 9	1998	95	12					7157	7162		10.1073/pnas.95.12.7157			6	Multidisciplinary Sciences	Science & Technology - Other Topics	ZT829	WOS:000074131900105	9618555	Bronze, Green Published			2020-06-26	J	Chu, P; Murray, S; Lissin, D; vonZastrow, M				Chu, P; Murray, S; Lissin, D; vonZastrow, M			delta and kappa opioid receptors are differentially regulated by dynamin-dependent endocytosis when activated by the same alkaloid agonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE FORMATION; PROTEIN-KINASE-C; OPIATE RECEPTOR; MOLECULAR MECHANISMS; DOWN-REGULATION; INTERNALIZATION; DESENSITIZATION; SEQUESTRATION; RESENSITIZATION; MUTANT	Many alkaloid drugs used as analgesics activate multiple opioid receptors. Mechanisms that distinguish the actions of these drugs on the regulation of individual mu, delta, and kappa receptors are not understood. We have observed that individual cloned opioid receptors differ Significantly in their regulation by rapid endocytosis in the presence of alkaloid drug etorphine, a potent agonist of mu, delta, and kappa opioid receptors. Internalization of epitope-tagged delta opioid receptors from the plasma membrane is detectable within 10 min in the presence of etorphine. In contrast, kappa receptors expressed in the same cells remain in the plasma membrane and are not internalized for greater than or equal to 60 min, even when cells are exposed to saturating concentrations of etorphine. The rapid internalization of delta receptors is specifically inhibited in cells expressing K44E mutant dynamin I, suggesting that type-specific internalization of opioid receptors is mediated by clathrin-coated pits. Examination of a series of chimeric mutant kappa/delta receptors indicates that at least two receptor domains, including the highly divergent carboxyl-termindi cytoplasmic tail, determine the type specificity of this endocytic mechanism. We conclude that structurally homologous opioid receptors are differentially sorted by clathrin-mediated endocytosis following-activation by the same agonist ligand. These studies identify a fundamental mechanism of receptor regulation mediating type-specific effects of analgesic drugs that activate more than one type of opioid receptor.	UNIV CALIF SAN FRANCISCO,NINA IRELAND LAB,LANGLEY PORTER INST,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR NEUROBIOL & PSYCHIAT,SAN FRANCISCO,CA 94143					NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA00218]; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH19552]		Akil H, 1996, NIDA Res Monogr, V161, P127; Baba T, 1995, COLD SPRING HARB SYM, V60, P235, DOI 10.1101/SQB.1995.060.01.027; Blake AD, 1996, CHEM BIOL, V3, P967, DOI 10.1016/S1074-5521(96)90163-5; Blake AD, 1997, J BIOL CHEM, V272, P782, DOI 10.1074/jbc.272.2.782; Bohm SK, 1996, J BIOL CHEM, V271, P22003; CARON MG, 1993, RECENT PROG HORM RES, V48, P277; Cvejic S, 1996, J BIOL CHEM, V271, P4073; Evans CJ, 1993, BIOL BASIS SUBSTANCE, P31; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HUGHES J, 1977, BRIT MED BULL, V33, P157, DOI 10.1093/oxfordjournals.bmb.a071416; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Krueger KM, 1997, J BIOL CHEM, V272, P5; LAW PY, 1984, J BIOL CHEM, V259, P4096; Law PY, 1997, MOL PHARMACOL, V51, P152; LAW PY, 1982, MOL PHARMACOL, V72, P1; MENG F, 1995, J BIOL CHEM, V270, P12730, DOI 10.1074/jbc.270.21.12730; MESTEK A, 1995, J NEUROSCI, V15, P2396; Mostafapour S, 1996, RECEPT SIGNAL TRANS, V6, P151; PEI G, 1995, MOL PHARMACOL, V48, P173; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RAYNOR K, 1994, J PHARMACOL EXP THER, V270, P1381; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Raynor K, 1996, NIDA Res Monogr, V161, P83; Reisine T, 1996, ANN NY ACAD SCI, V780, P168, DOI 10.1111/j.1749-6632.1996.tb15121.x; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	35	131	134	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27124	27130		10.1074/jbc.272.43.27124			7	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	YC659	WOS:A1997YC65900049	9341153	Bronze			2020-06-26	J	Miao, H; Qin, BY; Yang, Y; Chen, DH				Miao, H; Qin, BY; Yang, Y; Chen, DH			Ultrastructural changes in rat locus coeruleus induced by chronic opioids	ACTA NEUROPATHOLOGICA			English	Article						locus coeruleus; ultrastructure; dihydroetorphine; morphine; opioids	OPIATE WITHDRAWAL; MORPHINE; NEURONS; NORADRENALINE; CERULEUS; RELEASE; BRAIN	The locus coeruleus (LC) is a major noradrenergic nucleus in the brain. The activity of the LC neurons is chronically regulated by opioids. So far, very little is known about the morphological changes induced by chronic treatment with opioids. In the present study, the effects of chronic treatment with morphine and dihydroetorphine, a new narcotic analgesic with lower physical dependence potential than morphine, were investigated on the ultrastructure of the rat LC. Rats received saline or increasing doses of morphine or dihydroetorphine for 5 days by twice daily subcutaneous injections. Withdrawal was precipitated in half of the opioid-treated rats by a single intraperitoneal injection of naloxone 4 h after the last injections of opioids. The ultrastructure of the LC was examined by electron microscopy. Results showed that chronic morphine treatment induced a marked injury to the LC neurons. The primary changes in the cell body were the indentation of nuclei, the fragmentation and degranulation of rough endoplasmic reticulum, as well as the disaggregation of polyribosomes. Myelinoid bodies were seen in the processes. An accumulation of presynaptic vesicles was observed in some of the terminals which formed synaptic junctions with the LC neurons as compared to the normal controls. Naloxone-precipitated withdrawal from morphine did not stop the morphine-induced injury on the LC neurons except that less accumulation of presynaptic vesicles occurred. Chronic dihydroetorphine treatment only induced a slight change in the ultrastructure of the LC neurons. These results indicate that the LC neurons are more vulnerable to chronic treatment with morphine than to that with dihydroetorphine.	ACAD MIL MED SCI,CTR INSTRUMENTAL ANAL,BEIJING 100850,PEOPLES R CHINA; ACAD MIL MED SCI,INST BASIC MED SCI,BEIJING 100850,PEOPLES R CHINA	Miao, H (reprint author), ACAD MIL MED SCI,INST PHARMACOL & TOXICOL,27 TAIPING RD,BEIJING 100850,PEOPLES R CHINA.						AGHAJANIAN GK, 1978, NATURE, V276, P186, DOI 10.1038/276186a0; AKAOKA H, 1991, J NEUROSCI, V11, P3830; ALBERTS B, 1994, MOL BIOL CELL, P655; ARBILLA S, 1978, NATURE, V271, P559, DOI 10.1038/271559a0; DONE C, 1992, EUR J PHARMACOL, V215, P333, DOI 10.1016/0014-2999(92)90052-6; DUMAN RS, 1988, J PHARMACOL EXP THER, V246, P1033; GREGORIOS JB, 1985, J NEUROPATH EXP NEUR, V44, P404, DOI 10.1097/00005072-198507000-00004; GROVES PM, 1980, J COMP NEUROL, V193, P841, DOI 10.1002/cne.901930402; HOLMES PV, 1995, SYNAPSE, V19, P197, DOI 10.1002/syn.890190307; HUANG M, 1982, Acta Pharmacologica Sinica, V3, P9; HUANG M, 1982, Acta Pharmacologica Sinica, V3, P81; JIANG ZN, 1992, CHIN J NEW DRUG, V1, P34; KOOB GF, 1992, TRENDS NEUROSCI, V15, P186, DOI 10.1016/0166-2236(92)90171-4; MIAO H, 1994, CLIN J PHARM TOXICOL, V8, P179; MOORE RY, 1979, ANNU REV NEUROSCI, V2, P113, DOI 10.1146/annurev.ne.02.030179.000553; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; QIN BY, 1993, NEW DRUGS CLIN REMED, V12, P119; RASMUSSEN K, 1990, J NEUROSCI, V10, P2308; SHA LJ, 1993, NEW DRUGS CLIN REMED, V12, P27; TEMPEL A, 1987, P NATL ACAD SCI USA, V84, P4308, DOI 10.1073/pnas.84.12.4308; VALENTINO RJ, 1988, J PHARMACOL EXP THER, V244, P1178; WANG SF, 1992, CHIN J CLIN PHARM, V8, P106	22	4	15	0	7	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	AUG	1997	94	2					109	115		10.1007/s004010050681			7	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	XL459	WOS:A1997XL45900002	9255384				2020-06-26	J	Vogelnest, L; Ralph, HK				Vogelnest, L; Ralph, HK			Chemical immobilisation of giraffe to facilitate short procedures	AUSTRALIAN VETERINARY JOURNAL			English	Article						giraffe; Giraffa camelopardalis; chemical immobilisation		Objective To describe the chemical immobilisation of giraffe (Giraffa camelopardalis) for short procedures at Taronga Zoo. Design A clinical report. Animals Five giraffe. Procedure The weight of each animal was determined and pre-immobilisation fasting, careful preparation of the site, and planning were carried out prior to each procedure. Etorphine and acetylpromazine were used as the sole immobilising agents. During immobilisation, elevation of the head and constant monitoring of the heart rate, respiratory rate and temperature were employed; blood pressure and blood oxygen saturation (SpO(2)) were monitored in one case 5. Intravenous fluids were administered. None of the animals was intubated, and supplemental oxygen was administered via an intranasal cannula in case 5. Ar the end of the procedures, diprenorphine was administered to reverse immobilisation. Results Induction times were 8 to 15 min. The mean heart rate, respiratory rate and rectal temperature were 58.6 beats per min, 12.2 breaths per min and 37.1 degrees C, respectively. SpO(2) in case 5 increased to over 90% with the administration of supplemental oxygen. Recovery to standing after reversal of immobilisation was rapid (2 or 3 min) in three cases, but rook 30 and 31 min in the other two. Conclusions Successful immobilisation of giraffe relies on consideration of all variables prior to and during the procedure. Careful selection and preparation of the venue and presence of sufficient numbers of adequately trained personnel are essential. Body weight determination allows accurate calculation of immobilising agent dose. Pre-immobilisation fasting followed by elevation of head and neck help preclude regurgitation and aspiration. Relevant vital signs monitoring, fluid replacement and oxygen supplementation promote cardiopulmonary homeostasis. Preoperative planning to ensure efficient performance of the procedure helps minimise recumbency time and increases the likelihood of a successful outcome.		Vogelnest, L (reprint author), TARONGA ZOO,POB 20,MOSMAN,NSW 20889,AUSTRALIA.						BUSH M, 1976, J AM VET MED ASSOC, V169, P884; Bush M., 1993, ZOO WILD ANIMAL MED, V3, P545; BUSH M, 1976, P ANN M AM ASS ZOO V, P151; CALLE PP, 1988, ZOO BIOL, V7, P243, DOI 10.1002/zoo.1430070306; CUNNINGHAM M, 1994, WILDLIFE P, V233, P253; GEISER DR, 1992, J ZOO WILDLIFE MED, V23, P189; *ISIS, 1996, PHYSL DAT REF VAL, P643; Schumacher J., 1992, EQUINE SURG, P674; WALKER DF, 1980, BOVINE EQUINE UROGEN, P7; WIENTER WR, 1986, ZOO BIOL, P371; YORK W, 1973, J ZOO ANIM MED, P17	11	7	10	0	7	AUSTRALIAN VETERINARY ASSN	VICTORIA	272 BRUNSWICK RD BRUNSWICK, VICTORIA 3056, AUSTRALIA	0005-0423			AUST VET J	Aust. Vet. J.	MAR	1997	75	3					180	182		10.1111/j.1751-0813.1997.tb10061.x			3	Veterinary Sciences	Veterinary Sciences	WQ333	WOS:A1997WQ33300008	9088507				2020-06-26	J	Blake, AD; Bot, G; Freeman, JC; Reisine, T				Blake, AD; Bot, G; Freeman, JC; Reisine, T			Differential opioid agonist regulation of the mouse mu opioid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIATE RECEPTORS; ADENYLYL-CYCLASE; CLONED HUMAN; MORPHINE; CELLS; MECHANISMS; ETORPHINE; TOLERANCE; MODEL	mu opioid receptors mediate the analgesia induced by morphine. Prolonged use of morphine causes tolerance development and dependence. To investigate the molecular basis of tolerance and dependence, the cloned mouse mu opioid receptor with an amino-terminal epitope tag was stably expressed in human embryonic kidney (HEK) 293 cells, and the effects of prolonged opioid agonist treatment on receptor regulation were examined, In HEK 293 cells the expressed mu receptor showed high affinity, specific, saturable binding of radioligands and a pertussis toxin-sensitive inhibition of adenylyl cyclase. Pretreatment (1 h, 3 h, or overnight) of cells with 1 mu M morphine or [D-Ala(2)MePhe(4),Gly(ol)(5)] enkephalin (DAMGO) resulted in no apparent receptor desensitization, as assessed by opioid inhibition of forskolin-stimulated cAMP levels. In contrast, the morphine and DAMGO pretreatments (3 h) resulted in a 3-4-fold compensatory increase in forskolin-stimulated cAMP accumulation. The opioid agonists methadone and buprenorphine are used in the treatment of addiction because of a markedly lower abuse potential. Pretreatment of mu receptor-expressing HEK 293 cells with methadone or buprenorphine abolished the ability of opioids to inhibit adenylyl cyclase. No compensatory increase in forskolin-stimulated cAMP accumulation was found with methadone or buprenorphine; these opioids blocked the compensatory effects observed with morphine and DAMGO. Taken together, these results indicate that methadone and buprenorphine interact differently with the mouse mu receptor than either morphine or DAMGO. The ability of methadone and buprenorphine to desensitize the mu receptor and block the compensatory rise in forskolin stimulated cAMP accumulation may be an underlying mechanism by which these agents are effective in the treatment of morphine addiction.	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104					NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA05636, DA08951]		ARDEN JR, 1995, J NEUROCHEM, V65, P1636; AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; Blake A., 1995, Society for Neuroscience Abstracts, V21, P1350; BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; CHAKRABARTI S, 1995, MOL BRAIN RES, V30, P269, DOI 10.1016/0169-328X(95)00014-J; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cowan A, 1995, BUPRENORPHINE COMBAT; FUKUDA K, 1995, J BIOL CHEM, V270, P6702, DOI 10.1074/jbc.270.12.6702; Harlow E, 1988, ANTIBODIES LAB MANUA; HEERDING J, 1994, REGUL PEPTIDES, V54, P119, DOI 10.1016/0167-0115(94)90418-9; HERZ A, 1993, HDB EXPT THERAPEUTIC, V104; JASINSKI DR, 1975, CLIN PHARMACOL THER, V17, P267; KAUFMAN DL, 1995, J BIOL CHEM, V270, P15877, DOI 10.1074/jbc.270.26.15877; KOSTERLITZ HW, 1972, AGONIST ANTAGONIST A, P121; Law S. F., 1995, Society for Neuroscience Abstracts, V21, P1350; LOH HH, 1990, ANNU REV PHARMACOL, V30, P123; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; PUTTFARCKEN PS, 1989, LIFE SCI, V45, P1937, DOI 10.1016/0024-3205(89)90548-1; PUTTFARCKEN PS, 1988, MOL PHARMACOL, V33, P520; RAYNOR K, 1995, J PHARMACOL EXP THER, V272, P423; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; REISINE T, 1993, TRENDS NEUROSCI, V16, P506, DOI 10.1016/0166-2236(93)90194-Q; REISINE T, 1995, NEUROPHARMACOLOGY, V34, P463, DOI 10.1016/0028-3908(95)00025-2; REISINE T, 1996, [No title captured], P521; ROTHMAN RB, 1995, SYNAPSE, V21, P60, DOI 10.1002/syn.890210109; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; Thomas JM, 1996, MOL PHARMACOL, V49, P907; TOLKOVSKY AM, 1982, MOL PHARMACOL, V22, P648; TSU RC, 1995, J NEUROCHEM, V64, P2700; Wang WW, 1995, P NATL ACAD SCI USA, V92, P12436, DOI 10.1073/pnas.92.26.12436; WHEELERACETO H, 1991, EUR J PHARMACOL, V195, P411, DOI 10.1016/0014-2999(91)90485-9	33	117	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					782	790		10.1074/jbc.272.2.782			9	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	WC048	WOS:A1997WC04800015	8995364	Bronze			2020-06-26	J	Osofsky, SA				Osofsky, SA			A practical anesthesia monitoring protocol for free-ranging adult African elephants (Loxodonta africana)	JOURNAL OF WILDLIFE DISEASES			English	Article						African elephant; Loxodonta africana; etorphine HCl; anesthesia; oxygen saturation; pulse oximetry	BLOOD-GAS VALUES; PULSE OXIMETRY; CHEMICAL IMMOBILIZATION; HYALURONIDASE; ZIMBABWE	Twenty free-ranging adult African elephants (Loxodonta africana) in northern Botswana were immobilized with a mean (+/-SD) of 9.5 +/- 0.5 mg etorphine hydrochloride and 2,000 IU hyaluronidase by intramuscular (IM) dart. The mean time to recumbency was 8.7 +/- 2.4 min. All animals were maintained in lateral recumbency. The anesthesia monitoring protocol included cardiothoracic auscultation; palpation of auricular pulse for quality and regularity; checking of rectal temperature, and monitoring of respiratory; and heart rates. Results of basic physiologic measurements were similar to those of previous field studies of African elephants immobilized with etorphine or etorphine-hyaluronidase. In addition, continuous real-time pulse rate and percent oxygen saturation of hemoglobin (SpO(2)) readings were obtained on 16 elephants with a portable pulse oximeter. Duration of pulse oximetry monitoring ranged from 3 to 24 min (mean +/- SD = 8.2 +/- 4.8 min). Differences between minimum and maximum SpO(2) values for any given elephant ranged from 1 to 6 percentage points, evidence for relatively stable trends. The SpO(2) readings ranged from 70% to 96% among the 16 elephants, with a mean of 87.3 +/- 2.8%. Fifteen of 16 elephants monitored with a pulse oximeter had mean SpO(2) values greater than or equal to 81 +/- 2.4%, with 11 having mean SpO(2) values greater than or equal to 85 +/- 1.5%. All 20 animals recovered uneventfully following reversal: diprenorphine at 23.3 +/- 1.5 mg intravenous (IV) with 11.7 +/- 0.5 mg IM, or 24 mg diprenorphine given all IV.	BOTSWANA DEPT WILDLIFE & NATL PARKS,GABORONE,BOTSWANA							ALLEN JL, 1992, VET REC, V130, P354, DOI 10.1136/vr.130.16.354; BARTELS H, 1963, AM J PHYSIOL, V205, P331; COTE CJ, 1988, ANESTHESIOLOGY, V68, P184, DOI 10.1097/00000542-198802000-00002; DHINDSA DS, 1972, RESP PHYSIOL, V14, P332, DOI 10.1016/0034-5687(72)90038-2; DUNLOP CI, 1994, J AM VET MED ASSOC, V205, P1439; EBEDES H, 1975, Madoqua, V9, P19; Erhardt W., 1990, Journal of the Association of Veterinary Anaesthetists of Great Britain and Ireland, V17, P30; Estes RD, 1991, BEHAV GUIDE AFRICAN, P259; HAIGH JC, 1979, J AM VET MED ASSOC, V175, P916; Harthoorn A.M., 1973, P14; Harthoorn A.M., 1973, P51; HARTHOORN AM, 1976, [No title captured]; Hawkey C.M., 1989, COLOUR ATLAS COMP VE, P9; HEARD DJ, 1986, J AM VET MED ASSOC, V189, P1071; HONEYMAN VL, 1992, J ZOO WILDLIFE MED, V23, P205; JACOBSON ER, 1988, J ZOO WILDLIFE MED, V19, P1, DOI 10.2307/20094842; JACOBSON JD, 1992, AM J VET RES, V53, P537; KELLEHER JF, 1989, J CLIN MONITOR, V5, P37, DOI 10.1007/BF01618369; KLEIHAUER E, 1965, NATURE, V207, P424, DOI 10.1038/207424a0; KOCK MD, 1993, J ZOO WILDLIFE MED, V24, P1; KOCK MD, 1992, J ZOO WILDLIFE MED, V23, P181; Kock RA, 1993, ZOO WILD ANIMAL MED, V3, P436; MIHM FG, 1988, J ZOO WILDLIFE MED, V19, P106, DOI 10.2307/20094865; RAATH JP, 1993, WILDLIFE DECISION SU, P484; RIEGEL K, 1967, RESP PHYSIOL, V2, P182; RIGGS A, 1963, J BIOL CHEM, V238, P2983; TYLER IL, 1985, ANESTH ANALG, V64, P1108; WALLACH JD, 1968, J AM VET MED ASSOC, V153, P793; WHITEHAIR KJ, 1990, VET SURG, V19, P243, DOI 10.1111/j.1532-950X.1990.tb01179.x	29	8	10	0	5	WILDLIFE DISEASE ASSN, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897	0090-3558			J WILDLIFE DIS	J. Wildl. Dis.	JAN	1997	33	1					72	77		10.7589/0090-3558-33.1.72			6	Veterinary Sciences	Veterinary Sciences	WE491	WOS:A1997WE49100009	9027693				2020-06-26	J	Sternini, C; Spann, M; Anton, B; Keith, DE; Bunnett, NW; vonZastrow, M; Evans, C; Brecha, NC				Sternini, C; Spann, M; Anton, B; Keith, DE; Bunnett, NW; vonZastrow, M; Evans, C; Brecha, NC			Agonist-selective endocytosis of mu opioid receptor by neurons in vivo	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						opioid receptors; opiate alkaloids; motility; enteric neurons; motor neurons	PROTEIN-COUPLED RECEPTOR; SUBSTANCE-P; MOLECULAR-BIOLOGY; INTERNALIZATION; RESENSITIZATION; SEQUESTRATION; TRAFFICKING; MECHANISMS; ENKEPHALIN; PEPTIDES	Opiate alkaloids are potent analgesics that exert multiple pharmacological effects in the nervous system by activating G protein-coupled receptors. Receptor internalization upon stimulation may be important for desensitization and resensitization, which affect cellular responsiveness to ligands. Here, we investigated the agonist-induced internalization of the mu opioid receptor (MOR) in vivo by using the guinea pig ileum as a model system and immunohistochemistry with an affinity-purified antibody to the C terminus of rat MOR, Antibody specificity was confirmed by the positive staining of human embryonic kidney 293 cells transfected with epitope-tagged MOR cDNA, by the lack of staining of cells transfected with the delta or kappa receptor cDNA, and by the abolition of staining when the MOR antibody was preadsorbed with the MOR peptide fragment, Abundant MOR immunoreactivity (MOR-IR) was localized to the cell body, dendrites, and axonal processes of myenteric neurons, Immunostaining was primarily confined to the plasma membrane of cell bodies and processes. Within 15 min of an intraperitoneal injection of the opiate agonist etorphine, intense MOR IR was present in vesiclelike structures, which were identified as endosomes by confocal microscopy, At 30 min, MOR-IR was throughout the cytoplasm and in perinuclear vesicles, MOR-IR was still internalized at 120 min, Agonist-induced endocytosis was completely inhibited by the opiate antagonist naloxone. Interestingly, morphine, a high-affinity MOR agonist, did not cause detectable internalization, but it partially inhibited the etorphine-induced MOR endocytosis. These results demonstrate the occurrence of agonist-selective MOR endocytosis in neurons naturally expressing this receptor in vivo and suggest the existence of different mechanisms regulating cellular responsiveness to ligands.	UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT NEUROBIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT PSYCHIAT & BIOBEHAV SCI, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, OPIOID RES CTR, LOS ANGELES, CA 90024 USA; UNIV CALIF SAN FRANCISCO, DEPT SURG, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MOL & CELLULAR PHARMACOL, SAN FRANCISCO, CA 94143 USA	Sternini, C (reprint author), W LOS ANGELES VET AFFAIRS MED CTR, CURE,DIGEST DIS RES CTR,11301 WILSHIRE BLVD, BLDG 115, ROOM 203, LOS ANGELES, CA 90073 USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 05010, P50 DA005010]; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK 39957, DK 41301]		BOWDEN JJ, 1994, P NATL ACAD SCI USA, V91, P8964, DOI 10.1073/pnas.91.19.8964; BRASS LF, 1994, J BIOL CHEM, V269, P2943; CARON MG, 1993, RECENT PROG HORM RES, V48, P277; DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185; FURNESS JB, 1983, NEUROSCIENCE, V8, P653, DOI 10.1016/0306-4522(83)90001-5; FURNESS JB, 1987, [No title captured]; GARLAND AM, 1996, IN PRESS MOL PHARM; Gershon Michael D., 1994, P381; GRADY EF, 1995, MOL BIOL CELL, V6, P509; GRADY EF, 1996, IN PRESS NEUROSCIENC; HERZ A, 1993, HDB EXPT PHARM OPIOI, V2; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; Keith D., 1995, Society for Neuroscience Abstracts, V21, P1353; KROMER W, 1988, PHARMACOL REV, V40, P121; LOH HH, 1988, SYNAPSE, V2, P457, DOI 10.1002/syn.890020414; LUTZ RA, 1992, J RECEPTOR RES, V12, P267, DOI 10.3109/10799899209074796; Mansour A., 1993, HDB EXPT PHARM, P79; MANTYH PW, 1995, P NATL ACAD SCI USA, V92, P2622, DOI 10.1073/pnas.92.7.2622; MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937; MASTROGIACOMO A, 1994, J NEUROCHEM, V62, P873; MINAMI M, 1995, NEUROSCI RES, V23, P121, DOI 10.1016/0168-0102(95)00933-K; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; OLSON GA, 1989, PEPTIDES, V10, P205, DOI 10.1016/0196-9781(89)90098-3; PASTERNAK GW, 1993, CLIN NEUROPHARMACOL, V16, P1, DOI 10.1097/00002826-199302000-00001; PEI G, 1995, MOL PHARMACOL, V48, P173; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; REISINE T, 1993, TRENDS NEUROSCI, V16, P506, DOI 10.1016/0166-2236(93)90194-Q; Sim LJ, 1996, J NEUROSCI, V16, P2684; SIMON EJ, 1991, MED RES REV, V11, P357, DOI 10.1002/med.2610110402; SIMON EJ, 1993, OPIOIDS, V1, P3; STERNINI C, 1992, SOMATOSENS MOT RES, V9, P45, DOI 10.3109/08990229209144762; STERNINI C, 1988, ANNU REV PHYSIOL, V50, P81; Sternini C, 1995, ANALGESIA, V1, P762; STERNINI C, 1995, J COMP NEUROL, V359, P2; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; UHL GR, 1994, TRENDS NEUROSCI, V17, P89, DOI 10.1016/0166-2236(94)90110-4; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VONZASTROW M, 1994, REGUL PEPTIDES, V54, P315, DOI 10.1016/0167-0115(94)90516-9; WATERFIELD AA, 1977, EUR J PHARMACOL, V43, P107, DOI 10.1016/0014-2999(77)90123-6; WU GQ, 1991, CHINESE J ONCOL, V13, P64; YU SS, 1993, J BIOL CHEM, V268, P337	42	270	273	0	8	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	AUG 20	1996	93	17					9241	9246		10.1073/pnas.93.17.9241			6	Multidisciplinary Sciences	Science & Technology - Other Topics	VD434	WOS:A1996VD43400082	8799185	Bronze, Green Published			2020-06-26	J	Keith, DE; Murray, SR; Zaki, PA; Chu, PC; Lissin, DV; Kang, L; Evans, CJ; vonZastrow, M				Keith, DE; Murray, SR; Zaki, PA; Chu, PC; Lissin, DV; Kang, L; Evans, CJ; vonZastrow, M			Morphine activates opioid receptors without causing their rapid internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; NG108-15 HYBRID-CELLS; MU-OPIATE RECEPTOR; PHARMACOLOGICAL CHARACTERIZATION; INTRACELLULAR TRAFFICKING; ADRENERGIC-RECEPTOR; PHOSPHORYLATION; ENKEPHALIN; MEMBRANE; CLONING	We have examined the endocytic trafficking of epitope-tagged delta and mu opioid receptors expressed in human embryonic kidney (HEK) 293 cells, These receptors are activated by peptide agonists (enkephalins) as well as by the alkaloid agonist drugs etorphine and morphine. Enkephalins and etorphine cause opioid receptors to internalize rapidly (t(1/2) similar to 6 min) by a mechanism similar to that utilized by a number of other classes of receptor, as indicated by localization of internalized opioid receptors in transferrin-containing endosomes and inhibition of opioid receptor internalization by hypertonic media, Remarkably, morphine does not stimulate the rapid internalization of either delta or mu opioid receptors, even at high concentrations that strongly inhibit adenylyl cyclase, These data indicate that agonist ligands, which have similar effects on receptor-mediated signaling, can have dramatically different effects on the intracellular trafficking of a G protein-coupled receptor.	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,NINA IRELAND LAB,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOLEC PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF LOS ANGELES,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024					NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA-16042]; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [P50 DA005010, DA-05010, DA-00218]		ARDEN JR, 1995, J NEUROCHEM, V65, P1636; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FUKUDA K, 1995, FEBS LETT, V373, P177, DOI 10.1016/0014-5793(95)01034-C; GARLAND AM, 1994, BIOCHEM J, V303, P177, DOI 10.1042/bj3030177; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUGHES J, 1977, BRIT MED BULL, V33, P157, DOI 10.1093/oxfordjournals.bmb.a071416; JASPER JR, 1992, BIOCHEM PHARMACOL, V43, P119, DOI 10.1016/0006-2952(92)90268-N; KAUFMAN DL, 1995, J BIOL CHEM, V270, P15877, DOI 10.1074/jbc.270.26.15877; KONG HY, 1993, J BIOL CHEM, V268, P23055; Kosterlitz H W, 1978, Adv Biochem Psychopharmacol, V18, P31; LAW PY, 1984, J BIOL CHEM, V259, P4096; LAW SK, 1982, P NATL ACAD SCI USA, V72, P1; LOUIE AK, 1988, BIOCHEM BIOPH RES CO, V152, P1369, DOI 10.1016/S0006-291X(88)80436-4; MESTEK A, 1995, J NEUROSCI, V15, P2396; METZGER TG, 1995, FEBS LETT, V375, P1, DOI 10.1016/0014-5793(95)01185-H; NESTLER EJ, 1993, CRIT REV NEUROBIOL, V7, P23; Okayama H, 1992, Biotechnology, V24, P270; PEI G, 1995, MOL PHARMACOL, V48, P173; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; SCHMID I, 1988, CYTOMETRY, V9, P533, DOI 10.1002/cyto.990090605; SMITH CFC, 1983, LIFE SCI, V33, P327, DOI 10.1016/0024-3205(83)90509-X; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VONZASTROW M, 1994, REGUL PEPTIDES, V54, P315, DOI 10.1016/0167-0115(94)90516-9; VONZASTROW M, 1993, MOL PHARMACOL, V44, P166; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736	32	451	457	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19021	19024		10.1074/jbc.271.32.19021			4	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	VB684	WOS:A1996VB68400004	8702570	Bronze			2020-06-26	J	Tokuyama, S; Nakamura, F; Nakao, K; Takahashi, M; Kaneto, H				Tokuyama, S; Nakamura, F; Nakao, K; Takahashi, M; Kaneto, H			A potent mu-opioid receptor agonist, dihydroetorphine, fails to produce the conditioned place preference in mice	JAPANESE JOURNAL OF PHARMACOLOGY			English	Article						dihydroetorphine; morphine; conditioned place preference	DEPENDENCE; MORPHINE; DISSOCIATION; TOLERANCE; SUBTYPES	Reinforcing effects of dihydroetorphine (DHE) and morphine were evaluated by the conditioned place preference paradigm. Both DHE and morphine produced an antinociceptive effect in a dose-dependent manner. On the other hand, DHE (0.1, 1, 3 and 10 mu g/kg, i.p.) failed to induce the conditioned preference, while morphine (0.1, 1, 3 and 10 mg/kg, i.p.) caused a dose-dependent preference for the drug-paired place. Thus, these characteristic properties of DHE make it attractive for development as a novel potent analgesic compound that has less dependence liability.		Tokuyama, S (reprint author), NAGASAKI UNIV,FAC PHARMACEUT SCI,DEPT PHARMACOL,1-14 BUNKYO MACHI,NAGASAKI 852,JAPAN.						Carr DG, 1989, NEUROPHARMACOLOGICAL, P264; Huang M, 1982, Zhongguo Yao Li Xue Bao, V3, P81; Huang M, 1982, Zhongguo Yao Li Xue Bao, V3, P9; KANETO H, 1985, J PHARM PHARMACOL, V37, P507, DOI 10.1111/j.2042-7158.1985.tb03054.x; LING GSF, 1983, EUR J PHARMACOL, V86, P487; MUCHA RF, 1985, PSYCHOPHARMACOLOGY, V86, P274, DOI 10.1007/BF00432213; MUCHA RF, 1982, BRAIN RES, V243, P91, DOI 10.1016/0006-8993(82)91123-4; SIMONE DA, 1985, LIFE SCI, V36, P829, DOI 10.1016/0024-3205(85)90206-1; SUZUKI T, 1993, BRAIN RES, V602, P45, DOI 10.1016/0006-8993(93)90239-J; Tokuyama S, 1996, BIOL PHARM BULL, V19, P477; TOKUYAMA S, 1994, BIOL PHARM BULL, V17, P1056; TOKUYAMA S, 1993, BIOL PHARM BULL, V16, P774; WANG DX, 1991, CHIN J PHARM TOXICOL, V5, P161; WOLOZIN BL, 1981, P NATL ACAD SCI-BIOL, V78, P6181, DOI 10.1073/pnas.78.10.6181; WOOD PL, 1983, NEUROSCI LETT, V37, P291, DOI 10.1016/0304-3940(83)90446-9	15	8	8	0	1	JAPANESE PHARMACOLOGICAL SOC	KYOTO	EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO 604, JAPAN	0021-5198			JPN J PHARMACOL	Jpn. J. Pharmacol.	AUG	1996	71	4					357	360		10.1254/jjp.71.357			4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	VD802	WOS:A1996VD80200014	8886936	Bronze			2020-06-26	J	Bertolucci, M; Perego, C; DeSimoni, MG				Bertolucci, M; Perego, C; DeSimoni, MG			Central opiate modulation of peripheral IL-6 in rats	NEUROREPORT			English	Article						interleukin-1; interleukin-6; morphine; naloxone; central nervous system; beta-endorphin; etorphin	TUMOR-NECROSIS-FACTOR; OPIOID RECEPTORS; IMMUNE-RESPONSES; GENE-EXPRESSION; INTERLEUKIN-6; BRAIN; ENDOTOXIN; MORPHINE; IMMUNOSUPPRESSION; INFLAMMATION	THE effect of opiate agonists and antagonists on the induction of serum interleukin-6 (IL-6), an inflammatory cytokine that plays a major role in the acute phase response, was studied. Morphine (10 mu g, i.c.v. or 15 mg kg(-1), i.p.), beta-endorphin (0.5 or 5 mu g, i.c.v.) and etorphin (10 mg kg(-1), i.p.) induced IL-6. Moreover, morphine potentiated the IL-6 response induced by IL-1 beta (400 ng, i.p. or i.c.v.). When injected intraperitoneally, the opiate antagonist naloxone hydrochloride, antagonized the IL-6 response induced by either i.c.v. or i.p. IL-1 beta. This effect was not seen with naloxone methiodide, which does not cross the blood-brain barrier. The data show that central opiates are effective modulators of the inflammatory cytokine IL-6.	MARIO NEGRI INST PHARMACOL RES,I-20157 MILAN,ITALY				Perego, Carlo/0000-0002-0259-0003			BARTON BE, 1993, INFECT IMMUN, V61, P1496, DOI 10.1128/IAI.61.4.1496-1499.1993; BROWN SL, 1987, J IMMUNOL, V139, P3181; CARR DB, 1982, SCIENCE, V217, P845, DOI 10.1126/science.6285473; CARR DJJ, 1991, P SOC EXP BIOL MED, V198, P710; DESIMONI MG, 1995, ENDOCRINOLOGY, V136, P897, DOI 10.1210/en.136.3.897; DESIMONI MG, 1993, AM J PHYSIOL, V265, pR739; DESIMONI MG, 1990, J EXP MED, V171, P1773, DOI 10.1084/jem.171.5.1773; DULANEY R, 1992, PROG NEUROENDOCRINIM, V5, P179; HERNANDEZ MC, 1993, J PHARMACOL EXP THER, V267, P1336; HSUEH CM, 1992, BRAIN RES, V578, P142, DOI 10.1016/0006-8993(92)90241-Z; LOW KG, 1992, ENDOCRINOLOGY, V131, P1908, DOI 10.1210/en.131.4.1908; MACALUSO A, 1994, J NEUROSCI, V14, P2377; PANERAI AE, 1995, J NEUROIMMUNOL, V58, P71, DOI 10.1016/0165-5728(94)00189-U; PETERSON PK, 1993, BIOCHEM PHARMACOL, V46, P343, DOI 10.1016/0006-2952(93)90508-T; RADULOVIC J, 1994, BRAIN RES, V661, P189, DOI 10.1016/0006-8993(94)91196-7; ROTHWELL NJ, 1991, TRENDS PHARMACOL SCI, V12, P430, DOI 10.1016/0165-6147(91)90623-Z; SCHOBITZ B, 1994, PROG NEUROBIOL, V44, P397, DOI 10.1016/0301-0082(94)90034-5; SHAVIT Y, 1986, P NATL ACAD SCI USA, V83, P7114, DOI 10.1073/pnas.83.18.7114; SIBINGA NES, 1988, ANNU REV IMMUNOL, V6, P219; SUNDAR SK, 1989, P NATL ACAD SCI USA, V86, P6398, DOI 10.1073/pnas.86.16.6398; TILG H, 1994, BLOOD, V83, P113; ULICH TR, 1991, AM J PATHOL, V138, P1097; WEBER RJ, 1989, SCIENCE, V245, P188, DOI 10.1126/science.2749256	23	29	31	0	1	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	0959-4965			NEUROREPORT	Neuroreport	APR 26	1996	7	6					1181	1184		10.1097/00001756-199604260-00017			4	Neurosciences	Neurosciences & Neurology	VK184	WOS:A1996VK18400017	8817528				2020-06-26	J	Lloyd, DR; Rose, RJ; Duffield, AM; Suann, CJ				Lloyd, DR; Rose, RJ; Duffield, AM; Suann, CJ			Effects of sodium bicarbonate and sodium chloride on the elimination of etorphine in equine urine	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							HORSES; RADIOIMMUNOASSAY; FUROSEMIDE; EXCRETION; PLASMA		UNIV SYDNEY,DEPT VET CLIN SCI,SYDNEY,NSW 2006,AUSTRALIA; AUSTRALIAN JOCKEY CLUB LAB,RANDWICK,NSW 2031,AUSTRALIA							BADEWITZDODD L, 1992, DRUGS SPORT; BONNAIRE Y, 1989, J ANAL TOXICOL, V13, P193, DOI 10.1093/jat/13.4.193; COMBIE J, 1981, J EQUINE VET SCI, V1, P203; COMBIE J, 1979, P 3 INT S EQ MED CON, P31; LLOYD DR, 1995, BRIT VET J, V151, P523, DOI 10.1016/S0007-1935(05)80024-7; LLOYD DR, 1992, P 9 INT C RAC AN VET, V2, P131; LLOYD DR, 1992, AUST EQUINE VET, V10, P122; MILLER JR, 1977, RES COMMUN CHEM PATH, V17, P447; ROBERTS BL, 1976, RES COMMUN CHEM PATH, V15, P257; ROSE RJ, 1992, EQUINE VET J, V24, P75, DOI 10.1111/j.2042-3306.1992.tb02785.x; SOMA LR, 1984, AM J VET RES, V45, P1743; STANLEY S, 1991, J ANAL TOXICOL, V15, P305, DOI 10.1093/jat/15.6.305; STEVENSON AJ, 1990, J VET PHARMACOL THER, V13, P93, DOI 10.1111/j.1365-2885.1990.tb00753.x; SUANN CJ, 1990, P 8 INT C RAC AN VET, P215; TAI CL, 1988, AM J VET RES, V49, P622; Tobin T., 1981, DRUGS PERFORMANCE HO; ULECIA N, 1979, IRISH VET J, V33, P99; WOODS WE, 1986, RES COMMUN CHEM PATH, V52, P237	18	0	0	0	4	PRESTON PUBLICATIONS INC	NILES	7800 MERRIMAC AVE PO BOX 48312, NILES, IL 60648	0146-4760			J ANAL TOXICOL	J. Anal. Toxicol.	MAR-APR	1996	20	2					81	88		10.1093/jat/20.2.81			8	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	TZ698	WOS:A1996TZ69800001	8868397	Bronze			2020-06-26	J	Smith, RF; Jackson, LS; Moore, A				Smith, RF; Jackson, LS; Moore, A			Establishing the cut-off concentration for the detection of etorphine in horse urine	ANALYST			English	Article						etorphine; kinetics; equine; radioimmunoassay		An I-125 radioimmunoassay to determine the pattern of urinary excretion of etorphine (a semisynthetic opiate agonist) after its administration to horses is described. Three thoroughbred horses were each given 5, 15, 30 and 100 mu g of etorphine intramuscularly. Urine was collected for up to 72 after administration. The maximum etorphine concentration after administration of a dose of 5 mu g was 711 pg ml(-1) (concentrations were greater than 100 pg ml(-1) after 23 h in all three horses); a 15 mu g gave 2661 pg ml(-1) (levels remained above 100 pg ml(-1) for more than 44 h in each horse); a 30 mu g dose gave a maximum of 3344 pg ml(-1) (levels were above 100 pg ml(-1) for 24, 72, and 72 h); and 100 mu g gave in excess of 10 000 pg ml(-1) (levels were greater than 300 pg ml(-1) for up to 70 h). Forty-eight urine samples from horses not given etorphine all had levels of etorphine less than 100 pg ml(-1). There was no increase in apparent etorphine concentrations after hydrolysis of samples with beta-glucuronidase and aryl sulfatase. The half-lives of etorphine equivalents (calculated with a mono-exponential equation after the 100 mu g dose) in the urine of the three horses were 569, 803 and 821 min, respectively. We conclude that radioimmunoassay can provide a useful first line screening procedure for the assessment of etorphine use in racing horses.	SHEFFIELD HALLAM UNIV,HLTH RES INST,SHEFFIELD S1 1WB,S YORKSHIRE,ENGLAND; PAIN RELIEF UNIT,OXFORD OX3 7LJ,ENGLAND; HORSE RACING FORENS LAB,NEWMARKET CB8 7DT9,SUFFOLK,ENGLAND	Smith, RF (reprint author), SHEFFIELD HALLAM UNIV,DIV BIOMED SCI,POND ST,SHEFFIELD S1 1WB,S YORKSHIRE,ENGLAND.						BONNAIRE Y, 1989, J ANAL TOXICOL, V13, P193, DOI 10.1093/jat/13.4.193; Friedrich G, 1991, Beitr Gerichtl Med, V49, P111; GLASEL JA, 1981, J CHROMATOGR, V213, P337, DOI 10.1016/S0021-9673(00)81918-4; JASINSKI D, 1979, CLIN PHARM EXP THER, V17, P267; STANLEY S, 1991, J ANAL TOXICOL, V15, P305, DOI 10.1093/jat/15.6.305; SUANN C, 1990, P 8 INT C RAC AN VET; TAI CL, 1988, AM J VET RES, V49, P622; Tobin T., 1981, DRUGS PERFORMANCE HO	8	0	0	0	1	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK MILTON ROAD, CAMBRIDGE, CAMBS, ENGLAND CB4 4WF	0003-2654			ANALYST	Analyst	JAN	1996	121	1					67	69		10.1039/an9962100067			3	Chemistry, Analytical	Chemistry	TX374	WOS:A1996TX37400014	8588699				2020-06-26	J	Wang, WW; Shahrestanifar, M; Jin, J; Howells, RD				Wang, WW; Shahrestanifar, M; Jin, J; Howells, RD			Studies on mu and delta opioid receptor selectivity utilizing chimeric and site-mutagenized receptors	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article							PHARMACOLOGICAL CHARACTERIZATION; FUNCTIONAL EXPRESSION; CLONING; BRAIN; BINDING; SUBTYPES; AGONIST; POTENT; CELLS; CDNA	Opioid receptors are members of the guanine nucleotide binding protein (G protein)-coupled receptor family. Three types of opioid receptors have been cloned and characterized and are referred to as the delta, kappa, and mu types. Analysis of receptor chimeras and site-directed mutant receptors has provided a great deal of information about functionally important amino acid side chains that constitute the ligand-binding domains and G-protein-coupling domains of G-protein-coupled receptors, We have constructed delta/mu opioid receptor chimeras that were expressed in human embryonic kidney 293 cells in order to define receptor domains that are responsible for receptor type selectivity, All chimeric receptors and wild-type delta and mu opioid receptors displayed high-affinity binding of etorphine (an agonist), naloxone (an antagonist), and bremazocine (a mixed agonist/antagonist). In contrast, chimeras that lacked the putative first extracellular loop of the Er receptor did not bind the mu-selective peptide [D-Ala(2),MePhe(4),Gly(5)-ol] enkephalin (DAMGO). Chimeras that lacked the putative third extracellular loop of the delta receptor did not bind the delta-selective peptide, [D-Ser(2),D-Leu(5)] enkephalin-Thr (DSLET), Point mutations in the putative third extracellular loop of the wild-type delta receptor that converted vicinal arginine residues to glutamine abolished DSLET binding while not affecting bremazocine, etorphine, and naltrindole binding, We conclude that amino acids in the putative first extracellular loop of the mu receptor are critical for high-affinity DAMGO binding and that arginine residues in the putative third extracellular loop of the delta receptor are important for high-affinity DSLET binding.	UNIV MED & DENT NEW JERSEY,DEPT BIOCHEM & MOLEC BIOL,NEWARK,NJ 07103					NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [2 S07 RR05393]		ABOOD ME, 1994, J NEUROSCI RES, V37, P714, DOI 10.1002/jnr.490370605; CARTER BD, 1993, P NATL ACAD SCI USA, V90, P4062, DOI 10.1073/pnas.90.9.4062; CHEN Y, 1993, MOL PHARMACOL, V44, P8; CHILDERS SR, 1993, HDB EXPT PHARM, V104, P189; COX BM, 1993, HDB EXPT PHARM, V104, P145; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FUKUDA K, 1995, J BIOL CHEM, V270, P6702, DOI 10.1074/jbc.270.12.6702; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; HJORTH SA, 1995, MOL PHARMACOL, V47, P1089; HOWELLS RD, 1982, J PHARMACOL EXP THER, V222, P629; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KONG HY, 1994, P NATL ACAD SCI USA, V91, P8042, DOI 10.1073/pnas.91.17.8042; KONG HY, 1993, J BIOL CHEM, V268, P23055; LAUGWITZ KL, 1993, NEURON, V10, P233, DOI 10.1016/0896-6273(93)90314-H; Mansour A., 1993, HDB EXPT PHARM, P79; MENG F, 1995, J BIOL CHEM, V270, P12730, DOI 10.1074/jbc.270.21.12730; MENG F, 1993, P NATL ACAD SCI USA, V90, P9954, DOI 10.1073/pnas.90.21.9954; MINAMI M, 1995, FEBS LETT, V364, P23, DOI 10.1016/0014-5793(95)00340-F; ONOGI T, 1995, FEBS LETT, V357, P93, DOI 10.1016/0014-5793(94)01341-W; PRATHER PL, 1994, J BIOL CHEM, V269, P21293; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; REISINE T, 1993, TRENDS NEUROSCI, V16, P506, DOI 10.1016/0166-2236(93)90194-Q; ROMER D, 1980, LIFE SCI, V27, P971, DOI 10.1016/0024-3205(80)90107-1; SCHILLER PW, 1992, P NATL ACAD SCI USA, V89, P11871, DOI 10.1073/pnas.89.24.11871; SHAHRESTANIFAR M, 1994, REGUL PEPTIDES, V54, P269, DOI 10.1016/0167-0115(94)90493-6; Simon Eric J., 1994, P321; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.biochem.63.1.101; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; WANG JB, 1994, J BIOL CHEM, V269, P25966; WANG WW, 1994, GENE, V143, P261, DOI 10.1016/0378-1119(94)90107-4; XUE JC, 1995, J BIOL CHEM, V270, P12977; XUE JC, 1994, J BIOL CHEM, V269, P30195; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736	35	83	84	0	1	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	DEC 19	1995	92	26					12436	12440		10.1073/pnas.92.26.12436			5	Multidisciplinary Sciences	Science & Technology - Other Topics	TL421	WOS:A1995TL42100101	8618916	Green Published, Bronze			2020-06-26	J	WANG, DX; LU, XQ; QIN, BY				WANG, DX; LU, XQ; QIN, BY			DIHYDROETORPHINE IS A MU-RECEPTOR-SELECTIVE LIGAND	JOURNAL OF PHARMACY AND PHARMACOLOGY			English	Article							BINDING; AGONIST	The selectivity to opioid receptors of dihydroetorphine, a potent analgesic with only mild physical dependence, was investigated using radioligand binding assay and its analgesic activity in mice determined. The relative affinity ratio of dihydroetorphine to mu-, delta- and kappa- opioid receptors was 333:1:1. The analgesic effect of intracerebro-ventricular injection in mice could be antagonized by the mu-antagonist beta-funaltrexamine but could not be antagonized by delta- and kappa-selective antagonists naltrindole and norbinaltorphimine. We conclude that dihydroetorphine is a selective ligand for the mu-opioid receptor.		WANG, DX (reprint author), ACAD MIL MED SCI, INST PHARMACOL & TOXICOL, BEIJING 100850, PEOPLES R CHINA.		Wang, Danxin/I-5810-2019	Wang, Danxin/0000-0002-7134-3065			BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COTTON R, 1985, BRIT J PHARMACOL, V84, P927, DOI 10.1111/j.1476-5381.1985.tb17387.x; HANDA BK, 1981, EUR J PHARMACOL, V70, P531, DOI 10.1016/0014-2999(81)90364-2; HUANG M, 1982, Acta Pharmacologica Sinica, V3, P9; HUANG M, 1982, Acta Pharmacologica Sinica, V3, P81; LING GSF, 1984, SCIENCE, V226, P462, DOI 10.1126/science.6541807; MAGNAN J, 1982, N-S ARCH PHARMACOL, V319, P197, DOI 10.1007/BF00495865; PEDIGO NW, 1975, J PHARMACOL EXP THER, V193, P845; PORRECA F, 1987, J PHARMACOL EXP THER, V241, P393; QIN BY, 1994, REGULATORY PEPTID S1, V1, P293; QIN BY, 1993, NEW DRUGS CLIN REMED, V12, P119; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7; WANG DX, 1991, CHIN J PHARM TOXICOL, V5, P161; WANG DX, 1992, CHIN J PHARM TOXICOL, V6, P36; ZHANG WG, 1988, PHARM CALCULATIONS P, P100	15	27	31	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3573	2042-7158		J PHARM PHARMACOL	J. Pharm. Pharmacol.	AUG	1995	47	8					669	673		10.1111/j.2042-7158.1995.tb05857.x			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	RT173	WOS:A1995RT17300011	8583370				2020-06-26	J	DUTTAROY, A; YOBURN, BC				DUTTAROY, A; YOBURN, BC			THE EFFECT OF INTRINSIC EFFICACY ON OPIOID TOLERANCE	ANESTHESIOLOGY			English	Article						ANALGESIA, OPIOID, CONTINUOUS INFUSION INTERMITTENT ADMINISTRATION INTRINSIC EFFICACY TOLERANCE; ANALGESICS, OPIOID, ETORPHINE FENTANYL MEPERIDINE MORPHINE OXYCODONE	CANCER PAIN; ANTINOCICEPTIVE AGENTS; BETA-FUNALTREXAMINE; CONTINUOUS INFUSION; MU-AGONISTS; MORPHINE; RAT; MANAGEMENT; MAGNITUDE; FENTANYL	Background: The intrinsic efficacy of opioid analgesics has been suggested to play a role in the development of tolerance to these agents. However, the effect of differences in dosing protocol on tolerance to opioid analgesics of high or low efficacy has not been addressed. Therefore, the effect of opioid intrinsic efficacy on tolerance in mice was determined in protocols of continuous and intermittent administration of equieffective doses of opioid agonists. Methods: Initial antinociceptive median effective doses (ED(50)s) for five opioid agonists that vary in intrinsic efficacy were estimated in untreated mice. Groups of mice received continuous infusions of morphine, fentanyl, or etorphine for 72 h or 7 days from osmotic minipumps implanted subcutaneously. The infusion doses were calculated as multiples of the initial antinociceptive ED(50). An inert placebo was implanted subcutaneously in controls. At the end of treatment, the pumps and placebos were removed, and 4-24 h later, mice were tested in dose-response studies (tail flick) using the same drug that had been chronically administered. In another study using intermittent dosing, mice received subcutaneous injections every 24 h for 3 days of saline or morphine, etorphine, fentanyl, oxycodone, or meperidine, or received subcutaneous injections every 24 h for 7 days of saline or morphine, etorphine, or fentanyl. Daily doses were calculated as multiples of the initial antinociceptive ED(50). Twenty-four hours after the last injection, mice were tested in dose-response studies. Results: High-intrinsic-efficacy compounds (e.g., etorphine and fentanyl) produced less tolerance than a lower-intrinsic-efficacy drug (morphine) in 72-h and 7-day infusion studies. Tolerance for all compounds after intermittent treatment with equieffective doses was similar, and intrinsic efficacy had no effect on the magnitude of tolerance after intermittent dosing. Conclusions: These results indicate that the intrinsic efficacy of opioid analgesics is inversely related to the degree of tolerance after continuous infusion, but that intrinsic efficacy does not significantly affect tolerance after once-daily intermittent administration of these agents. These findings may be of clinical utility in understanding the development of tolerance to the antinociceptive effects of opioids.	ST JOHNS UNIV,COLL PHARM & ALLIED HLTH PROFESS,DEPT PHARMACEUT SCI,QUEENS,NY 11439					NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 04185]		ADAMS JU, 1990, J PHARMACOL EXP THER, V255, P1027; CERLETTI C, 1976, PHARMACOL BIOCHEM BE, V4, P323, DOI 10.1016/0091-3057(76)90249-5; CHERNY NI, 1993, CANCER-AM CANCER SOC, V72, P3393, DOI 10.1002/1097-0142(19931201)72:11+<3393::AID-CNCR2820721606>3.0.CO;2-O; COLLIN E, 1993, PAIN, V55, P319, DOI 10.1016/0304-3959(93)90007-C; COMER SD, 1992, J PHARMACOL EXP THER, V262, P1051; Finney DJ, 1973, PROBIT ANAL; FOLEY KM, 1991, NEW PHARMACOTHERAPY, P181; FRANCE CP, 1990, J PHARMACOL EXP THER, V254, P626; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; KENAKIN T, 1993, PHARM ANAL DRUG RECE, P1; KISSIN I, 1991, ANESTHESIOLOGY, V75, P813, DOI 10.1097/00000542-199111000-00013; LIAO CS, 1982, LIFE SCI, V29, P2617; LUFTY K, 1991, J PHARMACOL EXP THER, V256, P575; MJANGER E, 1991, J PHARMACOL EXP THER, V258, P544; NICKERSON M, 1956, NATURE, V178, P697, DOI 10.1038/178697b0; PARONIS CA, 1992, J PHARMACOL EXP THER, V262, P1; PAYNE R, 1984, CANCER TREAT REP, V68, P173; PERRY DC, 1982, MOL PHARMACOL, V21, P272; SHETTER AG, 1986, NEUROSURGERY, V18, P740, DOI 10.1227/00006123-198606000-00011; SOSNOWSKI M, 1990, ANESTHESIOLOGY, V73, P1141, DOI 10.1097/00000542-199012000-00012; STEPHENSON RP, 1956, BRIT J PHARM CHEMOTH, V11, P379, DOI 10.1111/j.1476-5381.1956.tb00006.x; STEVENS CW, 1989, J PHARMACOL EXP THER, V250, P1; STEVENS CW, 1989, J PHARMACOL EXP THER, V251, P216; YOBURN BC, 1985, J PHARMACOL EXP THER, V235, P282; YOBURN BC, 1993, J PHARMACOL EXP THER, V265, P314; ZERNIG G, 1994, J PHARMACOL EXP THER, V269, P57	26	169	174	0	10	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQUARE, PHILADELPHIA, PA 19106	0003-3022			ANESTHESIOLOGY	Anesthesiology	MAY	1995	82	5					1226	1236		10.1097/00000542-199505000-00018			11	Anesthesiology	Anesthesiology	QW587	WOS:A1995QW58700020	7741298				2020-06-26	J	WHELAN, G; FLECKNELL, PA				WHELAN, G; FLECKNELL, PA			ANESTHESIA OF LABORATORY RABBITS USING ETORPHINE METHOTRIMEPRAZINE AND MIDAZOLAM	LABORATORY ANIMALS			English	Article						ETORPHINE; METHOTRIMEPRAZINE; MIDAZOLAM; RABBITS; ANESTHESIA	FENTANYL-FLUANISONE; NEUROLEPTANALGESIA	The use of etorphine (a potent mu-opioid), methotrimeprazine (a phenothiazine tranquillizer) and midazolam (a benzodiazepine) in laboratory rabbits is described. The central ear artery was cannulated under local anaesthesia using lignocaine/prilocaine cream, enabling cardiovascular monitoring in conscious animals. Anaesthesia was characterized by respiratory arrest, profound analgesia and a stable cardiovascular system (after commencing intermittent positive pressure ventilation). Reversal of anaesthesia with buprenorphine (a partial mu agonist) did not reduce the degree of post-operative respiratory depression, but shortened the period of unconsciousness considerably. This anaesthetic regimen can only be recommended for rabbits that are free of respiratory disease and if facilities for IPPV are available.		WHELAN, G (reprint author), UNIV NEWCASTLE UPON TYNE,SCH MED,CTR COMPARAT BIOL,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.			Flecknell, Paul/0000-0002-1075-1129			CHAN KN, 1988, ARCH DIS CHILD, V63, P162, DOI 10.1136/adc.63.2.162; Flecknell P. A., 1990, Journal of the Association of Veterinary Anaesthetists of Great Britain and Ireland, V17, P24; FLECKNELL PA, 1990, LAB ANIM-UK, V24, P142, DOI 10.1258/002367790780890121; FLECKNELL PA, 1984, LAB ANIM, V18, P143, DOI 10.1258/002367784780891406; FLECKNELL PA, 1989, LAB ANIM, V23, P147, DOI 10.1258/002367789780863655; FLECKNELL PA, 1983, LAB ANIM, V17, P104, DOI 10.1258/002367783780959420; FLECKNELL PA, 1987, LABORATORY ANIMAL AN; GREEN CJ, 1981, LABORATORY ANIMAL HD, V8; WIXSON SK, 1987, LAB ANIM SCI, V37, P726	9	3	3	0	0	ROYAL SOC MEDICINE SERVICES LTD	LONDON	1 WIMPOLE STREET, LONDON, ENGLAND W1M 8AE	0023-6772			LAB ANIM	Lab. Anim.	JAN	1995	29	1					83	89		10.1258/002367795780740384			7	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	QC738	WOS:A1995QC73800010	7707683				2020-06-26	J	HATTINGH, J; KNOX, CM; RAATH, JP				HATTINGH, J; KNOX, CM; RAATH, JP			ARTERIAL BLOOD-PRESSURE OF THE AFRICAN ELEPHANT (LOXODONTA-AFRICANA) UNDER ETORPHINE ANESTHESIA AND AFTER REMOBILIZATION WITH DIPRENORPHINE	VETERINARY RECORD			English	Note									UNIV WITWATERSRAND,SCH DENT,DEPT GEN PHYSIOL,JOHANNESBURG,SOUTH AFRICA; DEPT NAT CONSERVAT,SKUKUZA 1350,SOUTH AFRICA							BOGAN JA, 1978, VET REC, V103, P471, DOI 10.1136/vr.103.21.471; DANIEL M, 1972, VET REC, V90, P336, DOI 10.1136/vr.90.12.336; DUNLOP CI, 1985, VET SURG, V14, P71, DOI 10.1111/j.1532-950X.1985.tb00826.x; DUNLOP CI, 1988, VET SURG, V3, P167; HEARD DJ, 1992, J ZOO WILDLIFE MED, V23, P197; HONEYMAN VL, 1992, J ZOO WILDLIFE MED, V23, P205; KOCK MD, 1990, J ZOO WILDLIFE MED, V21, P414; LEBLANC PH, 1987, J ZOO WILDLIFE MED, V18, P141, DOI 10.2307/20094825; LEES P, 1975, EQUINE VET J, V7, P18	9	2	3	0	2	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.	NOV 5	1994	135	19					458	459		10.1136/vr.135.19.458			2	Veterinary Sciences	Veterinary Sciences	PR178	WOS:A1994PR17800005	7863595				2020-06-26	J	SCHWARTZ, JP; NISHIYAMA, N; WILSON, D; TANIWAKI, T				SCHWARTZ, JP; NISHIYAMA, N; WILSON, D; TANIWAKI, T			RECEPTOR-MEDIATED REGULATION OF NEUROPEPTIDE GENE-EXPRESSION IN ASTROCYTES	GLIA			English	Article						ENKEPHALIN; PROENKEPHALIN MESSENGER-RNA; SOMATOSTATIN; BETA-ADRENERGIC RECEPTOR; OPIATE RECEPTOR; NALTREXONE	NERVE GROWTH-FACTOR; P-IMMUNOREACTIVE ASTROCYTES; DEVELOPING RAT CEREBELLUM; MOUSE ASTROGLIAL CELLS; FACTOR MESSENGER-RNA; OPIOID RECEPTORS; DEVELOPMENTAL EXPRESSION; CULTURED ASTROCYTES; HIPPOCAMPAL-NEURONS; BRAIN ASTROCYTES	One of the functions of glial receptors is to regulate synthesis and release of a variety of neuropeptides and growth factor peptides, which in turn act on neurons or other glia. Because of the potential importance of these interactions in injured brain, we have examined the role of two different receptors in the regulation of astrocyte neuropeptide synthesis. Stimulation of beta-adrenergic receptors on type 1 astrocytes resulted in increased mRNA and protein for the proenkephalin (PE) and somatostatin genes. This receptor also increased expression of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). The potential role of opiate receptors was examined in several ways. Treatment of newborn rats for 7 days with the opiate antagonist naltrexone, prior to preparation of astrocytes, had no effect on PE mRNA or met-enkephalin content but resulted in a significant increase in NGF content. However, treatment of astrocytes in culture with met-enkephalin, morphine, or naltrexone had no effect on any of these parameters. No opiate binding could be detected, using either etorphine or bremazocine, to membranes of astrocytes prepared from cortex, cerebellum, striatum, or hippocampus of 1-day, 7-day, or 14-day postnatal rats. Thus we conclude that type I astrocytes do not express opiate receptors and that the in vivo effects of naltrexone are mediated indirectly via some other cell type/receptor. (C) 1994 Wiley-Liss, Inc.		SCHWARTZ, JP (reprint author), NINCDS, CLIN NEUROSCI BRANCH, MOLEC GENET SECT, BLDG 9, ROOM 1W115, BETHESDA, MD 20892 USA.						ADAMO M, 1988, ENDOCRINOLOGY, V123, P2526; BALLOTTI R, 1987, EMBO J, V6, P3633, DOI 10.1002/j.1460-2075.1987.tb02695.x; CINTRA A, 1989, ACTA PHYSIOL SCAND, V137, P557, DOI 10.1111/j.1748-1716.1989.tb08799.x; DESCHEPPER CF, 1986, BRAIN RES, V374, P195, DOI 10.1016/0006-8993(86)90411-7; EHRENREICH H, 1991, BRAIN RES, V538, P54, DOI 10.1016/0006-8993(91)90375-6; EHRENREICH H, 1991, NEW BIOL, V3, P135; ERIKSSON PS, 1993, NEUROSCIENCE, V54, P401, DOI 10.1016/0306-4522(93)90261-D; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FERRARA N, 1988, BRAIN RES, V462, P223, DOI 10.1016/0006-8993(88)90550-1; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; FURUKAWA S, 1986, BIOCHEM BIOPH RES CO, V136, P57, DOI 10.1016/0006-291X(86)90876-4; FURUKAWA S, 1987, BIOCHEM BIOPH RES CO, V147, P1048, DOI 10.1016/S0006-291X(87)80176-6; FUXE K, 1991, NEUROSCI LETT, V123, P107, DOI 10.1016/0304-3940(91)90169-T; GAUL G, 1992, P ROY SOC B-BIOL SCI, V249, P57, DOI 10.1098/rspb.1992.0083; GIAID A, 1991, HISTOCHEMISTRY, V95, P303; GIAID A, 1989, P NATL ACAD SCI USA, V86, P7634, DOI 10.1073/pnas.86.19.7634; Gomez-Pinilla F, 1990, Neuroreport, V1, P211; HATTEN ME, 1988, DEV BIOL, V125, P280, DOI 10.1016/0012-1606(88)90211-4; HAUSER KF, 1990, BRAIN RES, V522, P347, DOI 10.1016/0006-8993(90)91482-V; HENDRICKSON CM, 1980, NEUROPHARMACOLOGY, V19, P731, DOI 10.1016/0028-3908(80)90064-7; INTEBI AD, 1990, NEUROSCIENCE, V34, P545, DOI 10.1016/0306-4522(90)90163-X; KADLE R, 1988, BRAIN RES, V460, P60, DOI 10.1016/0006-8993(88)90429-5; KOSTYK SK, 1989, BRAIN RES, V504, P284, DOI 10.1016/0006-8993(89)91369-3; LARGE TH, 1986, SCIENCE, V234, P352, DOI 10.1126/science.3764415; LEE ME, 1990, J CLIN INVEST, V86, P141, DOI 10.1172/JCI114677; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; MASTERS BA, 1990, ANN NY ACAD SCI, V611, P522; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MELNER MH, 1990, EMBO J, V9, P791, DOI 10.1002/j.1460-2075.1990.tb08175.x; MICHEL JP, 1986, BRAIN RES, V377, P383, DOI 10.1016/0006-8993(86)90886-3; MITSUO K, 1993, J MOL NEUROSCI, V4, P21, DOI 10.1007/BF02736687; MOBLEY WC, 1989, NEURON, V3, P655, DOI 10.1016/0896-6273(89)90276-6; ODERFELDNOWAK B, 1992, NEUROCHEM INT, V21, P455, DOI 10.1016/0197-0186(92)90197-Y; PEARCE B, 1985, NEUROSCI LETT, V55, P157, DOI 10.1016/0304-3940(85)90012-6; ROTWEIN P, 1988, P NATL ACAD SCI USA, V85, P265, DOI 10.1073/pnas.85.1.265; ROUGON G, 1983, NATURE, V305, P715, DOI 10.1038/305715a0; SCHWARTZ JP, 1992, GLIA, V5, P75, DOI 10.1002/glia.440050111; SCHWARTZ JP, 1992, INT REV NEUROBIOL, V34, P1, DOI 10.1016/S0074-7742(08)60096-3; SCHWARTZ JP, 1990, CELL MOL NEUROBIOL, V10, P447, DOI 10.1007/BF00711186; SCHWARTZ JP, 1993, ANN NY ACAD SCI, V679, P226, DOI 10.1111/j.1749-6632.1993.tb18302.x; SCHWARTZ JP, 1988, DEV BRAIN RES, V40, P311, DOI 10.1016/0165-3806(88)90144-7; SCHWARTZ JP, 1993, IN PRESS TROPHIC REG; SCHWARTZ JP, 1993, ASTROCYTES PHARM FUN, P229; SHINODA H, 1992, DEV BRAIN RES, V67, P205, DOI 10.1016/0165-3806(92)90220-Q; SHINODA H, 1989, SCIENCE, V245, P415, DOI 10.1126/science.2569236; SHOZUHARA H, 1992, J NEUROCHEM, V59, P175, DOI 10.1111/j.1471-4159.1992.tb08888.x; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; SPRUCE BA, 1990, EMBO J, V9, P1787, DOI 10.1002/j.1460-2075.1990.tb08303.x; STIENEMARTIN A, 1991, J NEUROSCI RES, V29, P538, DOI 10.1002/jnr.490290415; STORNETTA RL, 1988, SCIENCE, V242, P1444, DOI 10.1126/science.3201232; TARRIS RH, 1986, PEDIATR RES, V20, P367, DOI 10.1203/00006450-198604000-00022; TRIMMER PA, 1986, DEV BRAIN RES, V27, P151, DOI 10.1016/0165-3806(86)90241-5; VARON SS, 1979, NEUROSCI RES PROGR B, V17; VAYSSE PJJ, 1990, J NEUROCHEM, V55, P624, DOI 10.1111/j.1471-4159.1990.tb04179.x; VILIJN MH, 1988, P NATL ACAD SCI USA, V85, P6551, DOI 10.1073/pnas.85.17.6551; WOODWARD WR, 1992, J NEUROSCI, V12, P142; YAMAKUNI T, 1987, FEBS LETT, V223, P117, DOI 10.1016/0014-5793(87)80520-3; YOSHIZAWA T, 1990, SCIENCE, V247, P462, DOI 10.1126/science.2405487; YOSHIZAWA T, 1989, NEUROSCI LETT, V102, P179, DOI 10.1016/0304-3940(89)90075-X; ZAFRA F, 1992, J NEUROSCI, V12, P4793; ZAGON IS, 1990, NEUROSCIENCE, V34, P479, DOI 10.1016/0306-4522(90)90156-X; ZAGON IS, 1985, SCIENCE, V227, P1049, DOI 10.1126/science.3883485	62	45	46	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JUN	1994	11	2					185	190		10.1002/glia.440110212			6	Neurosciences	Neurosciences & Neurology	NP160	WOS:A1994NP16000011	7927646				2020-06-26	J	WHELAN, G; FLECKNELL, PA				WHELAN, G; FLECKNELL, PA			THE USE OF ETORPHINE/METHOTRIMEPRAZINE AND MIDAZOLAM AS AN ANESTHETIC TECHNIQUE IN LABORATORY RATS AND MICE	LABORATORY ANIMALS			English	Article						RATS; MICE; ANESTHESIA; ETORPHINE; METHOTRIMEPRAZINE; MIDAZOLAM; BLOOD GAS ANALYSIS; FENTANYL; FLUANISONE	FENTANYL-FLUANISONE; KETAMINE-XYLAZINE; ANESTHESIA	The results of a preliminary evaluation of etorphine/methotrimeprazine ('Small Animal Immobilon') and midazolam in rats and mice are reported, and this regimen is compared to fentanyl/fluanisone/midazolam in mice. In rats, a surgical plane of anaesthesia with good muscle relaxation was produced, but blood gas analysis showed the presence of severe hypoxia, hypercapnia and acidosis. In mice etorphine/methotrimeprazine/midazolam and fentanyl/fluanisone/midazolam produced adequate anaesthesia, but blood gas analysis showed severe respiratory depression with both regimens. Since etorphine/methotrimeprazine/midazolam produced severe respiratory depression in rats and mice it is suggested that this regimen is used with caution. Administration of supplemental oxygen would seem advisable when using either etorphine/methotrimeprazine/midazolam or fentanyl/fluanisone/midazolam in rats and mice.		WHELAN, G (reprint author), UNIV NEWCASTLE UPON TYNE,SCH MED,CTR COMPARAT BIOL,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.			Flecknell, Paul/0000-0002-1075-1129			CALDERONE L, 1986, EXP EYE RES, V42, P331, DOI 10.1016/0014-4835(86)90026-6; FISKER AV, 1982, LAB ANIM, V16, P109, DOI 10.1258/002367782781110197; FLECKNELL PA, 1984, LAB ANIM, V18, P143, DOI 10.1258/002367784780891406; FOLLE L, 1975, ACTA BIOL MED GER, V35, P605; GREEN C, 1975, ANIM ANAESTH, V8, P13; HARKNESS JE, 1989, BIOL MED RABBITS ROD, P41; HU C, 1992, LAB ANIM-UK, V26, P15, DOI 10.1258/002367792780809075; LOVELL DP, 1986, LAB ANIM, V20, P85, DOI 10.1258/002367786780865142; SIEMANN DW, 1980, RADIAT RES, V81, P303, DOI 10.2307/3575406; SKOLLEBORG KC, 1990, LAB ANIM, V24, P221, DOI 10.1258/002367790780866100; SKOULIS NP, 1989, TOXICOLOGY, V57, P287, DOI 10.1016/0300-483X(89)90117-0; WIXSON SK, 1987, LAB ANIM SCI, V37, P736	12	15	15	0	1	ROYAL SOC MEDICINE SERVICES LTD	LONDON	1 WIMPOLE STREET, LONDON, ENGLAND W1M 8AE	0023-6772			LAB ANIM	Lab. Anim.	JAN	1994	28	1					70	77		10.1258/002367794781065735			8	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	MV135	WOS:A1994MV13500011	8158972				2020-06-26	J	NI, Q; XU, H; PARTILLA, JS; STARK, PA; CARROLL, FI; BRINE, GA; ROTHMAN, RB				NI, Q; XU, H; PARTILLA, JS; STARK, PA; CARROLL, FI; BRINE, GA; ROTHMAN, RB			STEREOCHEMICAL REQUIREMENTS FOR PSEUDOIRREVERSIBLE INHIBITION OF OPIOID MU RECEPTOR-BINDING BY THE 3-METHYLFENTANYL CONGENERS, RTI-46144 AND ITS ENANTIOMERS - EVIDENCE FOR DIFFERENT BINDING DOMAINS	SYNAPSE			English	Article						MU-RECEPTORS; OPIOID RECEPTORS; FENTANYL; RECEPTOR BINDING	RAT-BRAIN; PSEUDOALLOSTERIC MODULATION; LIGAND-BINDING; OPIATE; SITES; (+)-CIS-3-METHYLFENTANYL; AFFINITY; COMPLEX; IDENTIFICATION; TRANSPORTER	Fentanyl and its congeners are of interest not only because of their clinical applications, but also because certain members of this series of opioid analgesics exhibit unique properties, such as acting as pseudoirreversible inhibitors of mu receptor binding, both in vitro and in vivo. Previous studies showed that pretreatment of membranes with (+)-cis-3-methylfentanyl resulted in a lower affinity interaction of [H-3]ohm-efentanyl with the mu binding site, as well as an increased dissociation rate. The present study was undertaken to determine the stereochemical requirements for pseudoirreversible inhibition of mu receptor binding using the methylfentanyl congeners, (+/-)-cis-N-[1-(2-hydroxy-2-phenylethyl)-3-methyl-4-piperidyl]-N-phenylpropanamide HCl (RTI-4614-4) and its four resolved enantiomers. A R configuration of the 2-hydroxy group was essential for high affinity binding and pseudoirreversible inhibition. The two enantiomers with this configuration, 1b ((2R,3R,4S)-N-[1-(2-hydroxy-2-phenylethyl)-3-methyl-4-piperidyl]-N-phenylpropanamide oxalate) and 1c ((2R,3S,4R)-N-[1-(2-hydroxy-2-phenylethyl)-3-methyl-4-piperidyl]-N-phenylpropanamide HCl), acted as pseudoirreversible inhibitors of the mu receptor as labeled with [H-3][D-Ala2-MePhe4,Gly-ol5]enkephalin, [H-3]fentanyl or [H-3]etorphine. RTI-4614-4, 1b, and 1c decreased the Bmax of [H-3][D-Ala2-MePhe4,Gly-ol5]enkephalin binding sites without altering the dissociation rate. These drugs had a lesser effect on steady-state [H-3]fentanyl and [H-3]etorphine binding but did produce statistically significant changes in the parameters of the two-component dissociation model, which accurately described the dissociation of these [H-3]ligands. Viewed collectively, these data indicate that the mechanism of the pseudoirreversible inhibition appears to depend on the radioligand used to label the mu receptor. To explain these data, a pseudoallosteric model is proposed that postulates that certain mu ligands bind to different domains of the drug recognition site of the mu receptor and that the prebinding of pseudoirreversible inhibitors to the recognition site changes the domains available to a radioligand, leading to alterations in steady-state binding levels and dissociation kinetics. (C) 1993 Wiley-Liss, Inc.	NIDA, ADDICT RES CTR, CLIN PSYCHOPHARMACOL SECT, POB 5180, BALTIMORE, MD 21224 USA; RES TRIANGLE INST, RES TRIANGLE PK, NC 27709 USA							AKUNNE HC, 1991, SYNAPSE, V8, P289, DOI 10.1002/syn.890080407; AKUNNE HC, 1992, NEUROCHEM RES, V17, P1275, DOI 10.1007/BF00968412; BAND L, 1990, LIFE SCI, V47, P2231, DOI 10.1016/0024-3205(90)90154-J; BRINE GA, 1992, MED CHEM RES, V2, P34; Casy A. F., 1986, OPIOID ANALGESICS CH, P287; CHOUDHARY MS, 1992, MOL PHARMACOL, V42, P627; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; EVARDSEN O, 1992, MOL BRAIN RES, V14, P166; GUAN XM, 1992, MOL PHARMACOL, V41, P695; JIN WQ, 1981, SCI SINICA, V24, P710; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KNOTT GD, 1972, 1972 P ONL INT C, V1, P497; KULA NS, 1991, NEUROPHARMACOLOGY, V30, P89, DOI 10.1016/0028-3908(91)90047-F; LAHTI RA, 1985, EUR J PHARMACOL, V109, P281, DOI 10.1016/0014-2999(85)90431-5; LEYSEN J, 1977, EUR J PHARMACOL, V43, P253, DOI 10.1016/0014-2999(77)90025-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOSBERG HI, 1983, P NATL ACAD SCI-BIOL, V80, P5871, DOI 10.1073/pnas.80.19.5871; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEVE KA, 1991, MOL PHARMACOL, V39, P733; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; REID AA, 1990, LIFE SCI, V47, pPL77, DOI 10.1016/0024-3205(90)90531-U; ROSENBAUM JS, 1984, BRAIN RES, V291, P317, DOI 10.1016/0006-8993(84)91264-2; ROTHMAN RB, 1991, LIFE SCI, V48, pPL111; ROTHMAN RB, 1992, PEPTIDES, V13, P1137, DOI 10.1016/0196-9781(92)90020-4; ROTHMAN RB, 1987, PEPTIDES, V8, P1015, DOI 10.1016/0196-9781(87)90130-6; ROTHMAN RB, 1989, NEUROPHARMACOLOGY, V28, P1349, DOI 10.1016/0028-3908(89)90009-9; ROTHMAN RB, 1991, PEPTIDES, V12, P151, DOI 10.1016/0196-9781(91)90182-O; ROTHMAN RB, 1988, J PHARMACOL EXP THER, V247, P405; TOLKOVSKY AM, 1982, MOL PHARMACOL, V22, P648; VANBEVER WF, 1974, J MED CHEM, V17, P1047, DOI 10.1021/jm00256a003; WILSON RS, 1975, J MED CHEM, V18, P240, DOI 10.1021/jm00237a003; WOLOZIN BL, 1981, P NATL ACAD SCI-BIOL, V78, P6181, DOI 10.1073/pnas.78.10.6181; XU H, 1991, NEUROPHARMACOLOGY, V30, P455, DOI 10.1016/0028-3908(91)90006-W; ZHU GC, 1992, J CELL BIOCHEM, V50, P159	34	11	11	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0887-4476	1098-2396		SYNAPSE	Synapse	DEC	1993	15	4					296	306		10.1002/syn.890150406			11	Neurosciences	Neurosciences & Neurology	MJ928	WOS:A1993MJ92800005	8153877				2020-06-26	J	COTE, TE; GOSSE, ME; WEEMS, HB				COTE, TE; GOSSE, ME; WEEMS, HB			SOLUBILIZATION OF HIGH-AFFINITY, GUANINE NUCLEOTIDE-SENSITIVE MU-OPIOID RECEPTORS FROM 7315C CELL-MEMBRANES	JOURNAL OF NEUROCHEMISTRY			English	Article						MU-OPIOID RECEPTOR; SOLUBILIZATION; [H-3]ETORPHINE; [H-3][D-ALA(2),N-ME-PHE(4)-GLY(5)-OL]ENKEPHALIN	GTP-BINDING PROTEIN; OPIATE RECEPTOR; RAT-BRAIN; AGONIST BINDING; RECONSTITUTION; PURIFICATION; GI	High-affinity mu-opioid receptors have been solubilized from 7315c cell membranes. Occupancy of the membrane-associated receptors with morphine before their solubilization in the detergent 3-[(3-cholamidopropyl) dimethyl]-l -propane sulfonate was critical for stabilization of the receptor. The solubilized opioid receptor bound [H-3]etorphine with high affinity (K(D)) = 0.304 +/- 0.06 nM; B(max) = 154 +/- 33 fmol/mg of protein). Of the membrane-associated [H-3]etorphine binding sites, 40 +/- 5% were recovered in the solubilized fraction. Both mu-selective and nonselective enkephalins competed with [H-3]etorphine for the solubilized binding sites; in contrast, delta- and K-opioid enkephalins failed to compete with [H-3]etorphine for the solubilized binding sites at concentrations of < 1 muM. The mu-selective ligand [H-3][D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin also bound with high affinity (K(D) = 0.79 nM; B(max) = 108 +/- 17 fmol/mg of protein) to the solubilized material. Of the membrane-associated [H-3][D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin binding sites, 43 +/- 3% were recovered in the solubilized material. Guanosine 5'-O-(3-thiotriphosphate), GTP, and guanosine 5'-O-(2-thiodiphosphate), but not adenylylimidodiphosphate, diminished [H-3][D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin binding in a concentration-dependent manner. Finally, mu-opioid receptors from rat brain membranes were also solubilized in a high-affinity, guanine nucleotide-sensitive state if membrane-associated receptors were occupied with morphine before and during their solubilization with the detergent 3-[(3-cholamidopro-pyl)dimethyl]-1-propane sulfonate.		COTE, TE (reprint author), UNIFORMED SERV UNIV HLTH SCI,DEPT PHARMACOL,4301 JONES BRIDGE RD,BETHESDA,MD 20814, USA.						AUB DL, 1986, J BIOL CHEM, V261, P9333; CHO TM, 1986, P NATL ACAD SCI USA, V83, P4138, DOI 10.1073/pnas.83.12.4138; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FREY EA, 1989, EUR J PHARM-MOLEC PH, V172, P347, DOI 10.1016/0922-4106(89)90015-1; FREY EA, 1984, ENDOCRINOLOGY, V115, P1797, DOI 10.1210/endo-115-5-1797; GIOANNINI TL, 1985, J BIOL CHEM, V260, P5117; GOSSE ME, 1989, MOL ENDOCRINOL, V3, P315, DOI 10.1210/mend-3-2-315; HJELMELAND LM, 1980, P NATL ACAD SCI-BIOL, V77, P6368, DOI 10.1073/pnas.77.11.6368; JAFFE JH, 1985, [No title captured], P491; LAW SF, 1991, J BIOL CHEM, V266, P17885; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; MANECKJEE R, 1985, P NATL ACAD SCI USA, V82, P594, DOI 10.1073/pnas.82.2.594; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OFRI D, 1992, J NEUROCHEM, V58, P628, DOI 10.1111/j.1471-4159.1992.tb09764.x; PUTTFARCKEN P, 1986, MOL PHARMACOL, V30, P81; SCHOFIELD PR, 1989, EMBO J, V8, P489, DOI 10.1002/j.1460-2075.1989.tb03402.x; SIMONDS WF, 1980, P NATL ACAD SCI-BIOL, V77, P4623, DOI 10.1073/pnas.77.8.4623; TEMPEL A, 1982, LIFE SCI, V31, P1401, DOI 10.1016/0024-3205(82)90391-5; TOCQUE B, 1987, EUR J PHARMACOL, V143, P127, DOI 10.1016/0014-2999(87)90742-4; UEDA H, 1988, P NATL ACAD SCI USA, V85, P7013, DOI 10.1073/pnas.85.18.7013; XIE GX, 1992, P NATL ACAD SCI USA, V89, P4214; ZUKIN RS, 1981, LIFE SCI, V29, P2681	23	12	12	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	SEP	1993	61	3					973	978		10.1111/j.1471-4159.1993.tb03610.x			6	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	LT335	WOS:A1993LT33500022	8395567				2020-06-26	J	LAZAR, DF; MEDZIHRADSKY, F				LAZAR, DF; MEDZIHRADSKY, F			ALTERED TRANSITION BETWEEN AGONIST-FAVORING AND ANTAGONIST-FAVORING STATES OF MU-OPIOID RECEPTOR IN BRAIN MEMBRANES WITH MODIFIED MICROVISCOSITY	JOURNAL OF NEUROCHEMISTRY			English	Article						RAT BRAIN CORTEX; FLUORESCENCE POLARIZATION; MEMBRANE FLUIDITY; OPIOID AGONISTS AND ANTAGONISTS; CHOLESTEROL; FATTY ACIDS	OPIATE AGONISTS; FATTY-ACIDS; BINDING; CHOLESTEROL; MODULATION; TEMPERATURE; EXPRESSION; REAGENTS; CLONING; LIPIDS	In unmodified synaptosomal brain membranes the presence of NaCl inhibited the binding to mu receptors of the tritiated opioid agonists etorphine, Tyr-D-Ala-Gly-(Me)Phe-Gly-ol, and sufentanil by 53,43, and 37%, respectively, and increased that of the antagonist [H-3]naltrexone by 54%. On the other hand, in membranes whose microviscosity was increased by incorporation of cholesteryl hemisuccinate (CHS) the effects of sodium on opioid agonist and antagonist binding were abolished and strongly reduced, respectively. Furthermore, in the modified membranes the ability of sodium to protect the opioid receptor from inactivation by the sulfhydryl-reactive agent N-ethylmaleimide (NEM) was diminished. In CHS-treated membranes whose elevated microviscosity was reduced by the incorporation of oleic acid, the effectiveness of sodium in modulating opioid binding and attenuating receptor inactivation by NEM was restored. The results implicate membrane microviscosity in the mechanism by which sodium modulates the conversion between agonist- and antagonist-favoring states of mu opioid receptor.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109					NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA04087]		CAHILL AL, 1976, BIOCHEM PHARMACOL, V25, P2257, DOI 10.1016/0006-2952(76)90007-1; CLARK MJ, 1988, EUR J PHARMACOL, V148, P343, DOI 10.1016/0014-2999(88)90112-4; CREESE I, 1975, LIFE SCI, V16, P1837, DOI 10.1016/0024-3205(75)90287-8; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FISCHEL SV, 1981, MOL PHARMACOL, V20, P269; FONG TM, 1987, BIOCHEMISTRY-US, V26, P3871, DOI 10.1021/bi00387a020; HASEGAWA JI, 1987, J NEUROCHEM, V49, P1007, DOI 10.1111/j.1471-4159.1987.tb09987.x; HITZEMANN R, 1985, EUR J PHARMACOL, V108, P171, DOI 10.1016/0014-2999(85)90722-8; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; LAZAR DF, 1992, J NEUROCHEM, V59, P1233, DOI 10.1111/j.1471-4159.1992.tb08432.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELL DC, 1990, BIOCHEMISTRY-US, V29, P9143, DOI 10.1021/bi00491a007; OFRI D, 1992, RECEPTOR, V2, P109; PASTERNAK GW, 1975, MOL PHARMACOL, V11, P340; PASTERNAK GW, 1975, NATURE, V253, P563, DOI 10.1038/253563a0; PERT CB, 1973, SCIENCE, V182, P1359, DOI 10.1126/science.182.4119.1359; PUTTFARCKEN P, 1986, MOL PHARMACOL, V30, P81; REMMERS AE, 1990, J NEUROCHEM, V55, P1993, DOI 10.1111/j.1471-4159.1990.tb05787.x; REMMERS AE, 1991, J NEUROCHEM, V57, P1265; REMMERS AE, 1991, P NATL ACAD SCI USA, V88, P2171, DOI 10.1073/pnas.88.6.2171; SIMON EJ, 1975, P NATL ACAD SCI USA, V72, P2404, DOI 10.1073/pnas.72.6.2404; SIMON EJ, 1981, BASIC NEUROCHEMISTRY, P255; SWANN AC, 1984, ARCH BIOCHEM BIOPHYS, V233, P354, DOI 10.1016/0003-9861(84)90456-9; TEFFT RE, 1986, BIOCHEMISTRY-US, V25, P3709, DOI 10.1021/bi00360a035; TREISTMAN SN, 1987, BIOCHIM BIOPHYS ACTA, V898, P109, DOI 10.1016/0005-2736(87)90029-0; YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G; ZHANG XF, 1989, BIOCHIM BIOPHYS ACTA, V976, P53, DOI 10.1016/S0005-2728(89)80188-4	27	6	6	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	SEP	1993	61	3					1135	1140		10.1111/j.1471-4159.1993.tb03630.x			6	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	LT335	WOS:A1993LT33500042	8395559				2020-06-26	J	EVANS, CJ; KEITH, DE; MORRISON, H; MAGENDZO, K; EDWARDS, RH				EVANS, CJ; KEITH, DE; MORRISON, H; MAGENDZO, K; EDWARDS, RH			CLONING OF A DELTA OPIOID RECEPTOR BY FUNCTIONAL EXPRESSION	SCIENCE			English	Article							MOLECULAR CHARACTERIZATION; PEPTIDES; BINDING; BRAIN; PROTEIN	Opiate drugs have potent analgesic and addictive properties. These drugs interact with receptors that also mediate the response to endogenous opioid peptide ligands. However, the receptors for opioids have eluded definitive molecular characterization. By transient expression in COS cells and screening with an iodinated analog of the opioid peptide enkephalin, a complementary DNA clone encoding a functional delta opioid receptor has been identified. The sequence shows homology to G protein-coupled receptors, in particular the receptors for somatostatin, angiotensin, and interleukin-8.	UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90024	EVANS, CJ (reprint author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT,LOS ANGELES,CA 90024, USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [P50 DA005010, DA05010]		AKIL H, 1984, ANNU REV NEUROSCI, V7, P223, DOI 10.1146/annurev.ne.07.030184.001255; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Bertolucci M., 1992, Society for Neuroscience Abstracts, V18, P1368; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADBURY AF, 1976, NATURE, V260, P165, DOI 10.1038/260165a0; DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.bi.60.070191.003253; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUGHES J, 1975, NATURE, V258, P577, DOI 10.1038/258577a0; KLEE WA, 1974, P NATL ACAD SCI USA, V71, P3474, DOI 10.1073/pnas.71.9.3474; LAW PY, 1983, MOL PHARMACOL, V23, P26; LAW PY, 1982, MOL PHARMACOL, V21, P438; LOH HH, 1988, SYNAPSE, V2, P457, DOI 10.1002/syn.890020414; LOH HH, 1990, ANNU REV PHARMACOL, V30, P123; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; MAIDMENT NT, 1989, NEUROSCIENCE, V33, P549, DOI 10.1016/0306-4522(89)90407-7; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; MATTIA A, 1992, J PHARMACOL EXP THER, V260, P518; MILLER RJ, 1978, LIFE SCI, V22, P379, DOI 10.1016/0024-3205(78)90284-9; MILLIGAN CE, 1992, MOL BIOL CELL, V3, P242; MULDER H, 1991, EUR J PHARMACOL, V205, P211; PASTERNAK GW, 1988, OPIATE RECEPTORS, P75; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; SCHOFIELD PR, 1989, EMBO J, V8, P489, DOI 10.1002/j.1460-2075.1989.tb03402.x; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; TERENIUS L, 1973, ACTA PHARMACOL TOX, V32, P317; TERENIUS L, 1976, EUR J PHARMACOL, V38, P211, DOI 10.1016/0014-2999(76)90221-1; WEBER E, 1983, TRENDS NEUROSCI, V6, P333, DOI 10.1016/0166-2236(83)90150-9; XIE GX, 1992, P NATL ACAD SCI USA, V89, P4124, DOI 10.1073/pnas.89.9.4124	31	1127	1142	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1952	1955		10.1126/science.1335167			4	Multidisciplinary Sciences	Science & Technology - Other Topics	KD088	WOS:A1992KD08800037	1335167				2020-06-26	J	LANE, CM; ELDE, R; LOH, HH; LEE, NM				LANE, CM; ELDE, R; LOH, HH; LEE, NM			REGULATION OF AN OPIOID-BINDING PROTEIN IN NG108-15 CELLS PARALLELS REGULATION OF DELTA-OPIOID RECEPTORS	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						IMMUNOFLUORESCENCE; CONFOCAL MICROSCOPY; ANTIBODIES; TRANSFECTION	HYBRID-CELLS; OPIATE RECEPTOR; RAT-BRAIN; MOLECULAR CHARACTERIZATION; PURIFICATION; MICROSCOPY; ANTIBODY	An opioid-binding protein has recently been purified,from bovine brain and cloned, and its cDNA sequence has been obtained. Indirect evidence suggests that this protein has a role in opioid-receptor function. However, because direct testing of its function by expression of its cDNA has not yet been possible and because its structure bears no resemblance to G protein-coupled receptors, the role of this protein in opioid-receptor activity is still in question. An antibody raised to a portion of the predicted amino acid sequence of opioid-binding cell-adhesion molecule (OBCAM) specifically labeled the surface of NG108-15 cells, as visualized by immunofluorescence with confocal microscopy. Furthermore, chronic treatment of these cells with opioid agonist, which down-regulates opioid receptors, reduced OBCAM immunoreactivity (ir). Down-regulation of both opioid receptors and OBCAM-ir was greatest after chronic treatment of NG108-15 cells with delta-opioid agonists, as well as with nonselective agonists such as etorphine, whereas other agonists including [D-Ala2-N-MePhe4-Gly-ol]enkephalin, morphine, levorphanol, dynorphin A-(1-13), and U-50,488H were less effective or ineffective. Chronic treatment of NG108-15 cells with muscarinic agonists had no effect on OBCAM-ir. Furthermore, NG108-15 cells transfected with an antisense construct to OBCAM have a reduced density of opioid-binding sites as well as reduced OBCAM-ir. Taken together, these results strongly suggest that OBCAM has a role in opioid-receptor function in NG108-15 cells.	UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455	LANE, CM (reprint author), UNIV MINNESOTA,DEPT PHARMACOL,MINNEAPOLIS,MN 55455, USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-06299, DA-02643, DA-05695]		ANN DK, 1992, J BIOL CHEM, V267, P7921; BRELJE TC, 1989, DIABETES, V38, P808, DOI 10.2337/diabetes.38.6.808; CHANG KJ, 1979, J BIOL CHEM, V254, P2610; CHO TM, 1986, P NATL ACAD SCI USA, V83, P4138, DOI 10.1073/pnas.83.12.4138; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; GIOANNINI TL, 1985, J BIOL CHEM, V260, P5117; HASSAN AHS, 1989, NEUROSCIENCE, V32, P269, DOI 10.1016/0306-4522(89)90126-7; HASSELL J, 1974, J HISTOCHEM CYTOCHEM, V22, P223, DOI 10.1177/22.4.223; HAZUM E, 1979, SCIENCE, V206, P1077, DOI 10.1126/science.227058; JOHNSON GD, 1982, J IMMUNOL METHODS, V55, P231, DOI 10.1016/0022-1759(82)90035-7; KLEIN WL, 1979, BIOCHEM BIOPH RES CO, V90, P506, DOI 10.1016/0006-291X(79)91264-6; LAW PY, 1983, MOL PHARMACOL, V23, P26; LAW PY, 1982, MOL PHARMACOL, V22, P1; LAW PY, 1983, MOL PHARMACOL, V24, P413; LOH HH, 1990, ANNU REV PHARMACOL, V30, P123; ORNATOWSKA M, 1992, J CHEM NEUROANAT, V5, P95, DOI 10.1016/0891-0618(92)90037-Q; ROY S, 1988, BIOCHEM BIOPH RES CO, V154, P688, DOI 10.1016/0006-291X(88)90194-5; ROY S, 1988, BIOCHEM BIOPH RES CO, V150, P237, DOI 10.1016/0006-291X(88)90511-6; SCHOFIELD PR, 1989, EMBO J, V8, P489, DOI 10.1002/j.1460-2075.1989.tb03402.x; SIMONDS WF, 1985, P NATL ACAD SCI USA, V82, P4974, DOI 10.1073/pnas.82.15.4974; WHITE JG, 1987, J CELL BIOL, V105, P41, DOI 10.1083/jcb.105.1.41; XIE GX, 1992, P NATL ACAD SCI USA, V89, P4124, DOI 10.1073/pnas.89.9.4124	22	11	11	0	1	NATL ACAD PRESS	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	DEC 1	1992	89	23					11234	11238		10.1073/pnas.89.23.11234			5	Multidisciplinary Sciences	Science & Technology - Other Topics	KA903	WOS:A1992KA90300028	1333602	Green Published, Bronze			2020-06-26	J	KLEIN, P; NELSON, WL				KLEIN, P; NELSON, WL			O-3-(2-CARBOMETHOXYALLYL) ETHERS OF OPIOID LIGANDS DERIVED FROM OXYMORPHONE, NALTREXONE, ETORPHINE, DIPRENORPHINE, NORBINALTORPHIMINE, AND NALTRINDOLE - UNEXPECTED O-3-DEALKYLATION IN THE OPIOID RADIOLIGAND DISPLACEMENT ASSAY	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							RECEPTOR MEDIATED PHENOMENA; DIRECTED ACYLATING AGENT; OPIATE-RECEPTOR; RAT-BRAIN; IRREVERSIBLE LIGANDS; AFFINITY LABELS; NARCOTIC ANALGESICS; ALKYLATING AGENT; GAMMA-LACTONE; DELTA-OPIATE	O3-(2-Carbomethoxyallyl) ether derivatives of some phenolic 4,5-epoxymorphinan opioid ligands have been prepared in a simple one-step procedure, and their behavior in the radioligand receptor assay was compared to their phenolic precursors. These O3-ether ligands appeared to show significant affinity for opioid receptors, about 2-fold less than the parent phenols, and their receptor selectivities were similar. However, on close examination of the stability of a representative ether 2b in the radioligand displacement assay, considerable O3-dealkylation was observed. The dealkylation process occurred even after denaturation of the proteins of the membrane preparation, and it occurred in the presence of model nucleophiles imidazole and thiophenol. Thus, what apparently was unusual activity is explained by O3-dealkylation to the parent phenol (e.g., 2a). Saturated ether analog 2c was not dealkylated under the conditions of the radioligand displacement assay and was a very weak opioid ligand. We conclude that the conversion of the O3(2-carbomethoxyallyl) ether electrophilic ligands to their parent phenols accounts for their activity in the opioid radioligand displacement assay.	UNIV WASHINGTON, SCH PHARM, DEPT MED CHEM, SEATTLE, WA 98195 USA					NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-03933, DA-06675]		ABBOTT FV, 1988, LIFE SCI, V43, P1685, DOI 10.1016/0024-3205(88)90479-1; ADLER TK, 1963, J PHARMACOL EXP THER, V140, P155; ARCHER S, 1983, J MED CHEM, V26, P1775, DOI 10.1021/jm00366a024; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3281, DOI 10.1021/ja00989a032; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3273, DOI 10.1021/ja00989a031; BENTLEY KW, 1969, J CHEM SOC C, P2385, DOI 10.1039/j39690002385; BIDLACK JM, 1981, P NATL ACAD SCI-BIOL, V78, P636, DOI 10.1073/pnas.78.1.636; BIDLACK JM, 1989, BIOCHEMISTRY-US, V28, P4333, DOI 10.1021/bi00436a031; BIDLACK JM, 1990, MOL PHARMACOL, V37, P50; BLANE GF, 1967, J PHARM PHARMACOL, V19, P367, DOI 10.1111/j.2042-7158.1967.tb09562.x; BURKE TR, 1986, J MED CHEM, V29, P1087, DOI 10.1021/jm00156a030; BURKE TR, 1984, J MED CHEM, V27, P1570, DOI 10.1021/jm00378a008; CARUSO TP, 1980, J PHARMACOL EXP THER, V213, P539; Casy A. F., 1986, OPIOID ANALGESICS CH, P69; CASY AF, 1989, ADV DRUG RES, V18, P177; CHATTERJIE N, 1975, J MED CHEM, V18, P490, DOI 10.1021/jm00239a010; CHEN ZR, 1991, LIFE SCI, V48, P2165, DOI 10.1016/0024-3205(91)90150-A; CHRISTENSEN CB, 1987, PHARMACOL TOXICOL, V60, P75, DOI 10.1111/j.1600-0773.1987.tb01724.x; DECOSTA BR, 1990, J LABELLED COMPD RAD, V28, P1257, DOI 10.1002/jlcr.2580281105; DECOSTA BR, 1989, J MED CHEM, V32, P281, DOI 10.1021/jm00122a001; DECOSTA BR, 1990, J MED CHEM, V33, P1171, DOI 10.1021/jm00166a014; FANG SN, 1984, J MED CHEM, V27, P1090, DOI 10.1021/jm00374a026; FANTOZZI R, 1981, MOL PHARMACOL, V20, P8; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; HENNIES HH, 1988, ARZNEIMITTEL-FORSCH, V38-2, P877; INTURRISI CE, 1983, LIFE SCI, V33, P773, DOI 10.1016/0024-3205(83)90616-1; JOHANNESSON T, 1963, ACTA PHARMACOL TOX, V20, P165; KAMM J J, 1971, Xenobiotica, V1, P273; KIM CH, 1989, J MED CHEM, V32, P1392, DOI 10.1021/jm00126a040; KLEE WA, 1982, FEBS LETT, V150, P125, DOI 10.1016/0014-5793(82)81318-5; KLEIN P, 1991, J MED CHEM, V34, P2438, DOI 10.1021/jm00112a019; KLEIN P, 1990, J MED CHEM, V33, P2286, DOI 10.1021/jm00170a038; KOOLPE GA, 1985, J MED CHEM, V28, P949, DOI 10.1021/jm00145a018; KOOLPE GA, 1984, J MED CHEM, V27, P1718, DOI 10.1021/jm00378a032; Lenz G. R., 1986, OPIATES, P101; Lewis J W, 1973, Adv Biochem Psychopharmacol, V8, P123; LEWIS JW, 1971, ANNU REV PHARMACOLOG, V11, P241, DOI 10.1146/annurev.pa.11.040171.001325; LIN HK, 1978, NATURE, V271, P383, DOI 10.1038/271383a0; MAY M, 1968, J PHARM SCI, V57, P881; MCKILLOP A, 1974, TETRAHEDRON, V30, P1379, DOI 10.1016/S0040-4020(01)97250-3; MEFFIN PJ, 1980, J CHROMATOGR, V183, P352, DOI 10.1016/S0378-4347(00)81716-8; MOHACSI E, 1982, J MED CHEM, V25, P1264, DOI 10.1021/jm00352a037; NEWMAN AH, 1990, ANNU REP MED CHEM, V25, P271; OGURI K, 1989, CHEM PHARM BULL, V37, P955; OGURI K, 1987, LIFE SCI, V41, P1457, DOI 10.1016/0024-3205(87)90710-7; OLSEN LD, 1990, J MED CHEM, V33, P737, DOI 10.1021/jm00164a043; PASTERNAK GW, 1987, LIFE SCI, V41, P2845, DOI 10.1016/0024-3205(87)90431-0; PAUL D, 1989, J PHARMACOL EXP THER, V251, P477; PERT CB, 1973, P NATL ACAD SCI USA, V70, P2243, DOI 10.1073/pnas.70.8.2243; PORTOGHESE PS, 1979, J MED CHEM, V22, P168, DOI 10.1021/jm00188a008; PORTOGHESE PS, 1978, J MED CHEM, V21, P598, DOI 10.1021/jm00205a002; PORTOGHESE PS, 1990, J MED CHEM, V33, P1547, DOI 10.1021/jm00168a004; PORTOGHESE PS, 1980, J MED CHEM, V23, P233, DOI 10.1021/jm00177a002; PORTOGHESE PS, 1987, J MED CHEM, V30, P238, DOI 10.1021/jm00385a002; PORTOGHESE PS, 1988, J MED CHEM, V31, P836, DOI 10.1021/jm00399a026; PORTOGHESE PS, 1977, J MED CHEM, V20, P1020, DOI 10.1021/jm00218a006; PORTOGHESE PS, 1990, J MED CHEM, V33, P1714, DOI 10.1021/jm00168a028; PORTOGHESE PS, 1982, CHEM REGULATION BIOL, P181; RICE KC, 1983, SCIENCE, V220, P314, DOI 10.1126/science.6132444; SAYRE LM, 1983, J MED CHEM, V26, P503, DOI 10.1021/jm00358a009; SAYRE LM, 1983, J MED CHEM, V26, P1229, DOI 10.1021/jm00363a005; SAYRE LM, 1984, J MED CHEM, V27, P1325, DOI 10.1021/jm00376a018; SIMON EJ, 1991, MED RES REV, V11, P357, DOI 10.1002/med.2610110402; SIMON EJ, 1988, OPIATE RECEPTORS, P165; STILL WC, 1978, J ORG CHEM, V43, P2923, DOI 10.1021/jo00408a041; TAKEMORI AE, 1985, ANNU REV PHARMACOL, V25, P193; TAKEMORI AE, 1981, EUR J PHARMACOL, V70, P445, DOI 10.1016/0014-2999(81)90355-1; TERENIUS L, 1973, ACTA PHARMACOL TOX, V33, P377	68	6	6	0	1	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	NOV 27	1992	35	24					4589	4594		10.1021/jm00102a012			6	Chemistry, Medicinal	Pharmacology & Pharmacy	KA520	WOS:A1992KA52000012	1335078				2020-06-26	J	RICHARDSON, A; DEMOLIOUMASON, C; BARNARD, EA				RICHARDSON, A; DEMOLIOUMASON, C; BARNARD, EA			GUANINE NUCLEOTIDE-BINDING PROTEIN-COUPLED AND PROTEIN-UNCOUPLED STATES OF OPIOID RECEPTORS AND THEIR RELEVANCE TO THE DETERMINATION OF SUBTYPES	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						ARYLACETAMIDES; BREMAZOCINE; KAPPA-RECEPTORS	GUINEA-PIG BRAIN; RAT-BRAIN; SELECTIVE AGONIST; AFFINITY STATES; VAS-DEFERENS; SITES; MEMBRANES; HETEROGENEITY; ANTAGONIST; RESOLUTION	Opioid receptors are currently classified as mu, delta, and kappa types, but various subtypes have also been proposed. We have investigated whether subtypes exist by using [H-3]bremazocine. [H-3]Bremazocine binds to twice as many naloxone-sensitive sites as other nonselective opioid agonists, as shown in four membrane types that have very different ratios of mu, delta, and kappa receptor types. [H-3]Bremazocine binding is completely inhibited by an excess (in unlabeled form) of other opioid ligands, with Hill coefficients of 0.8-0.95. These paradoxes can be explained if there are high- and low-affinity states of the mu, delta, and kappa receptors and bremazocine binds with similar affinities to both states. We propose that these states a.re the guanine nucleotide-binding protein (G-protein)-coupled form and the uncoupled form of each receptor. As evidence for this proposal, the [H-3]bremazocine binding suffered little or no loss with G-protein-uncoupling treatments, whereas binding of other opioid agonists was fully sensitive. We conclude that [H-3]bremazocine offers a tool for the measurement of the total pools of coupled and uncoupled opioid receptors and that much of the previous characterization of opioid receptor subtypes reflects, instead, a significant pool of G-protein-uncoupled opioid receptors.	MRC,MOLEC NEUROBIOL UNIT,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND			Richardson, Alan/I-4631-2015; Richardson, Alan/E-7615-2010	Richardson, Alan/0000-0003-1825-3375; 			AHMED MS, 1986, MEMBRANE BIOCHEM, V6, P255, DOI 10.3109/09687688609065452; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOEYNAEMS JM, 1980, [No title captured]; CITRI Y, 1980, NATURE, V287, P297, DOI 10.1038/287297a0; CLARK CR, 1988, BRIT J PHARMACOL, V93, P618, DOI 10.1111/j.1476-5381.1988.tb10319.x; CLARK JA, 1989, J PHARMACOL EXP THER, V251, P461; CORBETT AD, 1986, BRIT J PHARMACOL, V89, P245, DOI 10.1111/j.1476-5381.1986.tb11141.x; DEMOLIOUMASON CD, 1986, J NEUROCHEM, V46, P1118, DOI 10.1111/j.1471-4159.1986.tb00626.x; EVANS T, 1985, BIOCHEM J, V232, P751, DOI 10.1042/bj2320751; FRANCES B, 1985, EUR J PHARMACOL, V117, P223, DOI 10.1016/0014-2999(85)90607-7; GILLAN MGC, 1982, BRIT J PHARMACOL, V77, P461, DOI 10.1111/j.1476-5381.1982.tb09319.x; HAYES A, 1985, EUR J PHARMACOL, V110, P317, DOI 10.1016/0014-2999(85)90558-8; HUNTER JC, 1990, BRIT J PHARMACOL, V101, P183, DOI 10.1111/j.1476-5381.1990.tb12110.x; KENT RS, 1980, MOL PHARMACOL, V17, P14; LAHTI RA, 1985, EUR J PHARMACOL, V109, P281, DOI 10.1016/0014-2999(85)90431-5; LEFF SE, 1985, MOL PHARMACOL, V27, P184; LYNCH CJ, 1988, FEBS LETT, V229, P54, DOI 10.1016/0014-5793(88)80796-8; MACDERMOT J, 1979, P NATL ACAD SCI USA, V76, P1135, DOI 10.1073/pnas.76.3.1135; MCKNIGHT AT, 1985, NEUROPHARMACOLOGY, V24, P1011, DOI 10.1016/0028-3908(85)90184-4; MILLER L, 1986, BRIT J PHARMACOL, V87, P595, DOI 10.1111/j.1476-5381.1986.tb10202.x; MORRIS BJ, 1989, NEUROSCIENCE, V29, P433, DOI 10.1016/0306-4522(89)90070-5; MOSBERG HI, 1983, P NATL ACAD SCI-BIOL, V80, P5871, DOI 10.1073/pnas.80.19.5871; NOCK B, 1988, EUR J PHARMACOL, V154, P27, DOI 10.1016/0014-2999(88)90359-7; PORTHE G, 1981, BIOCHEM BIOPH RES CO, V101, P1, DOI 10.1016/S0006-291X(81)80002-2; RICHARDSON A, 1989, ADV BIOSCI OXFORD, V75, P13; ROBSON LE, 1985, EUR J PHARMACOL, V112, P65, DOI 10.1016/0014-2999(85)90239-0; ROTHMAN RB, 1990, PEPTIDES, V11, P311, DOI 10.1016/0196-9781(90)90088-M; TIBERI M, 1990, EUR J PHARM-MOLEC PH, V188, P379, DOI 10.1016/0922-4106(90)90198-7; WERLING LL, 1988, MOL PHARMACOL, V33, P423; WOOD MS, 1989, J NEUROCHEM, V53, P173, DOI 10.1111/j.1471-4159.1989.tb07310.x; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	31	40	40	0	0	NATL ACAD PRESS	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	NOV 1	1992	89	21					10198	10202		10.1073/pnas.89.21.10198			5	Multidisciplinary Sciences	Science & Technology - Other Topics	JW798	WOS:A1992JW79800046	1332034	Green Published, Bronze			2020-06-26	J	JOLICOEUR, LM; NASSIRI, MR; SHIPMAN, C; CHOI, HK; FLYNN, GL				JOLICOEUR, LM; NASSIRI, MR; SHIPMAN, C; CHOI, HK; FLYNN, GL			ETORPHINE IS AN OPIATE ANALGESIC PHYSICOCHEMICALLY SUITED TO TRANSDERMAL DELIVERY	PHARMACEUTICAL RESEARCH			English	Note						ETORPHINE; OPIATE ANALGESIC; TRANSDERMAL DELIVERY; CANCER; PAIN MANAGEMENT	CHRONIC CANCER PAIN; NARCOTIC ANALGESICS; FENTANYL		UNIV MICHIGAN,COLL PHARM,ANN ARBOR,MI 48109; UNIV MICHIGAN,COLL DENT,DEPT BIOL & MAT SCI,ANN ARBOR,MI 48109							BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; BLANE GF, 1970, P BR PHARM SOC 2ND 4, V39, P252; Flynn G.L., 1979, MODERN PHARM, P263; Flynn GL, 1985, PERCUTANEOUS ABSORPT, P17; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; GUY RH, 1985, [No title captured], P3; INTURRISI CE, 1984, AM J MED, V77, P27, DOI 10.1016/S0002-9343(84)80100-X; MISER AW, 1989, PAIN, V37, P15, DOI 10.1016/0304-3959(89)90148-6; NASSIRI MR, 1991, PHARMACOL TOXICOL, V69, P17, DOI 10.1111/j.1600-0773.1991.tb00402.x; ROY SD, 1989, PHARM RES-DORDR, V6, P825, DOI 10.1023/A:1015944018555; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; SHIMM DS, 1979, JAMA-J AM MED ASSOC, V241, P2408, DOI 10.1001/jama.241.22.2408; WALSH TD, 1984, PAIN, V18, P1, DOI 10.1016/0304-3959(84)90121-0	13	11	11	0	4	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013	0724-8741			PHARMACEUT RES	Pharm. Res.	JUL	1992	9	7					963	965		10.1023/A:1015877621976			3	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	JC561	WOS:A1992JC56100025	1438016				2020-06-26	J	MCCONNAUGHEY, MM; WONG, SC; INGENITO, AJ				MCCONNAUGHEY, MM; WONG, SC; INGENITO, AJ			DYNORPHIN RECEPTOR CHANGES IN HIPPOCAMPUS OF THE SPONTANEOUSLY HYPERTENSIVE RAT	PHARMACOLOGY			English	Article						KAPPA-RECEPTOR; SPONTANEOUSLY HYPERTENSIVE RATS; OPIATE; DYNORPHIN; [H-3]-ETORPHINE	A 1-8; IMMUNOREACTIVITY; STRESS	Dynorphin receptor binding sites in hippocampal membrane preparations were assessed in spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats at 4, 8, 12 and 16 weeks of age. At 4 weeks of age, before hypertension is manifested, SHRs had significantly more hippocampal dynorphin receptor binding sites than WKY controls. At 8, 12 and 16 weeks of age, however, when hypertension is seen, SHRs showed significantly fewer hippocampal binding sites than WKY rats. No receptor affinity changes for dynorphin were seen between the two strains of rats at any age. These results suggest that hippocampal receptor changes involving the opioid system may play a role in the central component of blood pressure control.		MCCONNAUGHEY, MM (reprint author), E CAROLINA UNIV,SCH MED,DEPT PHARMACOL,GREENVILLE,NC 27858, USA.						BLUMENTHAL SJ, 1982, CLIN EXP HYPER THE A, V4, P55; BUNAG RD, 1982, HYPERTENSION, V4, P898, DOI 10.1161/01.HYP.4.6.898; CHAVKIN C, 1983, LIFE SCI, V33, P13, DOI 10.1016/0024-3205(83)90432-0; CORBETT AD, 1982, NATURE, V299, P79, DOI 10.1038/299079a0; FEUERSTEIN G, 1984, NEUROPEPTIDES, V5, P295, DOI 10.1016/0143-4179(84)90086-6; GAIDA W, 1985, CLIN SCI, V68, P35, DOI 10.1042/cs0680035; GOLDSTEIN A, 1980, P NATL ACAD SCI-BIOL, V77, P6207, DOI 10.1073/pnas.77.10.6207; HALLBACK M, 1974, ACTA PHYSIOL SCAND, V90, P684, DOI 10.1111/j.1748-1716.1974.tb05636.x; IAMS SG, 1979, J LAB CLIN MED, V94, P608; LAURENT S, 1983, EUR J PHARMACOL, V96, P165, DOI 10.1016/0014-2999(83)90547-2; LI SJ, 1990, NEUROCHEM RES, V15, P1141, DOI 10.1007/BF01101717; LI SJ, 1989, NEUROPEPTIDES, V13, P197, DOI 10.1016/0143-4179(89)90092-9; LINDSLEY DF, 1984, LIMBIC SYSTEM BASIC, P310; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGNAN J, 1988, DEV BRAIN RES, V38, P300, DOI 10.1016/0165-3806(88)90057-0; MCCARTY R, 1983, NEUROSCI BIOBEHAV R, V7, P493, DOI 10.1016/0149-7634(83)90029-5; MCGINTY JF, 1983, P NATL ACAD SCI-BIOL, V80, P589, DOI 10.1073/pnas.80.2.589; MCLEAN S, 1987, J COMP NEUROL, V255, P497, DOI 10.1002/cne.902550403; NOBACK CR, 1986, NERVOUS SYSTEM INTRO, P260; SAPOLSKY RM, 1986, HIPPOCAMPUS, V3, P257; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEIFERT W, 1983, [No title captured]; Siggins G R, 1986, Adv Neurol, V44, P501; TEYLER TJ, 1984, BRAIN RES BULL, V12, P711, DOI 10.1016/0361-9230(84)90152-7; VIDAL C, 1984, NEUROPEPTIDES, V5, P237, DOI 10.1016/0143-4179(84)90071-4; WONG SC, 1990, FASEB J, V4, pA1002; XIE CW, 1986, NEUROSCI LETT, V65, P224, DOI 10.1016/0304-3940(86)90309-5	27	17	17	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0031-7012			PHARMACOLOGY	Pharmacology	JUL	1992	45	1					52	57		10.1159/000138972			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	JG425	WOS:A1992JG42500007	1354877				2020-06-26	J	MICHEL, A; VILLENEUVE, G; DIMAIO, J				MICHEL, A; VILLENEUVE, G; DIMAIO, J			A PROPOSAL FOR THE MOLECULAR-BASIS OF MU AND DELTA OPIATE RECEPTOR DIFFERENTIATION BASED ON MODELING OF 2 TYPES OF CYCLIC ENKEPHALINS AND A NARCOTIC ALKALOID	JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN			English	Article						CYCLIC OPIOID PEPTIDE; RECEPTOR SELECTIVITY; CONFORMATIONAL SEARCH; ENKEPHALIN	OPIOID-PEPTIDES; CONFORMATIONAL-ANALYSIS; BINDING-SITES; RAT-BRAIN; ANALOGS; SELECTIVITY; INVITRO; LIGANDS; H-1-NMR; POTENT	The molecular basis underlying the divergent receptor selectivity of two cyclic opioid peptides Tyr-c[N(delta)-D-Orn-2-Gly-Phe-Leu-] (c-ORN) and [D-Pen2, L-Cys5]-enkephalinamide (c-PEN) was investigated using a molecular modeling approach. Ring closure and conformational searching procedures were used to determine low-energy cyclic backbone conformers. Following reinsertion of amino acid side chains, the narcotic alkaloid 7-alpha-[(1R)-1-methyl-1-hydroxy-3-phenylpropyl]-6,14-endoethenotetrahydro oripavine (PEO) was used as a flexible template for bimolecular superpositions with each of the determined peptide ring conformers using the coplanarity and cocentricity of the phenolic rings as the minimum constraint. A vector space of PEO, accounting for all possible orientations for the C21-aromatic ring of PEO served as a geometrical locus for the aromatic ring of the Phe4 residue in the opioid peptides. Although a vast number of polypeptide conformations satisfied the criteria of the opiate pharmacophore, they could be grouped into three classes differing in magnitude and sign of the torsional angle values of the tyrosyl side chain. Only class III conformers for both c-ORN and c-PEN, having tyramine dihedral angles chi-1 = -150-degrees +/- 30-degrees and chi-2 = -155-degrees +/- 20-degrees, had significant structural and conformational properties that were mutually compatible while respecting the PEO vector space. Comparison of these properties in the context of the divergent receptor selectivity of the studied opioid peptides suggests that the increased distortion of the peptide backbone in the closure region of c-PEN together with the pendant beta,beta-dimethyl group, combine to generate a steric volume which is absent in c-ORN and that may be incompatible with a restrictive topography of the mu-receptor. The nature and stereochemistry of substituents adjacent to the closure region of the peptides could also modulate receptor selection by interacting with a charged (delta) or neutral (mu) subsite.	NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,MONTREAL H4P 2R2,QUEBEC,CANADA	MICHEL, A (reprint author), UNIV SHERBROOKE,FAC SCI,DEPT CHIM,CHIM STRUCT LAB,SHERBROOKE J1K 2R1,QUEBEC,CANADA.						BELLENEY J, 1987, INT J PEPT PROT RES, V30, P356; BENTLEY KW, 1972, AGONIST ANTAGONIST A, P7; BRADBURY AF, 1976, NATURE, V260, P165, DOI 10.1038/260165a0; CHANG KJ, 1981, P NATL ACAD SCI-BIOL, V78, P4141, DOI 10.1073/pnas.78.7.4141; CHANG KJ, 1981, MOL PHARMACOL, V20, P1; CHANG KJ, 1979, MOL PHARMACOL, V16, P91; CHILDERS SR, 1979, EUR J PHARMACOL, V55, P11, DOI 10.1016/0014-2999(79)90142-0; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; DIMAIO J, 1986, J MED CHEM, V29, P1658, DOI 10.1021/jm00159a016; DIMAIO J, 1982, J MED CHEM, V25, P1432, DOI 10.1021/jm00354a008; DIMAIO J, 1980, P NATL ACAD SCI-BIOL, V77, P7162, DOI 10.1073/pnas.77.12.7162; DIMAIO J, UNPUB; DIMAIO J, 1979, PEPTIDES STRUCTURE B, P889; DUKA T, 1981, NEUROSCI LETT, V21, P119, DOI 10.1016/0304-3940(81)90368-2; FOURNIEZALUSKI MC, 1981, MOL PHARMACOL, V20, P484; FREED ME, 1976, J MED CHEM, V19, P476, DOI 10.1021/jm00226a005; FROIMOWITZ M, 1989, INT J PEPT PROT RES, V34, P88; GELIN BR, 1979, BIOCHEMISTRY-US, V18, P1256, DOI 10.1021/bi00574a022; GOLDSTEIN A, 1976, SCIENCE, V193, P1081, DOI 10.1126/science.959823; HALL D, 1985, BIOPOLYMERS, V24, P935, DOI 10.1002/bip.360240603; HRUBY VJ, 1988, J AM CHEM SOC, V110, P3351, DOI 10.1021/ja00219a002; HUTCHINS CW, 1984, J MED CHEM, V27, P521, DOI 10.1021/jm00370a015; KERLAVAGE AR, 1987, TRENDS PHARMACOL SCI, V8, P426, DOI 10.1016/0165-6147(87)90230-6; KESSLER H, 1985, INT J PEPT PROT RES, V25, P267; KESSLER H, 1981, ANGEW CHEM INT EDIT, V20, P124, DOI 10.1002/anie.198101241; KEYS C, 1988, MOL PHARMACOL, V33, P528; LARSON DL, 1973, J MED CHEM, V16, P195, DOI 10.1021/jm00261a005; LIPKOWSKI AW, 1986, J MED CHEM, V29, P1222, DOI 10.1021/jm00157a018; LOEW G, 1986, MOL PHARMACOL, V29, P546; LOEW GH, 1978, P NATL ACAD SCI USA, V75, P7, DOI 10.1073/pnas.75.1.7; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; MAMMI NJ, 1985, J AM CHEM SOC, V107, P4008, DOI 10.1021/ja00299a041; MARSHALL G, 1990, SYBYL SOFTWARE PROBL, V2, P2; MICHEL AG, 1988, CAN J CHEM, V66, P2498, DOI 10.1139/v88-393; MOSBERG HI, 1983, LIFE SCI, V32, P2565, DOI 10.1016/0024-3205(83)90239-4; MOSBERG HI, 1982, BIOCHEM BIOPH RES CO, V106, P506, DOI 10.1016/0006-291X(82)91139-1; MOSBERG HI, 1987, INT J PEPT PROT RES, V29, P282; MOSBERG HI, 1983, P NATL ACAD SCI-BIOL, V80, P5871, DOI 10.1073/pnas.80.19.5871; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; PORTOGHESE PS, 1980, J MED CHEM, V23, P233, DOI 10.1021/jm00177a002; PORTOGHESE PS, 1988, J MED CHEM, V31, P281, DOI 10.1021/jm00397a001; PORTOGHESE PS, 1981, J MED CHEM, V24, P782, DOI 10.1021/jm00139a004; RAMAKRISHNAN K, 1982, J MED CHEM, V25, P1423, DOI 10.1021/jm00354a006; ROQUES BP, 1982, REGUL PEPTIDES, P321; SCHILLER PW, 1982, NATURE, V297, P74, DOI 10.1038/297074a0; SCHILLER PW, 1989, J MED CHEM, V32, P698, DOI 10.1021/jm00123a035; SCHILLER PW, 1981, BIOCHEM BIOPH RES CO, V101, P337, DOI 10.1016/0006-291X(81)91265-1; SCHILLER PW, 1983, LIFE SCI, V33, P319, DOI 10.1016/0024-3205(83)90507-6; SCHILLER PW, 1983, PEPTIDES STRUCTURE F, P269; SCHWYZER R, 1986, BIOCHEMISTRY-US, V25, P6335, DOI 10.1021/bi00368a075; SHERMAN DB, 1989, BIOCHEM BIOPH RES CO, V162, P1126, DOI 10.1016/0006-291X(89)90790-0; SHIOTANI S, 1976, J MED CHEM, V19, P803, DOI 10.1021/jm00228a013; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; SNYDER SH, 1980, J NEUROCHEM, V35, P5, DOI 10.1111/j.1471-4159.1980.tb12483.x; VANDENHENDE JH, 1967, J AM CHEM SOC, V89, P2901, DOI 10.1021/ja00988a017; WILKES BC, 1987, BIOPOLYMERS, V26, P1431, DOI 10.1002/bip.360260817; ZIMMERMAN SS, 1977, MACROMOLECULES, V10, P1, DOI 10.1021/ma60055a001; 1988, SYBYL MOL MODELLING; 1988, JUN AM CRYST ASS ANN	59	8	8	0	0	ESCOM SCI PUBL BV	LEIDEN	PO BOX 214, 2300 AE LEIDEN, NETHERLANDS	0920-654X			J COMPUT AID MOL DES	J. Comput.-Aided Mol. Des.	DEC	1991	5	6					553	569		10.1007/BF00135314			17	Biochemistry & Molecular Biology; Biophysics; Computer Science, Interdisciplinary Applications	Biochemistry & Molecular Biology; Biophysics; Computer Science	HL835	WOS:A1991HL83500005	1667926				2020-06-26	J	STANLEY, S; JEGANATHAN, A; WOOD, T; HENRY, P; TURNER, S; WOODS, WE; GREEN, M; TAI, HH; WATT, D; BLAKE, J; TOBIN, T				STANLEY, S; JEGANATHAN, A; WOOD, T; HENRY, P; TURNER, S; WOODS, WE; GREEN, M; TAI, HH; WATT, D; BLAKE, J; TOBIN, T			MORPHINE AND ETORPHINE .14. DETECTION BY ELISA IN EQUINE URINE	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							RACING HORSES; IMMUNOASSAY DETECTION; DRUGS; BLOOD	We have raised antibodies to morphine and etorphine and developed one-step enzyme-linked immunosorbent assays (ELISA) for these drugs as part of a panel of post race tests for drugs in racing horses. These tests are simple, can be completed in 2 h, and can be read by visual inspection. The morphine ELISA has an I50 for morphine of about 1.5 ng/mL, while the etorphine ELISA has an I50 for etorphine of 250 pg/mL. Cross-reactivity studies show that the antimorphine antibody cross-reacts well with levorphanol, hydromorphone, and oxycodone, while the anti-etorphine antibody showed no cross-reactivity with buprenorphine, diprenorphine, oxymorphone, morphine, or thebaine. The morphine test readily detected parent morphine or its metabolites in equine urine for at least 8 h after administration of 50 mg/horse, while a 0.1-mu-g/kg dose of etorphine was detectable for up to 48 h post dosing. For each test the background activity in post-race urines was equal to or less than the I50 for the standard curves, making them useful equine forensic tests. Each of these tests has detected "positives" in post race urine samples and as such these tests are capable of substantially improving the speed and efficacy of both pre-race and post-race testing for morphine, etorphine, and their congeners in racing horses.	UNIV KENTUCKY,KENTUCKY EQUINE DRUG RES,LEXINGTON,KY 40546; UNIV KENTUCKY,GRAD CTR TOXICOL,LEXINGTON,KY 40546; UNIV KENTUCKY,DEPT CHEM,LEXINGTON,KY 40546; UNIV KENTUCKY,DEPT VET SCI,LEXINGTON,KY 40546	STANLEY, S (reprint author), UNIV KENTUCKY,MAXWELL H GLUCK EQUINE RES CTR,LEXINGTON,KY 40546, USA.						BOOTH NH, 1988, VET PHARM THERAPEUTI, P290; COMBIE J, 1982, CLIN CHEM, V28, P83; GILMAN AG, 1985, [No title captured]; JANDIL SP, 1979, ANAL CHEM, V51, P269; JASINSKI DR, 1975, CLIN PHARMACOL THER, V17, P267; KWIATKOWSKI S, 1988, RES COMMUN CHEM PATH, V61, P391; MUIR WW, 1978, AM J VET RES, V39, P1632; ROWLEY GL, 1975, J BIOL CHEM, V250, P3759; SAMS R, 1989, COMMUNICATION; SUANN C, 1990, 8TH P INT C RAC AN V; TOBIN T, 1988, RES COMMUN CHEM PATH, V60, P97; Tobin T., 1981, DRUGS PERFORMANCE HO; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; WOODS WE, 1986, RES COMMUN CHEM PATH, V52, P237; 1977, LANCET          0723, P178	15	8	8	0	1	PRESTON PUBLICATIONS INC	NILES	7800 MERRIMAC AVE PO BOX 48312, NILES, IL 60648	0146-4760			J ANAL TOXICOL	J. Anal. Toxicol.	NOV-DEC	1991	15	6					305	310		10.1093/jat/15.6.305			6	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	GQ814	WOS:A1991GQ81400004	1779658				2020-06-26	J	SIMANTOV, R; HOLLT, V				SIMANTOV, R; HOLLT, V			REGULATION OF PROENKEPHALIN-A GENE-EXPRESSION IN AGGREGATING FETAL-RAT BRAIN-CELLS	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						ENKEPHALIN; MESSENGER RNA; DEPOLARIZATION; GENE EXPRESSION; AGGREGATING CELLS; NEURONAL CELL CULTURE	PREPROENKEPHALIN MESSENGER-RNA; ADRENAL CHROMAFFIN CELLS; ENKEPHALIN; BIOSYNTHESIS; DEPOLARIZATION; INCREASES; RELEASE; MEDULLA	1. Aggregating fetal rat brain cells express a significant amount of proenkephalin A (PENK) mRNA, and a selective radioimmunoassay shows that this mRNA is also translated into enkephalins. 2. Depolarization with potassium chloride (KCl) or veratridine increases the expression of PENK mRNA in a time-dependent fashion, with a maximal increase of sixfold. It is interesting, however, that depolarization of the same cultures with KCl has no effect on the expression of prodynorphin mRNA. 3. An increase in PENK mRNA levels has been also observed in cultures treated with 8-Br-cAMP, phorbol 12-myristate-13-acetate (TPA), or dexamethasone. 4. However, incubation of the cultures with the opioid agonist etorphine or the antagonist naltrexone did not alter PENK gene expression, suggesting that there is not feedback control of opioids on PENK biosynthesis in these cells. 5. The increase in PENK mRNA in depolarized and in TPA-, dexamethasone-, or 8-Br-cAMP-treated cultures was not accompanied by a significant increase in the amount of free immunoreactive met-enkephalin. Fetal brain cell cultures are therefore a useful neuronal model system for studying the mechanism that regulated the expression of PENK mRNA.	WEIZMANN INST SCI, DEPT MOLEC GENET & VIROL, IL-76100 REHOVOT, ISRAEL; UNIV MUNICH, DEPT PHYSIOL, W-8000 MUNICH 2, GERMANY							BARG J, 1990, NEUROSCI LETT, V111, P222, DOI 10.1016/0304-3940(90)90372-G; BOMMER M, 1987, J NEUROCHEM, V49, P1688, DOI 10.1111/j.1471-4159.1987.tb02426.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; EIDEN LE, 1984, NATURE, V312, P661, DOI 10.1038/312661a0; FISCHERCOLBRIE R, 1988, P NATL ACAD SCI USA, V85, P3240, DOI 10.1073/pnas.85.9.3240; HOLLT V, 1987, NEUROSCI LETT, V73, P90, DOI 10.1016/0304-3940(87)90037-1; KANAMATSU T, 1986, P NATL ACAD SCI USA, V83, P9245, DOI 10.1073/pnas.83.23.9245; KELY N, 1987, J BIOL CHEM, V262, P4083; KLEY N, 1988, J BIOL CHEM, V263, P2003; KLEY N, 1986, EMBO J, V5, P967, DOI 10.1002/j.1460-2075.1986.tb04310.x; KNODEL EL, 1980, BRAIN RES, V197, P565, DOI 10.1016/0006-8993(80)91148-8; LAGAMMA EF, 1988, BRAIN RES, V441, P292, DOI 10.1016/0006-8993(88)91407-2; LAGAMMA EF, 1985, P NATL ACAD SCI USA, V82, P8252, DOI 10.1073/pnas.82.23.8252; LAGAMMA EF, 1989, MOL BRAIN RES, V5, P131, DOI 10.1016/0169-328X(89)90004-1; MORRIS BJ, 1988, P NATL ACAD SCI USA, V85, P3226, DOI 10.1073/pnas.85.9.3226; NARANJO JR, 1986, P NATL ACAD SCI USA, V83, P1513, DOI 10.1073/pnas.83.5.1513; PRUSS RM, 1988, J BIOL CHEM, V263, P13173; REIMER S, 1990, PROG CLIN BIOL RES, V328, P215; Schwartz J P, 1988, Brain Res, V468, P311; SCHWARTZ JP, 1988, MOL BRAIN RES, V3, P141, DOI 10.1016/0169-328X(88)90059-9; SIEGEL RE, 1985, NEUROPEPTIDES, V6, P543, DOI 10.1016/0143-4179(85)90117-9; SIMANTOV R, 1986, DEV BRAIN RES, V26, P301, DOI 10.1016/0165-3806(86)90297-X; SIMANTOV R, 1989, J NEUROCHEM, V52, P305, DOI 10.1111/j.1471-4159.1989.tb10931.x; YOSHIKAWA K, 1985, P NATL ACAD SCI USA, V82, P589, DOI 10.1073/pnas.82.2.589	25	3	3	0	1	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	APR	1991	11	2					245	251		10.1007/BF00769037			7	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	EZ379	WOS:A1991EZ37900002	2029727				2020-06-26	J	WANG, XJ; HAN, JS				WANG, XJ; HAN, JS			MODIFICATION BY CHOLECYSTOKININ OCTAPEPTIDE OF THE BINDING OF MU-OPIOID, DELTA-OPIOID, AND KAPPA-OPIOID RECEPTORS	JOURNAL OF NEUROCHEMISTRY			English	Article										WANG, XJ (reprint author), BEIJING MED UNIV,DEPT PHYSIOL,BEIJING 100083,PEOPLES R CHINA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA03983]		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COTTON R, 1985, BRIT J PHARMACOL, V84, P927, DOI 10.1111/j.1476-5381.1985.tb17387.x; DING XZ, 1985, ACTA PHARMACOL SIN, V6, P241; FARIS PL, 1983, SCIENCE, V219, P310, DOI 10.1126/science.6294831; FUXE K, 1980, EUR J PHARMACOL, V67, P329, DOI 10.1016/0014-2999(80)90521-X; FUXE K, 1987, RECEPTOR RECEPTOR IN, P22; HAN JS, 1986, PAIN, V27, P101, DOI 10.1016/0304-3959(86)90227-7; HAN JS, 1985, NEUROPEPTIDES, V5, P399, DOI 10.1016/0143-4179(85)90038-1; HARFSTRAND A, 1986, J HYPERTENS, V4, pS251; KAROUM F, 1981, J PHARMACOL EXP THER, V261, P321; LAHTI RA, 1985, EUR J PHARMACOL, V109, P281, DOI 10.1016/0014-2999(85)90431-5; LI Y, 1989, BRAIN RES, V480, P105, DOI 10.1016/0006-8993(89)91572-2; NEMEROFF CB, 1978, SCIENCE, V200, P793, DOI 10.1126/science.565535; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHENOLIKAR S, 1988, FASEB J, V2, P2753; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; TERENIUS L, 1976, 6TH P INT C PHARM, V1, P153; UNGAR G, 1976, OPIATES ENDOGENOUS O, P121; VONEULER G, 1988, TOXICOLOGY, V49, P149, DOI 10.1016/0300-483X(88)90187-4; WANG XJ, 1989, LIFE SCI, V45, P117, DOI 10.1016/0024-3205(89)90285-3; WANG XJ, 1990, IN PRESS BRAIN RES; ZAJAC JM, 1985, J NEUROCHEM, V44, P1605, DOI 10.1111/j.1471-4159.1985.tb08802.x	22	67	77	0	5	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	OCT	1990	55	4					1379	1382		10.1111/j.1471-4159.1990.tb03149.x			4	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	DZ465	WOS:A1990DZ46500040	2168937				2020-06-26	J	KREEGER, TJ; SEAL, US				KREEGER, TJ; SEAL, US			IMMOBILIZATION OF GRAY WOLVES (CANIS-IUPUS) WITH SUFENTANIL CITRATE	JOURNAL OF WILDLIFE DISEASES			English	Note									VET ADM MED CTR,MINNEAPOLIS,MN 55417	KREEGER, TJ (reprint author), UNIV MINNESOTA,DEPT ECOL & BEHAV BIOL,MINNEAPOLIS,MN 55455, USA.						BALLARD WB, 1982, J WILDLIFE DIS, V18, P339, DOI 10.7589/0090-3558-18.3.339; DOBBS HE, 1968, J PHARMACOL EXP THER, V160, P407; FULLER TK, 1981, J WILDLIFE MANAGE, V45, P271, DOI 10.2307/3807901; KREEGER TJ, 1987, J WILDLIFE DIS, V23, P463, DOI 10.7589/0090-3558-23.3.463; KREEGER TJ, 1990, J WILDLIFE DIS, V26, P162; KREEGER TJ, 1988, J WILDLIFE DIS, V25, P89; LEYSEN JE, 1983, EUR J PHARMACOL, V87, P209, DOI 10.1016/0014-2999(83)90331-X; MARSBOOM R, 1985, 17TH C INT UN GAM BI; ROSENBAUM JS, 1984, BRAIN RES, V291, P317, DOI 10.1016/0006-8993(84)91264-2; Seal U.S., 1987, P191; TOBEY RW, 1985, J WILDLIFE DIS, V21, P188, DOI 10.7589/0090-3558-21.2.188; Wiesner H, 1984, J ZOO ANIM MED, V15, P18	12	6	7	0	1	WILDLIFE DISEASE ASSN, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897	0090-3558			J WILDLIFE DIS	J. Wildl. Dis.	OCT	1990	26	4					561	563		10.7589/0090-3558-26.4.561			3	Veterinary Sciences	Veterinary Sciences	EF705	WOS:A1990EF70500024	2147448	Bronze			2020-06-26	J	KLEIN, P; NELSON, WL; YAO, YH; SIMON, EJ				KLEIN, P; NELSON, WL; YAO, YH; SIMON, EJ			ELECTROPHILIC ALPHA-METHYLENE-GAMMA-LACTONE AND ISOTHIOCYANATE OPIOID LIGANDS RELATED TO ETORPHINE	JOURNAL OF MEDICINAL CHEMISTRY			English	Article									UNIV WASHINGTON,SCH PHARM,DEPT MED CHEM,SEATTLE,WA 98195; NYU MED CTR,DEPT PSYCHIAT,NEW YORK,NY 10016; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016					NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-03933, DA-00017]		BARBER RB, 1975, J MED CHEM, V18, P1074, DOI 10.1021/jm00245a006; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3281, DOI 10.1021/ja00989a032; BENTLEY KW, 1969, J CHEM SOC C, P2237, DOI 10.1039/j39690002237; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3267, DOI 10.1021/ja00989a030; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3273, DOI 10.1021/ja00989a031; BENTLEY KW, 1971, ALKALOIDS, V13, P1; BHATT MV, 1984, TETRAHEDRON LETT, V25, P3497; BIDLACK JM, 1989, BIOCHEMISTRY-US, V28, P4333, DOI 10.1021/bi00436a031; BURKE TR, 1986, J MED CHEM, V29, P1087, DOI 10.1021/jm00156a030; BURKE TR, 1984, J MED CHEM, V27, P1570, DOI 10.1021/jm00378a008; CASSADY JM, 1983, ORG SYNTH, V61, P77; Casy A F, 1978, Prog Drug Res, V22, P149; CASY AF, 1986, OPIATES, P101; CASY AF, 1989, ADV DRUG RES, V18, P177; DECOSTA BR, 1989, J MED CHEM, V32, P281, DOI 10.1021/jm00122a001; FEINBERG AP, 1976, P NATL ACAD SCI USA, V73, P4215, DOI 10.1073/pnas.73.11.4215; FULMOR W, 1967, J AM CHEM SOC, V89, P3322, DOI 10.1021/ja00989a601; HARTHOORN AM, 1966, J AM VET MED ASSOC, V149, P875; HOWELLS RD, 1982, J PHARMACOL EXP THER, V222, P629; HUTCHINS CW, 1981, J MED CHEM, V24, P773, DOI 10.1021/jm00139a002; HUTCHINS CW, 1984, J MED CHEM, V27, P521, DOI 10.1021/jm00370a015; JACOBSON AE, 1983, LIFE SCI, V33, P159, DOI 10.1016/0024-3205(83)90468-X; KIM CH, 1989, J MED CHEM, V32, P1392, DOI 10.1021/jm00126a040; KING J. M., 1965, AFR WILDLIFE J, V3, P19, DOI 10.1111/j.1365-2028.1965.tb00734.x; KLEE WA, 1982, FEBS LETT, V150, P125, DOI 10.1016/0014-5793(82)81318-5; KOOLPE GA, 1985, J MED CHEM, V28, P949, DOI 10.1021/jm00145a018; KOOLPE GA, 1984, J MED CHEM, V27, P1718, DOI 10.1021/jm00378a032; LAWSON JA, 1977, J MED CHEM, V20, P165, DOI 10.1021/jm00211a037; LESSOR RA, 1986, J MED CHEM, V29, P2136, DOI 10.1021/jm00161a002; Lewis J W, 1973, Adv Biochem Psychopharmacol, V8, P123; LEWIS JW, 1971, ANNU REV PHARMACOLOG, V11, P241, DOI 10.1146/annurev.pa.11.040171.001325; LIN HK, 1978, NATURE, V271, P383, DOI 10.1038/271383a0; LOEW GH, 1979, J MED CHEM, V22, P603, DOI 10.1021/jm00192a001; OHLER E, 1970, ANGEW CHEM INT EDIT, V9, P457, DOI 10.1002/anie.197004571; OLOFSON RA, 1984, J ORG CHEM, V49, P2081, DOI 10.1021/jo00185a072; OLSEN LD, 1990, J MED CHEM, V33, P737, DOI 10.1021/jm00164a043; PORTOGHESE PS, 1982, CHEM REGULATION BIOL, P181; RICE KC, 1983, SCIENCE, V220, P314, DOI 10.1126/science.6132444; RICE KC, 1907, J MED CHEM, V20, P164; SAKURAI H, 1979, SYNTHESIS-STUTTGART, P740; SAYRE LM, 1983, J MED CHEM, V26, P1229, DOI 10.1021/jm00363a005; SIMON EJ, 1975, J PHARMACOL EXP THER, V192, P531; SIMON EJ, 1988, OPIATE RECEPTORS, P165; STILL WC, 1978, J ORG CHEM, V43, P2923, DOI 10.1021/jo00408a041; TAKEMORI AE, 1985, ANN REV PHARM TOXICO, V25, P183; VANDENHENDE JH, 1967, J AM CHEM SOC, V89, P2901, DOI 10.1021/ja00988a017; VERESHCHAGIN LI, 1972, ZH ORG KHIM+, V8, P1143; WALLACH JD, 1966, J AM VET MED ASSOC, V149, P871; WALLACH JD, 1969, VET MED SM ANIM CLIN, V64, P53; WILLIARD PG, 1980, TETRAHEDRON LETT, V21, P3731, DOI 10.1016/0040-4039(80)80164-X	50	13	14	0	1	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036	0022-2623			J MED CHEM	J. Med. Chem.	AUG	1990	33	8					2286	2296		10.1021/jm00170a038			11	Chemistry, Medicinal	Pharmacology & Pharmacy	DQ907	WOS:A1990DQ90700038	2165166				2020-06-26	J	BONNAIRE, Y; PLOU, P; PAGES, N; BOUDENE, C; JOUANY, JM				BONNAIRE, Y; PLOU, P; PAGES, N; BOUDENE, C; JOUANY, JM			GC/MS CONFIRMATORY METHOD FOR ETORPHINE IN HORSE URINE	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article									UNIV PARIS 11,TOXICOL LAB,F-91405 ORSAY,FRANCE; UNIV ROUEN HAUTE NORMANDIE,TOXICOL LAB,F-76130 MT ST AIGNAN,FRANCE	BONNAIRE, Y (reprint author), LAB FEDERAT NATL SOC COURSES,169 AV DIV LECLERC,F-92290 CHATENAY MALABRY,FRANCE.						CATLIN D, 1973, CLIN CHEM, V19, P216; FEHN J, 1985, J ANAL TOXICOL, V9, P134, DOI 10.1093/jat/9.3.134; FENIMORE DC, 1976, ANAL CHEM, V48, P2289, DOI 10.1021/ac50008a065; GLASEL JA, 1981, J CHROMATOGR, V213, P337, DOI 10.1016/S0021-9673(00)81918-4; GORODETZKY CW, 1975, CLIN PHARMACOL THER, V17, P273; JINDAL SP, 1978, J PHARM SCI, V67, P260, DOI 10.1002/jps.2600670236; MCADAMS J, 1981, Q HORSE TRACK   0806; MCBURNEY LJ, 1986, J ANAL TOXICOL, V10, P56, DOI 10.1093/jat/10.2.56; MEAMS D, 1984, BLOOD HORSE     1006, P7016; TAI CL, 1988, AM J VET RES, V49, P622; TOBIN T, 1985, 6TH P INT C RAC AN V; WEIDENBACH PW, 1985 P ANN M ASS OFF; WOODS WE, 1975, RES COMMUN CHEM PATH, V7, P272	13	5	5	0	0	PRESTON PUBLICATIONS INC	NILES	7800 MERRIMAC AVE PO BOX 48312, NILES, IL 60648	0146-4760			J ANAL TOXICOL	J. Anal. Toxicol.	JUL-AUG	1989	13	4					193	196		10.1093/jat/13.4.193			4	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	AF944	WOS:A1989AF94400001	2779167				2020-06-26	J	ATTALI, B; SAYA, D; VOGEL, Z				ATTALI, B; SAYA, D; VOGEL, Z			KAPPA-OPIATE AGONISTS INHIBIT ADENYLATE-CYCLASE AND PRODUCE HETEROLOGOUS DESENSITIZATION IN RAT SPINAL-CORD	JOURNAL OF NEUROCHEMISTRY			English	Article									WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL							ATTALI B, 1986, Society for Neuroscience Abstracts, V12, P1012; Attali B, 1986, NIDA Res Monogr, V75, P434; Attali B, 1986, NIDA Res Monogr, V75, P141; ATTALI B, 1982, NEUROPEPTIDES, V3, P53, DOI 10.1016/0143-4179(82)90065-8; ATWEH SF, 1983, BRIT MED BULL, V39, P47, DOI 10.1093/oxfordjournals.bmb.a071789; BLUME AJ, 1979, P NATL ACAD SCI USA, V76, P5626, DOI 10.1073/pnas.76.11.5626; COLLIER HOJ, 1975, NATURE, V255, P159, DOI 10.1038/255159b0; CRAIN SM, 1986, BRAIN RES, V370, P61, DOI 10.1016/0006-8993(86)91105-4; CRAIN SM, 1979, LIFE SCI, V25, P1797, DOI 10.1016/0024-3205(79)90426-0; CRAIN SM, 1987, BRAIN RES, V400, P185, DOI 10.1016/0006-8993(87)90670-6; DELANDER GE, 1983, EUR J PHARMACOL, V94, P35, DOI 10.1016/0014-2999(83)90439-9; DUGGAN AW, 1979, BRIT J PHARMACOL, V67, P51; DVORKIN B, 1985, Society for Neuroscience Abstracts, V11, P1198; GIRARDOT JM, 1983, J NEUROCHEM, V41, P848, DOI 10.1111/j.1471-4159.1983.tb04818.x; HO IK, 1973, J PHARMACOL EXP THER, V185, P347; HOKFELT T, 1977, P NATL ACAD SCI USA, V74, P3081, DOI 10.1073/pnas.74.7.3081; JONES SL, 1986, BRAIN RES, V364, P315, DOI 10.1016/0006-8993(86)90844-9; JURNA I, 1984, N-S ARCH PHARMACOL, V327, P23, DOI 10.1007/BF00504987; KELLY PD, 1982, NEUROPEPTIDES, V2, P319, DOI 10.1016/0143-4179(82)90069-5; KLEE WA, 1975, LIFE SCI, V16, P1869, DOI 10.1016/0024-3205(75)90293-3; KUROSE H, 1983, J BIOL CHEM, V258, P4870; LAW PY, 1983, MOL PHARMACOL, V24, P413; LAW PY, 1981, J NEUROCHEM, V36, P1834, DOI 10.1111/j.1471-4159.1981.tb00438.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD RL, 1986, J PHYSIOL-LONDON, V377, P237, DOI 10.1113/jphysiol.1986.sp016184; MACLAWHON RW, 1981, J NEUROCHEM, V37, P132; MUDGE AW, 1979, P NATL ACAD SCI USA, V76, P526, DOI 10.1073/pnas.76.1.526; PATERSON SJ, 1986, P NATL ACAD SCI USA, V83, P6216, DOI 10.1073/pnas.83.16.6216; PATERSON SJ, 1983, BRIT MED BULL, V39, P31, DOI 10.1093/oxfordjournals.bmb.a071787; PEREZREYES E, 1986, J NEUROCHEM, V46, P1508, DOI 10.1111/j.1471-4159.1986.tb01769.x; RANSOM BR, 1977, J NEUROPHYSIOL, V40, P1132; ROMER D, 1980, LIFE SCI, V27, P971, DOI 10.1016/0024-3205(80)90107-1; ROY AC, 1975, LIFE SCI, V16, P1857, DOI 10.1016/0024-3205(75)90291-X; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P590, DOI 10.1073/pnas.72.2.590; SMITH MM, 1984, J PHARMACOL EXP THER, V228, P425; STEVENS CW, 1988, J PHARMACOL EXP THER, V244, P63; TRAYNOR JR, 1987, NEUROPEPTIDES, V10, P313, DOI 10.1016/S0143-4179(87)90065-5; TSANG D, 1978, BRAIN RES, V152, P521, DOI 10.1016/0006-8993(78)91107-1; VOGEL Z, 1988, Society for Neuroscience Abstracts, V14, P83; WALCZAK SA, 1979, BRAIN RES, V160, P105, DOI 10.1016/0006-8993(79)90604-8; YAKSH TL, 1985, EUR J PHARMACOL, V117, P81, DOI 10.1016/0014-2999(85)90474-1; YAKSH TL, 1983, J PHARMACOL EXP THER, V226, P303; ZIEGLGANSBERGER W, 1979, BRAIN RES, V167, P53, DOI 10.1016/0006-8993(79)90262-2	44	124	124	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	FEB	1989	52	2					360	369		10.1111/j.1471-4159.1989.tb09130.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	R8429	WOS:A1989R842900005	2536070				2020-06-26	J	DALBY, KJ				DALBY, KJ			IMMOBILON SUPPLY TO HOLDERS OF HOME OFFICE LICENSED DART GUNS	VETERINARY RECORD			English	Letter																	0	0	0	0	0	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.	JAN 7	1989	124	1					22	22		10.1136/vr.124.1.22-c			1	Veterinary Sciences	Veterinary Sciences	R7962	WOS:A1989R796200020	2916302				2020-06-26	J	KAMERLING, S; WOOD, T; DEQUICK, D; WECKMAN, TJ; TAI, C; BLAKE, JW; TOBIN, T				KAMERLING, S; WOOD, T; DEQUICK, D; WECKMAN, TJ; TAI, C; BLAKE, JW; TOBIN, T			NARCOTIC ANALGESICS, THEIR DETECTION AND PAIN MEASUREMENT IN THE HORSE - A REVIEW	EQUINE VETERINARY JOURNAL			English	Review									UNIV KENTUCKY,MAXWELL H GLUCK EQUINE RES CTR,LEXINGTON,KY 40546; LOUISIANA STATE UNIV,COLL VET MED,DEPT VET PHYSIOL PHARMACOL & TOXICOL,BATON ROUGE,LA 70803							AMADON RS, 1937, J AM VET MED ASSOC, V91, P674; BAUM RM, 1985, CHEM ENG NEWS   0909, P7; BEECHER HK, 1957, PHARMACOL REV, V9, P59; BLAKE JW, 1986, 6TH P INT C RAC AN V, P205; BLAKE JW, 1978, IRISH VET J      DEC, P209; BOOTH NH, 1982, VET PHARM THERAPEUTI; CHAPMAN CR, 1985, PAIN, V22, P1, DOI 10.1016/0304-3959(85)90145-9; COMBIE J, 1979, J EQUINE MED SURG, V3, P377; COMBIE J, 1981, AM J VET RES, V42, P1523; COMBIE J, 1978, 2ND P EQ PHARM S; COMBIE J, 1979, 3RD P INT S EQ MED C, P367; COMBIE J, 1982, CLIN CHEM, V28, P38; COMBIE JD, 1983, AM J VET RES, V44, P870; DAVIS LE, 1970, AM J VET RES, V31, P1631; DEQUICK DJ, 1984, THESIS U KENTUCKY LE; HEEL RC, 1978, DRUGS, V16, P473, DOI 10.2165/00003495-197816060-00001; HOUDE RW, 1979, BR J CLIN PHARM, V7, P2975; HUGHES J, 1975, NATURE, V258, P577, DOI 10.1038/258577a0; Janssen P.A., 1985, OPIOIDS ANESTHESIA, P37; KALPRAVIDH M, 1984, AM J VET RES, V45, P217; KAMERLING S, 1988, EQUINE VET J, V20, P114, DOI 10.1111/j.2042-3306.1988.tb01471.x; KAMERLING SG, 1986, J PHARM PHARMACOL, V38, P40, DOI 10.1111/j.2042-7158.1986.tb04464.x; KAMERLING SG, 1985, GEN PHARMACOL, V16, P253, DOI 10.1016/0306-3623(85)90078-3; KAMERLING SG, 1985, J PHARMACOL METHOD, V13, P267, DOI 10.1016/0160-5402(85)90027-0; KAMERLING SG, 1985, 6TH P INT C RAC AN V, P37; KOSTERLITZ HW, 1973, COMMITTEE PROBLEMS D, P131; LI CH, 1976, NATURE, V260, P622, DOI 10.1038/260622a0; LOWE JE, 1978, J EQUINE MED SURG, V2, P286; LOWE JE, 1969, P AM ASS EQUINE PRAC, V15, P31; Martin W. R., 1984, PHARMACOL REV, V35, P283; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MARTIN WR, 1964, J PHARMACOL EXP THER, V146, P385; MARTIN WR, 1967, PHARMACOL REV, V19, P463; MARTIN WR, 1964, J PHARMACOL EXP THER, V114, P8; MICHIELS M, 1977, EUR J CLIN PHARMACOL, V12, P153, DOI 10.1007/BF00645137; MUIR WW, 1978, AM J VET RES, V39, P1632; MUIR WW, 1979, AM J VET RES, V40, P1417; NUGENT TE, 1982, RES COMMUN CHEM PATH, V35, P405; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; PIPPI NL, 1979, J EQUINE MED SURG, V3, P430; PIPPI NL, 1979, AM J VET RES, V40, P1082; POOLE CF, 1986, CHROMATOGR FORUM, V1, P27; ROBERTSON JT, 1981, AM J VET RES, V42, P41; ROGER T, 1985, AM J VET RES, V46, P31; ROSENBAUM JS, 1984, BRAIN RES, V291, P317, DOI 10.1016/0006-8993(84)91264-2; SCHULZ R, 1979, LIFE SCI, V24, P843, DOI 10.1016/0024-3205(79)90368-0; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; SNYDER SH, 1977, NEW ENGL J MED, V296, P266, DOI 10.1056/NEJM197702032960511; TAI C, 1987, AM J VET RES, V49, P622; TOBIN T, 1978, J EQUINE MED SURG, V2, P397; TOBIN T, 1979, J EQUINE MED SURG, V3, P284; TOBIN T, 1979, J EQUINE MED SURG, V3, P191; TOBIN T, 1984, EQUINE VET J, V16, P43, DOI 10.1111/j.2042-3306.1984.tb01848.x; TOBIN T, 1979, IRISH VET J, V33, P169; TOBIN T, 1988, IN PRESS RES COMM CH; TOBIN T, 1986, J EQUINE VET SCI, V6, P333; Tobin T., 1981, DRUGS PERFORMANCE HO; TOBIN T, 1985, 6TH P INT C RAC AN V, P113; TOBIN T, 1986, P ASS OFFICIAL RACIN; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7; WOODS WE, 1986, AM J VET RES, V47, P2180; WOODS WE, 1986, RES COMMUN CHEM PATH, V52, P237; 1977, LANCET, V2, P178	63	33	33	1	2	EQUINE VETERINARY JOURNAL LTD	NEWMARKET	GRASEBY HOUSE, ENXING ROAD, NEWMARKET, SUFFOLK, ENGLAND CB8 0AU	0425-1644			EQUINE VET J	Equine Vet. J.	JAN	1989	21	1					4	12		10.1111/j.2042-3306.1989.tb02081.x			9	Veterinary Sciences	Veterinary Sciences	T1198	WOS:A1989T119800002	2563969				2020-06-26	J	SIMANTOV, R; LEVY, R				SIMANTOV, R; LEVY, R			NEURONAL ACTIVATION REGULATES THE EXPRESSION OF OPIOID RECEPTORS - POSSIBLE ROLE OF GLIAL-DERIVED FACTORS AND VOLTAGE-DEPENDENT ION CHANNELS	JOURNAL OF NEUROCHEMISTRY			English	Article										SIMANTOV, R (reprint author), WEIZMANN INST SCI,DEPT GENET,IL-76100 REHOVOT,ISRAEL.						BARG J, 1988, IN PRESS INT J DEV N; BLACK IB, 1984, SCIENCE, V225, P1266, DOI 10.1126/science.6147894; BLAUSTEIN MP, 1975, J PHYSIOL-LONDON, V247, P617, DOI 10.1113/jphysiol.1975.sp010950; CHANG KJ, 1979, J BIOL CHEM, V254, P2610; Fambrough D M, 1979, Prog Brain Res, V49, P325; FAWCETT JW, 1985, TRENDS NEUROSCI, V8, P201, DOI 10.1016/0166-2236(85)90079-7; FRANK E, 1987, TRENDS NEUROSCI, V10, P188, DOI 10.1016/0166-2236(87)90143-3; GLAZER T, 1980, EUR J PHARMACOL, V65, P319; GODDARD GA, 1976, BRAIN RES, V110, P331, DOI 10.1016/0006-8993(76)90406-6; Hamprecht B, 1977, Int Rev Cytol, V49, P99; HOKFELT T, 1980, NATURE, V284, P515, DOI 10.1038/284515a0; HONEGGER P, 1979, NATURE, V282, P305, DOI 10.1038/282305a0; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P1041; KLEE WA, 1974, P NATL ACAD SCI USA, V71, P3474, DOI 10.1073/pnas.71.9.3474; KNODEL EL, 1980, BRAIN RES, V197, P565, DOI 10.1016/0006-8993(80)91148-8; LAGAMMA EF, 1985, P NATL ACAD SCI USA, V82, P8252, DOI 10.1073/pnas.82.23.8252; LENOIR D, 1984, BRAIN RES, V304, P285, DOI 10.1016/0006-8993(84)90332-9; PATTERSON PH, 1978, ANNU REV NEUROSCI, V1, P1, DOI 10.1146/annurev.ne.01.030178.000245; SIMANTOV R, 1986, DEV BRAIN RES, V26, P301, DOI 10.1016/0165-3806(86)90297-X; SIMANTOV R, 1984, CENTRAL PERIPHERAL E, P65; STALLCUP WB, 1979, J PHYSIOL-LONDON, V286, P525, DOI 10.1113/jphysiol.1979.sp012635	21	14	14	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	JAN	1989	52	1					305	309		10.1111/j.1471-4159.1989.tb10931.x			5	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	R3744	WOS:A1989R374400042	2535711				2020-06-26	J	GASTHUYS, F; VANDAMME, R; DEMOOR, A; DEMEURICHY, W				GASTHUYS, F; VANDAMME, R; DEMOOR, A; DEMEURICHY, W			HEMODYNAMIC, METABOLIC AND PHYSICAL RESPONSES TO A NEUROLEPTANALGESIC GLYCERYL GUAIACOLATE COMBINATION IN THE HORSE	VETERINARY RESEARCH COMMUNICATIONS			English	Article									ROYAL ZOOL SOC,ANTWERP,BELGIUM	GASTHUYS, F (reprint author), STATE UNIV GHENT,FAC VET MED,LARGE ANIM SURG CLIN,B-9000 GHENT,BELGIUM.						ALFORD BT, 1974, J AM VET MED ASSOC, V164, P702; BOOTH NH, 1977, VET PHARM THERAPEUTI, P318; BOWMAN WC, 1981, [No title captured], V54, P47; CARDINET GH, 1980, CLIN BIOCH DOMESTIC, P535; DAVIS LE, 1972, AM J VET RES, V31, P469; de Moor A, 1978, Zentralbl Veterinarmed A, V25, P189; GARNER HE, 1972, VET MED SMALL ANIMAL, V55, P408; Harthoorn A. M., 1971, Textbook of veterinary anaesthesia, P404; HARTHOORN AM, 1966, J AM VET MED ASSOC, V149, P875; HARTHOORN AM, 1971, J AM VET ASS, P404; Hillidge C J, 1975, Equine Vet J, V7, P148, DOI 10.1111/j.2042-3306.1975.tb03254.x; HILLIDGE CJ, 1978, EQUINE VET J, V10, P60, DOI 10.1111/j.2042-3306.1978.tb02217.x; HILLIDGE CJ, 1974, RES VET SCI, V17, P395, DOI 10.1016/S0034-5288(18)33663-4; HILLIDGE CJ, 1974, VET REC, V94, P476; HILLIDGE CJ, 1971, VET REC, V89, P280, DOI 10.1136/vr.89.10.280-a; HUBBELL JAE, 1980, AM J VET RES, V41, P1751; JENKINS JT, 1972, VET REC, V90, P207, DOI 10.1136/vr.90.8.207; KOCK RA, 1986, J ASS VET ANAESTHETI, V14, P120; LEES P, 1983, VET RES COMMUN, V7, P201, DOI 10.1007/BF02228617; MUYLLE E, 1984, EQUINE VET J, V16, P447, DOI 10.1111/j.2042-3306.1984.tb01974.x; Nelson L., 1978, P753; ROBERTSON SA, 1987, EQUINE VET J, V19, P214, DOI 10.1111/j.2042-3306.1987.tb01383.x; SCHLARMA.B, 1973, AM J VET RES, V34, P411; Simesen M.G., 1980, CLIN BIOCH DOMESTIC, P576; TOBIN T, 1978, J EQUINE MED SURGERY, V9, P397; TRIM CM, 1985, EQUINE VET J, V17, P41, DOI 10.1111/j.2042-3306.1985.tb02038.x; WALLACH JD, 1967, J AM VET MED ASSOC, V151, P870; WEINER N, 1985, PHARMACOL BASIS THER, P145	28	1	1	0	2	KLUWER ACADEMIC PUBL	DORDRECHT	SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS	0165-7380			VET RES COMMUN	Vet. Res. Commun.		1989	13	2					113	126		10.1007/BF00346721			14	Veterinary Sciences	Veterinary Sciences	CA257	WOS:A1989CA25700004	2505440				2020-06-26	J	SEMAFUKO, WEB; FOLLETT, DL; DIXON, WR				SEMAFUKO, WEB; FOLLETT, DL; DIXON, WR			EFFECT OF ETORPHINE ON ADRENERGIC NEUROTRANSMISSION IN THE RAT AND GUINEA-PIG HEART	PHARMACOLOGY			English	Article									UNIV KANSAS,SCH PHARM,DEPT PHARMACOL & TOXICOL,LAWRENCE,KS 66045					NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR 5606]; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA03504]		ANTON AH, 1962, J PHARMACOL EXP THER, V138, P360; CHAMINADE M, 1983, LIFE SCI, V33, P21, DOI 10.1016/0024-3205(83)90434-4; DIXON WR, 1985, FED PROC, V44, P2851; DIXON WR, 1985, PHARMACOLOGIST, V27, P205; DUMONT M, 1984, CAN J PHYSIOL PHARM, V62, P1284, DOI 10.1139/y84-215; EULIE PJ, 1984, BRIT J PHARMACOL, V83, P783, DOI 10.1111/j.1476-5381.1984.tb16233.x; FUDER H, 1986, N-S ARCH PHARMACOL, V332, P148, DOI 10.1007/BF00511405; GADDIS RR, 1985, PHARMACOLOGY, V30, P205, DOI 10.1159/000138070; GADDIS RR, 1982, J PHARMACOL EXP THER, V221, P282; GADDIS RR, 1982, J PHARMACOL EXP THER, V223, P77; HUGHES J, 1977, BRIT J PHARMACOL, V61, P639, DOI 10.1111/j.1476-5381.1977.tb07557.x; ILLES P, 1985, EUR J PHARMACOL, V107, P397, DOI 10.1016/0014-2999(85)90271-7; ILLES P, 1985, J PHARMACOL EXP THER, V232, P526; JACKISCH R, 1986, J NEUROCHEM, V46, P1802; LANG RE, 1983, LIFE SCI, V32, P399, DOI 10.1016/0024-3205(83)90086-3; Langer SZ, 1981, PHARMACOL REV, V32, P337; LEDDA F, 1984, EUR J PHARMACOL, V102, P443, DOI 10.1016/0014-2999(84)90565-X; LEDDA F, 1982, EUR J PHARMACOL, V85, P247, DOI 10.1016/0014-2999(82)90476-9; LIMBERGER N, 1986, N-S ARCH PHARMACOL, V334, P166, DOI 10.1007/BF00505817; MONTEL H, 1973, BRIT J PHARMACOL, V49, P628, DOI 10.1111/j.1476-5381.1973.tb08538.x; PATERSON SJ, 1983, BRIT MED BULL, V39, P31, DOI 10.1093/oxfordjournals.bmb.a071787; RAMME D, 1986, N-S ARCH PHARMACOL, V334, P48, DOI 10.1007/BF00498739; REFSHAUGE C, 1974, LIFE SCI, V14, P311, DOI 10.1016/0024-3205(74)90061-7; SANDER GE, 1981, PEPTIDES, V2, P403, DOI 10.1016/S0196-9781(81)80095-2; SCHADT JC, 1985, J PHARMACOL EXP THER, V232, P656; SEMAFUKO WEB, 1987, J CARDIOVASC PHARM, V10, P16, DOI 10.1097/00005344-198707000-00003; SEMAFUKO WEB, 1986, FASEB J, V45, P668; SEMAFUKO WEB, 1984, PHARMACOLOGIST, V26, P43; SNYDER SH, 1980, J NEUROCHEM, V35, P5, DOI 10.1111/j.1471-4159.1980.tb12483.x; STARKE K, 1985, N-S ARCH PHARMACOL, V329, P206, DOI 10.1007/BF00501214; STARKE K, 1977, REV PHYSIOL BIOCH P, V77, P1, DOI 10.1007/BFb0050157; SZABO B, 1986, ARCH PHARM, V332, P50; UMBREIT WW, 1957, [No title captured]; VIVEROS OH, 1979, MOL PHARMACOL, V16, P1101; VONKUGELGEN I, 1985, EUR J PHARMACOL, V118, P97, DOI 10.1016/0014-2999(85)90667-3; WAKADE AR, 1981, N-S ARCH PHARMACOL, V317, P302, DOI 10.1007/BF00501310; WEIHE E, 1983, LIFE SCI, V33, P711, DOI 10.1016/0024-3205(83)90601-X; WEIHE E, 1985, NEUROPEPTIDES, V5, P453, DOI 10.1016/0143-4179(85)90052-6; WESTFALL TC, 1977, PHYSIOL REV, V57, P659; Zar JH, 1974, BIOSTATISTICAL ANAL	40	1	1	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0031-7012			PHARMACOLOGY	Pharmacology	SEP	1988	37	3					195	202		10.1159/000138463			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	P8422	WOS:A1988P842200007	2852373				2020-06-26	J	WONG, YH; DEMOLIOUMASON, CD; BARNARD, EA				WONG, YH; DEMOLIOUMASON, CD; BARNARD, EA			ADP-RIBOSYLATION WITH PERTUSSIS TOXIN MODULATES THE GTP-SENSITIVE OPIOID LIGAND-BINDING IN DIGITONIN-SOLUBLE EXTRACTS OF RAT-BRAIN MEMBRANES	JOURNAL OF NEUROCHEMISTRY			English	Article									MRC,MOLEC NEUROBIOL UNIT,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND							ABOOD ME, 1985, BIOCHEM BIOPH RES CO, V127, P477, DOI 10.1016/S0006-291X(85)80185-6; BLUME AJ, 1978, LIFE SCI, V22, P1843, DOI 10.1016/0024-3205(78)90602-1; BOWEN WD, 1982, CELL MOL NEUROBIOL, V2, P115, DOI 10.1007/BF00711077; BURNS DL, 1983, J BIOL CHEM, V258, P1435; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; CODINA J, 1983, P NATL ACAD SCI-BIOL, V80, P4276, DOI 10.1073/pnas.80.14.4276; COSTA T, 1983, LIFE SCI, V33, P219, DOI 10.1016/0024-3205(83)90482-4; DEMOLIOUMASON CD, 1984, FEBS LETT, V170, P378, DOI 10.1016/0014-5793(84)81348-4; DEMOLIOUMASON CD, 1986, J NEUROCHEM, V46, P1129, DOI 10.1111/j.1471-4159.1986.tb00627.x; DEMOLIOUMASON CD, 1986, J NEUROCHEM, V46, P1118, DOI 10.1111/j.1471-4159.1986.tb00626.x; DOUGLAS MG, 1976, P NATL ACAD SCI USA, V73, P1083, DOI 10.1073/pnas.73.4.1083; FALLOON J, 1986, FEBS LETT, V209, P352, DOI 10.1016/0014-5793(86)81141-3; GIERSCHIK P, 1986, J BIOL CHEM, V261, P8058; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HSIA JA, 1984, J BIOL CHEM, V259, P1086; KAMIKUBO K, 1987, LIFE SCI, V40, P1791, DOI 10.1016/0024-3205(87)90090-7; KATADA T, 1986, J BIOL CHEM, V261, P8182; KATADA T, 1984, J BIOL CHEM, V259, P3578; KLEE WA, 1985, MOL MECHANISMS TRANS, P117; KOSKI G, 1981, J BIOL CHEM, V256, P1536; KUNO T, 1983, BIOCHEM BIOPH RES CO, V115, P325, DOI 10.1016/0006-291X(83)91007-0; KUROSE H, 1983, J BIOL CHEM, V258, P4870; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN NE, 1981, MOL PHARMACOL, V20, P255; MANNING DR, 1984, J BIOL CHEM, V259, P749; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MURAYAMA T, 1984, J BIOL CHEM, V259, P761; NEER EJ, 1984, J BIOL CHEM, V259, P4222; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TSAI SC, 1984, J BIOL CHEM, V259, P5320; UI M, 1984, ADV EXP MED BIOL, V175, P1; UI M, 1985, P551; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WONG SKF, 1985, BIOCHEM J, V231, P39, DOI 10.1042/bj2310039; WONG SKF, 1985, BIOCHEM J, V232, P191, DOI 10.1042/bj2320191; WUSTER M, 1984, BIOCHEM BIOPH RES CO, V123, P1107, DOI 10.1016/S0006-291X(84)80247-8; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660	38	17	17	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	JUL	1988	51	1					114	121		10.1111/j.1471-4159.1988.tb04843.x			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	N9761	WOS:A1988N976100017	2837532				2020-06-26	J	HARRIS, NC; RYALL, RW				HARRIS, NC; RYALL, RW			OPIATES DISTINGUISH SPINAL EXCITATION FROM INHIBITION EVOKED BY NOXIOUS HEAT STIMULI IN THE RAT - RELEVANCE TO THEORIES OF ANALGESIA	BRITISH JOURNAL OF PHARMACOLOGY			English	Article									UNIV CAMBRIDGE,DEPT PHARMACOL,HILLS RD,CAMBRIDGE CB2 2QD,ENGLAND					Wellcome TrustWellcome Trust		BELCHER G, 1978, BRAIN RES, V145, P303, DOI 10.1016/0006-8993(78)90864-8; CALVILLO O, 1974, CAN J PHYSIOL PHARM, V52, P1207, DOI 10.1139/y74-158; CLARK SL, 1983, BRIT J PHARMACOL, V78, P307, DOI 10.1111/j.1476-5381.1983.tb09396.x; CLARK SL, 1983, BRIT J PHARMACOL, V79, P807, DOI 10.1111/j.1476-5381.1983.tb10019.x; DUGGAN AW, 1977, BRIT J PHARMACOL, V61, P65, DOI 10.1111/j.1476-5381.1977.tb09740.x; DUGGAN AW, 1987, BRAIN RES, V403, P345, DOI 10.1016/0006-8993(87)90073-4; GEBHART GF, 1984, J NEUROPHYSIOL, V51, P75; HARRIS N C, 1986, British Journal of Pharmacology, V89, p803P; HOKFELT T, 1976, NEUROSCIENCE, V1, P131, DOI 10.1016/0306-4522(76)90008-7; HOKFELT T, 1977, SUBSTANCE P, P117; IGGO A, 1974, ADV NEUROL, V4, P1; JESSEL TM, 1977, NATURE, V268, P548; KURAISHI Y, 1985, BRAIN RES, V325, P294, DOI 10.1016/0006-8993(85)90326-9; LEAH JD, 1985, NEUROSCIENCE, V16, P683, DOI 10.1016/0306-4522(85)90201-5; MAUBORGNE A, 1987, J NEUROCHEM, V48, P529, DOI 10.1111/j.1471-4159.1987.tb04125.x; MAYER ML, 1978, NEUROPHARMACOLOGY, V17, P533, DOI 10.1016/0028-3908(78)90061-8; MENETREY D, 1977, EXP BRAIN RES, V27, P15; PINI A, 1986, J PHYSIOL-LONDON, V378, pP42; RYALL RW, 1986, P INT UNION PHYSL SC, V16; Schmidt CF, 1933, J PHARMACOL EXP THER, V47, P411; SCHOUENBORG J, 1986, BRAIN RES, V379, P394, DOI 10.1016/0006-8993(86)90798-5; WALL PD, 1981, NEUROSCIENCE, V6, P2205, DOI 10.1016/0306-4522(81)90008-7; WALL PD, 1982, SUBSTANCE P NERVOUS, P249; WIESENFELDHALLIN Z, 1986, BRAIN RES, V372, P172, DOI 10.1016/0006-8993(86)91473-3; WOOLF CJ, 1982, NEUROSCI LETT, V29, P67, DOI 10.1016/0304-3940(82)90366-4; YAKSH TL, 1980, NATURE, V286, P155, DOI 10.1038/286155a0; YAKSH TL, 1986, SPINAL AFFERENT PROC, V8, P165	27	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0007-1188			BRIT J PHARMACOL	Br. J. Pharmacol.	MAY	1988	94	1					185	191		10.1111/j.1476-5381.1988.tb11514.x			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	N0864	WOS:A1988N086400023	3401636	Green Published			2020-06-26	J	ROQUEBERT, J; DELGOULET, C				ROQUEBERT, J; DELGOULET, C			CARDIOVASCULAR EFFECTS OF ETORPHINE IN RATS	JOURNAL OF AUTONOMIC PHARMACOLOGY			English	Article										ROQUEBERT, J (reprint author), UNIV BORDEAUX 11, UER PHARM, PHARMACODYNAM LAB, 3 PL VICTOIRE, F-33075 BORDEAUX, FRANCE.						BELLET M, 1980, BRIT J PHARMACOL, V71, P365, DOI 10.1111/j.1476-5381.1980.tb10949.x; BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; BOLME P, 1978, EUR J PHARMACOL, V48, P319, DOI 10.1016/0014-2999(78)90090-0; DASHWOOD MR, 1983, ARCH INT PHARMACOD T, V266, P77; FEUERSTEIN G, 1985, PEPTIDES, V6, P51, DOI 10.1016/0196-9781(85)90134-2; FUDER H, 1986, N-S ARCH PHARMACOL, V332, P148, DOI 10.1007/BF00511405; GAUTRET B, 1984, EUR J PHARMACOL, V102, P159, DOI 10.1016/0014-2999(84)90351-0; GAUTRET B, 1985, J CARDIOVASC PHARM, V7, P649, DOI 10.1097/00005344-198507000-00006; LAURENT S, 1983, EUR J PHARMACOL, V96, P165, DOI 10.1016/0014-2999(83)90547-2; MANARA L, 1982, LIFE SCI, V31, P1271, DOI 10.1016/0024-3205(82)90359-9; PETTY MA, 1982, EUR J PHARMACOL, V81, P449, DOI 10.1016/0014-2999(82)90110-8; RICHARDS ML, 1985, EUR J PHARMACOL, V114, P343, DOI 10.1016/0014-2999(85)90379-6; SAPRU HN, 1981, J PHARMACOL EXP THER, V217, P228; SHIPLEY RE, 1947, P SOC EXP BIOL MED, V64, P453; SUN FY, 1985, NEUROPEPTIDES, V5, P595, DOI 10.1016/0143-4179(85)90088-5; VOLLMER R R, 1980, Pharmacologist, V22, P273; WILLETTE RN, 1982, EUR J PHARMACOL, V78, P61, DOI 10.1016/0014-2999(82)90372-7; WILLETTE RN, 1982, J CARDIOVASC PHARM, V4, P1006, DOI 10.1097/00005344-198211000-00020	18	9	9	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0144-1795			J AUTON PHARMACOL	J. Auton. Pharmacol.	MAR	1988	8	1					39	43		10.1111/j.1474-8673.1988.tb00167.x			5	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	N0478	WOS:A1988N047800005	3392053				2020-06-26	J	WALKER, JM; BOWEN, WD; THOMPSON, LA; FRASCELLA, J; LEHMKUHLE, S; HUGHES, HC				WALKER, JM; BOWEN, WD; THOMPSON, LA; FRASCELLA, J; LEHMKUHLE, S; HUGHES, HC			DISTRIBUTION OF OPIATE RECEPTORS WITHIN VISUAL STRUCTURES OF THE CAT BRAIN	EXPERIMENTAL BRAIN RESEARCH			English	Article									BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912; DARTMOUTH COLL,DEPT PSYCHOL,HANOVER,NH 03755	WALKER, JM (reprint author), BROWN UNIV,DEPT PSYCHOL,PROVIDENCE,RI 02912, USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA07736]; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21745]		AKIL H, 1984, ANNU REV NEUROSCI, V7, P223, DOI 10.1146/annurev.ne.07.030184.001255; BERKLEY KJ, 1973, J NEUROPHYSIOL, V36, P940; BROOKES A, 1984, NEUROPHARMACOLOGY, V23, P207, DOI 10.1016/S0028-3908(84)80016-7; CASEY KL, 1966, J NEUROPHYSIOL, V29, P727; CHEVALIER G, 1984, EXP BRAIN RES, V53, P320; DUKA T, 1981, NEUROSCI LETT, V21, P119, DOI 10.1016/0304-3940(81)90368-2; GODFRAIN.J, 1972, BRAIN RES, V44, P503, DOI 10.1016/0006-8993(72)90316-2; GRAHAM J, 1977, J COMP NEUROL, V173, P629, DOI 10.1002/cne.901730403; GRAYBIEL AM, 1984, NEUROSCIENCE, V12, P191, DOI 10.1016/0306-4522(84)90147-7; GRAYBIEL AM, 1975, BRAIN RES, V96, P1, DOI 10.1016/0006-8993(75)90566-1; GRAYBIEL AM, 1981, MULTIPLE SENSORY COR, P285; GRILLY DM, 1980, PSYCHOPHARMACOLOGY, V70, P213, DOI 10.1007/BF00435317; GUBLER U, 1982, NATURE, V295, P206, DOI 10.1038/295206a0; HERKENHAM M, 1982, J NEUROSCI, V2, P1129; HERKENHAM M, 1980, P NATL ACAD SCI-BIOL, V77, P5532, DOI 10.1073/pnas.77.9.5532; HICKS TP, 1984, EXP BRAIN RES, V55, P359; HIKOSAKA O, 1983, J NEUROPHYSIOL, V49, P1230; HIKOSAKA O, 1983, J NEUROPHYSIOL, V49, P1254; HIKOSAKA O, 1983, J NEUROPHYSIOL, V49, P1285; HIKOSAKA O, 1983, J NEUROPHYSIOL, V49, P1268; HUGHES HC, 1980, J COMP NEUROL, V193, P937, DOI 10.1002/cne.901930408; HUIDOBRO F, 1978, BRIT J PHARMACOL, V64, P167, DOI 10.1111/j.1476-5381.1978.tb17286.x; IWAMOTO ET, 1981, J PHARMACOL EXP THER, V217, P451; JACOBS BL, 1979, AM SCI, V67, P396; KAKIDANI H, 1982, NATURE, V298, P245, DOI 10.1038/298245a0; KANASEKI T, 1974, J COMP NEUROL, V158, P319, DOI 10.1002/cne.901580307; KERR FWL, 1979, MECHANISMS PAIN ANAL, P113; KHACHATURIAN H, 1983, J COMP NEUROL, V220, P310, DOI 10.1002/cne.902200305; KHACHATURIAN H, 1982, PEPTIDES, V3, P941, DOI 10.1016/0196-9781(82)90063-8; KRUPA M, 1984, NEUROSCI LETT, V51, P13, DOI 10.1016/0304-3940(84)90255-6; KUHAR MJ, 1986, ANNU REV NEUROSCI, V9, P27; LATIES VG, 1986, ADV BEHAV PHARMACOL, V5, P21; LEANDER JD, 1983, J PHARMACOL EXP THER, V224, P89; LEWIS ME, 1983, J COMP NEUROL, V216, P339, DOI 10.1002/cne.902160310; LORD JAH, 1977, NATURE, V267, P494; MANSOUR A, 1987, J NEUROSCI, V7, P2445; MANSOUR A, 1986, BRAIN RES, V399, P69, DOI 10.1016/0006-8993(86)90601-3; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MASON R, 1981, EXP BRAIN RES, V43, P25; MASON R, 1978, EXP BRAIN RES, V31, P51; MCLEAN S, 1986, BRAIN RES, V378, P49, DOI 10.1016/0006-8993(86)90285-4; MINCIACCHI D, 1987, BRAIN RES, V410, P21, DOI 10.1016/S0006-8993(87)80016-1; MIZE R R, 1986, Investigative Ophthalmology and Visual Science, V27, P205; MUCHA RF, 1985, PSYCHOPHARMACOLOGY, V86, P274, DOI 10.1007/BF00432213; MUCHA RF, 1984, PSYCHOPHARMACOLOGY, V82, P241, DOI 10.1007/BF00427782; MUCKE L, 1982, EXP BRAIN RES, V46, P1; NAKANISHI S, 1979, NATURE, V278, P423, DOI 10.1038/278423a0; NIELSEN EB, 1983, PSYCHOPHARMACOLOGY, V80, P24, DOI 10.1007/BF00427488; NIMI K, 1973, J HIRNFORSCH, V14, P303; NODA M, 1982, NATURE, V295, P202, DOI 10.1038/295202a0; NORITA M, 1986, NEUROSCI LETT, V65, P104, DOI 10.1016/0304-3940(86)90128-X; OLSON CR, 1983, PROG BRAIN RES, V58, P239, DOI 10.1016/S0079-6123(08)60025-4; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; POGGIO GF, 1960, B JOHNS HOPKINS HOSP, V106, P266; RACZKOWSKI D, 1981, BRAIN RES, V221, P185, DOI 10.1016/0006-8993(81)91072-6; ROSENQUIST AC, 1985, [No title captured], V3, P81; ROTHENBERG S, 1979, PHARMACOL BIOCHEM BE, V11, P521, DOI 10.1016/0091-3057(79)90035-2; SPRAGG S. D. S., 1940, COMPAR PSYCHOL MONOGR, V15, P1; STERLING P, 1973, BRAIN RES, V54, P347, DOI 10.1016/0006-8993(73)90059-0; UPDYKE BV, 1977, J COMP NEUROL, V173, P81, DOI 10.1002/cne.901730106; WALKER JM, 1987, EUR J PHARMACOL, V134, P53, DOI 10.1016/0014-2999(87)90130-0; WEST KB, 1982, PSYCHOPHARMACOLOGY, V76, P320, DOI 10.1007/BF00449118; WILKISON DM, 1982, EXP NEUROL, V77, P519, DOI 10.1016/0014-4886(82)90225-4; WILLIAMS JT, 1982, NATURE, V299, P74, DOI 10.1038/299074a0; WISE SP, 1982, SCIENCE, V218, P387, DOI 10.1126/science.6289441; YAKSH TL, 1977, J PHARMACOL EXP THER, V202, P411; YORK DH, 1977, BRAIN RES, V130, P383, DOI 10.1016/0006-8993(77)90287-6	67	20	21	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0014-4819			EXP BRAIN RES	Exp. Brain Res.		1988	73	3					523	532		10.1007/BF00406610			10	Neurosciences	Neurosciences & Neurology	R5458	WOS:A1988R545800010	2852119				2020-06-26	J	STOJILKOVIC, SS; DUFAU, ML; CATT, KJ				STOJILKOVIC, SS; DUFAU, ML; CATT, KJ			RECEPTORS AND SECRETORY ACTIONS OF SIGMA-PHENCYCLIDINE AGONISTS IN ANTERIOR-PITUITARY-CELLS	ENDOCRINOLOGY			English	Article										STOJILKOVIC, SS (reprint author), NICHHD, ENDOCRINOL & REPROD RES BRANCH, 9000 ROCKVILLE PIKE, BLDG 10, ROOM 8C407, BETHESDA, MD 20892 USA.						ALBUQUERQUE EX, 1983, FED PROC, V42, P2584; ARONSTAM RS, 1980, MOL PHARMACOL, V18, P179; BARDO MT, 1982, J NEUROCHEM, V39, P1751, DOI 10.1111/j.1471-4159.1982.tb08015.x; BARTSCHAT DK, 1986, P NATL ACAD SCI USA, V83, P189, DOI 10.1073/pnas.83.1.189; BLANK MS, 1986, ENDOCRINOLOGY, V118, P2097, DOI 10.1210/endo-118-5-2097; BLAUSTEIN MP, 1983, P NATL ACAD SCI-BIOL, V80, P3855, DOI 10.1073/pnas.80.12.3855; BOGGAN WO, 1982, LIFE SCI, V30, P1581, DOI 10.1016/0024-3205(82)90247-8; BUNN SJ, 1985, NEUROSCI LETT, V55, P317, DOI 10.1016/0304-3940(85)90455-0; CACICEDO L, 1986, LIFE SCI, V38, P617, DOI 10.1016/0024-3205(86)90055-X; CAMPBELL RC, 1975, STATISTICS BIOL; CATT KJ, 1976, METHODS RECEPTOR RES, V1, P175; CHANG JP, 1986, J BIOL CHEM, V261, P9105; CHAO CC, 1986, LIFE SCI, V39, P527, DOI 10.1016/0024-3205(86)90509-6; CONTRERAS PC, 1986, J PHARMACOL EXP THER, V238, P1101; CONTRERAS PC, 1986, EUR J PHARMACOL, V121, P9, DOI 10.1016/0014-2999(86)90386-9; COX BM, 1982, LIFE SCI, V31, P1645, DOI 10.1016/0024-3205(82)90179-5; CREVELING CR, 1985, NEUROPEPTIDES, V5, P353, DOI 10.1016/0143-4179(85)90026-5; DAMICO GA, 1983, EUR J PHARMACOL, V88, P283, DOI 10.1016/0014-2999(83)90578-2; DELITALA G, 1984, OPIOID MODULATION EN; FAGG GE, 1986, TRENDS PHARMACOL SCI, V7, P357, DOI 10.1016/0165-6147(86)90386-X; GUNDLACH AL, 1985, EUR J PHARMACOL, V113, P465, DOI 10.1016/0014-2999(85)90100-1; HABERMANN E, 1979, EUR J BIOCHEM, V94, P355, DOI 10.1111/j.1432-1033.1979.tb12901.x; HAMPTON RY, 1982, LIFE SCI, V30, P2147, DOI 10.1016/0024-3205(82)90288-0; HERZ A, 1984, OPIOID MODULATION EN, P11; HYDE CL, 1982, ENDOCRINOLOGY, V111, P1421, DOI 10.1210/endo-111-4-1421; KALRA SP, 1984, OPIOID MODULATION EN, P171; KHAZAN N, 1985, NEUROPEPTIDES, V5, P339, DOI 10.1016/0143-4179(85)90022-8; MAAYANI S, 1980, LIFE SCI, V26, P2011, DOI 10.1016/0024-3205(80)90634-7; MARAGOS WF, 1986, EUR J PHARMACOL, V123, P173; MARIC D, 1982, IRCS MED SCI-BIOCHEM, V10, P533; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MASON WT, 1986, NEUROENDOCRINOLOGY, V43, P205, DOI 10.1159/000124529; MAY PB, 1979, HORM RES, V10, P57, DOI 10.1159/000178989; MENDELSOHN LG, 1984, BIOCHEM PHARMACOL, V33, P3529, DOI 10.1016/0006-2952(84)90133-3; MICKELSON MM, 1984, NEUROPEPTIDES, V5, P149, DOI 10.1016/0143-4179(84)90049-0; MORGAN RO, 1987, J BIOL CHEM, V262, P1166; MORLEY JE, 1984, OPIOID MODULATION EN; MULLINS LJ, 1979, AM J PHYSIOL, V236, pC103; Naor Z, 1986, Adv Prostaglandin Thromboxane Leukot Res, V16, P225; NAOR Z, 1980, ENDOCRINOLOGY, V107, P1144, DOI 10.1210/endo-107-4-1144; PANERAI AE, 1985, ENDOCRINOLOGY, V117, P1096, DOI 10.1210/endo-117-3-1096; PATERSON SJ, 1983, BRIT MED BULL, V39, P31, DOI 10.1093/oxfordjournals.bmb.a071787; PECHNICK R, 1985, J PHARMACOL EXP THER, V232, P170; PECHNICK R, 1985, J PHARMACOL EXP THER, V232, P163; PECHNICK RN, 1986, LIFE SCI, V38, P291, DOI 10.1016/0024-3205(86)90315-2; QUIRION R, 1981, P NATL ACAD SCI-BIOL, V78, P5881, DOI 10.1073/pnas.78.9.5881; QUIRION R, 1984, PEPTIDES, V5, P967, DOI 10.1016/0196-9781(84)90124-4; QUIRION R, 1983, LIFE SCI, V33, P227, DOI 10.1016/0024-3205(83)90484-8; RAFFERTY MF, 1985, FEBS LETT, V181, P318, DOI 10.1016/0014-5793(85)80284-2; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; SHANNON HE, 1983, J PHARMACOL EXP THER, V225, P144; SHEARMAN GT, 1982, EUR J PHARMACOL, V82, P167, DOI 10.1016/0014-2999(82)90506-4; SIKAR R, 1983, LIFE SCI S1, V33, P259; STOJILKOVIC SS, 1987, ENDOCRINOLOGY, V121, P384, DOI 10.1210/endo-121-1-384; SU TP, 1982, J PHARMACOL EXP THER, V223, P284; TAM SW, 1983, P NATL ACAD SCI-BIOL, V80, P6703, DOI 10.1073/pnas.80.21.6703; TAM SW, 1985, EUR J PHARMACOL, V109, P33, DOI 10.1016/0014-2999(85)90536-9; THOMSON AM, 1985, NATURE, V313, P479, DOI 10.1038/313479a0; TSAI MC, 1980, MOL PHARMACOL, V18, P159; VINCENT JP, 1983, FED PROC, V42, P2570; VINCENT JP, 1979, P NATL ACAD SCI USA, V76, P4678, DOI 10.1073/pnas.76.9.4678; WALLIS M, 1986, J ENDOCRINOL, V109, P313; WIESNER JB, 1985, ENDOCRINOLOGY, V116, P475, DOI 10.1210/endo-116-1-475; WIESNER JB, 1984, LIFE SCI, V34, P1463, DOI 10.1016/0024-3205(84)90061-4; YUN W, 1986, P NATL ACAD SCI USA, V83, P2724, DOI 10.1073/pnas.83.8.2724; ZUKIN RS, 1981, MOL PHARMACOL, V20, P246; ZUKIN SR, 1979, P NATL ACAD SCI USA, V76, P5372, DOI 10.1073/pnas.76.10.5372; ZUKIN SR, 1983, BRAIN RES, V258, P277, DOI 10.1016/0006-8993(83)91151-4	68	19	19	0	0	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0013-7227	1945-7170		ENDOCRINOLOGY	Endocrinology	DEC	1987	121	6					2044	2054		10.1210/endo-121-6-2044			11	Endocrinology & Metabolism	Endocrinology & Metabolism	L1362	WOS:A1987L136200018	2824179				2020-06-26	J	BOLGER, GT; MARCUS, KA; THIBOU, R; SKOLNICK, P; WEISSMAN, BA				BOLGER, GT; MARCUS, KA; THIBOU, R; SKOLNICK, P; WEISSMAN, BA			ENHANCEMENT OF [H-3] DAGO1 BINDING TO RAT-BRAIN BY LOW CONCENTRATIONS OF MONO-VALENT CATIONS	CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY			English	Article									NIADDK,BIOORGAN CHEM LAB,BETHESDA,MD 20892; ISRAEL INST BIOL RES,DEPT PHARMACOL,IL-70450 NESS ZIONA,ISRAEL							BIRDSALL NJM, 1978, MOL PHARMACOL, V14, P723; BOLGER GT, 1986, BR J PHARM, V88, P851; BOURHIM N, 1985, BIOCHEM BIOPH RES CO, V129, P328, DOI 10.1016/0006-291X(85)90155-X; BOWEN WD, 1982, CELL MOL NEUROBIOL, V2, P115, DOI 10.1007/BF00711077; BOWEN WD, 1981, P NATL ACAD SCI-BIOL, V78, P4818, DOI 10.1073/pnas.78.8.4818; CHAUPHAM TT, 1978, LIFE SCI, V23, P1293, DOI 10.1016/0024-3205(78)90508-8; CHILDERS SR, 1980, J NEUROCHEM, V34, P583, DOI 10.1111/j.1471-4159.1980.tb11184.x; COHEN-ARMON M, 1985, P NATL ACAD SCI USA, V82, P3524, DOI 10.1073/pnas.82.10.3524; CREESE I, 1975, LIFE SCI, V16, P1837, DOI 10.1016/0024-3205(75)90287-8; DALY JW, 1982, J TOXICOL-TOXIN REV, V1, P33, DOI 10.3109/15569548209016467; DEMOLIOUMASON CD, 1986, J NEUROCHEM, V46, P1118, DOI 10.1111/j.1471-4159.1986.tb00626.x; EISEMANN G, 1976, NEUROSCI RES PROG B, V14, P165; FRANCES B, 1985, EUR J PHARMACOL, V117, P223, DOI 10.1016/0014-2999(85)90607-7; GILLAN MGC, 1980, BRIT J PHARMACOL, V70, P481, DOI 10.1111/j.1476-5381.1980.tb08727.x; GILLAN MGC, 1982, BRIT J PHARMACOL, V77, P461, DOI 10.1111/j.1476-5381.1982.tb09319.x; GOLDSTEIN A, 1984, TRENDS PHARMACOL SCI, V5, P503, DOI 10.1016/0165-6147(84)90527-3; GOODMAN RR, 1980, P NATL ACAD SCI-BIOL, V77, P6239, DOI 10.1073/pnas.77.10.6239; HANDA BK, 1981, EUR J PHARMACOL, V70, P531, DOI 10.1016/0014-2999(81)90364-2; HITZEMANN R, 1985, EUR J PHARMACOL, V108, P171, DOI 10.1016/0014-2999(85)90722-8; KELLY PD, 1982, NEUROPEPTIDES, V2, P319, DOI 10.1016/0143-4179(82)90069-5; KILLIAN AK, 1981, LIFE SCI, V28, P1239, DOI 10.1016/0024-3205(81)90449-5; KOSTERLITZ HW, 1981, BRIT J PHARMACOL, V73, pP299; KUROWSKI M, 1982, BRAIN RES, V249, P345, DOI 10.1016/0006-8993(82)90068-3; LESLIE FM, 1980, J PHARMACOL EXP THER, V214, P395; LING GSF, 1984, SCIENCE, V226, P462, DOI 10.1126/science.6541807; LOEW GH, 1983, LIFE SCI, V33, P163; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTZ RA, 1984, BIOCHEM BIOPH RES CO, V122, P265, DOI 10.1016/0006-291X(84)90469-8; MARTIN WR, 1967, PHARMACOL REV, V19, P463; MEUNIER JC, 1983, MOL PHARMACOL, V24, P23; MILLER GL, 1959, ANAL CHEM, V31, P964, DOI 10.1021/ac60149a611; MORRIS CH, 1985, TRENDS PHARM SCI, V6, P315; PASTERNAK GW, 1982, LIFE SCI, V31, P1303, DOI 10.1016/0024-3205(82)90367-8; PERRY DC, 1982, MOL PHARMACOL, V21, P272; PERT CB, 1974, MOL PHARMACOL, V10, P868; PFEIFFER A, 1982, J NEUROSCI, V2, P912; PFEIFFER A, 1982, MOL PHARMACOL, V21, P266; QUIRION R, 1982, CELL MOL NEUROBIOL, V2, P333, DOI 10.1007/BF00710853; REITH MEA, 1984, J NEUROSCI METH, V12, P151, DOI 10.1016/0165-0270(84)90014-1; ROTH BL, 1982, BRAIN RES, V250, P101, DOI 10.1016/0006-8993(82)90956-8; ROTH BL, 1984, J NEUROCHEM, V42, P1677, DOI 10.1111/j.1471-4159.1984.tb12759.x; SADEE W, 1982, J NEUROCHEM, V39, P659, DOI 10.1111/j.1471-4159.1982.tb07943.x; SIMON EJ, 1978, FED PROC, V37, P141; SIMON EJ, 1975, J PHARMACOL EXP THER, V192, P531; SPAIN JW, 1984, NEUROPEPTIDES, V5, P145, DOI 10.1016/0143-4179(84)90048-9; WOLOZIN BL, 1981, P NATL ACAD SCI-BIOL, V78, P6181, DOI 10.1073/pnas.78.10.6181; WOOD PL, 1983, NEUROSCI LETT, V37, P291, DOI 10.1016/0304-3940(83)90446-9; YEAGLE PL, 1986, BIOPHYS J, V49; ZAJAC JM, 1985, J NEUROCHEM, V44, P1605, DOI 10.1111/j.1471-4159.1985.tb08802.x	50	4	4	0	0	NATL RESEARCH COUNCIL CANADA	OTTAWA	RESEARCH JOURNALS, MONTREAL RD, OTTAWA ON K1A 0R6, CANADA	0008-4212			CAN J PHYSIOL PHARM	Can. J. Physiol. Pharmacol.	NOV	1987	65	11					2338	2345		10.1139/y87-370			8	Pharmacology & Pharmacy; Physiology	Pharmacology & Pharmacy; Physiology	L7398	WOS:A1987L739800030	2835135				2020-06-26	J	MAURER, PJ; RAPOPORT, H				MAURER, PJ; RAPOPORT, H			NITROGEN-BRIDGED CONFORMATIONALLY CONSTRAINED ETORPHINE ANALOGS - SYNTHESIS AND BIOLOGICAL EVALUATION	JOURNAL OF MEDICINAL CHEMISTRY			English	Article									UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720							BELLEAU B, 1974, J MED CHEM, V17, P907, DOI 10.1021/jm00254a029; BELLEAU B, 1974, J MED CHEM, V17, P908, DOI 10.1021/jm00254a030; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3267, DOI 10.1021/ja00989a030; Dixon W.J., 1965, AM STAT ASS J, P967; FEINBERG AP, 1976, P NATL ACAD SCI USA, V73, P4215, DOI 10.1073/pnas.73.11.4215; FULMOR W, 1967, J AM CHEM SOC, V89, P3322, DOI 10.1021/ja00989a601; HORI M, 1983, CHEM PHARM BULL, V31, P2520; JANSSEN PAJ, 1963, ARZNEIMITTEL-FORSCH, V13, P502; KOBYLECKI RJ, 1982, J MED CHEM, V25, P116, DOI 10.1021/jm00344a005; KOBYLECKI RJ, 1982, J MED CHEM, V25, P1278, DOI 10.1021/jm00353a002; KOLB VM, 1978, J PHARM SCI, V67, P999, DOI 10.1002/jps.2600670735; LOEW GH, 1978, J MED CHEM, V21, P101, DOI 10.1021/jm00199a018; MAGNUS P, 1982, ORGANOMETALLICS, V1, P553, DOI 10.1021/om00063a027; MANCUSO AJ, 1981, SYNTHESIS-STUTTGART, P165; ORERE DM, 1977, J CHEM SOC CHEM COMM, P280, DOI 10.1039/c39770000280; PETERSON DJ, 1968, J ORG CHEM, V33, P780, DOI 10.1021/jo01266a061; RUBINSTEIN R, 1974, TETRAHEDRON, V30, P1201, DOI 10.1016/S0040-4020(01)97290-4; SCHWAB LS, 1980, J MED CHEM, V23, P698, DOI 10.1021/jm00180a028; WHITMORE FC, 1946, J AM CHEM SOC, V68, P481, DOI 10.1021/ja01207a036	19	11	11	0	0	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036	0022-2623			J MED CHEM	J. Med. Chem.	NOV	1987	30	11					2016	2026		10.1021/jm00394a016			11	Chemistry, Medicinal	Pharmacology & Pharmacy	K6551	WOS:A1987K655100016	3669010				2020-06-26	J	BENTLEY, KW				BENTLEY, KW			A BRUSH WITH ETORPHINE	VETERINARY RECORD			English	Letter																LEWISJONES, 1987, VET REC, V121	1	3	3	0	0	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.	OCT 17	1987	121	16					384	384		10.1136/vr.121.16.384-a			1	Veterinary Sciences	Veterinary Sciences	K5940	WOS:A1987K594000017	3424601				2020-06-26	J	KREEGER, TJ; PLOTKA, ED; SEAL, US				KREEGER, TJ; PLOTKA, ED; SEAL, US			IMMOBILIZATION OF WHITE-TAILED DEER BY ETORPHINE AND XYLAZINE AND ITS ANTAGONISM BY NALMEFENE AND YOHIMBINE	JOURNAL OF WILDLIFE DISEASES			English	Article									MARSHFIELD MED FDN INC,MARSHFIELD,WI 54449; VET ADM MED CTR,RES SERV,MINNEAPOLIS,MN 55417	KREEGER, TJ (reprint author), UNIV MINNESOTA,DEPT FISHERIES & WILDLIFE,ST PAUL,MN 55108, USA.						AITKENHEAD A R, 1984, Anesthesiology (Hagerstown), V61, pA381, DOI 10.1097/00000542-198409001-00381; DIXON R, 1986, CLIN PHARMACOL THER, V39, P49, DOI 10.1038/clpt.1986.9; FISHMAN J, 1973, J PHARMACOL EXP THER, V187, P575; Fowler M. E., 1978, ZOO WILD ANIMAL MED; GAL TJ, 1985, ANESTHESIA, V63, pA508; HAIGH JC, 1982, CHEM IMMOBILIZATION, P51; HALL LW, 1983, VET ANESTHESIA; HSU WH, 1984, J AM VET MED ASSOC, V185, P1301; JESSUP DA, 1983, J AM VET MED ASSOC, V183, P1339; KREEGER TJ, 1986, J WILDLIFE DIS, V22, P600, DOI 10.7589/0090-3558-22.4.600; MECH LD, 1985, J WILDLIFE DIS, V21, P405, DOI 10.7589/0090-3558-21.4.405; NGAI SH, 1976, ANESTHESIOLOGY, V44, P398, DOI 10.1097/00000542-197605000-00008; PRESNELL K R, 1973, Journal of Wildlife Diseases, V9, P336; SPRAKER TR, 1982, CHEM IMMOBILISATION, P87; WOOLF A, 1970, J AM VET MED ASSOC, V157, P636	15	9	9	0	2	WILDLIFE DISEASE ASSN, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897	0090-3558			J WILDLIFE DIS	J. Wildl. Dis.	OCT	1987	23	4					619	624		10.7589/0090-3558-23.4.619			6	Veterinary Sciences	Veterinary Sciences	K8530	WOS:A1987K853000015	3682088				2020-06-26	J	PESCE, G; LANG, MA; RUSSELL, JT; RODBARD, D; GAINER, H				PESCE, G; LANG, MA; RUSSELL, JT; RODBARD, D; GAINER, H			CHARACTERIZATION OF KAPPA-OPIOID RECEPTORS IN NEUROSECRETOSOMES FROM BOVINE POSTERIOR PITUITARY	JOURNAL OF NEUROCHEMISTRY			English	Article									NICHHD,THEORET & PHYS BIOL LAB,BETHESDA,MD 20892; NICHHD,NEUROCHEM & NEUROIMMUNOL LAB,BETHESDA,MD 20892							BICKNELL RJ, 1982, NATURE, V298, P161, DOI 10.1038/298161a0; BICKNELL RJ, 1985, NEUROENDOCRINOLOGY, V41, P142, DOI 10.1159/000124168; BINDLER E, 1967, J CELL BIOL, V34, P185, DOI 10.1083/jcb.34.1.185; BLOOM F, 1977, LIFE SCI, V20, P43, DOI 10.1016/0024-3205(77)90126-6; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BUNN SJ, 1985, NEUROSCI LETT, V55, P317, DOI 10.1016/0304-3940(85)90455-0; CARTER DA, 1984, NEUROENDOCRINOL LETT, V6, P95; CASTANAS E, 1985, J NEUROCHEM, V45, P677, DOI 10.1111/j.1471-4159.1985.tb04046.x; CASTANAS E, 1985, J NEUROCHEM, V45, P688, DOI 10.1111/j.1471-4159.1985.tb04047.x; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CLARKE G, 1979, NATURE, V282, P746, DOI 10.1038/282746a0; CORBETT AD, 1982, NATURE, V299, P79, DOI 10.1038/299079a0; DELEAN A, 1978, AM J PHYSL, V235, pE77; GERSTBERGER R, 1986, NEUROENDOCRINOLOGY, V42, P376, DOI 10.1159/000124475; GIRAUD P, 1983, J NEUROCHEM, V41, P154, DOI 10.1111/j.1471-4159.1983.tb11827.x; GOLDSTEIN A, 1980, P NATL ACAD SCI-BIOL, V77, P6207, DOI 10.1073/pnas.77.10.6207; GOLDSTEIN A, 1984, TRENDS PHARMACOL SCI, V5, P503, DOI 10.1016/0165-6147(84)90527-3; HERKENHAM M, 1985, 15TH ANN M SOC NEUR, V11, P582; HOLLT V, 1980, NEUROSCI LETT, V18, P149, DOI 10.1016/0304-3940(80)90318-3; ITO S, 1981, LIFE SCI, V29, P1457, DOI 10.1016/0024-3205(81)90010-2; IVERSEN LL, 1980, NATURE, V284, P350, DOI 10.1038/284350a0; JAMES IF, 1982, LIFE SCI, V31, P1331, DOI 10.1016/0024-3205(82)90374-5; KHACHATURIAN H, 1985, TRENDS NEUROSCI, V8, P111, DOI 10.1016/0166-2236(85)90048-7; KNEPEL W, 1983, J PHYSIOL-LONDON, V341, P507, DOI 10.1113/jphysiol.1983.sp014820; KUMAR MSA, 1979, LIFE SCI, V25, P1687, DOI 10.1016/0024-3205(79)90410-7; LIGHTMAN SL, 1982, J NEUROSCI, V2, P78; LIGHTMAN SL, 1983, NATURE, V305, P235, DOI 10.1038/305235a0; LUTZ RA, 1984, BIOCHEM BIOPH RES CO, V122, P265, DOI 10.1016/0006-291X(84)90469-8; LUTZBUCHER B, 1980, EUR J PHARMACOL, V66, P375, DOI 10.1016/0014-2999(80)90470-7; MARTIN R, 1981, NATURE, V289, P502, DOI 10.1038/289502a0; MARTIN R, 1985, S PEPTIDES RECEPTORS, V6, P182; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAO K, 1981, REGUL PEPTIDES, V2, P201, DOI 10.1016/0167-0115(81)90014-8; NORDMANN JJ, 1986, EXP BRAIN RES, V61, P560; PATERSON SJ, 1983, BRIT MED BULL, V39, P31, DOI 10.1093/oxfordjournals.bmb.a071787; ROSSIER J, 1980, FED PROC, V39, P2555; ROSSIER J, 1979, NATURE, V277, P653, DOI 10.1038/277653a0; ROSSIER J, 1977, P NATL ACAD SCI USA, V74, P5162, DOI 10.1073/pnas.74.11.5162; SIMANTOV R, 1977, BRAIN RES, V124, P178, DOI 10.1016/0006-8993(77)90877-0; VANLEEUWEN FW, 1983, NEUROSCIENCE, V8, P229, DOI 10.1016/0306-4522(83)90062-3; WATSON SJ, 1981, P NATL ACAD SCI-BIOL, V78, P1260, DOI 10.1073/pnas.78.2.1260; WEBER E, 1982, NATURE, V299, P77, DOI 10.1038/299077a0; WHITNALL MH, 1983, SCIENCE, V222, P1137, DOI 10.1126/science.6648526; WOOD PL, 1982, NEUROPHARMACOLOGY, V21, P487, DOI 10.1016/0028-3908(82)90038-7; ZAMIR N, 1984, J NEUROSCI, V4, P1248; ZEIN MA, 1984, NEUROENDOCRINOLOGY, V39, P392	46	19	19	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	AUG	1987	49	2					421	427		10.1111/j.1471-4159.1987.tb02882.x			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	J1698	WOS:A1987J169800013	3037028				2020-06-26	J	STOJILKOVIC, SS; DUFAU, ML; CATT, KJ				STOJILKOVIC, SS; DUFAU, ML; CATT, KJ			OPIATE RECEPTOR SUBTYPES IN THE RAT HYPOTHALAMUS AND NEUROINTERMEDIATE LOBE	ENDOCRINOLOGY			English	Article										STOJILKOVIC, SS (reprint author), NICHHD, ENDOCRINOL & REPROD RES BRANCH, 9000 ROCKVILLE PIKE, BLDG 10, ROOM 8C407, BETHESDA, MD 20892 USA.						ABOUSAMRA AB, 1984, ENDOCRINOLOGY, V115, P1471; ARONSTAM RS, 1980, MOL PHARMACOL, V18, P179; BARDO MT, 1982, J NEUROCHEM, V39, P1751, DOI 10.1111/j.1471-4159.1982.tb08015.x; BHANOT R, 1983, ENDOCRINOLOGY, V112, P399, DOI 10.1210/endo-112-1-399; BICKNELL RJ, 1982, NATURE, V298, P161, DOI 10.1038/298161a0; BLANK MS, 1986, ENDOCRINOLOGY, V118, P2097, DOI 10.1210/endo-118-5-2097; BUNN SJ, 1985, NEUROSCI LETT, V55, P317, DOI 10.1016/0304-3940(85)90455-0; CAMPBELL RC, 1975, STATISTICS BIOL; CARTER DA, 1984, NEUROENDOCRINOL LETT, V6, P98; CATT KJ, 1976, METHODS RECEPTOR RES, V1, P175; CHANG KJ, 1981, P NATL ACAD SCI-BIOL, V78, P4141, DOI 10.1073/pnas.78.7.4141; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CICERO TJ, 1983, LIFE SCI, V33, P1231, DOI 10.1016/0024-3205(83)90003-6; CLARKE G, 1979, NATURE, V282, P746, DOI 10.1038/282746a0; CONE RI, 1983, J NEUROSCI, V3, P2146; CORBETT A, 1982, NATURE, V299, P7938; CREVELING CR, 1985, NEUROPEPTIDES, V5, P353, DOI 10.1016/0143-4179(85)90026-5; CUPO A, 1984, NEUROPEPTIDES, V4, P375, DOI 10.1016/0143-4179(84)90113-6; DIEZ JA, 1982, BIOCHEM BIOPH RES CO, V108, P1313, DOI 10.1016/0006-291X(82)92143-X; FALKE N, 1985, NEUROSCI LETT, V61, P317; FEUERSTEIN G, 1984, EUR J PHARMACOL, V100, P245, DOI 10.1016/0014-2999(84)90232-2; FEUERSTEIN G, 1984, CLIN EXP HYPERTENS A, V6, P1973, DOI 10.3109/10641968409046111; GARZON J, 1983, LIFE SCI, V33, P291, DOI 10.1016/0024-3205(83)90500-3; GERSTBERGER R, 1986, NEUROENDOCRINOLOGY, V42, P376, DOI 10.1159/000124475; GILLAN MGC, 1985, J NEUROCHEM, V45, P1034, DOI 10.1111/j.1471-4159.1985.tb05520.x; HAHN EF, 1979, BIOCHEM BIOPH RES CO, V90, P819, DOI 10.1016/0006-291X(79)91901-6; HAMPTON RY, 1982, LIFE SCI, V30, P2147, DOI 10.1016/0024-3205(82)90288-0; HARTMAN RD, 1986, ENDOCRINOLOGY, V119, P1; HERZ A, 1984, OPIOID MODULATION EN, P11; IVERSEN LL, 1980, NATURE, V284, P350, DOI 10.1038/284350a0; KNEPEL W, 1983, LIFE SCI, V33, P499, DOI 10.1016/0024-3205(83)90550-7; LEANDER JD, 1983, EUR J PHARMACOL, V87, P481, DOI 10.1016/0014-2999(83)90089-4; LIGHTMAN SL, 1983, NATURE, V305, P235, DOI 10.1038/305235a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARIC D, 1982, IRCS MED SCI, V10, P535; MARTIN R, 1983, LIFE SCI, V33, P69, DOI 10.1016/0024-3205(83)90446-0; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MILLINGTON WR, 1985, NEUROPEPTIDES, V6, P365, DOI 10.1016/0143-4179(85)90009-5; MORRIS B, 1983, LIFE SCI, V33, P511, DOI 10.1016/0024-3205(83)90553-2; NORDMANN JJ, 1986, EXP BRAIN RES, V61, P560; OKA T, 1983, LIFE SCI, V33, P311, DOI 10.1016/0024-3205(83)90505-2; PATERSON SJ, 1983, BRIT MED BULL, V39, P31, DOI 10.1093/oxfordjournals.bmb.a071787; PECHNIK R N, 1985, Life Sciences, V38, P291; PETRAGLIA F, 1982, ENDOCRINOLOGY, V111, P1224, DOI 10.1210/endo-111-4-1224; QUIRION R, 1983, LIFE SCI, V33, P183, DOI 10.1016/0024-3205(83)90473-3; QUIRION R, 1981, P NATL ACAD SCI-BIOL, V78, P5881, DOI 10.1073/pnas.78.9.5881; QUIRION R, 1984, PEPTIDES, V5, P967, DOI 10.1016/0196-9781(84)90124-4; QUIRION R, 1983, LIFE SCI, V33, P227, DOI 10.1016/0024-3205(83)90484-8; ROSSIER J, 1979, NATURE, V277, P653, DOI 10.1038/277653a0; SEIZINGER BR, 1984, ENDOCRINOLOGY, V115, P662, DOI 10.1210/endo-115-2-662; SIMANTOV R, 1977, BRAIN RES, V124, P178, DOI 10.1016/0006-8993(77)90877-0; SPAIN JW, 1983, LIFE SCI, V33, P235, DOI 10.1016/0024-3205(83)90486-1; SPAMPINATO S, 1986, LIFE SCI, V38, P403, DOI 10.1016/0024-3205(86)90062-7; TAM SW, 1985, EUR J PHARMACOL, V109, P33, DOI 10.1016/0014-2999(85)90536-9; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VIGNON J, 1983, BRAIN RES, V280, P194, DOI 10.1016/0006-8993(83)91193-9; VINCENT JP, 1983, FED PROC, V42, P2570; WEBER E, 1978, P NATL ACAD SCI USA, V75, P6134, DOI 10.1073/pnas.75.12.6134; WILKINSON M, 1982, ENDOCRINOLOGY, V110, P1046, DOI 10.1210/endo-110-3-1046; YOSHIKAWA K, 1983, ENDOCRINOLOGY, V113, P1218, DOI 10.1210/endo-113-4-1218; ZAKARIAN S, 1982, BIOCHEM J, V202, P561, DOI 10.1042/bj2020561; ZAKARIAN S, 1979, P NATL ACAD SCI USA, V76, P5972, DOI 10.1073/pnas.76.11.5972; ZAMIR N, 1985, ENDOCRINOLOGY, V117, P1687, DOI 10.1210/endo-117-4-1687; ZUKIN SR, 1979, P NATL ACAD SCI USA, V76, P5372, DOI 10.1073/pnas.76.10.5372	64	38	39	0	0	ENDOCRINE SOC	BETHESDA	4350 EAST WEST HIGHWAY SUITE 500, BETHESDA, MD 20814-4110	0013-7227			ENDOCRINOLOGY	Endocrinology	JUL	1987	121	1					384	394		10.1210/endo-121-1-384			11	Endocrinology & Metabolism	Endocrinology & Metabolism	H8812	WOS:A1987H881200054	3036471				2020-06-26	J	PLOTKA, ED; SEAL, US; EAGLE, TC; ASA, CS; TESTER, JR; SINIFF, DB				PLOTKA, ED; SEAL, US; EAGLE, TC; ASA, CS; TESTER, JR; SINIFF, DB			RAPID REVERSIBLE IMMOBILIZATION OF FERAL STALLIONS USING ETORPHINE HYDROCHLORIDE, XYLAZINE HYDROCHLORIDE AND ATROPINE SULFATE	JOURNAL OF WILDLIFE DISEASES			English	Article									VET ADM MED CTR,RES SERV,MINNEAPOLIS,MN 55417; UNIV MINNESOTA,DEPT BIOCHEM,ST PAUL,MN 55108; UNIV MINNESOTA,DEPT ECOL,ST PAUL,MN 55108; UNIV MINNESOTA,DEPT FISHERIES & WILDLIFE,ST PAUL,MN 55108; UNIV MINNESOTA,DEPT ECOL & BEHAV BIOL,MINNEAPOLIS,MN 55455; POPULAT COUNCIL,NEW YORK,NY 10021; NEW YORK ZOOL SOC,BRONX,NY 10460	PLOTKA, ED (reprint author), MARSHFIELD MED RES FDN,MARSHFIELD,WI 54449, USA.						ALFORD BT, 1974, J AM VET MED ASSOC, V164, P702; BENSON GJ, 1979, AM J VET RES, V40, P1411; BERGER J, 1983, J WILDLIFE DIS, V19, P265, DOI 10.7589/0090-3558-19.3.265; BLAKE JG, 1981, J MAMMAL, V62, P58, DOI 10.2307/1380477; BORCHARD RE, 1980, EVALUATION CHEM REST; BUTERA TS, 1978, VET MED SM ANIM CLIN, V73, P490; CHAPMAN D, 1973, VET REC, V93, P113; COX JE, 1973, VET REC, V93, P354, DOI 10.1136/vr.93.13.354; DANIEL M, 1972, VET REC, V90, P336, DOI 10.1136/vr.90.12.336; Ensminger M. E., 1969, HORSES HORSEMANSHIP; FUENTES VO, 1978, VET REC, V102, P106, DOI 10.1136/vr.102.5.106; GOLDBERG MR, 1983, PHARMACOL REV, V35, P143; HAIGH JC, 1978, P AM ASS ZOO VET, P21; HILLIDGE CJ, 1974, VET REC, V94, P476; HSU WH, 1984, J AM VET MED ASSOC, V185, P1301; HSU WH, 1985, J AM VET MED ASSOC, V186, P320; JACOBSON ER, 1985, J AM VET MED ASSOC, V187, P1195; JESSUP DA, 1985, J AM VET MED ASSOC, V187, P1253; JESSUP DA, 1983, J AM VET MED ASSOC, V183, P1339; KERR DD, 1972, AM J VET RES, V33, P525; KERR DD, 1972, AM J VET RES, V33, P777; MECH LD, 1985, J WILDLIFE DIS, V21, P405, DOI 10.7589/0090-3558-21.4.405; MOORE DE, 1979, IMMOBILIZATION REPOR; MUIR WW, 1979, AM J VET RES, V40, P1417; OSTLE B, 1969, STATISTICS RES; RENECKER LA, 1985, J AM VET MED ASSOC, V187, P1199; SCHLARMA.B, 1973, AM J VET RES, V34, P411; SEAL US, 1985, J WILDLIFE DIS, V21, P411, DOI 10.7589/0090-3558-21.4.411; SEAL US, 1985, J WILDLIFE DIS, V21, P48, DOI 10.7589/0090-3558-21.1.48; SEAL US, 1977, J ZOO ANIM MED, V8, P7; Snedecor G.W., 1967, STATISTICAL METHODS; ZINN RS, 1970, J AM VET MED ASSOC, V157, P1495	32	12	12	0	4	WILDLIFE DISEASE ASSN, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897	0090-3558			J WILDLIFE DIS	J. Wildl. Dis.	JUL	1987	23	3					471	478		10.7589/0090-3558-23.3.471			8	Veterinary Sciences	Veterinary Sciences	J3415	WOS:A1987J341500020	3625909				2020-06-26	J	STEFANO, GB; BRAHAM, E; FINN, P; AIELLO, E; LEUNG, MK				STEFANO, GB; BRAHAM, E; FINN, P; AIELLO, E; LEUNG, MK			AGING ALTERATIONS IN THE MODULATION OF CENTRAL DOPAMINERGIC CILIOINHIBITION BY ETORPHINE IN THE MARINE MUSSEL, MYTILUS-EDULIS - DECREASE IN THE INHIBITION OF PRESYNAPTIC DOPAMINE RELEASE	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article									SUNY COLL OLD WESTBURY,BIOL SCI PROGRAM,OLD WESTBURY,NY 11568; FORDHAM UNIV,DEPT BIOL SCI,BRONX,NY 10458; SUNY COLL OLD WESTBURY,CHEM PROGRAM,OLD WESTBURY,NY 11568	STEFANO, GB (reprint author), SUNY COLL OLD WESTBURY,MULTIDISCIPLINARY CTR STUDY AGING,OLD WESTBURY,NY 11568, USA.			Stefano, George/0000-0002-8146-0740	PHS HHSUnited States Public Health Service [8180]; ADAMHA HHS [ADAMHA-MARC 17138]		AIELLO E, 1965, BIOL BULL-US, V129, P431, DOI 10.2307/1539722; AIELLO E, 1986, CELL MOL NEUROBIOL, V6, P17, DOI 10.1007/BF00742972; BIANCHI CP, 1986, COMP OPIOID RELATED, V2, P59; CATAPANE EJ, 1978, J EXP BIOL, V74, P101; CHAPMAN A, 1984, CELL MOL NEUROBIOL, V4, P143, DOI 10.1007/BF00711001; CODD EE, 1980, ENDOGENOUS EXOGENOUS, P63; FLANAGAN T, 1986, COMP OPIOID RELATED, V1, P165; GOSSELIN RE, 1961, J CELL COMP PHYSL, V58, P18; KREAM RM, 1980, J BIOL CHEM, V225, P9218; LEUNG MK, 1987, PROG NEUROBIOL, V28, P131, DOI 10.1016/0301-0082(87)90009-8; LEUNG MK, 1984, P NATL ACAD SCI-BIOL, V81, P955, DOI 10.1073/pnas.81.3.955; MAKMAN HH, 1984, INVERTEBRATE MODELS, P165; MALANGA CJ, 1972, COMP BIOCHEM PHYSIOL, V43, P825, DOI 10.1016/0300-9629(72)90153-3; MARTIN R, 1983, 12TH C EUR END SHEFF; PAPARO A, 1970, Comparative and General Pharmacology, V1, P241, DOI 10.1016/0010-4035(70)90059-5; STEFANO GB, 1976, SCIENCE, V194, P539, DOI 10.1126/science.973139; STEFANO GB, 1982, J PHARMACOL EXP THER, V222, P759; STEFANO GB, 1984, BRAIN RES, V298, P362, DOI 10.1016/0006-8993(84)91438-0; STEFANO GB, 1981, BRAIN RES, V225, P107, DOI 10.1016/0006-8993(81)90321-8; STEFANO GB, 1981, SCIENCE, V213, P928, DOI 10.1126/science.6266017; STEFANO GB, 1982, CELL MOL NEUROBIOL, V2, P167, DOI 10.1007/BF00711145; STEFANO GB, 1982, COMP BIOCHEM PHYS C, V72, P349, DOI 10.1016/0306-4492(82)90103-4; STEFANO GB, 1975, BIOL BULL-US, V148, P141, DOI 10.2307/1540655; STEFANO GB, 1981, CELL MOL NEUROBIOL, V4, P343; STEFANO GB, 1980, BRAIN RES, V181, P445; STEFANO GB, 1986, COMP OPIOID RELATED, V2, P199; STEFANO GB, 1986, COMP OPIOID RELATED, V2, P271	27	1	1	0	0	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013	0272-4340			CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	JUN	1987	7	2					209	219		10.1007/BF00711555			11	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	K0077	WOS:A1987K007700005	3652116				2020-06-26	J	ROBERTSON, SA				ROBERTSON, SA			METABOLIC AND HORMONAL RESPONSES TO NEUROLEPTANALGESIA (ETORPHINE AND ACEPROMAZINE) IN THE HORSE	EQUINE VETERINARY JOURNAL			English	Article									DEPT VET SURG,BRISTOL BS18 7DU,ENGLAND							BOYD AE, 1974, METABOLISM, V23, P531, DOI 10.1016/0026-0495(74)90081-X; COWAN JC, 1977, J MOL CELL CARDIOL, V9, P327, DOI 10.1016/S0022-2828(77)80038-2; DANIEL M, 1972, VET REC, V90, P336, DOI 10.1136/vr.90.12.336; DUNCOMBE WG, 1964, CLIN CHIM ACTA, V9, P122, DOI 10.1016/0009-8981(64)90004-X; GUPTA DK, 1969, LANCET, V2, P1209, DOI 10.1016/S0140-6736(69)90749-1; GUTMANN I, 1974, [No title captured]; Hall L. W., 1983, VET ANAESTHESIA; Hillidge C J, 1975, Equine Vet J, V7, P148, DOI 10.1111/j.2042-3306.1975.tb03254.x; HILLIDGE CJ, 1978, EQUINE VET J, V10, P60, DOI 10.1111/j.2042-3306.1978.tb02217.x; HILLIDGE CJ, 1974, RES VET SCI, V17, P395, DOI 10.1016/S0034-5288(18)33663-4; HILLIDGE CJ, 1974, VET REC, V94, P476; HILLIDGE CJ, 1971, VET REC, V89, P280, DOI 10.1136/vr.89.10.280-a; HILLIDGE CJ, 1975, P BR PHARM SOC, P375; JENKINS JT, 1972, VET REC, V90, P207, DOI 10.1136/vr.90.8.207; KURIEN VA, 1969, LANCET, V2, P185; KURIEN VA, 1966, LANCET, V2, P122; Lees P., 1975, Equine Veterinary Journal, V7, P184, DOI 10.1111/j.2042-3306.1975.tb03265.x; MACKENZIE G, 1977, THESIS U GLASGOW; OLIVER MF, 1968, LANCET, V1, P710; OPIE LH, 1970, NATURE, V227, P1055, DOI 10.1038/2271055a0; ROBERTSON SA, 1984, THESIS U BRISTOL; SCHLARMA.B, 1973, AM J VET RES, V34, P411; STJERNSTROM H, 1981, CLIN PHYSIOL, V1, P59, DOI 10.1111/j.1475-097X.1981.tb00874.x; TAGGART P, 1973, LANCET, V2, P341; TAGGART P, 1971, LANCET, V1, P363; TRAYNOR C, 1981, BRIT J ANAESTH, V53, P153, DOI 10.1093/bja/53.2.153; WERNER W, 1970, [No title captured], V252, P224	27	7	8	0	2	EQUINE VETERINARY JOURNAL LTD	NEWMARKET	GRASEBY HOUSE, ENXING ROAD, NEWMARKET, SUFFOLK, ENGLAND CB8 0AU	0425-1644			EQUINE VET J	Equine Vet. J.	MAY	1987	19	3					214	217		10.1111/j.2042-3306.1987.tb01383.x			4	Veterinary Sciences	Veterinary Sciences	H6148	WOS:A1987H614800013	3301321				2020-06-26	J	BARCHFELDROTHSCHILD, CC; MEDZIHRADSKY, F				BARCHFELDROTHSCHILD, CC; MEDZIHRADSKY, F			HETEROGENEITY OF OPIOID RECEPTOR-BINDING IN BRAIN-SLICES	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article									UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109					NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 00254]		BARCHFELD CC, 1982, LIFE SCI, V31, P1661, DOI 10.1016/0024-3205(82)90180-1; BLUME AJ, 1978, P NATL ACAD SCI USA, V75, P1713, DOI 10.1073/pnas.75.4.1713; BLUME AJ, 1979, P NATL ACAD SCI USA, V76, P5626, DOI 10.1073/pnas.76.11.5626; BOXENBAU.HG, 1974, J PHARMACOKINET BIOP, V2, P123, DOI 10.1007/BF01061504; CHANG KJ, 1983, P NATL ACAD SCI-BIOL, V80, P940, DOI 10.1073/pnas.80.4.940; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLARK MJ, 1986, LIFE SCI, V39, P1721, DOI 10.1016/0024-3205(86)90090-1; CLARK MJ, 1987, IN PRESS NEUROPHARMA; CLARK MJ, 1986, RES MONOGRAPH NATL I, V75, P145; DAVIS ME, 1977, P NATL ACAD SCI USA, V74, P5764, DOI 10.1073/pnas.74.12.5764; FISCHEL SV, 1981, MOL PHARMACOL, V20, P269; FISCHEL SV, 1985, J NEUROSCI RES, V13, P369, DOI 10.1002/jnr.490130304; FISCHEL SV, 1986, NEUROPHARMACOLOGY, V25, P351, DOI 10.1016/0028-3908(86)90229-7; FROST JJ, 1984, ANN NEUROL, V15, pS85; GARZON J, 1984, J PHARMACOL EXP THER, V231, P33; GEARY WA, 1983, J PHARMACOL EXP THER, V225, P234; GILLAN MGC, 1982, BRIT J PHARMACOL, V77, P461, DOI 10.1111/j.1476-5381.1982.tb09319.x; GOODMAN FR, 1973, NEUROPHARMACOLOGY, V12, P867, DOI 10.1016/0028-3908(73)90039-7; GOODMAN RR, 1982, P NATL ACAD SCI-BIOL, V79, P5703, DOI 10.1073/pnas.79.18.5703; HERKENHAM M, 1981, SCIENCE, V211, P1166; JACOBSON W, 1984, BRAIN RES BULL, V13, P481, DOI 10.1016/0361-9230(84)90028-5; JAMES IF, 1984, MOL PHARMACOL, V25, P337; KATZ JB, 1977, BRAIN RES, V120, P263, DOI 10.1016/0006-8993(77)90905-2; KLOTZ IM, 1982, SCIENCE, V217, P1247, DOI 10.1126/science.6287580; KOSTERLITZ HW, 1980, PROC R SOC SER B-BIO, V210, P113, DOI 10.1098/rspb.1980.0122; LOWRY OH, 1983, J BIOL CHEM, P265; MCILWAIN H, 1962, PRACTICAL NEUROCHEMI, P206; MEDZIHRADSKY F, 1976, BRAIN RES, V108, P212, DOI 10.1016/0006-8993(76)90180-3; MEDZIHRADSKY F, 1984, LIFE SCI, V34, P2013; MOLINOFF PB, 1981, LIFE SCI, V29, P427, DOI 10.1016/0024-3205(81)90208-3; PAPPIUS HM, 1962, CAN J BIOCHEM PHYS, V40, P885; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7; ROGERS NF, 1985, LIFE SCI, V37, P307, DOI 10.1016/0024-3205(85)90500-4; ROSENBAUM JS, 1984, MOL PHARMACOL, V25, P242; ROSENBAUM JS, 1985, J PHARMACOL EXP THER, V233, P735; SIMANTOV R, 1982, BIOCHIM BIOPHYS ACTA, V721, P478, DOI 10.1016/0167-4889(82)90104-5; VONVOIGTLANDER PF, 1982, PROG NEURO-PSYCHOPH, V6, P467, DOI 10.1016/S0278-5846(82)80130-9; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7; WOODS JH, 1979, MECHANISMS PAIN ANAL, P429	40	2	2	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012	0360-4012			J NEUROSCI RES	J. Neurosci. Res.		1987	18	2					358	365		10.1002/jnr.490180214			8	Neurosciences	Neurosciences & Neurology	L0193	WOS:A1987L019300013	2891857				2020-06-26	J	FABBRI, A; FRAIOLI, F; ISIDORI, A				FABBRI, A; FRAIOLI, F; ISIDORI, A			OPIOID-PEPTIDES IN THE TESTIS AND THE MALE GENITAL-TRACT - PRESENCE AND POSSIBLE FUNCTION	JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION			English	Review										FABBRI, A (reprint author), UNIV ROME LA SAPIENZA,CATTEDRA ANDROL,MED CLIN 5,I-00161 ROMA,ITALY.						ATWEH SF, 1983, BRIT MED BULL, V39, P47, DOI 10.1093/oxfordjournals.bmb.a071789; BARDIN CW, 1984, ANN NY ACAD SCI, V438, P365; BHANOT R, 1984, J ENDOCRINOL, V102, P133, DOI 10.1677/joe.0.1020133; BLANK MR, 1982, SCIENCE, V203, P1129; BLANK MS, 1986, ENDOCRINOLOGY, V118, P2097, DOI 10.1210/endo-118-5-2097; BLOOM FE, 1983, ANNU REV PHARMACOL, V23, P151, DOI 10.1146/annurev.pa.23.040183.001055; BOITANI C, 1986, ENDOCRINOLOGY, V118, P1513, DOI 10.1210/endo-118-4-1513; BRESLOW E, 1979, ANNU REV BIOCHEM, V48, P251, DOI 10.1146/annurev.bi.48.070179.001343; CHANG KJ, 1984, TINS, V7, P34; CHENG MC, 1985, J CLIN INVEST, V75, P832, DOI 10.1172/JCI111779; CHINLING CC, 1984, P NATL ACAD SCI US, V81, P5672; CICERO TJ, 1975, NEW ENGL J MED, V292, P882, DOI 10.1056/NEJM197504242921703; CICERO TJ, 1979, ENDOCRINOLOGY, V104, P1286, DOI 10.1210/endo-104-5-1286; CIVELLI O, 1985, P NATL ACAD SCI USA, V82, P4291, DOI 10.1073/pnas.82.12.4291; DECAROLIS C, 1984, EXPERIENTIA, V40, P738; DELITALA G, 1981, ACTA ENDOCRINOL-COP, V97, P150, DOI 10.1530/acta.0.0970150; FABBRI A, 1985, J CLIN ENDOCR METAB, V60, P807, DOI 10.1210/jcem-60-4-807; FABBRI A, 1985, ENDOCRINOLOGY, V117, P2544, DOI 10.1210/endo-117-6-2544; FABBRI A, 1985, 67TH P END SOC M BAL; Fabbri A., 1984, OPIOID PEPTIDES PERI, P61; FABBRI A, IN PRESS BIORHYTHMS; FORESTA C, 1984, HORM METAB RES, V16, P111; FRAIOLI F, 1984, CLIN ENDOCRINOL, V20, P299, DOI 10.1111/j.1365-2265.1984.tb00086.x; FRAIOLI F, 1984, ANN NY ACAD SCI, V438, P365, DOI 10.1111/j.1749-6632.1984.tb38297.x; FRAIOLI F, 1982, HORM METAB RES, V16, P312; GERENDAI I, 1986, ENDOCRINOLOGY, V118, P2039, DOI 10.1210/endo-118-5-2039; GERENDAI I, 1983, ANDROLOGIA, V15, P398; GERENDAI I, 1984, ENDOCRINOLOGY, V115, P1645, DOI 10.1210/endo-115-4-1645; GESSA GL, 1979, SCIENCE, V204, P203, DOI 10.1126/science.432642; GIZANGGINSBERG E, 1985, DEV BIOL, V111, P293, DOI 10.1016/0012-1606(85)90484-1; GROSSMAN A, 1983, CLIN ENDOCRINOL META, V12, P725, DOI 10.1016/S0300-595X(83)80062-0; HAKANSON R, 1983, TIPS             JAN, P41; HEDGER MP, 1984, ANN NY ACAD SCI, V438, P371, DOI 10.1111/j.1749-6632.1984.tb38298.x; HIMURA H, 1983, J ENDOCRINOL INVEST, V6, P139; HUGHES J, 1983, BRIT MED BULL, V39, P17, DOI 10.1093/oxfordjournals.bmb.a071785; KALRA SP, 1983, ENDOCR REV, V4, P311, DOI 10.1210/edrv-4-4-311; KALRA SP, 1983, ROLE PEPTIDES PROTEI, P63; KILPATRICK DL, 1986, ENDOCRINOLOGY, V119, P370, DOI 10.1210/endo-119-1-370; KILPATRICK DL, 1986, P NATL ACAD SCI USA, V83, P5015, DOI 10.1073/pnas.83.14.5015; KRIEGER DT, 1983, SCIENCE, V222, P975, DOI 10.1126/science.6139875; LEBOUILLE JLM, 1986, ENDOCRINOLOGY, V118, P372, DOI 10.1210/endo-118-1-372; LEROITH D, 1982, PEPTIDES, V3, P211, DOI 10.1016/0196-9781(82)90080-8; MARCUS ZH, 1979, J REPROD IMMUNOL, V1, P97, DOI 10.1016/0165-0378(79)90010-X; MARGIORIS AM, 1986, 68 P END SOC M AN; MARGIORIS AN, 1983, ENDOCRINOLOGY, V113, P663, DOI 10.1210/endo-113-2-663; MARGIORIS AN, 1985, 67TH P END SOC M BAL; MELIS GB, 1984, NEUROENDOCRINOLOGY, V39, P60; OLSON GA, 1984, PEPTIDES, V5, P975, DOI 10.1016/0196-9781(84)90125-6; PARVINEN M, 1984, MOL CELL ENDOCRINOL, V37, P331, DOI 10.1016/0303-7207(84)90103-5; PETRAGLIA F, 1984, J ENDOCRINOL, V101, P33, DOI 10.1677/joe.0.1010033; PICCOLI R, 1986, J ENDOCRINOL INVEST, V9, P43; PINTAR JE, 1984, SCIENCE, V225, P632, DOI 10.1126/science.6740329; PITOUT MJ, 1976, INT J BIOCHEM, V7, P149, DOI 10.1016/0020-711X(76)90012-4; PIVA F, 1985, ENDOCRINOLOGY, V117, P766, DOI 10.1210/endo-117-2-766; PRAKASH C, 1976, SCAND J IMMUNOL, V5, P77, DOI 10.1111/j.1365-3083.1976.tb02994.x; RASMUSSEN DD, 1983, J CLIN ENDOCR METAB, V57, P881, DOI 10.1210/jcem-57-5-881; ROBSON LE, 1983, HDB PSYCHOPHARMACOLO, V17, P13; SASTRY BVR, 1982, BIOCHEM PHARMACOL, V31, P3519; SCHELLER RH, 1983, CELL, V32, P7, DOI 10.1016/0092-8674(83)90492-0; SCHER PM, 1982, J ANDROL, V3, P35; SERRA G, 1982, SESSUOLOGIA, V4, P277; SHAHA C, 1984, ENDOCRINOLOGY, V114, P1584, DOI 10.1210/endo-114-5-1584; SHAHA C, 1984, OPIOID PEPTIDES PERI, P53; SHARP B, 1981, J CLIN ENDOCR METAB, V52, P586, DOI 10.1210/jcem-52-3-586; SHARP B, 1980, BIOCHEM BIOPH RES CO, V95, P618, DOI 10.1016/0006-291X(80)90830-X; SHARPE R, 1986, CLIN ENDOCRINOL META, V15, P184; SHARPE RM, 1981, NATURE, V290, P785, DOI 10.1038/290785a0; SINGER R, 1985, EXPERIENTIA, V41, P64, DOI 10.1007/BF02005876; SIRINATHSINGHJI DJS, 1983, NATURE, V301, P62, DOI 10.1038/301062a0; SPERA G, 1984, OPIOID PEPTIDES PERI, P73; STITES DP, 1975, NATURE, V253, P727, DOI 10.1038/253727a0; TSONG SD, 1982, ENDOCRINOLOGY, V110, P2204, DOI 10.1210/endo-110-6-2204; TSONG SD, 1982, BIOL REPROD, V27, P759; VALENCA MM, 1986, ENDOCRINOLOGY, V118, P32, DOI 10.1210/endo-118-1-32; VOGEL DL, 1983, ENDOCRINOLOGY, V112, P1115, DOI 10.1210/endo-112-3-1115; WEBER RJ, 1984, CENTRAL PERIPHERAL E, P35; WILKES MM, 1981, LIFE SCI, V28, P2355, DOI 10.1016/0024-3205(81)90500-2	77	6	6	0	0	EDITRICE KURTIS S R L	MILANO	VIA LUIGI ZOJA, 30-20153 MILANO, ITALY	0391-4097			J ENDOCRINOL INVEST	J. Endocrinol. Invest.	DEC	1986	9	6					521	528		10.1007/BF03346980			8	Endocrinology & Metabolism	Endocrinology & Metabolism	G0920	WOS:A1986G092000014	2952705				2020-06-26	J	PRATT, S; PRYOR, SC				PRATT, S; PRYOR, SC			DOPAMINE-SENSITIVE AND OCTOPAMINE-SENSITIVE ADENYLATE-CYCLASE IN THE BRAIN OF ADULT CULEX-PIPIENS MOSQUITOS	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Note										PRATT, S (reprint author), SUNY COLL OLD WESTBURY, DEPT BIOL SCI, OLD WESTBURY, NY 11568 USA.				NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR-08180]		BODNARYK RP, 1982, INSECT BIOCHEM, V12, P1, DOI 10.1016/0020-1790(82)90064-6; BODNARYK RP, 1979, INSECT BIOCHEM, V9, P155, DOI 10.1016/0020-1790(79)90045-3; BODNARYK RP, 1979, J NEUROCHEM, V33, P275, DOI 10.1111/j.1471-4159.1979.tb11729.x; BODNARYK RP, 1980, INSECT BIOCHEM, V10, P169, DOI 10.1016/0020-1790(80)90069-4; CATAPANE EJ, 1979, J EXP BIOL, V83, P315; CATAPANE EJ, 1978, J EXP BIOL, V74, P101; DAHL E, 1966, Z ZELLFORSCH MIK ANA, V71, P489, DOI 10.1007/BF00349609; DAVID JC, 1979, CR ACAD SCI D NAT, V288, P1207; DYMOND GR, 1979, INSECT BIOCHEM, V9, P535, DOI 10.1016/0020-1790(79)90074-X; EULER USV, 1961, NATURE, V190, P170; EVANS PD, 1981, J PHYSIOL-LONDON, V318, P99; EVANS PD, 1978, J EXP BIOL, V73, P235; EVANS PD, 1978, J NEUROCHEM, V30, P1009, DOI 10.1111/j.1471-4159.1978.tb12393.x; FUZEAUBRAESCH S, 1979, EXPERIENTIA, V35, P1349, DOI 10.1007/BF01964001; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; GOODMAN CS, 1979, SCIENCE, V204, P1219, DOI 10.1126/science.36661; HARMAR AJ, 1977, MOL PHARMACOL, V13, P512; HIRIPI L, 1984, CELL MOL NEUROBIOL, V4, P199, DOI 10.1007/BF00733585; HOYLE G, 1975, J EXP ZOOL, V193, P425, DOI 10.1002/jez.1401930321; KILPATRICK AT, 1980, INSECT NEUROBIOLOGY, P342; NATHANSON JA, 1973, SCIENCE, V180, P308, DOI 10.1126/science.180.4083.308; NATHANSON JA, 1976, TRACE AMINES BRAIN, P161; ROBERTSON HA, 1974, J PHYSIOL-LONDON, V237, pP34; ROBERTSON HA, 1976, EXPERIENTIA, V32, P552, DOI 10.1007/BF01990155; STEFANO GB, 1981, CELL MOL NEUROBIOL, V1, P57, DOI 10.1007/BF00736039	25	15	15	0	2	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	SEP	1986	6	3					325	329		10.1007/BF00711117			5	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	F1022	WOS:A1986F102200008	3100044				2020-06-26	J	DIMAIO, J; BAYLY, CI; VILLENEUVE, G; MICHEL, A				DIMAIO, J; BAYLY, CI; VILLENEUVE, G; MICHEL, A			TOPOLOGICAL SIMILARITIES BETWEEN A CYCLIC ENKEPHALIN ANALOG AND A POTENT OPIATE ALKALOID - A COMPUTER-MODELING APPROACH	JOURNAL OF MEDICINAL CHEMISTRY			English	Article									UNIV SHERBROOKE,FAC SCI,DEPT CHEM,SHERBROOKE J1K 2R1,QUEBEC,CANADA	DIMAIO, J (reprint author), BIOMEGA LABS,CHOMEDEY H7S 2G5,QUEBEC,CANADA.						BECKETT AH, 1954, J PHARM PHARMACOL, V6, P986, DOI 10.1111/j.2042-7158.1954.tb11033.x; BRADBURY AF, 1976, NATURE, V260, P165, DOI 10.1038/260165a0; BUSHER HH, 1976, NATURE, V261, P423; DEBER CM, 1976, ACCOUNTS CHEM RES, V9, P106, DOI 10.1021/ar50099a005; DESSLER H, 1983, 8TH P AM PEPT S, P295; DIMAIO J, 1982, J MED CHEM, V25, P1432, DOI 10.1021/jm00354a008; DIMAIO J, 1980, P NATL ACAD SCI-BIOL, V77, P7162, DOI 10.1073/pnas.77.12.7162; DIMAIO J, 1982, LIFE SCI, V31, P2253, DOI 10.1016/0024-3205(82)90131-X; DIMAIO J, 1979, 6TH P AM PEPT S, P889; FEINBERG AP, 1976, P NATL ACAD SCI USA, V73, P4215, DOI 10.1073/pnas.73.11.4215; FREED ME, 1976, J MED CHEM, V19, P476, DOI 10.1021/jm00226a005; GORIN FA, 1977, P NATL ACAD SCI USA, V74, P5179, DOI 10.1073/pnas.74.11.5179; GORIN FA, 1978, J SUPRAMOL STRUCT, V9, P119; HORN AS, 1976, NATURE, V260, P795, DOI 10.1038/260795a0; HUDSON D, 1980, INT J PEPT PROT RES, V15, P122; HUTCHINS CW, 1981, J MED CHEM, V24, P773, DOI 10.1021/jm00139a002; HUTCHINS CW, 1984, J MED CHEM, V27, P521, DOI 10.1021/jm00370a015; KESSLER H, 1985, INT J PEPT PROT RES, V25, P267; KLYNE W, 1960, EXPERIENTIA, V16, P521, DOI 10.1007/BF02158433; LEWIS JW, 1971, ANNU REV PHARMACOLOG, V11, P241, DOI 10.1146/annurev.pa.11.040171.001325; LOEW GH, 1978, P NATL ACAD SCI USA, V75, P7, DOI 10.1073/pnas.75.1.7; LOEW GH, 1979, J MED CHEM, V22, P603, DOI 10.1021/jm00192a001; MARYANOFF BE, 1978, J PHARM SCI, V67, P590, DOI 10.1002/jps.2600670448; MORGAN BA, 1976, J PHARM PHARM, P28; MORLEY JS, 1980, ANNU REV PHARMACOL, V20, P81, DOI 10.1146/annurev.pa.20.040180.000501; RAMAKRISHNAN K, 1982, J MED CHEM, V25, P1423, DOI 10.1021/jm00354a006; SCHILLER PW, 1980, J MED CHEM, V23, P290, DOI 10.1021/jm00177a016; SCHILLER PW, 1977, BIOCHEMISTRY-US, V16, P1831, DOI 10.1021/bi00628a011; SCHILLER PW, 1982, NATURE, V297, P74, DOI 10.1038/297074a0; SCHILLER PW, 1984, PEPTIDES ANAL SYNTHE, P220; SCHILLER PW, 1983, PEPTIDES STRUCTURE F, P269; SHAW JS, 1982, LIFE SCI, V31, P1259, DOI 10.1016/0024-3205(82)90356-3; SHIOTANI S, 1976, J MED CHEM, V19, P803, DOI 10.1021/jm00228a013; VANDENHENDE JH, 1967, J AM CHEM SOC, V89, P2901, DOI 10.1021/ja00988a017	34	17	17	0	0	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036	0022-2623			J MED CHEM	J. Med. Chem.	SEP	1986	29	9					1658	1663		10.1021/jm00159a016			6	Chemistry, Medicinal	Pharmacology & Pharmacy	D7923	WOS:A1986D792300016	3746814				2020-06-26	J	SHETTY, SS; FRANK, GB				SHETTY, SS; FRANK, GB			MECHANISM FOR THE OPIOID-INDUCED TWITCH POTENTIATIONS OF FROGS SKELETAL-MUSCLE	CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY			English	Article										SHETTY, SS (reprint author), UNIV ALBERTA,DEPT PHARMACOL,EDMONTON T6G 2H7,ALBERTA,CANADA.						ARY TE, 1983, EUR J PHARMACOL, V94, P211, DOI 10.1016/0014-2999(83)90410-7; BIANCHI CP, 1959, J GEN PHYSIOL, V42, P803, DOI 10.1085/jgp.42.4.803; ENDO M, 1975, P JPN ACAD, V51, P479, DOI 10.2183/pjab1945.51.479; FABIATO A, 1982, CAN J PHYSIOL PHARM, V60, P556, DOI 10.1139/y82-075; FRANK GB, 1984, CAN J PHYSIOL PHARM, V62, P374, DOI 10.1139/y84-059; FRANK GB, 1975, CAN J PHYSIOL PHARM, V53, P92, DOI 10.1139/y75-012; FRANK GB, 1975, J PHYSIOL-LONDON, V252, P585, DOI 10.1113/jphysiol.1975.sp011160; FRANK GB, 1979, P W PHARMACOL SOC, V22, P309; HILL AV, 1954, PROC R SOC SER B-BIO, V143, P81, DOI 10.1098/rspb.1954.0055; HODGKIN AL, 1960, J PHYSIOL-LONDON, V153, P404, DOI 10.1113/jphysiol.1960.sp006542; HUTTER OF, 1960, J PHYSIOL-LONDON, V151, P89; INOUE F, 1962, J PHARMACOL EXP THER, V136, P190; KRAYER O, 1946, PHYSIOL REV, V26, P383; MARWAHA J, 1980, PROG NEURO-PSYCHOPHA, V4, P145, DOI 10.1016/0364-7722(80)90031-4; OOTA I, 1980, JPN J PHYSIOL, V30, P231; RUSSELL J, 1982, EUR J PHARMACOL, V78, P255, DOI 10.1016/0014-2999(82)90026-7; SANDOW A, 1956, FED PROC, V15, P162; SANDOW ALEXANDER, 1965, FEDERATION PROC, V24, P1116; SHETTY SS, 1985, J PHARMACOL EXP THER, V234, P233; SHETTY SS, 1984, CAN J PHYSIOL PHARM, V62, P559, DOI 10.1139/y84-089; WEISS GB, 1981, NEW PERSPECTIVES CAL, P83; ZAR JH, 1974, BIOSTAT ANAL, P151	22	3	2	0	0	NATL RESEARCH COUNCIL CANADA	OTTAWA	RESEARCH JOURNALS, MONTREAL RD, OTTAWA ON K1A 0R6, CANADA	0008-4212			CAN J PHYSIOL PHARM	Can. J. Physiol. Pharmacol.	JUL	1986	64	7					983	992		10.1139/y86-168			10	Pharmacology & Pharmacy; Physiology	Pharmacology & Pharmacy; Physiology	D9350	WOS:A1986D935000018	3490300				2020-06-26	J	BLANK, MS; FABBRI, A; CATT, KJ; DUFAU, ML				BLANK, MS; FABBRI, A; CATT, KJ; DUFAU, ML			INHIBITION OF LUTEINIZING-HORMONE RELEASE BY MORPHINE AND ENDOGENOUS OPIATES IN CULTURED PITUITARY-CELLS	ENDOCRINOLOGY			English	Article									NICHHD,ENDOCRINOL & REPROD RES BRANCH,MOLEC ENDOCRINOL SECT,BLDG 10,ROOM 8C-407,BETHESDA,MD 20892					NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD-15073]		AZIZI F, 1973, STEROIDS, V22, P467, DOI 10.1016/0039-128X(73)90002-0; BLANK MS, 1985, ENDOCRINOLOGY, V116, P1778, DOI 10.1210/endo-116-5-1778; BLANK MS, 1982, NEUROENDOCRINOLOGY, V35, P309, DOI 10.1159/000123399; BLANK MS, 1985, CLIN RES, V33, pA599; Bloom F E, 1978, Adv Biochem Psychopharmacol, V18, P89; CICERO TJ, 1979, ENDOCRINOLOGY, V104, P1286, DOI 10.1210/endo-104-5-1286; DELEAN A, 1978, AM J PHYSIOL, V235, pE97; DROUVA SV, 1981, NEUROENDOCRINOLOGY, V32, P162; FABBRI A, 1985, ENDOCRINOLOGY, V117, P2544, DOI 10.1210/endo-117-6-2544; FORMAN LJ, 1983, P SOC EXP BIOL MED, V173, P14, DOI 10.3181/00379727-173-1-RC1; GROSSMAN A, 1983, BRIT MED BULL, V39, P83, DOI 10.1093/oxfordjournals.bmb.a071796; HYDE CL, 1982, ENDOCRINOLOGY, V111, P1421, DOI 10.1210/endo-111-4-1421; ISHIZUKA B, 1982, LIFE SCI, V31, P2113, DOI 10.1016/0024-3205(82)90103-5; KALRA SP, 1981, ENDOCRINOLOGY, V109, P1805, DOI 10.1210/endo-109-6-1805; LAW PY, 1979, J NEUROCHEM, V33, P1177, DOI 10.1111/j.1471-4159.1979.tb05262.x; LIGHTMAN SL, 1983, NATURE, V305, P235, DOI 10.1038/305235a0; MENDELSON JH, 1975, J PHARMACOL EXP THER, V192, P211; RIVIER C, 1977, ENDOCRINOLOGY, V100, P238, DOI 10.1210/endo-100-1-238; SANTEN RJ, 1975, FERTIL STERIL, V26, P538; SCHULZ R, 1981, NATURE, V294, P757, DOI 10.1038/294757a0; SIMANTOV R, 1977, BRAIN RES, V124, P178, DOI 10.1016/0006-8993(77)90877-0; WEHRENBERG WB, 1982, ENDOCRINOLOGY, V111, P879, DOI 10.1210/endo-111-3-879; WILKES MM, 1981, LIFE SCI, V28, P2355, DOI 10.1016/0024-3205(81)90500-2; Winer B. J., 1971, STATISTICAL PRINCIPL	24	131	133	0	0	ENDOCRINE SOC	BETHESDA	4350 EAST WEST HIGHWAY SUITE 500, BETHESDA, MD 20814-4110	0013-7227			ENDOCRINOLOGY	Endocrinology	MAY	1986	118	5					2097	2101		10.1210/endo-118-5-2097			5	Endocrinology & Metabolism	Endocrinology & Metabolism	C0034	WOS:A1986C003400053	3009150				2020-06-26	J	BARKER, CT				BARKER, CT			IMMOBILON	VETERINARY RECORD			English	Letter																1986, VET REC, V118, P283; 1986, VET REC, V118, P344	2	1	1	0	0	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.	APR 5	1986	118	14					406	406		10.1136/vr.118.14.406-b			1	Veterinary Sciences	Veterinary Sciences	A7345	WOS:A1986A734500014	3716097				2020-06-26	J	GILLBERG, PG; WIKSTEN, B				GILLBERG, PG; WIKSTEN, B			EFFECTS OF SPINAL-CORD LESIONS AND RHIZOTOMIES ON CHOLINERGIC AND OPIATE RECEPTOR-BINDING SITES IN RAT SPINAL-CORD	ACTA PHYSIOLOGICA SCANDINAVICA			English	Article									UNIV UPPSALA,AKAD SJUKHUSET,DEPT NEUROL,S-75185 UPPSALA,SWEDEN	GILLBERG, PG (reprint author), UNIV UPPSALA,AKAD HOSP,DEPT NEUROL,S-75185 UPPSALA,SWEDEN.						ABRAHAMS VC, 1984, J COMP NEUROL, V223, P448, DOI 10.1002/cne.902230309; AQUILONIUS SM, 1981, BRAIN RES, V211, P329, DOI 10.1016/0006-8993(81)90705-8; AQUILONIUS SM, 1983, BRAIN MICRODISSECTIO, P155; ARIMATSU Y, 1981, J COMP NEUROL, V198, P603, DOI 10.1002/cne.901980405; ATWEH SF, 1978, NEUROPHARMACOLOGY, V17, P65, DOI 10.1016/0028-3908(78)90175-2; CHARLTON G, 1981, BRAIN RES, V218, P372; FONNUM F, 1973, BRAIN RES, V62, P497, DOI 10.1016/0006-8993(73)90714-2; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; GILLBERG PG, 1985, ACTA NEUROL SCAND, V72, P299; GILLBERG PG, 1984, BRAIN RES, V300, P327, DOI 10.1016/0006-8993(84)90843-6; GULYA K, 1984, NEUROCHEM INT, V6, P123, DOI 10.1016/0197-0186(84)90036-6; GWYN DG, 1966, SCIENCE, V153, P1543, DOI 10.1126/science.153.3743.1543; GWYN DG, 1972, BRAIN RES, V47, P289, DOI 10.1016/0006-8993(72)90640-3; HOUSER CR, 1983, BRAIN RES, V266, P97, DOI 10.1016/0006-8993(83)91312-4; JESSELL T, 1979, BRAIN RES, V168, P247, DOI 10.1016/0006-8993(79)90167-7; KANAZAWA I, 1979, NEUROSCI LETT, V13, P325, DOI 10.1016/0304-3940(79)91514-3; KAYAALP SO, 1980, BRAIN RES, V196, P429; LAMOTTE C, 1976, BRAIN RES, V112, P407, DOI 10.1016/0006-8993(76)90296-1; MOLANDER C, 1984, J COMP NEUROL, V230, P133, DOI 10.1002/cne.902300112; NINKOVIC M, 1981, BRAIN RES, V230, P111, DOI 10.1016/0006-8993(81)90395-4; NINKOVIC M, 1983, BRAIN RES, V272, P57, DOI 10.1016/0006-8993(83)90364-5; POLZTEJERA G, 1975, NATURE, V258, P349, DOI 10.1038/258349a0; REXED B, 1954, J COMP NEUROL, V100, P297, DOI 10.1002/cne.901000205; ROTTER A, 1979, BRAIN RES REV, V1, P207, DOI 10.1016/0165-0173(79)90005-5; SATOH K, 1983, BRAIN RES BULL, V11, P693, DOI 10.1016/0361-9230(83)90013-8; SCATTON B, 1984, NEUROSCI LETT, V49, P239, DOI 10.1016/0304-3940(84)90296-9; TAYLOR JE, 1982, J NEUROCHEM, V39, P521, DOI 10.1111/j.1471-4159.1982.tb03975.x; WALBERG F, 1982, BRAIN STEM CONTROL S, P1; WAMSLEY JK, 1981, J NEUROSCI, V1, P176; WHITEHOUSE PJ, 1983, ANN NEUROL, V14, P8, DOI 10.1002/ana.410140103; YAKSH TL, 1985, EUR J PHARMACOL, V117, P81, DOI 10.1016/0014-2999(85)90474-1; YOUNG WS, 1979, BRAIN RES, V179, P255	32	44	44	0	0	BLACKWELL SCIENCE LTD	OXFORD	OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL	0001-6772			ACTA PHYSIOL SCAND	Acta Physiol. Scand.	APR	1986	126	4					575	582		10.1111/j.1748-1716.1986.tb07857.x			8	Physiology	Physiology	A9194	WOS:A1986A919400014	3012950				2020-06-26	J	DEMOLIOUMASON, CD; BARNARD, EA				DEMOLIOUMASON, CD; BARNARD, EA			DISTINCT SUBTYPES OF THE OPIOID RECEPTOR WITH ALLOSTERIC INTERACTIONS IN BRAIN MEMBRANES	JOURNAL OF NEUROCHEMISTRY			English	Article									UNIV LONDON IMPERIAL COLL SCI & TECHNOL,DEPT BIOCHEM,LONDON SW7 2AZ,ENGLAND							AUDIGIER Y, 1981, EUR J PHARMACOL, V74, P273, DOI 10.1016/0014-2999(81)90045-5; BARRETT RW, 1983, LIFE SCI, V33, P2439, DOI 10.1016/0024-3205(83)90638-0; BLUME AJ, 1978, LIFE SCI, V22, P1843, DOI 10.1016/0024-3205(78)90602-1; BLUME AJ, 1980, PSYCHOPHARMACOLOGY B, V11, P369; BOEYNAEMS JM, 1977, MOL CELL ENDOCRINOL, V7, P275, DOI 10.1016/0303-7207(77)90030-2; BOEYNAEMS JM, 1980, OUTLINES RECEPTOR TH, P81; BOWEN WD, 1982, CELL MOL NEUROBIOL, V2, P115, DOI 10.1007/BF00711077; BOWEN WD, 1981, P NATL ACAD SCI-BIOL, V78, P4818, DOI 10.1073/pnas.78.8.4818; CHANG KJ, 1979, MOL PHARMACOL, V16, P91; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHILDERS SR, 1980, J NEUROCHEM, V34, P583, DOI 10.1111/j.1471-4159.1980.tb11184.x; CODINA J, 1983, P NATL ACAD SCI-BIOL, V80, P4276, DOI 10.1073/pnas.80.14.4276; DEMOLIOUMASON CD, 1984, FEBS LETT, V170, P378, DOI 10.1016/0014-5793(84)81348-4; DEMOLIOUMASON CD, 1986, J NEUROCHEM, V46, P1129, DOI 10.1111/j.1471-4159.1986.tb00627.x; FERGUSON KM, 1982, FED PROC, V41, P1407; GILLAN MGC, 1982, BRIT J PHARMACOL, V77, P461, DOI 10.1111/j.1476-5381.1982.tb09319.x; GREVEL J, 1983, SCIENCE, V221, P1198, DOI 10.1126/science.6310750; HAZUM E, 1981, LIFE SCI, V28, P2973, DOI 10.1016/0024-3205(81)90274-5; HAZUM E, 1979, NATURE, V282, P626, DOI 10.1038/282626a0; HAZUM E, 1980, P NATL ACAD SCI-BIOL, V77, P3038, DOI 10.1073/pnas.77.5.3038; HESS HH, 1978, ANAL BIOCHEM, V85, P295, DOI 10.1016/0003-2697(78)90304-4; KOSTERLITZ HW, 1981, BRIT J PHARMACOL, V73, P939, DOI 10.1111/j.1476-5381.1981.tb08749.x; KOUAKOU Y, 1982, MOL PHARMACOL, V21, P564; LARSEN NE, 1981, MOL PHARMACOL, V20, P255; LEVITZKI A, 1978, QUANTITATIVE ASPECTS, P80; MUNSON PJ, 1984, COMPUTERS ENDOCRINOL, P117; NISHIMURA SL, 1984, MOL PHARMACOL, V25, P29; PATERSON SJ, 1983, BRIT MED BULL, V39, P31, DOI 10.1093/oxfordjournals.bmb.a071787; PERRY DC, 1982, MOL PHARMACOL, V21, P272; PERT CB, 1974, MOL PHARMACOL, V10, P868; PFEIFFER A, 1982, MOL PHARMACOL, V21, P266; QUIRION R, 1982, CELL MOL NEUROBIOL, V2, P333, DOI 10.1007/BF00710853; ROMER D, 1980, LIFE SCI, V27, P971, DOI 10.1016/0024-3205(80)90107-1; ROTHMAN R, 1983, J NEUROBIOL, V14, P341, DOI 10.1002/neu.480140502; ROTHMAN RB, 1982, MOL PHARMACOL, V21, P548; SCHULZ R, 1981, J PHARMACOL EXP THER, V219, P547; SCHULZ R, 1980, NATURE, V285, P242, DOI 10.1038/285242a0; SIMON EJ, 1975, P NATL ACAD SCI USA, V72, P2404, DOI 10.1073/pnas.72.6.2404; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; SIMON EJ, 1975, J PHARMACOL EXP THER, V192, P531; SMITH JR, 1980, P NATL ACAD SCI-BIOL, V77, P281, DOI 10.1073/pnas.77.1.281; WILLIAMS JT, 1981, BRAIN RES, V226, P304, DOI 10.1016/0006-8993(81)91103-3; WOLOZIN BL, 1981, P NATL ACAD SCI-BIOL, V78, P6181, DOI 10.1073/pnas.78.10.6181; WOOD PL, 1981, NEUROPHARMACOLOGY, V20, P1215, DOI 10.1016/0028-3908(81)90067-8; ZUKIN RS, 1981, LIFE SCI, V29, P2681	45	64	64	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	APR	1986	46	4					1118	1128		10.1111/j.1471-4159.1986.tb00626.x			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	A4074	WOS:A1986A407400016	3005504				2020-06-26	J	DEMOLIOUMASON, CD; BARNARD, EA				DEMOLIOUMASON, CD; BARNARD, EA			CHARACTERIZATION OF OPIOID RECEPTOR SUBTYPES IN SOLUTION	JOURNAL OF NEUROCHEMISTRY			English	Article									UNIV LONDON IMPERIAL COLL SCI & TECHNOL,DEPT BIOCHEM,LONDON SW7 2AZ,ENGLAND							BOEYNAEMS JM, 1980, OUTLINES RECEPTOR TH, P81; CHOW T, 1983, MOL PHARMACOL, V24, P203; CORBETT AD, 1982, NATURE, V299, P79, DOI 10.1038/299079a0; DEMOLIOUMASON CD, 1984, FEBS LETT, V170, P378, DOI 10.1016/0014-5793(84)81348-4; DEMOLIOUMASON CD, 1986, J NEUROCHEM, V46, P1118, DOI 10.1111/j.1471-4159.1986.tb00626.x; HAZUM E, 1980, P NATL ACAD SCI-BIOL, V77, P3038, DOI 10.1073/pnas.77.5.3038; HOWELLS RD, 1982, J PHARMACOL EXP THER, V222, P629; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KOSKI G, 1981, J BIOL CHEM, V256, P1536; LAI FA, 1984, EUR J PHARMACOL, V103, P349; LEVITZKI A, 1978, QUANTITATIVE ASPECTS, P72; RUEGG UT, 1980, EUR J PHARMACOL, V64, P367, DOI 10.1016/0014-2999(80)90247-2	12	24	24	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	APR	1986	46	4					1129	1136		10.1111/j.1471-4159.1986.tb00627.x			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	A4074	WOS:A1986A407400017	2869106				2020-06-26	J	KLEIN, C; LEVY, R; SIMANTOV, R				KLEIN, C; LEVY, R; SIMANTOV, R			SUBCELLULAR COMPARTMENTATION OF OPIOID RECEPTORS - MODULATION BY ENKEPHALIN AND ALKALOIDS	JOURNAL OF NEUROCHEMISTRY			English	Article									WEIZMANN INST SCI,DEPT GENET,IL-76100 REHOVOT,ISRAEL							BAGINSKI ES, 1974, [No title captured], V2, P876; BARAM D, 1983, J NEUROCHEM, V40, P55, DOI 10.1111/j.1471-4159.1983.tb12652.x; BLANCHARD SG, 1983, J BIOL CHEM, V258, P1092; BRETZ R, 1977, EUR J BIOCHEM, V77, P181, DOI 10.1111/j.1432-1033.1977.tb11656.x; BROWN JA, 1983, J BIOL CHEM, V258, P5323; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; CATT KJ, 1979, NATURE, V280, P109, DOI 10.1038/280109a0; CHANG KJ, 1982, NATURE, V296, P446, DOI 10.1038/296446a0; CUATRECASAS P, 1969, P NATL ACAD SCI USA, V63, P450, DOI 10.1073/pnas.63.2.450; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s; Fishman W.H., 1974, METHOD ENZYMAT AN, V2, P929; GARBAYJAUREGUIBERRY C, 1984, P NATL ACAD SCI-BIOL, V81, P7718, DOI 10.1073/pnas.81.24.7718; GERLACH U, 1974, METHOD ENZYMAT AN, V2, P871; GLASEL JA, 1980, BIOCHEM BIOPH RES CO, V95, P263, DOI 10.1016/0006-291X(80)90733-0; GLASER T, 1981, FEBS LETT, V131, P63, DOI 10.1016/0014-5793(81)80888-5; Hamprecht B, 1977, Int Rev Cytol, V49, P99; KHAN MN, 1982, J BIOL CHEM, V257, P5969; KLEE WA, 1974, P NATL ACAD SCI USA, V71, P3474, DOI 10.1073/pnas.71.9.3474; KLEE WA, 1982, FEBS LETT, V150, P125, DOI 10.1016/0014-5793(82)81318-5; LAW PY, 1982, MOL PHARMACOL, V22, P1; LAW PY, 1984, J BIOL CHEM, V259, P4096; LAW PY, 1983, MOL PHARMACOL, V24, P413; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NEWMAN EL, 1984, BIOCHEMISTRY-US, V23, P5385, DOI 10.1021/bi00318a001; NOVIKOFF AB, 1976, P NATL ACAD SCI USA, V73, P2781, DOI 10.1073/pnas.73.8.2781; OBRINK B, 1977, BIOCHEM BIOPH RES CO, V77, P665, DOI 10.1016/S0006-291X(77)80030-2; PASTAN IH, 1981, SCIENCE, V214, P504, DOI 10.1126/science.6170111; PERT CB, 1974, BRAIN RES, V70, P184, DOI 10.1016/0006-8993(74)90228-5; PERTOFT H, 1978, BIOCHEM J, V174, P309, DOI 10.1042/bj1740309; Posner B I, 1981, Recent Prog Horm Res, V37, P539; ROTH BL, 1981, J BIOL CHEM, V256, P117; ROTH BL, 1984, J NEUROCHEM, V42, P1677, DOI 10.1111/j.1471-4159.1984.tb12759.x; SEGLEN PO, 1980, MOL PHARMACOL, V18, P468; SIMANTOV R, 1982, BIOCHIM BIOPHYS ACTA, V721, P478, DOI 10.1016/0167-4889(82)90104-5; SIMANTOV R, 1978, EUR J PHARMACOL, V47, P319, DOI 10.1016/0014-2999(78)90240-6; SIMANTOV R, 1976, BRAIN RES, V107, P650, DOI 10.1016/0006-8993(76)90155-4; SIMANTOV R, 1984, CENTRAL PERIPHERAL E, P65; STADEL JM, 1983, J BIOL CHEM, V258, P3032; WALDO GL, 1983, J BIOL CHEM, V258, P3900; WANG CC, 1983, J BIOL CHEM, V258, P5129; WILLINGHAM MC, 1983, P NATL ACAD SCI-BIOL, V80, P5617, DOI 10.1073/pnas.80.18.5617	42	9	9	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	APR	1986	46	4					1137	1144		10.1111/j.1471-4159.1986.tb00628.x			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	A4074	WOS:A1986A407400018	3005505				2020-06-26	J	SCHUNZEL, G; WOLF, G; ROTHE, F; SEIDLER, E				SCHUNZEL, G; WOLF, G; ROTHE, F; SEIDLER, E			HISTOPHOTOMETRIC EVALUATION OF GLUTAMATE-DEHYDROGENASE ACTIVITY OF THE RAT HIPPOCAMPAL-FORMATION DURING POSTNATAL-DEVELOPMENT, WITH SPECIAL REFERENCE TO THE GLUTAMATE TRANSMITTER METABOLISM	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article									MED ACAD MAGDEBURG,INST BIOL,DDR-3090 MAGDEBURG,GER DEM REP; HUMBOLDT UNIV,INST ANAT,DDR-1040 BERLIN,GER DEM REP							BARCA MA, 1982, CELL MOL BIOL, V28, P187; BAUDRY M, 1981, MOL CELL BIOCHEM, V38, P5, DOI 10.1007/BF00235685; BAUDRY M, 1981, DEV BRAIN RES, V1, P37, DOI 10.1016/0165-3806(81)90092-4; BLACK IB, 1972, J NEUROCHEM, V19, P1367, DOI 10.1111/j.1471-4159.1972.tb01461.x; COTMAN CW, 1981, GLUTAMATE TRANSMITTE, P117; FAGG GE, 1983, NEUROSCIENCE, V9, P701, DOI 10.1016/0306-4522(83)90263-4; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; GRIEF KF, 1982, J NEURO SCI, V2, P843; HAMBERGER A, 1979, BRAIN RES, V168, P531, DOI 10.1016/0006-8993(79)90307-X; MELLGREN SI, 1967, Z ZELLFORSCH MIK ANA, V78, P167, DOI 10.1007/BF00334762; Minkwitz H G, 1976, J Hirnforsch, V17, P213; NICKLAS WJ, 1984, OLIVOPONTOCEREBELLAR, P245; POKORNY J, 1981, BRAIN RES BULL, V7, P113, DOI 10.1016/0361-9230(81)90075-7; Roberts E, 1981, Adv Biochem Psychopharmacol, V27, P91; ROTHE F, 1984, NEUROCHEM RES, V9, P661, DOI 10.1007/BF00964512; ROTHE F, 1983, DEV BRAIN RES, V11, P67, DOI 10.1016/0165-3806(83)90202-X; SCHMIDT W, 1984, J HIRNFORSCH, V25, P505; Schunzel G, 1984, Acta Histochem Suppl, V30, P319; SCHUNZEL G, 1982, ACTA HISTOCHEM, V71, P145, DOI 10.1016/S0065-1281(82)80028-7; SEIDLER E, 1980, HISTOCHEM J, V12, P619, DOI 10.1007/BF01012017; SHANK RP, 1981, LIFE SCI, V28, P837, DOI 10.1016/0024-3205(81)90044-8; SHANK RP, 1983, J NEUROSCI RES, V9, P47, DOI 10.1002/jnr.490090107; SMOLEN A, 1980, BRAIN RES, V181, P315, DOI 10.1016/0006-8993(80)90615-0; Storm-Mathisen J, 1981, GLUTAMATE TRANSMITTE, P89; STORMMATHISEN J, 1983, NATURE, V301, P517, DOI 10.1038/301517a0; SUBBALAKSHMI GYCV, 1985, NEUROCHEM RES, V10, P239, DOI 10.1007/BF00964570; WENZEL J, 1981, J HIRNFORSCH, V22, P639; WOLF G, 1984, J HIRNFORSCH, V25, P249; WOLF G, 1983, ACTA HISTOCHEM, V72, P15, DOI 10.1016/S0065-1281(83)80004-X; WOLF G, 1984, DEV BRAIN RES, V14, P15, DOI 10.1016/0165-3806(84)90004-X; WONG PTH, 1981, J NEUROCHEM, V36, P501, DOI 10.1111/j.1471-4159.1981.tb01620.x	31	21	21	0	1	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013	0272-4340			CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	MAR	1986	6	1					31	42		10.1007/BF00742973			12	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	C6902	WOS:A1986C690200003	2872962				2020-06-26	J	FARAHBAKHSH, ZT; DEAMER, DW; LEE, NM; LOH, HH				FARAHBAKHSH, ZT; DEAMER, DW; LEE, NM; LOH, HH			ENZYMATIC RECONSTITUTION OF BRAIN MEMBRANE AND MEMBRANE OPIATE RECEPTORS	JOURNAL OF NEUROCHEMISTRY			English	Article									UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF LOS ANGELES,DEPT ZOOL,LOS ANGELES,CA 90024							BATZRI S, 1973, BIOCHIM BIOPHYS ACTA, V298, P1015, DOI 10.1016/0005-2736(73)90408-2; BIDLACK JM, 1981, P NATL ACAD SCI-BIOL, V78, P636, DOI 10.1073/pnas.78.1.636; BROEKHUYSE RM, 1968, BIOCHIM BIOPHYS ACTA, V152, P307, DOI 10.1016/0005-2760(68)90038-6; CHO TM, 1981, LIFE SCI, V28, P2651, DOI 10.1016/0024-3205(81)90723-2; COLARD O, 1980, BIOCH BIOPHYS ACTA, V618, P888; CRAIN RC, 1980, BIOCHIM BIOPHYS ACTA, V620, P37, DOI 10.1016/0005-2760(80)90182-4; DEAMER DW, 1980, J CELL BIOL, V84, P461, DOI 10.1083/jcb.84.2.461; DEPIERRE J, 1976, BIOCH ANAL MEMBRANES, P79; EIBEL H, 1969, EUR J BIOCHEM, V9, P250; Fisher K, 1974, Methods Enzymol, V32, P35; FOLCH J, 1957, J BIOL CHEM, V226, P497; HAUSER H, 1972, H-S Z PHYSIOL CHEM, V353, P1579, DOI 10.1515/bchm2.1972.353.2.1579; HEIDMANN T, 1980, EUR J BIOCH, V110, P6; HIGGINS JA, 1972, J CELL BIOL, V55, P282, DOI 10.1083/jcb.55.2.282; HOLUB BJ, 1979, LIPIDS, V14, P529, DOI 10.1007/BF02533526; ICHIDA S, 1976, JPN J PHARM, V26, P36; INSEL PA, 1978, BIOCHEMISTRY-US, V17, P5269, DOI 10.1021/bi00617a029; JARNEFELT J, 1972, BIOCHIM BIOPHYS ACTA, V266, P91, DOI 10.1016/0005-2736(72)90123-X; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KAMP HH, 1973, BIOCHIM BIOPHYS ACTA, V318, P313, DOI 10.1016/0005-2736(73)90196-X; KIMELBERG HK, 1972, BIOCHIM BIOPHYS ACTA, V282, P277, DOI 10.1016/0005-2736(72)90334-3; KNOWLES AF, 1975, J BIOL CHEM, V250, P3538; KORNBERG RD, 1971, BIOCHEMISTRY-US, V10, P1111; LAW PY, 1981, J NEUROCHEM, V36, P1834, DOI 10.1111/j.1471-4159.1981.tb00438.x; LENAZ G, 1975, J BIOENERG, V7, P223, DOI 10.1007/BF01558409; LIMBIRD LE, 1976, MOL PHARMACOL, V12, P559; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADDEN TD, 1981, BIOCHIM BIOPHYS ACTA, V641, P265, DOI 10.1016/0005-2736(81)90590-3; MARTONOSI A, 1968, J BIOL CHEM, V243, P61; MARTONOSI A, 1971, ARCH BIOCH BIOPHYS, V174, P529; MOORE NF, 1977, BIOCHEMISTRY-US, V16, P4708, DOI 10.1021/bi00640a027; MORIMOTO K, 1978, J BIOL CHEM, V253, P5056; PERT CB, 1973, P NATL ACAD SCI USA, V70, P2243, DOI 10.1073/pnas.70.8.2243; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; Post R. L., 1967, METHOD ENZYMOL, V10, P762, DOI 10.1016/0076-6879 (67)10125-0; RUEGG UT, 1980, EUR J PHARMACOL, V64, P367, DOI 10.1016/0014-2999(80)90247-2; RYDSTROM J, 1974, BIOCHEM BIOPH RES CO, V60, P448, DOI 10.1016/0006-291X(74)90224-1; SIMON EJ, 1975, SCIENCE, V190, P389, DOI 10.1126/science.1182043; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; SIMONDS WF, 1980, P NATL ACAD SCI-BIOL, V77, P4623, DOI 10.1073/pnas.77.8.4623; SUN GY, 1980, BIOCHEM BIOPH RES CO, V94, P1278, DOI 10.1016/0006-291X(80)90558-6; TANAKA R, 1965, ARCH BIOCHEM BIOPHYS, V111, P583, DOI 10.1016/0003-9861(65)90239-0; TANIGUCHI K, 1971, J BIOCHEM, V69, P543; TERENIUS L, 1973, ACTA PHARMACOL TOX, V32, P317; THOMPSON W, 1978, J BIOL CHEM, V250, P2712; VANDENBOSCH H, 1972, REV PHYSL, V66, P14; WELTZIEN HU, 1979, J BIOL CHEM, V254, P2652; WHEELER KP, 1970, NATURE, V255, P449; WISE RW, 1980, EUR J BIOCHEM, V109, P201, DOI 10.1111/j.1432-1033.1980.tb04785.x	49	17	17	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	MAR	1986	46	3					953	962		10.1111/j.1471-4159.1986.tb13062.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	A0619	WOS:A1986A061900040	3005499				2020-06-26	J	FURLEY, CW				FURLEY, CW			EFFECT OF CHEMICAL IMMOBILIZATION ON THE HEART-RATE AND HEMATOLOGICAL VALUES IN CAPTIVE GAZELLES	VETERINARY RECORD			English	Note										FURLEY, CW (reprint author), AL AIN ZOO & AQUARIUM,POB 1204,ABU DHABI,U ARAB EMIRATES.						BECKER M, 1980, RES VET SCI, V29, P21; BRANDER GC, 1977, VET APPLIED PHARM TH, P81; DREVEMO S, 1974, Journal of Wildlife Diseases, V10, P377; HARTHOORN AM, 1976, CHEM CAPTURE ANIMALS, P283; Hawkey C., 1980, The comparative pathology of zoo animals, P625; JACOBSON ER, 1983, J AM VET MED ASSOC, V183, P1260; KOCAN AA, 1981, J AM VET MED ASSOC, V179, P1153; LEES P, 1976, VET REC, V99, P55, DOI 10.1136/vr.99.3.55; OLSEN JH, 1984, J ZOO ANIM MED, V15, P5, DOI 10.2307/20094671; Seal U.S., 1976, Journal Zool Anim Med, V7, P7, DOI 10.2307/20094340; SEAL US, 1972, J WILDLIFE MANAGE, V36, P1034, DOI 10.2307/3799230	11	3	3	0	0	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.	FEB 15	1986	118	7					178	180		10.1136/vr.118.7.178			3	Veterinary Sciences	Veterinary Sciences	A1117	WOS:A1986A111700006	3962130				2020-06-26	J	FUDER, H; BUDER, M; RIERS, HD; ROTHACHER, G				FUDER, H; BUDER, M; RIERS, HD; ROTHACHER, G			ON THE OPIOID RECEPTOR SUBTYPE INHIBITING THE EVOKED RELEASE OF H-3 NORADRENALINE FROM GUINEA-PIG ATRIA INVITRO	NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY			English	Article										FUDER, H (reprint author), UNIV MAINZ,INST PHARMAKOL,OBERE ZAHLBACHER STR 67,D-6500 MAINZ,FED REP GER.						ANGUS JA, 1984, BRIT J PHARMACOL, V81, P201, DOI 10.1111/j.1476-5381.1984.tb10762.x; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; BARLOW RB, 1980, QUANTITATIVE ASPECTS, P88; BHARGAVA HN, 1984, HDB STEREOISOMERS DR, P401; FUDER H, 1982, N-S ARCH PHARMACOL, V318, P210, DOI 10.1007/BF00500482; FUDER H, 1985, BRIT J PHARMACOL, V86, P905, DOI 10.1111/j.1476-5381.1985.tb11113.x; GRAEFE KH, 1973, BIOCHEM PHARMACOL, V22, P1147, DOI 10.1016/0006-2952(73)90231-1; HUGHES J, 1983, BRIT MED BULL, V39, P1; ILLES P, 1985, EUR J PHARMACOL, V107, P397, DOI 10.1016/0014-2999(85)90271-7; ILLES P, 1980, BRAIN RES, V191, P511, DOI 10.1016/0006-8993(80)91299-8; ILLES P, 1985, J PHARMACOL EXP THER, V232, P526; ITO Y, 1980, J PHYSIOL-LONDON, V307, P367, DOI 10.1113/jphysiol.1980.sp013440; JACKISCH R, 1985, Naunyn-Schmiedeberg's Archives of Pharmacology, V329, pR95; KAMIKAWA Y, 1983, BRIT J PHARMACOL, V78, P693, DOI 10.1111/j.1476-5381.1983.tb09422.x; LANG RE, 1983, LIFE SCI, V32, P399, DOI 10.1016/0024-3205(83)90086-3; LEDDA F, 1984, EUR J PHARMACOL, V102, P443, DOI 10.1016/0014-2999(84)90565-X; LEDDA F, 1982, EUR J PHARMACOL, V85, P247, DOI 10.1016/0014-2999(82)90476-9; LORD AH, 1973, NATURE, V267, P495; MAGNAN J, 1982, N-S ARCH PHARMACOL, V319, P197, DOI 10.1007/BF00495865; MARTIN DR, 1984, PHARM REV, V35, P283; MCCULLOCH MW, 1974, CLIN EXP PHARMACOL P, V1, P275, DOI 10.1111/j.1440-1681.1974.tb00550.x; MERZ H, 1982, QUO VADIS ANALGESIA, P295; MILNER JD, 1982, BRIT J PHARMACOL, V76, P45, DOI 10.1111/j.1476-5381.1982.tb09189.x; MONTEL H, 1973, BRIT J PHARMACOL, V49, P628, DOI 10.1111/j.1476-5381.1973.tb08538.x; OKA T, 1982, EUR J PHARMACOL, V77, P137, DOI 10.1016/0014-2999(82)90008-5; OKA T, 1980, [No title captured], V73, P235; PATERSON SJ, 1983, BRIT MED BULL, V39, P31, DOI 10.1093/oxfordjournals.bmb.a071787; SANGER DJ, 1981, NEUROPHARMACOLOGY, V20, P45, DOI 10.1016/0028-3908(81)90040-X; SMITH CFC, 1983, LIFE SCI, V33, P327, DOI 10.1016/0024-3205(83)90509-X; SNYDER SH, 1984, SCIENCE, V224, P22, DOI 10.1126/science.6322304; STARKE K, 1985, N-S ARCH PHARMACOL, V329, P206, DOI 10.1007/BF00501214; STARKE K, 1977, REV PHYSIOL BIOCH P, V77, P1, DOI 10.1007/BFb0050157; STEPHENSON RP, 1956, BRIT J PHARM CHEMOTH, V11, P379, DOI 10.1111/j.1476-5381.1956.tb00006.x; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; WATERFIELD AA, 1975, LIFE SCI, V16, P1787, DOI 10.1016/0024-3205(75)90275-1; WEIHE E, 1983, LIFE SCI, V33, P711, DOI 10.1016/0024-3205(83)90601-X; WEIHE E, 1985, NEUROPEPTIDES, V5, P453, DOI 10.1016/0143-4179(85)90052-6; WEITZELL R, 1984, N-S ARCH PHARMACOL, V328, P186, DOI 10.1007/BF00512070; WONGDUSTING K, 1985, EUR J PHARM, V111, P65; WUSTER M, 1979, NEUROSCI LETT, V15, P193, DOI 10.1016/0304-3940(79)96112-3; YOSHIMURA K, 1982, EUR J PHARMACOL, V84, P17, DOI 10.1016/0014-2999(82)90152-2	41	45	46	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0028-1298			N-S ARCH PHARMACOL	Naunyn-Schmiedebergs Arch. Pharmacol.	FEB	1986	332	2					148	155		10.1007/BF00511405			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	A2185	WOS:A1986A218500006	2871496				2020-06-26	J	JAUZAC, P; FRANCES, B; PUGET, A; MOISAND, C; MEUNIER, JC				JAUZAC, P; FRANCES, B; PUGET, A; MOISAND, C; MEUNIER, JC			DIFFERENTIAL REGULATION OF 2 MOLECULAR-FORMS OF A MU-OPIOID RECEPTOR TYPE BY SODIUM-IONS, MANGANESE IONS AND BY GUANYL-5'-YL IMIDODIPHOSPHATE	JOURNAL OF RECEPTOR RESEARCH			English	Article									CNRS, PHARMACOL & TOXICOL FONDAMENTALES LAB, 205 ROUTE NARBONNE, F-31400 TOULOUSE, FRANCE; CHU RANGUEIL, BIOCHEM LAB 4, F-31400 TOULOUSE, FRANCE							BLUME AJ, 1979, P NATL ACAD SCI USA, V76, P5626, DOI 10.1073/pnas.76.11.5626; BOWEN WD, 1981, P NATL ACAD SCI-BIOL, V78, P4818, DOI 10.1073/pnas.78.8.4818; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; BROWN DA, 1980, NATURE, V283, P673, DOI 10.1038/283673a0; CHANCE B, 1955, METHOD ENZYMOL, V2, P764, DOI 10.1016/S0076-6879(55)02300-8; CHANG KJ, 1979, J BIOL CHEM, V254, P2610; CHANG KJ, 1981, P NATL ACAD SCI-BIOL, V78, P4141, DOI 10.1073/pnas.78.7.4141; CHILDERS SR, 1980, J NEUROCHEM, V34, P583, DOI 10.1111/j.1471-4159.1980.tb11184.x; CODINA J, 1983, P NATL ACAD SCI-BIOL, V80, P4276, DOI 10.1073/pnas.80.14.4276; COOPER DMF, 1982, J NEUROCHEM, V38, P1164, DOI 10.1111/j.1471-4159.1982.tb05365.x; DELEAN A, 1984, MOL PHARMACOL, V26, P498; DUGGAN AW, 1983, PHARMACOL REV, V35, P219; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FEINBERG AP, 1976, P NATL ACAD SCI USA, V73, P4215, DOI 10.1073/pnas.73.11.4215; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KILPATRICK BF, 1983, J BIOL CHEM, V258, P3528; KOSKI G, 1982, J BIOL CHEM, V257, P4035; KOSKI G, 1981, P NATL ACAD SCI-BIOL, V78, P4185, DOI 10.1073/pnas.78.7.4185; KOSTERLITZ HW, 1981, BRIT J PHARMACOL, V73, P939, DOI 10.1111/j.1476-5381.1981.tb08749.x; KOUAKOU Y, 1982, MOL PHARMACOL, V21, P564; LIMBIRD LE, 1980, J BIOL CHEM, V255, P1854; LIMBIRD LE, 1978, P NATL ACAD SCI USA, V75, P228, DOI 10.1073/pnas.75.1.228; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEUNIER JC, 1982, LIFE SCI, V31, P1327, DOI 10.1016/0024-3205(82)90373-3; MEUNIER JC, 1983, MOL PHARMACOL, V24, P23; NORTH RA, 1985, J PHYSIOL-LONDON, V364, P265, DOI 10.1113/jphysiol.1985.sp015743; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; PASTERNAK GW, 1975, MOL PHARMACOL, V11, P735; PERT CB, 1973, SCIENCE, V182, P1359, DOI 10.1126/science.182.4119.1359; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; PFEIFFER A, 1982, J NEUROSCI, V2, P912; PUGET A, 1984, NEUROPEPTIDES, V5, P129, DOI 10.1016/0143-4179(84)90044-1; PUGET A, 1983, CR ACAD SCI III-VIE, V296, P475; RACKER E, 1955, METHOD ENZYMOL, V1, P500, DOI 10.1016/0076-6879(55)01084-7; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; ROSS EM, 1980, ANNU REV BIOCHEM, V49, P553, DOI 10.1146/annurev.bi.49.070180.002533; RUEGG UT, 1981, P NATL ACAD SCI-BIOL, V78, P4635, DOI 10.1073/pnas.78.7.4635; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P590, DOI 10.1073/pnas.72.2.590; SIMON EJ, 1975, SCIENCE, V190, P389, DOI 10.1126/science.1182043; SIMON EJ, 1975, J PHARMACOL EXP THER, V192, P531; SIMON J, 1984, J NEUROCHEM, V43, P957, DOI 10.1111/j.1471-4159.1984.tb12830.x; SMITH SK, 1982, J BIOL CHEM, V257, P471; SMITH SK, 1981, P NATL ACAD SCI-BIOL, V78, P4026, DOI 10.1073/pnas.78.7.4026; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7; ZUKIN RS, 1980, BRAIN RES, V186, P238	47	15	15	0	0	MARCEL DEKKER INC	NEW YORK	270 MADISON AVE, NEW YORK, NY 10016 USA	0197-5110			J RECEPTOR RES	J. Recept. Res.		1986	6	1					1	25		10.3109/10799898609073921			25	Cell Biology	Cell Biology	C4118	WOS:A1986C411800001	3012080				2020-06-26	J	AHMED, MS; SCHINFELD, JS; JONES, R; CAVINATO, AG; BAKER, C				AHMED, MS; SCHINFELD, JS; JONES, R; CAVINATO, AG; BAKER, C			CORRELATION BETWEEN THE NUMBER OF PLACENTAL OPIOID RECEPTORS, MODE OF DELIVERY, AND MATERNAL NARCOTIC USE	MEMBRANE BIOCHEMISTRY			English	Article									UNIV TENNESSEE,CTR HLTH SCI,DEPT BIOCHEM,MEMPHIS,TN 38163; UNIV TENNESSEE,CTR HLTH SCI,DEPT OBSTET & GYNECOL,MEMPHIS,TN 38163					NIADDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [GRAM-07408]		ABBOUD TK, 1983, AM J OBSTET GYNECOL, V146, P927, DOI 10.1016/0002-9378(83)90966-3; Ahmed M S, 1981, Placenta Suppl, V3, P115; AHMED MS, 1983, MEMBRANE BIOCHEM, V5, P35, DOI 10.3109/09687688309149632; FACCHINETTI F, 1983, OBSTET GYNECOL, V62, P764; GENAZZANI AR, 1984, AM J OBSTET GYNECOL, V148, P198, DOI 10.1016/S0002-9378(84)80176-3; GOLAND RS, 1981, J CLIN ENDOCR METAB, V52, P74, DOI 10.1210/jcem-52-1-74; GOLDSTEIN A, 1976, SCIENCE, V193, P1081, DOI 10.1126/science.959823; GOODLIN RC, 1981, AM J OBSTET GYNECOL, V139, P16, DOI 10.1016/0002-9378(81)90403-8; HERVONEN A, 1981, CELL TISSUE RES, V214, P33; LAGAMMA EF, 1982, AM J OBSTET GYNECOL, V143, P933, DOI 10.1016/0002-9378(82)90477-X; PANERAI AE, 1983, J CLIN ENDOCR METAB, V57, P537, DOI 10.1210/jcem-57-3-537; PILKINGTON JW, 1983, AM J OBSTET GYNECOL, V145, P111, DOI 10.1016/0002-9378(83)90352-6; RASMUSSEN DD, 1983, J CLIN ENDOCR METAB, V57, P881, DOI 10.1210/jcem-57-5-881; Sastry BV, 1979, PHARMACOL REV, V30, P65; SHAABAN MM, 1982, AM J OBSTET GYNECOL, V144, P560, DOI 10.1016/0002-9378(82)90228-9; TAO PL, 1984, P W PHARMACOL SOC, V27, P557; VALETTE A, 1980, BIOCHEM PHARMACOL, V29, P2657, DOI 10.1016/0006-2952(80)90082-9; WARDLAW SL, 1979, J CLIN ENDOCR METAB, V49, P888, DOI 10.1210/jcem-49-6-888	18	12	12	0	0	TAYLOR & FRANCIS	BRISTOL	1900 FROST ROAD, SUITE 101, BRISTOL, PA 19007-1598	0149-046X			MEMBRANE BIOCHEM			1986	6	3					255	267		10.3109/09687688609065452			13	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	F7076	WOS:A1986F707600004	3029549				2020-06-26	J	BENALAL, D; BACHRACH, U				BENALAL, D; BACHRACH, U			OPIATES AND CULTURED NEURO-BLASTOMA X GLIOMA-CELLS - EFFECT ON CYCLIC-AMP AND POLYAMINE LEVELS AND ON ORNITHINE DECARBOXYLASE AND PROTEIN-KINASE ACTIVITIES	BIOCHEMICAL JOURNAL			English	Article										BENALAL, D (reprint author), HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MOLEC BIOL,IL-91010 JERUSALEM,ISRAEL.						BACHRACH U, 1975, P NATL ACAD SCI USA, V72, P3087, DOI 10.1073/pnas.72.8.3087; BACHRACH U, 1979, LIFE SCI, V25, P1879, DOI 10.1016/0024-3205(79)90608-8; BACHRACH U, 1973, FUNCTION NATURALLY O, P108; BLOSSER JC, 1975, FED PROC, V34, P713; BROWN BL, 1972, ADV CYCL NUCL RES<D>, V2, P25; BYUS CV, 1975, SCIENCE, V187, P650, DOI 10.1126/science.163486; CALDARERA CM, 1970, ANN NY ACAD SCI, V171, P709, DOI 10.1111/j.1749-6632.1970.tb39383.x; COHEN SS, 1971, INTRO POLYAMINES, P89; EINSENBERG RM, 1980, LIFE SCI, V26, P935; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; JANNE J, 1978, BIOCHIM BIOPHYS ACTA, V473, P241, DOI 10.1016/0304-419X(78)90015-X; KLEE WA, 1974, P NATL ACAD SCI USA, V71, P3474, DOI 10.1073/pnas.71.9.3474; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAENO H, 1971, J BIOL CHEM, V246, P134; MCMILLAN DE, 1970, J PHARMACOL EXP THER, V175, P443; PURI SK, 1975, LIFE SCI, V16, P759, DOI 10.1016/0024-3205(75)90352-5; Seiler N, 1970, Methods Biochem Anal, V18, P259, DOI 10.1002/9780470110362.ch5; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P590, DOI 10.1073/pnas.72.2.590; SHARMA SK, 1977, P NATL ACAD SCI USA, V74, P3365, DOI 10.1073/pnas.74.8.3365; STOKES KB, 1979, J NEUROCHEM, V34, P1058; TELL GP, 1975, FEBS LETT, V51, P242, DOI 10.1016/0014-5793(75)80896-9	22	25	25	0	0	PORTLAND PRESS	LONDON	59 PORTLAND PLACE, LONDON, ENGLAND W1N 3AJ	0264-6021			BIOCHEM J	Biochem. J.		1985	227	2					389	395		10.1042/bj2270389			7	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	AGE72	WOS:A1985AGE7200006	2988499	Green Published			2020-06-26	J	OWEN, F; BOURNE, RC; POULTER, M; CROW, TJ; PATERSON, SJ; KOSTERLITZ, HW				OWEN, F; BOURNE, RC; POULTER, M; CROW, TJ; PATERSON, SJ; KOSTERLITZ, HW			TRITIATED ETORPHINE AND NALOXONE BINDING TO OPIOID RECEPTORS IN CAUDATE-NUCLEUS IN SCHIZOPHRENIA	BRITISH JOURNAL OF PSYCHIATRY			English	Article									UNIV ABERDEEN MARISCHAL COLL,RES ADDICT DRUGS UNIT,ABERDEEN AB9 1AS,SCOTLAND	OWEN, F (reprint author), CLIN RES CTR,DIV PSYCHIAT,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.		crow, timothy J/M-8327-2014	crow, timothy J/0000-0002-5482-6655			BENNETT JP, 1979, ARCH GEN PSYCHIAT, V36, P927; DEAKIN JFW, 1980, BIOCH SCHIZOPHRENIA; FEIGHNER JP, 1972, ARCH GEN PSYCHIAT, V26, P57, DOI 10.1001/archpsyc.1972.01750190059011; JACQUET YF, 1976, SCIENCE, V194, P632, DOI 10.1126/science.185695; KOSTERLITZ HW, 1981, BRIT J PHARMACOL, V73, pP299; MACKAY AVP, 1979, BRIT J PSYCHIAT, V135, P470, DOI 10.1192/bjp.135.5.470; OWEN F, 1978, LANCET, V2, P223, DOI 10.1016/S0140-6736(78)91740-3; OWEN F, 1979, LIFE SCI, V25, P385, DOI 10.1016/0024-3205(79)90270-4; OWEN F, 1983, CELL SURFACE RECEPTO; REISINE TD, 1980, [No title captured]; SUTHERLAND EW, 1949, J BIOL CHEM, V180, P825; TERENIUS L, 1976, NEUROSCI LETT, V3, P157, DOI 10.1016/0304-3940(76)90086-0; WHITAKER PM, 1981, ARCH GEN PSYCHIAT, V38, P278; Wing J., 1974, MEASUREMENT CLASSIFI	14	9	9	0	1	ROYAL COLLEGE OF PSYCHIATRISTS	LONDON	BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON, ENGLAND SW1X 8PG	0007-1250			BRIT J PSYCHIAT	Br. J. Psychiatry		1985	146	MAY					507	509		10.1192/bjp.146.5.507			3	Psychiatry	Psychiatry	AHP76	WOS:A1985AHP7600008	2990627				2020-06-26	J	FABBRI, A; TSAIMORRIS, CH; LUNA, S; FRAIOLI, F; DUFAU, ML				FABBRI, A; TSAIMORRIS, CH; LUNA, S; FRAIOLI, F; DUFAU, ML			OPIATE RECEPTORS ARE PRESENT IN THE RAT TESTIS - IDENTIFICATION AND LOCALIZATION IN SERTOLI CELLS	ENDOCRINOLOGY			English	Note									UNIV ROMA LA SAPIENZA,IST CLIN MED GEN 05,ROME,ITALY	FABBRI, A (reprint author), NICHHD,MOLEC ENDOCRINOL SECT,BETHESDA,MD 20205, USA.			Tsai Morris, Chon Hwa/0000-0002-8113-0979			AQUILANO DR, 1984, ENDOCRINOLOGY, V114, P499, DOI 10.1210/endo-114-2-499; BARDIN CW, 1984, ANN NY ACAD SCI, V238, P346; Fabbri A., 1984, OPIOID PEPTIDES PERI, P61; GERENDAI I, 1983, ANDROLOGIA, V15, P398; GERENDAI I, 1984, ENDOCRINOLOGY, V115, P1645, DOI 10.1210/endo-115-4-1645; GUNSALUS GL, 1978, SCIENCE, V200, P65, DOI 10.1126/science.635573; KETELSLEGERS JM, 1975, BIOCHEMISTRY, V14, P30; MARGIORIS AN, 1983, ENDOCRINOLOGY, V113, P663, DOI 10.1210/endo-113-2-663; PINTAR JE, 1984, SCIENCE, V225, P632, DOI 10.1126/science.6740329; ROBSON LE, 1983, HDB PSYCHOPHARMACOLO, V17, P13; SCHER PM, 1982, J ANDROL, V3, P35; SHAHA C, 1984, ENDOCRINOLOGY, V114, P1584, DOI 10.1210/endo-114-5-1584; SHARP B, 1980, BIOCHEM BIOPH RES CO, V95, P618, DOI 10.1016/0006-291X(80)90830-X; TSAIMORRIS CH, 1985, ENDOCRINOLOGY, V116, P38, DOI 10.1210/endo-116-1-38; TSONG SD, 1982, BIOL REPROD, V27, P755; TSONG SD, 1982, ENDOCRINOLOGY, V110, P2204, DOI 10.1210/endo-110-6-2204; TUNG PS, 1984, BIOL REPROD, V30, P199, DOI 10.1095/biolreprod30.1.199	17	96	96	0	0	ENDOCRINE SOC	BETHESDA	4350 EAST WEST HIGHWAY SUITE 500, BETHESDA, MD 20814-4110	0013-7227			ENDOCRINOLOGY	Endocrinology		1985	117	6					2544	2546		10.1210/endo-117-6-2544			3	Endocrinology & Metabolism	Endocrinology & Metabolism	AUJ60	WOS:A1985AUJ6000041	2998740				2020-06-26	J	ACETO, MD; HARRIS, LS; WOODS, JH; KATZ, JL; SMITH, CB; MEDZIHRADSKY, F; JACOBSON, AE; SHIOTANI, S				ACETO, MD; HARRIS, LS; WOODS, JH; KATZ, JL; SMITH, CB; MEDZIHRADSKY, F; JACOBSON, AE; SHIOTANI, S			PHARMACOLOGICAL ACTIONS OF THE RACEMIC AND THE ENANTIOMERIC 1,4-DIMETHYL-10-HYDROXY-2,3,4,5,6,7-HEXAHYDRO-1,6-METHANO-1H-4-BENZAZONINES (C-HOMOBENZOMORPHANS)	JAPANESE JOURNAL OF PHARMACOLOGY			English	Article									UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; NIADDKD,CHEM LAB,MED CHEM SECT,BETHESDA,MD 20205; TOYAMA UNIV,COLL LIBERAL ARTS,TOYAMA 930,JAPAN	ACETO, MD (reprint author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL,RICHMOND,VA 23298, USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-00254]; PHS HHSUnited States Public Health Service [271-77-3404]		ACETO MD, 1978, EUR J PHARMACOL, V50, P203, DOI 10.1016/0014-2999(78)90352-7; AGER JH, 1969, J MED CHEM, V12, P288, DOI 10.1021/jm00302a020; Atwell L., 1978, LAB ANIM, V7, P42; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; DEWEY WL, 1970, J PHARMACOL EXP THER, V175, P435; EDDY NB, 1953, J PHARMACOL EXP THER, V107, P385; FRASER HR, 1962, 24TH M NRC NAS US; JACOBSON AE, 1965, J MED CHEM, V8, P563, DOI 10.1021/jm00329a003; JASINSKI DR, 1969, 31ST M NRC NAS US; KOSTERLITZ HW, 1969, 31ST M NRC NAS US; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAY EL, 1976, PSYCHOPHARMACOLOGICA, V4, P35; MEDZIHRADSKY F, 1976, BRAIN RES, V108, P212, DOI 10.1016/0006-8993(76)90180-3; MEDZIHRADSKY F, 1971, J NEUROCHEM, V18, P1599, DOI 10.1111/j.1471-4159.1971.tb00023.x; PATON WDM, 1957, BRIT J PHARM CHEMOTH, V12, P119, DOI 10.1111/j.1476-5381.1957.tb01373.x; PEARL J, 1966, J PHARMACOL EXP THER, V154, P319; PERT CB, 1973, SCIENCE, V182, P1359, DOI 10.1126/science.182.4119.1359; Seevers MH, 1936, J PHARMACOL EXP THER, V56, P147; Seevers MH, 1963, PHYSIOL PHARMACOL, P565; SEIGEL S, 1956, [No title captured], P116; SHIOTANI S, 1978, J MED CHEM, V21, P153, DOI 10.1021/jm00200a001; SHIOTANI S, 1979, J MED CHEM, V22, P1558, DOI 10.1021/jm00198a027; SHIOTANI S, 1976, J MED CHEM, V19, P803, DOI 10.1021/jm00228a013; TEIGER DG, 1974, J PHARMACOL EXP THER, V190, P408; VILLARREAL JE, 1970, ADV MENTAL SCI, V2, P83	25	2	2	0	0	JAPANESE PHARMACOLOGICAL SOC	KYOTO	EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO 604, JAPAN	0021-5198			JPN J PHARMACOL	Jpn. J. Pharmacol.		1985	39	1					7	19		10.1254/jjp.39.7			13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	APH91	WOS:A1985APH9100002	4068392	Bronze			2020-06-26	J	NOZAKI, M; CHO, TM				NOZAKI, M; CHO, TM			EFFECTS OF 5,5'-DITHIOBIS-(2-NITROBENZOIC ACID) ON OPIATE BINDING TO BOTH THE MEMBRANE-BOUND RECEPTOR AND THE PARTIALLY PURIFIED OPIATE RECEPTOR	JOURNAL OF NEUROCHEMISTRY			English	Article									UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143					NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-00564, DA-01583]		AHMED MS, 1979, ENDOGENOUS EXOGENOUS, P51; BOWEN WD, 1982, CELL MOL NEUROBIOL, V2, P115, DOI 10.1007/BF00711077; CHO TM, 1983, P NATL ACAD SCI-BIOL, V80, P5176, DOI 10.1073/pnas.80.17.5176; LOH HH, 1974, LIFE SCI, V14, P2231, DOI 10.1016/0024-3205(74)90105-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NIWA M, 1983, LIFE SCI, V33, P211, DOI 10.1016/0024-3205(83)90480-0; NOZAKI M, 1982, LIFE SCI, V31, P1339, DOI 10.1016/0024-3205(82)90376-9; PASTERNAK GW, 1975, MOL PHARMACOL, V11, P340; SIMON EJ, 1975, P NATL ACAD SCI USA, V72, P2404, DOI 10.1073/pnas.72.6.2404; WILSON HA, 1975, NATURE, V253, P448, DOI 10.1038/253448a0	10	8	8	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.		1985	45	2					461	464		10.1111/j.1471-4159.1985.tb04010.x			4	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AMB58	WOS:A1985AMB5800019	2989428				2020-06-26	J	CASTANAS, E; BOURHIM, N; GIRAUD, P; BOUDOURESQUE, F; CANTAU, P; OLIVER, C				CASTANAS, E; BOURHIM, N; GIRAUD, P; BOUDOURESQUE, F; CANTAU, P; OLIVER, C			INTERACTION OF OPIATES WITH OPIOID BINDING-SITES IN THE BOVINE ADRENAL-MEDULLA .2. INTERACTION WITH KAPPA-SITES	JOURNAL OF NEUROCHEMISTRY			English	Article										CASTANAS, E (reprint author), UER NORD,NEUROENDOCRINOL EXPTL LAB,CNRS,UA 560,BD P DRAMAND,F-13326 MARSEILLE 15,FRANCE.		Castanas, Elias/E-7007-2010	Castanas, Elias/0000-0002-8370-1835			ATTALI B, 1982, NEUROPEPTIDES, V3, P53, DOI 10.1016/0143-4179(82)90065-8; AUDIGIER Y, 1983, VET PHARM TOXICOLOGY, P451; BARDO MT, 1982, J NEUROCHEM, V39, P1751, DOI 10.1111/j.1471-4159.1982.tb08015.x; BOEYNAEMS JM, 1975, J CYCLIC NUCL PROT, V1, P123; BRUNS RF, 1983, ANAL BIOCHEM, V132, P74, DOI 10.1016/0003-2697(83)90427-X; CASTANAS E, 1983, LIFE SCI, V33, P295, DOI 10.1016/0024-3205(83)90501-5; CASTANAS E, 1984, MOL PHARMACOL, V25, P38; CASTANAS E, 1985, J NEUROCHEM, V45, P677, DOI 10.1111/j.1471-4159.1985.tb04046.x; CHANG KJ, 1981, P NATL ACAD SCI-BIOL, V78, P4141, DOI 10.1073/pnas.78.7.4141; CHAPMAN DB, 1980, ANNU REV PHARMACOL, V20, P553, DOI 10.1146/annurev.pa.20.040180.003005; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CORBETT AD, 1982, NATURE, V299, P79, DOI 10.1038/299079a0; COSTA E, 1983, FED PROC, V42, P2946; KOSTERLITZ HW, 1984, KAPPA RECEPTORS THEI, P265; LOH HH, 1980, ANNU REV PHARMACOL, V20, P201, DOI 10.1146/annurev.pa.20.040180.001221; MAGNAN J, 1982, LIFE SCI, V31, P1359, DOI 10.1016/0024-3205(82)90381-2; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OLIVEIRA CR, 1984, J NEUROCHEM, V43, P455, DOI 10.1111/j.1471-4159.1984.tb00921.x; PFEIFFER A, 1982, J NEUROSCI, V2, P912; ROSSIER J, 1981, LIFE SCI, V28, P781, DOI 10.1016/0024-3205(81)90161-2; SADEE W, 1982, J NEUROCHEM, V39, P659, DOI 10.1111/j.1471-4159.1982.tb07943.x; SNYDER SH, 1975, HDB PSYCHOPHARMACOLO, P329; THAKUR AK, 1980, ANAL BIOCHEM, V107, P279, DOI 10.1016/0003-2697(80)90385-1; WEILAND GA, 1981, LIFE SCI, V29, P313, DOI 10.1016/0024-3205(81)90324-6	24	98	98	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.		1985	45	3					688	699		10.1111/j.1471-4159.1985.tb04047.x			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	ANY57	WOS:A1985ANY5700004	2993510				2020-06-26	J	GRIFFIN, MT; LAW, PY; LOH, HH				GRIFFIN, MT; LAW, PY; LOH, HH			INVOLVEMENT OF BOTH INHIBITORY AND STIMULATORY GUANINE-NUCLEOTIDE BINDING-PROTEINS IN THE EXPRESSION OF CHRONIC OPIATE REGULATION OF ADENYLATE-CYCLASE ACTIVITY IN NG108-15 CELLS	JOURNAL OF NEUROCHEMISTRY			English	Article									UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,LANGLEY PORTER PSYCHIAT INST,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143				Law, Ping-Yee/0000-0002-5364-1093	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-00564, 5-K02DA 70554]		CODINA J, 1983, P NATL ACAD SCI-BIOL, V80, P4276, DOI 10.1073/pnas.80.14.4276; GILLMAN AG, 1984, J CLIN INVEST, V73, P1; HANSKI E, 1981, J BIOL CHEM, V256, P2911; HILDEBRANDT JD, 1983, NATURE, V302, P706, DOI 10.1038/302706a0; HSIA JA, 1984, J BIOL CHEM, V259, P1086; KATADA T, 1982, J BIOL CHEM, V257, P7210; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; KUROSE H, 1983, J BIOL CHEM, V258, P4870; LAW PY, 1982, MOL PHARMACOL, V21, P483; LAW PY, 1983, MOL PHARMACOL, V24, P413; LAW PY, 1982, MOL PHARMACOL, V72, P1; Lefkowitz R J, 1980, Curr Top Cell Regul, V17, P205; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNING DR, 1983, J BIOL CHEM, V258, P7059; MURAYAMA T, 1983, J BIOL CHEM, V258, P319; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PFEUFFER T, 1977, J BIOL CHEM, V252, P7224; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SHARMA SK, 1977, P NATL ACAD SCI USA, V74, P3365, DOI 10.1073/pnas.74.8.3365; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; TRABER J, 1975, NATURE, V253, P120, DOI 10.1038/253120a0	21	43	43	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.		1985	45	5					1585	1589		10.1111/j.1471-4159.1985.tb07230.x			5	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	ASH78	WOS:A1985ASH7800034	3930663				2020-06-26	J	TOBEY, RW; BALLARD, WB				TOBEY, RW; BALLARD, WB			INCREASED MORTALITY IN GRAY WOLVES CAPTURED WITH ACEPROMAZINE AND ETORPHINE HYDROCHLORIDE IN COMBINATION	JOURNAL OF WILDLIFE DISEASES			English	Note										TOBEY, RW (reprint author), ALASKA DEPT FISH & GAME,POB 47,GLENNALLEN,AK 99588, USA.						BALLARD WB, 1982, J WILDLIFE DIS, V18, P339, DOI 10.7589/0090-3558-18.3.339; BISHOP R H, 1974, Naturaliste Canadien (Quebec), V101, P559; CHALMERS, 1982, NONINFECTIOUS DISEAS, P84; GOODMAN, 1970, PHARM BASIS THERAPEU, P155; PERTZ C, 1978, J AM VET MED ASSOC, V173, P1243; Seal U. S, 1970, Int. Zoo Yb., V10, P157, DOI 10.1111/j.1748-1090.1970.tb01324.x; SKOOG, 1968, THESIS U CALIFORNIA; SOMA, 1971, TXB VET ANESTHESIA; TAYLOR, 1979, 15TH P N AM MOOS C W, P169	9	5	5	0	1	WILDLIFE DISEASE ASSN, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897	0090-3558			J WILDLIFE DIS	J. Wildl. Dis.		1985	21	2					188	190		10.7589/0090-3558-21.2.188			3	Veterinary Sciences	Veterinary Sciences	AGJ74	WOS:A1985AGJ7400025	3999256				2020-06-26	J	SEAL, US; SINIFF, DB; TESTER, JR; WILLIAMS, TD				SEAL, US; SINIFF, DB; TESTER, JR; WILLIAMS, TD			CHEMICAL IMMOBILIZATION AND BLOOD ANALYSIS OF FERAL HORSES (EQUUS-CABALLUS)	JOURNAL OF WILDLIFE DISEASES			English	Article									UNIV MINNESOTA,DEPT FISHERIES & WILDLIFE,ST PAUL,MN 55108; UNIV MINNESOTA,DEPT BIOCHEM,ST PAUL,MN 55108; UNIV MINNESOTA,DEPT ECOL & BEHAV BIOL,MINNEAPOLIS,MN 55455; AGUAJITO VET HOSP,MONTEREY,CA 93940	SEAL, US (reprint author), VET ADM MED CTR,RES SERV,MINNEAPOLIS,MN 55417, USA.						BERGER J, 1983, J WILDLIFE DIS, V19, P265, DOI 10.7589/0090-3558-19.3.265; BLAKE JG, 1981, J MAMMAL, V62, P58, DOI 10.2307/1380477; BOGAN JA, 1978, VET REC, V103, P471, DOI 10.1136/vr.103.21.471; BORCHARD RE, 1980, EVALUATION CHEM REST; DOBBS HE, 1972, VET REC, V91, P40, DOI 10.1136/vr.91.2.40; EVANS DJ, 1974, VET REC, V95, P70, DOI 10.1136/vr.95.3.70; EVANS DJ, 1974, EQUINE VET J, V9, P148; FUENTES VO, 1978, VET REC, V102, P106, DOI 10.1136/vr.102.5.106; HARTHOORN AM, 1976, CHEM CAPTURE ANIMALS, P202; HILLIDGE CJ, 1977, VET REC, V94, P476; JENKINS JT, 1972, VET REC, V90, P207, DOI 10.1136/vr.90.8.207; JONES DM, 1972, VET ANN, V13, P320; KERR DD, 1972, AM J VET RES, V33, P525; KIRKPATRICK JF, 1979, J WILDLIFE MANAGE, V43, P801, DOI 10.2307/3808770; MOORE DE, 1979, IMMOBILIZATION REPOR; MUIR WW, 1979, AM J VET RES, V40, P1417; SCHALM OW, 1975, VET HEMATOLOGY, P164; SEAL US, 1983, J WILDLIFE MANAGE, V47, P704, DOI 10.2307/3808606; SEAL US, 1977, J ZOO ANIM MED, V8, P7; SEAL US, 1978, J WILDLIFE MANAGE, V42, P776, DOI 10.2307/3800768; Tavernor W. D., 1960, Veterinary Record, V72, P569; WRIGHT FH, 1982, P AM ASS ZOO VET SEA, P109	22	13	13	0	3	WILDLIFE DISEASE ASSN, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897	0090-3558			J WILDLIFE DIS	J. Wildl. Dis.		1985	21	4					411	416		10.7589/0090-3558-21.4.411			6	Veterinary Sciences	Veterinary Sciences	ATQ91	WOS:A1985ATQ9100012	4078978	Bronze			2020-06-26	J	MANECKJEE, R; ZUKIN, RS; ARCHER, S; MICHAEL, J; OSEIGYIMAH, P				MANECKJEE, R; ZUKIN, RS; ARCHER, S; MICHAEL, J; OSEIGYIMAH, P			PURIFICATION AND CHARACTERIZATION OF THE MU-OPIATE RECEPTOR FROM RAT-BRAIN USING AFFINITY-CHROMATOGRAPHY	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article									YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,1300 MORRIS PK AVE,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROSCI,BRONX,NY 10461; RENSSELAER POLYTECH INST,DEPT CHEM,COGSWELL LAB,TROY,NY 12181					NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 01674, DA-00069, DA 01843]		AGNEW WS, 1979, BIOCHEMISTRY-US, V18, P1912, DOI 10.1021/bi00577a010; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3267, DOI 10.1021/ja00989a030; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3273, DOI 10.1021/ja00989a031; BIDLACK JM, 1981, P NATL ACAD SCI-BIOL, V78, P636, DOI 10.1073/pnas.78.1.636; BIDLACK JM, 1980, LIFE SCI, V27, P331, DOI 10.1016/0024-3205(80)90201-5; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; CHANG KJ, 1981, FED PROC, V40, P2729; CHOW T, 1983, MOL PHARMACOL, V24, P203; CODINA J, 1983, P NATL ACAD SCI-BIOL, V80, P4276, DOI 10.1073/pnas.80.14.4276; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; GIOANNINI T, 1982, BIOCHEM BIOPH RES CO, V105, P1120; GIOANNINI TL, 1984, BIOCHEM BIOPH RES CO, V119, P624, DOI 10.1016/S0006-291X(84)80295-8; HOWELLS RD, 1982, J PHARMACOL EXP THER, V222, P629; KLEE WA, 1982, FEBS LETT, V150, P125, DOI 10.1016/0014-5793(82)81318-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN HK, 1978, NATURE, V271, P383, DOI 10.1038/271383a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANECKJEE R, 1983, BIOCHEMISTRY-US, V22, P6058, DOI 10.1021/bi00295a003; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MURAYAMA T, 1983, J BIOL CHEM, V258, P3319; PASTERNAK GW, 1974, MOL PHARM, V11, P478; RUEGG UT, 1980, EUR J PHARMACOL, V64, P367, DOI 10.1016/0014-2999(80)90247-2; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; SIMONDS WF, 1980, P NATL ACAD SCI-BIOL, V77, P4623, DOI 10.1073/pnas.77.8.4623; ZUKIN RS, 1979, P NATL ACAD SCI USA, V76, P1593, DOI 10.1073/pnas.76.4.1593; ZUKIN RS, 1981, LIFE SCI, V29, P2681	26	67	67	0	0	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.		1985	82	2					594	598		10.1073/pnas.82.2.594			5	Multidisciplinary Sciences	Science & Technology - Other Topics	ADL23	WOS:A1985ADL2300072	2982164	Green Published, Bronze			2020-06-26	J	NICOLAS, P; LI, CH				NICOLAS, P; LI, CH			BETA-ENDORPHIN-(1-27) IS A NATURALLY-OCCURRING ANTAGONIST TO ETORPHINE-INDUCED ANALGESIA	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article									UNIV CALIF SAN FRANCISCO,MOLEC ENDOCRINOL LAB,SAN FRANCISCO,CA 94143			Nicolas, Pierre/C-7908-2009		NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA03434]; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM02907]		AKIL H, 1981, NEUROPEPTIDES, V1, P429, DOI 10.1016/0143-4179(81)90041-X; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; BLAKE J, 1978, INT J PEPT PROT RES, V11, P323; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; EIPPER BA, 1981, J BIOL CHEM, V256, P5689; FELBERG W, 1977, BR J PHARM, V60, P445; FERRARA P, 1979, BIOCHEM BIOPH RES CO, V89, P786, DOI 10.1016/0006-291X(79)91847-3; GEISOW MJ, 1977, NATURE, V269, P167, DOI 10.1038/269167a0; HAMMONDS RG, 1982, INT J PEPT PROT RES, V19, P556; HAMMONDS RG, 1984, P NATL ACAD SCI-BIOL, V81, P1389, DOI 10.1073/pnas.81.5.1389; HOUGHTEN RA, 1980, INT J PEPT PROT RES, V16, P311; KOOB GF, 1983, BRIT MED BULL, V39, P89, DOI 10.1093/oxfordjournals.bmb.a071797; LI CH, 1977, J MED CHEM, V20, P325, DOI 10.1021/jm00213a001; LI CH, 1982, P NATL ACAD SCI-BIOL, V79, P1042, DOI 10.1073/pnas.79.4.1042; LOH HH, 1976, P NATL ACAD SCI USA, V73, P2895, DOI 10.1073/pnas.73.8.2895; MAINS RE, 1981, J BIOL CHEM, V256, P5683; NG TB, 1981, INT J PEPT PROT RES, V18, P443; NICOLAS P, 1982, P NATL ACAD SCI-BIOL, V79, P2191, DOI 10.1073/pnas.79.7.2191; NICOLAS P, 1984, P NATL ACAD SCI-BIOL, V81, P3074, DOI 10.1073/pnas.81.10.3074; SMYTH DG, 1978, BIOCHEM J, V175, P261, DOI 10.1042/bj1750261; SMYTH DG, 1983, BRIT MED BULL, V39, P25, DOI 10.1093/oxfordjournals.bmb.a071786; SMYTH DG, 1979, NATURE, V279, P252, DOI 10.1038/279252a0; TAKEMORI AE, 1972, EUR J PHARMACOL, V20, P85, DOI 10.1016/0014-2999(72)90219-1; TAKEMORI AE, 1969, J PHARMACOL EXP THER, V169, P39; YAMASHIRO D, 1983, INT J PEPT PROT RES, V21, P219; YAMASHIRO D, 1980, INT J PEPT PROT RES, V16, P70; YEUNG HW, 1978, INT J PEPT PROT RES, V12, P42; ZAKARIAN S, 1979, P NATL ACAD SCI USA, V76, P5972, DOI 10.1073/pnas.76.11.5972; ZAORAL M, 1981, INT J PEPT PROT RES, V17, P292	29	43	43	0	0	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.		1985	82	10					3178	3181		10.1073/pnas.82.10.3178			4	Multidisciplinary Sciences	Science & Technology - Other Topics	AHX37	WOS:A1985AHX3700025	2987913	Green Published, Bronze			2020-06-26	J	PEARCE, PC; DORR, L; KOCK, R				PEARCE, PC; DORR, L; KOCK, R			ANESTHETIC DEATH IN A BLACK FALLOW DEER	VETERINARY RECORD			English	Note										PEARCE, PC (reprint author), ZOOL SOC LONDON,INST ZOOL,LONDON NW1 4RY,ENGLAND.			Kock, Richard/0000-0002-6561-3209			Ettinger S. J., 1975, Textbook of veterinary internal medicine: diseases of the dog and cat, volume 2,, P918; Hillidge C J, 1975, Equine Vet J, V7, P148, DOI 10.1111/j.2042-3306.1975.tb03254.x	2	1	1	0	0	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1985	116	22					591	593		10.1136/vr.116.22.591-a			3	Veterinary Sciences	Veterinary Sciences	AJN92	WOS:A1985AJN9200009	3892876				2020-06-26	J	DUMONT, M; LEMAIRE, S				DUMONT, M; LEMAIRE, S			OPIOID RECEPTORS IN BOVINE ADRENAL-MEDULLA	CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY			English	Article									CHU SHERBROOKE,DEPT PHYSIOL & PHARMACOL,SHERBROOKE J1H 5N4,QUEBEC,CANADA							ATTALI B, 1982, NEUROPEPTIDES, V3, P53, DOI 10.1016/0143-4179(82)90065-8; AUDIGIER Y, 1982, LIFE SCI, V31, P1287, DOI 10.1016/0024-3205(82)90363-0; BOUBLIK JH, 1983, J RECEPTOR RES, V3, P463, DOI 10.3109/10799898309041853; BRADBURY AF, 1976, NATURE, V260, P793, DOI 10.1038/260793a0; CASTANAS E, 1984, MOL PHARMACOL, V25, P38; CHANG KJ, 1979, J BIOL CHEM, V254, P2610; CHANG KJ, 1981, P NATL ACAD SCI-BIOL, V78, P4141, DOI 10.1073/pnas.78.7.4141; CHANG KJ, 1979, MOL PHARMACOL, V16, P91; CHAVKIN C, 1979, MOL PHARMACOL, V15, P751; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COX BM, 1982, LIFE SCI, V31, P1645, DOI 10.1016/0024-3205(82)90179-5; DEAN DM, 1982, J NEUROCHEM, V38, P606, DOI 10.1111/j.1471-4159.1982.tb08674.x; DUMONT M, 1983, LIFE SCI, V32, P287, DOI 10.1016/0024-3205(83)90042-5; FISCHLI W, 1982, P NATL ACAD SCI-BIOL, V79, P5435, DOI 10.1073/pnas.79.17.5435; GACEI G, 1980, FEBS LETT, V118, P245, DOI 10.1016/0014-5793(80)80229-8; GILBERT PE, 1976, J PHARMACOL EXP THER, V198, P66; GILLAN MGC, 1982, BRIT J PHARMACOL, V77, P461, DOI 10.1111/j.1476-5381.1982.tb09319.x; GOLDSTEIN A, 1979, P NATL ACAD SCI USA, V76, P6666, DOI 10.1073/pnas.76.12.6666; GUILLEMIN R, 1977, SCIENCE, V197, P1367, DOI 10.1126/science.197601; HANDA BK, 1981, EUR J PHARMACOL, V70, P531, DOI 10.1016/0014-2999(81)90364-2; HEXUM TD, 1980, NEUROPEPTIDES, V1, P137, DOI 10.1016/0143-4179(80)90016-5; HUGHES J, 1975, NATURE, V258, P577, DOI 10.1038/258577a0; KANGAWA K, 1981, BIOCHEM BIOPH RES CO, V99, P871, DOI 10.1016/0006-291X(81)91244-4; KIMURA S, 1980, P NATL ACAD SCI-BIOL, V77, P1681, DOI 10.1073/pnas.77.3.1681; KOSTERLITZ HW, 1975, ANNU REV PHARMACOL, V15, P29, DOI 10.1146/annurev.pa.15.040175.000333; KOSTERLITZ HW, 1981, BRIT J PHARMACOL, V73, P939, DOI 10.1111/j.1476-5381.1981.tb08749.x; KOSTERLITZ HW, 1980, PROC R SOC SER B-BIO, V210, P113, DOI 10.1098/rspb.1980.0122; KUMAKURA K, 1980, NATURE, V283, P489, DOI 10.1038/283489a0; LEMAIRE S, 1982, BIOCHEM BIOPH RES CO, V108, P51, DOI 10.1016/0006-291X(82)91830-7; LEMAIRE S, 1981, J NEUROCHEM, V36, P886, DOI 10.1111/j.1471-4159.1981.tb01677.x; LEMAIRE S, 1978, J MED CHEM, V21, P1232, DOI 10.1021/jm00210a012; LEMAIRE S, 1980, NATURE, V288, P303, DOI 10.1038/288303b0; LEMAIRE S, 1982, ADV BIOSCI, V36, P249; LEWIS RV, 1979, BIOCHEM BIOPH RES CO, V89, P822, DOI 10.1016/0006-291X(79)91852-7; LEWIS RV, 1980, SCIENCE, V208, P1459, DOI 10.1126/science.7384787; LI CH, 1976, P NATL ACAD SCI USA, V73, P1145, DOI 10.1073/pnas.73.4.1145; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MIZUNO K, 1980, BIOCHEM BIOPH RES CO, V97, P1283, DOI 10.1016/S0006-291X(80)80005-2; OKA T, 1982, EUR J PHARMACOL, V77, P137, DOI 10.1016/0014-2999(82)90008-5; PASTERNAK GW, 1975, MOL PHARMACOL, V11, P340; PASTERNAK GW, 1983, LIFE SCI, V33, P167, DOI 10.1016/0024-3205(83)90470-8; PERT CB, 1973, P NATL ACAD SCI USA, V70, P2243, DOI 10.1073/pnas.70.8.2243; PFEIFFER A, 1981, NEUROPEPTIDES, V2, P89, DOI 10.1016/0143-4179(81)90057-3; PIERCEY MF, 1982, LIFE SCI, V31, P1197, DOI 10.1016/0024-3205(82)90341-1; PILAPIL C, 1983, LIFE SCI, V33, P263, DOI 10.1016/0024-3205(83)90493-9; QUIRION R, 1982, CELL MOL NEUROBIOL, V2, P333, DOI 10.1007/BF00710853; SAIANI L, 1982, J NEUROCHEM, V39, P1669, DOI 10.1111/j.1471-4159.1982.tb08001.x; SCHULTZBERG M, 1978, NEUROSCIENCE, V3, P1169, DOI 10.1016/0306-4522(78)90137-9; SCHULZ R, 1979, LIFE SCI, V24, P843, DOI 10.1016/0024-3205(79)90368-0; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; STERN AS, 1980, ARCH BIOCHEM BIOPHYS, V205, P606, DOI 10.1016/0003-9861(80)90144-7; TERENIUS L, 1973, ACTA PHARMACOL TOX, V33, P377; TRAFICANTE LJ, 1980, LIFE SCI, V26, P1697, DOI 10.1016/0024-3205(80)90178-2; VIVEROS OH, 1979, MOL PHARMACOL, V16, P1101; WOOD PL, 1982, LIFE SCI, V31, P2313, DOI 10.1016/0024-3205(82)90145-X; WOOD PL, 1981, NEUROPHARMACOLOGY, V20, P1215, DOI 10.1016/0028-3908(81)90067-8; WUSTER M, 1980, NEUROSCI LETT, V20, P79, DOI 10.1016/0304-3940(80)90237-2; WUSTER M, 1979, NEUROSCI LETT, V15, P193, DOI 10.1016/0304-3940(79)96112-3; ZUKIN RS, 1981, LIFE SCI, V29, P2681	62	14	14	0	1	NATL RESEARCH COUNCIL CANADA	OTTAWA	RESEARCH JOURNALS, MONTREAL RD, OTTAWA ON K1A 0R6, CANADA	0008-4212			CAN J PHYSIOL PHARM	Can. J. Physiol. Pharmacol.		1984	62	10					1284	1291		10.1139/y84-215			8	Pharmacology & Pharmacy; Physiology	Pharmacology & Pharmacy; Physiology	TQ486	WOS:A1984TQ48600006	6095979				2020-06-26	J	CHAPMAN, A; GONZALES, G; BURROWES, WR; ASSANAH, P; IANNONE, B; LEUNG, MK; STEFANO, GB				CHAPMAN, A; GONZALES, G; BURROWES, WR; ASSANAH, P; IANNONE, B; LEUNG, MK; STEFANO, GB			ALTERATIONS IN HIGH-AFFINITY BINDING CHARACTERISTICS AND LEVELS OF OPIOIDS IN INVERTEBRATE GANGLIA DURING AGING - EVIDENCE FOR AN OPIOID COMPENSATORY MECHANISM	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article									SUNY COLL OLD WESTBURY,DEPT BIOL SCI,OLD WESTBURY,NY 11568; SUNY COLL OLD WESTBURY,DEPT CHEM,OLD WESTBURY,NY 11568				Stefano, George/0000-0002-8146-0740	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [MBRS-RR08180]; ADAMHA HHS [ADAMHA-MARC 17138]		BURRELL DE, 1983, COMP BIOCHEM PHYS C, V74, P59, DOI 10.1016/0742-8413(83)90149-4; FORMAN LJ, 1981, NEUROBIOL AGING, V2, P281, DOI 10.1016/0197-4580(81)90036-1; GAMBERT SR, 1980, NEUROENDOCRINOLOGY, V31, P252, DOI 10.1159/000123083; GREEN J, 1968, BIOL ESTUARINE ANIMA, P144; HESS GD, 1981, NEUROBIOL AGING, V2, P49, DOI 10.1016/0197-4580(81)90059-2; KREAM RM, 1980, J BIOL CHEM, V225, P9218; LEUNG M, 1983, LIFE SCI, V33, P77, DOI 10.1016/0024-3205(83)90448-4; LEUNG MK, 1984, P NATL ACAD SCI-BIOL, V81, P955, DOI 10.1073/pnas.81.3.955; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MESSING RB, 1981, J NEUROCHEM, V36, P784, DOI 10.1111/j.1471-4159.1981.tb01659.x; OLSON GA, 1981, PEPTIDES, V2, P349, DOI 10.1016/S0196-9781(81)80128-3; STEFANO GB, 1982, CELL MOL NEUROBIOL, V2, P249, DOI 10.1007/BF00711152; STEFANO GB, 1982, CELL MOL NEUROBIOL, V2, P347, DOI 10.1007/BF00710854; STEFANO GB, 1984, BRAIN RES, V298, P362, DOI 10.1016/0006-8993(84)91438-0; STEFANO GB, 1982, BRAIN RES, V253, P205, DOI 10.1016/0006-8993(82)90687-4; STEFANO GB, 1981, CELL MOL NEUROBIOL, V1, P57, DOI 10.1007/BF00736039; STEFANO GB, 1981, BRAIN RES, V225, P107, DOI 10.1016/0006-8993(81)90321-8; STEFANO GB, 1979, LIFE SCI, V24, P1617, DOI 10.1016/0024-3205(79)90024-9; STEFANO GB, 1982, CELL MOL NEUROBIOL, V2, P167, DOI 10.1007/BF00711145; STEFANO GB, 1982, COMP BIOCHEM PHYS C, V72, P349, DOI 10.1016/0306-4492(82)90103-4; STEFANO GB, 1980, J PHARM EXP THER, V222, P759; STEFANO GB, 1981, SCIENCE, V213, P930; STEFANO GB, 1981, CELL MOL NEUROBIOL, V4, P343; STEFANO GB, 1980, BRAIN RES, V181, P445; STERN AS, 1979, P NATL ACAD SCI US, V76, P6683	25	15	15	0	1	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013	0272-4340			CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.		1984	4	2					143	155		10.1007/BF00711001			13	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	TM111	WOS:A1984TM11100004	6488243				2020-06-26	J	FRANKLIN, PH; HOSS, W				FRANKLIN, PH; HOSS, W			OPIATES STIMULATE LOW KM GTPASE IN BRAIN	JOURNAL OF NEUROCHEMISTRY			English	Article										FRANKLIN, PH (reprint author), UNIV ROCHESTER, SCH MED & DENT, MED CTR, CTR BRAIN RES, ROCHESTER, NY 14642 USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [1 F31 DA05232, DA 01851]; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 14577]		AKTORIES K, 1982, MOL PHARMACOL, V21, P336; BLUME AJ, 1979, P NATL ACAD SCI USA, V76, P5626, DOI 10.1073/pnas.76.11.5626; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P4155, DOI 10.1073/pnas.75.9.4155; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; CHANG KJ, 1979, MOL PHARMACOL, V16, P91; COLLIER HOJ, 1974, NATURE, V248, P24, DOI 10.1038/248024a0; COOPER DMF, 1982, J NEUROCHEM, V38, P1164, DOI 10.1111/j.1471-4159.1982.tb05365.x; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; JAKOBS KH, 1983, EUR J BIOCHEM, V132, P125, DOI 10.1111/j.1432-1033.1983.tb07336.x; JAKOBS KH, 1983, NATURE, V303, P177, DOI 10.1038/303177a0; JAKOBS KH, 1979, MOL CELL ENDOCRINOL, V16, P147, DOI 10.1016/0303-7207(79)90023-6; KOSKI G, 1981, P NATL ACAD SCI-BIOL, V78, P4185, DOI 10.1073/pnas.78.7.4185; LAW PY, 1981, J NEUROCHEM, V36, P1834, DOI 10.1111/j.1471-4159.1981.tb00438.x; LIMBIRD LE, 1981, BIOCHEM J, V195, P1; MINNEMAN KP, 1976, NATURE, V262, P313, DOI 10.1038/262313a0; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; ROSS EM, 1980, ANNU REV BIOCHEM, V49, P553, DOI 10.1146/annurev.bi.49.070180.002533; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P590, DOI 10.1073/pnas.72.2.590; WALCZAK SA, 1979, BRAIN RES, V160, P105, DOI 10.1016/0006-8993(79)90604-8	19	29	29	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.		1984	43	4					1132	1135		10.1111/j.1471-4159.1984.tb12853.x			4	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	TJ329	WOS:A1984TJ32900031	6147391				2020-06-26	J	PERACCHIA, F; BIANCHI, G; FIOCCHI, R; PETRILLO, P; TAVANI, A; MANARA, L				PERACCHIA, F; BIANCHI, G; FIOCCHI, R; PETRILLO, P; TAVANI, A; MANARA, L			CENTRAL AND PERIPHERAL INHIBITION OF GASTROINTESTINAL TRANSIT IN RATS - NARCOTICS DIFFER SUBSTANTIALLY BY ACTING AT EITHER OR BOTH LEVELS	JOURNAL OF PHARMACY AND PHARMACOLOGY			English	Note									MARIO NEGRI INST PHARMACOL RES,I-20157 MILAN,ITALY							BIANCHI G, 1982, LIFE SCI, V30, P1875, DOI 10.1016/0024-3205(82)90467-2; BIANCHI G, 1984, J PHARM PHARMACOL, V36, P326, DOI 10.1111/j.2042-7158.1984.tb04384.x; BIANCHI G, 1983, GASTROENTEROLOGY, V85, P852; DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478; FERRETTI P, 1981, RES COMMUN SUBSTANCE, V2, P1; FIOCCHI R, 1982, LIFE SCI, V31, P2221, DOI 10.1016/0024-3205(82)90123-0; JAFFE JH, 1980, GOODMAN GILMANS PHAR, P494; MANARA L, 1980, ENDOGENOUS EXOGENOUS, P143; PORRECA F, 1983, European Journal of Pharmacology, V86, P135; TAVANI A, 1980, LIFE SCI, V27, P2211, DOI 10.1016/0024-3205(80)90386-0; TAVANI A, 1979, EUR J PHARMACOL, V59, P151, DOI 10.1016/0014-2999(79)90039-6; TAVANI A, 1979, J PHARMACOL EXP THER, V211, P140	12	18	18	0	0	ROYAL PHARMACEUTICAL SOC GREAT BRITAIN	LONDON	1 LAMBETH HIGH ST, LONDON, ENGLAND SE1 7JN	0022-3573			J PHARM PHARMACOL	J. Pharm. Pharmacol.		1984	36	10					699	701		10.1111/j.2042-7158.1984.tb04850.x			3	Pharmacology & Pharmacy	Pharmacology & Pharmacy	TN318	WOS:A1984TN31800015	6150093				2020-06-26	J	JONES, DM				JONES, DM			PHYSICAL AND CHEMICAL METHODS OF CAPTURING DEER	VETERINARY RECORD			English	Article										JONES, DM (reprint author), ZOOL SOC LONDON,REGENTS PK,LONDON NW1 4RY,ENGLAND.							0	17	17	0	6	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1984	114	5					109	112		10.1136/vr.114.5.109			4	Veterinary Sciences	Veterinary Sciences	SC899	WOS:A1984SC89900004	6702078				2020-06-26	J	THORNGRAY, BE; LEVITT, RA				THORNGRAY, BE; LEVITT, RA			RAT-BRAIN SITES RESPONSIVE TO ETORPHINE - ANALGESIA AND CATATONIA	BEHAVIORAL NEUROSCIENCE			English	Article									UNIV ALABAMA,BIRMINGHAM,AL 35294	THORNGRAY, BE (reprint author), OHIO STATE UNIV,DEPT PSYCHOL,COLUMBUS,OH 43210, USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [1F 31 DA05143-01]		ALGERI S, 1980, EUR J PHARMACOL, V68, P383, DOI 10.1016/0014-2999(80)90539-7; BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; BONNET KA, 1975, PHARMACOL BIOCHEM BE, V3, P47, DOI 10.1016/0091-3057(75)90079-9; COSTALL B, 1974, PSYCHOPHARMACOLOGIA, V35, P203, DOI 10.1007/BF00437749; DILL RE, 1977, NEUROPHARMACOLOGY, V16, P323, DOI 10.1016/0028-3908(77)90068-5; EVANS WO, 1961, PSYCHOPHARMACOLOGIA, V2, P318, DOI 10.1007/BF00404119; HILLER JM, 1973, RES COMMUN CHEM PATH, V6, P1052; Jaffe JH, 1975, PHARM BASIS THERAPEU; KUHAR MJ, 1973, NATURE, V245, P447, DOI 10.1038/245447a0; LAMOTTE CC, 1978, BRAIN RES, V155, P374, DOI 10.1016/0006-8993(78)91033-8; LEWIS VA, 1977, BRAIN RES, V124, P283, DOI 10.1016/0006-8993(77)90886-1; LOMAX P, 1966, EXPERIENTIA, V22, P249, DOI 10.1007/BF01900940; PELLEGRINO LJ, 1967, [No title captured]; PERT A, 1979, ENDORPHINS MENTAL HL; PERT A, 1978, BASIS ADDICTION; PERT CB, 1974, BRAIN RES, V70, P184, DOI 10.1016/0006-8993(74)90228-5; ROGERS RJ, 1977, PHARM BIOCH BEHAV, V6, P385; ROGERS RJ, 1978, BRAIN RES, V153, P211; SCHUBERT P, 1970, HISTOCHEMISTRY, V22, P277, DOI 10.1007/BF00306105; SEGAL D, 1979, ENDORPHINS MENTAL HL; THORN B, 1980, NEUROPHARMACOLOGY, V20, P203; THORNGRAY BE, 1981, NEUROPHARMACOLOGY, V20, P763, DOI 10.1016/0028-3908(81)90226-4; WILCOX RE, 1978, PHARMACOL BIOCHEM BE, V9, P425, DOI 10.1016/0091-3057(78)90035-7; YAKSH TL, 1978, PAIN, V4, P299, DOI 10.1016/0304-3959(77)90145-2; YAKSH TL, 1976, SCIENCE, V192, P1357, DOI 10.1126/science.1273597; YAKSH TL, 1976, BRAIN RES, V114, P83, DOI 10.1016/0006-8993(76)91009-X; YEUNG JC, 1977, PAIN, V4, P23, DOI 10.1016/0304-3959(77)90084-7	27	11	11	0	0	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242	0735-7044			BEHAV NEUROSCI	Behav. Neurosci.		1983	97	5					768	778		10.1037/0735-7044.97.5.768			11	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	RL369	WOS:A1983RL36900008	6685525				2020-06-26	J	CLARK, SL; RYALL, RW				CLARK, SL; RYALL, RW			THE ANTI-NOCICEPTIVE ACTION OF ETORPHINE IN THE DORSAL HORN IS DUE TO A DIRECT SPINAL ACTION AND NOT TO ACTIVATION OF DESCENDING INHIBITION	BRITISH JOURNAL OF PHARMACOLOGY			English	Article										CLARK, SL (reprint author), UNIV CAMBRIDGE,DEPT PHARMACOL,CAMBRIDGE CB2 2QD,ENGLAND.						AZAMI J, 1982, PAIN, V12, P229, DOI 10.1016/0304-3959(82)90155-5; BASBAUM AI, 1978, J COMP NEUROL, V178, P209, DOI 10.1002/cne.901780203; BELCHER G, 1978, BRAIN RES, V151, P307, DOI 10.1016/0006-8993(78)90887-9; BELCHER G, 1978, BRAIN RES, V145, P303, DOI 10.1016/0006-8993(78)90864-8; BENNETT GJ, 1979, BRAIN RES, V172, P243, DOI 10.1016/0006-8993(79)90536-5; BERMAN AL, 1968, [No title captured]; BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; BRADLEY PB, 1974, BRIT J PHARMACOL, V50, P47, DOI 10.1111/j.1476-5381.1974.tb09591.x; BRAMWELL GJ, 1974, BRAIN RES, V73, P167, DOI 10.1016/0006-8993(74)91017-8; CALVILLO O, 1974, CAN J PHYSIOL PHARM, V52, P1207, DOI 10.1139/y74-158; CARSTENS E, 1980, J NEUROPHYSIOL, V43, P332; CLARK SL, 1982, J PHYSIOL-LONDON, V328, pP45; DAVIES J, 1978, BRIT J PHARMACOL, V63, P87, DOI 10.1111/j.1476-5381.1978.tb07778.x; DICKENSON AH, 1979, BRAIN RES, V170, P95, DOI 10.1016/0006-8993(79)90943-0; DUGGAN AW, 1977, BRIT J PHARMACOL, V61, P65, DOI 10.1111/j.1476-5381.1977.tb09740.x; DUGGAN AW, 1979, PAIN, V6, P149, DOI 10.1016/0304-3959(79)90122-2; DUGGAN AW, 1980, BRIT J PHARMACOL, V69, P461, DOI 10.1111/j.1476-5381.1980.tb07035.x; ENGBERG I, 1968, J PHYSIOL-LONDON, V194, P225, DOI 10.1113/jphysiol.1968.sp008403; FIELDS HL, 1977, BRAIN RES, V126, P441, DOI 10.1016/0006-8993(77)90596-0; GEBHART GF, 1982, NEUROSCIENCE, V7, pS78; GUILBAUD G, 1977, BRAIN RES, V126, P355, DOI 10.1016/0006-8993(77)90732-6; HANAOKA K, 1978, J PHARMACOL EXP THER, V207, P476; Herz A, 1971, ADV DRUG RES, V6, P79; JACQUET YF, 1976, BRAIN RES, V103, P501, DOI 10.1016/0006-8993(76)90448-0; JOHNSTON SE, 1981, NEUROSCI LETT, V26, P43, DOI 10.1016/0304-3940(81)90423-7; KITAHATA LM, 1974, ANESTHESIOLOGY, V41, P39, DOI 10.1097/00000542-197407000-00008; LEBARS D, 1980, BRAIN RES, V202, P223, DOI 10.1016/S0006-8993(80)80050-3; LEBARS D, 1980, BRAIN RES, V189, P467, DOI 10.1016/0006-8993(80)90106-7; LEBARS D, 1975, BRAIN RES, V98, P261, DOI 10.1016/0006-8993(75)90005-0; LEVY RA, 1979, EUR J PHARMACOL, V57, P43, DOI 10.1016/0014-2999(79)90102-X; LEWIS VA, 1977, BRAIN RES, V124, P283, DOI 10.1016/0006-8993(77)90886-1; LYNN B, 1979, J PHYSIOL-LONDON, V287, P493, DOI 10.1113/jphysiol.1979.sp012672; LYNN B, 1980, PAIN, V8, P189, DOI 10.1016/0304-3959(88)90006-1; MISRA AL, 1976, J PHARMACOL EXP THER, V196, P257; OLIVERAS JL, 1974, EXP BRAIN RES, V20, P32; OSSENBERG FW, 1975, J PHARMACOL EXP THER, V194, P111; PERT A, 1974, BRAIN RES, V80, P135, DOI 10.1016/0006-8993(74)90731-8; ROSENFELD JP, 1980, PAIN, V9, P307, DOI 10.1016/0304-3959(80)90045-7; TAKAGI H, 1980, TRENDS PHARMACOL SCI, V1, P182; WANG JK, 1979, ANESTHESIOLOGY, V50, P149, DOI 10.1097/00000542-197902000-00013; WEST DC, 1982, NEUROSCI, V7, pS226; WILLER JC, 1980, BRAIN RES, V187, P212, DOI 10.1016/0006-8993(80)90507-7; WILLIS WD, 1977, J NEUROPHYSIOL, V40, P968; YAKSH TL, 1977, J PHARMACOL EXP THER, V202, P411; YAKSH TL, 1978, EXP NEUROL, V60, P23, DOI 10.1016/0014-4886(78)90166-8; ZORMAN G, 1981, BRAIN RES, V219, P137, DOI 10.1016/0006-8993(81)90273-0	46	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0007-1188			BRIT J PHARMACOL	Br. J. Pharmacol.		1983	78	2					307	319		10.1111/j.1476-5381.1983.tb09396.x			13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	QB851	WOS:A1983QB85100009	6338986	Green Published			2020-06-26	J	ROTHMAN, R; WESTFALL, TC				ROTHMAN, R; WESTFALL, TC			FURTHER EVIDENCE FOR AN OPIOID RECEPTOR COMPLEX	JOURNAL OF NEUROBIOLOGY			English	Article									ST LOUIS UNIV,SCH MED,DEPT PHARMACOL,ST LOUIS,MO 63104; UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908							BOWEN WD, 1981, P NATL ACAD SCI-BIOL, V78, P4818, DOI 10.1073/pnas.78.8.4818; BRADY LS, 1982, J PHARMACOL EXP THER, V222, P190; BRADY LS, 1981, J PHARMACOL EXP THER, V218, P613; BYRNE WL, 1980, EXOGENOUS OPIATE AGO, P67; CHANG KJ, 1979, J BIOL CHEM, V254, P2610; CHANG KJ, 1979, MOL PHARMACOL, V16, P91; CHAPMAN DB, 1980, EUR J PHARMACOL, V65, P369, DOI 10.1016/0014-2999(80)90341-6; COX BM, 1982, LIFE SCI, V31, P1645, DOI 10.1016/0024-3205(82)90179-5; CRAVES FB, 1978, J PHARMACOL EXP THER, V206, P492; DAIGUJI M, 1981, LIFE SCI, V28, P2705, DOI 10.1016/0024-3205(81)90171-5; GOODMAN RR, 1980, P NATL ACAD SCI-BIOL, V77, P6239, DOI 10.1073/pnas.77.10.6239; HERZ A, 1971, ADV DRUG RES, V6, P29; HUGHES J, 1975, NATURE, V258, P577, DOI 10.1038/258577a0; LAW PY, 1978, RES COMMUN CHEM PATH, V21, P409; LEE NM, 1980, LIFE SCI, V26, P1459, DOI 10.1016/0024-3205(80)90266-0; LEE NM, 1980, EUR J PHARMACOL, V68, P181, DOI 10.1016/0014-2999(80)90319-2; LEVITZKI A, 1971, BIOCHEMISTRY-US, V10, P3371, DOI 10.1021/bi00794a009; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; MUNSON PJ, 1983, J RECEPTOR RES, V3; PERT CB, 1980, NEURAL PEPTIDES NEUR, P581; PFEIFFER A, 1982, EUR J PHARM, V77, P759; ROBSON LE, 1979, PROC R SOC SER B-BIO, V205, P425, DOI 10.1098/rspb.1979.0076; ROTHMAN RB, 1982, MOL PHARMACOL, V21, P538; ROTHMAN RB, 1982, NEUROCHEM RES, V7, P1375, DOI 10.1007/BF00966066; ROTHMAN RB, 1980, FED PROC, V39, P385; ROTHMAN RB, 1981, EUR J PHARMACOL, V72, P365, DOI 10.1016/0014-2999(81)90577-X; ROTHMAN RB, 1982, MOL PHARMACOL, V21, P548; ROTHMAN RB, 1982, THESIS U VIRGINIA; SARNE Y, 1982, EUR J PHARMACOL, V81, P227, DOI 10.1016/0014-2999(82)90440-X; SCHULZ R, 1980, MOL PHARMACOL, V18, P395; SIMANTOV R, 1978, EUR J PHARMACOL, V47, P319, DOI 10.1016/0014-2999(78)90240-6; SMITH JR, 1980, P NATL ACAD SCI-BIOL, V77, P281, DOI 10.1073/pnas.77.1.281; VAUGHT JL, 1982, LIFE SCI, V30, P1443, DOI 10.1016/0024-3205(82)90558-6; VAUGHT JL, 1979, J PHARMACOL EXP THER, V208, P86; VAUGHT JL, 1979, J PHARMACOL EXP THER, V211, P280	35	27	27	0	0	JOHN WILEY & SONS INC	NEW YORK	605 THIRD AVE, NEW YORK, NY 10158-0012	0022-3034			J NEUROBIOL	J. Neurobiol.		1983	14	5					341	351		10.1002/neu.480140502			11	Neurosciences	Neurosciences & Neurology	RH187	WOS:A1983RH18700001	6311973				2020-06-26	J	FLECKNELL, PA; JOHN, M; MITCHELL, M; SHUREY, C; SIMPKIN, S				FLECKNELL, PA; JOHN, M; MITCHELL, M; SHUREY, C; SIMPKIN, S			NEUROLEPTANALGESIA IN THE RABBIT	LABORATORY ANIMALS			English	Article										FLECKNELL, PA (reprint author), CLIN RES CTR,DIV COMPARAT MED,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.			Flecknell, Paul/0000-0002-1075-1129			GREEN CJ, 1978, LAB ANIM, V12, P85, DOI 10.1258/002367778780953206; GREEN CJ, 1979, LABORATORY ANIMAL HD, V8; WHITE GL, 1976, LAB ANIM SCI, V26, P804	3	29	29	0	2	ROYAL SOC MEDICINE PRESS LTD	LONDON	1 WIMPOLE STREET, LONDON, ENGLAND W1M 8AE	0023-6772			LAB ANIM	Lab. Anim.		1983	17	2					104	109		10.1258/002367783780959420			6	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	QN607	WOS:A1983QN60700006	6865315	Bronze			2020-06-26	J	AHMED, MS				AHMED, MS			CHARACTERIZATION OF SOLUBILIZED OPIATE RECEPTORS FROM HUMAN-PLACENTA	MEMBRANE BIOCHEMISTRY			English	Article										AHMED, MS (reprint author), UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA.						Ahmed M S, 1981, Placenta Suppl, V3, P115; AHMED MS, 1981, P INT NARCOTIC RES C, P77; AHMED MS, 1980, 8TH ROCH TROPH C ROC; BIDLACK JM, 1981, P NATL ACAD SCI-BIOL, V78, P636, DOI 10.1073/pnas.78.1.636; BIDLACK JM, 1980, LIFE SCI, V27, P331, DOI 10.1016/0024-3205(80)90201-5; DROUVA SV, 1981, NEUROENDOCRINOLOGY, V32, P163, DOI 10.1159/000123150; FLETCHER JE, 1980, LANCET, V1, P310; HJELMELAND LM, 1980, P NATL ACAD SCI-BIOL, V77, P6368, DOI 10.1073/pnas.77.11.6368; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OLUBADEWO JO, 1978, J PHARMACOL EXP THER, V204, P433; Sastry B V, 1981, Placenta Suppl, V3, P327; SASTRY BVR, 1980, BIOCHEM PHARMACOL, V29, P475, DOI 10.1016/0006-2952(80)90536-5; SIMONDS WF, 1980, P NATL ACAD SCI-BIOL, V77, P4623, DOI 10.1073/pnas.77.8.4623; VALETTE A, 1980, BIOCHEM PHARMACOL, V29, P2657, DOI 10.1016/0006-2952(80)90082-9; VALETTE A, 1979, FEBS LETT, V103, P362, DOI 10.1016/0014-5793(79)81363-0; WOOD PL, 1981, NEUROSCI LETT, V23, P75, DOI 10.1016/0304-3940(81)90190-7; YAMAGUCHI R, 1971, TOHOKU J EXP MED, V105, P129, DOI 10.1620/tjem.105.129	17	21	21	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0149-046X			MEMBRANE BIOCHEM			1983	5	1					35	47		10.3109/09687688309149632			13	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	RL967	WOS:A1983RL96700003	6316106				2020-06-26	J	GIBSON, DA; VERNADAKIS, A				GIBSON, DA; VERNADAKIS, A			EFFECTS OF N-LAAM ON [ETORPHINE-H-3 BINDING IN NEURONAL-ENRICHED CELL-CULTURES	NEUROCHEMICAL RESEARCH			English	Note									UNIV COLORADO,SCH MED,DEPT PSYCHIAT,DENVER,CO 80262	GIBSON, DA (reprint author), UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262, USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 02131]		BLUME AJ, 1978, LIFE SCI, V22, P1843, DOI 10.1016/0024-3205(78)90602-1; BOOHER J, 1972, Neurobiology (Copenhagen), V2, P97; CRAIN SM, 1978, BRAIN RES, V157, P196, DOI 10.1016/0006-8993(78)91014-4; GIBSON DA, 1982, DEV BRAIN RES, V4, P23; GIBSON DA, 1982, DEV BRAIN RES; GOLDSTEIN A, 1977, NATURE, V265, P362, DOI 10.1038/265362a0; HENDRICKSON CM, 1980, NEUROPHARMACOLOGY, V19, P731, DOI 10.1016/0028-3908(80)90064-7; HILLER JM, 1978, BRAIN RES, V145, P396, DOI 10.1016/0006-8993(78)90875-2; KLEE WA, 1974, P NATL ACAD SCI USA, V71, P3474, DOI 10.1073/pnas.71.9.3474; KLEE WA, 1976, NATURE, V263, P609, DOI 10.1038/263609a0; PETTMANN B, 1979, NATURE, V281, P378, DOI 10.1038/281378a0; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P590, DOI 10.1073/pnas.72.2.590; SLOTKIN TA, 1979, LIFE SCI, V24, P1623, DOI 10.1016/0024-3205(79)90244-3; VERNADAKIS A, 1982, J NEUROSCI RES, V7, P111, DOI 10.1002/jnr.490070203	14	8	8	0	1	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013	0364-3190			NEUROCHEM RES	Neurochem. Res.		1983	8	9					1197	1202		10.1007/BF00964933			6	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	RH088	WOS:A1983RH08800010	6633793				2020-06-26	J	CHO, TM; GE, BL; YAMATO, C; SMITH, AP; LOH, HH				CHO, TM; GE, BL; YAMATO, C; SMITH, AP; LOH, HH			ISOLATION OF OPIATE BINDING-COMPONENTS BY AFFINITY-CHROMATOGRAPHY AND RECONSTITUTION OF BINDING ACTIVITIES	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES			English	Article									UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143	CHO, TM (reprint author), UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143, USA.						ABOOD LG, 1975, EUR J PHARMACOL, V32, P66, DOI 10.1016/0014-2999(75)90324-6; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BIDLACK JM, 1981, P NATL ACAD SCI-BIOL, V78, P636, DOI 10.1073/pnas.78.1.636; BIDLACK JM, 1980, LIFE SCI, V27, P331, DOI 10.1016/0024-3205(80)90201-5; CHANG HW, 1979, BIOCHEMISTRY-US, V18, P172, DOI 10.1021/bi00568a026; CHO TM, 1981, LIFE SCI, V28, P2651, DOI 10.1016/0024-3205(81)90723-2; CHO TM, 1979, MOL PHARMACOL, V16, P393; CUATRECASAS P, 1972, P NATL ACAD SCI USA, V69, P318, DOI 10.1073/pnas.69.2.318; CUATRECASAS P, 1973, BIOCHEMISTRY-US, V12, P3547, DOI 10.1021/bi00742a031; HASEGAWA J, 1981, ADV ENDOGENOUS EXOGE, P83; HOWELLS RD, 1982, J PHARMACOL EXP THER, V222, P629; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; KEAN EL, 1968, J LIPID RES, V9, P319; LAW PY, 1979, BIOCH PHARM, V28, P2257; LEE NM, 1980, LIFE SCI, V26, P1459, DOI 10.1016/0024-3205(80)90266-0; LOH HH, 1974, LIFE SCI, V14, P2231, DOI 10.1016/0024-3205(74)90105-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PASTERNAK GW, 1974, MOL PHARMACOL, V10, P183; SIMON EJ, 1972, P NATL ACAD SCI USA, V69, P1835, DOI 10.1073/pnas.69.7.1835; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; SIMONDS WF, 1980, P NATL ACAD SCI-BIOL, V77, P4623, DOI 10.1073/pnas.77.8.4623; TOVEY KC, 1974, CLIN CHIM ACTA, V56, P221, DOI 10.1016/0009-8981(74)90133-8; WU YC, 1976, BIOCHEM PHARMACOL, V25, P1551	23	43	43	0	0	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418	0027-8424			P NATL ACAD SCI-BIOL			1983	80	17					5176	5180		10.1073/pnas.80.17.5176			5	Biology	Life Sciences & Biomedicine - Other Topics	RE891	WOS:A1983RE89100002	6310562	Green Published, Bronze			2020-06-26	J	SIMPSON, AM; SUTTIE, JM; SHARMAN, GAM; CORRIGAL, W				SIMPSON, AM; SUTTIE, JM; SHARMAN, GAM; CORRIGAL, W			INFLUENCE OF SOME SEDATIVE DRUGS ON THE APPETITE OF RED DEER	VETERINARY RECORD			English	Note										SIMPSON, AM (reprint author), ROWETT RES INST,DEPT PHYSIOL,BUCKSBURN AB2 9SB,ABERDEEN,SCOTLAND.						BROCKMAN RP, 1981, RES VET SCI, V30, P383, DOI 10.1016/S0034-5288(18)32565-7; HSU WH, 1981, ENDOCRINOLOGY, V109, P825, DOI 10.1210/endo-109-3-825; SYMONDS HW, 1976, VET REC, V99, P234, DOI 10.1136/vr.99.12.234; YEREX D, 1982, FARMING DEER, P45	4	3	3	0	0	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1983	112	16					385	385		10.1136/vr.112.16.385-a			1	Veterinary Sciences	Veterinary Sciences	QM491	WOS:A1983QM49100007	6857983				2020-06-26	J	FINCK, AD; NGAI, SH				FINCK, AD; NGAI, SH			OPIATE RECEPTOR MEDIATION OF KETAMINE ANALGESIA	ANESTHESIOLOGY			English	Article									COLUMBIA UNIV COLL PHYS & SURG,DEPT ANAESTHESIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032					NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [1 R01 GM-26407]		ADAMS PM, 1980, NEUROPHARMACOLOGY, V19, P151, DOI 10.1016/0028-3908(80)90130-6; COHEN ML, 1973, ANESTHESIOLOGY, V39, P370, DOI 10.1097/00000542-197310000-00003; COWIE AL, 1978, BRIT J PHARMACOL, V64, P565, DOI 10.1111/j.1476-5381.1978.tb17319.x; DINGLEDINE R, 1973, BRIT J PHARMACOL, V48, P718, DOI 10.1111/j.1476-5381.1973.tb08261.x; FRATTA W, 1980, EUR J PHARMACOL, V61, P389, DOI 10.1016/0014-2999(80)90079-5; FROMHERZ K, 1951, ARCH INT PHARMACOD T, V85, P387; GLICK SD, 1979, EUR J PHARMACOL, V59, P103, DOI 10.1016/0014-2999(79)90029-3; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; HOLLT V, 1978, FED PROC, V37, P158; HOLLT V, 1978, FACTORS AFFECTING AC, P207; HOLLT V, 1976, OPIATES ENDOGENOUS O, P345; KLOOG Y, 1977, EUR J PHARMACOL, V45, P221, DOI 10.1016/0014-2999(77)90002-4; KOSTERLITZ HW, 1970, BRIT J PHARMACOL, V39, P398, DOI 10.1111/j.1476-5381.1970.tb12903.x; LAKIN ML, 1978, P W PHARMACOL SOC, V21, P27; MAAYANI S, 1974, BIOCHEM PHARMACOL, V23, P1263, DOI 10.1016/0006-2952(74)90330-X; MARIETTA MP, 1977, J PHARMACOL EXP THER, V202, P157; NORTH RA, 1977, BRIT J PHARMACOL, V61, P541, DOI 10.1111/j.1476-5381.1977.tb07546.x; RYDER S, 1978, EUR J PHARMACOL, V49, P15, DOI 10.1016/0014-2999(78)90217-0; SADOVE MS, 1971, ANESTH ANAL CURR RES, V50, P452; SIMANTOV R, 1976, MOL PHARMACOL, V12, P987; SIMON EJ, 1975, J PHARMACOL EXP THER, V192, P531; SLOGOFF S, 1974, ANESTH ANALG, V53, P354; SMITH DJ, 1980, LIFE SCI, V26, P789, DOI 10.1016/0024-3205(80)90285-4; VINCENT JP, 1978, BRAIN RES, V152, P176, DOI 10.1016/0006-8993(78)90145-2; WHITE PF, 1980, ANESTHESIOLOGY, V52, P231, DOI 10.1097/00000542-198003000-00008	25	139	145	0	5	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0003-3022			ANESTHESIOLOGY	Anesthesiology		1982	56	4					291	297		10.1097/00000542-198204000-00011			7	Anesthesiology	Anesthesiology	NH937	WOS:A1982NH93700010	6278991				2020-06-26	J	SHARMA, SK; KHANNA, NC				SHARMA, SK; KHANNA, NC			ASCORBATE SUPPRESSES THE OPIATE-INDUCED COMPENSATORY INCREASE IN CYCLIC-AMP IN NEURO-BLASTOMA X GLIOMA HYBRID-CELLS	BIOCHEMICAL JOURNAL			English	Article										SHARMA, SK (reprint author), ALL INDIA INST MED SCI,DEPT BIOCHEM,NEW DELHI 110029,INDIA.						BABA A, 1981, J BIOL CHEM, V256, P3679; DUNLAP CE, 1979, MOL PHARMACOL, V16, P105; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; HENRY RJ, 1964, CLIN CHEM PRINCIPLES, P715; LESLIE FM, 1980, J NEUROCHEM, V34, P219, DOI 10.1111/j.1471-4159.1980.tb04645.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P590, DOI 10.1073/pnas.72.2.590; SHARMA SK, 1977, P NATL ACAD SCI USA, V74, P3365, DOI 10.1073/pnas.74.8.3365; TRABER J, 1975, LIFE SCI, V16, P1863, DOI 10.1016/0024-3205(75)90292-1; WILKENING D, 1980, J NEUROCHEM, V34, P321, DOI 10.1111/j.1471-4159.1980.tb06600.x	11	7	7	0	0	PORTLAND PRESS	LONDON	59 PORTLAND PLACE, LONDON W1N 3AJ, ENGLAND	0264-6021			BIOCHEM J	Biochem. J.		1982	208	1					43	46		10.1042/bj2080043			4	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	PM156	WOS:A1982PM15600006	6297463	Green Published			2020-06-26	J	SAIANI, L; GUIDOTTI, A				SAIANI, L; GUIDOTTI, A			OPIATE RECEPTOR-MEDIATED INHIBITION OF CATECHOLAMINE RELEASE IN PRIMARY CULTURES OF BOVINE ADRENAL CHROMAFFIN CELLS	JOURNAL OF NEUROCHEMISTRY			English	Article									ST ELIZABETHS HOSP,NIMH,PRECLIN PHARMACOL LAB,WASHINGTON,DC 20032							ADLER MW, 1981, LIFE SCI, V28, P1543, DOI 10.1016/0024-3205(81)90307-6; BLUME AJ, 1978, P NATL ACAD SCI USA, V75, P1713, DOI 10.1073/pnas.75.4.1713; CHANG KJ, 1979, J BIOL CHEM, V254, P2610; CHANG KJ, 1981, P NATL ACAD SCI-BIOL, V78, P4141, DOI 10.1073/pnas.78.7.4141; CHAVKIN C, 1979, MOL PHARMACOL, V15, P751; CHAVKIN C, 1981, NATURE, V291, P591, DOI 10.1038/291591a0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHILDERS SR, 1979, EUR J PHARMACOL, V55, P11, DOI 10.1016/0014-2999(79)90142-0; COSTA E, 1980, NATURE, V288, P304, DOI 10.1038/288304a0; COSTA E, 1981, FED PROC, V40, P160; GRAY EG, 1962, J ANAT, V96, P79; HEXUM TD, 1980, LIFE SCI, V27, P1211, DOI 10.1016/0024-3205(80)90474-9; HOKFELT T, 1980, NEURAL PEPTIDES NEUR, P1; KILPATRICK DL, 1981, P NATL ACAD SCI-BIOL, V78, P3265, DOI 10.1073/pnas.78.5.3265; KILPATRICK DL, 1980, J NEUROCHEM, V35, P679, DOI 10.1111/j.1471-4159.1980.tb03707.x; KUMAKURA K, 1980, NATURE, V283, P489, DOI 10.1038/283489a0; LEMAIRE S, 1981, J NEUROCHEM, V36, P886, DOI 10.1111/j.1471-4159.1981.tb01677.x; LEMAIRE S, 1980, NATURE, V288, P303, DOI 10.1038/288303b0; LEMAIRE S, 1981, SYNTHESIS STORAGE SE; LESLIE FM, 1980, J PHARMACOL EXP THER, V214, P395; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG JM, 1979, P NATL ACAD SCI USA, V76, P4079, DOI 10.1073/pnas.76.8.4079; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MARTIN WR, 1981, LIFE SCI, V28, P1547, DOI 10.1016/0024-3205(81)90308-8; MIZUNO K, 1980, BIOCHEM BIOPH RES CO, V97, P1283, DOI 10.1016/S0006-291X(80)80005-2; MIZUNO K, 1980, BIOCHEM BIOPH RES CO, V95, P1482, DOI 10.1016/S0006-291X(80)80064-7; PERT CB, 1974, MOL PHARMACOL, V10, P868; ROBSON LE, 1979, PROC R SOC SER B-BIO, V205, P425, DOI 10.1098/rspb.1979.0076; SCHULTZBERG M, 1978, NEUROSCIENCE, V3, P1169, DOI 10.1016/0306-4522(78)90137-9; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; SMITH JR, 1980, P NATL ACAD SCI-BIOL, V77, P281, DOI 10.1073/pnas.77.1.281; SNYDER SH, 1980, J NEUROCHEM, V35, P5, DOI 10.1111/j.1471-4159.1980.tb12483.x; STERN AS, 1979, P NATL ACAD SCI USA, V76, P6680, DOI 10.1073/pnas.76.12.6680; UNSICKER K, 1981, J NEUROSCI METH, V4, P227, DOI 10.1016/0165-0270(81)90034-0; VIVEROS OH, 1979, MOL PHARMACOL, V16, P1101; WUSTER M, 1980, NEUROSCI LETT, V20, P79, DOI 10.1016/0304-3940(80)90237-2; YANG HYT, 1980, LIFE SCI, V27, P1119, DOI 10.1016/0024-3205(80)90461-0; ZUKIN RS, 1981, LIFE SCI, V29, P2681	39	105	105	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.		1982	39	6					1669	1673		10.1111/j.1471-4159.1982.tb08001.x			5	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	PS545	WOS:A1982PS54500019	6292366				2020-06-26	J	BALLARD, WB; FRANZMANN, AW; GARDNER, CL				BALLARD, WB; FRANZMANN, AW; GARDNER, CL			COMPARISON AND ASSESSMENT OF DRUGS USED TO IMMOBILIZE ALASKAN GRAY WOLVES (CANIS-LUPUS) AND WOLVERINES (GULO-GULO) FROM A HELICOPTER	JOURNAL OF WILDLIFE DISEASES			English	Article									ALASKA DEPT FISH & GAME,MOOSE RES CTR,SOLDOTNA,AK 99669	BALLARD, WB (reprint author), ALASKA DEPT FISH & GAME,POB 47,GLENNALLEN,AK 99588, USA.		Brainerd, Scott M./A-1172-2010				Ballard W.B., 1981, NELCHINA BASIN WOLF; BALLARD WB, 1982, WOLVES WORLD; BISHOP R H, 1974, Naturaliste Canadien (Quebec), V101, P559; Franzmann A.W., 1974, Journal Zool Anim Med, V5, P26, DOI 10.2307/20094236; FULLER TK, 1981, J WILDLIFE MANAGE, V45, P271, DOI 10.2307/3807901; HASH HS, 1980, J WILDLIFE MANAGE, V44, P713, DOI 10.2307/3808026; MECH LD, 1974, [No title captured], V11, P315; Seal U. S, 1970, Int. Zoo Yb., V10, P157, DOI 10.1111/j.1748-1090.1970.tb01324.x; SKOOG RO, 1968, [No title captured]; SNEDECOR GW, 1973, [No title captured]; TAYLOR KP, 1979, P N AM MOOSE C WORKS, V15, P169; van Ballenberghe V., 1975, Wildlife Monogr, VNo. 43, P1	12	19	19	0	5	WILDLIFE DISEASE ASSN, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897	0090-3558			J WILDLIFE DIS	J. Wildl. Dis.		1982	18	3					339	342		10.7589/0090-3558-18.3.339			4	Veterinary Sciences	Veterinary Sciences	PB754	WOS:A1982PB75400009	7131656				2020-06-26	J	FISKER, AV; STAGE, I; PHILIPSEN, HP				FISKER, AV; STAGE, I; PHILIPSEN, HP			USE OF ETORPHINE-ACEPROMAZINE AND DIPRENORPHINE IN REVERSIBLE NEUROLEPTANALGESIA OF RATS	LABORATORY ANIMALS			English	Article										FISKER, AV (reprint author), ROYAL DENT COLL,DEPT ORAL PATHOL,DK-8000 AARHUS C,DENMARK.						BROOK JM, 1977, VET REC, V100, P574; BROWN JH, 1980, BRIT J ANAESTH, V52, P1101, DOI 10.1093/bja/52.11.1101; FERGUSON JW, 1979, J NATL CANCER I, V63, P1383; FIRN S, 1973, LANCET, V2, P95; Firn S., 1974, LANCET, Vi, P577; FISKER AV, 1978, THESIS ROYAL DENTAL; GARCIA DA, 1975, LAB ANIM SCI, V25, P585; GOODRICH PGE, 1977, VET REC, V100, P458, DOI 10.1136/vr.100.21.458; GREEN C J, 1975, Laboratory Animals (London), V9, P161, DOI 10.1258/002367775780994574; GREEN CJ, 1981, LAB ANIM, V15, P171, DOI 10.1258/002367781780958919; GREEN CJ, 1981, LAB ANIM, V15, P163, DOI 10.1258/002367781780959107; GREEN CJ, 1979, LABORATORY ANIMAL HD, V8; HELLEKANT G, 1976, SCANDLAS NYT, V3, P15; HERMANSEN K, 1974, ACTA PHARMACOL TOX, V34, P189; JONES JB, 1968, LAB ANIM CARE, V18, P642; LEWIS GE, 1972, LAB ANIM SCI, V22, P430; LUMB WV, 1963, SMALL ANIMAL ANESTHE, P381; MOLLER BR, 1978, SCANDLAS NYT, V5, P93; ORR CM, 1977, VET REC, V100, P574; VAUDREY JC, 1974, VET REC, V94, P52; VOLANS GN, 1976, BRIT MED J, V2, P472, DOI 10.1136/bmj.2.6033.472-c	21	25	25	0	1	ROYAL SOC MEDICINE PRESS LTD	LONDON	1 WIMPOLE STREET, LONDON, ENGLAND W1M 8AE	0023-6772			LAB ANIM	Lab. Anim.		1982	16	2					109	113		10.1258/002367782781110197			5	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	NK856	WOS:A1982NK85600001	7078053				2020-06-26	J	CLOUET, DH; WILLIAMS, N				CLOUET, DH; WILLIAMS, N			THE ROLE OF CALMODULIN IN OPIOID-INDUCED CHANGES IN THE PHOSPHORYLATION OF RAT STRIATAL SYNAPTIC MEMBRANE-PROTEINS	NEUROCHEMICAL RESEARCH			English	Article									SUNY DOWNSTATE MED CTR,BROOKLYN,NY 11203	CLOUET, DH (reprint author), NEW YORK STATE DIV SUBST ABUSE SERV,RES LAB,NEW YORK,NY, USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-00087]		BARTHOLINI G, 1981, HDB BIOL PSYCHIATR 4, P767; CLOUET DH, 1970, SCIENCE, V168, P854, DOI 10.1126/science.168.3933.854; CLOUET DH, 1978, CHARACTERISTICS FUNC, P307; CLOUET DH, 1980, ENDOGENOUS EXOGENOUS, P239; De ROBERTIS E., 1966, LIFE SCI, V5, P577, DOI 10.1016/0024-3205(66)90288-8; DELORENZO RJ, 1976, BIOCHEM BIOPH RES CO, V71, P590, DOI 10.1016/0006-291X(76)90828-7; Gibson R D, 1970, J Pharm Sci, V59, P426, DOI 10.1002/jps.2600590338; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; GREENGARD P, 1978, SCIENCE, V199, P145; HANBAUER I, 1979, NEUROPHARMACOLOGY, V18, P859, DOI 10.1016/0028-3908(79)90082-0; IWATSUBO K, 1977, J PHARMACOL EXP THER, V202, P429; KRUEGER BK, 1977, J BIOL CHEM, V252, P2764; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORITA K, 1981, ADV ENDOGENOUS EXOGE, P43; MORONI F, 1979, J PHARMACOL EXP THER, V208, P190; MUDGE AW, 1979, P NAT ACAD SCI US, V76, P530; OCALLAGHAN JP, 1979, J PHARMACOL EXP THER, V208, P96; RACAGNI G, 1976, NEUROPHARMACOLOGY, V15, P723, DOI 10.1016/0028-3908(76)90001-0; SHULMAN H, 1978, [No title captured], V271, P478; WILLIAMS N, 1982, J PHARMACOL EXP THER, V220, P278	20	13	13	0	0	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013	0364-3190			NEUROCHEM RES	Neurochem. Res.		1982	7	9					1135	1148		10.1007/BF00964891			14	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	PR310	WOS:A1982PR31000009	7177312				2020-06-26	J	HE, LF				HE, LF			EFFECT OF IONTOPHORETIC ETORPHINE AND ELECTROACUPUNCTURE ON NOCICEPTIVE RESPONSE FROM NUCLEUS LATERALIS ANTERIALIS OF THALAMUS IN RABBITS	ACUPUNCTURE & ELECTRO-THERAPEUTICS RESEARCH			English	Article										HE, LF (reprint author), NIDR,NEUROBIOL & ANESTHESIOL BRANCH,BETHESDA,MD 20205, USA.							0	3	3	0	0	COGNIZANT COMMUNICATION CORP	ELMSFORD	3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701	0360-1293			ACUPUNCTURE ELECTRO	Acupunct. Electro-Ther. Res.		1981	6	2-3					151	157		10.3727/036012981816952243			7	Integrative & Complementary Medicine; Neurosciences	Integrative & Complementary Medicine; Neurosciences & Neurology	MW689	WOS:A1981MW68900004	6120619				2020-06-26	J	STEFANO, GB; CATAPANE, EJ; KREAM, RM				STEFANO, GB; CATAPANE, EJ; KREAM, RM			CHARACTERIZATION OF THE DOPAMINE STIMULATED ADENYLATE-CYCLASE IN THE PEDAL GANGLIA OF MYTILUS-EDULIS - INTERACTIONS WITH ETORPHINE, BETA-ENDORPHIN, DALA, AND METHIONINE ENKEPHALIN	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article									E COAST NEUROSCI FDN INC,NORTHPORT,NY 11768	STEFANO, GB (reprint author), CUNY,MEDGAR EVERS COLL,DEPT NAT SCI,BROOKLYN,NY 11225, USA.			Stefano, George/0000-0002-8146-0740	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [1S06RR08171-01]; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [1-T32GM07641-01]		ARY M, 1977, J PHARMACOL EXP THER, V200, P271; BERRY MS, 1973, NATURE-NEW BIOL, V242, P250, DOI 10.1038/newbio242250a0; CARENZI A, 1975, J PHARMACOL EXP THER, V194, P311; CATAPANE EJ, 1979, J EXP BIOL, V83, P315; CATAPANE EJ, 1978, J EXP BIOL, V74, P101; CEDAR H, 1972, J GEN PHYSIOL, V60, P558, DOI 10.1085/jgp.60.5.558; CLOUET DH, 1975, LIFE SCI, V17, P35, DOI 10.1016/0024-3205(75)90230-1; DAHL E, 1966, Z ZELLFORSCH MIK ANA, V71, P489, DOI 10.1007/BF00349609; EIDELBERG E, 1975, J PHARMACOL EXP THER, V192, P50; FORN J, 1974, SCIENCE, V186, P1118, DOI 10.1126/science.186.4169.1118; IWATSUBO K, 1975, BIOCHEM PHARMACOL, V24, P1499, DOI 10.1016/0006-2952(75)90026-X; KEBABIAN JW, 1971, SCIENCE, V174, P1346, DOI 10.1126/science.174.4016.1346; KEBABIAN JW, 1976, SCIENCE, V193, P683, DOI 10.1126/science.181842; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KREAM RM, 1980, J BIOL CHEM, V255, P9218; LORD JAH, 1976, OPIATES ENDOGENOUS O, P275; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALANGA CJ, 1972, COMP BIOCHEM PHYSIOL, V43, P825, DOI 10.1016/0300-9629(72)90153-3; MALANGA CJ, 1980, FED P, V39; MILLER RJ, 1974, MOL PHARMACOL, V10, P759; OSBORNE NN, 1975, BIOCHEM PHARMACOL, V24, P2141, DOI 10.1016/0006-2952(75)90043-X; OSBORNE NN, 1977, EXPERIENTIA, V33, P917, DOI 10.1007/BF01951280; PERT CB, 1979, ENDOGENOUS EXOGENOUS, P87; PURI SK, 1971, PHARMACOLOGIST, V13, P280; PURI SK, 1975, LIFE SCI, V16, P759, DOI 10.1016/0024-3205(75)90352-5; SAAMIVAARA L, 1976, ANN MED EXP BIOL FEN, V47, P180; SIMANTOV R, 1976, OPIATES ENDOGENOUS O, P41; STEFANO GB, 1980, BRAIN RES, V181, P440, DOI 10.1016/0006-8993(80)90626-5; STEFANO GB, 1977, EXPERIENTIA, V33, P1341, DOI 10.1007/BF01920170; STEFANO GB, 1977, J PHARMACOL EXP THER, V203, P449; STEFANO GB, 1979, LIFE SCI, V24, P1617, DOI 10.1016/0024-3205(79)90024-9; STEFANO GB, 1979, LIFE SCI, V25, P291, DOI 10.1016/0024-3205(79)90298-4; SWEENEY D, 1963, SCIENCE, V139, P1051, DOI 10.1126/science.139.3559.1051; TREISTMAN SN, 1976, NATURE, V261, P62, DOI 10.1038/261062a0; VONEULER VS, 1961, NATURE, V190, P170; WALCZAK SA, 1979, BRAIN RES, V160, P105, DOI 10.1016/0006-8993(79)90604-8; WELSH JH, 1972, HDB EXP PHARMACOL, V33, P79; WILKENING D, 1976, LIFE SCI, V19, P1129, DOI 10.1016/0024-3205(76)90247-2	38	30	31	0	0	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013	0272-4340			CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.		1981	1	1					57	68		10.1007/BF00736039			12	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	MP405	WOS:A1981MP40500004	6286125				2020-06-26	J	STEFANO, GB				STEFANO, GB			DECREASE IN THE NUMBER OF HIGH-AFFINITY OPIATE BINDING-SITES DURING THE AGING PROCESS IN MYTILUS-EDULIS (BIVALVIA)	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article										STEFANO, GB (reprint author), CUNY, MEDGAR EVERS COLL, DEPT NAT SCI, BROOKLYN, NY 11225 USA.			Stefano, George/0000-0002-8146-0740	PHS HHSUnited States Public Health Service [08171]		Finch C E, 1978, Adv Exp Med Biol, V113, P15; FINCH CE, 1977, HDB BIOL AGING, P262; FINCH CE, 1978, ADV EXP MED BIOL, V113; GOVONI S, 1978, J PHARM PHARMACOL, V30, P448, DOI 10.1111/j.2042-7158.1978.tb13284.x; GREEN J, 1968, BIOL ESTUARINE ANIMA, P144; KREAM RM, 1979, BIOCHEM BIOPH RES CO, V90, P99, DOI 10.1016/0006-291X(79)91595-X; KREAM RM, 1980, J BIOL CHEM, V255, P9218; Leake L. D., 1980, INVERTEBRATE NEUROPH; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKMAN MH, 1980, BRAIN RES, V192, P177, DOI 10.1016/0006-8993(80)91017-3; McGeer P L, 1978, Adv Exp Med Biol, V113, P41; MESSING RB, 1980, LIFE SCI, V26, P921, DOI 10.1016/0024-3205(80)90112-5; SEVERSON JA, 1980, BRAIN RES, V192, P147, DOI 10.1016/0006-8993(80)91015-X; SEVERSON JA, 1978, 31ST M GER SOC DALL; SHIH JC, 1978, LIFE SCI, V23, P1441; STEFANO GB, 1980, BRAIN RES, V181, P440, DOI 10.1016/0006-8993(80)90626-5; STEFANO GB, 1979, LIFE SCI, V24, P1617, DOI 10.1016/0024-3205(79)90024-9; STEFANO GB, 1975, BIOL BULL-US, V148, P141, DOI 10.2307/1540655; STEFANO GB, 1978, SOC NEUR ABSTR, V4, P283; TERRY RD, 1976, NEUROBIOLOGY AGING, V3; THAL LJ, 1980, BRAIN RES, V192, P185, DOI 10.1016/0006-8993(80)91018-5; ZUKIN RS, 1979, P NATL ACAD SCI USA, V76, P1593, DOI 10.1073/pnas.76.4.1593	22	8	8	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.		1981	1	4					343	350		10.1007/BF00716269			8	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	NF168	WOS:A1981NF16800003	6101081				2020-06-26	J	YOUNG, AM; KATZ, JL; WOODS, JH				YOUNG, AM; KATZ, JL; WOODS, JH			BEHAVIORAL-EFFECTS OF LEVONANTRADOL AND NANTRADOL IN THE RHESUS-MONKEY	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article										YOUNG, AM (reprint author), UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109, USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 00154, DA 00254]		Aceto M D, 1979, NIDA Res Monogr, V27, P330; BALSTER RL, 1978, DRUG DISCRIMINATION, P131; BHARGAVA HN, 1978, PHARMACOL BIOCHEM BE, V8, P7, DOI 10.1016/0091-3057(78)90115-6; BUXBAUM DM, 1972, PSYCHOPHARMACOLOGIA, V25, P275, DOI 10.1007/BF00422507; CARDER B, 1975, SCIENCE, V190, P590, DOI 10.1126/science.1237929; CARNEY JM, 1977, PHARMACOL BIOCHEM BE, V7, P357, DOI 10.1016/0091-3057(77)90232-5; CHESHER GB, 1973, BRIT J PHARMACOL, V49, P588, DOI 10.1111/j.1476-5381.1973.tb08534.x; Cohen S, 1980, NIDA Res Monogr, V31, P199; DENEAU G, 1969, PSYCHOPHARMACOLOGIA, V16, P30, DOI 10.1007/BF00405254; DENEAU GA, 1971, PHARMACOLOGIST, V13, P246; DENEAU GA, 1963, P COMMITTEE PROBLEMS; FREDERICKSON RCA, 1976, J PHARMACOL EXP THER, V199, P375; HARRIS LS, 1979, MECHANISMS PAIN ANAL, P467; HARRIS RT, 1974, PSYCHOPHARMACOLOGIA, V37, P23, DOI 10.1007/BF00426679; HEIN DW, J PHARMACOL EXP THER; HERLING S, PSYCHOPHARMACOLOGY; JONES RT, 1976, [No title captured], P627; KAYMAKCALAN S, 1974, PSYCHOPHARMACOLOGIA, V35, P123, DOI 10.1007/BF00429579; Kaymakcalan S, 1972, CANNABIS ITS DERIVAT, P142; MCMILLAN DE, 1971, ANN NY ACAD SCI, V191, P83, DOI 10.1111/j.1749-6632.1971.tb13990.x; MCMILLAN DE, 1972, ARCH INT PHARMACOD T, V198, P132; MILNE GM, 1980, NIDA RES MONOGR, V27, P84; PICKENS R, 1973, 4 BAY S PSYCH DEP, P78; Siemens A J, 1980, NIDA Res Monogr, V31, P167; SOFIA RD, 1973, J PHARMACOL EXP THER, V186, P646; VILLARREAL JE, 1973, AGONIST ANTAGONIST A, P73; Weissman A, 1978, STIMULUS PROPERTIES, P99; WOODS JH, 1980, DRUG ALCOHOL DEPEN, V5, P223, DOI 10.1016/0376-8716(80)90182-9; WOODS JH, 1979, MECHANISMS PAIN ANAL, P429; WOODS JH, FED P; WOODS JH, 1978, NATIONAL I DRUG ABUS, V18, P54	31	24	24	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0091-2700			J CLIN PHARMACOL	J. Clin. Pharmacol.		1981	21	8-9					S348	S360		10.1002/j.1552-4604.1981.tb02614.x			13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	MJ289	WOS:A1981MJ28900049	6271836				2020-06-26	J	MUCHA, RF; VOLKOVSKIS, C; KALANT, H				MUCHA, RF; VOLKOVSKIS, C; KALANT, H			CONDITIONED INCREASES IN LOCOMOTOR-ACTIVITY PRODUCED WITH MORPHINE AS AN UNCONDITIONED STIMULUS, AND THE RELATION OF CONDITIONING TO ACUTE MORPHINE EFFECT AND TOLERANCE	JOURNAL OF COMPARATIVE AND PHYSIOLOGICAL PSYCHOLOGY			English	Article									UNIV TORONTO,DEPT PHARMACOL,TORONTO M5S 1A8,ONTARIO,CANADA; ADDICT RES FDN,TORONTO M5S 2S1,ONTARIO,CANADA							BABBINI M, 1972, BRIT J PHARMACOL, V46, P213, DOI 10.1111/j.1476-5381.1972.tb06866.x; BARDO MT, 1979, PHARMACOL BIOCHEM BE, V10, P481, DOI 10.1016/0091-3057(79)90221-1; BINDRA D, 1967, J COMP PHYSIOL PSYCH, V63, P288, DOI 10.1037/h0024371; BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; BOLLES RC, 1973, J COMP PHYSIOL PSYCH, V83, P510, DOI 10.1037/h0034666; CAMPBELL BA, 1960, J COMP PHYSIOL PSYCH, V53, P240, DOI 10.1037/h0044975; CAPPELL H, 1978, AUG M AM PSYCH ASS T; COLLIER HOJ, 1976, BRIT J PHARMACOL, V58, P193, DOI 10.1111/j.1476-5381.1976.tb10396.x; DOBBS HE, 1968, J PHARMACOL EXP THER, V160, P407; EIKELBOOM R, 1979, PSYCHOPHARMACOLOGY, V61, P31, DOI 10.1007/BF00426807; ELLIS HV, 1970, J PHARMACOL EXP THER, V175, P627; GOLDSTEIN A, 1974, LIFE SCI, V14, P615, DOI 10.1016/0024-3205(74)90396-8; HERING B, 1979, COMMUNICATION   1213; HERZ A, 1973, 4 BAYER S PSYCH DEP; HOLLAND PC, 1977, J EXP PSYCHOL ANIM B, V3, P77, DOI 10.1037/0097-7403.3.1.77; JAFFE JH, 1975, PHARMACOLOGICAL BASI; KAMAT KA, 1974, RES COMMUN CHEM PATH, V7, P367; KAYAN S, 1973, J PHARMACOL EXP THER, V185, P300; KIRK RE, 1968, [No title captured]; KOSTERLITZ HW, 1975, BRIT J PHARMACOL, V53, P131, DOI 10.1111/j.1476-5381.1975.tb07340.x; KUMAR R, 1971, BRIT J PHARMACOL, V42, P473, DOI 10.1111/j.1476-5381.1971.tb07132.x; LINSEMAN MA, 1974, BRAIN RES, V80, P146, DOI 10.1016/0006-8993(74)90733-1; LYNCH JJ, 1976, J NERV MENT DIS, V163, P47, DOI 10.1097/00005053-197607000-00007; MARTIN GE, 1977, PHARMACOL BIOCHEM BE, V7, P463, DOI 10.1016/0091-3057(77)90215-5; MUCHA RF, 1978, LIFE SCI, V23, P357, DOI 10.1016/0024-3205(78)90021-8; MUCHA RF, 1980, PHYSIOL BEHAV, V24, P425, DOI 10.1016/0031-9384(80)90230-9; PEREZCRUET J, 1976, PAVLOVIAN J BIOL SCI, V11, P237; PERT A, 1978, BASES ADDICTION; PETERSON GB, 1972, SCIENCE, V177, P1009, DOI 10.1126/science.177.4053.1009; PICKENS RW, 1967, PSYCHOPHARMACOLOGIA, V11, P88, DOI 10.1007/BF00401511; PINEL JPJ, 1973, CAN J PSYCHOL, V27, P112, DOI 10.1037/h0082451; RUSH ML, 1970, EUR J PHARMACOL, V11, P22, DOI 10.1016/0014-2999(70)90249-9; SHEFFIELD FD, 1953, J COMP PHYSIOL PSYCH, V47, P97; SHERMAN JE, 1979, LEARN MOTIV, V10, P383, DOI 10.1016/0023-9690(79)90055-9; SIEGEL S, 1975, J COMP PHYSIOL PSYCH, V89, P498, DOI 10.1037/h0077058; SIEGEL S, 1976, SCIENCE, V193, P323, DOI 10.1126/science.935870; SIEGEL S, 1978, J COMP PHYSIOL PSYCH, V92, P1137, DOI 10.1037/h0077525; SIEGEL S, 1977, J EXP PSYCHOL ANIM B, V3, P1, DOI 10.1037/0097-7403.3.1.1; SPRAGG S. D. S., 1940, COMPAR PSYCHOL MONOGR, V15, P1; Tilson H.A., 1973, PHARM BIO B, V1, P149; VANDERKOOY D, 1978, PHYSIOL PSYCHOL, V6, P199, DOI 10.3758/BF03326712; VASKO MR, 1978, J PHARMACOL EXP THER, V207, P848	42	83	83	0	3	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242	0021-9940			J COMP PHYSIOL PSYCH			1981	95	2					351	362		10.1037/h0077778			12	Psychology, Biological	Psychology	LL319	WOS:A1981LL31900015	6262390				2020-06-26	J	LEMAIRE, S; LIVETT, B; TSENG, R; MERCIER, P; LEMAIRE, I				LEMAIRE, S; LIVETT, B; TSENG, R; MERCIER, P; LEMAIRE, I			STUDIES ON THE INHIBITORY-ACTION OF OPIATE COMPOUNDS IN ISOLATED BOVINE ADRENAL CHROMAFFIN CELLS - NON-INVOLVEMENT OF STEREOSPECIFIC OPIATE BINDING-SITES	JOURNAL OF NEUROCHEMISTRY			English	Article									MCGILL UNIV,MONTREAL H3G 1A4,QUEBEC,CANADA; MONTREAL GEN HOSP,DIV NEUROL,MONTREAL H3G 1A4,QUEBEC,CANADA	LEMAIRE, S (reprint author), CTR HOSP UNIV SHERBROOKE,DEPT PHYSIOL & PHARMACOL,SHERBROOKE J1H 5N4,QUEBEC,CANADA.						CHAVKIN C, 1979, MOL PHARMACOL, V15, P751; DOUGLAS WW, 1975, HDB PHYSIOLOGY     7, V6, P367; GOLDSTEIN A, 1979, P NATL ACAD SCI USA, V76, P6666, DOI 10.1073/pnas.76.12.6666; HELLE KB, 1975, MOL CELL BIOCHEM, V6, P127, DOI 10.1007/BF01732006; HOCHMAN J, 1976, BIOCHIM BIOPHYS ACTA, V421, P168, DOI 10.1016/0304-4165(76)90180-X; HUGHES J, 1975, NATURE, V258, P577, DOI 10.1038/258577a0; HUGHES J, 1978, NEUROSCIENCE RES PRO, P296; IVERSEN LL, 1978, NATURE, V271, P679, DOI 10.1038/271679a0; KIMURA S, 1980, P NATL ACAD SCI-BIOL, V77, P1681, DOI 10.1073/pnas.77.3.1681; KIRSHNER N, 1972, PHARMACOL REV, V24, P385; KOSTERLITZ HW, 1968, BRIT J PHARMACOL, V33, P266, DOI 10.1111/j.1476-5381.1968.tb00988.x; KUMAKURA K, 1980, NATURE, V283, P489, DOI 10.1038/283489a0; LEMAIRE S, 1978, J MED CHEM, V21, P1232, DOI 10.1021/jm00210a012; LEMAIRE S, 1977, J AM CHEM SOC, V99, P1577, DOI 10.1021/ja00447a048; LEWIS RV, 1979, BIOCHEM BIOPH RES CO, V89, P822, DOI 10.1016/0006-291X(79)91852-7; LI CH, 1976, BIOCHEM BIOPH RES CO, V71, P19, DOI 10.1016/0006-291X(76)90243-6; LIVETT BG, NATURE; LUNDBERG JM, 1979, P NATL ACAD SCI USA, V76, P4079, DOI 10.1073/pnas.76.8.4079; MIURA Y, 1977, J LAB CLIN MED, V89, P421; PASTERNAK GW, 1975, MOL PHARMACOL, V11, P340; SCHNEIDER AS, 1979, LIFE SCI, V24, P1389, DOI 10.1016/0024-3205(79)90009-2; SCHULTZBERG M, 1978, NEUROSCIENCE, V3, P1169, DOI 10.1016/0306-4522(78)90137-9; SCHULTZBERG M, 1978, ACTA PHYSIOL SCAND, V103, P475, DOI 10.1111/j.1748-1716.1978.tb06243.x; SIMANTOV R, 1976, P NATL ACAD SCI USA, V73, P2515, DOI 10.1073/pnas.73.7.2515; STERN AS, 1979, P NATL ACAD SCI USA, V76, P6680, DOI 10.1073/pnas.76.12.6680; VIVEROS OH, 1979, MOL PHARMACOL, V16, P1101; WESTFALL TC, 1977, PHYSIOL REV, V57, P659; WILSON SP, 1977, J NEUROCHEM, V28, P687, DOI 10.1111/j.1471-4159.1977.tb10615.x; YANG HYT, 1980, NEUROPHARMACOLOGY, V19, P209, DOI 10.1016/0028-3908(80)90140-9	29	61	61	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.		1981	36	3					886	892		10.1111/j.1471-4159.1981.tb01677.x			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	LE513	WOS:A1981LE51300015	6259293				2020-06-26	J	HERKENHAM, M; PERT, CB				HERKENHAM, M; PERT, CB			MOSAIC DISTRIBUTION OF OPIATE RECEPTORS, PARAFASCICULAR PROJECTIONS AND ACETYLCHOLINESTERASE IN RAT STRIATUM	NATURE			English	Article									NIMH,BIOL PSYCHIAT BRANCH,BIOCHEM & PHARMACOL SECT,BETHESDA,MD 20205	HERKENHAM, M (reprint author), NIMH,NEUROPHYSIOL LAB,BETHESDA,MD 20205, USA.			Herkenham, Miles/0000-0003-2228-4238			BIRDSALL NJM, 1980, PROC R SOC SER B-BIO, V207, P1, DOI 10.1098/rspb.1980.0011; BOWEN WD, P NATN ACAD SCI US; DELATORRE JC, 1976, HISTOCHEMISTRY, V49, P81, DOI 10.1007/BF00495672; GOLDMAN PS, 1977, J COMP NEUROL, V171, P369, DOI 10.1002/cne.901710305; GOODMAN RR, 1980, P NATL ACAD SCI-BIOL, V77, P6239, DOI 10.1073/pnas.77.10.6239; GRAYBIEL AM, 1978, P NATL ACAD SCI USA, V75, P5723, DOI 10.1073/pnas.75.11.5723; GRAYBIEL AM, 1979, EXP BRAIN RES, V34, P189; GREYBIEL AM, 1980, SOC NEUR ABSTR, V6, P342; HARDY H, 1976, NEUROSCI LETT, V3, P1, DOI 10.1016/0304-3940(76)90090-2; HERKENHAM M, 1979, J COMP NEUROL, V183, P487, DOI 10.1002/cne.901830304; HERKENHAM M, 1980, P NATL ACAD SCI-BIOL, V77, P5532, DOI 10.1073/pnas.77.9.5532; HOKFELT T, 1980, NEURAL PEPTIDES NEUR, P1; HONG JS, 1978, J PHARMACOL EXP THER, V205, P141; IWATSUBO K, 1975, BIOCHEM PHARMACOL, V24, P1499, DOI 10.1016/0006-2952(75)90026-X; KALIL K, 1978, BRAIN RES, V140, P333, DOI 10.1016/0006-8993(78)90464-X; KEEFER DA, 1980, CELL TISSUE RES, V209, P167; KENT JL, DEV BRAIN REF; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; MENSAH PL, 1977, BRAIN RES, V137, P53, DOI 10.1016/0006-8993(77)91012-5; OLSON L, 1972, BRAIN RES, V44, P283, DOI 10.1016/0006-8993(72)90385-X; PARENTI M, 1980, FED PROC, V39, P516; PERT A, 1978, CHARACTERISTICS FUNC, V4, P389; PERT CB, 1975, LIFE SCI, V16, P1849, DOI 10.1016/0024-3205(75)90289-1; PERT CB, 1976, P NATL ACAD SCI USA, V73, P3729, DOI 10.1073/pnas.73.10.3729; PERT CB, 1980, NEURAL PEPTIDES NEUR, P581; POTTER A, 1979, BRAIN RES REV, V1, P185; RAGSDALE CW, 1979, SOC NEUR ABSTR, V5, P78; ROYCE GJ, 1978, BRAIN RES, V146, P145, DOI 10.1016/0006-8993(78)90224-X	28	451	451	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature		1981	291	5814					415	418		10.1038/291415a0			4	Multidisciplinary Sciences	Science & Technology - Other Topics	LS255	WOS:A1981LS25500026	6165892				2020-06-26	J	BIDLACK, JM; ABOOD, LG; OSEIGYIMAH, P; ARCHER, S				BIDLACK, JM; ABOOD, LG; OSEIGYIMAH, P; ARCHER, S			PURIFICATION OF THE OPIATE RECEPTOR FROM RAT-BRAIN	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES			English	Article									RENSSELAER POLYTECH INST,DEPT CHEM,TROY,NY 12181	BIDLACK, JM (reprint author), UNIV ROCHESTER,MED CTR,CTR BRAIN RES,ROCHESTER,NY 14642, USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 00464, DA-01674]; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 15345]		ARCHER S, 1979, J HETEROCYCLIC CHEM, V16, P389, DOI 10.1002/jhet.5570160240; BAKER BR, 1966, J HETEROCYCLIC CHEM, V3, P425, DOI 10.1002/jhet.5570030407; BIDLACK JM, 1980, LIFE SCI, V27, P331, DOI 10.1016/0024-3205(80)90201-5; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; Pert C B, 1980, Adv Biochem Psychopharmacol, V22, P581; RUEGG UT, 1980, EUR J PHARMACOL, V64, P367, DOI 10.1016/0014-2999(80)90247-2; SIMON EJ, 1975, SCIENCE, V190, P389, DOI 10.1126/science.1182043; SIMONDS WF, 1980, P NATL ACAD SCI-BIOL, V77, P4623, DOI 10.1073/pnas.77.8.4623; Snyder S H, 1979, Adv Biochem Psychopharmacol, V20, P543; ZUKIN RS, 1979, P NATL ACAD SCI USA, V76, P1593, DOI 10.1073/pnas.76.4.1593	13	96	96	0	1	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418	0027-8424			P NATL ACAD SCI-BIOL			1981	78	1					636	639		10.1073/pnas.78.1.636			4	Biology	Life Sciences & Biomedicine - Other Topics	LA963	WOS:A1981LA96300125	6264453	Bronze, Green Published			2020-06-26	J	HERLING, S; WOODS, JH				HERLING, S; WOODS, JH			DISCRIMINATIVE STIMULUS EFFECTS OF ETORPHINE IN RHESUS-MONKEYS	PSYCHOPHARMACOLOGY			English	Article									UNIV MICHIGAN,DEPT PSYCHOL,ANN ARBOR,MI 48109	HERLING, S (reprint author), UNIV MICHIGAN,DEPT PHARMACOL,ANN ARBOR,MI 48109, USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 00254, DA 00154]		BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; COLPAERT FC, 1978, PHARMACOL BIOCHEM BE, V9, P863, DOI 10.1016/0091-3057(78)90370-2; DOWNS DA, 1976, J PHARMACOL EXP THER, V196, P298; HEIN DW, J PHARMACOL EXP THER; HERLING S, 1980, J PHARMACOL EXP THER, V214, P139; HOFFMEISTER F, 1979, MECHANISMS PAIN ANAL, P447; JOHANSON CE, 1978, B NARCOTICS, V30, P43; KOSTERLITZ HW, 1974, NARCOTIC ANTAGONISTS, V8, P319; LAL H, 1977, DISCRIMINATIVE STIMU, P23; SCHAEFER GJ, 1977, J PHARMACOL EXP THER, V201, P67; SHANNON HE, 1976, J PHARMACOL EXP THER, V198, P54; TEAL JJ, 1980, J PHARMACOL EXP THER, V212, P368; WOODS JH, 1979, MECHANISMS PAIN ANAL, P429; YOUNG AM, 1980, PSYCHOPHARMACOLOGY, V70, P263, DOI 10.1007/BF00427883; YOUNG AM, 1980, 42ND SCI M COMM PROB	15	30	30	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0033-3158			PSYCHOPHARMACOLOGY	Psychopharmacology		1981	72	3					265	267		10.1007/BF00431828			3	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	LH696	WOS:A1981LH69600009	6784144				2020-06-26	J	GILLAN, MGC; KOSTERLITZ, HW; PATERSON, SJ				GILLAN, MGC; KOSTERLITZ, HW; PATERSON, SJ			COMPARISON OF THE BINDING CHARACTERISTICS OF TRITIATED OPIATES AND OPIOID-PEPTIDES	BRITISH JOURNAL OF PHARMACOLOGY			English	Article										GILLAN, MGC (reprint author), UNIV ABERDEEN,RES ADDICT DRUGS UNIT,ABERDEEN AB9 1FX,SCOTLAND.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 00662]		CHANG KJ, 1979, J BIOL CHEM, V254, P2610; CHANG KJ, 1979, MOL PHARMACOL, V16, P91; Chang Y., 1973, BIOCHEM PHARMACOL, V22, P3099; CHILDERS SR, 1979, EUR J PHARMACOL, V55, P11, DOI 10.1016/0014-2999(79)90142-0; GILBERT PE, 1976, J PHARMACOL EXP THER, V198, P66; GILLAN MGC, 1979, BRIT J PHARMACOL, V66, pP86; HANCOCK AA, 1979, MOL PHARMACOL, V16, P1; Hill A, 1910, J PHYSIOL-LONDON, V40, piv; HUTCHINSON M, 1975, BRIT J PHARMACOL, V55, P541, DOI 10.1111/j.1476-5381.1975.tb07430.x; KOSTERLITZ HW, 1980, BRIT J PHARMACOL, V68, P333, DOI 10.1111/j.1476-5381.1980.tb10422.x; KOSTERLITZ HW, 1978, ENDORPHINS ADV BIOCH, V18, P31; KOSTERLITZ HW, 1978, 40TH M COMM PROBL DR, V40, P139; LAW PY, 1978, RES COMMUN CHEM PATH, V21, P409; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; LORD JAH, 1976, OPIATES ENDOGENOUS O, P275; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MEUNIER JC, 1977, FEBS LETT, V77, P209, DOI 10.1016/0014-5793(77)80236-6; MILLER RJ, 1978, LIFE SCI, V22, P379, DOI 10.1016/0024-3205(78)90284-9; PASTERNAK GW, 1975, NATURE, V253, P563, DOI 10.1038/253563a0; PERT CB, 1979, ENDOGENOUS EXOGENOUS, P87; ROBSON LE, 1979, PROC R SOC SER B-BIO, V205, P425, DOI 10.1098/rspb.1979.0076; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIMANTOV R, 1978, EUR J PHARMACOL, V47, P319, DOI 10.1016/0014-2999(78)90240-6; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; SIMON EJ, 1975, J PHARMACOL EXP THER, V192, P531; WONG DT, 1973, LIFE SCI, V13, P1543, DOI 10.1016/0024-3205(73)90143-4	26	162	162	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0007-1188			BRIT J PHARMACOL	Br. J. Pharmacol.		1980	70	3					481	490		10.1111/j.1476-5381.1980.tb08727.x			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	KR966	WOS:A1980KR96600019	7437652	Green Published			2020-06-26	J	LESLIE, FM; DUNLAP, CE; COX, BM				LESLIE, FM; DUNLAP, CE; COX, BM			ASCORBATE DECREASES LIGAND-BINDING TO NEUROTRANSMITTER RECEPTORS	JOURNAL OF NEUROCHEMISTRY			English	Note										LESLIE, FM (reprint author), ADDICT RES FDN,PALO ALTO,CA 94304, USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-07063, DA-1199, DA-00054]		BENNETT JP, 1976, MOL PHARMACOL, V12, P373; BISHAYEE S, 1971, J NEUROCHEM, V18, P909, DOI 10.1111/j.1471-4159.1971.tb12020.x; DAVIS JN, 1977, BRAIN RES, V132, P327, DOI 10.1016/0006-8993(77)90425-5; DUNLAP CE, 1979, MOL PHARMACOL, V16, P105; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; GREENBERG DA, 1977, LIFE SCI, V20, P927, DOI 10.1016/0024-3205(77)90277-6; LEFKOWITZ RJ, 1977, P NATL ACAD SCI USA, V74, P515, DOI 10.1073/pnas.74.2.515; SCHAEFER A, 1975, BIOCHEM PHARMACOL, V24, P1781, DOI 10.1016/0006-2952(75)90457-8; SEEMAN P, 1975, P NATL ACAD SCI USA, V72, P4376, DOI 10.1073/pnas.72.11.4376; SEEMAN P, 1978, FED PROC, V37, P130; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; UPRICHARD DC, 1977, MOL PHARMACOL, V13, P454; WEIS W, 1975, ANN NY ACAD SCI, V258, P190, DOI 10.1111/j.1749-6632.1975.tb29279.x; YAMAMURA HI, 1974, P NATL ACAD SCI USA, V71, P1725, DOI 10.1073/pnas.71.5.1725; ZANNONI VG, 1973, DRUG METAB REV, V2, P57	15	109	109	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.		1980	34	1					219	221		10.1111/j.1471-4159.1980.tb04645.x			3	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	HV758	WOS:A1980HV75800031	6256473				2020-06-26	J	COX, BM; LESLIE, FM; DUNLAP, CE				COX, BM; LESLIE, FM; DUNLAP, CE			THE USE OF ASCORBATE AS A PROBE OF OPIOID RECEPTOR STRUCTURE - EVIDENCE FOR 2 INDEPENDENT MECHANISMS OF RECEPTOR DESTRUCTION BY ASCORBATE	JOURNAL OF RECEPTOR RESEARCH			English	Article										COX, BM (reprint author), ADDICT RES FDN,PALO ALTO,CA, USA.				PHS HHSUnited States Public Health Service [01199]		ABOOD LG, 1978, BIOCHIM BIOPHYS ACTA, V530, P35, DOI 10.1016/0005-2760(78)90124-8; BISHAYEE S, 1971, J NEUROCHEM, V18, P909, DOI 10.1111/j.1471-4159.1971.tb12020.x; CHANG KJ, 1979, J BIOL CHEM, V254, P2610; COX BM, ADV BIOCH PSYCHOPHAR; CREESE I, 1975, J PHARMACOL EXP THER, V194, P205; DUNLAP CE, 1979, MOL PHARMACOL, V16, P105; GOLDSTEIN A, 1971, P NAT ACAD SCI US, V68, P1741; LESLIE FM, 1980, J NEUROCHEM, V34, P219, DOI 10.1111/j.1471-4159.1980.tb04645.x; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; MEDZIHRADSKY F, 1976, BRAIN RES, V108, P121; PASTERNAK GW, 1974, MOL PHARMACOL, V10, P183; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; SCHAEFER A, 1975, BIOCHEM PHARMACOL, V24, P1781, DOI 10.1016/0006-2952(75)90457-8; SIMON EJ, 1975, P NATL ACAD SCI USA, V72, P2404, DOI 10.1073/pnas.72.6.2404; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; WILSON HA, 1975, NATURE, V253, P448, DOI 10.1038/253448a0	16	16	16	0	0	MARCEL DEKKER INC	NEW YORK	270 MADISON AVE, NEW YORK, NY 10016	0197-5110			J RECEPTOR RES	J. Recept. Res.		1980	1	2					329	354		10.3109/10799898009044104			26	Cell Biology	Cell Biology	KR767	WOS:A1980KR76700010	6271956				2020-06-26	J	HEBERT, DM; LAY, DW; TURNBULL, WG				HEBERT, DM; LAY, DW; TURNBULL, WG			IMMOBILIZATION OF COASTAL GRIZZLY BEARS WITH ETORPHINE HYDROCHLORIDE	JOURNAL OF WILDLIFE DISEASES			English	Article										HEBERT, DM (reprint author), FISH & WILDLIFE BRANCH, NANAIMO V9R 5CB, BC, CANADA.						BEEMAN LE, 1974, J WILDLIFE MANAGE, V38, P568, DOI 10.2307/3800893; GLENN L, 1972, W174 AL DEP FISH GAM; GLENN L, W175 AL DEP FISH GAM; LARSEN LH, 1967, POLAR REC, V13, P589; WALLACH JD, 1967, J AM VET MED ASSOC, V151, P870	5	3	4	0	1	WILDLIFE DISEASE ASSOC, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA	0090-3558	1943-3700		J WILDLIFE DIS	J. Wildl. Dis.		1980	16	3					339	342		10.7589/0090-3558-16.3.339			4	Veterinary Sciences	Veterinary Sciences	KE436	WOS:A1980KE43600006	7411738	Bronze			2020-06-26	J	KACHUR, JF; MILLER, RJ; FIELD, M				KACHUR, JF; MILLER, RJ; FIELD, M			CONTROL OF GUINEA-PIG INTESTINAL ELECTROLYTE SECRETION BY A DELTA-OPIATE RECEPTOR	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES			English	Article									UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA	KACHUR, JF (reprint author), UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA.						ALUMETS J, 1978, HISTOCHEMISTRY, V56, P187, DOI 10.1007/BF00495979; BASS P, 1973, J PHARMACOL EXP THER, V186, P183; BOLTON JE, 1977, J MEMBRANE BIOL, V35, P159, DOI 10.1007/BF01869947; BURKS TF, 1967, J PHARMACOL EXP THER, V156, P267; BURKS TF, 1967, J PHARMACOL EXP THER, V158, P264; BURKS TF, 1974, J PHARMACOL EXP THER, V191, P518; BURKS TF, 1976, OPIATES ENDOGENOUS O, P369; CHANG KJ, 1978, MOL PHARMACOL, V14, P961; CHANG KJ, 1979, J BIOL CHEM, V254, P2610; FIELD M, 1973, AM J PHYSIOL, V225, P852; FIELD M, 1971, AM J PHYSIOL, V220, P1388; FURNESS JB, 1980, NEUROSCIENCE, V5, P1, DOI 10.1016/0306-4522(80)90067-6; GUANDALINI S, 1980, AM J PHYSIOL, V238, pG67; HUTCHINSON M, 1975, BRIT J PHARMACOL, V55, P541, DOI 10.1111/j.1476-5381.1975.tb07430.x; KARIM SMM, 1977, PROSTAG OTH LIPID M, V13, P321, DOI 10.1016/0090-6980(77)90011-9; KOSTERLITZ HW, 1957, J PHYSIOL-LONDON, V136, P249, DOI 10.1113/jphysiol.1957.sp005757; KOSTERLITZ HW, 1979, MECHANISMS PAIN ANAL, P707; LINNOILA RI, 1978, NEUROSCIENCE, V3, P1187, DOI 10.1016/0306-4522(78)90138-0; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MILLER RJ, 1977, BIOCHEM BIOPH RES CO, V74, P1311, DOI 10.1016/0006-291X(77)90585-X; MILLER RJ, 1978, VITAM HORM, V36, P297; RACUSEN LC, 1978, GASTROENTEROLOGY, V74, P1081; REYNOLDS AK, 1957, MORPHINE ALLIED DRUG; STAHL KD, 1977, EUR J PHARMACOL, V46, P199, DOI 10.1016/0014-2999(77)90334-X; WATERFIELD AA, 1977, EUR J PHARMACOL, V43, P107, DOI 10.1016/0014-2999(77)90123-6	26	141	141	0	0	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI-BIOL			1980	77	5					2753	2756		10.1073/pnas.77.5.2753			4	Biology	Life Sciences & Biomedicine - Other Topics	JU568	WOS:A1980JU56800080	6248864	Green Published, Bronze			2020-06-26	J	MUCHA, RF; KALANT, H				MUCHA, RF; KALANT, H			LOG DOSE-RESPONSE CURVE FLATTENING IN RATS AFTER DAILY INJECTION OF OPIATES	PSYCHOPHARMACOLOGY			English	Article									ADDICT RES FDN,33 RUSSELL ST,TORONTO M5S 2S1,ONTARIO,CANADA; UNIV TORONTO,DEPT PHARMACOL,TORONTO M5S 1A1,ONTARIO,CANADA							BLASIG J, 1979, NEUROPHARMACOLOGY, V18, P473, DOI 10.1016/0028-3908(79)90073-X; BURKS TF, 1974, EUR J PHARMACOL, V25, P302, DOI 10.1016/0014-2999(74)90259-3; CICERO TJ, 1973, J PHARMACOL EXP THER, V184, P404; COPER H, 1978, BASES ADDICTION, P235; COX BM, 1975, BRIT J PHARMACOL, V53, P383, DOI 10.1111/j.1476-5381.1975.tb07374.x; COX BM, 1968, BRIT J PHARMACOL, V33, P245, DOI 10.1111/j.1476-5381.1968.tb00986.x; COX BM, 1978, CHARACTERISTICS FUNC, P13; ELLIS HV, 1970, J PHARMACOL EXP THER, V175, P627; FENNESSY MR, 1969, BRIT J PHARMACOL, V37, P436, DOI 10.1111/j.1476-5381.1969.tb10580.x; FERNANDES M, 1977, PSYCHOPHARMACOLOGY, V54, P197, DOI 10.1007/BF00426780; FERNANDES M, 1977, N-S ARCH PHARMACOL, V297, P53, DOI 10.1007/BF00508810; GOLDSTEIN AL, 1974, PRINCIPLES DRUG ACTI, P599; GRANAT FR, 1973, ARCH INT PHARMACOD T, V205, P52; GUNNE LM, 1960, ARCH INT PHARMACOD T, V129, P416; HERZ A, 1973, 4TH BAY S PSYCH DEP, P126; HOLLT V, 1978, FED PROC, V37, P158; HOLTZMAN SG, 1974, PSYCHOPHARMACOLOGIA, V39, P23, DOI 10.1007/BF00421455; Hug C.C., 1972, CHEM BIOL ASPECTS DR, P307; HUI KS, 1976, EXPERIENTIA, V32, P1313, DOI 10.1007/BF01953112; KALANT H, 1978, PSYCHOPHARMACOLOGY, V60, P59, DOI 10.1007/BF00429180; KALANT H, 1978, BASES ADDICTION, P199; MARTIN WR, 1964, J PHARMACOL EXP THER, V146, P385; MARTIN WR, 1963, PSYCHOPHARMACOLOGIA, V4, P247, DOI 10.1007/BF00408180; MAYER DJ, 1976, PAIN, V2, P379, DOI 10.1016/0304-3959(76)90080-4; MOTAMATSU T, 1977, CAN J NEUROL SCI, V4, P49; MUCHA RF, 1979, PHARMACOL BIOCHEM BE, V10, P397, DOI 10.1016/0091-3057(79)90204-1; MUCHA RF, 1978, LIFE SCI, V23, P357, DOI 10.1016/0024-3205(78)90021-8; MUCHA RF, 1977, P CAN FED BIOL SCI, V20, P381; OLSON RD, 1978, PHARMACOL BIOCHEM BE, V9, P111, DOI 10.1016/0091-3057(78)90020-5; ROSENFELD GC, 1977, J PHARMACOL EXP THER, V202, P654; SEEVERS MH, 1963, PHYSL PHARM, P565; SEWELL RDE, 1976, NEUROPHARMACOLOGY, V15, P683, DOI 10.1016/0028-3908(76)90037-X; SHOHAM S, 1974, BRIT J PHARMACOL, V52, P597, DOI 10.1111/j.1476-5381.1974.tb09729.x; SIEGEL S, 1976, SCIENCE, V193, P323, DOI 10.1126/science.935870; SIEGEL S, 1978, J COMP PHYSIOL PSYCH, V92, P1137, DOI 10.1037/h0077525; TAVANI A, 1979, J PHARMACOL EXP THER, V211, P140; THEISS P, 1975, EUR J PHARMACOL, V34, P263, DOI 10.1016/0014-2999(75)90251-4; THORNHILL JA, 1978, CAN J PHYSIOL PHARM, V56, P483, DOI 10.1139/y78-072; WAY EL, 1969, J PHARMACOL EXP THER, V167, P1	39	26	26	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0033-3158			PSYCHOPHARMACOLOGY	Psychopharmacology		1980	71	1					51	61		10.1007/BF00433252			11	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	KQ754	WOS:A1980KQ75400009	6779325				2020-06-26	J	YOUNG, AM; WOODS, JH				YOUNG, AM; WOODS, JH			BEHAVIOR MAINTAINED BY INTRAVENOUS-INJECTION OF CODEINE, COCAINE, AND ETORPHINE IN THE RHESUS MACAQUE AND THE PIGTAIL MACAQUE	PSYCHOPHARMACOLOGY			English	Article										YOUNG, AM (reprint author), UNIV MICHIGAN,DEPT PHARMACOL,ANN ARBOR,MI 48109, USA.			Young, Alice/0000-0002-0077-137X	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-00254]		BALSTER RL, 1973, J EXP ANAL BEHAV, V20, P119, DOI 10.1901/jeab.1973.20-119; CARNEY JM, 1976, PHARMACOL BIOCHEM BE, V5, P577, DOI 10.1016/0091-3057(76)90272-0; DENEAU G, 1969, PSYCHOPHARMACOLOGIA, V16, P30, DOI 10.1007/BF00405254; DOWNS DA, 1974, J PHARMACOL EXP THER, V191, P179; FERSTER CB, 1957, SCHEDULES REINFORCE, P39; GOLDBERG SR, 1976, J EXP ANAL BEHAV, V25, P93, DOI 10.1901/jeab.1976.25-93; GOLDBERG SR, 1976, [No title captured], P283; GOLDBERG SR, 1971, J PHARMACOL EXP THER, V171, P277; HOFFMEISTER F, 1973, J PHARMACOL EXP THER, V187, P8; HOFFMEISTER F, 1972, PSYCHOPHARMACOLOGIA, V23, P55, DOI 10.1007/BF00414414; HOFFMEISTER F, 1979, PSYCHOPHARMACOLOGY, V62, P181, DOI 10.1007/BF00427134; JOHANSON CE, 1978, J PHARMACOL EXP THER, V204, P118; JOHANSON CE, 1978, [No title captured], P325; MORETON JE, 1977, J PHARMACOL EXP THER, V203, P303; PICKENS R, 1978, [No title captured], V12, P1; SCHLICHTING UU, 1971, EXCERPTA MED INT 220, P62; SPEALMAN RD, 1979, J PHARMACOL EXP THER, V210, P206; WADE N, 1978, SCIENCE, V199, P280, DOI 10.1126/science.199.4326.280; Woods James H., 1978, PSYCHOPHARMACOLOGY G, p[595, 595]; WOODS JH, 1980, DRUG ALCOHOL DEPEN, V5, P223, DOI 10.1016/0376-8716(80)90182-9; WOOLVERTON WL, 1978, PHARMACOL BIOCHEM BE, V9, P327, DOI 10.1016/0091-3057(78)90293-9; YOUNG A M, 1979, Pharmacology Biochemistry and Behavior, V11, P43, DOI 10.1016/0091-3057(79)90295-8	22	16	16	0	3	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0033-3158			PSYCHOPHARMACOLOGY	Psychopharmacology		1980	70	3					263	271		10.1007/BF00427883			9	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	KQ424	WOS:A1980KQ42400007	6777798				2020-06-26	J	JINDAL, SP; LUTZ, T; VESTERGAARD, P				JINDAL, SP; LUTZ, T; VESTERGAARD, P			GAS CHROMATOGRAPHIC-MASS SPECTROMETRIC DETERMINATION OF ETORPHINE WITH STABLE ISOTOPE LABELED INTERNAL STANDARD	ANALYTICAL CHEMISTRY			English	Review										JINDAL, SP (reprint author), ROCKLAND RES INST,ORANGEBURG,NY 10962, USA.						AUDIER H, 1965, TETRAHEDRON LETT, P13; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3281, DOI 10.1021/ja00989a032; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3267, DOI 10.1021/ja00989a030; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3273, DOI 10.1021/ja00989a031; CHAO JM, 1974, ANAL CHEM, V46, P296, DOI 10.1021/ac60338a045; EBBIGHAUSEN WOR, 1974, BIOMED MASS SPECTROM, V1, P305, DOI 10.1002/bms.1200010503; GOHLKE RS, 1962, ANAL CHEM, V34, P1281, DOI 10.1021/ac60190a025; GORDETZKY CW, 1975, CLIN PHARMACOL THER, V17, P273; GORDON M, 1977, ANNU REP MED CHEM, V12, P20; HAMMAR CG, 1968, ANAL BIOCH, V25, P53; Holmstedt B, 1973, Adv Biochem Psychopharmacol, V7, P1; JASINSKI DR, 1975, CLIN PHARMACOL THER, V17, P267; JINDAL SP, 1978, J PHARM SCI, V67, P260, DOI 10.1002/jps.2600670236; King J. M., 1965, East African Wildlife Journal, V3, P19; MCMAHON R E, 1968, Advances in Tracer Methodology, V4, P29; NAKATA H, 1965, TETRAHEDRON LETT, P829; ROBINSON JD, 1975, RES COMMUN CHEM PATH, V10, P1; VEREBELY K, 1975, RES COMMUN CHEM PATH, V12, P67; WALLER GR, 1972, BIOCH APPLICATIONS M, P655; WHEELER DMS, 1967, J AM CHEM SOC, V89, P4494, DOI 10.1021/ja00993a044	20	4	4	0	0	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036	0003-2700			ANAL CHEM	Anal. Chem.		1979	51	2					269	271		10.1021/ac50038a027			3	Chemistry, Analytical	Chemistry	GG945	WOS:A1979GG94500027	420400				2020-06-26	J	LUCKE, JN				LUCKE, JN			EUTHANASIA IN SMALL ANIMALS	VETERINARY RECORD			English	Article										LUCKE, JN (reprint author), UNIV BRISTOL,DEPT VET SURG,BRISTOL BS8 1TH,AVON,ENGLAND.						CROFT G, 1976, HUMANE DESTRUCTION U, P3; HALL LW, 1971, WRIGHTS VETERINARY A, P154; LUCKE JN, 1975, VET REC, V97, P418, DOI 10.1136/vr.97.21.418; MACARTHUR JA, 1976, HUMANE DESTRUCTION U, P9; SANFORD J, 1976, HUMANE DESTRUCTION U, P18; 1976, UFAW HDB CARE MANAGE, P160; 1975, J SMALL ANIMAL PRACT, V16, P605; 1978, J AM VETERINARY MEDI, V173, P59	8	17	17	0	4	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1979	104	14					316	318		10.1136/vr.104.14.316			3	Veterinary Sciences	Veterinary Sciences	GR057	WOS:A1979GR05700008	121902				2020-06-26	J	JACOB, JJC; RAMABADRAN, K				JACOB, JJC; RAMABADRAN, K			ENHANCEMENT OF A NOCICEPTIVE REACTION BY OPIOID ANTAGONISTS IN MICE	BRITISH JOURNAL OF PHARMACOLOGY			English	Article										JACOB, JJC (reprint author), INST PASTEUR, PHARMACOL LAB, 28 RUE DOCTEUR ROUX, F-75724 PARIS, FRANCE.						AKIL H, 1976, SCIENCE, V191, P961, DOI 10.1126/science.1251210; AKIL H, 1976, [No title captured], P63; AUDIGIER Y, 1977, EUR J PHARMACOL, V41, P247, DOI 10.1016/0014-2999(77)90220-5; BARKER JL, 1977, APPROACHES CELL BIOL, V2, P340; BEECHER HK, 1957, PHARMACOL REV, V9, P59; BELL JA, 1977, EUR J PHARMACOL, V42, P147, DOI 10.1016/0014-2999(77)90354-5; BERKOWITZ B A, 1976, Clinical Pharmacokinetics, V1, P219, DOI 10.2165/00003088-197601030-00004; BERNTSON GG, 1977, BRAIN RES BULL, V2, P157, DOI 10.1016/0361-9230(77)90014-4; BRADBURY AF, 1976, NATURE, V260, P793, DOI 10.1038/260793a0; CLARKE FH, 1974, NARCOTIC ANTAGONISTS, V8, P81; COWAN A, 1977, BRIT J PHARMACOL, V60, P537, DOI 10.1111/j.1476-5381.1977.tb07532.x; COX BM, 1975, LIFE SCI, V16, P1777, DOI 10.1016/0024-3205(75)90272-6; ELLIOTT HW, 1976, LIFE SCI, V19, P1637, DOI 10.1016/0024-3205(76)90068-0; FREDERICKSON RCA, 1976, OPIATES ENDOGENOUS O, P239; GOLDFARB J, 1976, NEUROPHARMACOLOGY, V15, P785, DOI 10.1016/0028-3908(76)90009-5; GOLDSTEIN A, 1976, LIFE SCI, V18, P599, DOI 10.1016/0024-3205(76)90339-8; GOLDSTEIN A, 1975, P NATL ACAD SCI USA, V72, P2041, DOI 10.1073/pnas.72.6.2041; GRAF L, 1976, FEBS LETT, V64, P181, DOI 10.1016/0014-5793(76)80278-5; GREVERT P, 1977, PSYCHOPHARMACOLOGY, V53, P111, DOI 10.1007/BF00426478; GREVERT P, 1977, P NATL ACAD SCI USA, V74, P1291, DOI 10.1073/pnas.74.3.1291; GUILLEMIN R, 1976, CR ACAD SCI D NAT, V282, P783; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; Hambrook J.M., 1976, OPIATES ENDOGENOUS O, P295; Hardy JD, 1940, J CLIN INVEST, V19, P649, DOI 10.1172/JCI101168; HUGHES J, 1975, NATURE, V258, P577, DOI 10.1038/258577a0; HUGHES J, 1975, BRAIN RES, V88, P295, DOI 10.1016/0006-8993(75)90391-1; JACOB J, 1961, ARCH INT PHARMACOD T, V133, P296; JACOB J, 1966, METHODS DRUG EVALUAT, P278; JACOB JJ, 1976, ARCH INT PHARMACOD T, V222, P332; JACOB JJ, 1974, PSYCHOPHARMACOLOGIA, V37, P217, DOI 10.1007/BF00421535; KING CD, 1977, FED PROC, V36, P965; LEIMGRUBER W, 1974, NARCOTIC ANTAGONISTS, V8, P45; LI CH, 1976, NATURE, V260, P622, DOI 10.1038/260622a0; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; LORD JAH, 1976, OPIATES ENDOGENOUS O, P275; MADDEN J, 1977, NATURE, V265, P358, DOI 10.1038/265358a0; MAYER DJ, 1977, BRAIN RES, V121, P368, DOI 10.1016/0006-8993(77)90161-5; MERZ H, 1974, ADV BIOCHEM PSYCHOPH, V8, P91; OLIVERAS JL, 1977, BRAIN RES, V120, P221, DOI 10.1016/0006-8993(77)90902-7; PASTERNAK GW, 1975, LIFE SCI, V16, P1765, DOI 10.1016/0024-3205(75)90270-2; PERT A, 1976, LIFE SCI, V19, P1023, DOI 10.1016/0024-3205(76)90294-0; POMERANZ B, 1976, LIFE SCI, V19, P1757, DOI 10.1016/0024-3205(76)90084-9; POMERANZ B, 1977, EXP NEUROL, V54, P172, DOI 10.1016/0014-4886(77)90243-6; SIMANTOV R, 1976, OPIATES ENDOGENOUS O, P41; SOBKY AE, 1976, NATURE, V263, P783; TERENIUS L, 1974, ACTA PHARMACOL TOX, V35, P55; TERENIUS L, 1977, PSYCHONEUROENDOCRINO, V2, P53, DOI 10.1016/0306-4530(77)90031-2; TERENIUS L, 1975, OPIATE NARCOTICS NEU, P7; TREMBLAY E, 1976, PSYCHOPHARMACOLOGY, V49, P41; TULUNAY FC, 1975, EUR J PHARMACOL, V33, P65; WABEKE D, 1955, HANDLEIDING TOESTS V; WOOLF CJ, 1977, EUR J PHARMACOL, V45, P311, DOI 10.1016/0014-2999(77)90016-4; YAKSH TL, 1976, LIFE SCI, V18, P1193, DOI 10.1016/0024-3205(76)90192-2	53	115	117	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.		1978	64	1					91	98		10.1111/j.1476-5381.1978.tb08645.x			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	FP478	WOS:A1978FP47800014	698486	Green Published			2020-06-26	J	CERLETTI, C; COCCIA, P; MANARA, L; MENNINI, T; RECCHIA, M				CERLETTI, C; COCCIA, P; MANARA, L; MENNINI, T; RECCHIA, M			SUBCELLULAR-DISTRIBUTION OF ETORPHINE IN RAT-BRAIN AND EVIDENCE FOR INVIVO STEREOSPECIFIC BINDING	BRITISH JOURNAL OF PHARMACOLOGY			English	Article									IST RIC FARMACOL MARIO NEGRI,DEPT BIOSTAT,I-20157 MILAN,ITALY	CERLETTI, C (reprint author), IST RIC FARMACOL MARIO NEGRI,DRUG METAB LAB,I-20157 MILAN,ITALY.		Cerletti, Chiara/K-6447-2016	Cerletti, Chiara/0000-0002-4759-3179			ALDINIO C, 1976, THESIS U MILAN; BAREGGI SR, 1971, RES COMMUN CHEM PATH, V2, P347; BECKETT AH, 1954, J PHARM PHARMACOL, V6, P986, DOI 10.1111/j.2042-7158.1954.tb11033.x; BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; CERLETTI C, 1974, BRIT J PHARMACOL, V52, pP440; CLOUET DH, 1973, BIOCHEM PHARMACOL, V22, P1283, DOI 10.1016/0006-2952(73)90302-X; COX BM, 1964, BRIT J PHARM CHEMOTH, V22, P289, DOI 10.1111/j.1476-5381.1964.tb02034.x; DEROBERTIS E, 1962, J NEUROCHEM, V9, P23; GOLDSTEIN A, 1971, P NATL ACAD SCI USA, V68, P1742, DOI 10.1073/pnas.68.8.1742; GOLDSTEIN A, 1974, LIFE SCI, V14, P615, DOI 10.1016/0024-3205(74)90396-8; JOHNSON MK, 1960, BIOCHEM J, V77, P610, DOI 10.1042/bj0770610; KIRK RE, 1968, [No title captured]; KOSTERLITZ HW, 1968, BRIT J PHARMACOL, V33, P266, DOI 10.1111/j.1476-5381.1968.tb00988.x; LEYSEN J, 1977, LIFE SCI, V20, P281, DOI 10.1016/0024-3205(77)90323-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANARA L, 1972, EUR J PHARMACOL, V20, P109, DOI 10.1016/0014-2999(72)90223-3; MANARA L, 1972, EUR J PHARMACOL, V17, P183, DOI 10.1016/0014-2999(72)90288-9; MANARA L, 1974, LIFE SCI, V14, P2267, DOI 10.1016/0024-3205(74)90108-8; MANARA L, 1978, FACTORS AFFECTING AC; MANARA L, 1975, FEDN P, V34; MELLETT LB, 1959, J PHARMACOL EXP THER, V125, P97; MULE SJ, 1967, J PHARMACOL EXP THER, V157, P459; MULE SJ, 1975, PSYCHOPHARMACOLOGIA, V44, P125, DOI 10.1007/BF00420998; MULE SJ, 1974, RES COMMUN CHEM PATH, V9, P55; PERT CB, 1974, BRAIN RES, V70, P184, DOI 10.1016/0006-8993(74)90228-5; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; SMITH AP, 1976, RES COMMUN CHEM PATH, V15, P205; TERENIUS L, 1973, ACTA PHARMACOL TOX, V33, P377; Tukey JW, 1953, PROBLEM MULTIPLE COM; VANPRAAG D, 1966, P SOC EXP BIOL MED, V122, P6; WHITTAKER VP, 1964, BIOCHEM J, V90, P293, DOI 10.1042/bj0900293	32	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0007-1188			BRIT J PHARMACOL	Br. J. Pharmacol.		1978	62	1					31	38		10.1111/j.1476-5381.1978.tb07003.x			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	EJ663	WOS:A1978EJ66300005	620097	Green Published			2020-06-26	J	THORNHILL, JA; HIRST, M; GOWDEY, CW				THORNHILL, JA; HIRST, M; GOWDEY, CW			MEASUREMENT OF DIURNAL CORE TEMPERATURES OF RATS IN OPERANT CAGES BY AM TELEMETRY	CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY			English	Note										THORNHILL, JA (reprint author), UNIV WESTERN ONTARIO,DEPT PHARMACOL,LONDON N6A 5C1,ONTARIO,CANADA.						COX B, 1977, BRIT J PHARMACOL, V61, pP496; DECASTRO JM, 1977, PHYSIOL BEHAV, V19, P331, DOI 10.1016/0031-9384(77)90347-X; FRYER TB, 1966, J APPL PHYSIOL, V21, P295; KATO DS, 1970, AGR ENG, V5, P652; Mackay RS, 1970, BIOMEDICAL TELEMETRY; MARTIN GE, 1976, NEUR ABSTR, V2, P873; POOLE S, 1977, BRIT J PHARMACOL, V59, pP482; SHARP RW, 1974, J APPL PHYSIOL, V37, P617; SMITH EN, 1974, J APPL PHYSIOL, V36, P252; WINGET C. M., 1965, AMER J PHYSLOL, V209, P853	10	17	17	0	0	NATL RESEARCH COUNCIL CANADA	OTTAWA	RESEARCH JOURNALS, MONTREAL RD, OTTAWA ON K1A 0R6, CANADA	0008-4212			CAN J PHYSIOL PHARM	Can. J. Physiol. Pharmacol.		1978	56	6					1047	1050		10.1139/y78-167			4	Pharmacology & Pharmacy; Physiology	Pharmacology & Pharmacy; Physiology	GJ028	WOS:A1978GJ02800025	570446				2020-06-26	J	HILLIDGE, CJ				HILLIDGE, CJ			INFLUENCE OF NEUROLEPTANALGESIA ON SERUM ACTIVITY OF MUSCLE ENZYMES IN PONIES	EQUINE VETERINARY JOURNAL			English	Article										HILLIDGE, CJ (reprint author), ROYAL VET COLL,DEPT MED,FIELD STN,HATFIELD AL9 7TA,HERTFORDSHIRE,ENGLAND.							0	4	4	0	2	EQUINE VETERINARY JOURNAL LTD	NEWMARKET	GRASEBY HOUSE, ENXING ROAD, NEWMARKET, SUFFOLK, ENGLAND CB8 0AU	0425-1644			EQUINE VET J	Equine Vet. J.		1978	10	1					60	64		10.1111/j.2042-3306.1978.tb02217.x			5	Veterinary Sciences	Veterinary Sciences	EK421	WOS:A1978EK42100013	631108				2020-06-26	J	SQUIRES, RF; BRAESTRUP, C				SQUIRES, RF; BRAESTRUP, C			CHARACTERISTICS AND REGIONAL DISTRIBUTIONS OF 2 DISTINCT [NALOXONE-H-3 BINDING-SITES IN RAT-BRAIN	JOURNAL OF NEUROCHEMISTRY			English	Article										SQUIRES, RF (reprint author), AS FERROSAN,RES LABS,SYDMARKEN 1-5,DK-2860 SOEBORG,DENMARK.						AKERA T, 1976, LIFE SCI, V16, P1801; AUDIGIER Y, 1977, EUR J PHARMACOL, V41, P247, DOI 10.1016/0014-2999(77)90220-5; BARTHOLINI G, 1975, J PHARM PHARMACOL, V27, P439, DOI 10.1111/j.2042-7158.1975.tb09476.x; BLANE GF, 1968, J PHARM PHARMACOL, V20, P547, DOI 10.1111/j.2042-7158.1968.tb09803.x; BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; BRADLEY PB, 1976, NATURE, V261, P425, DOI 10.1038/261425a0; CREESE I, 1975, J PHARM EXP THER, V194, P209; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; KUHLENBECK H, 1960, Confin Neurol, V20, P407; LEE CY, 1975, J PHARMACOL EXP THER, V194, P583; LEYSEN J, 1976, ARCH INT PHARMACOD T, V220, P335; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; LORD JAH, 1976, OPIATES ENDOGENOUS O; PASTERNAK GW, 1975, NATURE, V253, P563, DOI 10.1038/253563a0; PASTERNAK GW, 1976, DISS ABSTR INT, V36, P3333; PERT CB, 1973, SCIENCE, V182, P1359, DOI 10.1126/science.182.4119.1359; PERT CB, 1973, P NATL ACAD SCI USA, V70, P2243, DOI 10.1073/pnas.70.8.2243; PERT CB, 1974, MOL PHARMACOL, V10, P868; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; SIMON EJ, 1975, J PHARMACOL EXP THER, V192, P531; SNYDER SH, 1975, NATURE, V257, P185, DOI 10.1038/257185a0; TERENIUS L, 1977, PSYCHONEUROENDOCRINO, V2, P53, DOI 10.1016/0306-4530(77)90031-2; TERENIUS L, 1973, ACTA PHARMACOL TOX, V33, P377	24	61	61	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.		1978	30	1					231	236		10.1111/j.1471-4159.1978.tb07056.x			6	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	EL984	WOS:A1978EL98400029	202679				2020-06-26	J	JINDAL, SP; VESTERGAARD, P				JINDAL, SP; VESTERGAARD, P			QUANTITATION OF ETORPHINE IN URINE BY SELECTIVE ION MONITORING USING TRITIATED ETORPHINE AS AN INTERNAL STANDARD	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Note										JINDAL, SP (reprint author), ROCKLAND RES INST,ORANGEBURG,NY 10962, USA.						BENTLEY KW, 1963, P CHEM SOC LONDON, P220; Bertilsson L, 1973, Adv Biochem Psychopharmacol, V7, P147; BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; GEHRKE CW, 1971, J CHROMATOGR, V57, P219, DOI 10.1016/0021-9673(71)80035-3; GORDETZKY CW, 1975, CLIN PHARMACOL THER, V17, P273; HAMMAR CG, 1968, ANAL BIOCHEM, V25, P532, DOI 10.1016/0003-2697(68)90131-0; Holmstedt B, 1973, Adv Biochem Psychopharmacol, V7, P1; JASINSKI DR, 1975, CLIN PHARMACOL THER, V17, P267; LISTER RE, 1964, J PHARM PHARMACOL, V16, P364, DOI 10.1111/j.2042-7158.1964.tb07475.x; MULE SJ, 1975, PSYCHOPHARMACOLOGIA, V44, P125, DOI 10.1007/BF00420998	10	7	7	0	0	AMER PHARMACEUTICAL ASSN	WASHINGTON	2215 CONSTITUTION AVE NW, WASHINGTON, DC 20037	0022-3549			J PHARM SCI	J. Pharm. Sci.		1978	67	2					260	261		10.1002/jps.2600670236			2	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	EL467	WOS:A1978EL46700035	621651				2020-06-26	J	LIN, HK; SIMON, EJ				LIN, HK; SIMON, EJ			PHOSPHOLIPASE-A INHIBITION OF OPIATE RECEPTOR-BINDING CAN BE REVERSED BY ALBUMIN	NATURE			English	Article										LIN, HK (reprint author), NYU,MED CTR,DEPT MED,NEW YORK,NY 10016, USA.						AZHAR S, 1976, J BIOL CHEM, V251, P7405; PASTERNAK GW, 1975, MOL PHARMACOL, V11, P340; PASTERNAK GW, 1975, MOL PHARMACOL, V11, P478; PASTERNAK GW, 1974, MOL PHARMACOL, V10, P183; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; SIMON EJ, 1975, P NATL ACAD SCI USA, V72, P2404, DOI 10.1073/pnas.72.6.2404; SIMON EJ, 1975, SCIENCE, V190, P389, DOI 10.1126/science.1182043; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; SIMON EJ, 1975, J PHARMACOL EXP THER, V192, P531; TERENIUS L, 1973, ACTA PHARMACOL TOX, V32, P317	10	77	77	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature		1978	271	5643					383	384		10.1038/271383a0			2	Multidisciplinary Sciences	Science & Technology - Other Topics	EJ045	WOS:A1978EJ04500055	202879				2020-06-26	J	WUSTER, M; HERZ, A				WUSTER, M; HERZ, A			OPIATE AGONIST ACTION OF ANTIDIARRHEAL AGENTS INVITRO AND INVIVO - FINDINGS IN SUPPORT FOR SELECTIVE ACTION	NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY			English	Article										WUSTER, M (reprint author), MAX PLANCK INST PSYCHIAT,NEUROPHARMAKOL ABT,D-8000 MUNICH 40,FED REP GER.						BLASIG J, 1973, PSYCHOPHARMACOLOGIA, V31, P111, DOI 10.1007/BF00419811; BURKS TF, 1976, EUR J PHARMACOL, V40, P279, DOI 10.1016/0014-2999(76)90063-7; CREESE I, 1975, J PHARMACOL EXP THER, V194, P205; DAJANI EZ, 1975, EUR J PHARMACOL, V34, P105, DOI 10.1016/0014-2999(75)90230-7; GARRETT ER, 1974, J PHARM SCI, V63, P1056, DOI 10.1002/jps.2600630705; Goodman L. S., 1975, PHARMACOL BASIS, P245; Herz A, 1971, ADV DRUG RES, V6, P79; HEYKANTS J, 1974, ARZNEIMITTEL-FORSCH, V24, P1649; HOLLT V, 1975, N-S ARCH PHARMACOL, V288, P163, DOI 10.1007/BF00500524; JANSSEN PAJ, 1959, J MED PHARMACEUT CH, V1, P299; Karim A, 1976, SYNTHETIC ANTIDIARRH, P132; KOSTERLITZ HW, 1975, EUR J PHARMACOL, V32, P10, DOI 10.1016/0014-2999(75)90317-9; KOSTERLITZ HW, 1975, ANNU REV PHARMACOL, V15, P29, DOI 10.1146/annurev.pa.15.040175.000333; MACKERER CR, 1976, J PHARMACOL EXP THER, V199, P131; NIEMEGEERS C, 1976, SYNTHETIC ANTIDIARRH, P65; PERT CB, 1974, MOL PHARMACOL, V10, P868; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; PERT CB, 1973, SCIENCE, V182, P1357; RANG HP, 1964, BRIT J PHARM CHEMOTH, V22, P356, DOI 10.1111/j.1476-5381.1964.tb02040.x; RINALDO JA, 1971, GASTROENTEROLOGY, V60, P438; STOKBROEKX RA, 1973, J MED CHEM, V16, P782, DOI 10.1021/jm00265a009; SUNDARESAN PR, 1975, J PHARMACOL EXP THER, V194, P593; TERENIUS L, 1975, ACTA PHARMACOL TOX, V37, P211; VANNUETEN JM, 1976, LIFE SCI, V18, P803, DOI 10.1016/0024-3205(76)90005-9; VANWIJNGAARDEN I, 1972, ARZNEI-FORSCHUNG, V22, P513; WALSH CT, 1975, J PHARMACOL EXP THER, V195, P303; WUSTER M, 1976, N-S ARCH PHARMACOL, V293, pR35; WUSTER M, 1976, OPIATES ENDOGENOUS O, P447	28	84	85	0	5	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0028-1298			N-S ARCH PHARMACOL	Naunyn-Schmiedebergs Arch. Pharmacol.		1978	301	3					187	194		10.1007/BF00507036			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	EQ511	WOS:A1978EQ51100007	204876				2020-06-26	J	BLUME, AJ				BLUME, AJ			INTERACTION OF LIGANDS WITH OPIATE RECEPTORS OF BRAIN MEMBRANES - REGULATION BY IONS AND NUCLEOTIDES	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article										BLUME, AJ (reprint author), ROCHE INST MOLEC BIOL,DEPT PHYSIOL CHEM & PHARMACOL,NUTLEY,NJ 07110, USA.						BIRNBAUMER L, 1969, J BIOL CHEM, V244, P3468; BIRNBAUMER L, 1971, J BIOL CHEM, V246, P1857; GOLDSTEIN A, 1977, NATURE, V265, P362, DOI 10.1038/265362a0; KEBABIAN JW, 1975, P NATL ACAD SCI USA, V72, P3735, DOI 10.1073/pnas.72.9.3735; KIMURA N, 1977, J BIOL CHEM, V252, P3829; KLEE WA, 1976, NATURE, V263, P609, DOI 10.1038/263609a0; LAD PM, 1977, J BIOL CHEM, V252, P5942; LEFKOWITZ RJ, 1977, J BIOL CHEM, V252, P5295; LEFKOWITZ RJ, 1974, J BIOL CHEM, V249, P6119; LONDOS C, 1974, P NATL ACAD SCI USA, V71, P3087, DOI 10.1073/pnas.71.8.3087; LONDOS C, 1975, J BIOL CHEM, V250, P3459; Maguire M E, 1977, Adv Cyclic Nucleotide Res, V8, P1; MAGUIRE ME, 1976, MOL PHARMACOL, V12, P335; MAKMAN MH, 1971, P NATL ACAD SCI USA, V68, P805; MUKHERJEE C, 1976, P NATL ACAD SCI USA, V73, P1494, DOI 10.1073/pnas.73.5.1494; PASTERNAK GW, 1975, NATURE, V253, P563, DOI 10.1038/253563a0; PASTERNAK GW, 1975, MOL PHARMACOL, V11, P735; PERT CB, 1973, SCIENCE, V182, P1359, DOI 10.1126/science.182.4119.1359; PFENFFER T, 1975, J BIOL CHEM, V250, P867; RODBELL M, 1974, J BIOL CHEM, V249, P59; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P590, DOI 10.1073/pnas.72.2.590; SIMANTOV R, 1976, MOL PHARMACOL, V12, P977; SIMANTOV R, 1976, MOL PHARMACOL, V12, P987; SUTHERLAND EW, 1960, PHARMACOL REV, V12, P265; WONG DT, 1976, TISSUE RESPONSES ADD, P391	25	279	279	0	2	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.		1978	75	4					1713	1717		10.1073/pnas.75.4.1713			5	Multidisciplinary Sciences	Science & Technology - Other Topics	EY183	WOS:A1978EY18300024	205867	Green Published, Bronze			2020-06-26	J	MIRANDA, F; CANDELARESI, G; SAMANIN, R				MIRANDA, F; CANDELARESI, G; SAMANIN, R			ANALGESIC EFFECT OF ETORPHINE IN RATS WITH SELECTIVE DEPLETIONS OF BRAIN MONO-AMINES	PSYCHOPHARMACOLOGY			English	Article										MIRANDA, F (reprint author), INST RICERCHE FARMACOL MARIO NEGRI, VIA ERITREA 62, I-20157 MILAN, ITALY.						ADLER M, 1975, EUR J PHARMACOL, V32, P39, DOI 10.1016/0014-2999(75)90320-9; AYHAN IH, 1972, PSYCHOPHARMACOLOGIA, V25, P183, DOI 10.1007/BF00423196; BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; BLASIG J, 1973, PSYCHOPHARMACOLOGIA, V33, P19; BLUNDELL C, 1977, J PHARM PHARMACOL, V29, P306, DOI 10.1111/j.2042-7158.1977.tb11319.x; BOWERS MB, 1971, NATURE, V229, P134, DOI 10.1038/229134a0; BREESE GR, 1971, BRIT J PHARMACOL, V42, P88, DOI 10.1111/j.1476-5381.1971.tb07089.x; BUXBAUM DM, 1973, J PHARMACOL EXP THER, V185, P317; CHANG CC, 1964, INT J NEUROPHARMACOL, V3, P643; CLOUET DH, 1970, SCIENCE, V168, P854, DOI 10.1126/science.168.3933.854; COX BM, 1968, BRIT J PHARMACOL, V33, P245, DOI 10.1111/j.1476-5381.1968.tb00986.x; CURZON G, 1970, BRIT J PHARMACOL, V39, P653, DOI 10.1111/j.1476-5381.1970.tb10373.x; ELCHISAK MA, 1973, RES COMMUN CHEM PATH, V6, P349; GOODLET I, 1974, EUR J PHARMACOL, V29, P241, DOI 10.1016/0014-2999(74)90022-3; HAUBRICH DR, 1973, BIOCHEM PHARMACOL, V22, P2753, DOI 10.1016/0006-2952(73)90135-4; KOE BK, 1966, J PHARMACOL EXP THER, V154, P499; KONIG JFR, 1963, [No title captured]; KUSCHINSKY K, 1972, EUR J PHARMACOL, V19, P119, DOI 10.1016/0014-2999(72)90086-6; LAVERTY R, 1968, ANAL BIOCHEM, V22, P269, DOI 10.1016/0003-2697(68)90316-3; LORENS SA, 1974, PHARMACOL BIOCHEM BE, V2, P215, DOI 10.1016/0091-3057(74)90055-0; MAJOR CT, 1971, BRIT J PHARMACOL, V42, P512, DOI 10.1111/j.1476-5381.1971.tb07137.x; NAKAMURA K, 1973, PSYCHOPHARMACOLOGIA, V31, P177, DOI 10.1007/BF00419817; Noble E P, 1967, Life Sci, V6, P281, DOI 10.1016/0024-3205(67)90157-9; PEREZCRUET J, 1975, LIFE SCI, V17, P349, DOI 10.1016/0024-3205(75)90484-1; PRICE MTC, 1975, BRAIN RES, V99, P189, DOI 10.1016/0006-8993(75)90626-5; REINHOLD K, 1973, N-S ARCH PHARMACOL, V278, P69, DOI 10.1007/BF00501864; SAMANIN R, 1973, PSYCHOPHARMACOLOGIA, V33, P365, DOI 10.1007/BF00437514; SAMANIN R, 1970, EUR J PHARMACOL, V10, P339, DOI 10.1016/0014-2999(70)90205-0; SAMANIN R, 1971, EUR J PHARMACOL, V16, P298, DOI 10.1016/0014-2999(71)90030-6; SAMANIN R, 1972, PSYCHOPHARMACOLOGIA, V25, P175, DOI 10.1007/BF00423195; SAMANIN R, 1977, FACTORS AFFECTING AC; SAMANIN R, 1975, 37TH P ANN SCI M COM, P690; SASA M, 1977, EUR J PHARMACOL, V42, P53, DOI 10.1016/0014-2999(77)90190-X; SAWA A, 1976, JPN J PHARMACOL, V26, P599, DOI 10.1254/jjp.26.599; SETHY VH, 1970, PSYCHOPHARMACOLOGIA, V17, P320, DOI 10.1007/BF00404237; SEWELL RDE, 1975, PSYCHOPHARMACOLOGIA, V42, P67, DOI 10.1007/BF00428828; TENEN SS, 1968, PSYCHOPHARMACOLOGIA, V12, P278, DOI 10.1007/BF00401407; URETSKY NJ, 1970, J NEUROCHEM, V17, P269, DOI 10.1111/j.1471-4159.1970.tb02210.x; YARBROUG.GG, 1973, J PHARMACOL EXP THER, V185, P328	39	4	4	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0033-3158	1432-2072		PSYCHOPHARMACOLOGY	Psychopharmacology		1978	58	1					105	109		10.1007/BF00426798			5	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	FE754	WOS:A1978FE75400015	97714				2020-06-26	J	MACDONALD, RL; NELSON, PG				MACDONALD, RL; NELSON, PG			SPECIFIC-OPIATE-INDUCED DEPRESSION OF TRANSMITTER RELEASE FROM DORSAL ROOT GANGLION-CELLS IN CULTURE	SCIENCE			English	Article										MACDONALD, RL (reprint author), NICHHD,DEV NEUROBIOL LAB,BETHESDA,MD 20014, USA.						BISCOE TJ, 1972, BRIT J PHARMACOL, V46, P201, DOI 10.1111/j.1476-5381.1972.tb06865.x; BRADLEY PB, 1974, BRIT J PHARMACOL, V50, P47, DOI 10.1111/j.1476-5381.1974.tb09591.x; CALVILLO O, 1974, CAN J PHYSIOL PHARM, V52, P1207, DOI 10.1139/y74-158; DOSTROVSKY J, 1973, NATURE-NEW BIOL, V246, P222, DOI 10.1038/newbio246222a0; DUGGAN AW, 1972, NEUROPHARMACOLOGY, V11, P189, DOI 10.1016/0028-3908(72)90091-3; HUBBARD JI, 1969, [No title captured]; KUNO M, 1971, PHYSIOL REV, V51, P647; LAMOTTE C, 1976, BRAIN RES, V112, P407, DOI 10.1016/0006-8993(76)90296-1; MARTIN AR, 1977, HDB PHYSL          1, V1, P329; RANSOM BR, 1977, J NEUROPHYSIOL, V40, P1151; RANSOM BR, 1977, J NEUROPHYSIOL, V40, P1132; SATOH M, 1976, BRAIN RES, V115, P99, DOI 10.1016/0006-8993(76)90825-8; SU PC, 1977, ANNUAL M SOC NEURO 3, P377; ZIEGLGANSBERGER W, 1976, BRAIN RES, V115, P111, DOI 10.1016/0006-8993(76)90826-X	14	139	139	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science		1978	199	4336					1449	1451		10.1126/science.204015			3	Multidisciplinary Sciences	Science & Technology - Other Topics	ER507	WOS:A1978ER50700024	204015				2020-06-26	J	DODMAN, NH; WATERMAN, AE				DODMAN, NH; WATERMAN, AE			CLINICAL OBSERVATIONS ON ANTAGONISM OF IMMOBILON BY NALOXONE IN DOGS	VETERINARY RECORD			English	Article										DODMAN, NH (reprint author), UNIV GLASGOW,VET HOSP,BEARSDEN,SCOTLAND.						CROOKS JC, 1976, VET REC, V99, P281; DEWEY WL, 1974, ADV BIOCHEM PSYCHOPH, V8, P263; EVANS JM, 1974, ANAESTHESIA, V29, P721, DOI 10.1111/j.1365-2044.1974.tb00759.x; EVANS JM, 1974, BRIT MED J, V2, P589, DOI 10.1136/bmj.2.5919.589; FINK M, 1968, CLIN PHARMACOL THER, V9, P568; HARTHOORN AM, 1976, CHEM CAPTURE ANIMALS, P309; HASBROUC.JD, 1971, ANESTH ANAL CURR RES, V50, P954, DOI 10.1213/00000539-197150060-00011; JASINSKI DR, 1968, CLIN PHARMACOL THER, V9, P215; KERSH ES, 1973, CHEST, V63, P112, DOI 10.1378/chest.63.1.112; LEVINE JD, 1978, NATURE, V272, P826, DOI 10.1038/272826a0; PADDLEFORD RR, 1973, J AM VET MED ASSOC, V163, P144; PALMINTERI A, 1966, J AM VET MED ASSOC, V148, P1396; VOLANS GN, 1976, BRIT MED J, V2, P472, DOI 10.1136/bmj.2.6033.472-c	13	4	4	0	1	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1978	103	15					334	335		10.1136/vr.103.15.334			2	Veterinary Sciences	Veterinary Sciences	FR336	WOS:A1978FR33600006	726197				2020-06-26	J	BOGAN, JA; MACKENZIE, G; SNOW, DH				BOGAN, JA; MACKENZIE, G; SNOW, DH			EVALUATION OF TRANQUILIZERS FOR USE WITH ETORPHINE AS NEUROLEPTANALGESIC AGENTS IN HORSE	VETERINARY RECORD			English	Note										BOGAN, JA (reprint author), UNIV GLASGOW,SCH VET,DEPT VET PHARMACOL,GLASGOW G12 8QQ,SCOTLAND.						AITKEN MM, 1972, P ASS VET ANAESTHETI, V3, P20; BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; CLARKE KW, 1969, VET REC, V85, P512, DOI 10.1136/vr.85.19.512; FUENTES VO, 1978, VET REC, V102, P106, DOI 10.1136/vr.102.5.106; HENRY DP, 1975, LIFE SCI, V16, P375, DOI 10.1016/0024-3205(75)90258-1; KERR DD, 1972, AM J VET RES, V33, P777; MACKENZIE G, 1977, VET REC, V101, P30, DOI 10.1136/vr.101.2.30; MCCASHIN FB, 1975, AM J VET RES, V36, P1421	8	13	15	0	2	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1978	103	21					471	472		10.1136/vr.103.21.471			2	Veterinary Sciences	Veterinary Sciences	FW529	WOS:A1978FW52900005	741607				2020-06-26	J	BONGSO, TA; PERERA, BMAO				BONGSO, TA; PERERA, BMAO			OBSERVATIONS ON USE OF ETORPHINE ALONE AND IN COMBINATION WITH ACEPROMAZINE MALEATE FOR IMMOBILIZATION OF AGGRESSIVE ASIAN ELEPHANTS(ELEPHAS-MAXIMUS)	VETERINARY RECORD			English	Note										BONGSO, TA (reprint author), UNIV SRI LANKA,DEPT VET CLIN STUDIES,PERADENIYA,SRI LANKA.						GRAY C W, 1970, Zoologica (New York), V55, P51; HARTHOORN AM, 1975, CHEMICAL CAPTURE ANI; JAINUDEEN MR, 1971, VET REC, V89, P686, DOI 10.1136/vr.89.26.686; Jones D.M., 1975, Oryx, V13, P185; Schmidt M.J., 1975, Journal Zool Anim Med, V6, P13	5	5	5	0	1	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1978	102	15					339	340		10.1136/vr.102.15.339			2	Veterinary Sciences	Veterinary Sciences	EU457	WOS:A1978EU45700010	565970				2020-06-26	J	SHARMA, SK; KLEE, WA; NIRENBERG, M				SHARMA, SK; KLEE, WA; NIRENBERG, M			OPIATE-DEPENDENT MODULATION OF ADENYLATE-CYCLASE	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article									NHLBI,BIOCHEM GENET LAB,BETHESDA,MD 20014; NIMH,GEN & COMP BIOCHEM LAB,BETHESDA,MD 20014							BLUME AJ, 1976, J BIOL CHEM, V251, P3399; COLLIER HOJ, 1975, LIFE SCI, V17, P85, DOI 10.1016/0024-3205(75)90242-8; COLLIER HOJ, 1974, NATURE, V248, P24, DOI 10.1038/248024a0; CONSTANTOPOULOS A, 1973, BIOCHEM BIOPH RES CO, V53, P794, DOI 10.1016/0006-291X(73)90162-9; ENGELHARD VH, 1976, P NATL ACAD SCI USA, V73, P4482, DOI 10.1073/pnas.73.12.4482; KLEIN WL, 1976, FED PROC, V35, P1576; LEFKOWITZ RJ, 1975, J BIOL CHEM, V250, P4418; LONDOS C, 1974, P NATL ACAD SCI USA, V71, P3087, DOI 10.1073/pnas.71.8.3087; MANGANIELLO VC, 1976, J BIOL CHEM, V251, P6205; ORLY J, 1975, P NATL ACAD SCI USA, V72, P3433, DOI 10.1073/pnas.72.9.3433; SABOL SL, 1977, FED PROC, V36, P736; SAHYOUN N, 1975, P NATL ACAD SCI USA, V72, P3438, DOI 10.1073/pnas.72.9.3438; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P590, DOI 10.1073/pnas.72.2.590; STURGILL TW, 1975, J CYCLIC NUCL PROT, V1, P21; TALLMAN JF, 1977, P NATL ACAD SCI USA, V74, P873, DOI 10.1073/pnas.74.3.873; TRABER J, 1975, NATURE, V253, P120, DOI 10.1038/253120a0; TRABER J, 1975, LIFE SCI, V16, P1863, DOI 10.1016/0024-3205(75)90292-1	19	257	259	0	0	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.		1977	74	8					3365	3369		10.1073/pnas.74.8.3365			5	Multidisciplinary Sciences	Science & Technology - Other Topics	DT270	WOS:A1977DT27000057	269396	Green Published, Bronze			2020-06-26	J	BLUME, AJ; SHORR, J; FINBERG, JPM; SPECTOR, S				BLUME, AJ; SHORR, J; FINBERG, JPM; SPECTOR, S			BINDING OF ENDOGENOUS NON-PEPTIDE MORPHINE-LIKE COMPOUND TO OPIATE RECEPTORS	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article									ROCHE INST MOLEC BIOL, DEPT PHYSIOL CHEM & PHARMACOL, NUTLEY, NJ 07110 USA							COX BM, 1975, LIFE SCI, V16, P1777, DOI 10.1016/0024-3205(75)90272-6; COX BM, 1976, P NATL ACAD SCI USA, V73, P1821, DOI 10.1073/pnas.73.6.1821; GINTZLER AR, 1976, P NATL ACAD SCI USA, V73, P2132, DOI 10.1073/pnas.73.6.2132; GOLDSTEIN A, 1977, NATURE, V265, P362, DOI 10.1038/265362a0; GUILLEMIN R, 1976, CR ACAD SCI D NAT, V282, P783; HUGHES J, 1975, NATURE, V258, P577, DOI 10.1038/258577a0; HUGHES J, 1975, BRAIN RES, V88, P295, DOI 10.1016/0006-8993(75)90391-1; KLEE WA, 1974, P NATL ACAD SCI USA, V71, P3474, DOI 10.1073/pnas.71.9.3474; KLEE WA, 1976, NATURE, V263, P609, DOI 10.1038/263609a0; KUPFERBERG H, 1964, J PHARMACOL EXP THER, V145, P247; PASTERNAK GW, 1975, LIFE SCI, V16, P1765, DOI 10.1016/0024-3205(75)90270-2; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P590, DOI 10.1073/pnas.72.2.590; SPECTOR S, 1970, SCIENCE, V168, P1347, DOI 10.1126/science.168.3937.1347; TERENIUS L, 1975, LIFE SCI, V16, P1759, DOI 10.1016/0024-3205(75)90269-6; WATERFIELD AA, 1977, EUR J PHARMACOL, V43, P107, DOI 10.1016/0014-2999(77)90123-6	16	43	43	0	0	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.		1977	74	11					4927	4931		10.1073/pnas.74.11.4927			5	Multidisciplinary Sciences	Science & Technology - Other Topics	EC593	WOS:A1977EC59300047	200939	Green Published, Bronze			2020-06-26	J	CHESNEY, J				CHESNEY, J			USE OF LARGE ANIMAL IMMOBILON	VETERINARY RECORD			English	Letter									AMERY FARM VET HOSP,ALTON,HAMPSHIRE,ENGLAND								0	0	0	0	1	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1977	101	11					215	215		10.1136/vr.101.11.215			1	Veterinary Sciences	Veterinary Sciences	DU114	WOS:A1977DU11400058	919264				2020-06-26	J	WHITTLE, BA; CROOKS, JL				WHITTLE, BA; CROOKS, JL			PENILE PROLAPSE WITH IMMOBILON	VETERINARY RECORD			English	Letter									RECKITT & COLMAN LTD, DIV PHARMACEUT, HULL HU8 7DS, N HUMBERSHIRE, ENGLAND							BOLZ W, 1969, VETERINARY MEDICAL R, P255; 1977, VETERINARY DATA SHEE, P76	2	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0042-4900	2042-7670		VET REC	Vet. Rec.		1977	101	15					312	312		10.1136/vr.101.15.312-a			1	Veterinary Sciences	Veterinary Sciences	DW499	WOS:A1977DW49900019	919297				2020-06-26	J	JONES, DM				JONES, DM			SEDATION AND ANESTHESIA OF BIRDS AND REPTILES	VETERINARY RECORD			English	Article									ZOOL SOC LONDON,LONDON NW1,ENGLAND							BACHRACH A, 1954, VETERINARY EXCERPTS, V14, P99; BETZ T. W., 1962, COPEIA, V2, P284; BIESTER HE, 1962, DISEASE POULTRY, P931; BOEVER WJ, 1975, VET MED SM ANIM CLIN, V70, P86; BORZIO F, 1973, VET MED SM ANIM CLIN, V68, P1364; COOPER JE, 1974, VET REC, V95, P37, DOI 10.1136/vr.95.2.37; COOPER JE, 1974, VET REC, V94, P437, DOI 10.1136/vr.94.19.437; COOPER JE, 1973, VET REC, V92, P474, DOI 10.1136/vr.92.18.474; COWIE AF, 1977, AMENDMENTS BSAVA MAN; DONOVAN EW, 1965, AVIAN DIS, V9, P227, DOI 10.2307/1588005; FRIEDBURG KM, 1962, J AM VET MED ASSOC, V141, P1157; GANDAL CP, 1969, DIS CAGE AVIARY BIRD, P217; GLENN JL, 1972, AM J VET RES, V33, P1901; GRONO L. R., 1961, AUSTRALIAN VET JOUR, V37, P463, DOI 10.1111/j.1751-0813.1961.tb08705.x; HARDING KA, 1977, VET REC, V100, P289, DOI 10.1136/vr.100.14.289; JACKSON OF, 1976, MANUAL CARE TREATMEN, P19; JONES DM, 1972, J ZOOLOGY, V166, P54; JONES DM, 1977, VETERINARY ANNUAL, P280; JONES DM, 1973, VETERINARY ANNUAL, P320; KARLSTROM EL, 1955, COPEIA, V1, P57; LEININGER F G, 1965, Vet Med Small Anim Clin, V60, P401; LEVINGER IM, 1973, BRIT VET J, V129, P296, DOI 10.1016/S0007-1935(17)36489-8; MANDELKER L, 1973, VET MED SM ANIM CLIN, V68, P487; MANDELKER L, 1972, VET MED SM ANIM CLIN, V67, P55; Marsboom R., 1965, International Zoo Yearbook, V5, P200, DOI 10.1111/j.1748-1090.1965.tb01645.x; MESSENT PR, 1976, MANUAL CARE TREATMEN, P1; RYDERDAVIES P, 1973, VET REC, V92, P507, DOI 10.1136/vr.92.19.507; WALLACH JD, 1967, J AM VET MED ASSOC, V151, P870; WALLACH JD, 1969, J AM VETERINARY MEDI, V153, P1017; WILLIAMS LE, 1965, P ANNUAL C S E ASSOC, P1	30	19	19	0	1	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1977	101	17					340	342		10.1136/vr.101.17.340			3	Veterinary Sciences	Veterinary Sciences	DX975	WOS:A1977DX97500007	22155				2020-06-26	J	SCHELS, HF; NOWROUZIAN, I				SCHELS, HF; NOWROUZIAN, I			EFFECTS OF REVERSIBLE NARCOTIC IMMOBILIZATION IN IRANIAN CAMEL	VETERINARY RECORD			English	Note									UNIV TEHRAN, FAC VET MED, DEPT LARGE ANIM MED OBSTET & SURG, TEHERAN, IRAN							CURASSON G, 1947, CHAMEAU MALADIES; DENNIG HK, 1972, VETERINAR MEDIZINISC, V3, P243; KHAMIS Y, 1973, VETERINAR MEDIZINISC, V4, P335; LEESE AS, 1927, TREATISE ONE HUMPED; ROSBOROUGH JP, 1974, ZBL VET MED A, V21, P149; Said AH, 1964, VET REC, V76, P550; SINGH RATAN, 1962, INDIAN VET JOUR, V39, P614	7	1	1	0	0	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON W1M 0AT, ENGLAND	0042-4900			VET REC	Vet. Rec.		1977	101	19					388	388		10.1136/vr.101.19.388			1	Veterinary Sciences	Veterinary Sciences	DZ775	WOS:A1977DZ77500016	595276				2020-06-26	J	LUCKE, JN				LUCKE, JN			IMMOBILON IN PEKINGESE	VETERINARY RECORD			English	Letter																	0	0	0	0	0	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1977	100	11					226	226		10.1136/vr.100.11.226			1	Veterinary Sciences	Veterinary Sciences	CX787	WOS:A1977CX78700012	855154				2020-06-26	J	MASON, J; WILSON, P				MASON, J; WILSON, P			EFFECT OF IMMOBILON UPON BLOOD-GLUCOSE LEVELS IN DOG	VETERINARY RECORD			English	Note									UNIV DUBLIN,TRINITY COLL,DEPT PRECLIN VET SCI,DUBLIN,IRELAND; UNIV DUBLIN,TRINITY COLL,DEPT CLIN VET SCI,DUBLIN,IRELAND								0	1	1	0	0	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1977	100	14					292	292		10.1136/vr.100.14.292			1	Veterinary Sciences	Veterinary Sciences	DA339	WOS:A1977DA33900013	860391				2020-06-26	J	SCORER, JW				SCORER, JW			DEATH OF BULL UNDER IMMOBILON	VETERINARY RECORD			English	Letter																RAFFERTY GC, 1976, VETERINARY REC  0103, P18	1	1	1	0	0	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1977	100	15					326	327		10.1136/vr.100.15.326			2	Veterinary Sciences	Veterinary Sciences	DA845	WOS:A1977DA84500014	867751				2020-06-26	J	FELGATE, CAG				FELGATE, CAG			DEATH OF A BULL UNDER IMMOBILON	VETERINARY RECORD			English	Letter																	0	0	0	0	0	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1977	100	18					391	391		10.1136/vr.100.18.391-b			1	Veterinary Sciences	Veterinary Sciences	DD265	WOS:A1977DD26500017	878240				2020-06-26	J	GOODRICH, PGE				GOODRICH, PGE			ACCIDENTAL SELF-INJECTION	VETERINARY RECORD			English	Letter																	0	18	18	0	0	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1977	100	21					458	459		10.1136/vr.100.21.458			2	Veterinary Sciences	Veterinary Sciences	DF799	WOS:A1977DF79900015	878254				2020-06-26	J	BRUNNER, B; BUCHER, K				BRUNNER, B; BUCHER, K			INSPIRATION INHIBITING EFFECT OF ETORPHINE-DERIVATIVES	AGENTS AND ACTIONS			English	Article									NC DEF LAB, ARMAMENT TECHNOL & PROCUREMENT GRP, CH-3752 WIMMIS, SWITZERLAND; UNIV BASEL BIOCTR, DEPT PHARMACOL, CH-4056 BASEL, SWITZERLAND							ALFORD BT, 1974, J AM VET MED ASSOC, V164, P702; BENTLEY KW, 1963, P CHEM SOC LONDON, P220; BENTLEY KW, 1971, ALKALOIDS, V13, P1; BERRY PA, 1974, BRIT J PHARMACOL, V52, pP146; BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; BUCHER K, 1949, HELV PHYSIOL PHARM A, V7, P470; BUCHER K, 1952, REFLEKTORISCHE BEEIN; CERLETTI C, 1974, BRIT J PHARMACOL, V52, pP440; HEAD H, J PHYSIOL, V10, P1; HERMANSEN K, 1974, ACTA PHARMACOL TOX, V34, P189; LISTER RE, 1964, J PHARM PHARMACOL, V16, P364, DOI 10.1111/j.2042-7158.1964.tb07475.x	11	1	1	0	0	BIRKHAUSER VERLAG AG	BASEL	VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND	0065-4299			AGENTS ACTIONS	Agents Actions		1976	6	6					755	757		10.1007/BF02026099			3	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	CN244	WOS:A1976CN24400013	1008021				2020-06-26	J	MACBEATH, JT; MOORE, BA				MACBEATH, JT; MOORE, BA			DOUBLE-BLIND CLINICAL-TRIAL OF ANALGESIC EFFECTS OF R AND S 218-M, A NEW POTENT ANALGESIC FOR RELIEF OF PAIN FOLLOWING ABDOMINAL-SURGERY - COMPARISON WITH MORPHINE SULFATE	BRITISH JOURNAL OF ANAESTHESIA			English	Article									UNIV MANCHESTER, HOPE HOSP, MED SCH, SALFORD, ENGLAND; UNIV LOUGHBOROUGH, DEPT MATH, LOUGHBOROUGH, ENGLAND							BEAVER WT, 1966, CLIN PHARMACOL THER, V7, P436; BEAVER WT, 1967, CLIN PHARMACOL THER, V8, P415; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3281, DOI 10.1021/ja00989a032; BLANE GF, 1968, J PHARM PHARMACOL, V20, P796, DOI 10.1111/j.2042-7158.1968.tb09641.x; DEKORNFELD T J, 1960, Anesth Analg, V39, P430; DEKORNFELD TJ, 1960, ANESTHESIOLOGY, V21, P159, DOI 10.1097/00000542-196003000-00005; DENTON JE, 1949, JAMA-J AM MED ASSOC, V141, P1051, DOI 10.1001/jama.1949.62910150002007; GORDON RA, 1960, CAN ANAESTH SOC J, V7, P32; HOPTON D, 1971, GUT, V12, P51, DOI 10.1136/gut.12.1.51; LASAGNA L, 1960, ANN NY ACAD SCI, V86, P28, DOI 10.1111/j.1749-6632.1960.tb42788.x; LASAGNA L, 1954, JAMA-J AM MED ASSOC, V156, P230, DOI 10.1001/jama.1954.02950030022008; LASAGNA L, 1962, LANCET, V2, P572; PARKHOUSE J, 1963, P ROY SOC MED, V56, P579, DOI 10.1177/003591576305600719; PARKHOUSE J, 1961, BRIT J ANAESTH, V33, P345, DOI 10.1093/bja/33.7.345; SIMPSON BR, 1961, BRIT J ANAESTH, V33, P336, DOI 10.1093/bja/33.7.336; SWERDLOW M, 1963, ACTA ANAESTH SCAND, V7, P1, DOI 10.1111/j.1399-6576.1963.tb00201.x; SWERDLOW M, 1963, ANESTH ANALG, V42, P588; SWERDLOW M, 1964, BRIT J ANAESTH, V36, P782, DOI 10.1093/bja/36.12.782; 1969, SUBMISSION COMMITTEE	19	2	2	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.		1976	48	2					97	104		10.1093/bja/48.2.97			8	Anesthesiology	Anesthesiology	BG331	WOS:A1976BG33100008	766798				2020-06-26	J	VOLANS, GN; WHITTLE, BA				VOLANS, GN; WHITTLE, BA			ACCIDENTAL INJECTION OF IMMOBILON	BRITISH MEDICAL JOURNAL			English	Letter									GUYS HOSP,POISONS UNIT,LONDON SE14,ENGLAND; RECKITT & COLMAN,DIV PHARM,HULL,ENGLAND							FIRM S, 1974, LANCET, V1, P577; FIRM S, 1973, LANCET, V2, P95; VAUDREY JC, 1974, VET REC, V94, P52; 1976, VETERINARY RECORD, V98, P514	4	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.		1976	2	6033					472	473		10.1136/bmj.2.6033.472-c			2	Medicine, General & Internal	General & Internal Medicine	CB241	WOS:A1976CB24100029	953617	Green Published, Bronze			2020-06-26	J	HILLIDGE, CJ				HILLIDGE, CJ			USE OF DOPRAM AS A RESPIRATORY STIMULANT FOLLOWING IMMOBILON IN PONY	EQUINE VETERINARY JOURNAL			English	Article									ROYAL VET COLL,DEPT MED,FIELD STN,HATFIELD,HERTFORDSHIRE,ENGLAND								0	3	3	0	0	EQUINE VETERINARY JOURNAL LTD	NEWMARKET	GRASEBY HOUSE, ENXING ROAD, NEWMARKET, SUFFOLK, ENGLAND CB8 0AU	0425-1644			EQUINE VET J	Equine Vet. J.		1976	8	4					173	175		10.1111/j.2042-3306.1976.tb03334.x			3	Veterinary Sciences	Veterinary Sciences	CT142	WOS:A1976CT14200008	976233				2020-06-26	J	BRADLEY, PB; BRIGGS, I; GAYTON, RJ; LAMBERT, LA				BRADLEY, PB; BRIGGS, I; GAYTON, RJ; LAMBERT, LA			EFFECTS OF MICROIONTOPHORETICALLY APPLIED METHIONINE ENKEPHALIN ON SINGLE NEURONS IN RAT BRAIN-STEM	NATURE			English	Article									MED SCH BIRMINGHAM,DEPT PHARMACOL,BIRMINGHAM B15 2TJ,ENGLAND; MED SCH BIRMINGHAM,MRC,NEUROPHARMACOL UNIT,BIRMINGHAM B15 2TJ,ENGLAND							BENJAMIN R M, 1970, Brain Research, V24, P525; BRADLEY PB, 1975, BRIT J PHARMACOL, V53, pP462; BRADLEY PB, 1974, BRIT J PHARMACOL, V50, P47, DOI 10.1111/j.1476-5381.1974.tb09591.x; BRAMWELL GJ, 1974, BRAIN RES, V73, P167, DOI 10.1016/0006-8993(74)91017-8; HERZ A, 1970, NEUROPHARMACOLOGY, V9, P539, DOI 10.1016/0028-3908(70)90004-3; HUGHES J, 1975, LIFE SCI, V16, P1753, DOI 10.1016/0024-3205(75)90268-4; HUGHES J, 1975, NATURE, V258, P577, DOI 10.1038/258577a0; MAYER DJ, 1971, SCIENCE, V174, P1351, DOI 10.1126/science.174.4016.1351; SATOH M, 1974, BRAIN RES, V82, P378, DOI 10.1016/0006-8993(74)90624-6; SNYDER SH, 1975, NATURE, V257, P185, DOI 10.1038/257185a0	10	124	124	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature		1976	261	5559					425	426		10.1038/261425a0			2	Multidisciplinary Sciences	Science & Technology - Other Topics	BT199	WOS:A1976BT19900045	934277				2020-06-26	J	LAZARUS, LH; LING, N; GUILLEMIN, R				LAZARUS, LH; LING, N; GUILLEMIN, R			BETA-LIPOTROPIN AS A PRO-HORMONE FOR MORPHINOMIMETIC PEPTIDES ENDORPHINS AND ENKEPHALINS	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article									SALK INST, LA JOLLA, CA 92037 USA							Bradbury AF, 1975, PEPTIDES CHEMISTRY S, P609; COX BM, 1975, LIFE SCI, V16, P1777, DOI 10.1016/0024-3205(75)90272-6; COX BM, 1976, P NATL ACAD SCI USA, V73, P1821, DOI 10.1073/pnas.73.6.1821; DAUL CB, 1975, NEUROPHARMACOLOGY, V14, P75, DOI 10.1016/0028-3908(75)90068-4; DAY RP, 1976, ENDOCRINOLOGY, V99, P93, DOI 10.1210/endo-99-1-93; DEWIED D, 1975, BIOCHEM PHARMACOL, V24, P1463, DOI 10.1016/0006-2952(75)90019-2; GANTEN D, 1971, SCIENCE, V173, P64, DOI 10.1126/science.173.3991.64; GUILLEMIN R, 1976, CR ACAD SCI D NAT, V282, P783; HUGHES J, 1975, NATURE, V258, P577, DOI 10.1038/258577a0; KLEE WA, 1974, NATURE, V248, P61, DOI 10.1038/248061a0; LI CH, 1964, NATURE, V201, P924, DOI 10.1038/201924a0; LI CH, 1976, P NATL ACAD SCI USA, V73, P1145, DOI 10.1073/pnas.73.4.1145; LING N, 1975, BIOCHEM BIOPH RES CO, V63, P801, DOI 10.1016/S0006-291X(75)80454-2; LOHMAR P, 1968, ENDOCRINOLOGY, V82, P898, DOI 10.1210/endo-82-5-898; LONG JM, 1961, ENDOCRINOLOGY, V69, P176, DOI 10.1210/endo-69-1-176; MARKS N, 1975, FEBS LETT, V55, P220, DOI 10.1016/0014-5793(75)80996-3; MOON HD, 1973, ANAT REC, V175, P529, DOI 10.1002/ar.1091750303; PATON WDM, 1968, J PHYSIOL-LONDON, V194, P13, DOI 10.1113/jphysiol.1968.sp008392; PEART WS, 1965, PHARMACOL REV, V17, P143; POTH MM, 1975, J NEUROCHEM, V25, P83, DOI 10.1111/j.1471-4159.1975.tb07698.x; SCOTT AP, 1974, BIOCHEM J, V139, P593, DOI 10.1042/bj1390593; WHITTAKER VP, 1964, BIOCHEM J, V90, P293, DOI 10.1042/bj0900293; YAMASHIRO D, 1974, P NATL ACAD SCI USA, V71, P4945, DOI 10.1073/pnas.71.12.4945	23	238	241	0	2	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.		1976	73	6					2156	2159		10.1073/pnas.73.6.2156			4	Multidisciplinary Sciences	Science & Technology - Other Topics	BV587	WOS:A1976BV58700084	1064883	Bronze, Green Published			2020-06-26	J	LAMPERT, A; NIRENBERG, M; KLEE, WA				LAMPERT, A; NIRENBERG, M; KLEE, WA			TOLERANCE AND DEPENDENCE EVOKED BY AN ENDOGENOUS OPIATE PEPTIDE	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article									NIMH,LAB GEN & COMP BIOCHEM,BETHESDA,MD 20014; NHLBI,LAB BIOCHEM GENET,BETHESDA,MD 20014							BELLUZZI JD, 1976, NATURE, V260, P625, DOI 10.1038/260625a0; BRADBURY AF, 1976, NATURE, V260, P793, DOI 10.1038/260793a0; BUSCHER HH, 1976, NATURE, V261, P423, DOI 10.1038/261423a0; COLLIER HOJ, 1974, NATURE, V248, P24, DOI 10.1038/248024a0; COX BM, 1976, P NATL ACAD SCI USA, V73, P1821, DOI 10.1073/pnas.73.6.1821; HUGHES J, 1975, NATURE, V258, P577, DOI 10.1038/258577a0; HUGHES J, 1975, BRAIN RES, V88, P295, DOI 10.1016/0006-8993(75)90391-1; LAZARUS LH, 1976, P NATL ACAD SCI USA, V73, P2156, DOI 10.1073/pnas.73.6.2156; PASTERNAK GW, 1976, MOL PHARMACOL, V12, P504; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P590, DOI 10.1073/pnas.72.2.590; TERENIUS L, 1975, LIFE SCI, V16, P1759, DOI 10.1016/0024-3205(75)90269-6; TESCHEMACHER H, 1975, LIFE SCI, V16, P1771, DOI 10.1016/0024-3205(75)90271-4; TRABER J, 1975, NATURE, V253, P120, DOI 10.1038/253120a0; TRABER J, 1975, LIFE SCI, V16, P1863, DOI 10.1016/0024-3205(75)90292-1	15	54	54	0	0	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.		1976	73	9					3165	3167		10.1073/pnas.73.9.3165			3	Multidisciplinary Sciences	Science & Technology - Other Topics	CE957	WOS:A1976CE95700049	1067610	Green Published, Bronze			2020-06-26	J	LEES, P; HILLIDGE, CJ				LEES, P; HILLIDGE, CJ			IMMOBILON - SOME COMMENTS ON ITS ACTION	VETERINARY RECORD			English	Letter									ROY VET COLL,DEPT PHYSIOL,HATFIELD,HERTFORDSHIRE,ENGLAND; ROY VET COLL,DEPT MED,HATFIELD,HERTFORDSHIRE,ENGLAND								0	4	4	1	3	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1976	99	3					55	56		10.1136/vr.99.3.55			2	Veterinary Sciences	Veterinary Sciences	BX361	WOS:A1976BX36100006	960514				2020-06-26	J	SUMMERHAYS, G				SUMMERHAYS, G			OVERDOSAGE WITH NALORPHINE HYDROBROMIDE FOLLOWING SELF-INFLICTED INJURY WITH IMMOBILON	VETERINARY RECORD			English	Note																BRANDER GC, 1971, VETERINARY APPLIED P; MARTINDALE, 1972, EXTRA PHARMACOPOEIA	2	7	8	0	1	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1976	99	12					236	236		10.1136/vr.99.12.236			1	Veterinary Sciences	Veterinary Sciences	CD520	WOS:A1976CD52000007	982757				2020-06-26	J	RAFFERTY, GC				RAFFERTY, GC			IMMOBILON-REVIVON IN BULL	VETERINARY RECORD			English	Letter																	0	1	1	0	0	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1976	98	1					18	18		10.1136/vr.98.1.18			1	Veterinary Sciences	Veterinary Sciences	BA928	WOS:A1976BA92800012	1258278				2020-06-26	J	HAIGH, JC				HAIGH, JC			IMMOBILIZATION OF BONGO (BOOCERCUS-EURYCUS) AND OTHER AFRICAN ANTELOPES IN CAPTIVITY	VETERINARY RECORD			English	Article									UNIV SASKATCHEWAN,WESTERN COLL VET MED,SASKATOON,SASKATCHEWAN,CANADA							GRAY CW, 1974, J ZOO AN MED, V5, P1; HAARTHOORN AM, 1972, VET REC, V91, P3; HAARTHOORN AM, 1971, TXB VETERINARY ANAES; JONES DM, 1972, VET ANN, V13, P320; MCWHIRTER N, 1974, GUINESS BOOK RECORDS; PEARSON C, 1975, COMMUNICATION; PIENAAR UD, 1968, [No title captured], V46, P17; PIENAAR UDV, 1973, CAPTURE CARE WILD AN, pCH3; Woodford M.H., 1972, East African Wildlife Journal, V10, P279; WOODFORD MH, 1974, COMMUNICATION; INT ZOO YB, V14	11	4	4	0	4	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1976	98	12					237	239		10.1136/vr.98.12.237			3	Veterinary Sciences	Veterinary Sciences	BJ818	WOS:A1976BJ81800005	1265986				2020-06-26	J	CROOKS, JL				CROOKS, JL			IMMOBILON IN DOGS	VETERINARY RECORD			English	Letter																MCLAREN, 1976, VET REC, V98, P245	1	0	0	0	0	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1976	98	15					308	308		10.1136/vr.98.15.308			1	Veterinary Sciences	Veterinary Sciences	BM397	WOS:A1976BM39700012	1274143				2020-06-26	J	LANE, DR				LANE, DR			ANTIDOTES TO TOXIC DRUGS	VETERINARY RECORD			English	Letter									LEAMINGTON SPA,LEAMINGTON,ENGLAND								0	0	0	0	0	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1976	98	19					390	390		10.1136/vr.98.19.390			1	Veterinary Sciences	Veterinary Sciences	BQ346	WOS:A1976BQ34600013	936445				2020-06-26	J	DEY, PK; FELDBERG, W				DEY, PK; FELDBERG, W			HYPERGLYCEMIA PRODUCED BY DRUGS WITH ANALGESIC PROPERTIES INTRODUCED INTO CEREBRAL-VENTRICLES OF CATS	BRITISH JOURNAL OF PHARMACOLOGY			English	Article									NATL INST MED RES,MILL HILL,LONDON NW7 1AA,ENGLAND							AKIMOTO K, 1933, JAP J MED SCI 4 PHAR, P7; BERGSTROM S, 1966, ACTA PHYSIOL SCAND, V67, P185, DOI 10.1111/j.1748-1716.1966.tb03299.x; BLANE GF, 1970, BRIT J PHARMACOL, V39, pP252; BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; BORISON HL, 1972, J PHARMAC EXP THER, V138, P229; CAMPBELL D, 1973, BRIT J PHARMAC, V49, P456; COLLIER HOJ, 1974, NATURE, V248, P24, DOI 10.1038/248024a0; COLLIER HOJ, 1974, NATURE, V252, P56, DOI 10.1038/252056a0; CUBE BV, 1970, N-S ARCH PHARMAKOL, V265, P455, DOI 10.1007/BF00997080; DEY PK, 1975, J PHYSIOL-LONDON, V246, P213, DOI 10.1113/jphysiol.1975.sp010887; DEY PK, IN PRESS; FELDBERG W, 1972, BRIT J PHARMACOL, V46, P602, DOI 10.1111/j.1476-5381.1972.tb06887.x; FELDBERG W, 1974, J PHYSIOL-LONDON, V238, P487, DOI 10.1113/jphysiol.1974.sp010539; HERZ A, 1970, NEUROPHARMACOLOGY, V9, P539, DOI 10.1016/0028-3908(70)90004-3; JAFFE JH, 1965, PHARMACOL BASIS, P258; KO C, 1935, JAP J MED SCI 4 PHAR, V8, P22; REYNOLDS AK, 1957, MORPHINE ALLIED DRUG; RO A, 1935, JAP J MED SCI 4 PHAR, V9, P59; SAI EISHOKU, 1941, FOLIA PHARMACOL JAP, V31, P45; SCHAUMANN O, 1940, [No title captured], V196, P109	20	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0007-1188			BRIT J PHARMACOL	Br. J. Pharmacol.		1975	54	2					163	170		10.1111/j.1476-5381.1975.tb06925.x			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AG574	WOS:A1975AG57400004	1148506	Green Published			2020-06-26	J	SIMON, EJ; GROTH, J				SIMON, EJ; GROTH, J			KINETICS OF OPIATE RECEPTOR INACTIVATION BY SULFHYDRYL REAGENTS - EVIDENCE FOR CONFORMATIONAL CHANGE IN PRESENCE OF SODIUM IONS	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article									NYU,MED CTR,DEPT MED,NEW YORK,NY 10016							CARTER JR, 1968, P NATL ACAD SCI USA, V60, P725, DOI 10.1073/pnas.60.2.725; GOLDSTEIN A, 1971, P NATL ACAD SCI USA, V68, P1742, DOI 10.1073/pnas.68.8.1742; GREGORY JD, 1955, J AM CHEM SOC, V77, P3922, DOI 10.1021/ja01619a073; HILLER JM, 1973, RES COMMUN CHEM PATH, V6, P1052; LEVISON ME, 1969, EXPERIENTIA, V25, P126, DOI 10.1007/BF01899076; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PERT CB, 1973, SCIENCE, V182, P1359, DOI 10.1126/science.182.4119.1359; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; SIMON E J, 1975, Neurosciences Research Program Bulletin, V13, P43; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; SIMON EJ, 1975, J PHARMACOL EXP THER, V192, P531; TERENIUS L, 1973, ACTA PHARMACOL TOX, V32, P317	12	180	180	0	1	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.		1975	72	6					2404	2407		10.1073/pnas.72.6.2404			4	Multidisciplinary Sciences	Science & Technology - Other Topics	AG703	WOS:A1975AG70300092	1056036	Green Published, Bronze			2020-06-26	J	SIMON, EJ; HILLER, JM; EDELMAN, I				SIMON, EJ; HILLER, JM; EDELMAN, I			SOLUBILIZATION OF A STEREOSPECIFIC OPIATE-MACROMOLECULAR COMPLEX FROM RAT-BRAIN	SCIENCE			English	Article									NYU,MED CTR,DEPT MED,NEW YORK,NY 10016							BLECHER M, 1972, ROLE MEMBRANES METAB, P367; GOLDSTEIN A, 1971, P NATL ACAD SCI USA, V68, P1742, DOI 10.1073/pnas.68.8.1742; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; POLLOCK JJ, 1974, EUR J BIOCHEM, V41, P439, DOI 10.1111/j.1432-1033.1974.tb03285.x; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; SIMON EJ, 1975, J PHARMACOL EXP THER, V192, P531; TERENIUS L, 1973, ACTA PHARMACOL TOX, V32, P317	9	85	85	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science		1975	190	4212					389	390		10.1126/science.1182043			2	Multidisciplinary Sciences	Science & Technology - Other Topics	AT244	WOS:A1975AT24400028	1182043				2020-06-26	J	GIBBS, EPJ; MCDIARMID, A; ROWE, JJ				GIBBS, EPJ; MCDIARMID, A; ROWE, JJ			MANAGEMENT OF DEER FOR EXPERIMENTAL STUDIES WITH FOOT-AND-MOUTH-DISEASE VIRUS	VETERINARY RECORD			English	Article									INST RES ANIM DIS,COMPTON,NEWBURY,BERKSHIRE,ENGLAND; FORESTRY COMM,RES STN,ALICE HOLT LODGE,FARNHAM,SURREY,ENGLAND; ANIM VIRUS RES INST,PIRBRIGHT,WOKING,SURREY,ENGLAND							BROOKSBY JB, 1965, VET REC, V77, P22; BURROWS R, 1966, J HYG-CAMB, V64, P81, DOI 10.1017/S0022172400040365; CHAPMAN D, 1973, VET REC, V93, P113; COCKBURN RNA, IN PRESS; FORMAN AJ, 1974, J COMP PATHOL, V84, P221, DOI 10.1016/0021-9975(74)90063-2; FORMAN AJ, 1974, J COMP PATHOL, V84, P215, DOI 10.1016/0021-9975(74)90062-0; GIBBS EPJ, IN PRESS; HARRINGTON R, 1974, VET REC, V94, P362, DOI 10.1136/vr.94.16.362; HARTHOORN AM, 1974, VET REC, V95, P337, DOI 10.1136/vr.95.15.337; HARTHOORN AM, 1974, NATURE, V247, P577, DOI 10.1038/247577a0; Jones D. M., 1973, Veterinary Annual, V13, P320; JONES DM, 1973, VET REC, V93, P26, DOI 10.1136/vr.93.1.26; MCDIARMID A, 1972, BRIT VET J, V128, P277, DOI 10.1016/S0007-1935(17)36931-2	13	3	3	0	1	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT	0042-4900			VET REC	Vet. Rec.		1975	96	23					503	506		10.1136/vr.96.23.503			4	Veterinary Sciences	Veterinary Sciences	AD760	WOS:A1975AD76000003	1136125				2020-06-26	